{"original_filename": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573.pdf", "predictions": {"document_type": "prospectus"}, "blobs": [{"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-0", "text": "Prospectus dated January 26, 2018\n", "page_number": 0, "bounding_box": {"top_left_x": 0.37182587666263606, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6269649334945586, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.25513905683192256}, "blob_type": "headline", "predictions": {}, "annotations": {"filing_date": ["January 26, 2018"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-1", "text": "Dermapharm Holding SEN", "page_number": 0, "bounding_box": {"top_left_x": 0.3041112454655381, "top_left_y": 0.11591103507271172, "lower_right_x": 0.6862152357920194, "lower_right_y": 0.16467065868263472, "height": 0.048759623609923, "width": 0.3821039903264813}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-2", "text": "      Prospectus\nfor the public offering\n", "page_number": 0, "bounding_box": {"top_left_x": 0.42019347037484883, "top_left_y": 0.18135158254918735, "lower_right_x": 0.5828295042321644, "lower_right_y": 0.20872540633019676, "height": 0.027373823781009415, "width": 0.16263603385731557}, "blob_type": "headline", "predictions": {}, "annotations": {"transaction": ["public offering"]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-3", "text": "of\n", "page_number": 0, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.22070145423438836, "lower_right_x": 0.507255139056832, "lower_right_y": 0.2292557741659538, "height": 0.00855431993156544, "width": 0.013905683192261209}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-4", "text": "        3,840,000 newly issued bearer shares with no par value (St\u00fcckaktien)\n        from a capital increase against contributions in cash to be resolved by\nan extraordinary shareholders\u2019 meeting of the Company on or about January 26, 2018\n", "page_number": 0, "bounding_box": {"top_left_x": 0.21221281741233375, "top_left_y": 0.24251497005988024, "lower_right_x": 0.788391777509069, "lower_right_y": 0.2840034217279726, "height": 0.04148845166809237, "width": 0.5761789600967352}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-5", "text": "and of\n", "page_number": 0, "bounding_box": {"top_left_x": 0.4788391777509069, "top_left_y": 0.2951240376390077, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.30710008554319934, "height": 0.011976047904191656, "width": 0.04292623941958884}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-6", "text": "7,860,000 existing bearer shares with no par value (St\u00fcckaktien)\n         from the holdings of the Selling Shareholder\n", "page_number": 0, "bounding_box": {"top_left_x": 0.28053204353083433, "top_left_y": 0.3177929854576561, "lower_right_x": 0.7152357920193471, "lower_right_y": 0.3455945252352438, "height": 0.027801539777587703, "width": 0.43470374848851273}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-7", "text": "and of\n", "page_number": 0, "bounding_box": {"top_left_x": 0.4782345828295042, "top_left_y": 0.35885372112917024, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.36911890504704875, "height": 0.010265183917878506, "width": 0.04413542926239428}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-8", "text": "            1,755,000 existing bearer shares with no par value (St\u00fcckaktien)\nfrom the holdings of the Selling Shareholder in connection with a possible over-allotment\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1977025392986699, "top_left_y": 0.38280581693755344, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.4101796407185629, "height": 0.027373823781009443, "width": 0.6051995163240629}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-9", "text": "and at the same time for the\n", "page_number": 0, "bounding_box": {"top_left_x": 0.405683192261185, "top_left_y": 0.4204448246364414, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.4311377245508982, "height": 0.010692899914456822, "width": 0.18923821039903266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-10", "text": "                    admission to trading on the regulated market (regulierter Markt)\n  of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) with simultaneous admission to the\nsub-segment of the regulated market with additional post-admission obligations (Prime Standard) of the\n                       Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse)\n", "page_number": 0, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.4991445680068435, "height": 0.05474764756201883, "width": 0.7013301088270858}, "blob_type": "paragraph", "predictions": {}, "annotations": {"listing_venue": ["Frankfurt Stock Exchange"]}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-11", "text": "(Fra\n\nof\n", "page_number": 0, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.4991445680068435, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.5196749358426005, "height": 0.020530367835757013, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-12", "text": "   up to 3,840,000 newly issued bearer shares with no par value (St\u00fcckaktien) from\n           a capital increase against contributions in cash to be resolved by\nan extraordinary shareholders\u2019 meeting of the Company on or about January 26, 2018\n", "page_number": 0, "bounding_box": {"top_left_x": 0.20918984280532044, "top_left_y": 0.5333618477331052, "lower_right_x": 0.788391777509069, "lower_right_y": 0.5748502994011976, "height": 0.04148845166809234, "width": 0.5792019347037485}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-13", "text": "and\n", "page_number": 0, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.5855431993156544, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.5975192472198461, "height": 0.011976047904191711, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-14", "text": "50,000,000 existing bearer shares with no par value (St\u00fcckaktien) (existing share capital),\n                     each such share with a notional value of \u20ac1.00\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1977025392986699, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.6364414029084687, "height": 0.02780153977758759, "width": 0.6051995163240629}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-15", "text": "of\n", "page_number": 0, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.649272882805817, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.6595380667236954, "height": 0.010265183917878451, "width": 0.015114873035066534}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-16", "text": " Dermapharm Holding SE\nPrice Range: \u20ac26.00 \u2013 \u20ac30.00\n", "page_number": 0, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.6736526946107785, "lower_right_x": 0.6051995163240629, "lower_right_y": 0.7001710863986313, "height": 0.02651839178785287, "width": 0.20918984280532044}, "blob_type": "headline", "predictions": {}, "annotations": {"initial_price_range": ["\u20ac26.00 \u2013 \u20ac30.00"], "issuer_name": ["Dermapharm Holding SE"]}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-17", "text": "International Securities Identification Number (ISIN): DE000A2GS5D8\n  German Securities Code (Wertpapierkennnummer (WKN)): A2GS5D\n                           Ticker Symbol: DMP\n", "page_number": 0, "bounding_box": {"top_left_x": 0.2569528415961306, "top_left_y": 0.7147134302822925, "lower_right_x": 0.7448609431680774, "lower_right_y": 0.756201881950385, "height": 0.04148845166809245, "width": 0.4879081015719468}, "blob_type": "headline", "predictions": {}, "annotations": {"isin": ["DE000A2GS5D8"], "ticker": ["DMP"]}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-18", "text": "Sole Global Coordinator and Sole Bookrunner\n", "page_number": 0, "bounding_box": {"top_left_x": 0.3385731559854897, "top_left_y": 0.7694610778443114, "lower_right_x": 0.6571946795646917, "lower_right_y": 0.7801539777587682, "height": 0.010692899914456766, "width": 0.318621523579202}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-19", "text": "Berenberg\n", "page_number": 0, "bounding_box": {"top_left_x": 0.4588875453446191, "top_left_y": 0.7899914456800684, "lower_right_x": 0.5411124546553809, "lower_right_y": 0.8041060735671514, "height": 0.014114627887082953, "width": 0.08222490931076182}, "blob_type": "undefined", "predictions": {}, "annotations": {"investment_bank": ["Berenberg"]}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-0-20", "text": "Co-Lead Manager\n  ODDO BHF\n", "page_number": 0, "bounding_box": {"top_left_x": 0.4347037484885127, "top_left_y": 0.8139435414884517, "lower_right_x": 0.5652962515114873, "lower_right_y": 0.8451668092386655, "height": 0.03122326775021378, "width": 0.13059250302297465}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-1-0", "text": "(This page has been left blank intentionally)\n", "page_number": 1, "bounding_box": {"top_left_x": 0.343409915356711, "top_left_y": 0.44097519247219846, "lower_right_x": 0.6571946795646917, "lower_right_y": 0.4550898203592814, "height": 0.014114627887082953, "width": 0.3137847642079807}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-0", "text": "TABLE OF CONTENTS\n", "page_number": 2, "bounding_box": {"top_left_x": 0.405683192261185, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.09837467921300257, "height": 0.013259195893926434, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-1", "text": "Page\n", "page_number": 2, "bounding_box": {"top_left_x": 0.841596130592503, "top_left_y": 0.11591103507271172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12617621899059026, "height": 0.010265183917878534, "width": 0.03869407496977029}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-2", "text": "Il.\n\nSUMMARY OF THE PROSPECTUS. .............cccccscsscseseseessssssseseseseeesessssssseseseesessesssesseseeeeneaseseseseesenes S-1\nA-\u2014 Introduction and Warnings\n\n  \n \n\nB \u2014 Issuer...\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nE \u2014 Offer ...c.cecececeececcsssesseeseseeseessssssseseeseeessseseees\n\nZUSAMMENFASSUNG DES PROSPEKTS .\n\nA \u2014 Einleitung und Warnhinweise........ ccc eeseeeceeeeseseseeeeeesesesecesesseseseseeesesseseneessesseseeeneseeneeaeaeees S-19\nB \u2014 Emittent......\n\nC \u2014 Wertpapiere. i\nDRISKKOM ssescscsvevoernoxersesesvsscerseveaconssnevenccaversnsasteretvess casevenversuteneuovvnoterotvestereeseeneoronaansuoeraekersninereiuaeeesentoN S-31\nE\u2014 Angebot.........\n\nRISK FACTORS\n\nTel Market and Business related: Risks wessiisicisscivoceswsnevcscavavevvcinsernerinwecenvvnsscavavewcansvereranweentwnsrenavenests 1\n1.2 Regulatory; Legal and! Tax-Risks'..cscoscencsvcnsnvsenonverrsesvesersenvecencerevevrneaesvececvecversaven wil.\n1.3 Risks Related to the Company\u2019s Shareholder Structure, the Shares and the Offering . sid\nGENERAL INFORMATION 6isccisccscnesimnncirancnnnmnmnmnnnmmnnnmmnmn anemia 27\n2:1 Responsibility Statement... ania\n22: Purpose of this Prospectus. wil\n2.3 Porward-lookitig Statements: csessssevcousserenssavennivereuisermnirenenarnnumenasierenusremnnsenmurnenene: 28\n2.4 Sources of Market Data............c speed\n2d Documents Available for Inspection.. @i30\n2.6 Currency Presentation and Presentation of Financial Information .......0.0.0.0: cece eeeeeeeeeneneeeeeee 31\nQe) Time Specifications Sl\n\n \n\n32\nwD\nwd\n\n34\n235\n+36\n\n36\n+36\n\n+36\n\nTHE OFFERING ..\n3.1 Subject Matter of the Offering\n3.2 Price Range, Offer Period, Offer Price and Allotment..\n3.3 Expected Timetable for the Offering..\n3.4 Information on the Shares .............0.\n\n \n \n\n \n\n \n\n \n\n3.5 Transferability of the Shares; Lock-up..\n3.6 Selling Shareholder\n37) Allotment Criteria ..\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.8 Stabilization Measures, Over-Allotments and Greenshoe Option..\n\n3.9 Lock-up Agreements and Limitations on Disposal .... 37\n3.10 Admission to the Frankfurt Stock Exchange and Commencement of Trading ... 238\n3.11 Designated Sponsors .......cccecessescesesesescseeeeeeseseseseeeessseseseseesesesesesesesseseeeeseseseeseesesaeseesnesesasseeaeee 38\n3.12 Interests of Parties Participating in the Offering .......00..000. 138\nPROCEEDS AND COSTS OF THE OFFERING AND LISTING. 23D\nREASONS FOR THE OFFERING AND LISTING AND USE OF PROCEED ............ +40\nDIVIDEND POLICY; RESULTS AND DIVIDENDS PER SHARE; USE OF PROFIT. wl\n6.1 General Provisions Relating to Profit Allocation and Dividend Payments .. we Al\n6.2 Dividend Policy and Earnings per Share... v2,", "page_number": 2, "bounding_box": {"top_left_x": -0.12636033857315598, "top_left_y": 0.12660393498716851, "lower_right_x": -0.11970979443772672, "lower_right_y": 0.850727117194183, "height": 0.7241231822070145, "width": 0.006650544135429259}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-3", "text": "  ", "page_number": 2, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.17664670658682635, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.2262617621899059, "height": 0.04961505560307955, "width": 0.7267230955259976}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-4", "text": "  ", "page_number": 2, "bounding_box": {"top_left_x": 0.3778718258766626, "top_left_y": 0.2600513259195894, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.28956372968349015, "height": 0.02951240376390074, "width": 0.49818621523579204}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-5", "text": "svsisisscscivivavecvcevesecveseoceencrnnscivcvasecuwsvereavensveveanavanacieauaecinwereaoanevcieaneiciavaTeTincierentonaNtTeTaseat", "page_number": 2, "bounding_box": {"top_left_x": 0.2678355501813785, "top_left_y": 0.35072711719418304, "lower_right_x": 0.8663845223700121, "lower_right_y": 0.3592814371257485, "height": 0.008554319931565468, "width": 0.5985489721886336}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-6", "text": "wessiisicisscivoceswsnevcscavavevvcinsernerinwecenvvnsscavavewcansvereranweentwnsrenavenests", "page_number": 2, "bounding_box": {"top_left_x": 0.437726723095526, "top_left_y": 0.3704020530367836, "lower_right_x": 0.8663845223700121, "lower_right_y": 0.3759623609923011, "height": 0.0055603079555175405, "width": 0.42865779927448605}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-7", "text": "scscesessessereousserenearemmereresiermniemnemmanarasnEMTEENTRCTE", "page_number": 2, "bounding_box": {"top_left_x": 0.3905683192261185, "top_left_y": 0.46065012831479896, "lower_right_x": 0.8579201934703748, "lower_right_y": 0.4619332763045338, "height": 0.0012831479897348341, "width": 0.46735187424425634}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-8", "text": "  ", "page_number": 2, "bounding_box": {"top_left_x": 0.3651753325272068, "top_left_y": 0.7433704020530368, "lower_right_x": 0.8555018137847642, "lower_right_y": 0.7639007698887939, "height": 0.020530367835757013, "width": 0.4903264812575574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-9", "text": "sccsresavesesessevereoneareronvsarexsoenersiveanexssccaneesoessnesonennesesvesal", "page_number": 2, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.8498716852010265, "lower_right_x": 0.8579201934703748, "lower_right_y": 0.8511548331907614, "height": 0.0012831479897348341, "width": 0.37424425634824665}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-2-10", "text": "", "page_number": 2, "bounding_box": {"top_left_x": 0.49758162031438935, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9525235243798118, "height": 0.008126603934987209, "width": 0.0054413542926239344}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-3-0", "text": "7.    CAPITALIZATION AND INDEBTEDNESS; STATEMENT ON WORKING CAPITAL ................ 43\n      7.1   Capitalization .................................................................................................................................. 43\n      7.2   Indebtedness .................................................................................................................................... 44\n      7.3   Statement on Working Capital ........................................................................................................ 44\n8.    DILUTION ................................................................................................................................................... 45\n9.    SELECTED CONSOLIDATED FINANCIAL INFORMATION .......................................................... 46\n      9.1   Consolidated Statement of Comprehensive Income ........................................................................ 47\n      9.2   Consolidated Statement of Financial Position ................................................................................. 47\n      9.3   Consolidated Statement of Cash Flows ........................................................................................... 48\n      9.4   Selected Financial Information of the Company ............................................................................. 48\n      9.5   Other Operating Data and Financial Data ....................................................................................... 49\n10.   MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF NET ASSETS, FINANCIAL\n      CONDITION AND RESULTS OF OPERATIONS ................................................................................. 51\n      10.1  Overview ......................................................................................................................................... 52\n      10.2  Key Factors Affecting Dermapharm\u2019s Business ............................................................................. 53\n      10.3  Results of Operations ...................................................................................................................... 59\n      10.4  Assets, Equity and Liabilities .......................................................................................................... 69\n      10.5  Liquidity and Capital Resources ..................................................................................................... 72\n      10.6  Additional Information from the Individual Financial Statements of the Company ....................... 78\n      10.7  Qualitative Disclosure on Financial Risks ...................................................................................... 79\n      10.8  Critical Accounting Policies and Use of Estimates and Assumptions ............................................ 81\n11.   MARKETS AND COMPETITION ........................................................................................................... 83\n      11.1  Markets............................................................................................................................................ 83\n      11.2  Competition ..................................................................................................................................... 86\n12.   BUSINESS DESCRIPTION ....................................................................................................................... 88\n      12.1  Overview ......................................................................................................................................... 88\n      12.2  Strengths.......................................................................................................................................... 90\n      12.3  Strategy ........................................................................................................................................... 94\n      12.4  Business Areas ................................................................................................................................ 96\n      12.5  Information Technology ................................................................................................................ 107\n      12.6  Intellectual Property ...................................................................................................................... 107\n      12.7  Real Property................................................................................................................................. 108\n      12.8  Employees ..................................................................................................................................... 108\n      12.9  Sustainability, Safety and the Environment .................................................................................. 109\n      12.10 Compliance Management .............................................................................................................. 109\n      12.11 Insurance ....................................................................................................................................... 109\n      12.12 Litigation ....................................................................................................................................... 110\n      12.13 Material Agreements ..................................................................................................................... 111\n13.   REGULATORY AND LEGAL ENVIRONMENT ................................................................................ 118\n      13.1  Pharmaceuticals............................................................................................................................. 118\n      13.2  Medical Devices ............................................................................................................................ 128\n      13.3  Healthcare Products ...................................................................................................................... 129\n      13.4  Trademarks.................................................................................................................................... 132\n", "page_number": 3, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8139435414884517, "height": 0.7288280581693756, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-3-1", "text": "ii\n", "page_number": 3, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.946535500427716, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9542343883661248, "height": 0.007698887938408894, "width": 0.010278113663845234}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-3-2", "text": "ii", "page_number": 3, "bounding_box": {"top_left_x": 0.4957678355501814, "top_left_y": 0.946535500427716, "lower_right_x": 0.5042321644498187, "lower_right_y": 0.9542343883661248, "height": 0.007698887938408894, "width": 0.008464328899637275}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-4-0", "text": "14. INFORMATION ON THE SELLING SHAREHOLDER .................................................................... 133\n15. GENERAL INFORMATION ON THE COMPANY AND DERMAPHARM .................................... 134\n    15.1  Formation, Incorporation, Commercial Name and Registered Office ........................................... 134\n    15.2  Fiscal Year and Duration............................................................................................................... 134\n    15.3  History of Dermapharm ................................................................................................................ 134\n    15.4  Corporate Purpose ......................................................................................................................... 135\n    15.5  Group Structure ............................................................................................................................. 135\n    15.6  Significant Subsidiaries ................................................................................................................. 135\n    15.7  Auditor .......................................................................................................................................... 136\n    15.8  Announcements and Paying Agent ............................................................................................... 136\n16. DESCRIPTION OF THE COMPANY\u2019S SHARE CAPITAL AND APPLICABLE\n    REGULATIONS ....................................................................................................................................... 137\n    16.1  Current Share Capital; Shares ....................................................................................................... 137\n    16.2  Development of the Share Capital................................................................................................. 137\n    16.3  Authorized Capital ........................................................................................................................ 137\n    16.4  Conditional Capital ....................................................................................................................... 138\n    16.5  Authorization to Purchase and Sell Treasury Shares..................................................................... 139\n    16.6  General Provisions Governing a Liquidation of the Company ..................................................... 140\n    16.7  General Provisions Governing a Change in the Share Capital ...................................................... 140\n    16.8  General Provisions Governing Subscription Rights ...................................................................... 140\n    16.9  Exclusion of Minority Shareholders.............................................................................................. 141\n    16.10 Shareholder Notification Requirements; Mandatory Takeover Bids; Directors\u2019 Dealings ........... 142\n    16.11 Short Selling Regulation (Ban on Naked Short-Selling) ............................................................... 144\n17. DESCRIPTION OF THE GOVERNING BODIES OF THE COMPANY .......................................... 145\n    17.1  Overview ....................................................................................................................................... 145\n    17.2  Management Board ....................................................................................................................... 147\n    17.3  Supervisory Board ......................................................................................................................... 150\n    17.4  Shareholdings of the Members of the Management Board and the Supervisory Board ................ 154\n    17.5  Certain Information Regarding the Members of the Management Board and the Supervisory\n          Board ............................................................................................................................................. 154\n    17.6  Shareholders\u2019 Meeting .................................................................................................................. 155\n    17.7  Corporate Governance .................................................................................................................. 157\n18. CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS .................................... 159\n    18.1  Relationships and Transactions with Related Parties .................................................................... 159\n    18.2  Relationships with Members of the Management Board and Supervisory Board ......................... 161\n19. UNDERWRITING .................................................................................................................................... 163\n    19.1  General .......................................................................................................................................... 163\n    19.2  Underwriting Agreement............................................................................................................... 163\n    19.3  Commissions ................................................................................................................................. 164\n    19.4  Greenshoe Option and Securities Loan ......................................................................................... 164\n    19.5  Termination; Indemnification ....................................................................................................... 164\n    19.6  Selling Restrictions ....................................................................................................................... 165\n    19.7  Other Interests of the Sole Bookrunner in the Offering ................................................................ 166\n", "page_number": 4, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8122326775021386, "height": 0.7271171941830624, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-4-1", "text": "", "page_number": 4, "bounding_box": {"top_left_x": 0.4939540507859734, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.013905683192261209}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-5-0", "text": "20. TAXATION IN THE FEDERAL REPUBLIC OF GERMANY ........................................................... 167\n    20.1  Taxation of the Company .............................................................................................................. 167\n    20.2  Taxation of Shareholders .............................................................................................................. 169\n    20.3  Taxation of Dividends of Shareholders with a Tax Residence in Germany .................................. 171\n    20.4  Taxation of Dividends of Shareholders without a Tax Residence in Germany............................. 174\n    20.5  Taxation of Capital Gains ............................................................................................................. 174\n    20.6  Special Treatment of Companies in the Financial and Insurance Sectors and Pension Funds ...... 176\n    20.7  Inheritance and Gift Tax ............................................................................................................... 176\n    20.8  The Proposed Financial Transactions Tax .................................................................................... 177\n    20.9  Other Taxes ................................................................................................................................... 177\n21. TAXATION IN THE GRAND DUCHY OF LUXEMBOURG ............................................................. 178\n    21.1  Withholding Taxes ........................................................................................................................ 178\n    21.2  Taxation of Dividend Income ....................................................................................................... 178\n    21.3  Taxation of Capital Gains ............................................................................................................. 180\n    21.4  Net Wealth Tax ............................................................................................................................. 181\n    21.5  Value Added Tax .......................................................................................................................... 181\n    21.6  Other Taxes ................................................................................................................................... 182\n22. FINANCIAL INFORMATION ................................................................................................................. F-1\n23. GLOSSARY ............................................................................................................................................... G-1\n24. RECENT DEVELOPMENTS AND OUTLOOK ................................................................................... O-1\n    24.1  Recent Developments................................................................................................................... O-1\n    24.2  Outlook......................................................................................................................................... O-2\n", "page_number": 5, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4516680923866553, "height": 0.36655260906757914, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-5-1", "text": "", "page_number": 5, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.014510278113663844}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-0", "text": "I.   SUMMARY OF THE PROSPECTUS\n", "page_number": 6, "bounding_box": {"top_left_x": 0.3524788391777509, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.314993954050786}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-1", "text": "         Summaries are made up of disclosure requirements known as elements (\u201cElements\u201d). These Elements\nare numbered in Sections A \u2212 E (A.1 \u2212 E.7). This summary contains all the Elements required to be included in\na summary for this type of security and issuer. Because some Elements are not required to be addressed, there\nmay be gaps in the numbering sequence of the Elements. Even though an Element may be required to be\ninserted in the summary because of the type of security and issuer, it is possible that no relevant information can\nbe given regarding the Element. In such cases, the summary includes a short description of the Element with the\nwords \u201cnot applicable\u201d.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-2", "text": "A \u2013 Introduction and Warnings\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.218562874251497, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.2296834901625321, "height": 0.011120615911035081, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-3", "text": "This summary should be read as an introduction to this prospectus (the\n\u201cProspectus\u201d). Any decision to invest in the securities should be based on\nconsideration of this Prospectus as a whole by the investor.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2788708297690334, "height": 0.0397775876817793, "width": 0.5804111245465537}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-4", "text": "A.1 Warnings.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.23909324208725408, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.25021385799828916, "height": 0.011120615911035081, "width": 0.11124546553808948}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-5", "text": "If any claims are asserted before a court of law based on the information contained in\nthis Prospectus, the investor appearing as plaintiff may have to bear the costs of\ntranslating this Prospectus prior to the commencement of the court proceedings\npursuant to the national legislation of the member states of the European Economic\nArea (\u201cEEA Member States\u201d).\n", "page_number": 6, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.28699743370402053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3541488451668092, "height": 0.06715141146278869, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-6", "text": "Dermapharm Holding SE (the \u201cCompany\u201d and, together with its direct and indirect\nconsolidated subsidiaries, \u201cDermapharm\u201d), together with Joh. Berenberg, Gossler &\nCo. KG, Hamburg, Germany (\u201cBerenberg\u201d), and ODDO BHF Aktiengesellschaft,\nFrankfurt am Main, Germany (\u201cODDO BHF\u201d and, together with Berenberg, the\n\u201cOffering Banks\u201d), assume responsibility for the contents of this summary,\nincluding any translations thereof, pursuant to Section 5 para. 2b no. 4 of the German\nSecurities Prospectus Act (Wertpapierprospektgesetz). Those persons who are\nresponsible for the summary, including any translations thereof, or for its issuance\n(von denen der Erlass ausgeht), can be held liable, but only if this summary is\nmisleading, inaccurate or inconsistent when read together with the other parts of the\nProspectus or if it does not provide, when read together with the other parts of the\nProspectus, all necessary key information.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5248075278015398, "height": 0.1625320786997434, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-7", "text": "Information         Not applicable. Consent by the Company regarding the use of this Prospectus for\nregarding the       subsequent resale or placement of shares has not been granted.\nsubsequent use of\nthe prospectus.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5333618477331052, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.5872540633019675, "height": 0.053892215568862256, "width": 0.711608222490931}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-8", "text": "A.2\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5333618477331052, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.544054747647562, "height": 0.010692899914456766, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-9", "text": "a\n", "page_number": 6, "bounding_box": {"top_left_x": 0.8706166868198307, "top_left_y": 0.5363558597091531, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.544054747647562, "height": 0.007698887938408894, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-10", "text": "B\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.13180169286577992, "lower_right_y": 0.6124893071000855, "height": 0.010692899914456766, "width": 0.011487303506650531}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-11", "text": "B \u2013 Issuer\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1336154776299879, "top_left_y": 0.6017964071856288, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.6124893071000855, "height": 0.010692899914456766, "width": 0.05985489721886336}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-12", "text": "B.1 Legal and       The Company\u2019s legal name is Dermapharm Holding SE. The Company is the holding\n    commercial name company of Dermapharm and primarily operates under the commercial name\n    of the issuer.  \u201cDermapharm\u201d. Dermapharm also operates under additional commercial names, in\n                    particular \u201cmibe\u201d, \u201cH\u00fcbner\u201d and \u201caxicorp\u201d, as well as individual brands for its\n                    specific pharmaceuticals and other healthcare products.\nB.2 Domicile, legal     The Company has its registered office at Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald,\n    form and            Germany (telephone: +49 (0) 89 6 41 86 0) and is registered in the commercial\n    legislation under   register of the local court (Amtsgericht) of Munich, Germany, under docket number\n    which the issuer    HRB 234575. The Company is organized under European law as a European\n    operates and its    company (Societas Europaea (SE)) and therefore subject to European legislations on\n    country of          such companies, especially to Council Regulation (EC) no. 2157/2001 of October 8,\n    incorporation.      2001 on the statute for a European company (SE), as amended. As a company\n                        registered in Germany, the Company is also subject to German law.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8075278015397775, "height": 0.18520102651839176, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"issuer_name": ["Dermapharm Holding SE"], "country_of_origin/headquarters": ["Germany"], "country_of_registration/incorporation": ["German"]}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-6-13", "text": "S-1\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9405474764756202, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-7-0", "text": "B.3 Operations and       Dermapharm is a leader in branded pharmaceuticals for selected markets in Germany\n    principal business   with an expanding international footprint. It applies formulation and development\n    activities of the    expertise to the development, manufacture and marketing of a broad assortment of\n    issuer and           branded pharmaceuticals that are no longer patent protected, holding approximately\n    principal markets    900 marketing authorizations (Arzneimittelzulassungen) for more than 200 active\n    in which the         pharmaceutical ingredients (\u201cAPIs\u201d). Dermapharm also offers a growing portfolio of\n    issuer competes.     other healthcare products such as cosmetics, food supplements, dietary products and\n                         medical devices. In addition, Dermapharm leverages its direct marketing expertise by\n                         importing pharmaceuticals from other EEA Member States for resale in the German\n                         market in order to profit from pricing differences between these markets.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-7-1", "text": "Dermapharm operates primarily in Germany, Europe\u2019s leading economy and, with\naggregate sales of \u20ac36.7 billion in the fiscal year ended December 31, 2016 (based on\nex-factory prices (Herstellerabgabepreise)), also its largest pharmaceuticals market\n(source: IQVIA). The German pharmaceuticals market benefits from certain general\ntrends, including the ageing of the population, chronification of diseases, increasing\nhealth awareness and higher spending on non-prescription pharmaceuticals sold over\nthe counter (\u201cOTC\u201d) and other healthcare products, reflecting increased\nself-medication. Dermapharm believes that it benefits from these trends and will\ncontinue to do so in the future. Dermapharm\u2019s sales in Germany accounted for\napproximately 92.6% of Dermapharm\u2019s revenues in the nine-month period ended\nSeptember 30, 2017. Dermapharm is also active in Austria and Switzerland and sales\nin these countries accounted for approximately 4.9% of Dermapharm\u2019s revenues in\nthe same nine-month period. In the future, Dermapharm plans to introduce selected\nproducts from its existing product portfolio as well as new product developments to\nadditional markets.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.432420872540633, "height": 0.20359281437125745, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-7-2", "text": "Pharmaceuticals and Other Healthcare Products\n", "page_number": 7, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.44097519247219846, "lower_right_x": 0.652962515114873, "lower_right_y": 0.4550898203592814, "height": 0.014114627887082953, "width": 0.35368802902055624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-7-3", "text": "Dermapharm\u2019s pharmaceuticals and other healthcare products cover multiple product\nareas with a broad assortment of products marketed under well-known brands.\nDermapharm focuses on the development, manufacture and marketing of\npharmaceuticals and other healthcare products for specifically targeted markets, in\nwhich Dermapharm generally holds a significant market share and generates\nattractive margins. Dermapharm is the German market leader in prescription vitamins\nthrough its vitamin D preparation Dekristol\u00ae 20,000 I.E. (based on number of\nprescriptions and revenues, excluding hospital sales (sources: INSIGHT Health;\nCompany information)). Its broad product assortment has also made Dermapharm the\nGerman market leader for prescription dermatologicals and systemic corticoids (in\neach case based on number of prescriptions and revenues for APIs offered by\nDermapharm, excluding hospital sales (sources: INSIGHT Health; Company\ninformation)). With regard to OTC products, Dermapharm is able to leverage its\ndevelopment and manufacturing know-how with prescription pharmaceuticals to\nobtain required marketing authorizations quickly and cost-efficiently. Other\nhealthcare products may be sold without marketing authorizations and benefit from\nDermapharm\u2019s long-standing relationships with pharmacies based on its\npharmaceuticals business and well-known brands. In the nine-month period ended\nSeptember 30, 2017, pharmaceuticals and other healthcare products accounted for\n46.8% of Dermapharm\u2019s revenues and 93.8% of its earnings before interest, taxes\ndepreciation and amortization (\u201cEBITDA\u201d).\n", "page_number": 7, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.46150556030795553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7493584260051326, "height": 0.28785286569717705, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-7-4", "text": "S-2\n", "page_number": 7, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9405474764756202, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-0", "text": "Parallel Imports\n", "page_number": 8, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.12152357920193474}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-1", "text": "Dermapharm\u2019s parallel import business, which operates under the well-known\n\u201caxicorp\u201d brand, benefits from the statutory requirement that a minimum of 5% of all\nprescription pharmaceuticals sold within the statutory healthcare system in Germany\nmust be imported from other EEA Member States to help reduce healthcare costs.\nThe actual market share of parallel imports in Germany exceeds this quota and\namounted to approximately 8.6% in the fiscal year ended December 31, 2016\n(source: INSIGHT Health). In the same fiscal year, Dermapharm covered\napproximately 89% of prescription pharmaceuticals available for sale in the German\nparallel import market and was the fourth largest parallel importer in Germany\n(source: INSIGHT Health). Its strong market expertise and stringent planning, which\nis continuously driven forward by both sales and sourcing experts, allow\nDermapharm to ensure an appropriate product mix and thereby maintain its targeted\nprofit margin. Parallel imports, including certain OTC products marketed by axicorp\nGmbH and its direct and indirect subsidiaries, accounted for 53.2% of Dermapharm\u2019s\nrevenues and 6.1% of its EBITDA in the nine-month period ended September 30,\n2017.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.10650128314798973, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32164242942686055, "height": 0.21514114627887082, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-2", "text": "In the fiscal year ended December 31, 2016, Dermapharm generated revenues of\n\u20ac444.5 million and EBITDA of \u20ac102.7 million. In the nine-month period ended\nSeptember 30, 2017, Dermapharm\u2019s revenues amounted to \u20ac349.7 million and its\nEBITDA totaled \u20ac82.9 million.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3853721129170231, "height": 0.05389221556886231, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-3", "text": "Dermapharm believes that the development of its business is supported by the\nfollowing strengths:\n", "page_number": 8, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.393071000855432, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.42087254063301965, "height": 0.027801539777587647, "width": 0.5798065296251511}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-4", "text": "\uf0b7   Leading pharmaceuticals manufacturer in attractive, selected product areas with\n    a broad product diversification.\n\uf0b7   Strategic focus on selected markets with particularly attractive margins.\n\uf0b7   Successful track record of product developments underpinned by operational\n    excellence and \u201call under one roof\u201d approach.\n\uf0b7   Effective sales organization.\n\uf0b7   Broad parallel import product offering sourced and marketed by a highly\n    integrated organization.\n\uf0b7   Strong profitability with credible cash flow generation and significant dividend\n    capacity.\n\uf0b7   Highly experienced and committed management team with a proven track\n    record.\nThe key elements of Dermapharm\u2019s strategy are:\n", "page_number": 8, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.43071000855431996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6625320786997434, "height": 0.23182207014542344, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-5", "text": "\uf0b7   Dermapharm seeks to expand its product portfolio through the introduction of\n    new products developed in-house.\n\uf0b7   Dermapharm plans to increase its international footprint.\n\uf0b7   Dermapharm intends to continue its track record of successful acquisitions to\n    further strengthen growth and profitability.\n\uf0b7   Dermapharm seeks to increase its sales of OTC and other healthcare products\n    through focused marketing efforts.\n\uf0b7   Dermapharm plans to further optimize operations and market analysis for its\n    parallel import business.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6702309666381523, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8246364414029085, "height": 0.1544054747647562, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-8-6", "text": "S-3\n", "page_number": 8, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-0", "text": "B.4a Most significant\n", "page_number": 9, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08597091531223268, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.09923011120615911, "height": 0.013259195893926434, "width": 0.154776299879081}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-1", "text": "The pharmaceuticals market is currently impacted by a\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08597091531223268, "lower_right_x": 0.6692865779927448, "lower_right_y": 0.09923011120615911, "height": 0.013259195893926434, "width": 0.37001209189842804}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-2", "text": "a number of key trends, which\n", "page_number": 9, "bounding_box": {"top_left_x": 0.6735187424425635, "top_left_y": 0.08597091531223268, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.09923011120615911, "height": 0.013259195893926434, "width": 0.20495767835550183}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-3", "text": "a\n", "page_number": 9, "bounding_box": {"top_left_x": 0.6692865779927448, "top_left_y": 0.0885372112917023, "lower_right_x": 0.6729141475211609, "lower_right_y": 0.0962360992301112, "height": 0.007698887938408894, "width": 0.0036275695284160303}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-4", "text": "a Most significa\n  recent trends\n", "page_number": 9, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.09965782720273739, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.111633875106929, "height": 0.011976047904191614, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-5", "text": "The pharmaceuticals market is currently impacted by a number of key trends, which\ntogether influence the performance of individual pharmaceuticals manufacturers such\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.09965782720273739, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11291702309666382, "height": 0.013259195893926434, "width": 0.5810157194679566}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-6", "text": "affecting the\n", "page_number": 9, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.11334473909324208, "lower_right_x": 0.2460701330108827, "lower_right_y": 0.12660393498716851, "height": 0.013259195893926434, "width": 0.09189842805320436}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-7", "text": "as Dermapharm, in particular:\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.11334473909324208, "lower_right_x": 0.5024183796856106, "lower_right_y": 0.12660393498716851, "height": 0.013259195893926434, "width": 0.20314389359129387}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-8", "text": "affecting the\nissuer and the\n", "page_number": 9, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.1270316509837468, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.1390076988879384, "height": 0.0119760479041916, "width": 0.1021765417170496}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-9", "text": "Demographic Developments and Chronification of Diseases\nWhile the global population is growing rapidly, there is a significant disparity\nbetween developing countries and the most highly developed countries, including\nGermany, where birth rates are at best stable. At the same time, the average life span\nis increasing, leading to a growing share of elderly people. The ageing of the\npopulation also increases the prevalence of various age-related diseases and\nconditions. On average, elderly people are more likely to administer several\npharmaceuticals at the same time. In addition, medical advances increase the total\nnumber of conditions and diseases that can be addressed with appropriate medication.\nDermapharm believes that the ageing of the population and the corresponding trend\ntowards polypharmacy will positively affect demand for its pharmaceuticals and\nother healthcare products.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.1343028229255774, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3045337895637297, "height": 0.17023096663815226, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-10", "text": "industries in\n", "page_number": 9, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.1407185628742515, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.15269461077844312, "height": 0.011976047904191628, "width": 0.09250302297460702}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-11", "text": "industries in\nwhich it operates.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.1544054747647562, "lower_right_x": 0.282950423216445, "lower_right_y": 0.16766467065868262, "height": 0.013259195893926434, "width": 0.12817412333736397}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-12", "text": "Increased Health Awareness and Self-Medication\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3109495295124038, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.3242087254063302, "height": 0.013259195893926434, "width": 0.35852478839177754}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-13", "text": "Increased availability and access to medical information lead to increasing health\nawareness. The number of people actively utilizing the Internet to gather information\non diseases and medical conditions is constantly growing. Through online research,\npatients can easily access various data on diseases, treatment options, relevant\npharmaceuticals, pharmaceuticals manufacturers as well as patient reviews. The\nincreased importance of the Internet also affects roads to market for pharmaceuticals.\nIncreased health awareness drives a general trend towards self-medication\n(i.e., patients administering OTC and other healthcare products for actual or\nperceived diseases and conditions, for preventive treatment as well as to increase\ntheir general well-being themselves). This trend has resulted in growing demand for\nsuch OTC and other healthcare products (e.g., dietary products and food\nsupplements). Dermapharm believes that increased health awareness and a trend\ntowards self-medication will positively affect demand for its OTC and other\nhealthcare products.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3319076133447391, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.523524379811805, "height": 0.19161676646706588, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-14", "text": "B.5 The group and         The Company is the holding company of Dermapharm. Dermapharm\u2019s business is\n    the issuer\u2019s          conducted by Dermapharm Aktiengesellschaft (\u201cDermapharm AG\u201d) and its various\n    position within       subsidiaries. The group of consolidated companies comprising Dermapharm includes\n    the group.            all companies whose financial and business policy can be controlled by the\n                          Company, either directly or indirectly, and the equity interests of Dermapharm whose\n                          financial and business policy can be influenced by the Company to a significant\n                          extent. As of the date of this Prospectus, Dermapharm comprises 26 companies, of\n                          which twelve are based in Germany.\nB.6 Name of persons       The Company\u2019s sole shareholder is Themis Beteiligungs-Aktiengesellschaft (the\n    who, directly or      \u201cSelling Shareholder\u201d). The shareholders of the Selling Shareholder are\n    indirectly, have a    Mr. Wilhelm Beier, who holds 80.00% of the shares of the Selling Shareholder as of\n    notifiable interest   the date of this Prospectus, Ms. Elisabeth Beier, who holds 19.26% of the shares of\n    in the issuer\u2019s       the Selling Shareholder as of the date of this Prospectus, and Mr. Michael Beier, who\n    capital or voting     holds the remaining 0.74% of the shares of the Selling Shareholder as of the date of\n    rights.               this Prospectus.\n     Different voting     Not applicable. All of the Company\u2019s shares confer the same voting rights.\n     rights of major\n     shareholders of\n     the issuer.\n     Direct or indirect   The Company is directly controlled by the Selling Shareholder due to its ownership\n     control.             of all voting rights in the Company and, as a result, its power to govern the financial\n                          and operating policies of the Company. The Selling Shareholder, in turn, is directly\n                          controlled by Mr. Wilhelm Beier due to his ownership of the majority of the voting\n                          rights in the Selling Shareholder and, as a result, his power to govern the financial\n                          and operating policies of the Selling Shareholder.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5299401197604791, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8943541488451668, "height": 0.3644140290846878, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-9-15", "text": "S-4\n", "page_number": 9, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9405474764756202, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-10-0", "text": "B.7 Selected historical The financial information contained in the following tables and discussion is taken or\n    key financial       derived from the audited consolidated financial statements of Dermapharm AG, the\n    information.        former parent entity of Dermapharm, as of and for the fiscal years ended\n                        December 31, 2016, 2015 and 2014, and the unaudited condensed consolidated\n                        interim financial statements of Dermapharm AG as of and for the nine-month period\n                        ended September 30, 2017 as well as the Company\u2019s audited individual financial\n                        statements as of September 30, 2017 and for the period from July 12, 2017 to\n                        September 30, 2017. Additional financial information relating to certain operational\n                        information is taken or derived from Dermapharm\u2019s accounting records or internal\n                        reporting system. The audited consolidated financial statements and the audited\n                        individual financial statements were prepared in accordance with International\n                        Financial Reporting Standards, as adopted by the European Union (\u201cIFRS\u201d). The\n                        unaudited condensed consolidated interim financial statements were prepared in\n                        accordance with IAS 34.\n", "page_number": 10, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.2754491017964072, "height": 0.19033361847733105, "width": 0.7605804111245466}, "blob_type": "paragraph", "predictions": {}, "annotations": {"periods_of_audited_financial_statements": ["forthefiscalyearsendedDecember 31, 2016, 2015 and 2014,"], "audited_financial_statements": ["from the audited consolidated financial statements of Dermapharm AG, theformerparententityofDermapharm,asofandforthefiscalyearsendedDecember 31, 2016, 2015 and 2014,"], "accounting_standards": ["IFRS"], "unaudited_interim_financial_statements": ["unaudited condensed consolidatedinterim financial statements"], "periods_of_unaudited_interim_fs": ["for the nine-month periodended September 30, 2017"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-10-1", "text": "Warth & Klein Grant Thornton AG Wirtschaftspr\u00fcfungsgesellschaft,\nJohannstra\u00dfe 39, 40476 Dusseldorf, Germany, has audited and issued an unqualified\naudit opinion with respect to Dermapharm AG\u2019s consolidated financial statements as\nof and for the fiscal years ended December 31, 2016, 2015 and 2014 as well as the\nCompany\u2019s audited individual financial statements as of September 30, 2017 and for\nthe period from July 12, 2017 to September 30, 2017. The aforementioned audited\nfinancial statements and the independent audit opinions thereon, and\nDermapharm AG\u2019s unaudited condensed consolidated interim financial statements as\nof and for the nine-month period ended September 30, 2017 are included in this\nProspectus.\n", "page_number": 10, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.1372968349016253, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-10-2", "text": "Where financial information in the following tables is labelled \u201caudited\u201d, this means\nthat it has been taken from the audited consolidated financial statements mentioned\nabove. The label \u201cunaudited\u201d is used in the following tables to indicate financial\ninformation that has not been taken from the audited consolidated financial\nstatements mentioned above, but was taken either from the unaudited condensed\ninterim consolidated financial statements mentioned above, or Dermapharm\u2019s\ninternal reporting system, or has been calculated based on figures from the\naforementioned sources.\n", "page_number": 10, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5337895637296834, "height": 0.10650128314798968, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-10-3", "text": "All of the financial information presented in the text and tables below is shown in\nmillions of Euro (in \u20ac million), except as otherwise stated. Certain financial\ninformation (including percentages) in the following tables has been rounded\naccording to established commercial standards. As a result, the aggregate amounts\n(sum totals or sub totals or differences or if numbers are put in relation) in the\nfollowing tables may not correspond in all cases to the aggregate amounts of the\nunderlying (unrounded) figures appearing elsewhere in this Prospectus. Furthermore,\nthese rounded figures may not add up exactly to the totals contained in the relevant\ntables. Financial information presented in parentheses denotes the negative of such\nnumber presented. In respect of financial information set out in this Prospectus, a\ndash (\u201c\u2013\u201d) signifies that the relevant figure is not available, while a zero (\u201c0.0\u201d)\nsignifies that the relevant figure is available but has been rounded to zero.\n", "page_number": 10, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5436270316509837, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7082976903336184, "height": 0.16467065868263475, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-10-4", "text": "S-5\n", "page_number": 10, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-11-0", "text": "Selected Consolidated Financial Information of Dermapharm AG\nConsolidated Statement of Comprehensive Income\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.594316807738815, "lower_right_y": 0.11976047904191617, "height": 0.034644995722840036, "width": 0.4740024183796856}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-11-1", "text": "                                                                                     For the fiscal year             For the nine-month period\n                                                                                    ended December 31,                 ended September 30,\n                                                                         2014               2015           2016        2016              2017\n                                                                                         (audited)                           (unaudited)\n                                                                                       (in \u20ac million)                       (in \u20ac million)\n Revenue ...................................................................................\n                                                                           391.3                 384.8      444.5        319.2          349.7\n Increase/decrease in finished goods and\n   work-in-process ....................................................................\n                                                                               8.3                  2.9        1.0         4.1             0.4\n Own work capitalized ..............................................................\n                                                                               8.5                  8.0        8.3         5.4             8.0\n Other operating income ............................................................\n                                                                               6.2                  9.9        9.9         5.2             4.1\n Cost of material ........................................................................\n                                                                         (237.1)                (215.9)    (252.8)     (181.5)         (196.0)\n Personnel expenses ..................................................................\n                                                                           (57.7)                (55.7)     (58.7)      (42.0)          (46.5)\n Depreciation and amortization .................................................\n                                                                           (28.3)                (22.9)     (14.4)      (10.3)          (11.2)\n                                                                           (48.0)\n Other operating expenses .........................................................              (50.3)     (51.0)      (35.1)          (38.1)\n Operating income ...................................................................\n                                                                              43.3                 60.8       86.8        65.1            70.4\n Result from investments measured at\n   equity....................................................................................\n                                                                               0.9                  1.0        1.5          1.1            1.2\n Financial income ......................................................................\n                                                                               3.3                  9.4        7.3          4.1            3.3\n                                                                           (12.0)\n Financial expenses ...................................................................          (15.8)     (12.7)        (8.4)          (7.8)\n Earnings before taxes .............................................................\n                                                                              35.5                 55.3       82.9         61.8           67.2\n                                                                             (2.2)\n Income taxes ............................................................................        (2.9)      (5.9)        (6.0)          (4.3)\n                                                                              33.2\nProfit/loss for the period ..........................................................              52.4       77.0         55.9           62.9\n", "page_number": 11, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4268605645851155, "height": 0.3006843455945253, "width": 0.7642079806529626}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-11-2", "text": "Consolidated Statement of Financial Position\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.44781864841745084, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.4602224123182207, "height": 0.01240376390076986, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-11-3", "text": "                                                                                                   As of                        As of\n                                                                                               December 31,                September 30,\n                                                                           2014                     2015        2016             2017\n                                                                                                 (audited)                   (unaudited)\n                                                                                               (in \u20ac million)               (in \u20ac million)\nAssets\n Intangible assets .......................................................................\n                                                                                  71.7                  68.0        70.0            129.7\n Goodwill ..................................................................................\n                                                                                  21.6                  16.4        17.0             17.0\n Property, plant and equipment .................................................  56.5                  53.4        53.4             52.9\n Investments measured at equity ...............................................     1.6                  2.7         3.2              4.4\n Investments ..............................................................................\n                                                                                    0.5                  0.2         0.3              0.2\n Other non-current financial assets ...........................................     9.2                 13.8        10.6             22.4\n                                                                                    1.0\n Deferred tax assets ...................................................................                 0.0         0.2              1.7\n Total non-current assets ........................................................\n                                                                                162.1                  154.6       154.7            228.3\n Inventories ...............................................................................\n                                                                                  71.5                  77.0        84.8             81.9\n Trade accounts receivable........................................................22.8                  17.4        26.3             34.7\n Other current financial assets ...................................................\n                                                                                  58.8                  42.5        40.0             68.7\n Other current assets .................................................................\n                                                                                    3.0                  1.4         1.7              2.0\n Income tax receivables \u2013 current .............................................     0.7                  1.0         0.4              0.4\n Cash and cash equivalents .......................................................11.6                   2.8         3.8             12.6\n                                                                                168.5\n Total current assets ...............................................................                  142.1       157.0            200.3\n                                                                                330.6\nTotal assets ...............................................................................           296.7       311.7            428.6\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7639007698887939, "height": 0.29897348160821213, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-11-4", "text": "S-6\n", "page_number": 11, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9405474764756202, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-12-0", "text": "                                                                                                  As of                            As of\n                                                                                              December 31,                    September 30,\n                                                                          2014                     2015        2016                 2017\n                                                                                                (audited)                       (unaudited)\n                                                                                              (in \u20ac million)                   (in \u20ac million)\nEquity and liabilities\n Issued capital ...........................................................................\n                                                                                   1.3                   1.3            1.3               1.3\n Capital reserves .......................................................................\n                                                                                   0.3                   0.3            0.3               0.3\n Retained earnings ....................................................................\n                                                                                 28.6                   39.5           56.3              70.0\n Other reserves ..........................................................................\n                                                                                (1.9)                    0.1          (1.0)             (2.1)\n                                                                                   5.7\n Non-controlling interests .........................................................                     3.3            3.9                 \uf02d\n Total equity ............................................................................\n                                                                                 34.0                   44.4           60.8              69.5\n Defined benefit obligations and other\n    accrued employee benefits ...................................................12.4                  12.1        13.3                 13.3\n Other provisions ......................................................................\n                                                                                   0.1                    \uf02d           \uf02d                    \uf02d\n Financial liabilities ..................................................................\n                                                                               161.5                  151.1        96.9                235.4\n Other non-current financial liabilities ......................................    9.9                 14.1        10.5                  8.1\n Other non-current liabilities .....................................................\n                                                                                 15.6                  13.3        11.5                 10.4\n                                                                                     \uf02d\n Deferred tax liabilities .............................................................                 0.2         3.4                  5.8\n Total non-current liabilities ..................................................\n                                                                               199.6                  190.7       135.5                272.9\n Other provisions ......................................................................\n                                                                                   6.1                  6.4         7.0                  6.0\n Financial liabilities ..................................................................\n                                                                                 20.4                  24.9        65.9                 43.4\n Trade accounts payable ...........................................................\n                                                                                 27.4                  18.1        24.5                 19.3\n Other current financial liabilities .............................................\n                                                                                 30.6                   2.4         4.3                  2.1\n Other current liabilities ............................................................\n                                                                                 11.4                   8.2        11.0                 11.5\n                                                                                   1.0\n Income tax liabilities ...............................................................                 1.5         2.8                  3.9\n                                                                                 97.0\n Total current liabilities ..........................................................                  61.6       115.4                 86.2\n                                                                               330.6\nTotal equity and liabilities.......................................................                   296.7       311.7                428.6\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47177074422583404, "height": 0.3866552609067579, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-12-1", "text": "Consolidated Statement of Cash Flows\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4991445680068435, "lower_right_x": 0.3893591293833132, "lower_right_y": 0.5119760479041916, "height": 0.01283147989734812, "width": 0.26844014510278114}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-12-2", "text": "                                                                                                                     As of and for the\n                                                                       As of and for the fiscal year             nine-month period ended\n                                                                          ended December 31,                         September 30,(1)\n                                                                   2014            2015             2016           2016             2017\n                                                                                (audited)                               (unaudited)\n                                                                              (in \u20ac million)                           (in \u20ac million)\nNet cash flows from operating activities ..................................\n                                                                          54.3               40.4     76.8            47.6           62.6\nNet cash flows used in investing activities ...............................\n                                                                        (21.9)              (0.9)   (12.3)          (11.7)         (84.9)\nNet cash from/used in financing activities ...............................  3.0            (55.6)   (55.9)          (47.9)           14.1\nNet increase/decrease in cash, cash\n  equivalents and bank overdrafts ....................................... 35.3             (16.2)          8.6      (12.0)          (8.2)\nCash, cash equivalents and bank\n  overdrafts(2) ..........................................................................\n                                                                            6.5             (9.6)     (1.1)         (21.6)          (9.3)\n", "page_number": 12, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.5171086398631308, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6877673224978614, "height": 0.1706586826347306, "width": 0.7551390568319227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-12-3", "text": "(1) Due to the termination of the Profit Transfer Agreement with effect from the end of December 31, 2017,\n    Dermapharm AG has changed the composition of its consolidated statement of cash flows, which is already reflected in\n    the financial information in the consolidated statement of cash flows shown in Dermapharm AG\u2019s unaudited condensed\n    consolidated interim financial statements for the nine-month period ended September 30, 2017. As a result, certain\n    comparable financial information with respect to the fiscal year ended December 31, 2016 shown in the consolidated\n    statement of cash flows in the consolidated financial statements for the fiscal year ended December 31, 2017 will differ\n    from the financial information shown in the consolidated statement of cash flows in Dermapharm AG\u2019s consolidated\n    financial statements for the fiscal years ended December 31, 2016, 2015 and 2014.\n(2) As at the end of the relevant period.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8105218135158255, "height": 0.11291702309666385, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-12-4", "text": "S-7\n", "page_number": 12, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9405474764756202, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-0", "text": "Selected Financial Information of the Company\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.3440145102781137}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-1", "text": "                                                                                          As of and for the period from July 12 to September 30\n                                                                                                                    2017\n                                                                                                             (audited and in \u20ac)\nTotal assets ...............................................................................                                          119,973.93\nTotal equity ..............................................................................                                           119,973.93\nNet loss.....................................................................................                                            (26.07)\nNet change in cash and cash equivalents .................................                                                              89,223.93\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.10564585115483319, "lower_right_x": 0.875453446191052, "lower_right_y": 0.19803250641573994, "height": 0.09238665526090675, "width": 0.7503022974607014}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-2", "text": "Additional Key Performance Indicators\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.2386655260906758, "height": 0.013259195893926434, "width": 0.2859733978234583}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-3", "text": "The Company\u2019s management board uses EBITDA as a key performance indicator in order to assess the success\nof Dermapharm\u2019s business. In addition, Dermapharm believes that the working capital, leverage ratio and equity\nwill be helpful for investors when assessing the performance and financial position of Dermapharm.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24593669803250642, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2865697177074423, "height": 0.04063301967493585, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-4", "text": "The following table provides additional operating and financial information with respect to Dermapharm for the\nperiods and dates indicated:\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32078699743370404, "height": 0.026946107784431128, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-5", "text": "                                                                           As of and for the fiscal year         As of and for the nine-month\n                                                                               ended December 31,                period ended September 30,\n                                                                       2014             2015            2016         2016             2017\n                                                                                   (audited and                           (unaudited)\n                                                                                    in \u20ac million,                        (in \u20ac million,\n                                                                            unless otherwise specified)           unless otherwise specified)\nRevenue....................................................................................\n                                                                         391.3                384.8      444.5         319.2          349.7\nRevenue growth (unaudited and in %)(1) ..................................       \uf02d              (1.7)      15.5             \uf02d            9.6\nEBIT (unaudited) .....................................................................\n                                                                           44.2                 61.7      88.3          66.1           71.7\nEBIT margin (unaudited and in %)(2) .......................................11.3                 16.0      19.9          20.7           20.5\nEBITDA (unaudited) ................................................................\n                                                                           72.5                 84.6     102.7          76.4           82.9\nEBITDA margin (unaudited and in %)(3) .................................    18.5                 22.0      23.1          23.9           23.7\nWorking capital (unaudited)(4) .................................................\n                                                                           58.5                 69.5      77.3             \uf02d           87.8\nLeverage ratio (unaudited and in %)(4) ....................................\n                                                                         744.9                461.6      305.4             \uf02d          397.7\nEquity ratio (unaudited and in %)(4).........................................8.6                13.9      18.3             \uf02d           16.2\n", "page_number": 13, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.3246364414029085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.523524379811805, "height": 0.19888793840889651, "width": 0.7551390568319227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-6", "text": "(1)   Reflecting the percentage change between the relevant periods.\n(2)   Defined as the quotient of EBIT divided by revenues.\n(3)   Defined as the quotient of EBITDA divided by revenues.\n(4)   As at the end of the relevant period.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5350727117194183, "lower_right_x": 0.532043530834341, "lower_right_y": 0.5872540633019675, "height": 0.05218135158254922, "width": 0.4147521160822249}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-7", "text": "Significant          The following significant changes in Dermapharm\u2019s financial condition and\nchanges to the       operating results occurred in the nine-month periods ended September 30, 2016 and\nissuer\u2019s financial   2017, in the fiscal years ended December 31, 2014, 2015 and 2016, and in the\ncondition and        subsequent period:\noperating results\n                     Recent Developments\nduring or\nsubsequent to the    On October 1, 2017, Dermapharm completed the acquisition of all shares in\nperiod covered by    Bio-Di\u00e4t-Berlin Gesellschaft mit beschr\u00e4nkter Haftung and Kr\u00e4uter K\u00fchne GmbH.\nthe historical key\n                     In November 2017, axicorp Pharma B.V. settled claims brought by private health\nfinancial\n                     insurance providers in respect of rebates in an aggregate amount of approximately\ninformation.\n                     \u20ac1.2 million. Furthermore, it paid \u20ac1.9 million, plus interest in an amount of\n                     \u20ac0.2 million, in respect of rebates to private health insurance providers for which\n                     Dermapharm had already received invoices, but which had not yet been claimed by\n                     these private health insurance providers in court.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8006843455945253, "height": 0.19888793840889651, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-8", "text": "On November 19, 2017, Dermapharm repaid the then outstanding variable tranche in\nan amount of \u20ac6.5 million under the promissory note agreements\n(Schuldscheindarlehen) with Bayerische Landesbank.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.8071000855431993, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8481608212147135, "height": 0.04106073567151414, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-13-9", "text": "S-8\n", "page_number": 13, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-0", "text": "On December 6, 2017, the Company\u2019s shareholders\u2019 meeting resolved to increase the\nCompany\u2019s share capital from \u20ac120,000.00 by \u20ac49,880,000.00 to \u20ac50,000,000.00 by\nissuing 49,880,000 new shares in the Company against contributions in kind in the\nform of 104,960 shares in Dermapharm AG by the Selling Shareholder\n(corresponding to 20.0% of the share capital of Dermapharm AG). In addition, the\nSelling Shareholder contributed the remaining 419,840 shares in Dermapharm AG\n(corresponding to 80.0% of the share capital of Dermapharm AG) to the Company\u2019s\nfree reserves (freie R\u00fccklagen) without consideration. The contribution and transfer\nof all shares in Dermapharm AG were completed with effect from the end of\nDecember 31, 2017 and the consummation of the capital increase was registered in\nthe commercial register of the local court (Amtsgericht) of Munich, Germany, on\nJanuary 4, 2018.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.16467065868263475, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-1", "text": "On December 20, 2017, Dermapharm acquired all shares in Strathmann GmbH & Co.\nKG, its sole general partner Strathmann Service GmbH and Biokirch GmbH\nPharmaproduktion und \u00c4rzteservice (together, \u201cStrathmann\u201d). Strathmann\ndistributes a broad product offering primarily comprising OTC products, which\ncomplement Dermapharm\u2019s existing product portfolio, in particular with respect to\nthe dermatologicals, women\u2019s healthcare and vitamins/minerals/enzymes product\nareas. In the fiscal year ended December 31, 2016, Strathmann generated aggregate\nrevenues of \u20ac27.9 million and EBITDA of \u20ac3.7 million (based on Strathmann\u2019s\nfinancial statements prepared in accordance with the German Commercial Code\n(Handelsgesetzbuch (\u201cHGB\u201d))).\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39349871685201027, "height": 0.1372968349016253, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-2", "text": "The profit transfer agreement between the Selling Shareholder and Dermapharm AG\n(the \u201cProfit Transfer Agreement\u201d) was terminated with effect from the end of\nDecember 31, 2017 (see C.7).\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3999144568006843, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4414029084687767, "height": 0.041488451668092396, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-3", "text": "On January 2, 2018, Dermapharm repaid the final tranche under its profit\nparticipation rights in registered form (auf den Namen lautende Genussrechte) in an\namount of \u20ac6.4 million.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.44781864841745084, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4893071000855432, "height": 0.04148845166809234, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-4", "text": "On January 23, 2018, Dermapharm acquired all shares in Trommsdorff GmbH & Co.\nKG and its sole general partner Cl. Lageman Gesellschaft mit beschr\u00e4nkter Haftung\n(together, \u201cTrommsdorff\u201d). Trommsdorff manufactures and markets 23 different\nprescription pharmaceuticals and OTC products, in particular Keltican\u00ae forte, a\ndietary product for the treatment of back pain, and Tromcardin \u00ae complex, which\ncombines certain minerals and vitamins for the treatment of cardiac arrhythmia.\nTrommsdorff also serves its former parent group as a toll manufacturer. In the fiscal\nyear ended December 31, 2016, Trommsdorff generated aggregate revenues of\n\u20ac52.0 million and EBITDA of \u20ac10.6 million (based on Trommsdorff\u2019s financial\nstatements prepared in accordance with HGB.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4957228400342173, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6330196749358425, "height": 0.13729683490162525, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-5", "text": "Nine-Month Periods Ended September 30, 2016 and September 30, 2017\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6398631308810949, "lower_right_x": 0.8198307134220073, "lower_right_y": 0.6535500427715997, "height": 0.01368691189050475, "width": 0.5205562273276905}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-6", "text": "In the nine-month period ended September 30, 2017, Dermapharm\u2019s revenues\nincreased from \u20ac319.2 million in the nine-month period ended September 30, 2016\nby \u20ac30.5 million, or 9.6%, to \u20ac349.7 million, reflecting the increase in sales for both\npharmaceuticals and other healthcare products as well as parallel imports.\nDermapharm\u2019s operating income also increased in the nine-month period ended\nSeptember 30, 2017, rising from \u20ac65.1 million in the nine-month period ended\nSeptember 30, 2016 by \u20ac5.3 million, or 8.1%, to \u20ac70.4 million as a result of the\nstrong performance of Dermapharm\u2019s pharmaceuticals and other healthcare products\nbusiness area. Due to these positive developments, Dermapharm\u2019s profit for the\nperiod increased by \u20ac7.0 million, or 12.5%, in the nine-month period ended\nSeptember 30, 2017 from a profit of \u20ac55.9 million in the nine-month period ended\nSeptember 30, 2016 to a profit of \u20ac62.9 million.\n", "page_number": 14, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6599657827202737, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8246364414029085, "height": 0.16467065868263475, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-14-7", "text": "S-9\n", "page_number": 14, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9405474764756202, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-15-0", "text": "Fiscal Years Ended December 31, 2015 and December 31, 2016\n", "page_number": 15, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7533252720677146, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4540507859733978}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-15-1", "text": "Revenues increased from \u20ac384.8 million in the fiscal year ended December 31, 2015\nby \u20ac59.7 million, or 15.5%, to \u20ac444.5 million in the fiscal year ended December 31,\n2016, primarily due to rising sales of Dekristol\u00ae 20,000 I.E., which rose by 38.2%.\nDermapharm\u2019s operating income increased from \u20ac60.8 million in the fiscal year\nended December 31, 2015 by \u20ac26.0 million, or 42.8%, to \u20ac86.8 million in the fiscal\nyear ended December 31, 2016, primarily due to Dermapharm\u2019s ability to increase\ngross profits and the reduction of personnel expenses. As a result of these positive\ndevelopments, Dermapharm\u2019s profit for the period increased from \u20ac52.4 million in\nthe fiscal year ended December 31, 2015 by \u20ac24.6 million, or 46.9%, to \u20ac77.0 million\nin the fiscal year ended December 31, 2016.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.13729683490162534, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-15-2", "text": "Fiscal Years Ended December 31, 2014 and December 31, 2015\n", "page_number": 15, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.24935842600513258, "lower_right_x": 0.7521160822249093, "lower_right_y": 0.2634730538922156, "height": 0.014114627887083009, "width": 0.45284159613059255}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-15-3", "text": "In the fiscal year ended December 31, 2015, revenues decreased slightly from\n\u20ac391.3 million in the fiscal year ended December 31, 2014 by \u20ac6.5 million, or 1.7%,\nto \u20ac384.8 million, as an increase of sales of pharmaceuticals and other healthcare\nproducts was more than offset by the decrease in revenues from Dermapharm\u2019s\nparallel import business. Dermapharm\u2019s operating income increased from\n\u20ac43.3 million in the fiscal year ended December 31, 2014 by \u20ac17.5 million, or 40.4%,\nto \u20ac60.8 million in the fiscal year ended December 31, 2015, reflecting the increase\nof Dermapharm\u2019s gross profits. These positive developments are also reflected in\nDermapharm\u2019s profit for the period, which increased from \u20ac33.2 million in the fiscal\nyear ended December 31, 2014 by \u20ac19.2 million, or 57.8%, to \u20ac52.4 million in the\nfiscal year ended December 31, 2015.\n", "page_number": 15, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.2711719418306245, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.14970059880239517, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-15-4", "text": "B.8 Selected key pro     Not applicable. The Company has not prepared any pro forma financial information.\n    forma financial\n    information.\nB.9 Profit forecast or   Not applicable. The Company has not prepared a profit forecast or profit estimate.\n    estimate.\nB.10 Qualifications in   Not applicable. The audit opinions on the audited historical financial statements\n     the audit report    included in this Prospectus have been issued without qualification.\n     on the historical\n     financial\n     information.\nB.11 Insufficiency of    Not applicable. The Company is of the opinion that Dermapharm is in a position to\n     the issuer\u2019s        meet the payment obligations that become due within the next twelve months.\n     working capital.\n\nC \u2013 Securities\nC.1 Type and class of    This initial public offering (the \u201cOffering\u201d) relates to the offering of 13,455,000\n    the securities       bearer shares of the Company with no par value (St\u00fcckaktien), each such share\n    being offered and    representing a notional value of \u20ac1.00, consisting of:\n    admitted to\n                         \uf0b7   3,840,000 newly issued bearer shares with no par value (St\u00fcckaktien) from a\n    trading.\n                             capital increase against contributions in cash (the \u201cIPO Capital Increase\u201d) to be\n                             resolved by an extraordinary shareholders\u2019 meeting of the Company on or about\n                             January 26, 2018 (the \u201cNew Shares\u201d);\n                         \uf0b7   7,860,000 existing bearer shares with no par value (St\u00fcckaktien) from the\n                             holdings of the Selling Shareholder (the \u201cExisting Shares\u201d and, together with\n                             the New Shares, the \u201cBase Shares\u201d); and\n                         \uf0b7   1,755,000 existing bearer shares with no par value (St\u00fcckaktien) from the\n                             holdings of the Selling Shareholder in connection with a possible over-allotment\n                             (the \u201cOver-Allotment Shares\u201d and, together with the Base Shares, the \u201cOffer\n                             Shares\u201d).\n", "page_number": 15, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8793840889649273, "height": 0.4520958083832335, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {"pro_forma_financial_information": ["has not prepared any pro forma financial information"], "profit_forecast": ["has not prepared a profit forecast or profit estimate"], "audit_report": ["without qualification."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-15-5", "text": "S-10\n", "page_number": 15, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-16-0", "text": "     Security             International Securities Identification Number (ISIN):     DE000A2GS5D8\n     identification\n                          German Securities Code (Wertpapierkennnummer\n     number.\n                          (WKN)):                                      A2GS5D\n                          Ticker Symbol:                                             DMP\n\nC.2 Currency of the       Euro.\n    securities issue.\nC.3 Number of shares      As of the date of this Prospectus, the share capital of the Company amounts to\n    issued and fully      \u20ac50,000,000.00 and is divided into 50,000,000 bearer shares with no par value\n    paid and par          (St\u00fcckaktien), each such share representing a notional value of \u20ac1.00. The share\n    value per share.      capital has been fully paid up.\nC.4 Rights attached to Each share in the Company carries one vote at the Company\u2019s shareholders\u2019 meeting.\n    the securities.    All of the Company\u2019s shares confer the same voting rights. There are no restrictions\n                       on voting rights.\nC.5 Restrictions on       Not applicable. The Company\u2019s shares are freely transferable in accordance with the\n    the free              legal requirements for bearer shares. Except for the restrictions set forth in E.5, there\n    transferability of    are no prohibitions on disposals or restrictions with respect to the transferability of\n    the securities.       the Company\u2019s shares.\nC.6 Application for       The Company expects to apply for the admission of its shares to trading on the\n    admission to          regulated market (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter\n    trading on a          Wertpapierb\u00f6rse) and, simultaneously, to the sub-segment thereof with additional\n    regulated market      post-admission obligations (Prime Standard) on or about January 29, 2018. The\n    and identity of all   listing approval (admission decision) for the Company\u2019s shares is expected to be\n    the regulated         granted on February 8, 2018. Trading in the Company\u2019s shares on the Frankfurt\n    markets where         Stock Exchange (Frankfurter Wertpapierb\u00f6rse) is expected to commence on\n    the securities are    February 9, 2018.\n    to be traded.\nC.7 Dividend policy.      With respect to the fiscal year ended December 31, 2017, the Company will not\n                          distribute a dividend, since Dermapharm AG is required to transfer its profits for the\n                          fiscal year ended December 31, 2017, if any, to the Selling Shareholder under the\n                          Profit Transfer Agreement. However, Dermapharm AG has provided the Selling\n                          Shareholder with certain shareholder loans. Consequently, the claims of the Selling\n                          Shareholder under the Profit Transfer Agreement with respect to the fiscal year ended\n                          December 31, 2017 will be offset against Dermapharm AG\u2019s claims under these\n                          shareholder loans and Dermapharm AG expects that its claims will exceed those of\n                          the Selling Shareholder by more than \u20ac50 million.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6295979469632165, "height": 0.5444824636441403, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {"isin": ["DE000A2GS5D8"], "ticker": ["DMP"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-16-1", "text": "Starting with the fiscal year ending December 31, 2018, the Company intends to pay\na dividend in the ordinary course of business of 50% to 60% of Dermapharm\u2019s profits\nfor the respective fiscal year calculated in accordance with IFRS. The Company aims\nto have a sustainable dividend policy that focuses on dividend continuity.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6394354148845167, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6928999144568007, "height": 0.05346449957228394, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-16-2", "text": "S-11\n", "page_number": 16, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03143893591293839}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-0", "text": "D \u2013 Risks\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.18863361547763, "lower_right_y": 0.09751924721984602, "height": 0.012403763900769887, "width": 0.06831922611850061}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-1", "text": "An investment in the Company\u2019s shares is subject to risks. Investors should carefully\nconsider the following risks when deciding whether to invest in the Company\u2019s\nshares. The market price of the Company\u2019s shares could decline if any of these risks\nwere to materialize, in which case investors could lose some or all of their\ninvestment.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1727972626176219, "height": 0.06715141146278872, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-2", "text": "The following risks, alone or together with additional risks and uncertainties not\ncurrently known to the Company, or that the Company might currently deem\nimmaterial, could have a material adverse effect on the business, financial condition,\ncash flows, results of operations and prospects of Dermapharm. The order in which\nthe risks are presented is not an indication of the likelihood of the risks actually\nmaterializing, or the significance or degree of the risks or the scope of any potential\nharm to the business, financial condition, cash flows, results of operations and\nprospects of Dermapharm. The risks mentioned herein may materialize individually\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.18092386655260906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.10992301112061592, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-3", "text": "                       prospects of Dermapharm. The risks\n                       or cumulatively.\nD.1 Key risks that are Market and Business related Risks\n    specific to the\n                       \uf0b7 Dermapharm could be adverse\n    issuer or its\n                          pharmaceuticals and healthcare m\n    industry.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.29127459366980324, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.3661248930710009, "height": 0.07485029940119764, "width": 0.43107617896009676}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-4", "text": "Dermapharm could be adversely affected by developments in the German\npharmaceuticals and healthcare markets.\nA significant portion of Dermapharm\u2019s revenues and EBITDA are derived from\nsales of a limited number of key products, in particular Dekristol \u00ae 20,000 I.E.\nDermapharm may not be able to successfully develop and market new products.\nDermapharm\u2019s efforts to expand its business into foreign markets expose\nDermapharm to risks associated with operating in unknown jurisdictions.\nDermapharm may be unable to identify and capitalize on attractive growth\nopportunities and even if it does engage in acquisitions, joint ventures or other\nbusiness combinations, such transactions may not develop as originally\nanticipated.\nDermapharm faces intense competition in all markets in which it operates.\nDermapharm depends on its ability to successfully market its prescription\npharmaceuticals to doctors who prescribe such pharmaceuticals to their patients.\nRebate agreements with statutory health insurance providers may adversely\naffect Dermapharm\u2019s business.\nHealthcare reforms and related changes to the framework applicable to the\npharmaceuticals industry may adversely affect Dermapharm\u2019s business.\nDermapharm depends on market perceptions, particularly with respect to the\nsafety, effectiveness and quality of its products.\nDermapharm depends on a limited number of suppliers for the raw materials\nneeded to manufacture its products and third-party manufacturers for its medical\ndevices and interruptions in Dermapharm\u2019s supply chain could have a material\nadverse effect on its business.\nDisruptions of Dermapharm\u2019s manufacturing processes and delays when\nlaunching new products may adversely affect Dermapharm\u2019s business.\nA reduction of parallel import quotas or an establishment of export restrictions or\npharmaceutical contingents and similar regulations may adversely affect\nDermapharm\u2019s parallel import business.\nDermapharm may not be able to resell pharmaceuticals it has imported as part of\nits parallel import business at attractive prices or at all.\nDermapharm may not be able to introduce and source the pharmaceuticals\nrequired to maintain its parallel import product offering.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.334901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8964927288280582, "height": 0.5615911035072711, "width": 0.5519951632406288}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-5", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.37254063301967494, "lower_right_x": 0.309552599758162, "lower_right_y": 0.3798118049615056, "height": 0.007271171941830634, "width": 0.009673518742442544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-6", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4067579127459367, "lower_right_x": 0.309552599758162, "lower_right_y": 0.41402908468776733, "height": 0.007271171941830634, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-7", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.42857142857142855, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.43669803250641576, "height": 0.008126603934987209, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-8", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.4649272882805817, "lower_right_x": 0.309552599758162, "lower_right_y": 0.4721984602224123, "height": 0.007271171941830579, "width": 0.009673518742442544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-9", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5265183917878529, "lower_right_x": 0.309552599758162, "lower_right_y": 0.5337895637296834, "height": 0.007271171941830579, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-10", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5483319076133447, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.5564585115483319, "height": 0.008126603934987209, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-11", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.5846877673224978, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.5915312232677502, "height": 0.006843455945252375, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-12", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6189050470487596, "lower_right_x": 0.309552599758162, "lower_right_y": 0.6261762189905903, "height": 0.00727117194183069, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-13", "text": "", "page_number": 17, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.6539777587681779, "lower_right_x": 0.309552599758162, "lower_right_y": 0.6599657827202737, "height": 0.005988023952095856, "width": 0.009673518742442544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-14", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.6907613344739093, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.6976047904191617, "height": 0.006843455945252375, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-15", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.7523524379811805, "lower_right_x": 0.309552599758162, "lower_right_y": 0.7596236099230111, "height": 0.00727117194183069, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-16", "text": "", "page_number": 17, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.7874251497005988, "lower_right_x": 0.309552599758162, "lower_right_y": 0.7934131736526946, "height": 0.0059880239520957446, "width": 0.009673518742442544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-17", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.8383233532934131, "lower_right_x": 0.309552599758162, "lower_right_y": 0.844311377245509, "height": 0.005988023952095856, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-18", "text": "\uf0b7\n", "page_number": 17, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.8721129170230967, "lower_right_x": 0.309552599758162, "lower_right_y": 0.8793840889649273, "height": 0.007271171941830579, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-17-19", "text": "S-12\n", "page_number": 17, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-0", "text": "\uf0b7   If third parties were to sell Dermapharm counterfeit or defective pharmaceuticals\n    as part of its parallel import business, Dermapharm could be held liable for\n    distributing such pharmaceuticals.\n\uf0b7   Dermapharm\u2019s existing financial liabilities could limit the cash flows available\n    for its operations, and any default with respect to Dermapharm\u2019s financial\n    liabilities could lead to the Company\u2019s insolvency.\n\uf0b7   Dermapharm may be unable to raise additional funds on acceptable terms or at\n    all, and an increase in the level of Dermapharm\u2019s indebtedness may adversely\n    affect its business.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.30169286577992743, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.13387510692899915, "width": 0.5785973397823458}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-1", "text": "Regulatory, Legal and Tax Risks\n", "page_number": 18, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.2322497861420017, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.24636441402908468, "height": 0.014114627887082981, "width": 0.2376058041112455}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-2", "text": "\uf0b7   Dermapharm is required to comply with the extensive regulations that govern its\n    products as well as other aspects of Dermapharm\u2019s business, and changes in the\n    regulatory environment may force Dermapharm to incur additional costs.\n\uf0b7   Dermapharm\u2019s existing compliance structure may not be sufficient and\n    non-compliance with laws and regulations may adversely affect Dermapharm\u2019s\n    business.\n\uf0b7   Dermapharm may become involved in various legal proceedings, including\n    patent litigation, which may expose Dermapharm to substantial liability or\n    adversely impact its business.\n\uf0b7   Dermapharm may face significant product liability claims that are not covered by\n    insurance.\n\uf0b7   Dermapharm may be adversely affected by changes to the general tax\n    environment and future tax audits and investigations, all of which may increase\n    Dermapharm\u2019s tax burden.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.3041112454655381, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47904191616766467, "height": 0.22284003421727971, "width": 0.5761789600967353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-3", "text": "Risks related to the Company\u2019s Shareholder Structure, the Shares and the\nOffering\n", "page_number": 18, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8313180169286578, "lower_right_y": 0.5132591958939264, "height": 0.027801539777587703, "width": 0.532043530834341}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-4", "text": "D.3 Key risks specific\n    to the securities.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.48545765611633873, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.5098374679213002, "height": 0.024379811804961515, "width": 0.1638452237001209}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-5", "text": "The Company\u2019s shares have not previously been publicly traded, and there is no\nguarantee that an active and liquid market for these shares will develop.\nThe Company\u2019s share price could fluctuate significantly, and investors could\nlose part or all of their investment in the Company\u2019s shares.\nThe Company may not be able to pay dividends in the foreseeable future.\nFollowing this Offering, the Selling Shareholder will retain a significant interest\nin the Company and the interests of the Selling Shareholder may conflict with\nthose of the Company and its other shareholders.\nFuture offerings of debt or equity securities by the Company could adversely\naffect the market price of the Company\u2019s shares, and future capital measures\ncould lead to a substantial dilution of the Company\u2019s shareholders (i.e., a\nreduction in the value of existing shareholders\u2019 interests in the Company).\nFuture sales by major shareholders could have a material adverse effect on the\nprice of the Company\u2019s shares.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7527801539777588, "height": 0.23310521813515828, "width": 0.5519951632406288}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-18-6", "text": "S-13\n", "page_number": 18, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-0", "text": "E \u2013 Offer\nE.1 Total net\n    proceeds.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.13344739093242086, "height": 0.04833190761334473, "width": 0.10701330108827087}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-1", "text": "The Company will only receive the proceeds of the Offering resulting from the sale\nof the New Shares. The Company will not receive any proceeds from the sale of the\nExisting Shares or the Over-Allotment Shares from the holdings of the Selling\nShareholder.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15953806672369547, "height": 0.053892215568862284, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-2", "text": "Assuming that the maximum number of New Shares (i.e., 3,840,000 shares) is\nplaced, the Company estimates that at the low end, mid-point or high end of the price\nrange for the Offering within which purchase orders may be placed of \u20ac26.00 to\n\u20ac30.00 per Offer Share (the \u201cPrice Range\u201d), gross proceeds attributable to the\nCompany would amount to approximately \u20ac99.8 million, \u20ac107.5 million or\n\u20ac115.2 million, respectively, and net proceeds would amount to approximately\n\u20ac96.0 million, \u20ac103.5 million and \u20ac111.0 million, respectively.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.16723695466210436, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2634730538922156, "height": 0.09623609923011123, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-3", "text": "Assuming a placement of all 7,860,000 Existing Shares and full exercise of the\nGreenshoe Option (as defined in E.3) totaling 1,755,000 shares, the Company\nestimates that at the low end, mid-point and high end of the Price Range, gross\nproceeds attributable to the Selling Shareholder would amount to approximately\n\u20ac250.0 million, \u20ac269.2 million and \u20ac288.5 million, respectively, and net proceeds\nwould amount to approximately \u20ac240.9 million, \u20ac259.6 million and \u20ac278.4 million,\nrespectively.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.26988879384088965, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3661248930710009, "height": 0.09623609923011123, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-4", "text": "The costs of the Company and the Selling Shareholder related to the Offering of the\nOffer Shares and listing of the Company\u2019s entire share capital, including\nunderwriting and placement commissions payable to Berenberg and the fixed fee\npayable to ODDO BHF, are expected to total approximately \u20ac13.6 million at the\nmid-point of the Price Range (assuming placement of all Base Shares, full exercise of\nthe Greenshoe Option (as defined in E.3) and payment of the discretionary fee in\nfull); of the total costs, the Selling Shareholder will bear approximately \u20ac9.6 million\nand the Company will bear the remaining amount of approximately \u20ac4.0 million.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.37254063301967494, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48246364414029086, "height": 0.10992301112061592, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-5", "text": "Estimate of the\ntotal expenses of\nthe issue/offer.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.3759623609923011, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.4136013686911891, "height": 0.03763900769888795, "width": 0.12575574365175335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-6", "text": "Estimated          Not applicable. Investors will not be charged expenses by the Company, the Selling\nexpenses charged   Shareholder or the Offering Banks. Investors will have to bear customary transaction\nto the investor.   and handling fees charged by their brokers or other financial institutions through\n                   which they hold their securities.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.4888793840889649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.544054747647562, "height": 0.05517536355859709, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-7", "text": "The Company intends to pursue the Offering and list its shares on the regulated\nmarket (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter\nWertpapierb\u00f6rse) and, simultaneously, on the sub segment with additional post\nadmission obligations (Prime Standard) of the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse) to receive the net proceeds from the Offering\nattributable to the Company and to gain access to the capital markets.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2974607013301088, "top_left_y": 0.5538922155688623, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6364414029084687, "height": 0.08254918733960648, "width": 0.5834340991535671}, "blob_type": "paragraph", "predictions": {}, "annotations": {"reasons_for_the_offering": ["The Company intends to pursue the Offering and list its shares on the regulatedmarket(regulierterMarkt)oftheFrankfurtStockExchange(FrankfurterWertpapierb\u00f6rse) and, simultaneously, on the sub segment with additional postadmissionobligations(PrimeStandard)oftheFrankfurtStockExchange(Frankfurter Wertpapierb\u00f6rse) to receive the net proceeds from the Offeringattributable to the Company and to gain access to the capital markets."]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-8", "text": "E.2a Reasons for the\n     offering.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5538922155688623, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.5786997433704021, "height": 0.02480752780153983, "width": 0.1505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-9", "text": "The Selling Shareholder intends to pursue the Offering to receive the net proceeds\nfrom the Offering attributable to the Selling Shareholder and to diversify its\ninvestments.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6809238665526091, "height": 0.038066723695466154, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-10", "text": "The Company currently intends to use the net proceeds attributable to the Company\nas follows: approximately \u20ac35 million are to be spent on in-house developments and\nan upgrade of Dermapharm\u2019s manufacturing facilities in Brehna, Germany, and a\nnew manufacturing facility in Neumarkt am Wallersee, Austria, approximately\n\u20ac20 million for Dermapharm\u2019s efforts to increase its international footprint (e.g., for\nfounding new enterprises in additional markets, hiring local sales managers and sales\npersonnel and similar investments) and between approximately \u20ac40 million and\n\u20ac50 million on the partial refinancing of a loan provided by Baden-W\u00fcrttembergische\nBank to partially finance the acquisition of Trommsdorff. The Company currently\nintends to spend any remaining net proceeds on general corporate purposes.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2974607013301088, "top_left_y": 0.6907613344739093, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8280581693755347, "height": 0.13729683490162536, "width": 0.5834340991535671}, "blob_type": "paragraph", "predictions": {}, "annotations": {"use_of_proceeds": ["The Company currently intends to use the net proceeds attributable to the Companyas follows: approximately \u20ac35 million are to be spent on in-house developments andan upgrade of Dermapharm\u2019s manufacturing facilities in Brehna, Germany, and anew manufacturing facility in Neumarkt am Wallersee, Austria, approximately\u20ac20 million for Dermapharm\u2019s efforts to increase its international footprint (e.g., forfounding new enterprises in additional markets, hiring local sales managers and salespersonnel and similar investments) and between approximately \u20ac40 million and\u20ac50 million on the partial refinancing of a loan provided by Baden-W\u00fcrttembergischeBank to partially finance the acquisition of Trommsdorff. The Company currentlyintends to spend any remaining net proceeds on general corporate purposes."]}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-11", "text": "Use of proceeds.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6907613344739093, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.7040205303678357, "height": 0.013259195893926434, "width": 0.12091898428053205}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-19-12", "text": "S-14\n", "page_number": 19, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-0", "text": "Assuming that the maximum number of New Shares (i.e., 3,840,000 shares) is\nplaced, the Company estimates that at the low end, mid-point and high end of the\nPrice Range, gross proceeds attributable to the Company would amount to\napproximately \u20ac99.8 million, \u20ac107.5 million and \u20ac115.2 million, respectively, and\nnet proceeds would amount to approximately \u20ac96.0 million, \u20ac103.5 million and\n\u20ac111.0 million, respectively.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.08254918733960649, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-1", "text": "Estimated net\namount of the\nproceeds.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.08511548331907613, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.1070133010882709}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-2", "text": "The Offering consists of initial public offerings in Germany and Luxembourg and\nprivate placements in certain jurisdictions outside Germany and Luxembourg. In the\nUnited States of America, the Offer Shares will only be offered and sold to qualified\ninstitutional buyers as defined in, and in reliance on, Rule 144A under the United\nStates Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), or pursuant to\nanother available exemption from, or in transactions not subject to, the registration\nrequirements of the Securities Act. Outside the United States of America, the Offer\nShares will be offered and sold only in offshore transactions in compliance with\nRegulation S under the Securities Act.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2974607013301088, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29769033361847735, "height": 0.12360992301112064, "width": 0.5828295042321645}, "blob_type": "paragraph", "predictions": {}, "annotations": {"rule_144a_applies": ["Rule 144A"], "regulation_s_applies": ["Regulation S"]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-3", "text": "E.3 Terms and\n", "page_number": 20, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.17536355859709152, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.18733960650128315, "height": 0.011976047904191628, "width": 0.11668681983071341}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-4", "text": "Terms and\nconditions of the\n", "page_number": 20, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.18905047048759624, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.20102651839178784, "height": 0.0119760479041916, "width": 0.12091898428053208}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-5", "text": "offer.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.20273738237810093, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.21471343028229256, "height": 0.011976047904191628, "width": 0.044135429262394194}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-6", "text": "The period during which investors may submit purchase orders for the Offer Shares\nis expected to commence on January 29, 2018, and to expire on February 8, 2018 (the\n\u201cOffer Period\u201d).\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3041060735671514, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3455945252352438, "height": 0.041488451668092396, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-7", "text": "Offer Period.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.156590084643289, "top_left_y": 0.30538922155688625, "lower_right_x": 0.2545344619105199, "lower_right_y": 0.3177929854576561, "height": 0.01240376390076986, "width": 0.09794437726723093}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-8", "text": "The offer price for this Offering (the \u201cOffer Price\u201d) and the final number of Offer\nShares placed in the Offering will be determined at the end of the bookbuilding\nprocess by the Company and the Selling Shareholder after consultation with\nBerenberg and are expected to be published on or about February 8, 2018. Should the\nplacement volume prove insufficient to satisfy all orders placed at the Offer Price,\nBerenberg, on behalf of the Offering Banks, reserves the right to reject orders, or to\nonly accept them in part.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.35201026518391787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4482463644140291, "height": 0.09623609923011123, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-9", "text": "Offer Price.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.156590084643289, "top_left_y": 0.35201026518391787, "lower_right_x": 0.2460701330108827, "lower_right_y": 0.3661248930710009, "height": 0.014114627887083009, "width": 0.08948004836759371}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-10", "text": "Delivery of the Offer Shares against payment of the Offer Price is expected to take\nplace on February 13, 2018. The Offer Shares will be made available to investors as\nco-ownership interests in the global share certificates.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.45466210436270316, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49615055603079555, "height": 0.041488451668092396, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-11", "text": "Delivery and\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15719467956469166, "top_left_y": 0.45808383233532934, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.4692044482463644, "height": 0.011120615911035081, "width": 0.09431680773881498}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-12", "text": "Delivery an\nSettlement.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15598548972188633, "top_left_y": 0.4696321642429427, "lower_right_x": 0.23760580411124546, "lower_right_y": 0.4820359281437126, "height": 0.012403763900769915, "width": 0.08162031438935913}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-13", "text": "In connection with the placement of the Offer Shares, Berenberg will act as the\nstabilization manager and may, as stabilization manager, make over-allotments and\ntake stabilization measures. As a result of these stabilization measures, investors\nmay, in addition to the Base Shares, be allocated up to 1,755,000 Over-Allotment\nShares as part of the allocation of the Offer Shares. For this purpose, Berenberg will\nbe provided with 1,755,000 Over-Allotment Shares from the holdings of the Selling\nShareholder in the form of a securities loan. The total number of Over-Allotment\nShares will not exceed 15% of the final number of Base Shares placed with investors.\nThe Selling Shareholder will grant Berenberg an option to acquire a number of the\nCompany\u2019s shares equal to the number of Over-Allotment Shares at the Offer Price,\nless agreed commissions (the \u201cGreenshoe Option\u201d). The Greenshoe Option may\nonly be exercised during the stabilization period and will terminate 30 calendar days\nafter the commencement of trading of the Company\u2019s shares. Berenberg is entitled to\nexercise the Greenshoe Option to the extent Over-Allotment Shares were allocated to\ninvestors in the Offering. The number of Over-Allotment Shares acquired under the\nGreenshoe Option is to be reduced by any shares of the Company held by Berenberg\nwhen the Greenshoe Option is exercised, if such shares were acquired by Berenberg\nin the context of stabilization measures.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5025662959794697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7493584260051326, "height": 0.24679213002566291, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-14", "text": "Stabilization\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5059880239520959, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.5166809238665526, "height": 0.010692899914456766, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-15", "text": "Measures,\n", "page_number": 20, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.5196749358426005, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.5303678357570573, "height": 0.010692899914456766, "width": 0.07738814993954052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-16", "text": "Over-Allotments\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15538089480048367, "top_left_y": 0.5329341317365269, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.544054747647562, "height": 0.011120615911035081, "width": 0.12515114873035066}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-17", "text": "and Greenshoe\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5470487596236099, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.5577416595380668, "height": 0.010692899914456877, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-18", "text": "Option.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.15538089480048367, "top_left_y": 0.5603079555175363, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.5735671514114628, "height": 0.013259195893926434, "width": 0.05683192261185008}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-20-19", "text": "S-15\n", "page_number": 20, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-0", "text": "Interests material Subject to the placement of the Existing Shares and the exercise of the Greenshoe\nto the issue/offer. Option, the Selling Shareholder will receive the proceeds from the sale of the\n                    Existing Shares and the Over-Allotment Shares (after deduction of fees and\n                    commissions). Accordingly, the Selling Shareholder has an interest in the success of\n                    the Offering at the best possible terms.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.0688622754491018, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-1", "text": "E.4\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08597091531223268, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-2", "text": "In connection with the Offering and the admission to trading of the Company\u2019s\nshares, the Offering Banks have formed a contractual relationship with the Company\nand the Selling Shareholder.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2018819503849444, "height": 0.04148845166809237, "width": 0.5804111245465537}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-3", "text": "Berenberg is acting for the Company and the Selling Shareholder on the Offering and\non coordinating the structuring and execution of the Offering. Upon successful\ncompletion of the Offering, Berenberg will receive a commission and the size of this\ncommission depends on the results of the Offering. As a result, Berenberg has a\nfinancial interest in the success of the Offering at the best possible terms.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.20829769033361847, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2771599657827203, "height": 0.06886227544910181, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-4", "text": "ODDO BHF is acting as co-lead manager and will receive a fixed fee for its services\nin connection with the Offering. As a result, ODDO BHF has a financial interest in\nthe success of the Offering.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32506415739948674, "height": 0.041488451668092396, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-5", "text": "The Offering Banks or their respective affiliates have, and may from time to time in\nthe future continue to have, business relations with Dermapharm and the Selling\nShareholder, including lending activities, or may perform services for Dermapharm\nor the Selling Shareholder in the ordinary course of business.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3866552609067579, "height": 0.05517536355859709, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-6", "text": "Not applicable. There are no conflicting interests with respect to the Offering or the\nlisting of the Company\u2019s shares\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42172797262617623, "height": 0.025235243798118034, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-7", "text": "Conflicting\n", "page_number": 21, "bounding_box": {"top_left_x": 0.15840386940749698, "top_left_y": 0.3964927288280582, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.40975192472198463, "height": 0.013259195893926434, "width": 0.08343409915356712}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-8", "text": "interests.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.4101796407185629, "lower_right_x": 0.22128174123337363, "lower_right_y": 0.4204448246364414, "height": 0.010265183917878506, "width": 0.06711003627569528}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-9", "text": "The Offer Shares are being offered for sale by the Offering Banks.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4221556886227545, "lower_right_x": 0.7484885126964933, "lower_right_y": 0.4435414884516681, "height": 0.021385799828913588, "width": 0.4492140266021765}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-10", "text": "E.5\n", "page_number": 21, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.43071000855431996, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.4414029084687767, "height": 0.010692899914456766, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-11", "text": "Name of the\n", "page_number": 21, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.43071000855431996, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.4414029084687767, "height": 0.010692899914456766, "width": 0.09189842805320436}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-12", "text": "person or entity\n                     In the underwriting agreement, entered into between the Company, the Selling\noffering to sell the\n                     Shareholder and the Offering Banks on January 26, 2018, the Company agreed that,\nsecurity and lock-\n                     during the period commencing on January 26, 2018 and ending six months after the\nup agreements\n                     first day of trading of the Company\u2019s shares on the Frankfurt Stock Exchange\n                     (Frankfurter Wertpapierb\u00f6rse) (currently expected to take place on February 9,\n                     2018), to the extent legally permissible, without the prior written consent of\n                     Berenberg, which may not be unreasonably withheld, the Company will not:\n", "page_number": 21, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.4439692044482464, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5461933276304534, "height": 0.10222412318220697, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {"lock-up_period": ["six months"]}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-13", "text": "\uf0b7   announce or effect an increase of the share capital of the Company from\n    authorized capital;\n\uf0b7   propose to its shareholders\u2019 meeting an increase of the share capital; or\n\uf0b7   announce, effect or propose the issuance of securities with conversion or option\n    rights on shares of the Company or economically similar transactions.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6390076988879384, "height": 0.08511548331907615, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-14", "text": "The foregoing will not apply to any capital increase in connection with the Offering.\nFurthermore, the Company may (i) issue or sell any shares or other securities to\nemployees and members of executive bodies of the Company or its subsidiaries\nunder management participation plans and (ii) pursue any corporate actions\nundertaken by the Company for the purpose of entering into any agreement\nregarding, or resolve upon, the entering into any joint venture or the acquisition of\nany companies, provided that the parties to the joint venture or acquiring entity to\nwhich such shares will be issued agree towards Berenberg to be bound by the same\nlock-up undertaking as the Selling Shareholder.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.646278870829769, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7677502138579982, "height": 0.12147134302822926, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-21-15", "text": "S-16\n", "page_number": 21, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-0", "text": "In addition, for the period commencing January 26, 2018 and ending twelve months\nafter the first day of trading of the Company\u2019s shares on the Frankfurt Stock\nExchange (Frankfurter Wertpapierb\u00f6rse) (currently expected to take place on\nFebruary 9, 2018), the Selling Shareholder has agreed that it will not, without the\nprior written consent of Berenberg, which may not be unreasonably withheld:\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.0688622754491018, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {"lock-up_period": ["twelve months"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-1", "text": "sell, market, transfer or otherwise dispose of, either directly or indirectly, any\nshares or other securities in the Company; or\nenter into any transaction economically equivalent to a sale of shares of the\nCompany (e.g., the issuance of options or conversion rights on shares of the\nCompany).\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.16381522668947818, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2386655260906758, "height": 0.07485029940119761, "width": 0.5519951632406288}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-2", "text": "", "page_number": 22, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.16467065868263472, "lower_right_x": 0.309552599758162, "lower_right_y": 0.17065868263473055, "height": 0.005988023952095828, "width": 0.009673518742442544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-3", "text": "\uf0b7\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.20145423438836613, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.20829769033361847, "height": 0.006843455945252347, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-4", "text": "The foregoing shall not apply to (i) transfers to affiliates or legal successors of the\nSelling Shareholder or to Mr. Wilhelm Beier, his spouse or his children, (ii) future\npledges granted to Berenberg or its affiliates having been agreed by Berenberg, and\n(iii) any transfers of shares to Berenberg or its affiliates pursuant to enforcement of\nany pledge entered into in accordance with (ii), provided in each case that such\ntransferee(s) agree(s) towards Berenberg to be bound by the same lock-up\nundertaking.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.24593669803250642, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34046193327630453, "height": 0.0945252352437981, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-5", "text": "According to Dermapharm AG\u2019s unaudited condensed consolidated interim financial\nstatements as of and for the nine-month period ended September 30, 2017,\nDermapharm\u2019s net book value (i.e., total assets less total non-current liabilities and\ntotal current liabilities) amounted to \u20ac69.5 million as of September 30, 2017, and\nwould amount to \u20ac1.39 per share of the Company based on 50,000,000 outstanding\nshares of the Company immediately prior to the Offering. Dermapharm\u2019s net book\nvalue is shown as total equity in Dermapharm AG\u2019s unaudited condensed\nconsolidated interim financial statements as of and for the nine-month period ended\nSeptember 30, 2017.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47177074422583404, "height": 0.12318220701454236, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-6", "text": "E.6\n", "page_number": 22, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.35885372112917024, "height": 0.010265183917878562, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-7", "text": "Amount and\n", "page_number": 22, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.3485885372112917, "lower_right_x": 0.250906892382104, "lower_right_y": 0.3592814371257485, "height": 0.010692899914456822, "width": 0.09673518742442566}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-8", "text": "Amount and\npercentage of\n", "page_number": 22, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.36227544910179643, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.37553464499572287, "height": 0.013259195893926434, "width": 0.1021765417170496}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-9", "text": "immediate\n", "page_number": 22, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.3759623609923011, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.3866552609067579, "height": 0.010692899914456766, "width": 0.08222490931076179}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-10", "text": "immediate\ndilution resulting\n", "page_number": 22, "bounding_box": {"top_left_x": 0.15719467956469166, "top_left_y": 0.3896492728828058, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.4037639007698888, "height": 0.014114627887082953, "width": 0.12817412333736397}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-11", "text": "from the offer.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.4033361847733105, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.41402908468776733, "height": 0.010692899914456822, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-12", "text": "The dilutive effect of the Offering is illustrated in the table below, demonstrating the\namount by which the Offer Price exceeds the net book value per share after\ncompletion of the Offering and assuming the Offering had been completed on\nSeptember 30, 2017. In this respect, the net book value as of September 30, 2017 is\nadjusted for the effects of the successful completion of the Offering, assuming (i) the\nexecution of the IPO Capital Increase for the maximum number of New Shares and\n(ii) an increase in the net book value by \u20ac103.5 million (assuming successful\nplacement of all New Shares at the mid-point of the Price Range and not taking into\naccount any tax effects). The adjusted net book value is expressed as a per share\nfigure, assuming 53,840,000 shares of the Company outstanding upon completion of\nthe Offering (this per share figure being referred to as the \u201cPost-IPO Equity\u201d):\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6291702309666382, "height": 0.15055603079555174, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-13", "text": "                                                                                                             As of\n                                                                                                     September 30, 2017\n                                                                                                         (unaudited)\n                                                                                                         (in \u20ac, unless\n                                                                                                     otherwise specified)\nNet book value per share as of September 30, 2017(1) ..................................................                 1.39\nTotal net proceeds from the Offering attributable to the\n  Company (in \u20ac million)(2) ..........................................................................................103.5\nPost-IPO Equity per share(3) .......................................................................................... 3.21\nAmount by which the offer price exceeds the Post-IPO Equity\n  per share (immediate dilution of new shareholders of the\n  Company) ..................................................................................................................\n                                                                                                                      24.79\nPercentage by which the Offer Price exceeds the Post-IPO\n  Equity per share (in %) .............................................................................................\n                                                                                                                      771.5\nAmount by which the Post-IPO Equity per share exceeds the net\n  book value per share immediately prior to the Offering\n  (immediate accretion to the existing shareholders of the\n  Company) ..................................................................................................................\n                                                                                                                        1.82\nPercentage by which the Post-IPO Equity per share exceeds the\n  net book value per share immediately prior to the Offering\n  (in %) ........................................................................................................................\n                                                                                                                      131.2\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9101796407185628, "height": 0.2741659538066723, "width": 0.5707376058041111}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-22-14", "text": "S-17\n", "page_number": 22, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-23-0", "text": "(1) Based on 50,000,000 outstanding shares of the Company immediately prior to the Offering and a net book value of\n    Dermapharm in an amount of \u20ac69.5 million as of September 30, 2017. Shown as total equity in Dermapharm AG\u2019s\n    unaudited condensed consolidated interim financial statements as of and for the nine-month period ended September 30,\n    2017.\n(2) Assuming successful placement of 3,840,000 New Shares at the mid-point of the Price Range and total costs of the\n    Offering to be borne by the Company in an amount of \u20ac4.0 million, including underwriting and placement commissions\n    payable to Berenberg as well as the fixed fee payable to ODDO BHF and assuming payment of the discretionary fee in\n    full.\n(3) Based on 53,840,000 shares of the Company outstanding following completion of the Offering.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.09880239520958084, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21214713430282292, "height": 0.11334473909324208, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-23-1", "text": "Each of the New Shares will have the same voting rights as the Company\u2019s existing\nshares. Prior to the Offering, the Selling Shareholder held 100.0% of the voting rights\nin the Company. Upon completion of the Offering (assuming full exercise of the\nGreenshoe Option and issuance of all New Shares), the aggregate voting rights held\nby the Selling Shareholder would amount to 75.0%.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2934131736526946, "height": 0.06800684345594524, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-23-2", "text": "E.7 Estimated            Not applicable. Investors will not be charged expenses by the Company, the Selling\n    expenses charged     Shareholder or the Offering Banks. Investors will have to bear customary transaction\n    to the investor by   and handling fees charged by their brokers or other financial institutions through\n    the issuer or        which they hold their securities.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35543199315654406, "height": 0.06159110350727115, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-23-3", "text": "the issue\nofferor.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.15598548972188633, "top_left_y": 0.35543199315654406, "lower_right_x": 0.21100362756952842, "lower_right_y": 0.3661248930710009, "height": 0.010692899914456822, "width": 0.05501813784764209}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-23-4", "text": "S-18\n", "page_number": 23, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-0", "text": "II.   ZUSAMMENFASSUNG DES PROSPEKTS\n", "page_number": 24, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6916565900846433, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.3730350665054414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-1", "text": "         Zusammenfassungen bestehen aus geforderten Angaben, die als Punkte (\u201ePunkte\u201d) bezeichnet werden.\nDiese Punkte sind in den Abschnitten A \u2013 E (A.1 \u2013 E.7) fortlaufend nummeriert. Diese Zusammenfassung enth\u00e4lt\nalle Punkte, die f\u00fcr die vorliegende Art von Wertpapier und Emittentin in eine Zusammenfassung aufzunehmen\nsind. Da einige Punkte nicht behandelt werden m\u00fcssen, k\u00f6nnen in der Nummerierungsreihenfolge L\u00fccken\nauftreten. Selbst wenn ein Punkt wegen der Art des Wertpapiers und der Emittentin in die Zusammenfassung\naufgenommen werden muss, ist es m\u00f6glich, dass in Bezug auf diesen Punkt keine relevanten Informationen\ngegeben werden k\u00f6nnen. In solchen F\u00e4llen enth\u00e4lt die Zusammenfassung eine kurze Beschreibung des Punkts\nmit dem Hinweis \u201eEntf\u00e4llt\u201d.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-2", "text": "A \u2013 Einleitung und Warnhinweise\nA.1 Warnhinweise.     Diese Zus\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.2322497861420017, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.2630453378956373, "height": 0.030795551753635575, "width": 0.24667472793228534}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-3", "text": "eise.   Diese Zusammenfassung sollte als Einf\u00fchrung zu diesem Prospekt (der \u201eProspekt\u201d)\n        verstanden werden. Der Anleger sollte jede Entscheidung zur Anlage in die\n        Wertpapiere auf die Pr\u00fcfung des gesamten Prospekts st\u00fctzen.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.24425634824667472, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2925577416595381, "height": 0.0397775876817793, "width": 0.6360338573155986}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-4", "text": "F\u00fcr den Fall, dass vor einem Gericht Anspr\u00fcche aufgrund der in diesem Prospekt\nenthaltenen Informationen geltend gemacht werden, k\u00f6nnte der als Kl\u00e4ger\nauftretende Anleger in Anwendung der einzelstaatlichen Rechtsvorschriften der\nMitgliedstaaten des Europ\u00e4ischen Wirtschaftsraums (\u201eEWR Mitgliedstaaten\u201d) die\nKosten f\u00fcr die \u00dcbersetzung des Prospekts vor Prozessbeginn zu tragen haben.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3006843455945252, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3678357570573139, "height": 0.06715141146278869, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-5", "text": "Die Dermapharm Holding SE (die \u201eGesellschaft\u201d und zusammen mit ihren direkten\nund indirekten, konsolidierten Tochtergesellschaften \u201eDermapharm\u201d), zusammen\nmit Joh. Berenberg, Gossler & Co. KG, Hamburg, Deutschland (\u201eBerenberg\u201d), und\nODDO BHF Aktiengesellschaft, Frankfurt am Main, Deutschland (\u201eODDO BHF\u201c\nund zusammen mit Berenberg die \u201eAnbietenden Banken\u201c), haben nach\n\u00a7 5 Abs. 2b Nr. 4 des Wertpapierprospektgesetzes die Verantwortung f\u00fcr den Inhalt\ndieser Zusammenfassung, einschlie\u00dflich etwaiger \u00dcbersetzungen hiervon,\n\u00fcbernommen. Diejenigen Personen, die die Verantwortung f\u00fcr die Zusammenfassung\neinschlie\u00dflich etwaiger \u00dcbersetzungen hiervon \u00fcbernommen haben oder von denen\nder Erlass ausgeht, k\u00f6nnen haftbar gemacht werden, jedoch nur f\u00fcr den Fall, dass die\nZusammenfassung irref\u00fchrend, unrichtig oder widerspr\u00fcchlich ist, wenn sie\nzusammen mit den anderen Teilen des Prospekts gelesen wird oder sie, wenn sie\nzusammen mit den anderen Teilen des Prospekts gelesen wird, nicht alle\nerforderlichen Schl\u00fcsselinformationen vermittelt.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3759623609923011, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5637296834901625, "height": 0.18776732249786138, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-6", "text": "Angaben \u00fcber     Entf\u00e4llt. Eine Zustimmung der Gesellschaft zur Verwendung dieses Prospekts f\u00fcr\neine sp\u00e4tere     eine sp\u00e4tere Weiterver\u00e4u\u00dferung oder Platzierung der Aktien wurde nicht erteilt.\nVerwendung des\n", "page_number": 24, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6146278870829769, "height": 0.04020530367835751, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-7", "text": "A.2\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5744225834046194, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.5851154833190761, "height": 0.010692899914456766, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-8", "text": "Prospekts.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6154833190761334, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.6287425149700598, "height": 0.013259195893926434, "width": 0.07738814993954052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-9", "text": "B\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.13180169286577992, "lower_right_y": 0.6535500427715997, "height": 0.010692899914456766, "width": 0.011487303506650531}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-10", "text": "B \u2013 Emittent\n", "page_number": 24, "bounding_box": {"top_left_x": 0.1336154776299879, "top_left_y": 0.6428571428571429, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.6535500427715997, "height": 0.010692899914456766, "width": 0.07920193470374848}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-11", "text": "Gesetzliche und   Die juristische Bezeichnung der Gesellschaft lautet Dermapharm Holding SE. Die\nkommerzielle      Gesellschaft ist die Holdinggesellschaft von Dermapharm und betreibt ihr Gesch\u00e4ft\nBezeichnung des   unter dem Handelsnamen \u201eDermapharm\u201c. Dermapharm betreibt ihr Gesch\u00e4ft auch\nEmittenten.       unter weiteren Handelsnamen, insbesondere \u201emibe\u201c, \u201eH\u00fcbner\u201c und \u201eaxicorp\u201c sowie\n                  unter individuellen Marken f\u00fcr ihre spezifischen Arzneimittel und anderen\n                  Gesundheitsprodukte.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6633875106928999, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.743798118049615, "height": 0.08041060735671512, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-12", "text": "B.1\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6633875106928999, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.6740804106073567, "height": 0.010692899914456766, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-13", "text": "B.2 Sitz und          Die Gesellschaft hat ihren satzungsm\u00e4\u00dfigen Sitz am Lil-Dagover-Ring 7, 82031\n    Rechtsform des    Gr\u00fcnwald, Deutschland (Telefon: +49 (0) 89 6 41 86 0), und ist im Handelsregister\n    Emittenten, das   des Amtsgerichts M\u00fcnchen, Deutschland, unter HRB 234575 eingetragen. Die\n    f\u00fcr den           Gesellschaft ist eine Europ\u00e4ische Gesellschaft (Societas Europaea (SE)) und\n    Emittenten        unterliegt daher europ\u00e4ischem Recht, insbesondere Verordnung (EG) Nr. 2157/2001\n    geltende Recht    des Rates vom 8. Oktober 2001 \u00fcber das Statut der Europ\u00e4ischen Gesellschaft (SE) in\n    und Land der      der jeweils g\u00fcltigen Fassung. Als eine in Deutschland eingetragene Gesellschaft\n    Gr\u00fcndung der      unterliegt die Gesellschaft auch deutschem Recht.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8618477331052181, "height": 0.10949529512403766, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-14", "text": "Gr\u00fcndung de\nGesellschaft.\n", "page_number": 24, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.8618477331052181, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.8725406330196749, "height": 0.010692899914456766, "width": 0.09250302297460702}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-24-15", "text": "S-19\n", "page_number": 24, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-25-0", "text": "Gesch\u00e4fts-         Dermapharm ist eine f\u00fchrende Herstellerin von Markenarzneimitteln f\u00fcr ausgew\u00e4hlte\nt\u00e4tigkeit und      M\u00e4rkte in Deutschland mit einer expandierenden internationalen Aufstellung. Sie\nHauptt\u00e4tigkeiten   nutzt ihre Expertise im Hinblick auf Rezepturen und Entwicklungen, um eine breite\ndes Emittenten     Palette von Markenarzneimitteln, die nicht mehr patentgesch\u00fctzt sind, zu entwickeln,\nsamt der hierf\u00fcr   herzustellen und zu vermarkten. Dermapharm verf\u00fcgt \u00fcber mehr als\nwesentlichen       900 Arzneimittelzulassungen f\u00fcr mehr als 200 Pharmawirkstoffe (active\nFaktoren.          pharmaceutical ingredients (\u201eAPIs\u201d)). Dermapharm bietet zudem ein wachsendes\n                   Portfolio an anderen Gesundheitsprodukten an, unter anderem Kosmetika,\n                   Nahrungserg\u00e4nzungsmittel, Di\u00e4tprodukte und Medizinprodukte. Zus\u00e4tzlich setzt\n                   Dermapharm ihre Kompetenz im Direktmarketing wirksam ein, indem sie\n                   Arzneimittel aus anderen EWR Mitgliedstaaten zum Weiterverkauf im deutschen\n                   Markt importiert, um von Preisdifferenzen zwischen diesen M\u00e4rkten zu profitieren.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.08597091531223268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.16381522668947818, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-25-1", "text": "B.3\n", "page_number": 25, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08597091531223268, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.09709153122326775, "height": 0.011120615911035067, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-25-2", "text": "Dermapharm ist prim\u00e4r in Deutschland t\u00e4tig, das nicht nur Europas f\u00fchrende\nVolkswirtschaft ist, sondern mit Gesamtums\u00e4tzen von \u20ac36,7 Milliarden im zum\n31. Dezember 2016 endenden Gesch\u00e4ftsjahr (basierend auf Herstellerabgabepreisen)\nauch der gr\u00f6\u00dfte Markt f\u00fcr Arzneimittel (Quelle: IQVIA). Der deutsche\nArzneimittelmarkt profitiert von bestimmten grundlegenden Trends, wie der Alterung\nder Bev\u00f6lkerung, der Chronifizierung von Krankheiten, einem zunehmenden\nGesundheitsbewusstsein sowie h\u00f6heren Ausgaben f\u00fcr rezeptfreie Arzneimittel (over\nthe counter pharmaceuticals (\u201eOTC\u201d)) und andere Gesundheitsprodukte, was die\nZunahme der Selbstmedikation widerspiegelt. Dermapharm geht davon aus, dass sie\nvon diesen Trends profitiert und dass dies auch in Zukunft der Fall sein wird. Die\nVerk\u00e4ufe von Dermapharm in Deutschland machten rund 92,6% des Umsatzes von\nDermapharm im zum 30. September 2017 endenden Neunmonatszeitraum aus.\nDermapharm ist auch in \u00d6sterreich und der Schweiz t\u00e4tig. Die Verk\u00e4ufe in diesen\nL\u00e4ndern machten rund 4,9% des Umsatzes von Dermapharm in derselben\nNeunmonatsperiode aus. Dermapharm plant, ausgew\u00e4hlte Produkte aus dem\nbestehenden Produktportfolio sowie neu entwickelte Produkte in zus\u00e4tzlichen\nM\u00e4rkten einzuf\u00fchren.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.2296834901625321, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-25-3", "text": "Arzneimittel und andere Gesundheitsprodukte\n", "page_number": 25, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4957228400342173, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.5098374679213002, "height": 0.014114627887082953, "width": 0.33917775090689245}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-25-4", "text": "Die Arzneimittel und anderen Gesundheitsprodukte von Dermapharm decken durch\nein breites Sortiment an Produkten, die unter bekannten Markennamen vertrieben\nwerden, zahlreiche Produktbereiche ab. Dermapharm fokussiert sich auf die\nEntwicklung, Herstellung und Vermarktung von Arzneimitteln und anderen\nGesundheitsprodukten f\u00fcr spezifisch ausgew\u00e4hlte M\u00e4rkte, in denen Dermapharm im\nAllgemeinen einen signifikanten Marktanteil h\u00e4lt und attraktive Margen\nerwirtschaftet. Dermapharm ist durch ihr Vitamin D Pr\u00e4parat Dekristol\u00ae 20.000 I.E.\ndie Marktf\u00fchrerin f\u00fcr verschreibungspflichtige Vitamine in Deutschland (basierend\nauf der Anzahl der Verschreibungen und der Ums\u00e4tze, ohne Ber\u00fccksichtigung von\nKrankenhausums\u00e4tzen (Quellen: INSIGHT Health; Informationen der Gesellschaft)).\nIhr breites Produktsortiment hat Dermapharm zugleich zur Marktf\u00fchrerin f\u00fcr\nverschreibungspflichtige dermatologische Produkte und systemische Kortikoide\ngemacht (basierend auf der Anzahl der Verschreibungen und der Ums\u00e4tze f\u00fcr von\nDermapharm angebotene APIs, ohne Ber\u00fccksichtigung von Krankenhausums\u00e4tzen\n(Quellen: INSIGHT Health; Informationen der Gesellschaft)). F\u00fcr OTC Produkte\nkann Dermapharm ihre Expertise bei der Entwicklung und Vermarktung von\nverschreibungspflichtigen Arzneimitteln wirksam nutzen, um die erforderlichen\nMarktzulassungen      rasch    und    kosteneffizient   zu    erlangen.    Andere\nGesundheitsprodukte k\u00f6nnen ohne Marktzulassungen vertrieben werden und\nDermapharm profitiert von ihren langj\u00e4hrigen Gesch\u00e4ftsbeziehungen zu Apotheken\nauf Basis ihres Pharmagesch\u00e4fts sowie bekannter Marken. Im zum 30. September\n2017 endenden Neunmonatszeitraum entfielen 46,8% des Umsatzes und 93,8% des\nErgebnisses vor Zinsen, Steuern und Abschreibungen (earnings before interest, taxes,\ndepreciation and amortization (\u201eEBITDA\u201d)) von Dermapharm auf Arzneimittel und\nandere Gesundheitsprodukte.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5162532078699743, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8588537211291702, "height": 0.34260051325919594, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-25-5", "text": "S-20\n", "page_number": 25, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-0", "text": "Parallelimporte\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.11608222490931075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-1", "text": "Das Parallelimportgesch\u00e4ft von Dermapharm, das unter der bekannten Marke\n\u201eaxicorp\u201d operiert, wird durch die gesetzliche Vorgabe beg\u00fcnstigt, dass mindestens\n5% aller verschreibungspflichtigen Arzneimittel, die im Rahmen des gesetzlichen\nGesundheitssystems      in   Deutschland      verkauft  werden,      aus    anderen\nEWR Mitgliedstaaten importiert werden m\u00fcssen, um zur Senkung der\nGesundheitskosten beizutragen. Der tats\u00e4chliche Marktanteil von Parallelimporten in\nDeutschland \u00fcbersteigt diesen Anteil und belief sich auf rund 8,6% im zum\n31. Dezember 2016 endenden Gesch\u00e4ftsjahr (Quelle: INSIGHT Health). Im gleichen\nGesch\u00e4ftsjahr deckte Dermapharm etwa 89% der verschreibungspflichtigen\nArzneimittel, die zum Weiterverkauf auf dem deutschen Parallelimportmarkt zur\nVerf\u00fcgung standen, ab und war der viertgr\u00f6\u00dfte Parallelimporteur in Deutschland\n(Quelle: INSIGHT Health). Ihre starke Marktexpertise sowie ihre stringente Planung,\ndie kontinuierlich von Verkaufs- und Beschaffungsexperten weiterentwickelt wird,\nerlauben es Dermapharm, einen geeigneten Produktmix sicherzustellen und somit\nihre angepeilte Gewinnmarge einzuhalten. Auf Parallelimporte, einschlie\u00dflich\nbestimmter OTC Produkte, die von der axicorp GmbH und deren direkten und\nindirekten Tochtergesellschaften vermarktet wurden, entfielen 53,2% des Umsatzes\nund 6,1% des EBITDA von Dermapharm im zum 30. September 2017 endenden\nNeunmonatszeitraum.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3627031650983747, "height": 0.2570573139435415, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-2", "text": "Im zum 31. Dezember 2016 endenden Gesch\u00e4ftsjahr erzielte Dermapharm einen\nUmsatz von \u20ac444,5 Mio. und ein EBITDA von \u20ac102,7 Mio. Im zum 30. September\n2017 endenden Neunmonatszeitraum beliefen sich der Umsatz von Dermapharm auf\n\u20ac349,7 Mio. und ihr EBITDA auf \u20ac82,9 Mio.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.37254063301967494, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42771599657827203, "height": 0.05517536355859709, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-3", "text": "Dermapharm glaubt, dass die Entwicklung ihres Unternehmens durch folgende\nSt\u00e4rken unterst\u00fctzt wird:\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4341317365269461, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4602224123182207, "height": 0.02609067579127461, "width": 0.5804111245465537}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-4", "text": "\uf0b7   F\u00fchrende Arzneimittelherstellerin in attraktiven, ausgew\u00e4hlten Produktbereichen\n    mit einer breiten Produktdiversifizierung.\n\uf0b7   Strategischer Fokus auf ausgew\u00e4hlte M\u00e4rkte mit besonders attraktiven Margen.\n\uf0b7   Historie von erfolgreichen Produktentwicklungen, unterst\u00fctzt durch operative\n    Spitzenleistungen und einen \u201eAlles unter einem Dach\u201c Ansatz.\n\uf0b7   Effektive Verkaufsorganisation.\n\uf0b7   Breites Produktangebot f\u00fcr Parallelimporte, das von einer hochintegrierten\n    Organisation beschafft und vermarktet wird.\n\uf0b7   Hohe Profitabilit\u00e4t mit glaubw\u00fcrdiger Erzielung von Cashflows und signifikanter\n    Dividendenkapazit\u00e4t.\n\uf0b7   H\u00f6chst erfahrenes und engagiertes F\u00fchrungsteam mit einer erwiesenen\n    Erfolgsgeschichte.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6834901625320787, "height": 0.2117194183062447, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-5", "text": "Die Schl\u00fcsselelemente der Strategie von Dermapharm sind:\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6907613344739093, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.704448246364414, "height": 0.01368691189050475, "width": 0.4014510278113664}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-6", "text": "\uf0b7   Dermapharm strebt danach, ihr Produktportfolio durch die Einf\u00fchrung neuer\n    Produkte, die sie selbst entwickelt, zu erweitern.\n\uf0b7   Dermapharm plant, ihre internationale Pr\u00e4senz zu vergr\u00f6\u00dfern.\n\uf0b7   Dermapharm beabsichtigt, ihre Erfolgsgeschichte gelungener \u00dcbernahmen\n    fortzusetzen, um ihr Wachstum und ihre Profitabilit\u00e4t weiter zu st\u00e4rken.\n\uf0b7   Dermapharm strebt danach, die Verkaufszahlen von OTC und anderen\n    Gesundheitsprodukten durch zielgerichtete Vermarktungsbem\u00fchungen zu\n    steigern.\n\uf0b7   Dermapharm      plant,    die    Abl\u00e4ufe     und   Marktanalysen   f\u00fcr   ihr\n    Parallelimportgesch\u00e4ft weiter zu optimieren.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8793840889649273, "height": 0.16809238665526083, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-26-7", "text": "S-21\n", "page_number": 26, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03143893591293839}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-0", "text": "Der Arzneimittelmarkt wird derzeit von einer Reihe von wesentlichen Trends\nbeeinflusst, die zusammen Auswirkungen auf die Leistung einzelner\nArzneimittelhersteller wie Dermapharm haben. Diese Trends sind insbesondere:\n", "page_number": 27, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-1", "text": "B.4a Wichtigste\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08597091531223268, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.09923011120615911, "height": 0.013259195893926434, "width": 0.11668681983071341}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-2", "text": "a Wichtigste\n  j\u00fcngste Trends,\n", "page_number": 27, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.09965782720273739, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.11291702309666382, "height": 0.013259195893926434, "width": 0.11668681983071344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-3", "text": "die sich auf den\n", "page_number": 27, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.11334473909324208, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.1253207869974337, "height": 0.011976047904191628, "width": 0.11668681983071344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-4", "text": "die sich auf den      Arzneimittelhersteller wie Dermapharm haben. Diese Trends sind insbesondere:\nEmittenten und\n                      Demographische Entwicklungen und die Chronifizierung von Krankheiten\ndie Branchen, in\ndenen er t\u00e4tig ist,   W\u00e4hrend die Weltbev\u00f6lkerung rasant w\u00e4chst, herrscht eine signifikante Disparit\u00e4t\nauswirken.            zwischen Entwicklungsl\u00e4ndern und den am h\u00f6chsten entwickelten L\u00e4ndern,\n                      einschlie\u00dflich Deutschland, wo die Geburtenraten bestenfalls stabil sind. Gleichzeitig\n                      w\u00e4chst die durchschnittliche Lebensdauer, was zu einem wachsenden Anteil \u00e4lterer\n                      Menschen f\u00fchrt. Die Alterung der Bev\u00f6lkerung erh\u00f6ht auch die H\u00e4ufigkeit\n                      verschiedener altersbedingter Krankheiten und Beschwerden. Bei \u00e4lteren Menschen\n                      besteht im Durchschnitt eine h\u00f6here Wahrscheinlichkeit, dass diese mehrere\n                      Arzneimittel zur gleichen Zeit einnehmen. Zudem f\u00fchren medizinische Fortschritte\n                      dazu, dass eine gr\u00f6\u00dfere Zahl von Krankheiten und Beschwerden mit entsprechenden\n                      Medikamenten behandelt werden kann. Dermapharm geht davon aus, dass sich die\n                      Alterung der Bev\u00f6lkerung und der damit einhergehende Trend zur Multimedikation\n                      positiv auf die Nachfrage nach den Arzneimitteln und anderen Gesundheitsprodukten\n                      von Dermapharm auswirken werden.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.1270316509837468, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3319076133447391, "height": 0.20487596236099231, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-5", "text": "Gestiegenes Gesundheitsbewusstsein und Selbstmedikation\n", "page_number": 27, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3383233532934132, "lower_right_x": 0.7255139056831923, "lower_right_y": 0.35243798118049613, "height": 0.014114627887082953, "width": 0.4262394195888755}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-6", "text": "Die erh\u00f6hte Verf\u00fcgbarkeit von sowie der bessere Zugang zu medizinischen\nInformationen f\u00fchren zu einem gr\u00f6\u00dferen Gesundheitsbewusstsein. Die Anzahl der\nMenschen, die das Internet aktiv zur Sammlung von Informationen \u00fcber Krankheiten\nund Beschwerden nutzen, w\u00e4chst stetig. Durch online Recherchen k\u00f6nnen Patienten\nleicht auf diverse Daten im Hinblick auf Krankheiten, Behandlungsm\u00f6glichkeiten,\neinschl\u00e4gige Arzneimittel, Arzneimittelhersteller sowie Bewertungen durch andere\nPatienten zugreifen. Der gestiegene Stellenwert des Internets beeinflusst auch den\nMarktzugang von Arzneimitteln. Das gr\u00f6\u00dfere Gesundheitsbewusstsein f\u00fchrt zu einem\nallgemeinen Trend hin zur Selbstmedikation (d.h. Patienten nehmen eigenst\u00e4ndig\nOTC und andere Gesundheitsprodukte f\u00fcr tats\u00e4chliche oder eingebildete Krankheiten\nund Beschwerden sowie zur Pr\u00e4vention und zur aktiven Verbesserung ihres\nWohlbefindens ein). Dieser Trend hat zu einer wachsenden Nachfrage nach solchen\nOTC und anderen Gesundheitsprodukten gef\u00fchrt (z.B. Di\u00e4tprodukte und\nNahrungserg\u00e4nzungsmittel). Dermapharm ist der Ansicht, dass sich das gr\u00f6\u00dfere\nGesundheitsbewusstsein und der Trend hin zur Selbstmedikation positiv auf die\nNachfrage nach den OTC und anderen Gesundheitsprodukten von Dermapharm\n", "page_number": 27, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.58169375534645, "height": 0.22155688622754494, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-7", "text": "                        auswirken werden.\nB.5 Beschreibung der    Die Gesellschaft ist die Holdinggesellschaft von Dermapharm. Dermapharm betreibt\n    Gruppe und der      ihr    Unternehmen       durch    die    Dermapharm      Aktiengesellschaft (die\n    Stellung des        \u201eDermapharm AG\u201d) sowie deren diverse Tochtergesellschaften. Die Gruppe der\n    Emittenten          konsolidierten Gesellschaften, aus denen Dermapharm besteht, beinhaltet alle\n    innerhalb dieser    Gesellschaften, deren Finanz- und Gesch\u00e4ftspolitik die Gesellschaft direkt oder\n    Gruppe.             indirekt kontrollieren kann sowie jene Beteiligungen von Dermapharm, deren\n                        Finanz- und Gesch\u00e4ftspolitik die Gesellschaft in signifikantem Ma\u00dfe beeinflusst\n                        werden k\u00f6nnen. Zum Datum dieses Prospekts umfasst Dermapharm\n                        26 Gesellschaften, von denen zw\u00f6lf in Deutschland ans\u00e4ssig sind.\nB.6 Name jeder          Die      Alleingesellschafterin    der    Gesellschaft    ist    die  Themis\n    Person, die eine    Beteiligungs-Aktiengesellschaft (die \u201eVer\u00e4u\u00dfernde Aktion\u00e4rin\u201d). Die Aktion\u00e4re\n    meldepflichtige     der Ver\u00e4u\u00dfernden Aktion\u00e4rin sind Herr Wilhelm Beier, der zum Datum dieses\n    direkte oder        Prospekts 80,00% der Aktien der Ver\u00e4u\u00dfernden Aktion\u00e4rin h\u00e4lt, Frau Elisabeth\n    indirekte           Beier, die zum Datum dieses Prospekts 19,26% der Aktien der Ver\u00e4u\u00dfernden\n    Beteiligung am      Aktion\u00e4rin h\u00e4lt und Herr Michael Beier, der zum Datum dieses Prospekts die\n    Eigenkapital des    verbleibenden 0,74% der Aktien der Ver\u00e4u\u00dfernden Aktion\u00e4rin h\u00e4lt.\n    Emittenten oder\n    einen Teil der\n    Stimmrechte h\u00e4lt.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5821214713430283, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8656971770744226, "height": 0.28357570573139435, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-27-8", "text": "S-22\n", "page_number": 27, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-0", "text": "Unterschiedliche\n", "page_number": 28, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.08597091531223268, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.09837467921300257, "height": 0.012403763900769887, "width": 0.12575574365175332}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-1", "text": "Entf\u00e4llt. Alle Aktien gew\u00e4hren die gleichen Stimmrechte.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08597091531223268, "lower_right_x": 0.685006045949214, "lower_right_y": 0.09923011120615911, "height": 0.013259195893926434, "width": 0.3857315598548972}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-2", "text": "Unterschiedliche\nStimmrechte der\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.09965782720273739, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.11206159110350727, "height": 0.012403763900769887, "width": 0.12575574365175335}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-3", "text": "Hauptanteils-\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.11334473909324208, "lower_right_x": 0.2539298669891173, "lower_right_y": 0.12788708297690335, "height": 0.014542343883661268, "width": 0.09975816203143895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-4", "text": "eigner.\nUnmittelbare      Die Gesellschaft wird von der Ver\u00e4u\u00dfernden Aktion\u00e4rin aufgrund deren Haltens\noder mittelbare   s\u00e4mtlicher Stimmrechte an der Gesellschaft und der daraus resultierenden\nBeteiligungen     M\u00f6glichkeit, die Finanz- und Gesch\u00e4ftspolitik der Gesellschaft zu bestimmen, direkt\noder              beherrscht. Die Ver\u00e4u\u00dfernde Aktion\u00e4rin wiederum wird direkt von Herrn Wilhelm\nBeherrschungs-    Beier beherrscht da diesem die Mehrheit der Stimmrechte an der Ver\u00e4u\u00dfernden\nverh\u00e4ltnisse.     Aktion\u00e4rin geh\u00f6ren und er folglich die M\u00f6glichkeit hat, die Finanz- und\n                  Gesch\u00e4ftspolitik der Ver\u00e4u\u00dfernden Aktion\u00e4rin zu bestimmen.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.1283147989734816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.11462788708297691, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-5", "text": "Die in den nachfolgenden Tabellen und der Diskussion enthaltenen\nFinanzinformationen wurden dem gepr\u00fcften Konzernabschluss der Dermapharm AG,\ndes fr\u00fcheren Mutterunternehmens von Dermapharm, f\u00fcr die zum 31 Dezember 2016,\n2015 and 2014 endenden Gesch\u00e4ftsjahre sowie dem ungepr\u00fcften verk\u00fcrzten\nKonzernzwischenabschluss der Dermapharm AG f\u00fcr den zum 30. September 2017\nendenden Neunmonatszeitraum und dem Einzelabschluss der Gesellschaft zum\n30. September 2017 sowie f\u00fcr den Zeitraum vom 12. Juli 2017 bis zum\n30. September 2017 entnommen oder aus diesen abgeleitet. Zus\u00e4tzliche\nFinanzinformationen in Bezug auf bestimmte operative Informationen wurden der\nBuchf\u00fchrung oder dem internen Berichtswesen von Dermapharm entnommen oder\naus diesen abgeleitet. Der gepr\u00fcfte Konzernabschluss sowie der gepr\u00fcfte\nEinzelabschluss wurden in \u00dcbereinstimmung mit den International Financial\nReporting Standards, wie sie in der Europ\u00e4ischen Union anzuwenden sind (\u201eIFRS\u201d),\nerstellt. Der ungepr\u00fcfte, verk\u00fcrzte Konzernzwischenabschluss wurde in\n\u00dcbereinstimmung mit IAS 34 erstellt.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.24935842600513258, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4550898203592814, "height": 0.20573139435414883, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-6", "text": "B.7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2506415739948674, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.262617621899059, "height": 0.0119760479041916, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-7", "text": "Ausgew\u00e4hlte\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.2506415739948674, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.26390076988879385, "height": 0.013259195893926434, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-8", "text": "wesentliche\n", "page_number": 28, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.2643284858853721, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.2763045337895637, "height": 0.0119760479041916, "width": 0.08706166868198309}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-9", "text": "wesentliche\nhistorische\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.2780153977758768, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.28999144568006846, "height": 0.011976047904191656, "width": 0.08282950423216445}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-10", "text": "Finanz-\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.2917023096663815, "lower_right_x": 0.21100362756952842, "lower_right_y": 0.30367835757057315, "height": 0.011976047904191656, "width": 0.05683192261185008}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-11", "text": "Finanz-\ninformationen.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.30538922155688625, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.31736526946107785, "height": 0.0119760479041916, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-12", "text": "Die Warth & Klein Grant Thornton AG Wirtschaftspr\u00fcfungsgesellschaft,\nJohannstra\u00dfe 39, 40476 D\u00fcsseldorf, Deutschland, hat den Konzernabschluss der\nDermapharm AG f\u00fcr die zum 31. Dezember 2016, 2015 und 2014 endenden\nGesch\u00e4ftsjahre sowie den Einzelabschluss der Gesellschaft zum 30. September 2017\nsowie f\u00fcr den Zeitraum vom 12. Juli 2017 bis zum 30. September 2017 gepr\u00fcft und\nuneingeschr\u00e4nkte Best\u00e4tigungsvermerke erteilt Der vorgenannten gepr\u00fcften\nAbschl\u00fcsse, die dazugeh\u00f6rigen Best\u00e4tigungsvermerke des unabh\u00e4ngigen\nAbschlusspr\u00fcfers und der ungepr\u00fcfte verk\u00fcrzte Konzernzwischenabschluss der\nDermapharm AG f\u00fcr den zum 30. September 2017 endenden Neunmonatszeitraum\nsind in diesem Prospekt enthalten.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.46150556030795553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5988023952095808, "height": 0.13729683490162525, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-13", "text": "Soweit Finanzinformationen in den folgenden Tabellen mit \u201egepr\u00fcft\u201c gekennzeichnet\nsind, bedeutet dies, dass sie dem oben erw\u00e4hnten gepr\u00fcften Konzernabschluss\nentnommen wurden. Mit der Kennzeichnung \u201eungepr\u00fcft\u201c werden in den folgenden\nTabellen Finanzinformationen gekennzeichnet, die nicht dem oben erw\u00e4hnten\ngepr\u00fcften Abschluss entnommen wurden, sondern entweder dem oben erw\u00e4hnten\nungepr\u00fcften verk\u00fcrzten Konzernzwischenabschluss oder dem internem\nBerichtswesen von Dermapharm entnommen oder auf Grundlage von Zahlen aus den\nzuvor genannten Quellen berechnet wurden.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.605218135158255, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7151411462788708, "height": 0.10992301112061587, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-28-14", "text": "S-23\n", "page_number": 28, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-29-0", "text": "Die im nachfolgendem Text und den untenstehenden Tabellen aufgef\u00fchrten\nFinanzinformationen werden in Millionen Euro (\u20ac Mio.) gezeigt, soweit nicht anders\nangegeben. Bestimmte Finanzinformationen (einschlie\u00dflich von Prozents\u00e4tzen) in\nden untenstehenden Tabellen wurden auf eine Dezimalstelle hinter dem Komma\nkaufm\u00e4nnisch gerundet. Daher entsprechen die Gesamtwerte (Summen oder\nZwischensummen oder Differenzen oder Zahlen, die in Bezug zueinander stehen) in\nden untenstehenden Tabellen m\u00f6glicherweise nicht in allen F\u00e4llen den Gesamtwerten\nder zugrundeliegenden (ungerundeten) Zahlen, die an anderer Stelle in diesem\nProspekt erscheinen. Weiterhin kann die Addition dieser gerundeten Zahlen in jenen\nTabellen von den in den Tabellen enthaltenen Summen abweichen. Bei in Klammern\nangegebenen Finanzinformationen handelt es sich um den negativen Wert der\ngezeigten Zahlen. In Bezug auf den Ausweis von Finanzinformationen in diesem\nProspekt bedeutet ein Gedankenstrich (\u201e\u2013\u201c), dass die jeweilige Zahl nicht verf\u00fcgbar\nist, w\u00e4hrend eine Null (\u201e0,0\u201c) bedeutet, dass die jeweilige Zahl zwar verf\u00fcgbar ist, sie\naber auf Null gerundet wurde.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08597091531223268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.20487596236099231, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-29-1", "text": "Ausgew\u00e4hlte Konzernfinanzinformationen der Dermapharm AG\nKonzerngesamtergebnisrechnung\n", "page_number": 29, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.29726261762189904, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.3319076133447391, "height": 0.03464499572284008, "width": 0.4740024183796856}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-29-2", "text": "                                                                                                                        F\u00fcr den zum\n                                                                                  F\u00fcr das zum                     30. September endenden\n                                                                       31. Dezember endende Gesch\u00e4ftsjahr          Neunmonatszeitraum\n                                                                       2014           2015          2016            2016             2017\n                                                                                    (gepr\u00fcft)                           (ungepr\u00fcft)\n                                                                                   (in \u20ac Mio.)                           (in \u20ac Mio.)\n Umsatzerl\u00f6se ...........................................................................\n                                                                         391,3                 384,8     444,5       319,2          349,7\n Erh\u00f6hung/Verminderung des Bestands an\n   fertigen und unfertigen Erzeugnissen ...................................  8,3                  2,9       1,0        4,1             0,4\n Aktivierte Eigenleistungen .......................................................\n                                                                             8,5                  8,0       8,3        5,4             8,0\n Sonstige betriebliche Ertr\u00e4ge ...................................................\n                                                                             6,2                  9,9       9,9        5,2             4,1\n Materialaufwand ......................................................................\n                                                                       (237,1)                (215,9)   (252,8)    (181,5)         (196,0)\n Personalaufwand ......................................................................\n                                                                         (57,7)                (55,7)    (58,7)     (42,0)          (46,5)\n Abschreibungen .......................................................................\n                                                                         (28,3)                (22,9)    (14,4)     (10,3)          (11,2)\n Sonstige betriebliche Aufwendungen .......................................\n                                                                         (48,0)                (50,3)    (51,0)     (35,1)          (38,1)\n Operatives Ergebnis ...............................................................\n                                                                            43,3                 60,8      86,8       65,1            70,4\n Ergebnis aus der nach der Equity Methode\n   bilanzierten Beteiligungen ...................................................\n                                                                             0,9                  1,0       1,5         1,1            1,2\n Finanzertr\u00e4ge ............................................................................\n                                                                             3,3                  9,4       7,3         4,1            3,3\n Finanzaufwendungen ...............................................................\n                                                                         (12,0)                (15,8)    (12,7)       (8,4)          (7,8)\n Ergebnis vor Steuern .............................................................\n                                                                            35,5                 55,3      82,9        61,8           67,2\n                                                                           (2,2)\n Ertragsteuern ............................................................................     (2,9)     (5,9)       (6,0)          (4,3)\n                                                                            33,2\nKonzernergebnis ......................................................................           52,4      77,0        55,9           62,9\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3383233532934132, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6501283147989735, "height": 0.3118049615055603, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-29-3", "text": "S-24\n", "page_number": 29, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-30-0", "text": "Konzernbilanz\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08511548331907613, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.09880239520958084, "height": 0.013686911890504708, "width": 0.10701330108827085}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-30-1", "text": "Konzernbilanz\n                                                                                        Zum                            Zum\n                                                                                   31. Dezember                   30. September\n                                                                    2014                2015       2016                2017\n                                                                                     (gepr\u00fcft)                     (ungepr\u00fcft)\n                                                                                    (in \u20ac Mio.)                     (in \u20ac Mio.)\nVerm\u00f6genswerte\n Immaterielle Verm\u00f6genswerte ....................                          71,7            68,0           70,0            129,7\n Gesch\u00e4fts- oder Firmenwert ........................                       21,6            16,4           17,0             17,0\n Sachanlagen ................................................              56,5            53,4           53,4             52,9\n At-Equity bewertete Beteiligungen .............                            1,6             2,7            3,2              4,4\n Beteiligungen ..............................................               0,5             0,2            0,3              0,2\n Sonstige langfristige nicht-finanzielle\n    Verm\u00f6genswerte .....................................                 9,2               13,8        10,6                22,4\n Aktive latente Steuern .................................                1,0                0,0         0,2                 1,7\n Summe langfristige Verm\u00f6genswerte ......                              162,1              154,6       154,7               228,3\n Vorr\u00e4te ........................................................       71,5               77,0        84,8                81,9\n Forderungen aus Lieferungen und\n    Leistungen ...............................................             22,8            17,4           26,3             34,7\n Sonstige kurzfristige finanzielle\n    Verm\u00f6genswerte .....................................                   58,8            42,5           40,0             68,7\n Sonstige kurzfristige Verm\u00f6genswerte .......                               3,0             1,4            1,7              1,7\n Forderungen aus Ertragssteuern \u2013\n    kurzfristig ................................................            0,7              1,0           0,4              0,4\n Zahlungsmittel und\n    Zahlungsmittel\u00e4quivalente ......................                    11,6                2,8         3,8                 3,8\n Summe kurzfristige Verm\u00f6genswerte .....                               168,5              142,1       157,0               200,3\nBilanzsumme ...............................................            330,6              296,7       311,7               428,6\n\nEigenkapital und Schulden\n Gezeichnetes Kapital ...................................                    1,3            1,3             1,3              1,3\n Kapitalr\u00fccklage ...........................................                 0,3            0,3             0,3              0,3\n Gewinnr\u00fccklagen ........................................                   28,6           39,5            56,3             70,0\n Sonstige R\u00fccklagen .....................................                  (1,9)            0,1           (1,0)            (2,1)\n Anteile nicht-beherrschender\n    Gesellschafter ..........................................               5,7             3,3            3,9                \uf02d\n Summe Eigenkapital .................................                      34,0            44,4           60,8             69,5\n R\u00fcckstellungen f\u00fcr Pensionen und\n    \u00e4hnliche Verpflichtungen ........................                   12,4               12,1           13,3             13,3\n Sonstige R\u00fcckstellungen .............................                   0,1                  \uf02d              \uf02d                \uf02d\n Finanzverbindlichkeiten ..............................                161,5              151,1           96,9            235,4\n Sonstige langfristige\n    Finanzverbindlichkeiten ..........................                   9,9               14,1        10,5                 8,1\n Sonstige langfristige Verbindlichkeiten ......                         15,6               13,3        11,5                10,4\n Passive latente Steuern ................................                  \uf02d                0,2         3,4                 3,4\n Summe langfristige Verbindlichkeiten ....                             199,6              190,7       135,5               272,9\n Sonstige R\u00fcckstellungen .............................                   6,1                6,4         7,0                 6,0\n Finanzverbindlichkeiten ..............................                 20,4               24,9        65,9                43,4\n Verbindlichkeiten aus Lieferungen und\n    Leistungen ...............................................             27,4            18,1           24,5             19,3\n Sonstige kurzfristige\n    Finanzverbindlichkeiten ..........................                  30,6                2,4         4,3                 2,1\n Sonstige kurzfristige Verbindlichkeiten ......                         11,4                8,2        11,0                11,0\n Ertragsteuerverbindlichkeiten .....................                     1,0                1,5         2,8                 3,9\n Summe kurzfristige Verbindlichkeiten ...                               97,0               61,6       115,4                86,2\nBilanzsummer ..............................................            330,6              296,7       311,7               428,6\n", "page_number": 30, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.864841745081266, "height": 0.7656116338751069, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-30-2", "text": "S-25\n", "page_number": 30, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-0", "text": "Konzernkapitalflussrechnung\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08511548331907613, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.21342200725513905}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-1", "text": "                                                                                                                   F\u00fcr den zum\n                                                                                F\u00fcr das zum                  30. September endenden\n                                                                     31. Dezember endende Gesch\u00e4ftsjahr       Neunmonatszeitraum(1)\n                                                                     2014           2015          2016         2016             2017\n                                                                                  (gepr\u00fcft)                        (ungepr\u00fcft)\n                                                                                 (in \u20ac Mio.)                        (in \u20ac Mio.)\nNetto-Cashflows aus laufender\n  Gesch\u00e4ftst\u00e4tigkeit .........................................          54,3           40,4           76,8        47,6           93,9\nNetto-Cashflows aus Investitionst\u00e4tigkeit ........                    (21,9)          (0,9)         (12,3)      (11,7)         (84,9)\nNetto-Cashflows aus\n  Finanzierungst\u00e4tigkeit ..................................              3,0         (55,6)         (55,9)      (47,9)         (17,2)\nNetto Zunahme/Abnahme von\n  Finanzmitteln ..............................................          35,3         (16,2)            8,6      (12,0)          (8,2)\nFinanzmittel(2) ..................................................       6,5          (9,6)          (1,1)      (21,6)          (9,3)\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28186484174508125, "height": 0.17621899059024806, "width": 0.7551390568319227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-2", "text": "Finanzmittel ..................................................   6,5   (9,6)   (1,1)        (21,6)         (9,3)\n\n(1) Aufgrund der Beendigung des Gewinnabf\u00fchrungsvertrags mit Wirkung zum Ende des 31. Dezember 2017 hat die\n    Dermapharm AG die Zusammensetzung ihrer Konzernkapitalflussrechnung ver\u00e4ndert, was bereits in den\n    Finanzinformationen in der Konzernkapitalflussrechnung, die im ungepr\u00fcften verk\u00fcrzten Konzernzwischenabschluss\n    der Dermapharm AG f\u00fcr den zum 30. September 2017 endenden Neunmonatszeitraum gezeigt wird, reflektiert ist.\n    Daher werden bestimmte Vergleichsfinanzinformationen f\u00fcr das zum 31. Dezember 2016 endende Gesch\u00e4ftsjahr, wie\n    sie in der Konzernkapitalflussrechnung im Konzernabschluss f\u00fcr das zum 31. Dezember 2017 endende Gesch\u00e4ftsjahr\n    gezeigt werden, von den Finanzinformationen in der Konzernkapitalflussrechnung im Konzernabschluss der\n    Dermapharm AG f\u00fcr die zum 31. Dezember 2016, 2015 und 2014 endenden Gesch\u00e4ftsjahre abweichen.\n(2) Zum Ende des betreffenden Zeitraums.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.2822925577416595, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40975192472198463, "height": 0.12745936698032512, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-3", "text": "Ausgew\u00e4hlte Finanzinformationen der Gesellschaft\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4238665526090676, "lower_right_x": 0.4879081015719468, "lower_right_y": 0.4375534644995723, "height": 0.013686911890504694, "width": 0.36698911729141476}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-4", "text": "                                                                                                      Zum 30. September sowie\n                                                                                        f\u00fcr den Zeitraum vom 12. Juli bis zum 30. September\n                                                                                                               2017\n                                                                                                         (gepr\u00fcft und in \u20ac)\nBilanzsumme Aktiva ................................................................                                                119.973,93\nBilanzsumme Passiva ...............................................................                                                119.973,93\nNetto Verlust ............................................................................                                            (26,07)\nNetto Ver\u00e4nderung der Zahlungsmittel und\n  Zahlungsmittel\u00e4quivalente ...................................................                                                     89.223,93\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.44439692044482465, "lower_right_x": 0.875453446191052, "lower_right_y": 0.561163387510693, "height": 0.1167664670658683, "width": 0.7503022974607014}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-5", "text": "Weitere Wesentliche Leistungskennzahlen\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.588109495295124, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.6017964071856288, "height": 0.01368691189050475, "width": 0.3041112454655381}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-6", "text": "Die Gesch\u00e4ftsleitung der Gesellschaft verwendet EBITDA als wesentliche Leistungskennzahl, um den\nGesch\u00e4ftserfolg von Dermapharm zu beurteilen. Zudem glaubt Dermapharm, dass das Umlaufverm\u00f6gen, die\nVerschuldungsquote und die Eigenkapitalquote f\u00fcr Anleger bei der Beurteilung der Leistung und Finanzlage\nvon Dermapharm hilfreich sind.\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6633875106928999, "height": 0.054747647562018775, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-7", "text": "Die nachfolgende Tabelle enth\u00e4lt zus\u00e4tzliche Betriebs- und Finanzinformationen \u00fcber Dermapharm f\u00fcr die\ngenannten Zeitr\u00e4ume und Zeitpunkte:\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6702309666381523, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.69803250641574, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-8", "text": "                                                                                                                    F\u00fcr den zum\n                                                                              F\u00fcr das zum                    30. September endenden\n                                                                   31. Dezember endende Gesch\u00e4ftsjahr          Neunmonatszeitraum\n                                                                   2014           2015          2016           2016             2017\n                                                                                                                    (ungepr\u00fcft)\n                                                                               (gepr\u00fcft und                   (in \u20ac Mio., soweit nicht\n                                                                 in \u20ac Mio., soweit nicht anders angegeben)      anders angegeben)\nUmsatzerl\u00f6se .................................................       391,3           384,8           444,5      319,2            349,7\nUmsatzwachstum (ungepr\u00fcft und in %)(1) .....                              \uf02d           (1,7)           15,5          \uf02d              9,6\nEBIT (ungepr\u00fcft)...........................................           44,2             61,7           88,3       66,1             71,7\nEBIT-Marge (ungepr\u00fcft und in %)(2) .............                      11,3             16,0           19,9       20,7             20,5\nEBITDA (ungepr\u00fcft) .....................................              72,5             84,6          102,7       76,4             82,9\nEBITDA-Marge (ungepr\u00fcft und in %)(3) .......                          18,5             22,0           23,1       23,9             23,7\nUmlaufverm\u00f6gen (ungepr\u00fcft)(4) ....................                    58,5             69,5           77,3          \uf02d             87,8\n", "page_number": 31, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7014542343883661, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8819503849443969, "height": 0.18049615055603085, "width": 0.7551390568319227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-31-9", "text": "S-26\n", "page_number": 31, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-0", "text": "                                                                                                                         F\u00fcr den zum\n                                                                                  F\u00fcr das zum                     30. September endenden\n                                                                       31. Dezember endende Gesch\u00e4ftsjahr           Neunmonatszeitraum\n                                                                       2014           2015          2016            2016             2017\n                                                                                                                         (ungepr\u00fcft)\n                                                                                   (gepr\u00fcft und                    (in \u20ac Mio., soweit nicht\n                                                                     in \u20ac Mio., soweit nicht anders angegeben)       anders angegeben)\nVerschuldungsquote (ungepr\u00fcft und\n  in %)(4) .......................................................        744,9           461,6           305,4           \uf02d            397,7\nEigenkapitalquote (ungepr\u00fcft und in %)(4) ....                             8,6            13,9            18,3            \uf02d            16,2\n", "page_number": 32, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.20872540633019676, "height": 0.12360992301112063, "width": 0.7587666263603385}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-1", "text": "(1)   Reflektiert die prozentuale Ver\u00e4nderung zwischen den betreffenden Zeitr\u00e4umen.\n(2)   Definiert als der Quotient aus dem EBIT geteilt durch die Umsatzerl\u00f6se.\n(3)   Definiert als der Quotient aus dem EBITDA geteilt durch die Umsatzerl\u00f6se.\n(4)   Zum Ende des betreffenden Zeitraums.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21899059024807527, "lower_right_x": 0.6360338573155986, "lower_right_y": 0.2703165098374679, "height": 0.05132591958939264, "width": 0.5205562273276905}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-2", "text": "Wesentliche       Die folgenden wesentlichen \u00c4nderungen in der Finanzlage und dem Betriebsergebnis\n\u00c4nderungen der    von Dermapharm traten in den zum 30. September 2016 und 2017 endenden\nFinanzlage und    Neunmonatszeitr\u00e4umen sowie in den zum 31. Dezember 2014, 2015 und 2016\ndes Betriebs-     endenden Gesch\u00e4ftsjahren sowie in dem darauffolgenden Zeitraum auf:\nergebnisses des\n                  J\u00fcngste Entwicklungen\nEmittenten in\noder nach dem     Am 1. Oktober 2017 hat Dermapharm den Erwerb aller Anteile an der\nvon den           Bio-Di\u00e4t-Berlin Gesellschaft mit beschr\u00e4nkter Haftung und der Kr\u00e4uter\nhistorischen      K\u00fchne GmbH abgeschlossen.\nFinanz-\n                  Im November 2017 hat sich die axicorp Pharma B.V. \u00fcber Klagen von privaten\ninformationen\n                  Krankenversicherern im Hinblick auf Rabatte in einer Gesamth\u00f6he von rund\nabgedeckten\n                  \u20ac1,2 Mio. verglichen. Zudem hat sie \u20ac1,9 Mio. nebst Zinsen in H\u00f6he von \u20ac0,2 Mio.\nZeitraum.\n                  an private Krankenversicherer im Hinblick auf Rabatte gezahlt, f\u00fcr die Dermapharm\n                  bereits Rechnungen erhalten hatte, die jedoch von diesen privaten\n                  Krankenversicherern noch nicht gerichtlich geltend gemacht worden waren.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5128314798973481, "height": 0.22925577416595377, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-3", "text": "hat", "page_number": 32, "bounding_box": {"top_left_x": 0.47158403869407495, "top_left_y": 0.5072711719418306, "lower_right_x": 0.4915356711003628, "lower_right_y": 0.5153977758768178, "height": 0.008126603934987209, "width": 0.019951632406287834}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-4", "text": "Dermapharm", "page_number": 32, "bounding_box": {"top_left_x": 0.49758162031438935, "top_left_y": 0.5072711719418306, "lower_right_x": 0.585247883917775, "lower_right_y": 0.5179640718562875, "height": 0.010692899914456877, "width": 0.0876662636033857}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-5", "text": "Am 19. November 2017 hat Dermapharm die zum damaligen Zeitpunkt ausstehende\nTranche in H\u00f6he von \u20ac6,5 Mio. Unter den Schuldscheindarlehen mit der Bayerischen\nLandesbank zur\u00fcckgezahlt.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.5132591958939264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5466210436270317, "height": 0.03336184773310524, "width": 0.5804111245465539}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-6", "text": "Am 6. Dezember 2017 hat die Hauptversammlung der Gesellschaft beschlossen, das\nGrundkapital der Gesellschaft von \u20ac120.000,00 um \u20ac49.880.000,00 auf\n\u20ac50.000.000,00 durch Ausgabe von 49.880.000 neuen Aktien der Gesellschaft gegen\nSacheinlage in Form von 104.960 Aktien der Dermapharm AG seitens der\nVer\u00e4u\u00dfernden Aktion\u00e4rin zu erh\u00f6hen (dies entspricht 20,0% des Grundkapitals der\nDermapharm AG). Zudem hat die Ver\u00e4u\u00dfernde Aktion\u00e4rin die verbleibenden\n419.840 Aktien der Dermapharm AG (dies entspricht 80,0% des Grundkapitals der\nDermapharm AG) ohne Gegenleistung in die freien R\u00fccklagen der Gesellschaft\neingebracht. Die Einbringung und \u00dcbertragung aller Aktien der Dermapharm AG\nwurden mit Wirkung zum Ende des 31. Dezember 2017 vollzogen und die\nDurchf\u00fchrung der Kapitalerh\u00f6hung wurde am 4. Januar 2018 in das Handelsregister\ndes Amtsgerichts M\u00fcnchen, Deutschland, eingetragen.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7181351582549187, "height": 0.16424294268605644, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-7", "text": "Am 20. Dezember 2017 hat Dermapharm alle Anteile an der Strathmann GmbH &\nCo. KG, deren alleiniger Komplement\u00e4rin, der Strathmann Service GmbH und der\nBiokirch GmbH Pharmaproduktion und \u00c4rzteservice (zusammen \u201cStrathmann\u201d)\nerworben. Strathmann vertreibt ein breites Produktangebot das \u00fcberwiegend OTC\nProdukte umfasst, die das bestehende Produktportfolio von Dermapharm erg\u00e4nzen,\ninsbesondere in den Produktbereichen Dermatologika, Gyn\u00e4kologie und\nVitamine/Mineralien/Enzyme. Im zum 31. Dezember 2016 endenden Gesch\u00e4ftsjahr\nhat Strathmann einen Gesamtumsatz in H\u00f6he von \u20ac27,9 Mio. und ein EBITDA in\nH\u00f6he von \u20ac3,7 Mio. erwirtschaftet (basierend auf den nach dem Handelsgesetzbuch\n(\u201cHGB\u201d) erstellten Abschl\u00fcssen von Strathmann).\n", "page_number": 32, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8622754491017964, "height": 0.13729683490162536, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-32-8", "text": "S-27\n", "page_number": 32, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-0", "text": "Der Gewinnabf\u00fchrungsvertrag zwischen der Ver\u00e4u\u00dfernden Aktion\u00e4rin und der\nDermapharm AG (der \u201eGewinnabf\u00fchrungsvertrag\u201d) wurde mit Wirkung zum\n31. Dezember 2017 beendet (siehe C.7).\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-1", "text": "Am 2. Januar 2018 hat Dermapharm die finale Tranche ihrer auf den Namen\nlautenden Genussrechte in H\u00f6he von \u20ac6,4 Mio. zur\u00fcckgezahlt.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.1330196749358426, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16082121471343028, "height": 0.027801539777587675, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-2", "text": "Am 23. Januar 2018 hat Dermapharm alle Anteilen an der Trommsdorff GmbH &\nCo. KG und deren alleiniger Komplement\u00e4rin, der Cl. Lageman Gesellschaft mit\nbeschr\u00e4nkter Haftung (zusammen \u201cTrommsdorff\u201d) erworben. Trommsdorff\nproduziert und vertreibt 23 verschiedene verschreibungspflichtige Arzneimittel und\nOTC Produkte, insbesondere Keltican\u00ae forte, ein Di\u00e4tprodukt zur Behandlung von\nR\u00fcckenschmerzen sowie Tromcardin\u00ae complex, das bestimmte Mineralien und\nVitamine zur Behandlung von Herzrhythmusst\u00f6rungen kombiniert. Trommsdorff\ndient ihrem ehemaligen Mutterkonzern zudem als Lohnherstellerin. Im zum 31.\nDezember 2016 endenden Gesch\u00e4ftsjahr hat Trommsdorff einen Gesamtumsatz in\nH\u00f6he von \u20ac52,0 Mio. und ein EBITDA in H\u00f6he von \u20ac10,6 Mio. erwirtschaftet\n(basierend auf den nach HGB erstellten Abschl\u00fcssen von Trommsdorff).\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.16723695466210436, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.15098374679213, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-3", "text": "Zum   30. September   2016   und   30. September   2017   endende\nNeunmonatszeitr\u00e4ume\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3246364414029085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35115483319076135, "height": 0.02651839178785287, "width": 0.5810157194679566}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-4", "text": "Im zum 30. September 2017 endenden Neunmonatszeitraum stiegen die\nUmsatzerl\u00f6se von Dermapharm von \u20ac319,2 Mio. im zum 30. September 2016\nendenden Neunmonatszeitraum um \u20ac30,5 Mio., oder 9,6%, auf \u20ac349,7 Mio., was den\nAnstieg der Verk\u00e4ufe sowohl von Arzneimitteln und anderen Gesundheitsprodukten\nals auch Parallelimporten widerspiegelt. Die betrieblichen Ertr\u00e4ge von Dermapharm\nstiegen ebenfalls im zum 30. September 2017 endenden Neunmonatszeitraum von\n\u20ac65,1 Mio. im zum 30. September 2016 endenden Neunmonatszeitraum um\n\u20ac5,3 Mio., oder 8,1%, auf \u20ac70,4 Mio., aufgrund der starken Entwicklung im\nGesch\u00e4ftsbereich Arzneimittel und andere Gesundheitsprodukte von Dermapharm.\nAufgrund dieser positiven Entwicklungen stieg das Konzernergebnis von\nDermapharm um \u20ac7,0 Mio., oder 12,5%, im zum 30. September 2017 endenden\nNeunmonatszeitraum von einem Konzernergebnis von \u20ac55,9 Mio. im zum\n30. September 2016 endenden Neunmonatszeitraum auf \u20ac62,9 Mio.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.35885372112917024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5372112917023096, "height": 0.1783575705731394, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-5", "text": "Zum 31. Dezember 2015 und 31. Dezember 2016 endende Gesch\u00e4ftsjahre\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8216444981862152, "lower_right_y": 0.5594525235243798, "height": 0.012403763900769915, "width": 0.5223700120918984}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-6", "text": "Die Umsatzerl\u00f6se stiegen von \u20ac384,8 Mio. im zum 31. Dezember 2015 endenden\nGesch\u00e4ftsjahr um \u20ac59,7 Mio., oder 15,5% auf \u20ac444,5 Mio. im zum 31. Dezember\n2016 endenden Gesch\u00e4ftsjahr, haupts\u00e4chlich aufgrund eines Anstiegs der\nVerkaufszahlen von Dekristol\u00ae 20.000 I.E., die um 38,2% zunahmen. Die\nbetrieblichen Ertr\u00e4ge stiegen von \u20ac60,8 Mio. im zum 31. Dezember 2015 endenden\nGesch\u00e4ftsjahr um \u20ac26,0 Mio., oder 42,8%, auf \u20ac86,8 Mio. im zum 31. Dezember\n2016 endenden Gesch\u00e4ftsjahr, im Wesentlichen aufgrund der F\u00e4higkeit von\nDermapharm, die Bruttoerl\u00f6se zu steigern und die Personalkosten zu senken. Diese\npositiven Entwicklungen hatten zur Folge, dass das Konzernergebnis von\nDermapharm von \u20ac52,4 Mio. im zum 31. Dezember 2015 endenden Gesch\u00e4ftsjahr\num \u20ac24,6 Mio., oder 46,9%, auf \u20ac77,0 Mio. im zum 31. Dezember 2016 endenden\nGesch\u00e4ftsjahr stieg.\n", "page_number": 33, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7288280581693756, "height": 0.16124893071000856, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-33-7", "text": "S-28\n", "page_number": 33, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-34-0", "text": "Zum 31. Dezember 2014 und 31. Dezember 2015 endende Gesch\u00e4ftsjahre\n", "page_number": 34, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.522974607013301}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-34-1", "text": "                        Im zum 31. Dezember 2014 endenden Gesch\u00e4ftsjahr sind die Umsatzerl\u00f6se von\n                        \u20ac391,3 Mio. im zum 31. Dezember 2015 endenden Gesch\u00e4ftsjahr um \u20ac6,5 Mio., oder\n                        1,7%, auf \u20ac384,8 Mio. leicht gesunken, da ein Anstieg der Verk\u00e4ufe von\n                        Arzneimitteln und anderen Gesundheitsprodukten durch den R\u00fcckgang der Ums\u00e4tze\n                        aus dem Parallelimportgesch\u00e4ft von Dermapharm mehr als kompensiert wurde. Die\n                        betrieblichen Ertr\u00e4ge von Dermapharm stiegen von \u20ac43,3 Mio. im zum 31. Dezember\n                        2014 endenden Gesch\u00e4ftsjahr um \u20ac17,5 Mio., oder 40,4%, auf \u20ac60,8 Mio. im zum\n                        31. Dezember 2015 endenden Gesch\u00e4ftsjahr, was den Anstieg der Bruttoerl\u00f6se von\n                        Dermapharm reflektiert. Diese positiven Entwicklungen spiegeln sich auch im\n                        Konzernergebnis von Dermapharm, das von \u20ac33,2 Mio. im zum 31. Dezember 2014\n                        endenden Gesch\u00e4ftsjahr um \u20ac19,2 Mio., oder 57,8%, auf \u20ac52,4 Mio. im zum\n                        31. Dezember 2015 endenden Gesch\u00e4ftsjahr stieg.\nB.8 Ausgew\u00e4hlte         Entf\u00e4llt. Die Gesellschaft hat keine Pro-forma-Finanzinformationen erstellt.\n    wesentliche Pro-\n    forma-Finanz-\n    informationen.\nB.9 Gewinnprognose      Entf\u00e4llt. Die Gesellschaft hat keine Gewinnprognose oder -sch\u00e4tzung erstellt.\n    oder -sch\u00e4tzung.\nB.10 Beschr\u00e4nkungen     Entf\u00e4llt. Die Pr\u00fcfvermerke f\u00fcr die in diesem Prospekt enthaltenen historischen\n     im Best\u00e4tigungs-   Finanzinformationen wurden ohne Einschr\u00e4nkungen erteilt.\n     vermerk zu den\n     historischen\n     Finanzinfor-\n     mationen.\nB.11 Nicht Ausreichen   Entf\u00e4llt. Die Gesellschaft ist der Ansicht, dass Dermapharm die\n     des Gesch\u00e4fts-     Zahlungsverpflichtungen erf\u00fcllen kann, die in den n\u00e4chsten zw\u00f6lf Monaten f\u00e4llig\n     kapitals des       werden.\n     Emittenten.\n\nC \u2013 Wertpapiere\nC.1 Art und Gattung     Dieses erstmalige \u00f6ffentliche Angebot (das \u201eAngebot\u201c) bezieht sich auf das Angebot\n    der angebotenen     von 13.455.000 auf den Inhaber lautenden St\u00fcckaktien der Gesellschaft, jeweils mit\n    und/oder zum        einem Nominalwert von \u20ac1,00, bestehend aus:\n    Handel\n                        \uf0b7   3.840.000 neu ausgegebenen, auf den Inhaber lautenden St\u00fcckaktien aus einer\n    zuzulassenden\n                            Kapitalerh\u00f6hung gegen Bareinlagen (die \u201eIPO Kapitalerh\u00f6hung\u201d), die in einer\n    Wertpapiere.\n                            au\u00dferordentlichen Hauptversammlung der Gesellschaft am oder um den\n                            26. Januar 2018 beschlossen werden soll (die \u201eNeuen Aktien\u201d);\n                        \uf0b7   7.860.000 bestehenden, auf den Inhaber lautenden St\u00fcckaktien aus dem Bestand\n                            der Ver\u00e4u\u00dfernden Aktion\u00e4rin (die \u201eBestehenden Aktien\u201c und zusammen mit\n                            den Neuen Aktien die \u201eBasisaktien\u201c); und\n                        \uf0b7   1.755.000 bestehenden, auf den Inhaber lautenden St\u00fcckaktien aus dem Bestand\n                            der Ver\u00e4u\u00dfernden Aktion\u00e4rin in Verbindung mit einer m\u00f6glichen Mehrzuteilung\n                            (die \u201eMehrzuteilungsaktien\u201d und zusammen mit den Basisaktien die\n                            \u201eAngebotsaktien\u201d).\n    Wertpapier-         International Securities Identification Number (ISIN):   DE000A2GS5D8\n    kennung.\n                        Wertpapierkennnummer (WKN):                              A2GS5D\n                        Ticker Symbol:                                           DMP\n\nC.2 W\u00e4hrung der         Euro.\n    Wertpapier-\n", "page_number": 34, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.878956372968349, "height": 0.7733105218135159, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-34-2", "text": "S-29\n", "page_number": 34, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-35-0", "text": "C.3 Zahl der            Zum Datum dieses Prospekts betr\u00e4gt das Grundkapital der Gesellschaft\n    ausgegebenen        \u20ac50.000.000,00 und ist eingeteilt in 50.000.000 auf den Inhaber lautende St\u00fcckaktien,\n    und voll            jeweils mit einem Nominalwert von \u20ac1,00. Das Grundkapital ist vollst\u00e4ndig\n    eingezahlten        eingezahlt.\n    Aktien sowie\n    Nennwert pro\n    Aktie.\nC.4 Mit den             Jede Aktie der Gesellschaft berechtigt zu einer Stimme in der Hauptversammlung der\n    Wertpapieren        Gesellschaft. Alle Aktien der Gesellschaft verleihen dieselben Stimmrechte. Es\n    verbundene          bestehen keine Stimmrechtsbeschr\u00e4nkungen.\n    Rechte.\nC.5 Beschr\u00e4nkungen      Entf\u00e4llt. Die Aktien der Gesellschaft sind in \u00dcbereinstimmung mit den gesetzlichen\n    f\u00fcr die freie       Bestimmungen f\u00fcr auf den Inhaber lautende St\u00fcckaktien frei \u00fcbertragbar. Au\u00dfer den\n    \u00dcbertragbarkeit     in E.5 angef\u00fchrten Beschr\u00e4nkungen bestehen keine Verbote oder Beschr\u00e4nkungen\n    der Wertpapiere.    hinsichtlich der \u00dcbertragbarkeit der Aktien der Gesellschaft.\nC.6 Antrag f\u00fcr die      Die Gesellschaft erwartet, dass sie die Zulassung der Aktien der Emittentin zum\n    Zulassung zum       regulierten Markt mit gleichzeitiger Zulassung zum Teilbereich des regulierten\n    Handel an einem     Marktes mit weiteren Zulassungsfolgepflichten (Prime Standard) an der Frankfurter\n    geregelten Markt.   Wertpapierb\u00f6rse am oder um den 29. Januar 2018 beantragen wird. Der\n                        Zulassungsbeschluss f\u00fcr die Aktien der Gesellschaft wird voraussichtlich am\n                        8. Februar 2018 erteilt werden. Der Handel mit den Aktien der Gesellschaft an der\n                        Frankfurter Wertpapierb\u00f6rse wird voraussichtlich am 9. Februar 2018 beginnen.\nC.7 Dividenden-         In Bezug auf das zum 31. Dezember 2017 endende Gesch\u00e4ftsjahr wird die\n    politik.            Gesellschaft keine Dividende aussch\u00fctten, da die Dermapharm AG verpflichtet ist,\n                        einen etwaigen Gewinn f\u00fcr das zum 31. Dezember 2017 endende Gesch\u00e4ftsjahr unter\n                        dem Gewinnabf\u00fchrungsvertrag an die Ver\u00e4u\u00dfernde Aktion\u00e4rin abzuf\u00fchren. Die\n                        Dermapharm AG hat der Ver\u00e4u\u00dfernden Aktion\u00e4rin jedoch bestimmte\n                        Gesellschafterdarlehen zur Verf\u00fcgung gestellt. Daher werden die Anspr\u00fcche der\n                        Ver\u00e4u\u00dfernden Aktion\u00e4rin im Hinblick auf das zum 31. Dezember 2017 endende\n                        Gesch\u00e4ftsjahr unter dem Gewinnabf\u00fchrungsvertrag mit den Anspr\u00fcchen der\n                        Dermapharm AG aus diesen Gesellschafterdarlehen verrechnet werden und die\n                        Dermapharm AG erwartet, dass ihre Anspr\u00fcche diejenigen der Ver\u00e4u\u00dfernden\n                        Aktion\u00e4rin um mehr als \u20ac50 Mio. \u00fcbersteigen werden.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.564585115483319, "height": 0.4794696321642429, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-35-1", "text": "Beginnend mit dem zum 31. Dezember 2018 endenden Gesch\u00e4ftsjahr beabsichtigt die\nGesellschaft, im ordentlichen Gesch\u00e4ftsgang eine Dividende von 50% bis 60% des\nnach IFRS berechneten Konzernergebnisses von Dermapharm f\u00fcr das jeweilige\nGesch\u00e4ftsjahr zu zahlen. Die Gesellschaft strebt eine nachhaltige Dividendenpolitik\nmit einem Fokus auf Dividendenkontinuit\u00e4t an.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5710008554319932, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6398631308810949, "height": 0.06886227544910173, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-35-2", "text": "S-30\n", "page_number": 35, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-0", "text": "D \u2013 Risiken\n", "page_number": 36, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.09837467921300257, "height": 0.013259195893926434, "width": 0.08282950423216445}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-1", "text": "Eine Investition in Aktien der Gesellschaft ist mit Risiken verbunden. Anleger sollten\nvor der Entscheidung \u00fcber eine Investition in Aktien der Gesellschaft die nachfolgend\nbeschriebenen Risiken sorgf\u00e4ltig bedenken. Der Marktpreis der Aktien der\nGesellschaft k\u00f6nnte sinken, wenn sich einzelne oder aller dieser Risiken\nverwirklichen sollten. In diesem Fall k\u00f6nnten die Anleger ihre Investition ganz oder\nteilweise verlieren.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1864841745081266, "height": 0.08083832335329341, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-2", "text": "Die folgenden Risiken k\u00f6nnten alleine oder zusammen mit weiteren Risiken und\nUnw\u00e4gbarkeiten, die der Gesellschaft derzeit nicht bekannt sind oder die die\nGesellschaft derzeit als unwesentlich erachtet, das Gesch\u00e4ft, die Finanzlage, die\nCashflows, die Ertr\u00e4ge und die Aussichten von Dermapharm erheblich\nbeeintr\u00e4chtigen. Die Reihenfolge, in der die Risiken angef\u00fchrt sind, stellt weder eine\nIndikation f\u00fcr die Wahrscheinlichkeit der tats\u00e4chlichen Verwirklichung dieser\nRisiken, noch der Signifikanz oder des Grads der Risiken oder des Ausma\u00dfes des\npotentiellen Schadens f\u00fcr das Gesch\u00e4ft, die Finanzlage, die Cashflows, die Ertr\u00e4ge\nund die Aussichten von Dermapharm dar. Die Risiken, die hierin erw\u00e4hnt werden,\nk\u00f6nnten einzeln oder kumulativ eintreten.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2974607013301088, "top_left_y": 0.19461077844311378, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32934131736526945, "height": 0.13473053892215567, "width": 0.5828295042321645}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-3", "text": "k\u00f6nnten einzeln oder kumulativ eintreten.\nMarkt- und gesch\u00e4ftsbezogene Risiken\n", "page_number": 36, "bounding_box": {"top_left_x": 0.29866989117291415, "top_left_y": 0.3297690333618477, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.35243798118049613, "height": 0.02266894781864842, "width": 0.2817412333736397}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-4", "text": "D.1\n", "page_number": 36, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.339606501283148, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.3515825491873396, "height": 0.0119760479041916, "width": 0.023579201934703753}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-5", "text": "Zentrale Risiken,\n", "page_number": 36, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.339606501283148, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.35286569717707444, "height": 0.013259195893926434, "width": 0.12575574365175335}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-6", "text": "die dem\n", "page_number": 36, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.3532934131736527, "lower_right_x": 0.21704957678355502, "lower_right_y": 0.3652694610778443, "height": 0.0119760479041916, "width": 0.06287787182587667}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-7", "text": "Dermapharm k\u00f6nnte negativ von Entwicklungen in den deutschen M\u00e4rkten f\u00fcr\nArzneimittel- und Gesundheitsprodukte betroffen sein.\nEin signifikanter Anteil der Umsatzerl\u00f6se und des EBITDA von Dermapharm\nstammt aus den Verk\u00e4ufen einer beschr\u00e4nkten Anzahl an Schl\u00fcsselprodukten,\ninsbesondere Dekristol\u00ae 20.000 I.E.\nDermapharm ist m\u00f6glicherweise nicht in der Lage, neue Produkte erfolgreich zu\nentwickeln und zu vermarkten.\nDie Bem\u00fchungen von Dermapharm, ihr Gesch\u00e4ft in ausl\u00e4ndische M\u00e4rkte zu\nexpandieren, setzen Dermapharm Risiken aus, die mit dem Betreiben von\nGesch\u00e4ft in unbekannten L\u00e4ndern einhergehen.\nDermapharm ist m\u00f6glicherweise nicht in der Lage, attraktive\nWachstumsm\u00f6glichkeiten zu identifizieren und zu nutzen. Selbst wenn sie sich\nan \u00dcbernahmen, Joint Ventures oder anderen Unternehmenszusammenschl\u00fcssen\nbeteiligt, k\u00f6nnten sich solche Transaktionen anders entwickeln als anf\u00e4nglich\nerwartet.\nDermapharm steht in intensivem Wettbewerb in allen M\u00e4rkten in denen sie t\u00e4tig\nist.\nDermapharm ist abh\u00e4ngig von ihrer F\u00e4higkeit, ihre verschreibungspflichtigen\nArzneimittel erfolgreich an \u00c4rzte, die ihren Patienten solche Arzneimittel\nverschreiben, zu vermarkten.\nRabattvereinbarungen mit gesetzlichen Krankenkassen k\u00f6nnten sich nachteilig\nauf die Gesch\u00e4ftst\u00e4tigkeit von Dermapharm auswirken.\nGesundheitsreformen und damit zusammenh\u00e4ngende \u00c4nderungen der\nRahmenbedingungen, die auf die Arzneimittelindustrie anwendbar sind, k\u00f6nnten\nsich nachteilig auf die Gesch\u00e4ftst\u00e4tigkeit von Dermapharm auswirken.\nDermapharm ist von der Wahrnehmung des Markts abh\u00e4ngig, insbesondere\nhinsichtlich der Sicherheit, Wirksamkeit und Qualit\u00e4t ihrer Produkte.\nDermapharm ist f\u00fcr die Rohstoffe, die zur Herstellung ihrer Produkte ben\u00f6tigt\nwerden, von einer begrenzten Anzahl von Lieferanten abh\u00e4ngig sowie von\nDrittherstellern f\u00fcr ihre Dekristol\u00ae 20.000 I.E. Weichkapseln und f\u00fcr ihre\nMedizinprodukte. Versorgungsausf\u00e4lle in der Lieferkette k\u00f6nnten zu einer\nerheblichen Beeintr\u00e4chtigung der Gesch\u00e4ftst\u00e4tigkeit von Dermapharm f\u00fchren.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8793840889649273, "height": 0.5171086398631308, "width": 0.5519951632406288}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-8", "text": "die dem\nEmittenten oder\n", "page_number": 36, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.3669803250641574, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.378956372968349, "height": 0.0119760479041916, "width": 0.12152357920193474}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-9", "text": "seiner Branche\n", "page_number": 36, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.3806672369546621, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.39264328485885375, "height": 0.011976047904191656, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-10", "text": "seiner Bran\neigen sind.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.3943541488451668, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.40718562874251496, "height": 0.012831479897348175, "width": 0.07738814993954052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-11", "text": "\uf0b7\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.3999144568006843, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.40718562874251496, "height": 0.007271171941830634, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-12", "text": "", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.44781864841745084, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.45466210436270316, "height": 0.006843455945252319, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-13", "text": "\uf0b7\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4833190761334474, "lower_right_x": 0.3059250302297461, "lower_right_y": 0.4914456800684346, "height": 0.008126603934987209, "width": 0.006650544135429315}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-14", "text": "\uf0b7\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5342172797262618, "lower_right_x": 0.3083434099153567, "lower_right_y": 0.5402053036783576, "height": 0.005988023952095856, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-15", "text": "", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6086398631308811, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.6154833190761334, "height": 0.006843455945252264, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-16", "text": "", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.6437125748502994, "lower_right_x": 0.30773881499395406, "lower_right_y": 0.6501283147989735, "height": 0.00641573994867406, "width": 0.008464328899637275}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-17", "text": "\uf0b7\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.695038494439692, "lower_right_x": 0.3083434099153567, "lower_right_y": 0.7010265183917879, "height": 0.005988023952095856, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-18", "text": "\uf0b7\n", "page_number": 36, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.7284003421727973, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.7356715141146278, "height": 0.007271171941830579, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-19", "text": "", "page_number": 36, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.7771599657827203, "lower_right_x": 0.30773881499395406, "lower_right_y": 0.7835757057313943, "height": 0.00641573994867406, "width": 0.008464328899637275}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-20", "text": "", "page_number": 36, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.8143712574850299, "lower_right_x": 0.30713422007255137, "lower_right_y": 0.8199315654405475, "height": 0.0055603079555175405, "width": 0.007255139056831894}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-36-21", "text": "S-31\n", "page_number": 36, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03143893591293839}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-0", "text": "\uf0b7   St\u00f6rungen in den Herstellungsprozessen von Dermapharm und Versp\u00e4tungen bei\n    der Einf\u00fchrung neuer Produkte k\u00f6nnten sich nachteilig auf die Gesch\u00e4ftst\u00e4tigkeit\n    von Dermapharm auswirken.\n\uf0b7   Eine Herabsetzung von Parallelimportquoten oder die Einf\u00fchrung von\n    Exportbeschr\u00e4nkungen oder Arzneimittelkontingenten und \u00e4hnliche Regelungen\n    k\u00f6nnten sich nachteilig auf das Parallelimportgesch\u00e4ft von Dermapharm\n    auswirken.\n\uf0b7   Dermapharm ist m\u00f6glicherweise nicht in der Lage, Arzneimittel, die sie im\n    Rahmen ihres Parallelimportgesch\u00e4fts importiert hat, zu attraktiven Preisen\n    weiterzuverkaufen oder \u00fcberhaupt zu verkaufen.\n\uf0b7   Dermapharm ist m\u00f6glicherweise nicht in der Lage, Arzneimittel, die sie ben\u00f6tigt,\n    um ihr Produktangebot im Bereich Parallelimporte aufrecht zu erhalten,\n    einzuf\u00fchren und einzukaufen.\n\uf0b7   Sollten Dritte Dermapharm im Rahmen ihres Parallelimportgesch\u00e4fts gef\u00e4lschte\n    oder fehlerhafte Arzneimittel verkaufen, k\u00f6nnte Dermapharm f\u00fcr den Vertrieb\n    solcher Arzneimittel haftbar gemacht werden.\n\uf0b7   Die bestehenden finanziellen Verbindlichkeiten von Dermapharm k\u00f6nnten die\n    Cashflows, die f\u00fcr ihr operatives Gesch\u00e4ft zur Verf\u00fcgung stehen, beschr\u00e4nken\n    und jeder Zahlungsausfall im Hinblick auf die finanziellen Verbindlichkeiten von\n    Dermapharm k\u00f6nnte zur Insolvenz der Gesellschaft f\u00fchren.\n\uf0b7   Dermapharm ist m\u00f6glicherweise nicht in der Lage, zus\u00e4tzliche Finanzmittel zu\n    akzeptablen Bedingungen zu erhalten oder \u00fcberhaupt zu erhalten. Eine Erh\u00f6hung\n    der Verschuldung von Dermapharm k\u00f6nnte sich nachteilig auf ihre\n    Gesch\u00e4ftst\u00e4tigkeit auswirken.\n", "page_number": 37, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4619332763045338, "height": 0.3733960650128315, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-1", "text": "Regulatorische, rechtliche und steuerliche Risiken\n", "page_number": 37, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.47177074422583404, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.48417450812660395, "height": 0.012403763900769915, "width": 0.35852478839177754}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-2", "text": "\uf0b7   Dermapharm muss umfassende Rechtsvorgaben im Hinblick auf ihre Produkte\n    und andere Aspekte ihrer Gesch\u00e4ftst\u00e4tigkeit einhalten. \u00c4nderungen des\n    regulatorischen Umfelds k\u00f6nnten dazu f\u00fchren, dass Dermapharm zus\u00e4tzliche\n    Kosten entstehen.\n\uf0b7   Die bestehende Compliance Struktur von Dermapharm ist m\u00f6glicherweise nicht\n    ausreichend und die Nichteinhaltung von Gesetzen und Rechtsvorgaben k\u00f6nnte\n    sich nachteilig auf die Gesch\u00e4ftst\u00e4tigkeit von Dermapharm auswirken.\n\uf0b7   Dermapharm k\u00f6nnte in verschiedene Rechtsstreitigkeiten verwickelt werden,\n    einschlie\u00dflich von Patentrechtsstreitigkeiten, die Dermapharm einer erheblichen\n    Haftungen aussetzen oder sich nachteilig auf ihre Gesch\u00e4ftst\u00e4tigkeit auswirken\n    k\u00f6nnten.\n\uf0b7   Dermapharm k\u00f6nnte erheblichen Produkthaftungsanspr\u00fcchen ausgesetzt sein, die\n    nicht durch eine Versicherung abgedeckt sind.\n\uf0b7   Dermapharm k\u00f6nnte durch \u00c4nderungen des generellen Steuerumfelds sowie\n    zuk\u00fcnftige Steuerpr\u00fcfungen und \u2013untersuchungen beeintr\u00e4chtigt werden, die\n    allesamt zu einer Erh\u00f6hung der Steuerlast von Dermapharm f\u00fchren k\u00f6nnten.\n", "page_number": 37, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7425149700598802, "height": 0.2502138579982891, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-3", "text": "Risiken im Zusammenhang mit der Gesellschaftsstruktur der Gesellschaft, den\nAktien und dem Angebot\n", "page_number": 37, "bounding_box": {"top_left_x": 0.2962515114873035, "top_left_y": 0.7493584260051326, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.776732249786142, "height": 0.027373823781009388, "width": 0.5695284159613059}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-4", "text": "D.3\n", "page_number": 37, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7493584260051326, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.7596236099230111, "height": 0.010265183917878562, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-5", "text": "Zentrale Risiken,\n", "page_number": 37, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.7493584260051326, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.762617621899059, "height": 0.013259195893926434, "width": 0.12636033857315598}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-6", "text": "Zentrale Risik\ndie den Wert-\n", "page_number": 37, "bounding_box": {"top_left_x": 0.15538089480048367, "top_left_y": 0.762617621899059, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.7733105218135158, "height": 0.010692899914456766, "width": 0.10096735187424427}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-7", "text": "die den Wert-\npapieren eigen\n", "page_number": 37, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.7763045337895638, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.7904191616766467, "height": 0.014114627887082953, "width": 0.11064087061668684}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-8", "text": "\uf0b7   Die Aktien der Gesellschaft sind bisher nicht an einer B\u00f6rse gehandelt worden\n    und es ist nicht sicher, dass sich ein aktiver und liquider Markt f\u00fcr diese Aktien\n    entwickeln wird.\n\uf0b7   Der Aktienkurs der Gesellschaft k\u00f6nnte erheblich schwanken und Anleger\n    k\u00f6nnten ihre Anlage in Aktien der Gesellschaft ganz oder teilweise verlieren.\n\uf0b7   Die Gesellschaft ist m\u00f6glicherweise nicht in der Lage, in absehbarer Zukunft\n    Dividenden zu zahlen.\n", "page_number": 37, "bounding_box": {"top_left_x": 0.3047158403869408, "top_left_y": 0.783147989734816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.893071000855432, "height": 0.10992301112061598, "width": 0.5755743651753326}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-9", "text": "papie\nsind.\n", "page_number": 37, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.7904191616766467, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.8006843455945253, "height": 0.010265183917878562, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-37-10", "text": "S-32\n", "page_number": 37, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-0", "text": "\uf0b7   Nach dem Angebot wird die Ver\u00e4u\u00dfernde Aktion\u00e4rin weiterhin eine wesentliche\n    Beteiligung an der Gesellschaft halten und die Interessen der Ver\u00e4u\u00dfernden\n    Aktion\u00e4rin k\u00f6nnten den Interessen der Gesellschaft und denen der anderen\n    Aktion\u00e4re widersprechen.\n\uf0b7   Zuk\u00fcnftige Angebote von Fremd- oder Eigenkapitalinstrumenten durch die\n    Gesellschaft k\u00f6nnten den Aktienkurs der Gesellschaft beeintr\u00e4chtigen und\n    zuk\u00fcnftige Kapitalma\u00dfnahmen k\u00f6nnten zu einer erheblichen Verw\u00e4sserung der\n    Aktion\u00e4re der Gesellschaft f\u00fchren (d.h. den Wert der Beteiligung der\n    bestehenden Aktion\u00e4re an der Gesellschaft vermindern).\n\uf0b7   Zuk\u00fcnftige Verk\u00e4ufe durch wesentliche Aktion\u00e4re der Gesellschaft k\u00f6nnten\n    einen erheblichen nachteiligen Effekt auf den Aktienkurs der Gesellschaft haben.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25320786997433703, "height": 0.16467065868263472, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-1", "text": "E \u2013 Angebot\n", "page_number": 38, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.2805816937553465, "height": 0.014114627887083009, "width": 0.09189842805320436}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-2", "text": "Die Gesellschaft erh\u00e4lt nur die Erl\u00f6se, die aus der Ver\u00e4u\u00dferung der Neuen Aktien im\nRahmen des Angebots erzielt werden. Die Gesellschaft erh\u00e4lt keine Erl\u00f6se aus der\nVer\u00e4u\u00dferung der Bestehenden Aktien oder der Mehrzuteilungsaktien aus dem\nBestand der Ver\u00e4u\u00dfernden Aktion\u00e4rin.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.28699743370402053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34046193327630453, "height": 0.053464499572284, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-3", "text": "E.1 Gesamtnetto-\n    erl\u00f6se.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28699743370402053, "lower_right_x": 0.2545344619105199, "lower_right_y": 0.3135158254918734, "height": 0.02651839178785287, "width": 0.13422007255139054}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-4", "text": "Unter der Annahme, dass die maximale Anzahl an Neuen Aktien (d.h. 3.840.000\nAktien) platziert wird, sch\u00e4tzt die Gesellschaft, dass zum Mindest-, Mittel- und\nH\u00f6chstwert der f\u00fcr das Angebot bestimmten Preisspanne, innerhalb derer\nKaufangebote von \u20ac26,00 bis \u20ac30,00 je Angebotsaktien platziert werden k\u00f6nnen (die\n\u201ePreisspanne\u201d), die der Gesellschaft zuflie\u00dfenden Bruttoerl\u00f6se rund \u20ac99,8 Mio.,\n\u20ac107,5 Mio. bzw. \u20ac115,2 Mio. und die Nettoerl\u00f6se rund \u20ac96,0 Mio., \u20ac103,5 Mio.\nbzw. \u20ac111,0 Mio. betragen werden.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.2950423216444982, "top_left_y": 0.34901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4448246364414029, "height": 0.09580838323353291, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-5", "text": "Unter der Annahme, dass alle 7.860.000 Bestehenden Aktien platziert werden und die\nGreenshoe Option (wie in E.3 definiert) f\u00fcr insgesamt 1.755.000 Aktien vollst\u00e4ndig\nausge\u00fcbt wird, sch\u00e4tzt die Gesellschaft, dass zum Mindest-, Mittel- und H\u00f6chstwert\nder Preisspanne die Bruttoerl\u00f6se, die der Ver\u00e4u\u00dfernden Aktion\u00e4rin zuflie\u00dfen, rund\n\u20ac250,0 Mio., \u20ac269,2 Mio. bzw. \u20ac288,5 Mio. und die Nettoerl\u00f6se rund \u20ac240,9 Mio.,\n\u20ac259,6 Mio. bzw. \u20ac278,4 Mio. betragen werden.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5337895637296834, "height": 0.08254918733960648, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-6", "text": "Die der Gesellschaft und der Ver\u00e4u\u00dfernden Aktion\u00e4rin durch das Angebot der\nAngebotsaktien und die B\u00f6rsennotierung s\u00e4mtlicher Aktien der Gesellschaft\nentstehenden Kosten, inklusive Konsortial- und Platzierungsprovisionen, die an\nBerenberg zu zahlen sind, sowie der festen Geb\u00fchr, die an die ODDO BHF zu zahlen\nist, werden sich zum Mittelwert der Preisspanne voraussichtlich auf \u20ac13,6 Mio.\nbelaufen (unter der Annahme der Platzierung aller Basisaktien und der vollst\u00e4ndigen\nAus\u00fcbung der Greenshoe-Option (wie in E.3 definiert) sowie der vollst\u00e4ndigen\nZahlung der Ermessensverg\u00fctung). Von den Gesamtkosten wird die Ver\u00e4u\u00dfernde\nAktion\u00e4rin rund \u20ac9,6 Mio. tragen und die Gesellschaft wird den verbleibenden Betrag\nvon rund \u20ac4,0 Mio. tragen.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.5414884516680923, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6775021385799829, "height": 0.13601368691189053, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-7", "text": "Gesch\u00e4tzte\nGesamtkosten\nder Emission/des\nAngebots.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5436270316509837, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.5962360992301112, "height": 0.05260906757912753, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-8", "text": "Gesch\u00e4tzte          Entf\u00e4llt. Anlegern werden von der Gesellschaft, der Ver\u00e4u\u00dfernden Aktion\u00e4rin oder\nKosten, die dem     den Anbietenden Banken keine Kosten in Rechnung gestellt. Anleger m\u00fcssen die\nAnleger in          \u00fcblichen Transaktions- und Abwicklungskosten tragen, die ihnen ihre depotf\u00fchrenden\nRechnung gestellt   Broker oder Finanzinstitute in Rechnung stellen.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6839178785286569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7425149700598802, "height": 0.05859709153122328, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-9", "text": "werden.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.7425149700598802, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.7523524379811805, "height": 0.009837467921300247, "width": 0.06348246674727934}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-10", "text": "Die Gesellschaft beabsichtigt das Angebot durchzuf\u00fchren und die Zulassung ihrer\nAktien am regulierten Markt der Frankfurter Wertpapierb\u00f6rse mit gleichzeitiger\nZulassung    zum     Teilbereich   des     regulierten  Markts     mit   weiteren\nZulassungsfolgepflichten (Prime Standard) der Frankfurter Wertpapierb\u00f6rse\nherbeizuf\u00fchren, um die der Gesellschaft zuflie\u00dfenden Nettoerl\u00f6se aus dem Angebot\nund Zugang zum Kapitalmarkt zu erhalten.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.762617621899059, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8417450812660393, "height": 0.07912745936698029, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-11", "text": "E.2a Gr\u00fcnde f\u00fcr das\n     Angebot.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.762617621899059, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.787852865697177, "height": 0.025235243798118034, "width": 0.1499395405078597}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-12", "text": "Die Ver\u00e4u\u00dfernde Aktion\u00e4rin beabsichtigt, das Angebot durchzuf\u00fchren, um die der\nVer\u00e4u\u00dfernden Aktion\u00e4rin zuflie\u00dfenden Nettoerl\u00f6se aus dem Angebot zu erhalten und\num ihre Investitionen zu diversifizieren.\n", "page_number": 38, "bounding_box": {"top_left_x": 0.2968561064087062, "top_left_y": 0.8515825491873396, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8887938408896493, "height": 0.037211291702309746, "width": 0.5828295042321644}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-38-13", "text": "S-33\n", "page_number": 38, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-0", "text": "Zweck-           Die Gesellschaft beabsichtigt derzeit, die auf die Gesellschaft entfallenden\nbestimmung der   Nettoerl\u00f6se wie folgt zu verwenden: rund \u20ac35 Mio. sollen f\u00fcr interne Entwicklungen\nErl\u00f6se.          und die Verbesserung der Produktionsst\u00e4tten von Dermapharm in Brehna,\n                 Deutschland, sowie dem Neubau einer Produktionsst\u00e4tte in Neumarkt am Wallersee,\n                 \u00d6sterreich, verwendet werden, rund \u20ac20 Mio. sollen f\u00fcr die Bestrebungen zur\n                 Ausweitung der internationalen Aufstellung von Dermapharm (z.B. f\u00fcr die Gr\u00fcndung\n                 neuer Unternehmen in weiteren M\u00e4rkten, die Anstellung \u00f6rtlicher Verkaufsleiter und\n                 Verkaufsmitarbeiter sowie \u00e4hnliche Investitionen) und zwischen rund \u20ac40 Mio. und\n                 \u20ac50 Mio. f\u00fcr die teilweise Refinanzierung eines von der Baden-W\u00fcrttembergischen\n                 Bank zur teilweisen Finanzierung der Akquisition von Trommsdorff gew\u00e4hrten\n                 Darlehens ausgegeben werden. Die Gesellschaft beabsichtigt derzeit, etwaige\n                 verbleibende Erl\u00f6se f\u00fcr allgemeine Unternehmenszwecke zu verwenden.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.0855431993156544, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.16424294268605646, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-1", "text": "Unter der Annahme, dass die maximale Anzahl an Neuen Aktien (d.h. 3.840.000\nAktien) platziert wird, rechnet die Gesellschaft damit, dass sich die Bruttoerl\u00f6se, die\nder Gesellschaft zuflie\u00dfen, zum Mindest-, Mittel- und H\u00f6chstwert der Preisspanne\njeweils auf rund \u20ac99,8 Mio., \u20ac107,5 Mio. und \u20ac115,2 Mio. und die Nettoerl\u00f6se\njeweils auf rund \u20ac96,0 Mio., \u20ac103,5 Mio. und \u20ac111,0 Mio. belaufen werden.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32506415739948674, "height": 0.06886227544910178, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-2", "text": "Gesch\u00e4tzte\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15538089480048367, "top_left_y": 0.2570573139435415, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.2694610778443114, "height": 0.012403763900769915, "width": 0.08162031438935913}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-3", "text": "Gesch\u00e4tzte\nNettoerl\u00f6se.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.27074422583404617, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.2827202737382378, "height": 0.011976047904191656, "width": 0.08706166868198309}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-4", "text": "Das Angebot besteht aus erstmaligen \u00f6ffentlichen Angeboten in Deutschland und\nLuxemburg sowie Privatplatzierungen in bestimmten Rechtsordnungen au\u00dferhalb\nDeutschlands und Luxemburgs. In den Vereinigten Staaten von Amerika werden die\nAngebotsaktien nur qualifizierten institutionellen Anlegern entsprechend und in\n\u00dcbereinstimmung mit und unter Berufung auf Rule 144A nach dem U.S. Securities\nAct von 1933 in der jeweils g\u00fcltigen Fassung (der \u201eSecurities Act\u201c) oder gem\u00e4\u00df\neiner anderen anwendbaren Ausnahme von den Registrierungsanforderungen des\nSecurities Act bzw. in Transaktionen, die diesen Registrierungsanforderungen nicht\nunterfallen, angeboten und verkauft. Au\u00dferhalb der Vereinigten Staaten von Amerika\nwerden die Angebotsaktien nur im Rahmen von Offshore-Transaktionen in\n\u00dcbereinstimmung mit der Regulation S des Securities Act angeboten und verkauft.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4820359281437126, "height": 0.1505560307955518, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-5", "text": "E.3 Angebots-\n", "page_number": 39, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.33276304533789564, "lower_right_x": 0.23035066505441354, "lower_right_y": 0.34602224123182207, "height": 0.013259195893926434, "width": 0.11003627569528415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-6", "text": "konditionen.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.34644995722840033, "lower_right_x": 0.2460701330108827, "lower_right_y": 0.358426005132592, "height": 0.011976047904191656, "width": 0.0912938331318017}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-7", "text": "Der Zeitraum, in dem Anleger Kaufangebote f\u00fcr die Angebotsaktien abgeben k\u00f6nnen,\nbeginnt voraussichtlich am 29. Januar 2018 und endet voraussichtlich am 8. Februar\n2018 (der \u201eAngebotszeitraum\u201c).\n", "page_number": 39, "bounding_box": {"top_left_x": 0.2950423216444982, "top_left_y": 0.4888793840889649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5303678357570573, "height": 0.04148845166809234, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-8", "text": "Angebotsfrist.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.49016253207869975, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.5029940119760479, "height": 0.01283147989734812, "width": 0.1070133010882709}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-9", "text": "Der Angebotspreis f\u00fcr dieses Angebot (der \u201eAngebotspreis\u201c) und die endg\u00fcltige\nAnzahl an Angebotsaktien, die im Rahmen des Angebots platziert werden, werden\nam Ende des Bookbuilding-Verfahrens von der Gesellschaft und der Ver\u00e4u\u00dfernden\nAktion\u00e4rin nach Beratung mit Berenberg festgesetzt und es wird erwartet, dass sie am\noder um den 8. Februar 2018 ver\u00f6ffentlicht werden. Sollte sich herausstellen, dass das\nPlatzierungsvolumen nicht ausreicht, um alle Auftr\u00e4ge, die zum Angebotspreis\nplatziert wurden, zu befriedigen, beh\u00e4lt sich Berenberg namens der Anbietenden\nBanken das Recht vor, Auftr\u00e4ge abzulehnen oder nur teilweise zu anzunehmen.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.2950423216444982, "top_left_y": 0.5367835757057314, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6467065868263473, "height": 0.10992301112061587, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-10", "text": "Angebotspreis.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5380667236954663, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.5508982035928144, "height": 0.01283147989734812, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-11", "text": "Die Lieferung der Angebotsaktien gegen Zahlung des Angebotspreises wird f\u00fcr den\n13. Februar 2018 erwartet. Die Angebotsaktien werden den Aktion\u00e4ren als\nMiteigentumsanteile an den Globalurkunden zur Verf\u00fcgung gestellt.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.2962515114873035, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6946107784431138, "height": 0.04148845166809245, "width": 0.5840386940749698}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-12", "text": "Lieferung und\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6544054747647562, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.6676646706586826, "height": 0.013259195893926434, "width": 0.1064087061668682}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-13", "text": "Lieferung und\nAbwicklung.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.6680923866552609, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.6809238665526091, "height": 0.01283147989734812, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-14", "text": "Im Zusammenhang mit der Platzierung der Angebotsaktien wird Berenberg als\nStabilisierungsmanager agieren und kann als solcher und in \u00dcbereinstimmung mit\nden      rechtlichen   Bestimmungen       Mehrzuteilungen      vornehmen      und\nStabilisierungsma\u00dfnahmen ergreifen. Aufgrund solcher Stabilisierungsma\u00dfnahmen\nk\u00f6nnen       Anlegern     zus\u00e4tzlich    zu     den      Basisaktien    bis     zu\n1.755.000 Mehrzuteilungsaktien als Teil der Zuteilung der Angebotsaktien zugeteilt\nwerden. Zu diesem Zweck werden Berenberg 1.755.000 Mehrzuteilungsaktien aus\ndem Bestand der Ver\u00e4u\u00dfernden Aktion\u00e4rin in Form eines Wertpapierdarlehens zur\nVerf\u00fcgung gestellt. Die Gesamtzahl der Mehrzuteilungsaktien wird dabei 15% der\nfinalen Anzahl der bei Anlegern platzierten Basisaktien nicht \u00fcbersteigen. Die\nVer\u00e4u\u00dfernde Aktion\u00e4rin wird Berenberg eine Option zum Erwerb einer Anzahl von\nAktien der Gesellschaft, die der Anzahl der Mehrzuteilungsaktien entspricht, zum\nAngebotspreis abz\u00fcglich der vereinbarten Provisionen einr\u00e4umen (die\n\u201eGreenshoe-Option\u201c).\n", "page_number": 39, "bounding_box": {"top_left_x": 0.2968561064087062, "top_left_y": 0.7010265183917879, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.893071000855432, "height": 0.19204448246364414, "width": 0.5834340991535671}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-15", "text": "Stabilisierungs-\n", "page_number": 39, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.704448246364414, "lower_right_x": 0.2678355501813785, "lower_right_y": 0.7155688622754491, "height": 0.011120615911035081, "width": 0.11305925030229749}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-16", "text": "ma\u00dfnahmen,\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.7181351582549187, "lower_right_x": 0.24969770253929868, "lower_right_y": 0.7288280581693756, "height": 0.010692899914456877, "width": 0.09552599758162034}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-17", "text": "Mehrzuteilung\n", "page_number": 39, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.7318220701454234, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.7429426860564585, "height": 0.011120615911035081, "width": 0.11185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-18", "text": "und Greenshoe\n", "page_number": 39, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.7455089820359282, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.756201881950385, "height": 0.010692899914456766, "width": 0.11064087061668684}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-19", "text": "Option.\n", "page_number": 39, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.7591958939264328, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.7720273738237811, "height": 0.01283147989734823, "width": 0.058041112454655375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-39-20", "text": "S-34\n", "page_number": 39, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-0", "text": "Die Greenshoe-Option darf nur w\u00e4hrend des Stabilisierungszeitraums ausge\u00fcbt\nwerden und wird 30 Kalendertage nach dem Beginn des Handelns mit den Aktien der\nGesellschaft enden. Berenberg ist berechtigt, die Greenshoe-Option in dem Umfang\nauszu\u00fcben, in dem Anlegern Mehrzuteilungsaktien im Rahmen des Angebots\nzugeteilt wurden. Die Anzahl der Mehrzuteilungsaktien, die im Rahmen der\nGreenshoe-Option erworben werden, ist um die Anzahl der Aktien Gesellschaft zu\nverringern, die von Berenberg am Tag der Aus\u00fcbung der Greenshoe-Option gehalten\nwerden,     sofern solche      Aktien von Berenberg im Rahmen von\nStabilisierungsma\u00dfnahmen erworben wurden.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20829769033361847, "height": 0.12318220701454234, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-1", "text": "Unter der Annahme, dass die Bestehenden Aktien platziert werden und die\nGreenshoe-Option ausge\u00fcbt wird, wird die Ver\u00e4u\u00dfernde Aktion\u00e4rin die Erl\u00f6se aus\ndem Verkauf der Bestehenden Aktien und der Mehrzuteilungsaktien (abz\u00fcglich\nGeb\u00fchren und Provisionen) erhalten. Dementsprechend hat die Ver\u00e4u\u00dfernde\nAktion\u00e4rin ein Interesse am Erfolg des Angebots.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2840034217279726, "height": 0.06886227544910178, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-2", "text": "E.4\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21599657827202737, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.227972626176219, "height": 0.011976047904191628, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-3", "text": "F\u00fcr die\n", "page_number": 40, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.21599657827202737, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.227972626176219, "height": 0.011976047904191628, "width": 0.05864570737605804}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-4", "text": "Emission/das\n", "page_number": 40, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.2296834901625321, "lower_right_x": 0.250906892382104, "lower_right_y": 0.24208725406330198, "height": 0.012403763900769887, "width": 0.09673518742442566}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-5", "text": "Emission/\nAngebot\n", "page_number": 40, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.24337040205303678, "lower_right_x": 0.22430471584038694, "lower_right_y": 0.2566295979469632, "height": 0.013259195893926434, "width": 0.0701330108827086}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-6", "text": "wesentliche\n", "page_number": 40, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.2570573139435415, "lower_right_x": 0.2400241837968561, "lower_right_y": 0.26903336184773313, "height": 0.011976047904191656, "width": 0.0852478839177751}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-7", "text": "wesentliche\nBeteiligungen.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.27074422583404617, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.2840034217279726, "height": 0.013259195893926434, "width": 0.1070133010882709}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-8", "text": "Im Zusammenhang mit dem Angebot und der B\u00f6rsennotierung der Aktien der\nGesellschaft sind die Anbietenden Banken eine vertragliche Beziehung mit der\nGesellschaft und der Ver\u00e4u\u00dfernden Aktion\u00e4rin eingegangen.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.2904191616766467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3319076133447391, "height": 0.041488451668092396, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-9", "text": "Berenberg handelt bei dem Angebot f\u00fcr die Gesellschaft und die Ver\u00e4u\u00dfernde\nAktion\u00e4rin und koordiniert die Strukturierung und die Durchf\u00fchrung des Angebots.\nNach erfolgreichem Vollzug des Angebots erh\u00e4lt Berenberg eine Provision, deren\nH\u00f6he vom Ergebnis des Angebots abh\u00e4ngt. Dementsprechend besteht f\u00fcr Berenberg\nein finanzielles Interesse an einem erfolgreichen Angebot zu den bestm\u00f6glichen\nBedingungen.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.3383233532934132, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.08254918733960648, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-10", "text": "ODDO BHF agiert als Co-Lead Manager und wird eine feste Geb\u00fchr f\u00fcr ihre Dienste\nim Zusammenhang mit dem Angebot erhalten. Daher hat ODDO BHF ein Interesse\nam Erfolg des Angebots.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46877673224978617, "height": 0.041488451668092396, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-11", "text": "Die Anbietenden Banken oder ihre jeweiligen verbundenen Unternehmen haben \u2013\nund k\u00f6nnten von Zeit zu Zeit in Zukunft erneut \u2013 Gesch\u00e4ftsbeziehungen zu\nDermapharm und der Ver\u00e4u\u00dfernden Aktion\u00e4rin unterhalten, einschlie\u00dflich von\nFinanzierungst\u00e4tigkeiten, oder k\u00f6nnte Dienstleistungen f\u00fcr Dermapharm oder die\nVer\u00e4u\u00dfernde Aktion\u00e4rin im Rahmen des gew\u00f6hnlichen Gesch\u00e4ftsbetriebs erbringen.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.2962515114873035, "top_left_y": 0.4751924721984602, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.544054747647562, "height": 0.06886227544910178, "width": 0.5840386940749698}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-12", "text": "    Interessen-        Entf\u00e4llt. Es bestehen keine Interessenkonflikte im Hinblick auf das Angebot oder die\n    konflikte.         B\u00f6rsennotierung der Aktien der Gesellschaft.\nE.5 Name der           Die Angebotsaktien werden von den Anbietenden Banken zum Verkauf angeboten.\n    Person/des\n                       In dem Konsortialvertrag, den die Gesellschaft, die Ver\u00e4u\u00dfernde Aktion\u00e4rin und die\n    Unternehmens,\n                       Anbietenden Banken am 26. Januar 2018 geschlossen haben, hat die Gesellschaft\n    die/das das\n                       zugestimmt, ohne die vorherige schriftliche Zustimmung von Berenberg, die nicht\n    Wertpapier zum\n                       unbillig verweigert werden darf, innerhalb eines Zeitraums, der am 26. Januar 2018\n    Verkauf anbietet\n                       beginnt und sechs Monate nach dem ersten Handelstag der Aktien der Gesellschaft an\n    sowie Lock-up-\n                       der Frankfurter Wertpapierb\u00f6rse (derzeit f\u00fcr den 9. Februar 2018 erwartet) endet,\n    Vereinbarungen\n                       soweit rechtlich zul\u00e4ssig nicht:\n", "page_number": 40, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7027373823781009, "height": 0.14884516680923865, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-13", "text": "\uf0b7   eine Erh\u00f6hung des Grundkapitals der Gesellschaft aus genehmigtem Kapital\n    anzuk\u00fcndigen oder zu bewirken;\n\uf0b7   ihrer Hauptversammlung eine Erh\u00f6hung des Grundkapitals vorzuschlagen; oder\n\uf0b7   eine Ausgabe von Wertpapieren mit Wandel- oder Optionsrechten auf Aktien der\n    Gesellschaft oder Handlungen mit einem vergleichbaren wirtschaftlichen Effekt\n    anzuk\u00fcndigen, zu bewirken oder vorzuschlagen.\n", "page_number": 40, "bounding_box": {"top_left_x": 0.30350665054413545, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8105218135158255, "height": 0.0992301112061591, "width": 0.5767835550181379}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-14", "text": "\uf0b7\n", "page_number": 40, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.7147134302822925, "lower_right_x": 0.30290205562273276, "lower_right_y": 0.7215568862275449, "height": 0.006843455945252375, "width": 0.0030229746070132846}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-15", "text": "", "page_number": 40, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.7489307100085543, "lower_right_x": 0.30290205562273276, "lower_right_y": 0.7553464499572284, "height": 0.006415739948674171, "width": 0.003627569528415975}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-16", "text": "", "page_number": 40, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.7724550898203593, "lower_right_x": 0.30290205562273276, "lower_right_y": 0.776732249786142, "height": 0.004277159965782706, "width": 0.0030229746070132846}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-40-17", "text": "S-35\n", "page_number": 40, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-0", "text": "Die vorstehenden Bestimmungen finden keine Anwendung auf Kapitalerh\u00f6hungen im\nZusammenhang mit dem Angebot. Des Weiteren kann die Gesellschaft (i) im\nRahmen von Managementbeteiligungspl\u00e4nen Aktien oder andere Wertpapiere an\nAngestellte und Mitglieder von Leitungsorganen der Gesellschaft oder ihrer\nTochtergesellschaften ausgeben oder verkaufen und (ii) unternehmerische Ma\u00dfnahme\nverfolgen, welche die Gesellschaft zum Zwecke des Abschlusses eines Vertrags im\nHinblick auf \u2013 oder die Beschlussfassung \u00fcber \u2013 das Eingehen eines Joint Ventures\noder den Erwerb von Gesellschaften vornimmt, wobei vorausgesetzt wird, dass die\nPartei des Joint Ventures oder der erworbenen Gesellschaft, an die solche Aktien\nausgegeben werden, sich gegen\u00fcber Berenberg verpflichtet, an die gleiche\nLock-up-Vereinbarung wie die Ver\u00e4u\u00dfernde Aktion\u00e4rin gebunden zu sein.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.2962515114873035, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.15098374679213, "width": 0.5840386940749698}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-1", "text": "F\u00fcr den Zeitraum, der am 26. Januar 2018 beginnt und zw\u00f6lf Monate nach dem ersten\nHandelstag der Aktien der Gesellschaft an der Frankfurter Wertpapierb\u00f6rse endet\n(derzeit f\u00fcr den 9. Februar 2018 erwartet), hat die Ver\u00e4u\u00dfernde Aktion\u00e4rin zus\u00e4tzlich\nzugestimmt, ohne vorherige schriftliche Zustimmung von Berenberg, die nicht\nunbillig verweigert werden darf, nicht:\n", "page_number": 41, "bounding_box": {"top_left_x": 0.2968561064087062, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.06886227544910181, "width": 0.5834340991535671}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-2", "text": "\uf0b7   direkt oder indirekt Aktien oder andere Wertpapiere der Gesellschaft zu\n    verkaufen, anzubieten, zu \u00fcbertragen oder auf andere Weise \u00fcber Aktien oder\n    andere Wertpapiere der Gesellschaft zu verf\u00fcgen; oder\n\uf0b7   eine Transaktion abzuschlie\u00dfen, die ein wirtschaftliches \u00c4quivalent zum Verkauf\n    von Aktien der Gesellschaft darstellt (z.B. die Ausgabe von Optionen oder\n    Wandlungsrechten f\u00fcr Aktien der Gesellschaft).\n", "page_number": 41, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.3212147134302823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40975192472198463, "height": 0.08853721129170233, "width": 0.5804111245465539}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-3", "text": "Das vorstehenden Bestimmungen finden keine Anwendung auf (i) die \u00dcbertragung\nvon Aktien an verbundene Unternehmen oder Rechtsnachfolger der Ver\u00e4u\u00dfernden\nAktion\u00e4rin, oder an Herrn Wilhelm Beier, seine Ehefrau oder seine Kinder,\n(ii) zuk\u00fcnftige Verpf\u00e4ndungen, die zugunsten von Berenberg oder mit ihr\nverbundenen Unternehmen mit Zustimmung von Berenberg gew\u00e4hrt wurden und\n(iii) jedwede \u00dcbertragung von Aktien an Berenberg oder an mit ihr verbundene\nUnternehmen im Rahmen der Zwangsvollstreckung aus einer Verpf\u00e4ndung, die in\n\u00dcbereinstimmung mit (ii) gew\u00e4hrt wurde, wobei in jedem Fall vorausgesetzt wird,\ndass die Beg\u00fcnstigte(n) sich gegen\u00fcber Berenberg verpflichtet(n), an die gleiche\nLock-up-Verpflichtung gebunden zu sein.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.2974607013301088, "top_left_y": 0.41402908468776733, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5538922155688623, "height": 0.13986313088109492, "width": 0.5828295042321645}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-4", "text": "Betrag und        Ausweislich des ungepr\u00fcften verk\u00fcrzten Konzernzwischenabschlusses der\nProzentsatz der   Dermapharm AG f\u00fcr den zum 30. September 2017 endenden Neunmonatszeitraum\naus dem Angebot   betrug der Nettobuchwert von Dermapharm (d.h. gesamte Verm\u00f6genswerte abz\u00fcglich\nresultierenden    langfristiger und kurzfristiger Verbindlichkeiten) zum 30. September 2017\nunmittelbaren     \u20ac69,5 Mio. und w\u00fcrde, basierend auf 50.000.000 ausstehenden Aktien der\nVerw\u00e4sserung.     Gesellschaft unmittelbar vor dem Angebot, \u20ac1,39 je Aktie der Gesellschaft betragen.\n                  Der Nettobuchwert von Dermapharm wird im ungepr\u00fcften verk\u00fcrzten\n                  Konzernzwischenabschlusses der Dermapharm AG f\u00fcr den zum 30. September 2017\n                  endenden Neunmonatszeitraum als gesamtes Eigenkapital gezeigt.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6839178785286569, "height": 0.1231822070145423, "width": 0.7261185006045949}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-5", "text": "E.6\n", "page_number": 41, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5607356715141146, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.5714285714285714, "height": 0.010692899914456766, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-6", "text": "Der verw\u00e4ssernde Effekt des Angebots ist in der untenstehenden Tabelle\nveranschaulicht, die den Betrag zeigt, um den der Angebotspreis den Nettobuchwert\nje Aktie nach Abschluss des Angebots \u00fcbersteigt und die unter der Annahme steht,\ndas Angebot sei am 30. September 2017 abgeschlossen worden. In dieser Hinsicht\nwird der Nettobuchwert zum 30. September 2017 um die Effekte des erfolgreichen\nVollzugs des Angebots unter der Annahme angepasst, dass (i) die IPO\nKapitalerh\u00f6hung f\u00fcr die maximale Anzahl von Neuen Aktien durchgef\u00fchrt wird und\n(ii) sich der auf die Aktion\u00e4re entfallende Nettobuchwert um \u20ac103,5 Mio. erh\u00f6ht\n(unter der Annahme, dass alle Neuen Aktien zum Mittelwert der Preisspanne\nerfolgreich platziert werden und ohne Ber\u00fccksichtigung von Steuereffekten). Der\nangepasste Nettobuchwert ist als Kennzahl je Aktie, unter der Annahme von\n53.840.000 ausstehenden Aktien der Gesellschaft nach Vollzug des Angebots\ndargestellt (diese Kennzahl je Aktie wird als \u201eEigenkapital nach dem IPO\u201c\nbezeichnet):\n", "page_number": 41, "bounding_box": {"top_left_x": 0.2950423216444982, "top_left_y": 0.6907613344739093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8819503849443969, "height": 0.19118905047048762, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-41-7", "text": "S-36\n", "page_number": 41, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-42-0", "text": "                                                                                                           Zum\n                                                                                                   30. September 2017\n                                                                                                       (ungepr\u00fcft)\n                                                                                                        (in \u20ac Mio.,\n                                                                                                   soweit nicht anders\n                                                                                                        angegeben)\nNettobuchwert je Aktie zum 30. September 2017(1) .....................................................                1,39\nAuf die Gesellschaft entfallende Nettoerl\u00f6se aus dem Angebot\n  (in \u20ac Mio.)(2) .............................................................................................................\n                                                                                                                    103,5\nEigenkapital nach dem IPO je Aktie(3) .........................................................................       3,21\nBetrag, um den der Angebotspreis das Eigenkapital nach dem\n  IPO je Aktie \u00fcbersteigt (unmittelbare Verw\u00e4sserung der\n  neuen Aktion\u00e4re der Gesellschaft)............................................................................     24,79\nProzentsatz, um den der Angebotspreis das Eigenkapital nach\n  dem IPO je Aktie \u00fcbersteigt (in %) ...........................................................................    771,5\nBetrag, um den das Eigenkapital nach dem IPO je Aktie den\n  Nettobuchwert je Aktie unmittelbar vor dem Angebot\n  \u00fcbersteigt (unmittelbarer Wertzuwachs der bestehenden\n  Aktion\u00e4re der Gesellschaft) ......................................................................................  1,82\nProzentsatz, um den das Eigenkapital nach dem IPO je Aktie\n  den Nettobuchwert je Aktie unmittelbar vor dem Angebot\n  \u00fcbersteigt (in %) .......................................................................................................\n                                                                                                                    131,2\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3041112454655381, "top_left_y": 0.0855431993156544, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.3721129170230967, "height": 0.2865697177074423, "width": 0.5707376058041111}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-42-1", "text": "(1) Basierend auf 50.000.000 ausstehenden Aktien der Gesellschaft unmittelbar vor dem Angebot und einem\n    Nettobuchwert von Dermapharm in H\u00f6he von \u20ac69,5 Mio. zum 30. September 2017. Im ungepr\u00fcften verk\u00fcrzten\n    Konzernzwischenabschluss der Dermapharm AG f\u00fcr den zum 30. September 2017 endenden Neunmonatszeitraum als\n    gesamtes Eigenkapital ausgewiesen.\n(2) Unter der Annahme der erfolgreichen Platzierung von 3.840.000 Neuen Aktien zum Mittelwert der Preisspanne und\n    von der Gesellschaft zu tragender Gesamtkosten des Angebots in H\u00f6he von \u20ac4,0 Mio., inklusive Banken- und\n    Platzierungsprovisionen, die an Berenberg zu zahlen sind und der festen Geb\u00fchr, die an ODDO BHF zu zahlen ist\n    sowie vollst\u00e4ndiger Zahlung der Ermessensverg\u00fctung.\n(3) Basierend auf 53.840.000 ausstehenden Aktien der Gesellschaft nach Durchf\u00fchrung des Angebots.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.38366124893071, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49615055603079555, "height": 0.11248930710008553, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-42-2", "text": "Jede Neue Aktie wird die gleichen Stimmrechte wie die bestehenden Aktien der\nGesellschaft verleihen. Vor dem Angebot hielt die Ver\u00e4u\u00dfernde Aktion\u00e4rin 100,0%\nder Stimmrechte der Gesellschaft. Nach Vollzug des Angebots (unter der Annahme\nder vollst\u00e4ndigen Aus\u00fcbung der Greenshoe-Option und Ausgabe aller Neuen Aktien)\nw\u00fcrden die von der Ver\u00e4u\u00dfernden Aktion\u00e4rin gehaltenen Stimmrechte insgesamt\n75,0% ausmachen.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.5094097519247219, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.08254918733960659, "width": 0.5810157194679566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-42-3", "text": "E.7 Ausgaben, die       Entf\u00e4llt. Anlegern werden von der Gesellschaft, der Ver\u00e4u\u00dfernden Aktion\u00e4rin oder\n    dem Anleger vom     den Anbietenden Banken keine Kosten in Rechnung gestellt. Anleger m\u00fcssen f\u00fcr die\n    Emittenten oder     \u00fcblichen Transaktions- und Bearbeitungsgeb\u00fchren aufkommen, die von ihren\n    Anbieter in         Brokern oder anderen Finanzinstituten, durch die sie ihre Aktien halten, erhoben\n    Rechnung gestellt   werden.\n    werden.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6800684345594525, "height": 0.07827202737382377, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-42-4", "text": "S-37\n", "page_number": 42, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03385731559854893}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-43-0", "text": "(This page has been left blank intentionally)\n", "page_number": 43, "bounding_box": {"top_left_x": 0.34280532043530837, "top_left_y": 0.42728828058169377, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.4414029084687767, "height": 0.014114627887082953, "width": 0.31499395405078595}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-43-1", "text": "S-38\n", "page_number": 43, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9302822925577416, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9409751924721984, "height": 0.010692899914456766, "width": 0.03446191051995168}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-0", "text": "RISK FACTORS\n", "page_number": 44, "bounding_box": {"top_left_x": 0.4649334945586457, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.12998790810157196}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-1", "text": "1.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.405683192261185, "top_left_y": 0.08597091531223268, "lower_right_x": 0.42019347037484883, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.014510278113663844}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-2", "text": "         An investment in the shares of Dermapharm Holding SE (the \u201cCompany\u201d and, together with its direct\nand indirect consolidated subsidiaries, \u201cDermapharm\u201d) is subject to risks. In addition to the other information\ncontained in this prospectus (the \u201cProspectus\u201d), investors should carefully consider the following risks when\ndeciding whether to invest in the Company\u2019s shares. The market price of the Company\u2019s shares could decline if\nany of these risks were to materialize, in which case investors could lose some or all of their investment.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7648125755743651}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-3", "text": "         The following risks, alone or together with additional risks and uncertainties not currently known to\nthe Company, or that the Company might currently deem immaterial, could have a material adverse effect on\nthe business, financial condition, cash flows, results of operations and prospects of Dermapharm. The order in\nwhich the risks are presented is not an indication of the likelihood of the risks actually materializing, or the\nsignificance or degree of the risks or the scope of any potential harm to the business, financial condition, cash\nflows, results of operations and prospects of Dermapharm. The risks mentioned herein may materialize\nindividually or cumulatively.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2840034217279726, "height": 0.09623609923011117, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-4", "text": "Market and Business related Risks\n", "page_number": 44, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3006843455945252, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.31137724550898205, "height": 0.010692899914456822, "width": 0.25211608222490933}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-5", "text": "1.1\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3011120615911035, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.31137724550898205, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-6", "text": "1.1.1   Dermapharm could be adversely affected by developments in the German pharmaceuticals and\n        healthcare markets.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.35372112917023096, "height": 0.025662959794696294, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.1Dermapharm could be adversely affected by developments in the German pharmaceuticals andhealthcare markets."]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-7", "text": "         Dermapharm develops, manufactures and markets branded pharmaceuticals that are no longer patent\nprotected as well as other healthcare products, primarily in the German market. Dermapharm also imports\npharmaceuticals from other member states of the European Economic Area for resale in Germany. In the\nnine-month period ended September 30, 2017, Dermapharm\u2019s revenues amounted to \u20ac349.7 million and its\nGerman sales, including sales of imported pharmaceuticals, accounted for approximately 92.6% of\nDermapharm\u2019s revenues during that period. As a result of this geographic focus, Dermapharm may be affected\nby changes in the German pharmaceuticals and healthcare markets.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4644995722840034, "height": 0.09538066723695465, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-8", "text": "         The German healthcare system is highly developed and most Germans are covered by statutory health\ninsurance (\u201cSHI\u201d) providers, which provide full or partial reimbursement for prescription pharmaceuticals. In\norder to limit healthcare costs, extensive legislation covering pricing for prescription pharmaceuticals has been\nimplemented, including limitations on potential price increases, a price moratorium (Preismoratorium) and\nmandatory rebates as well as the level of reimbursement from SHI providers. Moreover, such SHI providers\nseek additional price reductions through rebate agreements with individual manufacturers of prescription\npharmaceuticals. While Dermapharm attempts to limit the impact of this regulatory framework by targeting\ndirect payers (i.e., patients who bear pharmaceutical costs themselves and sales to whom are not subject to\npricing restrictions) with its prescription pharmaceuticals and increasing revenues from non-prescription\npharmaceuticals and other healthcare products, all of which are not subject to pricing restrictions, a substantial\nportion of Dermapharm\u2019s revenues and profits continues to be affected by the regulatory framework in\nGermany.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6355859709153122, "height": 0.16381522668947818, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-9", "text": "         Although already subject to extensive price restrictions, there can be no assurance that the German\npharmaceutical market will not be subject to additional or more onerous regulation in the future. The fact that\nGermany spends a greater portion of its gross domestic product on healthcare than any other country in the\nEuropean Union, has the second highest healthcare spending per capita, while also recording the highest share in\nterms of healthcare spending covered through public funding in the European Union (source: OECD Germany\n2017), could lead regulators to take further action to curb pharmaceuticals prices. Added pressure to take such\naction might stem from anticipated demographic developments, such as the ageing of the German population\nand the chronification of diseases, which increase the burden on the healthcare system while reducing the\nproportion of the population that contributes to it. Concerns with regards to the long-term solvency of the\nhealthcare system could become particularly acute in the event of a deterioration in the economic environment\nin Germany, which could increase the likelihood of increased price regulation, higher mandatory rebates,\nincluding for patent-free pharmaceuticals, the exclusion of certain pharmaceuticals from reimbursement by\nSHI providers or a reduction in the level of such reimbursement, all of which could adversely affect\nDermapharm\u2019s revenues and profits from its prescription pharmaceuticals and parallel import businesses.\nA deterioration in the economic environment could also adversely affect Dermapharm's revenues from sales of\nprescription pharmaceuticals to direct payers as well as sales of non-prescription pharmaceuticals and other\nhealthcare products since customers may decide to switch to cheaper, unbranded alternatives and/or reduce their\nconsumption of any pharmaceuticals and other healthcare products deemed not-essential.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8896492728828058, "height": 0.24679213002566291, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-44-10", "text": "", "page_number": 44, "bounding_box": {"top_left_x": 0.49455864570737607, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9516680923866553, "height": 0.00727117194183069, "width": 0.008464328899637219}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-0", "text": "         Negative developments in the German pharmaceuticals and healthcare markets or the legal framework\napplicable thereto could have a material adverse effect on Dermapharm\u2019s business, financial condition, cash\nflows, results of operations and prospects.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-1", "text": "1.1.2   A significant portion of Dermapharm\u2019s revenues and EBITDA are derived from sales of a limited\n        number of key products, in particular Dekristol\u00ae 20,000 I.E.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.13986313088109495, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.1680923866552609, "height": 0.028229255774165962, "width": 0.7636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.2A significant portion of Dermapharm\u2019s revenues and EBITDA are derived from sales of a limited\u00aenumber of key products, in particular Dekristol20,000 I.E."]}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-2", "text": "         In the nine-month period ended September 30, 2017, the pharmaceuticals and other healthcare products\nbusiness area accounted for 46.8% of Dermapharm\u2019s revenues and 93.8% of its earnings before interest, taxes,\ndepreciation and amortization (\u201cEBITDA\u201d). Dermapharm derives a substantial portion of revenues and\nEBITDA in this business area from sales of a limited number of key products, in particular Dermapharm\u2019s\nflagship product Dekristol\u00ae 20,000 I.E., a vitamin D preparation. In recent years, sales of Dekristol\u00ae 20,000 I.E.\nhave greatly benefited from the wide acceptance of medical studies demonstrating the adverse health\nconsequences of vitamin D deficiency and the increasing recognition of its prevalence among the general\npopulation and the fact that there is no competitor in the German market with a marketing authorization\n(Arzneimittelzulassung) for a vitamin D preparation with a similar combination of dosage and packaging size\n(Verpackungsgr\u00f6\u00dfe). As a result, revenues from the sale of Dekristol \u00ae 20,000 I.E. almost doubled from\napproximately \u20ac17.0 million in the fiscal year ended December 31, 2014 to approximately \u20ac32.9 million in the\nfiscal year ended December 31, 2016, while the number of packages sold increased from approximately\n1.9 million packages by approximately 53% to approximately 2.9 million packages in that same period. In the\nnine-month period ended September 30, 2017, Dekristol\u00ae 20,000 I.E. accounted for 7.7% of Dermapharm\u2019s\nrevenues and an even larger share of its EBITDA.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3866552609067579, "height": 0.20230966638152265, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-3", "text": "          There is no guarantee that sales of Dekristol\u00ae 20,000 I.E. will continue to grow or be sustainable at\ntheir current level. About half of such sales, based on Company estimates, are derived from sales to direct\npayers, making them particularly susceptible to adverse changes in market conditions and reductions in patient\npurchasing power, which could lead patients paying for Dekristol \u00ae 20,000 I.E.to cutting back their consumption\nor searching for cheaper alternatives to Dekristol\u00ae 20,000 I.E. Furthermore, if vitamin D deficiency is no longer\nconsidered a condition requiring treatment or if alternative forms of treatment are developed, this may reduce\ndemand for Dekristol\u00ae 20,000 I.E. In addition, if Dermapharm\u2019s competitors obtain marketing authorizations to\ndistribute products with the same dosage and packaging as Dekristol \u00ae 20,000 I.E., this could adversely affect\nDermapharm\u2019s revenues, result in pricing pressure or force Dermapharm to invest more heavily in marketing to\nmaintain its market position in the vitamin D market.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.393071000855432, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5303678357570573, "height": 0.13729683490162525, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-4", "text": "          Other key products of Dermapharm are Ampho-Moronal\u00ae, Dienovel\u00ae and Prednisolut\u00ae, which together\naccounted for aggregate revenues of \u20ac24.3 million in the fiscal year ended December 31, 2016. Other factors,\nincluding the introduction of competing products or alternative forms of treatment, unexpected side effects,\nrecalls, negative publicity as well as regulatory actions, could adversely affect sales of Dekristol \u00ae 20,000 I.E. or\nother key products of Dermapharm, which could also have a material adverse effect on Dermapharm.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5367835757057314, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6073567151411463, "height": 0.07057313943541488, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-5", "text": "        Negative developments affecting any of its key products, in particular Dekristol \u00ae 20,000 I.E., could\nhave a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations\nand prospects.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6120615911035072, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.6569717707442259, "height": 0.04491017964071864, "width": 0.7496977025392987}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-6", "text": "1.1.3   Dermapharm may not be able to successfully develop and market new products.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6702309666381523, "lower_right_x": 0.7333736396614269, "lower_right_y": 0.6843455945252352, "height": 0.014114627887082953, "width": 0.6154776299879081}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.3Dermapharm may not be able to successfully develop and market new products."]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-7", "text": "         Dermapharm holds approximately 900 marketing authorizations for more than 200 active\npharmaceutical ingredients (\u201cAPIs\u201d) and offers a broad assortment of branded pharmaceuticals, which are no\nlonger patent protected and have often been in the market for many years. Revenues from these pharmaceuticals\ntypically decline over time and consequently, Dermapharm\u2019s continued growth depends upon its ability to\ncontinue to successfully develop, introduce and commercialize new pharmaceuticals and other healthcare\nproducts in a timely manner. As of the date of this Prospectus, Dermapharm\u2019s product pipeline comprises more\nthan 40 ongoing development projects with new products for all of Dermapharm\u2019s product areas. This pipeline\nincludes 28 pharmaceuticals and other healthcare products, in particular dermatologicals, women\u2019s healthcare\nproducts and food supplements, which are expected to be marketable by 2023 and target selected markets where\nthe aggregate revenues from existing products marketed by competitors in Germany amounted to approximately\n\u20ac345 million in the fiscal year ended December 31, 2016 (source: INSIGHT Health).\n", "page_number": 45, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8485885372112917, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-45-8", "text": "", "page_number": 45, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5066505441354293, "lower_right_y": 0.9529512403763901, "height": 0.008982035928143728, "width": 0.013301088270858574}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-0", "text": "         However, there is no guarantee that Dermapharm will be able to successfully develop new products,\nsince even the reproduction of established formulas may prove to be more difficult and costly than originally\nanticipated. While Dermapharm possesses its own development capability, including the know-how to design\nand sponsor clinical studies required to obtain new marketing authorizations, it relies on contract research\norganizations and other third parties to assist in managing, monitoring and otherwise carrying out such clinical\nstudies. If these third parties do not successfully carry out the studies as instructed by Dermapharm, if the\nquality or accuracy of the data they obtain is compromised, or if they otherwise fail to comply with protocols for\nclinical studies or meet expected deadlines, Dermapharm\u2019s clinical studies may not meet regulatory\nrequirements. In addition, after Dermapharm submits an application to obtain a marketing authorization for a\nnew pharmaceutical, the relevant regulatory authority may change standards and/or request that Dermapharm\nconducts additional studies or evaluation. Therefore, Dermapharm may incur delays as well as higher costs than\noriginally anticipated when developing new products.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-1", "text": "         Moreover, manufacturers of originator pharmaceuticals for which Dermapharm is developing substitute\npatent-free pharmaceuticals may take steps to try to prevent the use of such substitutes (e.g., lower prices for\ntheir own pharmaceuticals, introduce innovative pharmaceuticals, change dosage forms or dosing regimens, file\nnew patents or patent extensions, initiate lawsuits or spread negative publicity), which may increase\nDermapharm\u2019s costs and delay or altogether prevent the introduction of new pharmaceuticals by Dermapharm.\nIn addition, manufacturers of originator pharmaceuticals increasingly launch authorized patent-free\npharmaceuticals or even non-pharmaceutical versions of their products (i.e., products that may be sold outside\npharmacies), which may adversely affect the market share Dermapharm can achieve for its new products.\nOriginator manufacturers do not face any significant barriers to entry into the markets for patent-free\npharmaceuticals and other healthcare products.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39349871685201027, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-2", "text": "          Even if Dermapharm is successful in developing new products there are various factors determining the\nsuccess of new product launches, some of which are outside Dermapharm\u2019s control (e.g., actions of competitors\nand customer perception regarding new products). Development of Dermapharm\u2019s patent-free pharmaceuticals\nusually takes about five years and the longer it takes to develop a product, the longer it may take for\nDermapharm to recover its development costs and generate profits, if it can do so at all. A product considered\npromising at the beginning of its development cycle may become less attractive if a competitor manages to\nreach the market earlier. In addition, Dermapharm may fail to correctly assess the potential market for new\nproducts. Given that Dermapharm generally does not target large-volume pharmaceuticals markets, such\nassessments are particularly difficult since there may be limited data available. In addition, the actual market at\nthe time of launch may be significantly less attractive than at the time development commenced (e.g., if\nalternative forms of treatment have been discovered or if more-advanced products have been introduced with\nrespect to the same ailments).\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3999144568006843, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.564585115483319, "height": 0.1646706586826347, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-3", "text": "         Failure to successfully develop and market new products in a timely manner could have a material\nadverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5710008554319932, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5988023952095808, "height": 0.02780153977758759, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-4", "text": "1.1.4   Dermapharm\u2019s efforts to expand its business into foreign markets expose Dermapharm to risks\n        associated with operating in unfamiliar countries.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.6415739948674081, "height": 0.026090675791274665, "width": 0.7636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.4Dermapharm\u2019s efforts to expand its business into foreign markets expose Dermapharm to risksassociated with operating in unfamiliar countries."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-5", "text": "         Apart from Germany, Dermapharm is also active in Austria and Switzerland and sales in these\ncountries accounted for approximately 4.9% of Dermapharm\u2019s revenues in the nine-month period ended\nSeptember 30, 2017. Dermapharm also has a presence in Eastern Europe (Croatia, Poland and the Ukraine). In\nthe future, Dermapharm plans to introduce selected products from its existing product portfolio as well as new\nproduct developments to additional markets. In a first phase, Dermapharm intends to enter adjacent markets in\nItaly, Spain and the United Kingdom, while in a second phase it plans to also enter markets in the Benelux\ncountries, the Czech Republic and Slovakia. With respect to medical devices bite away\u00ae and Herpotherm\u00ae,\nwhich Dermapharm recently acquired and for which it now holds the worldwide marketing rights, Dermapharm\nintends to market these devices worldwide. Through all of these expansion efforts, Dermapharm will make\nopportunistic judgements, targeting those foreign markets it considers particularly attractive at the time.\nHowever, there are many reasons why such efforts may fail, including:\n", "page_number": 46, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8058169375534645, "height": 0.14927288280581696, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-6", "text": "\uf0b7   different market environments and distribution channels (e.g., pharmacy chains);\n\uf0b7   lack of established marketing organizations and contacts with key customer groups, including\n    doctors and pharmacies;\n\uf0b7   lower recognition of Dermapharm\u2019s brands and trademarks and hesitance of customers to deal with\n    an unknown pharmaceuticals manufacturer;\n", "page_number": 46, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.8139435414884517, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8964927288280582, "height": 0.08254918733960648, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-46-7", "text": "", "page_number": 46, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9533789563729683, "height": 0.009409751924721932, "width": 0.010278113663845234}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-0", "text": "\uf0b7   lack of qualified management or adequately trained personnel;\n\uf0b7   divergent healthcare systems;\n\uf0b7   different buying behavior;\n\uf0b7   divergent cultures;\n\uf0b7   divergent labor regulations;\n\uf0b7   exchange rate fluctuations between the Euro and the British Pound;\n\uf0b7   different legal requirements for pharmaceuticals and other healthcare products;\n\uf0b7   different regulatory authorities who supervise the approval process for, and marketing of,\n    pharmaceuticals;\n\uf0b7   variations in protection of intellectual property and other legal rights; and\n\uf0b7   political uncertainties, including the currently unknown long-term effect of the United Kingdom\u2019s\n    \u201cBrexit\u201d decision.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32078699743370404, "height": 0.23224978614200173, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-1", "text": "         In addition, Dermapharm is required to obtain new marketing authorizations before marketing its\npharmaceuticals abroad, even when it has already obtained such authorizations in Germany, and may not be able\nto obtain such marketing authorizations (e.g., if local regulatory authorities impose additional restrictions or\nrequire additional information that Dermapharm is unable to provide).\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38323353293413176, "height": 0.05175363558597096, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-2", "text": "          When entering a new and unfamiliar market, Dermapharm is required to deal with, and adapt to, an\nunknown political and enforcement environment as well as different market practices, in particular when\nDermapharm enters markets outside Europe. Foreign companies may be subject to additional scrutiny and\nenforcement agencies may be stricter in their approach to such companies. In 2012, Dermapharm\u2019s Croatian\nentity Farmal d.d. (\u201cFarmal\u201d) was subject to an investigation by Croatian governmental authorities with respect\nto coupons Farmal had offered to doctors when marketing its pharmaceuticals. Farmal subsequently decided to\nsettle this matter by paying a fine. However, the negative publicity and disruption of business relationships\nresulting from the investigation had a material adverse impact on Dermapharm\u2019s business in Croatia\n(see \u201c1.2.2 Dermapharm\u2019s existing compliance structure may not be sufficient and non-compliance with laws\nand regulations may adversely affect Dermapharm\u2019s business.\u201d).\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.393071000855432, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5269461077844312, "height": 0.13387510692899918, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-3", "text": "       The materialization of any of the aforementioned risks could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5367835757057314, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.562874251497006, "height": 0.026090675791274553, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-4", "text": "5   Dermapharm may be unable to identify and capitalize on attractive growth opportunities and even if\n    it does engage in acquisitions, joint ventures or other business combinations, such transactions may\n    not develop as originally anticipated.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.5778443113772455, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6193327630453379, "height": 0.04148845166809245, "width": 0.7267230955259976}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.5Dermapharm may be unable to identify and capitalize on attractive growth opportunities and even ifit does engage in acquisitions, joint ventures or other business combinations, such transactions maynot develop as originally anticipated."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-5", "text": "Seaton", "page_number": 47, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5778443113772455, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.5829769033361848, "height": 0.0051325919589393365, "width": 0.035066505441354284}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-6", "text": "         Dermapharm continuously reviews the potential acquisition of technologies, pharmaceuticals and other\nproducts, intellectual property and complementary businesses. As part of its growth strategy, Dermapharm\nrecently acquired the right to market the medical devices bite away\u00ae for the external treatment of bites and\nstings from insects and Herpotherm\u00ae for the treatment of herpes symptoms. In addition, it also acquired\nBio-Di\u00e4t-Berlin Gesellschaft mit beschr\u00e4nkter Haftung and Kr\u00e4uter K\u00fchne GmbH (together,\n\u201cBio-Di\u00e4t-Berlin\u201d). Bio-Di\u00e4t-Berlin develops, produces and markets non-prescription pharmaceuticals sold\nover the counter (\u201cOTC\u201d) and other healthcare products, in particular food supplements for the treatment of\nrespiratory diseases and muscle aches. In December 2017 Dermapharm acquired all shares in Strathmann GmbH\n& Co. KG, its sole general partner Strathmann Service GmbH and Biokirch GmbH Pharmaproduktion und\n\u00c4rzteservice (together, \u201cStrathmann\u201d). Strathmann distributes a broad product offering primarily comprising\nOTC products, which complement Dermapharm\u2019s existing product portfolio, in particular with respect to the\ndermatologicals, women\u2019s healthcare and vitamins/minerals/enzymes product areas. Furthermore, in January\n2018 Dermapharm acquired all shares in Trommsdorff GmbH & Co. KG and its sole general partner\nCl. Lageman Gesellschaft mit beschr\u00e4nkter Haftung (together, \u201cTrommsdorff\u201d). Trommsdorff manufactures\nand markets 23 different prescription pharmaceuticals and OTC products, in particular Keltican\u00ae forte, a dietary\nproduct for the treatment of back pain, and Tromcardin \u00ae complex, which combines certain minerals and\nvitamins for the treatment of cardiac arrhythmia.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6325919589392643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.864841745081266, "height": 0.23224978614200165, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-47-7", "text": "", "page_number": 47, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9525235243798118, "height": 0.008126603934987209, "width": 0.014510278113663844}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-0", "text": "          While Dermapharm has carefully evaluated these acquisition opportunities, there is no guarantee that\nthey will develop as currently envisioned. In particular, Dermapharm plans to market the acquired medical\ndevices in various foreign markets. However, Dermapharm has no previous experience with marketing medical\ndevices in these markets, and entry into such markets is associated with various risks (see \u201c1.1.4 Dermapharm\u2019s\nefforts to expand its business into foreign markets expose Dermapharm to risks associated with operating in\nunfamiliar countries.\u201d). Furthermore, it may prove difficult to integrate the existing businesses of\nBio-Di\u00e4t-Berlin, including the online shop operated by it, Strathmann and Trommsdorff into Dermapharm\u2019s\nexisting offering of OTC and other healthcare products.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-1", "text": "          In addition to its recent acquisitions, Dermapharm plans to further capitalize on attractive growth\nopportunities through strategic acquisitions of other businesses, products or assets, or through joint ventures,\nstrategic agreements or other arrangements. However, there is no guarantee that Dermapharm will be able to\nidentify suitable acquisition or investment targets or other growth opportunities. Even if Dermapharm does\nidentify what it considers to be attractive growth opportunities, Dermapharm may not be able to capitalize on\nsuch opportunities on reasonable terms or at all, in particular due to the intense competition in the\npharmaceuticals industry. In addition, Dermapharm may be unable to obtain the necessary regulatory approvals,\nincluding approvals from competition authorities.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-2", "text": "         Even if Dermapharm actually engages in additional acquisitions, joint ventures or other business\ncombinations, such transactions may involve significant integration challenges (e.g., with respect to aligning the\npersonnel, operations and products of the acquired businesses), or involve risks associated with entering markets\nin which Dermapharm has limited or no prior experience, in particular markets outside of Europe, as well as\noperational complexities and require Dermapharm to invest substantial resources. They may also disrupt\nDermapharm\u2019s ongoing business and divert management\u2019s attention, all of which may adversely affect\nDermapharm\u2019s relationships with customers, employees, regulators or suppliers. Furthermore, Dermapharm\nmay be unable to realize synergies or other benefits expected to result from future acquisitions, joint ventures or\nother business combinations, or to generate additional revenues, which may prevent Dermapharm from\nachieving a return on such investments. In addition, Dermapharm may be required to expend more resources on\nthe integration of such acquisitions than originally anticipated and may incur unanticipated liabilities.\nFurthermore, Dermapharm may be unable to retain qualified officers and key employees, and it may be unable\nto replace such persons with similarly qualified personnel.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49615055603079555, "height": 0.17835757057313945, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-3", "text": "         Dermapharm may decide to finance future acquisitions or investments of Dermapharm through cash\nreserves, debt financing, or by issuing additional shares, which could dilute the holdings of the Company\u2019s\nexisting shareholders. However, there is no guarantee that Dermapharm will be able to obtain the required\nfinancing on acceptable terms or at all.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5025662959794697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5577416595380668, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-4", "text": "          In addition, certain acquisitions or investments could also result in an increase of the goodwill recorded\non the Company\u2019s consolidated statement of financial position, which may subsequently result in impairment\ncharges (see \u201e1.1.24 Goodwill and capitalized development costs are subject to impairment testing, which may\nresult in impairment charges.\u201c).\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5641573994867408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6193327630453379, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-5", "text": "       The materialization of any of the aforementioned risks could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.625748502994012, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6535500427715997, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-6", "text": "1.1.6   Dermapharm faces intense competition in all markets in which it operates.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6702309666381523, "lower_right_x": 0.6946795646916566, "lower_right_y": 0.6843455945252352, "height": 0.014114627887082953, "width": 0.5767835550181378}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.6Dermapharm faces intense competition in all markets in which it operates."]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-7", "text": "        With respect to all of its business areas, Dermapharm faces intense competition from various groups of\ncompetitors. These include other manufacturers of pharmaceuticals, including manufacturers of originator\npharmaceuticals and manufacturers who also market non-prescription versions of their prescription\npharmaceuticals, and other importers of pharmaceuticals.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7514970059880239, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-8", "text": "          Many of these competitors have longer operating histories and substantially greater resources than\nDermapharm and may be able to develop and distribute safer, more effective, more convenient and/or\nlower-priced products and respond faster to new or emerging market preferences than Dermapharm. If\nDermapharm\u2019s competitors are more successful than Dermapharm (e.g., due to higher development or\nmarketing capacities or greater market experience), this could adversely affect Dermapharm\u2019s market share or\nforce Dermapharm to lower its prices, thereby reducing its profit margins. In the parallel imports market,\nDermapharm\u2019s largest competitors have been in the market years or even decades before Dermapharm and\nconsequently benefit from long-established customer and supplier relationships. Even where Dermapharm is\nable to offer more attractive prices, it may not be able to penetrate such existing relationships and consequently\na significant share of potential customers and suppliers in the parallel import market may not be accessible to\nDermapharm.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7519247219846023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9084687767322498, "height": 0.15654405474764754, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-48-9", "text": "", "page_number": 48, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5024183796856106, "lower_right_y": 0.9525235243798118, "height": 0.008554319931565413, "width": 0.00906892382103991}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-0", "text": "         In recent years, the pharmaceuticals and healthcare industries have seen increased consolidation,\nresulting in ever larger competitors and placing further pressure on prices, development activities and customer\nretention. This competition may increase even further, if new products and competitors enter the market. In\nparticular, the markets for healthcare products and parallel imports of pharmaceuticals have lower barriers to\nentry compared to the prescription pharmaceuticals market, since the distribution of the relevant products may\nnot require marketing authorizations or the relevant approvals may be easier to obtain. Thus, the intense\ncompetition Dermapharm faces could intensify even further.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-1", "text": "         Intense competition could have a material adverse effect on Dermapharm\u2019s business, financial\ncondition, cash flows, results of operations and prospects.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.2155688622754491, "height": 0.027801539777587675, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-2", "text": "1.1.7   Dermapharm depends on its ability to successfully market its prescription pharmaceuticals to\n        doctors who prescribe such pharmaceuticals to their patients.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.13119709794437726, "top_left_y": 0.2296834901625321, "lower_right_x": 0.880894800483676, "lower_right_y": 0.2583404619332763, "height": 0.028656971770744222, "width": 0.7496977025392987}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.7Dermapharm depends on its ability to successfully market its prescription pharmaceuticals todoctors who prescribe such pharmaceuticals to their patients."]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-3", "text": "          Doctors represent Dermapharm\u2019s most important target group for prescription pharmaceuticals as they\ndirectly recommend and prescribe Dermapharm\u2019s products to patients. Should such doctors decide to\nrecommend and prescribe competitors\u2019 prescription pharmaceuticals instead of Dermapharm\u2019s products\n(e.g., due to more effective marketing measures of Dermapharm\u2019s competitors or real or perceived deficiencies\nof Dermapharm\u2019s pharmaceuticals), this could significantly adversely affect Dermapharm\u2019s revenues. In\naddition, doctors may choose alternative therapeutic options instead of prescribing Dermapharm\u2019s\npharmaceuticals, if doctors perceive such alternatives to be safer, more reliable, more effective, easier to\nadminister or less expensive than treatment with Dermapharm\u2019s pharmaceuticals.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38152266894781867, "height": 0.10863986313088109, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-4", "text": "          As of the date of this Prospectus, Dermapharm employs 60 German sales representatives who regularly\nvisit doctors relevant for Dermapharm\u2019s product areas. However, in individual cases doctors have in the past\ndeclined to receive visits from Dermapharm\u2019s salesforce and they may do so more frequently in the future. In\naddition, new legislation may further restrict the possibility of direct marketing efforts to doctors. In either such\ncase, Dermapharm may be unable to continue its successful direct marketing efforts, which may adversely affect\nits business.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4679213002566296, "height": 0.07827202737382377, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-5", "text": "         If due to new legislation pharmacies are given the final say over which prescription pharmaceuticals to\nprovide to patients, Dermapharm may not be able to achieve similar marketing success with such pharmacies\ncompared to its current success with doctors.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.518819503849444, "height": 0.04020530367835756, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-6", "text": "         Inability to successfully market its prescription pharmaceuticals to doctors could have a material\nadverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5543199315654406, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-7", "text": "1.8   Rebate agreements with SHI providers may adversely affect Dermapharm\u2019s business.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.14207980652962515, "top_left_y": 0.567579127459367, "lower_right_x": 0.772067714631197, "lower_right_y": 0.5795551753635586, "height": 0.0119760479041916, "width": 0.6299879081015719}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.8Rebate agreements with SHI providers may adversely affect Dermapharm\u2019s business."]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-8", "text": "         Large-volume parts of the German market for patent-free pharmaceuticals are characterized by rebate\nagreements between selected manufacturers and SHI providers. These exclusive or semi-exclusive agreements\nare generally awarded to the bidder offering the lowest price as part of a tender process, thereby providing for\nhigh volumes but only low margins due to the significant rebates involved. As of September 30, 2017, German\nSHI providers had entered into a total of 27,187 rebate agreements (source: Pro Generika \u2013 Q3 2017).\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6638152266894782, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-9", "text": "          While Dermapharm only opportunistically participates in tender processes to win such rebate\nagreements, inability to win the intended agreements could adversely affect its revenues. Even if Dermapharm\ndoes win, it may have miscalculated prices and/or manufacturing costs, thereby offering too large of a rebate\nand incurring a loss on the sale of prescription pharmaceuticals under the relevant rebate agreements. In\naddition, Dermapharm may in some cases decide to offer a price that is not cost-covering in order to win\nstrategically important rebate agreements. However, if Dermapharm underestimates demand under such\nagreements, it may incur a higher loss than originally anticipated.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6702309666381523, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.09623609923011123, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-10", "text": "         While many of Dermapharm\u2019s markets are generally not subject to rebate agreements due to their\nlimited size and number of competitors, this may change if SHI providers expand the use of rebate agreements\nor if additional competitors enter the market. In such a case, the combination of rebate agreements and added\ncompetition may quickly erode Dermapharm\u2019s strong market position in such markets and adversely impact its\nrevenues and profitability.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8417450812660393, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-49-11", "text": "", "page_number": 49, "bounding_box": {"top_left_x": 0.496372430471584, "top_left_y": 0.9448246364414029, "lower_right_x": 0.5066505441354293, "lower_right_y": 0.9533789563729683, "height": 0.008554319931565413, "width": 0.01027811366384529}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-0", "text": "         Furthermore, it is generally difficult for parallel importers of pharmaceuticals such as Dermapharm to\nparticipate in tender processes for exclusive or semi-exclusive rebate agreements with respect to the\npharmaceuticals they import, since parallel importers cannot ensure that they will be able to provide sufficient\nquantities of such pharmaceuticals for the duration of the relevant rebate agreement. An increased use of rebate\nagreements by SHI providers could therefore reduce the demand for prescription pharmaceuticals from parallel\nimports and adversely affect Dermapharm\u2019s parallel import business. In addition, while Dermapharm is able to\nparticipate in non-exclusive rebate agreements (so-called open house agreements), these agreements do not\nprovide any particular benefit to Dermapharm while forcing it to grant rebates on the relevant pharmaceuticals.\nConsequently, an increased use of non-exclusive rebate agreements by SHI providers could adversely affect\nDermapharm\u2019s parallel import business.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-1", "text": "        Inability to win tender processes with SHI providers or an expanded use of rebate agreements could\nhave a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations\nand prospects.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.04148845166809237, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-2", "text": "1.1.9   Healthcare reforms and related changes to the framework applicable to the pharmaceuticals\n        industry may adversely affect Dermapharm\u2019s business.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.2844311377245509, "lower_right_x": 0.880894800483676, "lower_right_y": 0.3092386655260907, "height": 0.024807527801539775, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.9Healthcare reforms and related changes to the framework applicable to the pharmaceuticalsindustry may adversely affect Dermapharm\u2019s business."]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-3", "text": "         The continuing increase in expenditures for pharmaceuticals has been the subject of considerable\ngovernment attention in Germany. Public scrutiny has increased political efforts to limit prices for\npharmaceuticals and led to the introduction of extensive pricing restrictions. Certain prescription\npharmaceuticals, in particular those with high volumes, are subject to a reference price, which is the maximum\nprice for which patients are reimbursed by SHI providers. All other prescription pharmaceuticals (i.e., those\nwithout a reference price) are subject to a mandatory manufacturer rebate, which, in the case of patent-free\npharmaceuticals, amounts to 6%, as well as a price moratorium (Preismoratorium), which was recently\nextended until 2022. Under this moratorium, pharmaceuticals manufacturers are required to compensate\nSHI providers and private health insurance providers for any price increases, limiting the benefits from price\nincreases for prescription pharmaceuticals. In addition, manufacturers of patent-free pharmaceuticals such as\nDermapharm are generally required to offer a mandatory rebate of 10% on the ex-factory price\n(Herstellerabgabepreis) of their patent-free prescription pharmaceuticals.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4893071000855432, "height": 0.1612489307100085, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-4", "text": "          Despite these already stringent regulations on pricing for prescription pharmaceuticals, SHI providers,\npoliticians and other third-party payers continue to seek ways to reduce or contain expenditures for\npharmaceuticals. They may decide to adopt additional measures (e.g., reducing or eliminating coverage for\ncertain prescription pharmaceuticals, lowering reimbursement levels, setting fixed prices for pharmaceuticals or\nincreasing the mandatory manufacturer rebate and/or rebate for patent-free pharmaceuticals or introducing\nadditional rebates), which could adversely impact pricing and demand for Dermapharm\u2019s pharmaceuticals. In\nthe future, European legal initiatives may also extend to pharmaceuticals pricing and the creation of a unilateral\nframework for price restrictions through the European Union, which may lead to additional price reductions in\nhigh-priced markets such as Germany.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4991445680068435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.621043627031651, "height": 0.12189905902480747, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-5", "text": "       Legislators may introduce regulation that require the prescription of APIs instead of a certain branded\npharmaceutical, in which case doctors or pharmacies may prefer to provide patients with unbranded\npharmaceuticals instead of Dermapharm\u2019s branded prescription pharmaceuticals.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6689478186484175, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-6", "text": "         Healthcare reforms could have a material adverse effect on Dermapharm\u2019s business, financial\ncondition, cash flows, results of operations and prospects.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.704448246364414, "height": 0.027373823781009388, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-7", "text": "1.10   Delays with respect to the invoicing of SHI providers and private health insurance providers make it\n       difficult for Dermapharm to predict the timing of when it will be required to pay such providers for\n       mandatory rebates and any increases in the level of reimbursements by SHI providers and private\n       health insurance providers to patients could adversely affect Dermapharm\u2019s profitability.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1396614268440145, "top_left_y": 0.7181351582549187, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7720273738237811, "height": 0.05389221556886237, "width": 0.7412333736396615}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.10Delays with respect to the invoicing of SHI providers and private health insurance providers make itdifficult for Dermapharm to predict the timing of when it will be required to pay such providers formandatory rebates and any increases in the level of reimbursements by SHI providers and privatehealth insurance providers to patients could adversely affect Dermapharm\u2019s profitability."]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-8", "text": "         The mandatory rebate of 10%, which Dermapharm is required to grant on the ex-factory price of its\npatent-free prescription pharmaceuticals to SHI providers and private health insurance providers, is not deducted\nupon sale of the relevant pharmaceuticals, but rather granted in the form of reimbursements to such\nSHI providers and private health insurance providers once they have submitted corresponding invoices to\nDermapharm. The same holds true for the mandatory manufacturer rebate of 6%, which Dermapharm is\nrequired to grant on any of its patent-free pharmaceuticals without a reference price. SHI providers and private\nhealth insurance providers will often take several months or even over a year to claim reimbursements from\nDermapharm in connection with mandatory rebates and there is no statute of limitations with respect to such\nreimbursement claims.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7865697177074422, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9067579127459366, "height": 0.12018819503849443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-50-9", "text": "", "page_number": 50, "bounding_box": {"top_left_x": 0.49334945586457074, "top_left_y": 0.9448246364414029, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9520958083832335, "height": 0.007271171941830579, "width": 0.009673518742442544}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-0", "text": "          Dermapharm cannot accurately predict the level of reimbursements which patients receive from\nSHI providers or private health insurance providers due to the lack of information on whether prescription\npharmaceuticals are purchased by direct payers and differences in reimbursement policies between different\nproviders. Therefore, Dermapharm is also unable to accurately predict the share of sales of its prescription\npharmaceuticals that is subject to mandatory rebates. Furthermore, SHI providers or private health insurance\nproviders may change their respective reimbursement policies, and such changes may even be enacted\nretroactively. Should the share of sales of Dermapharm\u2019s prescription pharmaceuticals that is subject to rebates\nincrease, this could adversely affect Dermapharm\u2019s profitability.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-1", "text": "          In order to account for mandatory rebates and rebates granted under rebate agreements with\nSHI providers, Dermapharm\u2019s revenues recognized in the Company\u2019s consolidated statement of comprehensive\nincome are stated net of estimated amounts for such rebates, which are deducted at the time the sales are\nrecognized. Deductions for rebates are estimated primarily on the basis of historical experience and future\nexpectations of sales development. Adjustments to deductions made in prior periods for accruals of rebates are\nrecognized as a decrease or increase of revenues subsequent periods, as the case may be. Therefore,\nDermapharm may be required to reduce its revenues in subsequent periods if it has miscalculated the actual\nlevel of rebates with respect to prior periods. Moreover, Dermapharm is required to maintain sufficient funds in\norder to fulfill reimbursement claims by SHI providers and private health insurance providers even if such\nclaims are asserted long after the sale of the relevant prescription pharmaceuticals, since such sales are not time\nbarred.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34901625320787, "height": 0.14756201881950387, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-2", "text": "        Delays with respect to the invoicing of SHI providers and private health insurance providers or changes\nin the level of reimbursements to patients by such providers could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35885372112917024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40034217279726264, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-3", "text": "1.1.11   Dermapharm\u2019s revenues may be adversely affected if it is faced with ever larger customers.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8119709794437727, "lower_right_y": 0.4294268605645851, "height": 0.012403763900769915, "width": 0.694074969770254}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.11Dermapharm\u2019s revenues may be adversely affected if it is faced with ever larger customers."]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-4", "text": "          Dermapharm generates its revenues from sales of prescription pharmaceuticals to pharmacies and\nhospitals, which are often supplied through pharmaceutical wholesalers. Its non-prescription pharmaceuticals\nare also sold in pharmacies, while healthcare products are generally sold in health stores and drugstores, most of\nwhom are also supplied through wholesalers. Some of these customer groups, in particular hospitals and health\nstores, are undergoing a process of consolidation. As a result of these developments, Dermapharm may be faced\nwith larger customers who exert greater purchasing power. At the same time, a consolidation of Dermapharm\u2019s\ncustomer base may lead to a concentration of credit risk with respect to such larger customers. In the past,\ncertain customers have already demanded special discounts from Dermapharm, and such demands may intensify\nin the future.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5637296834901625, "height": 0.11933276304533785, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-5", "text": "          With respect to pharmacies, Sections 7 and 8 of the German Pharmacy Act (Apothekengesetz) impose\nlimits on the ownership of German pharmacies, effectively preventing corporations from creating large\npharmacy chains. However, these provisions have been challenged in the past and there have been numerous\ninitiatives pushing for the abolition of restrictions on the ownership of German pharmacies. Should these efforts\nprove successful, Dermapharm might be faced with larger pharmacy chains in the future, who could demand\nsignificant rebates or decide not to offer Dermapharm\u2019s pharmaceuticals, which could adversely affect\nDermapharm\u2019s revenues. Already today, pharmacies are increasingly forming purchasing groups, which may\nprovide them with additional purchasing power, and consequently increase the pricing pressure Dermapharm\nfaces with respect to its pharmaceuticals. In addition, the number of pharmacies in Germany has decreased in\nrecent years, declining from 20,441 licensed pharmacies as of September 31, 2014 to 20,023 licensed\npharmacies as of December 31, 2016 (source: ABDA).\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7224123182207014, "height": 0.14798973481608202, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-6", "text": "         Furthermore, if any of the aforementioned customer groups of Dermapharm were to shrink (e.g., due to\na reduction in the overall number and market size of health stores or a trend towards online marketing of\nhealthcare products), there is no guarantee that Dermapharm will be able to achieve the same success by\nmarketing its products using other distribution channels.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7318220701454234, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7848588537211292, "height": 0.05303678357570574, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-7", "text": "         Increased purchasing power of larger customers could have a material adverse effect on Dermapharm\u2019s\nbusiness, financial condition, cash flows, results of operations and prospects.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8199315654405475, "height": 0.02651839178785287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-51-8", "text": "", "page_number": 51, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9529512403763901, "height": 0.008554319931565524, "width": 0.010278113663845234}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-0", "text": "1.1.12   Dermapharm depends on market perceptions, particularly with respect to the safety, effectiveness\n         and quality of its products.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.11120615911035073, "height": 0.026090675791274595, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.12Dermapharm depends on market perceptions, particularly with respect to the safety, effectivenessand quality of its products."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-1", "text": "         Dermapharm markets its products under well-known brands. Therefore, market perceptions are very\nimportant to Dermapharm\u2019s business, especially market perceptions with respect to the safety and quality of\nDermapharm\u2019s products. If any products manufactured or distributed by Dermapharm, including products resold\nas part of its parallel import business, or similar products that other companies distribute, are subject to market\nwithdrawals or recalls, or prove to be, or accused of being, harmful to customers, this could adversely impact\ndemand for such products. Negative publicity with respect to the quality of Dermapharm\u2019s products could have\nthe same effect.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21984602224123181, "height": 0.09366980325064156, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-2", "text": "the same effect.\n         From time to time, there has been significant publicity regarding the pricing of pharmaceuticals and\nhealthcare products in general, including negative publicity resulting from prices charged by competitors for\nnew products as well as price increases by competitors on older products that the public deemed excessive. Any\npricing pressure arising from social or political pressure to lower the price of pharmaceuticals or healthcare\nproducts could adversely impact Dermapharm\u2019s business.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2202737382378101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29769033361847735, "height": 0.07741659538066725, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-3", "text": "         In order to protect its brands and avoid negative publicity, Dermapharm may decide to recall certain\nproducts that do not meet its high quality standards, even where there is no danger to customers or legal\nobligation to recall such products. For example, in 2017 Dermapharm recalled certain batches of its\nMomecutan\u00ae skin cream, since the relevant batches were overly granular, making them unpleasant to apply to\nthe skin. Such voluntary product recalls may involve high costs and draw unwanted attention to such\nmanufacturing issues, thereby damaging Dermapharm\u2019s reputation for high product quality.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3866552609067579, "height": 0.07912745936698029, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-4", "text": "         Negative changes of market perceptions with respect to Dermapharm\u2019s products could have a material\nadverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.42258340461933275, "height": 0.026090675791274553, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-5", "text": "1.13   Dermapharm may be unable to successfully market its healthcare products, in particular medical\n       devices bite away\u00ae and Herpotherm\u00ae, through online marketing channels.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.14328899637243048, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.4619332763045338, "height": 0.024379811804961515, "width": 0.7327690447400241}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.13Dermapharm may be unable to successfully market its healthcare products, in particular medical\u00ae\u00aedevices bite awayand Herpotherm\u00ae, through online marketing channels."]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-6", "text": "          Some of Dermapharm\u2019s healthcare products are marketed and sold through different online channels.\nIn particular, medical devices bite away\u00ae and Herpotherm\u00ae are marketed through various online shops,\nespecially the online platform operated by Amazon EU S.\u00e0 r.l. As of the date of this Prospectus, these medical\ndevices had comparably high average user ratings and in the nine-month period ended September 30, 2017,\napproximately 288,000 units of bite away\u00ae and Herpotherm\u00ae were sold through such online shops. These online\nshops may, however, decide to no longer offer Dermapharm\u2019s products or offer them at less attractive terms\n(e.g., charging additional fees or changing the rankings and/or ratings for Dermapharm\u2019s products). There is no\nguarantee that Dermapharm would be able to achieve a similar marketing success through offline marketing in\nsuch case.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5988023952095808, "height": 0.12018819503849437, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-7", "text": "         In addition, Dermapharm\u2019s online marketing benefits from the fact that websites for its healthcare\nproducts show up in online searches of major search engines (e.g., the search engine operated by Google LLC).\nHowever, changes to the algorithms of these search engines could result in Dermapharm\u2019s product websites\nbeing ranked lower in, or even excluded from, search results and adversely affect Dermapharm\u2019s ability to\nmarket the relevant products online.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6766467065868264, "height": 0.06800684345594521, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-8", "text": "         Inability to successfully market its healthcare products through online marketing channels could have a\nmaterial adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and\nprospects.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6839178785286569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7249786142001711, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-52-9", "text": "9\n", "page_number": 52, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.9542343883661248, "height": 0.009837467921300247, "width": 0.010278113663845234}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-0", "text": "1.1.14   The expansion of social media platforms and new technologies presents risks and challenges for\n         Dermapharm\u2019s business and reputation.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.11077844311377245, "height": 0.02566295979469632, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.14The expansion of social media platforms and new technologies presents risks and challenges forDermapharm\u2019s business and reputation."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-1", "text": "          While Dermapharm only occasionally uses social media and new technologies to communicate about\nits business, marketing of its medical devices bite away\u00ae and Herpotherm\u00ae is more dependent on online\nmarketing and related ratings and reviews (see \u201c1.1.13 Dermapharm may be unable to successfully market its\nhealthcare products, in particular medical devices bite away\u00ae and Herpotherm\u00ae, through online marketing\nchannels.\u201d). However, the increasing use of such media by customers exposes Dermapharm to particular risks.\nIts customers may use social media and new technologies to comment on the effectiveness of Dermapharm\u2019s\nproducts and to report alleged side effects. When such matters arise, the nature of evidence-based healthcare and\nrestrictions on what pharmaceutical manufacturers may communicate about their products are not always well\nsuited to allow Dermapharm to rapidly defend its interests in the face of political and market pressures generated\nby social media and rapid news cycles, and this may result in overly restrictive regulatory actions, otherwise\nadversely affect Dermapharm\u2019s business and cause fluctuations in the Company\u2019s share price.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2771599657827203, "height": 0.15098374679213003, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-2", "text": "         In addition, unauthorized communications, such as press releases or posts on social media, purported to\nbe issued by Dermapharm, may contain information that is false, misleading or otherwise damaging. Negative\nor inaccurate posts or comments about Dermapharm, its products, business and directors or officers on any\nsocial networking website could seriously damage Dermapharm\u2019s reputation. In addition, its employees and\nrelated parties may use social media and mobile technologies inappropriately, which may give rise to liability,\nor lead to breaches of data security, loss of trade secrets or other intellectual property or public disclosure of\nsensitive information (e.g., information about Dermapharm\u2019s employees, clinical studies or customers).\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3798118049615056, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-3", "text": "          Failure to properly address risks and challenges from the increased use of social media and mobile\ntechnologies could have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows,\nresults of operations and prospects.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38622754491017963, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42771599657827203, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-4", "text": "1.1.15   The illegal distribution of counterfeit versions of Dermapharm\u2019s products or stolen products could\n         have a negative impact on Dermapharm\u2019s reputation.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.44439692044482465, "lower_right_x": 0.880894800483676, "lower_right_y": 0.47177074422583404, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.15The illegal distribution of counterfeit versions of Dermapharm\u2019s products or stolen products couldhave a negative impact on Dermapharm\u2019s reputation."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-5", "text": "          Third parties may illegally distribute and sell counterfeit versions of Dermapharm\u2019s products, which do\nnot meet the rigorous manufacturing and testing standards of Dermapharm\u2019s proprietary products. Counterfeit\npharmaceuticals and healthcare products are frequently unsafe or ineffective, and can be life threatening.\nCounterfeit products may contain harmful substances, the wrong dose of APIs or no APIs at all. However, to\ndistributors and users, counterfeit products may be virtually indistinguishable from corresponding authentic\nversions.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5641573994867408, "height": 0.07869974337040209, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-6", "text": "         Reports of adverse reactions to counterfeit products or increased levels of counterfeiting could\nmaterially adversely affect patient confidence in Dermapharm\u2019s authentic products and the harm caused by\nunsafe counterfeit products may mistakenly be attributed to such authentic products. In addition, thefts of\nDermapharm\u2019s products at warehouses, manufacturing facilities or in transit, could adversely affect\nDermapharm\u2019s reputation, if the stolen products are sold through unauthorized channels.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6424294268605646, "height": 0.06800684345594521, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-7", "text": "          Public loss of confidence in the integrity of Dermapharm\u2019s products due to counterfeiting or theft of\nsuch products could have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows,\nresults of operations and prospects.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6497005988023952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6911890504704876, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-8", "text": "1.1.16   Dermapharm depends on a limited number of suppliers for the raw materials needed to manufacture\n         its products and third-party manufacturers for its Dekristol\u00ae 20,000 I.E. soft capsules and\n         Dermapharm\u2019s medical devices. Interruptions in Dermapharm\u2019s supply chain could have a material\n         adverse effect on its business.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.704448246364414, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.7596236099230111, "height": 0.05517536355859709, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.16Dermapharm depends on a limited number of suppliers for the raw materials needed to manufacture\u00aeits productsandthird-partymanufacturers foritsDekristol20,000 I.E.softcapsulesandDermapharm\u2019s medical devices. Interruptions in Dermapharm\u2019s supply chain could have a materialadverse effect on its business."]}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-9", "text": "         The raw materials used in the manufacturing of Dermapharm\u2019s pharmaceuticals and other healthcare\nproducts consist of chemicals in various forms that are generally available from several sources. In some cases,\nhowever, the relevant raw materials are available only from a limited number of suppliers or even a single\nsupplier. Therefore, Dermapharm may not always have timely and sufficient access to raw materials or other\nproducts.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8413173652694611, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-10", "text": "        A significant portion of the raw materials required for Dermapharm\u2019s products may only be available\nfrom foreign sources, in particular suppliers from China and India, which may be subject to special risks of\ndoing business abroad, including:\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8481608212147135, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8896492728828058, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-53-11", "text": "", "page_number": 53, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-0", "text": "\uf0b7   inability of such manufacturers to meet international compliance standards for the manufacture of\n    raw materials in the pharmaceutical industry, which could lead to a suspension or ban of certain\n    suppliers;\n\uf0b7   differences in manufacturing standards, which may result in some of the raw materials not meeting\n    Dermapharm\u2019s requirements and force Dermapharm to reject shipments of such raw materials;\n\uf0b7   greater possibility of disruption due to transportation or communication problems;\n\uf0b7   delays in connection with the customs inspection of raw materials;\n\uf0b7   import tariffs and taxes levied on imports;\n\uf0b7   the relative instability of some foreign governments and economies;\n\uf0b7   interim price volatility based on labor unrest, materials or equipment shortages, export duties,\n    restrictions on the transfer of funds, or fluctuations in currency exchange rates;\n\uf0b7   international sanctions; and\n\uf0b7   uncertainty regarding recourse to a dependable legal system for the enforcement of contracts and\n    other rights.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3421727972626176, "height": 0.2536355859709153, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-1", "text": "        Many of Dermapharm\u2019s third-party suppliers are subject to various governmental regulations and,\naccordingly, Dermapharm itself is dependent on the regulatory compliance of these third parties. Dermapharm\nalso depends on the strength, enforceability and terms of its contracts with these third-party suppliers.\nDermapharm relies on complex shipping arrangements throughout the various stages of its supply chain, which\nmay be affected by factors that are not within its full control or hard to predict.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4174508126603935, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-2", "text": "         In addition, Dermapharm\u2019s suppliers may decide to increase the prices of raw materials required for the\nmanufacture of Dermapharm\u2019s products, either to increase their margins or pass on rising costs. There is no\nguarantee that Dermapharm will be able to pass on such rising raw materials prices to its customers, and, if\nDermapharm choses to increase prices for its products as a response to higher manufacturing costs, this may\nadversely affect demand for its products.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49272882805816937, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-3", "text": "          Furthermore, the soft capsules for Dermapharm\u2019s Dekristol\u00ae 20,000 I.E. vitamin D preparation, its\nmost significant product, are supplied by two European third-party suppliers. In addition, while Dermapharm\nowns the worldwide marketing rights for bite away\u00ae and Herpotherm\u00ae, the actual medical devices are\nmanufactured by Riemser Pharma GmbH. Should these suppliers suffer from disruptions (e.g., due to an\ninability to obtain the required materials or problems in their manufacturing processes), Dermapharm may not\nbe able to find other suppliers able to manufacture these products in time. In addition, should these third-party\nsuppliers decide to increase prices for their products for Dermapharm, there is no guarantee that Dermapharm\nwill be able to pass on price increases to customers.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.49786142001710865, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6090675791274593, "height": 0.1112061591103507, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-4", "text": "         Any inability to obtain raw materials and medical devices on a timely basis, or any significant price\nincreases for these items could have a material adverse effect on Dermapharm\u2019s business, financial condition,\ncash flows, results of operations and prospects.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6569717707442259, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-5", "text": ".1.17   Disruptions of Dermapharm\u2019s manufacturing processes and delays when launching new products\n        may adversely affect Dermapharm\u2019s business.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.13482466747279323, "top_left_y": 0.6736526946107785, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.7010265183917879, "height": 0.027373823781009388, "width": 0.7430471584038695}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.17Disruptions of Dermapharm\u2019s manufacturing processes and delays when launching new productsmay adversely affect Dermapharm\u2019s business."]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-6", "text": "s\n", "page_number": 54, "bounding_box": {"top_left_x": 0.8778718258766627, "top_left_y": 0.6809238665526091, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6843455945252352, "height": 0.0034217279726261873, "width": 0.0030229746070132846}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-7", "text": "         Based on the number of packages, approximately 90% of Dermapharm\u2019s pharmaceuticals and other\nhealthcare products were manufactured in-house in the nine-month period ended September 30, 2017 (including\npackages made from bulk products manufactured by third parties), with most of these products coming from\nDermapharm\u2019s main manufacturing facility in Brehna, Saxony-Anhalt, Germany. Many of Dermapharm\u2019s\nproducts are manufactured using technically complex processes requiring specialized facilities, specific raw\nmaterials and other production constraints. Such processes are increasingly reliant on the use of product specific\ndevices for administration, which may result in technical issues. Dermapharm also needs to be able to\nmanufacture sufficient quantities of its products to satisfy demand. Dermapharm may not be able to transform\nand adapt its existing manufacturing facilities to manufacture new products and to scale up manufacture of\nproducts currently under development once they are approved.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7147134302822925, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8502994011976048, "height": 0.13558597091531233, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-54-8", "text": "", "page_number": 54, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-0", "text": "          Dermapharm\u2019s products are subject to the risk of manufacturing stoppages and the risk of inventory\nlosses because of the difficulties inherent in the processing of the raw materials used to manufacture such\nproducts and the potential difficulties in accessing adequate amounts of raw materials that meet the required\nstandards. Additionally, specific conditions must be observed by both Dermapharm and its customers and\ndistributors for the storage and distribution of some of Dermapharm\u2019s products (e.g., cold storage). Failure to\nadhere to these requirements may result in inventory losses.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16723695466210436, "height": 0.08212147134302823, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-1", "text": "         The investigation and remediation of any identified or suspected manufacturing problems may cause\ndelays in Dermapharm\u2019s manufacturing processes, product recalls, or loss of revenues and inventories and delay\nthe launch of new products, which could damage Dermapharm\u2019s reputation and cause Dermapharm to incur\nsubstantial expenses. Should Dermapharm violate any of the laws that it must observe as part of its\nmanufacturing process, competent governmental authorities may shut down Dermapharm\u2019s facilities or demand\nremediation action.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2549187339606501, "height": 0.08083832335329341, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-2", "text": "          As part of the manufacturing process, Dermapharm also handles certain hazardous materials (e.g., acids\nor oils), which exposes it to particularly high risks. Mishandling of such hazardous substances could cause\npersonal injury, property damage and environmental contamination, and may result in the shutdown of affected\nmanufacturing facilities, significantly reduce the productivity and profitability of the affected facility and result\nin the imposition of fines and/or civil damages.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.2630453378956373, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3319076133447391, "height": 0.06886227544910184, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-3", "text": "           Should any manufacturing disruptions occur, in particular at Dermapharm\u2019s Brehna facility,\nDermapharm may not have alternative manufacturing capacities. Its ability to use backup facilities or set up new\nfacilities is limited due to the complexity of its manufacturing processes. Even where Dermapharm has backup\nsources of supply, including by manufacturing backup supplies of its principal APIs, such supplies may not be\nsufficient to meet Dermapharm\u2019s delivery obligations or market demand. In addition, certain rebate agreements\nwith SHI providers and supply agreements with hospitals impose strict delivery obligations on Dermapharm and\nif manufacturing disruptions were to prevent it from fulfilling these obligations, Dermapharm may be required\nto pay substantial contractual penalties (Vertragsstrafen).\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3383233532934132, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4482463644140291, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-4", "text": "       Any disruptions of Dermapharm\u2019s manufacturing processes could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45466210436270316, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48246364414029086, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-5", "text": "1.1.18   Dermapharm may experience disruptions of its logistics systems and distribution processes and\n         existing logistics capacities may prove insufficient.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4991445680068435, "lower_right_x": 0.880894800483676, "lower_right_y": 0.525235243798118, "height": 0.026090675791274553, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.18Dermapharm may experience disruptions of its logistics systems and distribution processes andexisting logistics capacities may prove insufficient."]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-6", "text": "         The operation, management and expansion of Dermapharm\u2019s distribution center in Brehna, which\nserves as Dermapharm\u2019s hub and logistical center for its pharmaceuticals and other healthcare products\nbusiness, are key to Dermapharm\u2019s business. The Brehna facility provides for inbound logistics, with a\nwarehouse containing over 2,500 consignment spaces and a storage system with approximately 21,000 pallet\nplaces as well as an information technology system that manages reporting and outbound logistics.\nDermapharm\u2019s entire pharmaceuticals and other healthcare products portfolio is distributed directly from the\nBrehna facility to national and international consumers. For its parallel import business, Friedrichsdorf, Hesse,\nGermany, serves as the central logistics facility, where all imported pharmaceuticals are received, repackaged\nand/or relabeled and then distributed to Dermapharm\u2019s customers. Consequently, if Dermapharm fails to operate\nand optimize these two facilities successfully and efficiently, it could result in excess or insufficient logistical\ncapacity, increase costs or harm Dermapharm\u2019s business in other ways.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6899059024807528, "height": 0.14970059880239517, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-7", "text": "          Any failure or interruption, partial or complete, of Dermapharm\u2019s logistics and distribution processes\n(e.g., as a result of software malfunctions, natural disasters, acts of terrorism, vandalism or sabotage) could\nimpair Dermapharm\u2019s ability to timely deliver its products and harm Dermapharm reputation. If Dermapharm\ncontinues to add logistics capabilities, new businesses or categories with different logistical requirements, or\nchanges its product mix, Dermapharm\u2019s logistics infrastructure will become increasingly complex and\nchallenging to operate. In particular, the integration of recently acquired businesses into Dermapharm\u2019s\nproduction and logistics structure may prove difficult and disruptive. Operational difficulties could result in\nshipping delays and customer dissatisfaction or cause Dermapharm\u2019s logistics costs to become high and\nuncompetitive. Any failure to successfully address such challenges in a cost-effective and timely manner could\nseverely disrupt Dermapharm\u2019s business and harm its reputation.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8336184773310522, "height": 0.13601368691189053, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-55-8", "text": "", "page_number": 55, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-0", "text": "          Delivery times for Dermapharm\u2019s products may vary due to a variety of factors (e.g., the product\nordered, the distance to the facility from which the product is shipped, the number of items ordered, the country\nin which the customer orders the product and the performance of the third-party shipping company carrying out\nthe distribution). There can be no assurance that customers will not expect or demand faster delivery times than\nDermapharm can provide, which could lead to loss of revenues from such customers. There is also a risk that\nDermapharm\u2019s current fulfillment capacity will prove insufficient to support its continued growth. Dermapharm\nmay not be able to locate suitable facilities on commercially acceptable terms in accordance with any future\nexpansion plans. Dermapharm may also need to increase capital expenditures with respect to additional logistics\ncapacities.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20786997433704021, "height": 0.12275449101796408, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-1", "text": "         The materialization of any of these risks could have a material adverse effect on Dermapharm\u2019s\nbusiness, financial condition, cash flows, results of operations and prospects.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-2", "text": "1.1.19   A reduction of parallel import quotas or an establishment of export restrictions or pharmaceutical\n         contingents and similar regulations may adversely affect Dermapharm\u2019s parallel import business.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.25791274593669805, "lower_right_x": 0.880894800483676, "lower_right_y": 0.2857142857142857, "height": 0.027801539777587647, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.19A reduction of parallel import quotas or an establishment of export restrictions or pharmaceuticalcontingents and similar regulations may adversely affect Dermapharm\u2019s parallel import business."]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-3", "text": "          Pursuant to the Framework Agreement on Drug Provision according to Section 129 of the Social Code,\nBook V (Rahmenvertrag \u00fcber die Arzneimittelversorgung nach \u00a7 129 Abs. 2 Sozialgesetzbuch V), at least 5% of\nall prescription pharmaceuticals sold within the statutory healthcare system in Germany must be brought into the\nmarket through parallel imports from other member states of the European Economic Area. According to\nSection 129 para. 1 no. 2 of the German Social Code, Book V (Sozialgesetzbuch F\u00fcnftes Buch), only parallel\nimports with prices that are at least \u20ac15.00 or 15% lower than the price of the German original pharmaceutical,\ntaking into account any mandatory rebates, count towards the 5% import quota. Dermapharm\u2019s parallel import\nbusiness leverages Dermapharm\u2019s direct marketing expertise in Germany by importing pharmaceuticals from\n25 member states of the European Economic Area for resale in the German market at a discount in order to\nallow pharmacies to fill their import quota. Economically, Dermapharm benefits from selling the imported\npharmaceuticals within Germany at a premium over the price of the respective pharmaceuticals in the sourcing\nmarket. In the nine-month period ended September 30, 2017, the parallel import business area accounted for\n53.2% of Dermapharm\u2019s revenues and 6.1% of its EBITDA.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47604790419161674, "height": 0.17536355859709152, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-4", "text": "          However, there is no guarantee that the minimum import quota for parallel imports will remain in\neffect in its current form in the future. Legislative bodies could decide to lower or even abolish this quota\n(e.g., due to lobbying from manufacturers of originator pharmaceuticals), in which case demand for\nDermapharm\u2019s imported pharmaceuticals could decline or cease and Dermapharm may be unable to sell any\ninventories it has already acquired. In addition, the German regulator may increase the price difference required\nfor pharmaceuticals to count towards the import quota, and Dermapharm may incur a loss when reselling\nimported pharmaceuticals at prices that meet such higher discount requirements.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5799828913601369, "height": 0.09452523524379819, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-5", "text": "          Furthermore, manufacturers of originator pharmaceuticals which Dermapharm imports as part of its\nparallel import business may attempt to establish maximum contingents of their pharmaceuticals for certain\nmarkets or maximum export quotas in the markets where Dermapharm is currently purchasing such\npharmaceuticals. This risk is supplemented by export restrictions for pharmaceuticals, which have already been\nimplemented in certain member states of the European Union (e.g., Poland, which prohibits the export of certain\npharmaceuticals, and Portugal, which has introduced a restrictive reporting system with respect to such exports)\nand are currently under discussion in various other member states. Such efforts, even if their compliance with\nEuropean laws is questionable, may prevent Dermapharm from obtaining pharmaceuticals for its parallel trade\nimport at acceptable prices and in sufficient amounts, or at all.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.588109495295124, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7100085543199316, "height": 0.12189905902480758, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-6", "text": "       Restrictions on Dermapharm\u2019s parallel import business could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7442258340461934, "height": 0.026090675791274665, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-56-7", "text": "", "page_number": 56, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-0", "text": "1.1.20   Dermapharm may not be able to resell pharmaceuticals it has imported as part of its parallel import\n         business at attractive prices or at all.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.11206159110350727, "height": 0.026946107784431142, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.20Dermapharm may not be able to resell pharmaceuticals it has imported as part of its parallel importbusiness at attractive prices or at all."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-1", "text": "         The success of Dermapharm\u2019s parallel import business depends on its ability to resell imported\npharmaceuticals to pharmaceutical wholesalers and through direct telephone marketing efforts to pharmacies.\nEven if Dermapharm has purchased pharmaceuticals abroad at what it considers to be attractive prices,\nDermapharm may be unable to resell such pharmaceuticals in the German market at a profit, or at all due to\nvarious reasons, including:\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-2", "text": "\uf0b7   lower demand for Dermapharm\u2019s imported pharmaceutical than originally anticipated, in particular\n    in case of delays in delivery or for pharmaceuticals which are subject to significant seasonality;\n\uf0b7   failure to successfully continue Dermapharm\u2019s direct marketing efforts (e.g., due to new legislation\n    restricting marketing calls to pharmacies or pharmacies requesting that Dermapharm cease to\n    directly contact them);\n\uf0b7   competitors, who are able to offer the same pharmaceutical at a lower price or in greater quantities;\n\uf0b7   price decreases in the German market for the relevant pharmaceutical, in particular where a new\n    reference price has been introduced between import and resale;\n\uf0b7   the expiration of patent protection for an imported pharmaceutical, leading to the introduction of\n    patent-free pharmaceuticals, which may in some cases even occur ahead of the scheduled patent\n    expiration (e.g., in cooperation with the originator manufacturer or if the relevant patent is\n    successfully challenged);\n\uf0b7   exchange rate fluctuations; and\n", "page_number": 57, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.20487596236099231, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43798118049615054, "height": 0.23310521813515822, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-3", "text": "required", "page_number": 57, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.4311377245508982, "lower_right_x": 0.5435308343409916, "lower_right_y": 0.441830624465355, "height": 0.010692899914456766, "width": 0.05562273276904478}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-4", "text": "loss in transit, if Dermapharm is still required to pay for the relevant pharmaceutical (i.e., if\nDermapharm bears the transportation risk or has made advanced payments) and unable to obtain\ncompensation for its losses from insurance providers.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.43798118049615054, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47005988023952094, "height": 0.03207869974337041, "width": 0.6729141475211609}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-5", "text": "          While Dermapharm has implemented a continuous planning process for the sourcing of its imported\npharmaceuticals, several months may elapse between the original planning and the arrival and repackaging of\nthese pharmaceuticals, increasing the risk that the market situation for a certain pharmaceutical changes and\nDermapharm is unable to resell imported pharmaceuticals. In addition, the overall parallel import market in\nGermany has shrunk in recent years, with revenues declining from \u20ac4.2 billion in the fiscal year ended\nDecember 31, 2014 to \u20ac3.9 billion in the fiscal year ended December 31, 2015, and decreasing further to\n\u20ac3.7 billion in the fiscal year ended December 31, 2016 (sources: B.A.H. 2014; B.A.H. 2015; B.A.H. 2016). This\ndecline of the overall parallel import market may lead to intensified competition and adversely affect\nDermapharm\u2019s revenues from its parallel import business area.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6005132591958939, "height": 0.12189905902480752, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-6", "text": "          Margins for individual pharmaceuticals may vary considerably. In general, demand from customers for\nhigh-margin imports is low, while demand for low-margin pharmaceuticals, for which there is only a limited\noffering from parallel importers, is considerably higher. In order to generate an attractive margin from its\nparallel import business, Dermapharm tries to ensure that each customer purchases a mixed basket with\npharmaceuticals from different product categories (i.e., Dermapharm will offer customers a selection of\nattractive low-margin pharmaceuticals, while also requiring them to purchase lower-demand pharmaceuticals\nthat generate a considerably higher margin for Dermapharm). However, there is no guarantee, that Dermapharm\nwill be able to convince its customers to accept sufficient quantities of its high-margin imports and consequently\nDermapharm faces a high risk that it will be unable to resell these pharmaceuticals.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7309666381522669, "height": 0.12232677502138578, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-7", "text": "         Inability to resell imported pharmaceuticals at attractive prices or at all could have a material adverse\neffect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7386655260906758, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7656116338751069, "height": 0.026946107784431073, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-57-8", "text": "", "page_number": 57, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-0", "text": "1.1.21   Dermapharm may not be able to introduce and source the pharmaceuticals required to maintain its\n         parallel import product offering.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.21Dermapharm may not be able to introduce and source the pharmaceuticals required to maintain itsparallel import product offering."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-1", "text": "         The success of Dermapharm\u2019s parallel import business depends on its ability to identify sufficient\npricing differences in the European pharmaceuticals market in order to source the pharmaceuticals required for\nDermapharm\u2019s broad parallel import product offering. If prices for pharmaceuticals increase in sourcing markets\nor decrease in the German pharmaceuticals market, Dermapharm may not be able to identify attractive sourcing\nopportunities. This risk might be compounded by the upcoming \u201cBrexit\u201d, since such exit of the United Kingdom\nfrom the common market may eliminate the United Kingdom as a sourcing market. In addition, competitors\nmay be able to identify and acquire attractive pharmaceuticals for parallel imports ahead of Dermapharm.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.0962360992301112, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-2", "text": "         Furthermore, Dermapharm depends on its ability to maintain a broad mix of high-margin and\nlow-margin pharmaceuticals in order to offer its customers an attractive product basket while still maintaining a\nsufficient margin. If Dermapharm is not able to source sufficient low-margin pharmaceuticals, which are\ngenerally in lower supply and therefore more attractive to Dermapharm\u2019s customers, this may adversely affect\nits revenues.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2964071856287425, "height": 0.06757912745936698, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-3", "text": "         When introducing new pharmaceuticals to its parallel import product offering, for which there is\ncurrently only a German marketing authorization but no centralized European marketing authorization,\nDermapharm is required to obtain a corresponding authorization (Bezugszulassung). While obtaining such\nauthorization is easier than obtaining a marketing authorization, it will still often take between 8 and 15 months\nand Dermapharm depends on the cooperation of various governmental authorities in Germany and its sourcing\ncountries. Due to the time required between filing for the corresponding authorization and the decision of the\ncompetent governmental authority, supply and demand for the relevant pharmaceutical may have changed\nsignificantly and Dermapharm may decide that sourcing such pharmaceutical is no longer attractive. In such\ncase, Dermapharm would lose all costs incurred in connection with the filing process and may miss out on a\nnew introduction that could be crucial for maintaining and improving its product mix.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4414029084687767, "height": 0.13387510692899912, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-4", "text": "         Inability to introduce and source the pharmaceuticals required to maintain its parallel import product\noffering could have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results\nof operations and prospects.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4893071000855432, "height": 0.03806672369546621, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-5", "text": "1.1.22   If third parties were to sell Dermapharm counterfeit or defective pharmaceuticals as part of its\n         parallel import business, Dermapharm could be held liable for distributing such pharmaceuticals.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.5320786997433704, "height": 0.026090675791274553, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.22If third parties were to sell Dermapharm counterfeit or defective pharmaceuticals as part of itsparallel import business, Dermapharm could be held liable for distributing such pharmaceuticals."]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-6", "text": "         Dermapharm\u2019s parallel import business requires it to purchase and resell pharmaceuticals that have not\nbeen manufactured by Dermapharm itself, and instead are manufactured and/or distributed by third parties\noutside Germany. While Dermapharm has established strict processes to verify the reliability of its suppliers and\nthereby ensure that its sources are reliable, Dermapharm may not always be able to ascertain whether the\npharmaceuticals it purchases are actually original products or counterfeit versions. Counterfeit pharmaceuticals\nare inherently dangerous (see \u201c1.1.15 The illegal distribution of counterfeit versions of Dermapharm\u2019s products\nor stolen products could have a negative impact on Dermapharm\u2019s reputation.\u201d). In addition, imported\npharmaceuticals may be defective, in particular if the original manufacturer does not maintain the same strict\nmanufacturing standards as Dermapharm.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6693755346449958, "height": 0.12232677502138589, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-7", "text": "          Dermapharm may be held liable by its customers or patients using Dermapharm\u2019s imported\npharmaceuticals if it unknowingly sells counterfeit or defective pharmaceuticals. In addition, Dermapharm\u2019s\nreputation may be harmed if it is found to have sold such pharmaceuticals and if Dermapharm still has\ncounterfeit or defective pharmaceuticals in its inventory, it will be required to destroy and write off such\ninventories. There is no guarantee that Dermapharm will be able to take full recourse against the suppliers who\nhave delivered counterfeit or defective pharmaceuticals (e.g., due to the limited financial capacities of such\nsuppliers or a need to initiate time consuming and expensive litigation), and in many cases Dermapharm will\nsettle such matters.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7835757057313943, "height": 0.10650128314798968, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-8", "text": "          If Dermapharm were to unknowingly import counterfeit or defective pharmaceuticals from third\nparties, this could have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows,\nresults of operations and prospects.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8340461933276304, "height": 0.04063301967493582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-58-9", "text": "", "page_number": 58, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-0", "text": "1.1.23   Dermapharm may discontinue the manufacture and distribution of certain of its existing or future\n         products, which may adversely impact its business.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.11077844311377245, "height": 0.02566295979469632, "width": 0.7642079806529626}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.23Dermapharm may discontinue the manufacture and distribution of certain of its existing or futureproducts, which may adversely impact its business."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-1", "text": "         Dermapharm continuously evaluates the performance of its products, and may determine that it is in\nDermapharm\u2019s best interest to discontinue the manufacture and distribution of certain of its current or future\nproducts. However, the discontinuance of products may cause Dermapharm\u2019s revenues to decline faster than\nrelated operating expenses, may cause Dermapharm to incur material charges associated with such\ndiscontinuances and may entail various other risks (e.g., inability to maintain good relations with customers who\npreviously purchased the discontinued products).\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.0825491873396065, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-2", "text": "         The discontinuance of certain products could have a material adverse effect on Dermapharm\u2019s\nbusiness, financial condition, cash flows, results of operations and prospects.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-3", "text": "1.1.24   Goodwill and capitalized development costs are subject to impairment testing, which may result in\n         impairment charges.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.25962360992301114, "lower_right_x": 0.880894800483676, "lower_right_y": 0.28357570573139435, "height": 0.0239520958083832, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.24Goodwill and capitalized development costs are subject to impairment testing, which may result inimpairment charges."]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-4", "text": "         As of September 30, 2017, the goodwill recorded on Dermapharm AG\u2019s consolidated statement of\nfinancial position amounted to \u20ac17.0 million, or approximately 4.0% of Dermapharm\u2019s total assets. In\nrecent years, the amount of goodwill has increased in connection with past acquisitions and may continue\nto increase if Dermapharm is able to capitalize on future growth opportunities by acquiring additional\nbusinesses or making other investments (see \u201c1.1.5 Dermapharm may be unable to identify and capitalize on\nattractive growth opportunities and even if it does engage in acquisitions, joint ventures or other business\ncombinations, such transactions may not develop as originally anticipated.\u201d).\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3956372968349016, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-5", "text": "        Under IAS 38, Dermapharm is generally required to capitalize development costs if certain criteria\nare met. Such capitalized development costs amounted to \u20ac30.2 million on Dermapharm AG\u2019s\nconsolidated statement of financial position as of September 30, 2017.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4439692044482464, "height": 0.04063301967493588, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-6", "text": "         Dermapharm is required to regularly evaluate whether events or circumstances have occurred to\nindicate that all, or a portion, of Dermapharm\u2019s goodwill and/or capitalized development costs are no\nlonger recoverable, in which case impairment charges recorded under other operating expenses would\nbecome necessary. Dermapharm incurred impairment charges on goodwill of \u20ac5.1 million allocated to\nFarmal in the fiscal year ended December 31, 2015 and \u20ac5.2 million allocated to Cancernova GmbH\nonkologische Arzneimittel in the fiscal year ended December 31, 2014. In addition, Dermapharm incurred\nimpairment charges on capitalized development costs of \u20ac4.7 million in the fiscal year ended\nDecember 31, 2014 in connection with the development of a spray for the treatment of asthma and chronic\nobstructive pulmonary disease, which Dermapharm decided to discontinue.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5739948674080411, "height": 0.1227544910179641, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-7", "text": "          Impairment charges in connection with goodwill or capitalized development costs recorded on the\nCompany\u2019s consolidated statement of financial position could have a material adverse effect on Dermapharm\u2019s\nresults of operations.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6227544910179641, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-8", "text": "1.1.25   Dermapharm may be subject to disruptions or failures of its information technology systems that\n         could have a material adverse effect on its business.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6360136869118905, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6638152266894782, "height": 0.027801539777587703, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.25Dermapharm may be subject to disruptions or failures of its information technology systems thatcould have a material adverse effect on its business."]}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-9", "text": "         Dermapharm relies on the efficient and uninterrupted operation of complex information technology\nsystems to operate its manufacturing processes and other parts of its business, in particular scarabPLUS \u2013\nPHARMA-ERP-System, Microsoft Dynamics NAV 2013, a marketing information system developed by\nQuintilesIMS, Dermapharm\u2019s proprietary ERP-System for its parallel import business and ADDIS\u00ae-CRM.\nDermapharm also stores data in its data centers upon which Dermapharm\u2019s business depends (e.g., proprietary\ninformation and customer details). A disruption, infiltration or failure of Dermapharm\u2019s information technology\nsystems or any of its data centers (e.g., due to software or hardware malfunctions, system implementations or\nupgrades, computer viruses, third party security breaches, including breaches from Dermapharm\u2019s providers,\nemployee error, theft or misuse, malfeasance, power disruptions, natural disasters or accidents) could cause\nbreaches of data security, loss of intellectual property or critical data, the release and misappropriation of\nsensitive information and impair Dermapharm\u2019s manufacturing and supply chain processes.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8280581693755347, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-10", "text": "         Furthermore, Dermapharm will replace the current information technology systems of Trommsdorff\nwith its own systems in order to fully integrate the acquired business. However, there is no guarantee that\nreplacing such information technology systems will proceed without interruptions and the costs for the transition\nmay exceed Dermapharm\u2019s current expectations.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8344739093242087, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8896492728828058, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-59-11", "text": "", "page_number": 59, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.0145102781136639}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-0", "text": "          While Dermapharm has implemented a number of protective measures (e.g., duplicate systems at\ndifferent locations, firewalls, antivirus software, patches, data encryption, log monitors, routine backups with\noffsite retention of storage media, system audits, data partitioning, routine password modifications and disaster\nrecovery procedures), such measures may not be implemented properly or may prove inadequate to prevent or\nfully address any of the aforementioned disruptions or failures of Dermapharm\u2019s information technology\nsystems.\n         Any disruptions or failures in Dermapharm\u2019s information technology systems could have a material\nadverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n\n1.1.26   The continued success of Dermapharm depends on its ability to attract and retain qualified key\n         employees.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.24422583404619333, "height": 0.1591103507271172, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.26The continued success of Dermapharm depends on its ability to attract and retain qualified keyemployees."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-1", "text": "          Due to the specialized nature of Dermapharm\u2019s business, Dermapharm is highly dependent upon its\nability to continue to attract and retain the members of its top management as well as qualified scientific,\ntechnical and sales personnel. Competition for qualified employees is especially intense in the pharmaceuticals\nindustry and Dermapharm\u2019s ability to hire qualified personnel depends on its ability to reward performance,\nincentivize its employees and pay competitive compensation. Loss of the services of, or failure to recruit,\nqualified personnel could have a significant adverse effect on Dermapharm\u2019s ability to develop and market its\nproducts. Due to Dermapharm\u2019s comparably small size and limited financial and other resources, it may be\ndifficult for Dermapharm to compete for the services of such qualified key employees.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25919589392643283, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3678357570573139, "height": 0.10863986313088109, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-2", "text": "          In addition, shifting demographic trends are expected to result in fewer students, fewer graduates and\nfewer people entering the workforce in Europe in the future. Moreover, many individuals of younger\ngenerations have changing expectations regarding their careers, engagement and the integration of work in their\noverall lifestyles, all of which may render such individuals less suitable to fill vacancies within Dermapharm.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4281437125748503, "height": 0.05218135158254916, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-3", "text": "overall lifestyles, all of which may render such individuals less suitable to fill vacancies within Dermapharm.\n       Any inability to attract and retain qualified personnel could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.42857142857142855, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.46407185628742514, "height": 0.035500427715996596, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-4", "text": "1.1.27   Dermapharm\u2019s existing financial liabilities could limit the cash flows available for its operations,\n         and any default with respect to Dermapharm\u2019s financial liabilities could lead to the Company\u2019s\n         insolvency.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4786142001710864, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5183917878528657, "height": 0.03977758768177925, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.27Dermapharm\u2019s existing financial liabilities could limit the cash flows available for its operations,and any default with respect to Dermapharm\u2019s financial liabilities could lead to the Company\u2019sinsolvency."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-5", "text": "         As of September 30, 2017, Dermapharm\u2019s total current and non-current financial liabilities\namounted to \u20ac278.8 million, including various loan agreements and promissory notes (Schuldscheindarlehen).\nThis level of indebtedness could adversely impact Dermapharm in various ways, including:\n", "page_number": 60, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5333618477331052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5744225834046194, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-6", "text": "\uf0b7   increasing Dermapharm\u2019s vulnerability to adverse economic and market development;\n\uf0b7   limiting its flexibility in planning for, or reacting to, changes in the market environment;\n\uf0b7   limiting its ability to obtain additional financing;\n\uf0b7   requiring the dedication of a substantial portion of Dermapharm\u2019s cash flows to servicing its\n    indebtedness, thereby reducing the funds available for other purposes;\n\uf0b7   increasing Dermapharm\u2019s vulnerability to interest rate increases, if the relevant financial liabilities\n    bear interest at floating interest rates or in case of a refinancing; and\n\uf0b7   placing Dermapharm at a competitive disadvantage to less-leveraged competitors and competitors\n    that have better access to capital resources.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5821214713430283, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7459366980325064, "height": 0.16381522668947812, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-7", "text": "          Dermapharm may not be able to maintain sufficient cash reserves or continue to generate cash\nflows at levels sufficient to make interest payments and other payments on its indebtedness when due. If\nDermapharm is unable to generate sufficient cash flows or otherwise obtain the funds required to make such\npayments when due, or if Dermapharm otherwise fails to comply with the various requirements under its\nexisting financial liabilities, Dermapharm would be in default. Such covenants include negative pledge and pari\npassu clauses, restrictions on substantial changes to the core business, limitations on the disposal of assets,\nrestrictions regarding the payment of dividends of certain entities of Dermapharm and financial covenants\nrelating to the equity ratio and leverage of Dermapharm. A default of Dermapharm would permit the relevant\nlenders to accelerate the maturity of Dermapharm\u2019s financial liabilities, which could cause the relevant debtor\nentity of Dermapharm to default on such liabilities. Such situation could ultimately lead to the insolvency of any\nor all Dermapharm entities, including the Company.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9029084687767323, "height": 0.1505560307955518, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-60-8", "text": "", "page_number": 60, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.0145102781136639}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-0", "text": "         Dermapharm\u2019s existing financial indebtedness or any default with respect to its financial liabilities\ncould have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of\noperations and prospects, and ultimately lead to an the insolvency of the Company.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-1", "text": "1.1.28   Dermapharm may be unable to raise additional funds on acceptable terms or at all, and an increase\n         in the level of Dermapharm\u2019s indebtedness may adversely affect its business.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12333736396614269, "top_left_y": 0.13986313088109495, "lower_right_x": 0.880894800483676, "lower_right_y": 0.16638152266894782, "height": 0.02651839178785287, "width": 0.7575574365175333}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.28Dermapharm may be unable to raise additional funds on acceptable terms or at all, and an increasein the level of Dermapharm\u2019s indebtedness may adversely affect its business."]}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-2", "text": "         In the future, Dermapharm may attempt to raise funds from additional debt financing to refinance its\nexisting debt or to fund potential acquisitions or investments in the context of its growth strategy (see\n\u201c1.1.4 Dermapharm\u2019s efforts to expand its business into foreign markets expose Dermapharm to risks\nassociated with operating in unfamiliar countries.\u201d), or for other purposes. However, there is no guarantee that\nDermapharm will be able to obtain the required or desired debt financing on acceptable terms or at all.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25149700598802394, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-3", "text": "          Furthermore, an increase of Dermapharm\u2019s indebtedness may require Dermapharm to pay higher\ninterest expenses or further restrict available cash flows, which may prevent Dermapharm from developing or\nenhancing its products, capitalizing on growth opportunities, or responding to competitive pressures or\nunanticipated customer demands (see \u201e1.1.27 Dermapharm\u2019s existing financial liabilities could limit the cash\nflows available for its operations, and any default with respect to Dermapharm\u2019s financial liabilities could lead\nto the Company\u2019s insolvency.\u201c).\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.25962360992301114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34046193327630453, "height": 0.08083832335329338, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-4", "text": "         Inability to raise additional funds on acceptable terms or at all or an increase in the level of\nDermapharm\u2019s indebtedness could have a material adverse effect on Dermapharm\u2019s business, financial\ncondition, cash flows, results of operations and prospects.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3887938408896493, "height": 0.04020530367835762, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-5", "text": "1.1.29   Dermapharm is subject to various risks for which it may not be adequately insured.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4033361847733105, "lower_right_x": 0.7575574365175333, "lower_right_y": 0.41317365269461076, "height": 0.009837467921300247, "width": 0.6366384522370012}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.29Dermapharm is subject to various risks for which it may not be adequately insured."]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-6", "text": "         While Dermapharm has purchased what it deems to be insurance coverage customary in the\npharmaceuticals industry, such insurance does not cover all risks associated with the operation of its business.\nAccidents and other events could potentially lead to interruptions of Dermapharm\u2019s business operations or to\nDermapharm incurring significant costs, all of which may not be fully covered by its insurance. In addition,\nDermapharm\u2019s insurance coverage is subject to various limitations and exclusions, retentions amounts and\nlimits. Furthermore, if any of Dermapharm\u2019s insurance providers becomes insolvent, Dermapharm may not be\nable to successfully claim payment from such insurance provider. In the future, Dermapharm may not be able to\nobtain coverage at current levels, or at all, and premiums for Dermapharm\u2019s insurance may increase\nsignificantly.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.43071000855431996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5538922155688623, "height": 0.1231822070145423, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-7", "text": "         A lack of adequate insurance coverage could have a material adverse effect on Dermapharm\u2019s business,\nfinancial condition, cash flows, results of operations and prospects.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5885372112917023, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-8", "text": "1.1.30   Exchange rate fluctuations and related hedges may adversely affect Dermapharm\u2019s results and the\n         value of some of its assets.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.13240628778718258, "top_left_y": 0.6017964071856288, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6291702309666382, "height": 0.027373823781009388, "width": 0.7484885126964934}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.30Exchange rate fluctuations and related hedges may adversely affect Dermapharm\u2019s results and thevalue of some of its assets."]}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-9", "text": "          Changes in foreign exchange rates between the Euro, Dermapharm\u2019s reporting currency, and other\ncurrencies, in particular the U.S. Dollar, the British Pound, the Swiss Franc, the Croatian Kuna and the\nNorwegian Krone, may result in significant increases or decreases in Dermapharm\u2019s reported revenues, costs\nand earnings as expressed in Euro, and in the reported value of Dermapharm\u2019s assets, liabilities and cash flows.\nDermapharm\u2019s parallel import business may be particularly adversely affected by exchange rate fluctuations, if\nthe Euro decreases, making it harder or impossible for Dermapharm to identify sufficient arbitrage opportunities\nin countries whose currency is not the Euro. In addition, the timing and extent of such fluctuations may be\ndifficult to predict. Furthermore, depending on the movements of particular exchange rates, Dermapharm may\nbe adversely affected at a time when the same currency movements benefit some of its competitors.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-10", "text": "         For its parallel import business area, Dermapharm generally hedges 50% of its net exposure over the\nnext six months with respect to expected cash outflows in any one foreign currency that are not offset by\ncorresponding cash inflows in such foreign currency, using derivative financial instruments, and in particular\nforward exchange contracts. The current market environment is taken into account in the execution of\nDermapharm\u2019s hedging strategy.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8417450812660393, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-61-11", "text": "", "page_number": 61, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.0145102781136639}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-0", "text": "         However, the future use of derivative hedging instruments is generally dependent on the availability of\nadequate credit lines with appropriate financial institutions. As a result, Dermapharm may be unable to use\nderivative financial instruments in the future, to the extent necessary, and its hedging strategy could therefore\nultimately be adversely affected. Furthermore, any hedging transactions executed in the form of derivative\nfinancial instruments may adversely affect Dermapharm\u2019s profits due to changes in the mark-to-market\nvaluation if hedge accounting is not applied.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-1", "text": "       Exchange rate fluctuations and hedging against such fluctuations could have a material adverse effect\non Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2018819503849444, "height": 0.027801539777587675, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-2", "text": "1.1.31   The Company may not be able to prepare the required financial statements in accordance with\n         IFRS in time, or at all.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.21599657827202737, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.24337040205303678, "height": 0.027373823781009415, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.31The Company may not be able to prepare the required financial statements in accordance withIFRS in time, or at all."]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-3", "text": "         In the future, the Company will be required to prepare annual and quarterly consolidated financial\nstatements under IFRS. Dermapharm has only recently begun to prepare such consolidated financial statements\nunder International Financial Reporting Standards, as adopted by the European Union (\u201cIFRS\u201d), by preparing\nthe audited consolidated financial statements of Dermapharm AG, the former parent entity of Dermapharm, as\nof and for the fiscal years ended December 31, 2016, 2015 and 2014. The Company\u2019s management is\nresponsible for the preparation and fair presentation of the consolidated financial statements in accordance with\nIFRS. These consolidated financial statements consist of the consolidated statement of financial position, the\nconsolidated statement of comprehensive income, changes in equity and cash flows for the relevant year, a\nsummary of the significant accounting policies and other explanatory information.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25962360992301114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38152266894781867, "height": 0.12189905902480752, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-4", "text": "          The Company is required to collect and consolidate the relevant operating and financial information\nfrom Dermapharm\u2019s group companies in order to be able to provide the consolidated information, which may\nprove time-consuming and complicated due to Dermapharm\u2019s organizational structure and limitations on\navailable personnel. Therefore, it may be difficult to prepare the required data on a group-wide basis in a timely\nmanner. Given that Dermapharm intends to expand further, these complications may increase. If the Company\nfails to collect and consolidate the relevant financial information efficiently or implement adequate controls, it\nmay not able to file accurate financial reports in time, or at all.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48417450812660395, "height": 0.09452523524379813, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-5", "text": "        Inability to prepare the required financial statements in accordance with IFRS in time, or at all, could\nhave a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations\nand prospects.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5337895637296834, "height": 0.04148845166809234, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-6", "text": "1.1.32   The Company is a holding company with no cash generating operations of its own and relies o\n         operating subsidiaries to provide the Company with the funds required to meet its financia\n         obligations and make dividend payments.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.13240628778718258, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8681983071342201, "lower_right_y": 0.5846877673224978, "height": 0.03763900769888795, "width": 0.7357920193470375}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.1.32The Company is a holding company with no cash generating operations of its own and relies onoperating subsidiaries to provide the Company with the funds required to meet its financialobligations and make dividend payments."]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-7", "text": "         The Company is a holding company with no material business operations of its own. The principal\nassets of the Company are its direct and indirect equity interests in the operating subsidiaries of Dermapharm.\nAs a result, the Company is dependent on loans, dividends and other payments from these subsidiaries in order\nto generate the funds required to meet the Company\u2019s financial obligations and make dividend payments, if\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6569717707442259, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-8", "text": "any.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.6599657827202737, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.6706586826347305, "height": 0.010692899914456766, "width": 0.02841596130592504}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-9", "text": "          The ability of the Company\u2019s subsidiaries to make distributions and other payments to the Company\nin turn depends on the subsidiaries\u2019 earnings and is subject to contractual and statutory limitations. As a\nshareholder in its subsidiaries, the Company\u2019s right to receive assets upon liquidation or reorganization of such\nsubsidiaries will be effectively subordinated to the claims of their respective creditors. Even if the Company is\nrecognized as a creditor of its subsidiaries, the Company\u2019s claims will still be subordinated to any security\ninterests that are senior to the Company\u2019s claims.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7591958939264328, "height": 0.08212147134302816, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-10", "text": "         If the Company does not receive sufficient distributions and other payments from its direct and indirect\nsubsidiaries, it may be unable to meet its financial obligations and make dividend payments.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7938408896492729, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-62-11", "text": "", "page_number": 62, "bounding_box": {"top_left_x": 0.49274486094316805, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.015114873035066534}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-0", "text": "1.1.33   Some of the market data presented in this Prospectus may be based on Company information and\n         estimates and should be considered with caution.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.1.33Some of the market data presented in this Prospectus may be based on Company information andestimates and should be considered with caution."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-1", "text": "         This Prospectus contains market data or cites sources containing market data relating to the size of the\npharmaceuticals industry and the markets for Dermapharm\u2019s products, including certain forecasts. Prospective\ninvestors are advised to consider such information with caution. The market data presented in this Prospectus\nmay be based on Company information and estimates, and may not be accurate, correct or complete. In addition,\nthe cited sources are based on information and assumptions that may be inaccurate or inappropriate, and their\nmethodology is inherently predictive and speculative. Dermapharm has not independently verified figures,\nmarket data or other information and the market data in this Prospectus may therefore be inaccurate and the\nprojected growth of the market may not be realized.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1099230111206159, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-2", "text": "Regulatory, Legal and Tax Risks\n", "page_number": 63, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.25278015397775877, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.26390076988879385, "height": 0.011120615911035081, "width": 0.23760580411124546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-3", "text": "1.2\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.2630453378956373, "height": 0.010265183917878506, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-4", "text": "1.2.1   Dermapharm is required to comply with the extensive regulations that govern its products as well as\n        other aspects of Dermapharm\u2019s business, and changes in the regulatory environment may force\n        Dermapharm to incur additional costs.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.13422007255139057, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8742442563482467, "lower_right_y": 0.31736526946107785, "height": 0.03721129170230969, "width": 0.7400241837968561}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.2.1Dermapharm is required to comply with the extensive regulations that govern its products as well asother aspects of Dermapharm\u2019s business, and changes in the regulatory environment may forceDermapharm to incur additional costs."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-5", "text": "         The manufacturing, distribution, processing, formulation, packaging, labeling, promotion and sale of\nDermapharm\u2019s products is subject to extensive regulation, in particular regulation implemented by Germany and\nthe European Union (e.g., requirements to obtain marketing authorizations, pricing restrictions, provisions on\nthe packaging of Dermapharm\u2019s products and restrictions on the distribution of pharmaceuticals and other\nhealthcare products). In the past, compliance with such regulation has resulted in increased expenses for\nDermapharm and has imposed greater administrative burdens on its organization. If additional requirements are\nintroduced in the future, they will likely require increased expenditures and may prevent Dermapharm from\ncontinuing to conduct its business as presently conducted.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.334901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4439692044482464, "height": 0.1090675791274594, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-6", "text": "          Future legislative measures aimed at limiting or reducing the costs of pharmaceuticals (see\n\u201c1.1.9 Healthcare reforms and related changes to the framework applicable to the pharmaceuticals industry\nmay adversely affect Dermapharm\u2019s business.\u201d) or other changes to the regulatory framework for the\ndistribution of pharmaceuticals (see \u201c1.1.19 A reduction of parallel import quotas or an establishment of export\nrestrictions or pharmaceutical contingents and similar regulations may adversely affect Dermapharm\u2019s parallel\nimport business.\u201d and \u201c1.1.8 Rebate agreements with SHI providers may adversely affect Dermapharm\u2019s\nbusiness.\u201d), in particular measures aimed at combating rising healthcare costs resulting from demographic\ndevelopments such as an ageing of the population (see \u201c1.1.1 Dermapharm could be adversely affected by\ndevelopments in the German pharmaceuticals and healthcare markets.\u201d), could adversely affect Dermapharm\u2019s\nbusiness.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5851154833190761, "height": 0.13387510692899918, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-7", "text": "          With respect to the packaging of Dermapharm\u2019s pharmaceuticals, according to the Commission\nDelegated Regulation (EU) 2016/161 of October 2, 2015 (the \u201cPackaging Regulation\u201d), all manufacturers of\nprescription pharmaceuticals distributed in the European Union are required to place a unique individual\nidentifier complying with certain technical specifications and consisting of a sequence of numeric or\nalphanumeric characters that is unique to any given pack on the packaging for such pharmaceuticals. The\nobligations under the Packaging Regulation will apply from February 9, 2019. The new packaging requirements\nunder the Packaging Regulation may require Dermapharm to adapt its packaging processes, likely causing\nadditional costs and increasing the risk that Dermapharm is unable to comply with such packaging requirements.\nIn particular, for its parallel import business Dermapharm is required to verify the unique identifiers for every\npackage of pharmaceuticals sourced from abroad, which significantly affects all processes in connection with\nthe receipt of new inventory and may adversely affect Dermapharm\u2019s parallel import business.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7450812660393499, "height": 0.15012831479897348, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-8", "text": "       In addition, changes to the framework to parallel imports of pharmaceuticals could adversely affect\nDermapharm\u2019s parallel import business (see \u201c1.1.19 A reduction of parallel import quotas or an establishment\nof export restrictions or pharmaceutical contingents and similar regulations may adversely affect\nDermapharm\u2019s parallel import business.\u201d).\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.806672369546621, "height": 0.05431993156544057, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-9", "text": "Dermapharm\u2019s parallel import business.\u201d).\n          With respect to environmental, safety and health laws and regulations, Dermapharm cannot accurately\npredict the outcome or timing of future expenditures that it may be required to make in order to comply with\nsuch laws as they apply to Dermapharm\u2019s business from time to time, in particular if such regulations become\nstricter over time.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8071000855431993, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8656971770744226, "height": 0.05859709153122328, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-63-10", "text": "", "page_number": 63, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-0", "text": "         Costs incurred in order to comply with regulations applicable to Dermapharm\u2019s business could have a\nmaterial adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and\nprospects.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-1", "text": "1.2.2   Dermapharm\u2019s existing compliance structure may not be sufficient and non-compliance with laws\n        and regulations may adversely affect Dermapharm\u2019s business.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12454655380894801, "top_left_y": 0.13986313088109495, "lower_right_x": 0.875453446191052, "lower_right_y": 0.1680923866552609, "height": 0.028229255774165962, "width": 0.7509068923821041}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.2.2Dermapharm\u2019s existing compliance structure may not be sufficient and non-compliance with lawsand regulations may adversely affect Dermapharm\u2019s business."]}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-2", "text": "          If Dermapharm fails to comply with applicable laws and regulations, it may breach representations\nmade to its customers or governmental authorities, who may take actions against Dermapharm or its products.\nThese persons may require labeling revisions, formulation or manufacturing changes, product modifications,\nrecalls, product seizures, total or partial suspension of manufacturing processes and/or distribution, shutdowns\nof manufacturing facilities, suspension of the review of Dermapharm\u2019s submissions for approval or additional\nsafety data for Dermapharm\u2019s new or existing pharmaceuticals or other remedial actions, any of which could\nhave a material adverse impact on Dermapharm\u2019s business (e.g., through increased costs for, or delays in,\nobtaining approvals of new products or an obligation to remove existing products from the market). In addition,\nviolations of the laws and regulations applicable to Dermapharm\u2019s business may be punishable by criminal and\ncivil sanctions, including substantial fines and penal sanctions, such as imprisonment.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31993156544054746, "height": 0.13558597091531222, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-3", "text": "          It is common for enforcement agencies to initiate investigations into sales and marketing practices as\nwell as pricing practices, regardless of merit. Such investigations and any related litigation could have a material\nadverse impact on Dermapharm\u2019s business (e.g., due to high expenditures for legal fees and compliance\nactivities, the imposition of fines and limitations on Dermapharm\u2019s operations, the diversion of management\nresources, harm to Dermapharm\u2019s reputation and decreased demand for its products).\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39520958083832336, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-4", "text": "         For example, Dermapharm\u2019s Croatian entity Farmal was the subject of an investigation by Croatian\ngovernmental authorities in 2012, who alleged that Farmal had violated applicable laws by offering coupons to\ndoctors to whom it marketed its pharmaceuticals. Farmal subsequently reached a settlement with the Croatian\nprosecutors, agreeing to pay a fine of approximately \u20ac0.3 million. In addition, all employees of Farmal that were\nimplicated in the investigation have also reached settlements, requiring them to pay minor fines and none of the\nemployees were convicted of criminal wrongdoing. As far as Dermapharm is aware, only the investigation\nagainst the former director of Farmal, whom Farmal dismissed immediately after the allegations surfaced, is still\npending as of the date of this Prospectus.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5115483319076134, "height": 0.10821214713430288, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-5", "text": "          Dermapharm has taken various steps in order to comply with applicable regulations, including\nappointing a compliance officer. Its compliance management system comprises, inter alia, compliance audits of\nthe relevant entities of Dermapharm, a compliance manual that includes Dermapharm\u2019s mandatory compliance\npolicies, regular training courses on relevant compliance risks and measures as well as adequate measures to\nallow employees to report potential compliance violations. However, there is no guarantee that Dermapharm\u2019s\ncompliance management system is sufficient to ensure that Dermapharm\u2019s employees, related parties and agents\nare or will be in compliance with all applicable laws and regulations. Furthermore, the criteria for determining\ncompliance are often complex and subject to change and new interpretation. If Dermapharm\u2019s employees,\nconsultants, agents or suppliers engage in corruption, fraud or other criminal or unauthorized behavior, the\ncompetent courts and governmental authorities may impose significant fines, require monitoring or\nself-monitoring, exclude Dermapharm from certain healthcare programs or impose other sanctions, such as the\nloss of business licenses or permits or other restrictions, and the failure to comply with laws and regulations may\nharm Dermapharm\u2019s reputation. These risks may encourage Dermapharm to enter into settlement agreements\nand such settlements may involve significant payment obligations and/or the imposition fines as well as\nadmissions of wrongdoing.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.723267750213858, "height": 0.20359281437125754, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-6", "text": "         In addition, in connection with additional businesses and companies Dermapharm acquired in the past\nor may acquire in the future, there is no guarantee that it has or will be able to identify cases of non-compliance\nthat may have occurred before Dermapharm completed such acquisitions. In this case, Dermapharm\u2019s business\nmay be adversely affected by such past non-compliance, even though it occurred before Dermapharm could\nexercise control over the relevant acquisition.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7318220701454234, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7989734816082121, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-7", "text": "         A violation of laws and regulations applicable to Dermapharm\u2019s business could have a material adverse\neffect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8071000855431993, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8336184773310522, "height": 0.02651839178785287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-64-8", "text": "", "page_number": 64, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-0", "text": "1.2.3   Dermapharm\u2019s business depends on intellectual property and the ability to protect such intellectual\n        property against infringements from third parties.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.2.3Dermapharm\u2019s business depends on intellectual property and the ability to protect such intellectualproperty against infringements from third parties."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-1", "text": "         Protecting its intellectual property is important to Dermapharm\u2019s business and its most important\nprotected trademarks are those related to its products, in particular Dekristol \u00ae 20,000 I.E., bite away\u00ae,\nHerpotherm\u00ae, sikapur\u00ae, Ampho-Moronal\u00ae, Solacutan\u00ae, Ciclocutan\u00ae, Minoxicutan\u00ae, Prednisolut\u00ae, Dienovel\u00ae,\nLactofem\u00ae, Finapil\u00ae, Panthenol-Augensalbe JENAPHARM\u00ae and Suxilep\u00ae. In addition, it holds patents for the\nmedical devices bite away\u00ae and Herpotherm\u00ae.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-2", "text": "          Dermapharm\u2019s future success will depend on its ability to obtain brands, patents, trademarks and trade\nsecret protection and to protect such intellectual property against infringements from third parties. However,\nthere is no guarantee that any of Dermapharm\u2019s future brands, processes or products can be adequately protected\nthrough intellectual property. Furthermore, Dermapharm may not have the resources to protect its intellectual\nproperty against infringements by third parties (e.g., due to a lack of evidence or the cost of proceedings) and\nsuch protection may not always be effective (e.g., if there are inconsistent judgements with respect to the same\nintellectual property rights). If Dermapharm fails to adequately protect its intellectual property, competitors\nmay manufacture and market products identical or similar to Dermapharm\u2019s current or existing products\nand utilize brands similar to those under which Dermapharm markets its products. In addition, if any of\nDermapharm\u2019s intellectual property rights are found to be invalid, Dermapharm\u2019s customers may claim\ndamages, alleging they have been over-charged or have over-paid for the relevant product.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35243798118049613, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-3", "text": "        Dermapharm also seeks to protect its trade secrets, unpatented proprietary know-how, processes\nand continuing technological innovation related to products and technology through confidentiality and\nnon-disclosure agreements with suppliers, employees, consultants, licensees and other pharmaceutical\ncompanies. If these agreements are breached, Dermapharm may not have adequate remedies for such\nbreaches. Disputes may arise concerning the ownership of intellectual property or the applicability of such\nconfidentiality agreements. Furthermore, Dermapharm\u2019s sensitive information may otherwise become\nknown to, or be independently developed by, its competitors.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35885372112917024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4550898203592814, "height": 0.09623609923011117, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-4", "text": "       Inability to maintain and defend its intellectual property could have a material adverse effect on\nDermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4893071000855432, "height": 0.02437981180496146, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-5", "text": "1.2.4   Dermapharm may become involved in various legal proceedings, including patent litigation, which\n        may expose Dermapharm to substantial liability or adversely impact its business.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5325064157399487, "height": 0.02651839178785287, "width": 0.7605804111245466}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Dermapharm may become involved in various legal proceedings, including patent litigation, whichmay expose Dermapharm to substantial liability or adversely impact its business."]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-6", "text": "          Dermapharm may become involved in litigation in the ordinary course of its business (e.g., with respect\nto alleged product liability, infringements on intellectual property, employment matters or breach of contract). It\nmay be expensive and time consuming for Dermapharm to bring or defend against such claims, which could\nresult in settlements or damages.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6013686911890505, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-7", "text": "          Patent infringement litigation may become particularly relevant to Dermapharm, if manufacturers\nof originator pharmaceuticals claim that Dermapharm has violated their respective patents. Such litigation\ninvolves many complex technical and legal issues and outcomes are often difficult to predict, and the risks\ninvolved can be substantial. For manufacturers of patent-free pharmaceuticals such as Dermapharm, an\nunfavorable outcome in a patent infringement suit may significantly adversely impact such manufacturer\u2019s\nbusiness (e.g., by delaying the launch of new products until expiration of the relevant patent or imposing\ndamages, which may be measured by the profits lost by the manufacturer of the relevant originator\npharmaceutical). Consequently, if any patent litigation matters involving Dermapharm\u2019s products are resolved\nunfavorably, Dermapharm may be enjoined from developing, manufacturing, or distributing the relevant product\nor incur additional expenses. In addition, if Dermapharm were to market and sell products prior to the resolution\nof related patent litigation, it could be held liable for lost profits if Dermapharm is found to have infringed on a\nvalid patent. Furthermore, such distribution efforts may be blocked by injunctions, in which case Dermapharm\nmay be unable to distribute inventories of products it obtained prior to the respective injunction.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.786142001710864, "height": 0.17750213857998287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-8", "text": "          In certain cases, Dermapharm may be required to obtain licenses from the holders of third-party\nintellectual property that cover aspects of its existing and future products in order to manufacture and/or\ndistribute such products, including in order to terminate or avoid patent litigation. Any payments under these\nlicenses may reduce Dermapharm\u2019s profits from such products and Dermapharm may not be able to obtain the\nrequired licenses on favorable terms or at all.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8614200171086399, "height": 0.06800684345594532, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-9", "text": "         Involvement in litigation could have a material adverse effect on Dermapharm\u2019s business, financial\ncondition, cash flows, results of operations and prospects.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8686911890504705, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8960650128314799, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-65-10", "text": "", "page_number": 65, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-0", "text": "1.2.5   Dermapharm may face significant product liability claims that are not covered by insurance.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8228536880290206, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.7049576783555018}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.2.5Dermapharm may face significant product liability claims that are not covered by insurance."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-1", "text": "         Product liability is a significant risk for any manufacturer of pharmaceuticals and Dermapharm may\nface claims for injuries allegedly resulting from the use of its products, in particular claims pursuant to\nSections 84 et seq. of the German Pharmaceuticals Act (Arzneimittelgesetz (\u201cAMG\u201d)). As Dermapharm expands\nits portfolio of available products, Dermapharm may experience increases in product liability claims. In\naddition, Dermapharm may be held liable for defects of pharmaceuticals it has imported and resold as part of its\nparallel import business. Such claims, regardless of their merits and ultimate success, are costly, divert\nmanagement\u2019s attention, may harm Dermapharm\u2019s reputation and impact demand for its products.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-2", "text": "         With respect to product liability exposure for pharmaceuticals, Dermapharm has taken out insurance\ncoverage as required by Section 94 para. 1 AMG. In addition, it has taken out general product liability insurance\ncovering its other healthcare products. However, product liability coverage for pharmaceutical manufacturers\nand manufacturers of healthcare products is increasingly expensive and difficult to obtain on reasonable terms.\nIn addition, where claims are made under insurance policies, insurance provider may reserve the right to deny\ncoverage on various grounds. Furthermore, such coverage may not cover claims asserted against Dermapharm\noutside Germany or the relevant insurance provider may become insolvent.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-3", "text": "       Product liability claims not covered by product insurance could have a material adverse effect on\nDermapharm\u2019s business, assets, financial condition, cash flows or results of operations.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3455945252352438, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-4", "text": "Dermapharm may be adversely affected by changes to the general tax environment and future tax\naudits and investigations, all of which may increase Dermapharm\u2019s tax burden.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.3900769888793841, "height": 0.027801539777587647, "width": 0.7031438935912938}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Dermapharm may be adversely affected by changes to the general tax environment and future taxaudits and investigations, all of which may increase Dermapharm\u2019s tax burden."]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-5", "text": "1.2.6\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.154776299879081, "lower_right_y": 0.3729683490162532, "height": 0.010692899914456766, "width": 0.03446191051995162}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-6", "text": "         Dermapharm is dependent on the general tax environment in the countries where it operates,\nparticularly in Germany. Dermapharm\u2019s tax burden depends on the application and interpretation of various tax\nlaws. Dermapharm\u2019s tax planning and optimization depend on the current and expected tax environment.\nAmendments to tax laws may take retroactive effect and their application or interpretation by tax authorities or\ncourts may change unexpectedly. These changes may cover matters such as taxable income, tax rates, indirect\ntaxation, transfer pricing, dividend taxation, controlled companies or a restriction of certain forms of tax relief.\nFurthermore, tax authorities may occasionally limit court decisions to their specific facts by way of\nnon-application decrees, which may further increase Dermapharm\u2019s tax burden.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5119760479041916, "height": 0.10863986313088109, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-7", "text": "         Final and binding tax assessments are only issued once tax audits with respect to previous periods have\nbeen completed, which is generally only the case after several years. Future tax audits and other investigations\nconducted by tax authorities could result in the assessment of additional taxes. This may, in particular, be the\ncase with respect to changes in the Company\u2019s shareholder structure, reorganization measures within\nDermapharm or impairment on properties, given that tax authorities could determine that they ought to be\ndisregarded for tax purposes. Any tax assessments that deviate from Dermapharm\u2019s expectations could lead to\nan increase in its tax obligations and could also give rise to interest payable on such additional taxes or fines.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6150556030795552, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-8", "text": "         Dermapharm may become a party to tax proceedings. The outcome of such tax proceedings may be\nhard to predict and may prove detrimental to Dermapharm.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6501283147989735, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-9", "text": "         The materialization of any of these risks could have a material adverse effect on Dermapharm\u2019s\nbusiness, financial condition, cash flows, results of operations and prospects.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6839178785286569, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-10", "text": "1.3     Risks Related to the Company\u2019s Shareholder Structure, the Shares and the Offering\n\n1.3.1   The Company\u2019s shares have not previously been publicly traded, and there is no guarantee that an\n        active and liquid market for these shares will develop.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7527801539777588, "height": 0.05517536355859709, "width": 0.7605804111245466}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The Company\u2019s shares have not previously been publicly traded, and there is no guarantee that anactive and liquid market for these shares will develop."]}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-11", "text": "         Prior to this initial public offering (the \u201cOffering\u201d), there was no public market for the Company\u2019s\nshares. The offer price for the shares offered in this Offering (the \u201cOffer Price\u201d) will be determined by way of a\nbookbuilding process. There is no guarantee that this Offer Price will correspond to the price at which the\nCompany\u2019s shares will be traded on the stock exchange after this Offering or that, following the listing, an\nactive and liquid market for the Company\u2019s shares will develop and persist. If such liquid market fails to\ndevelop, this could adversely affect the market price of the Company\u2019s shares and such market price could even\ndecline below the Offer Price.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8605645851154833, "height": 0.09452523524379808, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-12", "text": "         Consequently, investors may not be in a position to sell their shares in the Company at or above the\nOffer Price in the foreseeable future, or at all.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.8686911890504705, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8964927288280582, "height": 0.027801539777587703, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-66-13", "text": "", "page_number": 66, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-0", "text": "1.3.2   The Company\u2019s share price could fluctuate significantly, and investors could lose part or all of their\n        investment in the Company\u2019s shares.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.880894800483676, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7605804111245466}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.3.2The Company\u2019s share price could fluctuate significantly, and investors could lose part or all of theirinvestment in the Company\u2019s shares."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-1", "text": "        Following this Offering, the price of the Company\u2019s shares will be affected by the supply and demand\nfor the Company\u2019s shares, which may be influenced by numerous factors, many of which are beyond the\nCompany\u2019s control or can only be partly controlled by the Company, including:\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.04148845166809237, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-2", "text": "\uf0b7   fluctuations in actual or projected results of operations;\n", "page_number": 67, "bounding_box": {"top_left_x": 0.18198307134220074, "top_left_y": 0.1775021385799829, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.19076133447390933, "height": 0.013259195893926434, "width": 0.39842805320435315}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-3", "text": "\uf0b7   changes in projected earnings or failure to meet securities analysts\u2019 earnings expectations;\n\uf0b7   the absence of analyst coverage on Dermapharm;\n\uf0b7   negative analyst recommendations;\n\uf0b7   changes in trading volumes in the Company\u2019s shares;\n\uf0b7   changes in the Company\u2019s shareholder structure;\n\uf0b7   changes in macroeconomic conditions;\n\uf0b7   the activities of competitors and suppliers;\n\uf0b7   changes in the market valuations of comparable companies;\n\uf0b7   changes in investor and analyst perception with respect to Dermapharm or the pharmaceuticals\n    industry in general; and\n\uf0b7   changes in the statutory framework applicable to Dermapharm\u2019s business.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.1911890504704876, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.22968349016253206, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-4", "text": "         As a result, the Company\u2019s share price may be subject to substantial fluctuations. In addition, general\nmarket conditions and fluctuations of share prices and trading volumes could lead to pressure on the\nCompany\u2019s shares, even though there may not be a reason for this based on the business performance or\nearnings outlook of Dermapharm.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48246364414029086, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-5", "text": "          If the Company\u2019s share price declines as a result of the realization of any of these risks, investors could\nlose part or all of their investment in the Company\u2019s shares.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.4888793840889649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5166809238665526, "height": 0.027801539777587703, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-6", "text": "1.3.3   Dermapharm may fail to comply with the additional requirements, which will be applicable to it\n        following the Offering.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5299401197604791, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5573139435414884, "height": 0.027373823781009388, "width": 0.7605804111245466}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Dermapharm may fail to comply with the additional requirements, which will be applicable to itfollowing the Offering."]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-7", "text": "          Following the Offering, the Company will for the first time be subject to the legal requirements of a\ncompany listed on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter\nWertpapierb\u00f6rse) and the sub-segment of the regulated market with additional post admission obligations\n(Prime Standard) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse). Dermapharm\u2019s management\nwill need to develop the expertise necessary to comply with the numerous regulatory and other requirements\napplicable to public companies, including requirements relating to corporate governance, listing standards and\nsecurities and investor relations issues. Dermapharm\u2019s management will have to evaluate the internal control\nsystem independently with new thresholds of materiality, and to implement necessary changes to Dermapharm\u2019s\ninternal control system. There can be no guarantee that Dermapharm will be able to respond to these additional\nrequirements without difficulties and inefficiencies or compliance violations could cause it to incur significant\nadditional costs and/or could expose it to regulatory or civil litigation or penalties.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5710008554319932, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7219846022241232, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-8", "text": "         Failure to comply with the additional requirements applicable to Dermapharm following the Offering\ncould have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows, results of\noperations and prospects.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7284003421727973, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7698887938408896, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-67-9", "text": "", "page_number": 67, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-0", "text": "1.3.4   The Company may not be able to pay dividends in the foreseeable future.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6898428053204353, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5719467956469165}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["1.3.4The Company may not be able to pay dividends in the foreseeable future."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-1", "text": "          With respect to the fiscal year ended December 31, 2017, the Company will not distribute a dividend,\nsince Dermapharm Aktiengesellschaft, the former parent company of Dermapharm, will be required to transfer\nits profits for the fiscal year ended December 31, 2017, if any, to the Company\u2019s sole existing shareholder,\nThemis Beteiligungs-Aktiengesellschaft (the \u201cSelling Shareholder\u201d), under a profit transfer agreement with the\nSelling Shareholder.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-2", "text": "         Starting with the fiscal year ending December 31, 2018, the Company intends to pay a dividend in the\nordinary course of business of 50% to 60% of Dermapharm\u2019s profits for the respective fiscal year calculated in\naccordance with IFRS. The Company aims to have a sustainable dividend policy that focuses on dividend\ncontinuity. The results of operations set out in Dermapharm AG\u2019s audited consolidated financial statements and\nDermapharm AG\u2019s unaudited consolidated interim financial statements may not be indicative of the Company\u2019s\nfuture dividend payments.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-3", "text": "          Dividends may only be distributed from the net retained profit (Bilanzgewinn) of the Company.\nConsequently, it will only be able to make dividend payments in the envisaged amount if sufficient net retained\nprofits are available to the Company. The net retained profit is calculated based on the Company\u2019s individual\nfinancial statements prepared in accordance with the accounting principles of the German Commercial Code\n(Handelsgesetzbuch (\u201cHGB\u201d)). Accounting principles set forth in the HGB differ from IFRS in material\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3455945252352438, "height": 0.06544054747647565, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-4", "text": "respects.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.3592814371257485, "height": 0.010692899914456822, "width": 0.05864570737605804}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-5", "text": "         In addition, the Company\u2019s dividend payments depend on its ability to receive sufficient distributions\nand other payments from its direct and indirect subsidiaries (see \u201c1.1.32 The Company is a holding company\nwith no cash generating operations of its own and relies on operating subsidiaries to provide the Company with\nthe funds required to meet its financial obligations and make dividend payments.\u201d). There is no guarantee that\nsufficient net retained profits will be available to the Company in the future to pay dividends in the envisaged\namount, or at all.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4482463644140291, "height": 0.07912745936698035, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-6", "text": "          Furthermore, the continued operation and expansion of Dermapharm\u2019s business will require substantial\nfunding. Any determination to pay dividends in the future will be at the discretion of the Company\u2019s\nmanagement board and will depend upon the Company\u2019s results of operations, financial condition, contractual\nrestrictions, restrictions imposed by applicable laws and other factors management deems relevant.\nConsequently, the Company may not be able to pay dividends in the foreseeable future or at all.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.525235243798118, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-7", "text": "1.3.5   Following this Offering, the Selling Shareholder will retain a significant interest in the Company\n        and the interests of the Selling Shareholder may conflict with those of the Company and its othe\n        shareholders.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.5795551753635586, "height": 0.03934987168520099, "width": 0.7503022974607013}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Following this Offering, the Selling Shareholder will retain a significant interest in the Companyand the interests of the Selling Shareholder may conflict with those of the Company and its othershareholders."]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-8", "text": "          Following the successful completion of this Offering, the Selling Shareholder will continue to own\n75.0% of the Company\u2019s outstanding share capital (assuming placement of all existing shares sold from the\nholdings of the Existing Shareholder and full exercise of the greenshoe option granted in the course of this\nOffering) and therefore retain a majority of the votes in the Company\u2019s shareholders\u2019 meeting. The interests of\nthe Selling Shareholder may deviate from the Company\u2019s interests or those of other shareholders. Certain\nmeasures and transactions as well as dividend payments may be impossible to implement without the support of\nthe Selling Shareholder.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6903336184773311, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-9", "text": "          Conflicts between the interests of the Selling Shareholder and those of the Company or its other\nshareholders may have a material adverse effect on Dermapharm\u2019s business, financial condition, cash flows,\nresults of operations and prospects.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7386655260906758, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-68-10", "text": "25\n", "page_number": 68, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-0", "text": ".3.6   The Company may invest or spend the net proceeds from this offering in ways that shareholders\n       may not agree with or in ways that may not yield a return or benefit the price of the Company\u2019s\n       shares.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.13482466747279323, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7466747279322854}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["1.3.6The Company may invest or spend the net proceeds from this offering in ways that shareholdersmay not agree with or in ways that may not yield a return or benefit the price of the Company\u2019sshares."]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-1", "text": "          At the mid-point of the price range of \u20ac26.00 to \u20ac30.00 and assuming that the maximum number of\nnew shares of the Company is successfully placed, the Company will receive net proceeds of approximately\n\u20ac103.5 million from this Offering. The Company currently intends to use these net proceeds for in-house\ndevelopments and an upgrade of Dermapharm\u2019s manufacturing facilities in Brehna and a new manufacturing\nfacility in Neumarkt am Wallersee, Austria, Dermapharm\u2019s efforts to increase its international footprint, future\nacquisitions and the refinancing of existing indebtedness of Dermapharm, with any remainder to be spent on\ngeneral corporate purposes. However, the Company may decide to use the net proceeds from this Offering\ndifferently from its intentions as of the date of this Prospectus. The Company\u2019s management will have\nconsiderable discretion in the application of such net proceeds, and shareholders may not be able to assess\nwhether the proceeds are being used appropriately.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.13986313088109495, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2771599657827203, "height": 0.13729683490162534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-2", "text": "         Any failure to effectively utilize the net proceeds from this Offering could have a material adverse\neffect on Dermapharm\u2019s business, financial condition, cash flows, results of operations and prospects.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-3", "text": "1.3.7   Future offerings of debt or equity securities by the Company could adversely affect the market price\n        of the Company\u2019s shares, and future capital measures could lead to a substantial dilution of the\n        Company\u2019s shareholders (i.e., a reduction in the value of existing shareholders\u2019 interests in the\n        Company).\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.38323353293413176, "height": 0.05517536355859709, "width": 0.7611850060459492}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Future offerings of debt or equity securities by the Company could adversely affect the market priceof the Company\u2019s shares, and future capital measures could lead to a substantial dilution of theCompany\u2019s shareholders (i.e., a reduction in the value of existing shareholders\u2019 interests in theCompany)."]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-4", "text": "        Dermapharm may require additional capital in the future to finance its business operations and growth.\nThe Company may seek to raise such capital through the issuance of additional shares or debt securities with\nconversion rights (e.g., convertible bonds and option rights). An issuance of additional shares or debt securities\nwith conversion rights could potentially reduce the market price of the Company\u2019s shares.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.45038494439692045, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-5", "text": "          If such offerings of equity or debt securities with conversion rights are made without granting\nsubscription rights to the Company\u2019s existing shareholders, these offerings would dilute the economic and\nvoting rights of the Company\u2019s existing shareholders. Additionally, such dilution may arise from the acquisition\nor investments in companies in exchange, fully or in part, for newly issued shares of the Company, as well as\nfrom the exercise of stock options by Dermapharm\u2019s employees in the context of future stock option programs\nor the issuance of shares to employees in the context of future employee participation programs.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.539349871685201, "height": 0.08126603934987164, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-6", "text": "         Any future issuance of shares of the Company could reduce the market price of the Company\u2019s shares\nand dilute the holdings of existing shareholders.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5744225834046194, "height": 0.0273738237810095, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-7", "text": "1.3.8   Future sales by major shareholders could have a material adverse effect on the price of the\n        Company\u2019s shares.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.588109495295124, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6159110350727117, "height": 0.027801539777587703, "width": 0.7605804111245466}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Future sales by major shareholders could have a material adverse effect on the price of theCompany\u2019s shares."]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-8", "text": "         For various reasons, shareholders may sell all or some of their shares in the Company, including in\norder to diversify their investments. If one or more of the Company\u2019s major shareholders were to sell a\nsubstantial number of the Company\u2019s shares, or if market participants believe that such sales are about to occur,\nthe market price of the Company\u2019s shares could be materially adversely affected.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6843455945252352, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-9", "text": "1.3.9   An investment in the Company\u2019s shares by an investor whose principal currency is not the Euro\n        may be affected by exchange rate fluctuations.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.7254063301967494, "height": 0.027801539777587703, "width": 0.7611850060459492}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["An investment in the Company\u2019s shares by an investor whose principal currency is not the Euromay be affected by exchange rate fluctuations."]}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-10", "text": "          The Company\u2019s shares are, and any dividends to be paid in respect of them will be, denominated in\nEuros. An investment in the Company\u2019s shares by an investor whose principal currency is not the Euro will\nexpose such investor to exchange rate risks. Any depreciation of the Euro in relation to the principal currency of\nthe respective investor will reduce the value of the investment in the Company\u2019s shares or any dividends in\nrelation to such currency.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7386655260906758, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8075278015397775, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-69-11", "text": "26\n", "page_number": 69, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9443969204448246, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-0", "text": "GENERAL INFORMATION\n", "page_number": 70, "bounding_box": {"top_left_x": 0.4244256348246675, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6378476420798065, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.213422007255139}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-1", "text": "2.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.08597091531223268, "lower_right_x": 0.37726723095526, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.015114873035066534}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-2", "text": "Responsibility Statement\n", "page_number": 70, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.11591103507271172, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.1283147989734816, "height": 0.012403763900769887, "width": 0.18440145102781139}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-3", "text": "2.1\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11633875106929, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.12617621899059026, "height": 0.00983746792130026, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-4", "text": "          Dermapharm Holding SE, with its registered office at Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany\n(telephone: +49 (0) 89 6 41 86 0), and registered in the commercial register (Handelsregister) of the local court\n(Amtsgericht) of Munich, Germany, under docket number HRB 234575 (the \u201cCompany\u201d and, together with its\ndirect and indirect consolidated subsidiaries, \u201cDermapharm\u201d), together with Joh. Berenberg, Gossler & Co.\nKG, Hamburg, Germany (\u201cBerenberg\u201d or the \u201cSole Bookrunner\u201d or \u201cSole Global Coordinator\u201d), and\nODDO BHF Aktiengesellschaft, Frankfurt am Main, Germany (\u201cODDO BHF\u201d or the \u201cCo-Lead Manager\u201d\nand, together with Berenberg, the \u201cOffering Banks\u201d), assume responsibility for the contents of this prospectus\n(the \u201cProspectus\u201d) pursuant to Section 5 para. 4 of the German Securities Prospectus Act\n(Wertpapierprospektgesetz (\u201cWpPG\u201d)) and declare that the information contained in this Prospectus is, to best\nof their knowledge, correct and contains no material omissions.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27758768177929855, "height": 0.1343028229255774, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-5", "text": "        If any claims are asserted before a court of law based on the information contained in this Prospectus,\nthe investor appearing as plaintiff may have to bear the costs of translating this Prospectus prior to the\ncommencement of the court proceedings pursuant to the national legislation of the member states of the\nEuropean Economic Area (the \u201cEEA\u201d).\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28699743370402053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34046193327630453, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-6", "text": "         The information contained in this Prospectus will not be updated subsequent to the date hereof except\nfor any significant new event or significant error or inaccuracy relating to the information contained in this\nProspectus that may affect an assessment of the securities and occurs or comes to light following the approval of\nthis Prospectus, but before the completion of the public offering or admission of the securities to trading,\nwhichever is later. These updates must be disclosed in a prospectus supplement in accordance with\nSection 16 para. 1 sentence 1 WpPG.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4294268605645851, "height": 0.08083832335329344, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-7", "text": "Purpose of this Prospectus\n", "page_number": 70, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.44439692044482465, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.4576561163387511, "height": 0.013259195893926434, "width": 0.19407496977025393}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-8", "text": "2.2\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.44439692044482465, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.4550898203592814, "height": 0.010692899914456766, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-9", "text": "         This Prospectus relates to the offering of 13,455,000 bearer shares of the Company with no par value\n(St\u00fcckaktien), each such share representing a notional value of \u20ac1.00 (the \u201cOffering\u201d), consisting of:\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4991445680068435, "height": 0.027373823781009443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-10", "text": "\uf0b7   3,840,000 newly issued bearer shares with no par value (St\u00fcckaktien) from a capital increase\n    against contributions in cash (the \u201cIPO Capital Increase\u201d) to be resolved by an extraordinary\n    shareholders\u2019 meeting of the Company on or about January 26, 2018 (the \u201cNew Shares\u201d);\n\uf0b7   7,860,000 existing bearer shares with no par value (St\u00fcckaktien) from the holdings of Themis\n    Beteiligungs-Aktiengesellschaft (the \u201cSelling Shareholder\u201d) (the \u201cExisting Shares\u201d and, together\n    with the New Shares, the \u201cBase Shares\u201d); and\n\uf0b7   1,755,000 existing bearer shares with no par value (St\u00fcckaktien) from the holdings of the Selling\n    Shareholder in connection with a possible over-allotment (the \u201cOver-Allotment Shares\u201d and,\n    together with the Base Shares, the \u201cOffer Shares\u201d).\n", "page_number": 70, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6467065868263473, "height": 0.14071856287425144, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-11", "text": "          For the purpose of admission to trading on the regulated market (regulierter Markt) of the Frankfurt\nStock Exchange (Frankfurter Wertpapierb\u00f6rse) and the simultaneous admission to the sub-segment of the\nregulated market with additional post admission obligations (Prime Standard) of the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse), this Prospectus relates to up to 3,840,000 New Shares and 50,000,000 of the\nCompany\u2019s existing bearer shares with no par value (St\u00fcckaktien), each such share representing a notional value\nof \u20ac1.00.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7322497861420018, "height": 0.0791274593669804, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-12", "text": "         The Offering consists of initial public offerings in the Federal Republic of Germany (\u201cGermany\u201d) and\nthe Grand Duchy of Luxembourg (\u201cLuxembourg\u201d) and private placements in certain jurisdictions outside\nGermany and Luxembourg. In the United States of America (the \u201cUnited States\u201d), the Offer Shares will only be\noffered and sold to qualified institutional buyers (\u201cQIBs\u201d) as defined, and in reliance on, in Rule 144A\n(\u201cRule 144A\u201d) under the United States Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), or pursuant\nto another available exemption from, or in transactions not subject to, the registration requirements of the\nSecurities Act. Outside the United States, the Offer Shares will only be offered and sold in offshore transactions\nin compliance with Regulation S under the Securities Act (\u201cRegulation S\u201d).\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.742087254063302, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8515825491873396, "height": 0.10949529512403755, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-13", "text": "        This Prospectus has been approved solely by the German Federal Financial Supervisory Authority\n(Bundesanstalt f\u00fcr Finanzdienstleistungsaufsicht (\u201cBaFin\u201d)). BaFin has approved this Prospectus after having\nperformed an assessment of the coherence and comprehensibility of the information presented in this\nProspectus.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8584260051325919, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9131736526946108, "height": 0.054747647562018886, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-70-14", "text": "27\n", "page_number": 70, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9443969204448246, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-0", "text": "Forward-looking Statements\n", "page_number": 71, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3863361547762999, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.20798065296251514}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-1", "text": "2.3\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08597091531223268, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-2", "text": "         This Prospectus contains forward-looking statements. A forward-looking statement is any statement\nthat does not relate to historical facts or events or to facts or events as of the date of publication of this\nProspectus. This applies, in particular, to statements in this Prospectus containing information on Dermapharm\u2019s\nfuture earnings capacity, plans and expectations regarding its business growth and profitability, and the general\neconomic conditions to which Dermapharm is exposed. Statements made using words such as \u201cpredicts\u201d,\n\u201cforecasts\u201d, \u201cplans\u201d, \u201cintends\u201d, \u201cendeavors\u201d, \u201cexpects\u201d or \u201ctargets\u201d may be an indication of forward-looking\nstatements.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-3", "text": "          The forward-looking statements contained in this Prospectus are subject to risks and uncertainties, as\nthey relate to future events, and are based on estimates and assessments made to the best of the Company\u2019s\npresent knowledge. These forward-looking statements are based on assumptions, uncertainties and other factors,\nthe occurrence or non-occurrence of which could cause Dermapharm\u2019s actual results, including the financial\ncondition and profitability of Dermapharm, to differ materially from, or fail to meet, the expectations expressed\nor implied in the forward-looking statements. These expressions can be found in different sections of this\nProspectus, particularly in the sections titled \u201c1. Risk Factors\u201d, \u201c10. Management\u2019s Discussion and Analysis of\nNet Assets, Financial Condition and Results of Operations\u201d, \u201c11. Markets and Competition\u201d, \u201c24. Recent\nDevelopments and Outlook\u201d and wherever information is contained in this Prospectus regarding the Company\u2019s\nintentions, beliefs, or current expectations relating to its future financial condition and results of operations,\nplans, liquidity, business prospects, growth, strategy and profitability, as well as the economic and regulatory\nenvironment to which Dermapharm is subject.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3798118049615056, "height": 0.16467065868263475, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-4", "text": "         In light of these uncertainties and assumptions, it is also possible that the future events mentioned in\nthis Prospectus might not occur. In addition, the forward-looking estimates and forecasts reproduced in this\nProspectus from third-party reports could prove to be inaccurate (for more information on the third-party\nsources used in this Prospectus, see \u201c2.4 Sources of Market Data\u201d). Actual results, performance or events may\ndiffer materially from those in such statements due to, among other reasons:\n", "page_number": 71, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38622754491017963, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4550898203592814, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-5", "text": "\uf0b7   adverse developments of global economic conditions or economic conditions in Germany;\n\uf0b7   competition, including pharmaceutical advances achieved and patents attained by competitors as\n    well as new pharmaceuticals or other healthcare products introduced by competitors;\n\uf0b7   a shift in consumer preferences or reduced demand for Dermapharm\u2019s older pharmaceuticals and\n    other healthcare products in response to advances in technology;\n\uf0b7   availability of less expensive pharmaceuticals or other healthcare products;\n\uf0b7   challenges inherent in the development of new pharmaceuticals or other healthcare products,\n    including obtaining regulatory approvals;\n\uf0b7   changes in laws, regulations and governmental policies, particularly relating to the development of\n    pharmaceuticals (including clinical studies), approval procedures and environmental matters;\n\uf0b7   efficiency or safety concerns resulting in recalls or regulatory action;\n\uf0b7   environmental liabilities and compliance costs;\n\uf0b7   litigation and product liability claims;\n\uf0b7   dependence on third-party suppliers and contractors;\n\uf0b7   natural disasters, fires or explosions, sabotage or supply shortages;\n\uf0b7   increased raw material prices;\n\uf0b7   increased regulatory controls;\n\uf0b7   trends towards healthcare cost containment, including ongoing pricing pressure;\n\uf0b7   reputational risks in connection with the public perception of Dermapharm\u2019s products;\n\uf0b7   interruptions of Dermapharm\u2019s information technology systems;\n\uf0b7   fluctuations in interest and exchange rates; and\n\uf0b7   an inability to retain key employees of Dermapharm.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8999144568006844, "height": 0.43498716852010266, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-71-6", "text": "28\n", "page_number": 71, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9443969204448246, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9542343883661248, "height": 0.009837467921300247, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-0", "text": "        Moreover, it should be noted that all forward-looking statements only speak as of the date of this\nProspectus and that neither the Company nor the Offering Banks assume any obligation, except as required by\nlaw, to update any forward-looking statement or to conform any such statement to actual events or\ndevelopments.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.055175363558597104, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-1", "text": "        See \u201c1. Risk Factors\u201d for a further description of some of the factors that could influence the actual\noutcome of the matters described in the Company\u2019s forward-looking statements.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.174508126603935, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-2", "text": "Sources of Market Data\n", "page_number": 72, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.1911890504704876, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.20145423438836613, "height": 0.010265183917878534, "width": 0.17412333736396612}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-3", "text": "2.4\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19161676646706588, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.20145423438836613, "height": 0.009837467921300247, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-4", "text": "         Unless otherwise specified, the information contained in this Prospectus on the market environment,\nmarket developments, growth rates, market trends and competition in the markets in which Dermapharm\noperates are based on the Company\u2019s assessments. These assessments, in turn, are based in part on internal\nobservations of the markets and on various market studies.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.218562874251497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.26988879384088965, "height": 0.05132591958939264, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-5", "text": "The following sources were used in the preparation of this Prospectus:\n", "page_number": 72, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.28015397775876816, "lower_right_x": 0.6517533252720678, "lower_right_y": 0.29298545765611633, "height": 0.012831479897348175, "width": 0.47339782345828296}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-6", "text": "\uf0b7   Report by ABDA \u2013 Bundesvereinigung Deutscher Apothekenverb\u00e4nde e.V., \u201cDie Apotheke \u2013\n    Zahlen, Daten, Fakten 2017 (\u201cABDA\u201d);\n\uf0b7   Report by Bundesverband der Arzneimittelhersteller e.V., \u201cDer Arzneimittelmarkt in Deutschland\n    \u2013 Zahlen und Fakten 2014\u201d (\u201cB.A.H. 2014\u201d);\n\uf0b7   Report by Bundesverband der Arzneimittelhersteller e.V., \u201cDer Arzneimittelmarkt in Deutschland\n    \u2013 Zahlen und Fakten 2015\u201d (\u201cB.A.H. 2015\u201d);\n\uf0b7   Report by Bundesverband der Arzneimittelhersteller e.V., \u201cDer Arzneimittelmarkt in Deutschland\n    \u2013 Zahlen und Fakten 2016\u201d (\u201cB.A.H. 2016\u201d);\n\uf0b7   Report by Robert Koch-Institut, \u201cMedication of adults in Germany \u2013 Results of the German Health\n    Interview and Examination Suvey for Adults (DEGS1) (\u201cDEGS\u201d);\n\uf0b7   Data base by the Federal Statistical Office (Statistisches Bundesamt), last accessed January 24,\n    2018 (\u201cDestatis\u201d);\n\uf0b7   Report by Evaluate Ltd. dated July 2016, \u201cPharmaceutical Innovation in Europe \u2013 New\n    pharmaceutical breakthroughs approeaching \u2013 is the system set up to fund them all?\u201d (\u201cEvaluate \u2013\n    Europe\u201d);\n\uf0b7   Report by Evaluate Ltd. dated June 2017, \u201cWorld Preview 2017, Outlook to 2022\u201d (\u201cEvaluate \u2013\n    Global\u201d);\n\uf0b7   International Monetary Fund, \u201cWorld Economic Outlook October 2017\u201d (\u201cIMF \u2013 World\n    Economic Outlook\u201d);\n\uf0b7   Data base \u201cIQVIA Midas\u201d by IQVIA Commercial GmbH & Co. OHG, data inventory as of\n    Q4 2016 (\u201cIQVIA\u201d);\n\uf0b7   Data base by INSIGHT Health GmbH & Co. KG, last accessed January 24, 2018 (\u201cINSIGHT\n    Health\u201d);\n\uf0b7   Press release from INSIGHT Health GmbH & Co. KG dated February 2, 2017 \u201cSubstanzen im\n    Wert von 617 Millionen Euro werden in 2017 f\u00fcr den generischen Markt frei\u201d (\u201cINSIGHT Health\n    \u2013 Patent Expirations\u201d);\n\uf0b7   Report by Interpharma, \u201cPharma-Markt Schweiz 2017\u201d (\u201cInterpharma\u201d);\n\uf0b7   Report by the Organization for Economic Co-operation and Development (\u201cOECD\u201d), \u201cHealth at a\n    Glance 2017: OECD Indicators \u2013 How does Austria Compare\u201d (\u201cOECD Austria 2017\u201d);\n\uf0b7   Report by the OECD, \u201cState of Health in the EU \u2013 Germany \u2013 Country Health Profile 2017\u201d\n    (\u201cOECD Germany 2017\u201d);\n\uf0b7   Report by the OECD, \u201cHealth at a Glance 2017 \u2013 OECD Indicators\u201d (\u201cOECD \u2013 Health at a\n    Glance 2017\u201d);\n\uf0b7   Report by Pro Generika e.V., \u201cMarktdaten Pro Generika 2014\u201d (\u201cPro Generika \u2013 2014\u201d);\n\uf0b7   Report by Pro Generika e.V., \u201cMarktdaten Pro Generika 12/2016\u201d (\u201cPro Generika \u2013 2016\u201d);\n", "page_number": 72, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3006843455945252, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.913601368691189, "height": 0.6129170230966638, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-72-7", "text": "", "page_number": 72, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-0", "text": "\uf0b7   Report by Pro Generika e.V., \u201cMarktdaten Pro Generika 09/2017\u201d (\u201cPro Generika \u2013 Q3 2017\u201d);\n    and\n\uf0b7   Report by Verband Forschender Arzneimittelhersteller e.V., \u201ckompakt \u2013 Die Arzneimittelindustrie\n    in Deutschland\u201d (\u201cvfa\u201d).\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1497005988023952, "height": 0.06116338751069289, "width": 0.7007255139056833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-1", "text": "         It should be noted, in particular, that reference has been made in this Prospectus to information\nconcerning markets and market trends. Such information was obtained from the aforementioned sources. The\nCompany has accurately reproduced such information and, as far as it is aware and able to ascertain from\ninformation published by such third parties, no facts have been omitted that would render the reproduced\ninformation inaccurate or misleading. Nevertheless, prospective investors are advised to consider this data with\ncaution. For example, market studies are often based on information or assumptions that may not be accurate or\nappropriate, and their methodology is inherently predictive and speculative.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15697177074422583, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2523524379811805, "height": 0.09538066723695468, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-2", "text": "         Irrespective of the assumption of responsibility for the content of this Prospectus by the Company and\nthe Offering Banks (see \u201c2.1 Responsibility Statement\u201d), neither the Company nor the Offering Banks has\nindependently verified the figures, market data or other information on which third parties have based their\nstudies. Accordingly, the Company and the Offering Banks make no representation or warranty as to the\naccuracy of any such information from third-party studies included in this Prospectus. Prospective investors\nshould note that the Company\u2019s own estimates and statements of opinion and belief are not always based on\nstudies of third parties.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25962360992301114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35543199315654406, "height": 0.09580838323353291, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-3", "text": "Documents Available for Inspection\n", "page_number": 73, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.36911890504704875, "lower_right_x": 0.44014510278113667, "lower_right_y": 0.38323353293413176, "height": 0.014114627887083009, "width": 0.26178960096735193}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-4", "text": "2.5\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.369546621043627, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3798118049615056, "height": 0.010265183917878562, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-5", "text": "        For the period during which this Prospectus remains valid, the following documents will be available\nfor inspection during regular business hours at the Company\u2019s offices at Dermapharm Holding SE,\nLil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany (telephone: +49 (0) 89 6 41 86 0):\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43798118049615054, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-6", "text": "\uf0b7   the Company\u2019s articles of association (the \u201cArticles of Association\u201d);\n\uf0b7   the unaudited condensed consolidated interim financial statements of Dermapharm\n    Aktiengesellschaft (\u201cDermapharm AG\u201d) prepared in accordance with International Financial\n    Reporting Standards, as adopted by the European Union (\u201cIFRS\u201d), on interim financial reporting\n    (IAS 34) as of and for the nine-month period ended September 30, 2017;\n\uf0b7   the audited consolidated financial statements of Dermapharm AG prepared in accordance with\n    IFRS as of and for the fiscal years ended December 31, 2016, 2015 and 2014; and\n\uf0b7   the Company\u2019s audited individual financial statements as of September 30, 2017 and for the period\n    from July 12, 2017 to September 30, 2017 prepared in accordance with IFRS.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.44781864841745084, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.14414029084687768, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-7", "text": "         The aforementioned documents and this Prospectus are also available on the Company\u2019s website at\nwww.dermapharm.de under the \u201cInvestor Relations\u201d section. The Company\u2019s future consolidated financial\nstatements, individual financial statements and condensed interim consolidated financial statements will be\navailable from the Company on its website and the paying agent designated in this Prospectus\n(see \u201c15.8 Announcements and Paying Agent\u201d). The Company\u2019s consolidated and individual financial\nstatements will also be published in the German Federal Gazette (Bundesanzeiger).\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6826347305389222, "height": 0.08083832335329344, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-8", "text": "         Information on the Company\u2019s website www.dermapharm.de and information accessible via this\nwebsite is neither part of, nor incorporated by reference into, this Prospectus.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6903336184773311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.716852010265184, "height": 0.02651839178785287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-73-9", "text": "", "page_number": 73, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-0", "text": "2.6   Currency Presentation and Presentation of Financial Information\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.652962515114873, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5326481257557436}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-1", "text": "         In this Prospectus, \u201cEuro\u201d and \u201c\u20ac\u201d refer to the single European currency adopted by certain\nparticipating member states of the European Union, including Germany.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-2", "text": "         Where financial information in this Prospectus is labelled \u201caudited\u201d, this means that it has been taken\nfrom the audited financial statements mentioned above in \u201c2.5 Documents Available for Inspection\u201d. The label\n\u201cunaudited\u201d is used in this Prospectus to indicate financial information that has not been taken from the audited\nfinancial statements mentioned above but was taken either from Dermapharm AG\u2019s unaudited condensed\nconsolidated interim financial statements or Dermapharm\u2019s internal reporting system, or is based on calculations\nof figures from the sources mentioned before.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2292557741659538, "height": 0.0825491873396065, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-3", "text": "          All of the financial information presented in the text and tables below is shown in millions of Euro (in\n\u20ac million), except as otherwise stated. Certain financial information (including percentages) in the following\ntables has been rounded according to established commercial standards. As a result, the aggregate amounts (sum\ntotals or sub totals or differences or if numbers are put in relation) in the following tables may not correspond in\nall cases to the aggregate amounts of the underlying (unrounded) figures appearing elsewhere in this Prospectus.\nFurthermore, these rounded figures may not add up exactly to the totals contained in the relevant tables.\nFinancial information presented in parentheses denotes the negative of such number presented. In respect of\nfinancial information set out in this Prospectus, a dash (\u201c\u2013\u201d) signifies that the relevant figure is not available,\nwhile a zero (\u201c0.0\u201d) signifies that the relevant figure is available but has been rounded to zero.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.12018819503849443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-4", "text": "2.7   Time Specifications\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.3887938408896493, "height": 0.012831479897348175, "width": 0.20314389359129384}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-5", "text": "       References to \u201cCET\u201d in this Prospectus refer to Central European Time or Central European\nSummertime, as the case may be. References to time in this Prospectus refer to CET, unless stated otherwise.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.43028229255774164, "height": 0.026946107784431128, "width": 0.7575574365175333}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-74-6", "text": "", "page_number": 74, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-0", "text": "3.   THE OFFERING\n", "page_number": 75, "bounding_box": {"top_left_x": 0.40205562273276907, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.19286577992744858}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-1", "text": "3.1   Subject Matter of the Offering\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11591103507271172, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.1270316509837468, "height": 0.011120615911035081, "width": 0.281136638452237}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-2", "text": "         This Prospectus relates to the Offering of 13,455,000 bearer shares of the Company with no par value\n(St\u00fcckaktien), each such share representing a notional value of \u20ac1.00, consisting of:\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16937553464499572, "height": 0.02609067579127458, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-3", "text": "\uf0b7   3,840,000 New Shares;\n\uf0b7   7,860,000 Existing Shares; and\n\uf0b7   1,755,000 Over-Allotment Shares.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.1775021385799829, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.23267750213858, "height": 0.05517536355859709, "width": 0.2660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-4", "text": "         The Offering consists of initial public offerings in Germany and Luxembourg and private placements in\ncertain jurisdictions outside Germany and Luxembourg. In the United States, the Offer Shares will only be\noffered and sold to QIBs as defined in, and in reliance on, Rule 144A, or pursuant to another available\nexemption from, or in transactions not subject to, the registration requirements of the Securities Act. Outside the\nUnited States, the Offer Shares will be offered and sold only in offshore transactions in compliance with\n", "page_number": 75, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3195038494439692, "height": 0.07698887938408897, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {"regulation_s_applies": ["Regulation S"]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-5", "text": "         Immediately prior to the Offering, 100% of the Company\u2019s share capital was held by the Selling\nShareholder. Following completion of the Offering and assuming full placement of the Offer Shares and full\nexercise of the Greenshoe Option (see \u201c3.8 Stabilization Measures, Over-Allotments and Greenshoe Option\u201d),\nthe Selling Shareholder will hold 75.0% of the Company\u2019s share capital. Subject to the exercise of the\nGreenshoe Option, the Selling Shareholder will receive the proceeds from the sale of the Existing Shares and the\nOver-Allotment Shares (after deduction of fees and commissions). The Company will only receive the proceeds\nfrom the sale of the New Shares (after deduction of fees and commissions), but will not receive any proceeds\nfrom the sale of the Existing Shares or the Over-Allotment Shares from the holdings of the Selling Shareholder.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43969204448246363, "height": 0.10821214713430283, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-6", "text": "       Berenberg is acting as Sole Global Coordinator and Sole Bookrunner, while ODDO BHF is acting as\nCo-Lead Manager.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44781864841745084, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47305389221556887, "height": 0.025235243798118034, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-7", "text": "Price Range, Offer Period, Offer Price and Allotment\n", "page_number": 75, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4888793840889649, "lower_right_x": 0.56590084643289, "lower_right_y": 0.5025662959794697, "height": 0.01368691189050475, "width": 0.38754534461910517}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-8", "text": "3.2\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4888793840889649, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.49957228400342174, "height": 0.010692899914456822, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-9", "text": "        The price range for the Offering within which purchase orders may be placed is \u20ac26.00 to \u20ac30.00 per\nOffer Share (the \u201cPrice Range\u201d).\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5162532078699743, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.544054747647562, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"initial_price_range": ["\u20ac26.00 to \u20ac30.00"]}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-10", "text": "         The period during which investors may submit purchase orders for the Offer Shares is expected to\ncommence on January 29, 2018, and to expire on February 8, 2018 (the \u201cOffer Period\u201d). Offers to purchase\nOffer Shares may be submitted (i) until 12:00 p.m. (noon) CET by private investors and (ii) until\n2:00 p.m. (CET) by institutional investors on the last day of the Offer Period. Multiple purchase orders are\npermitted.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5504704875962361, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6189050470487596, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-11", "text": "         Subject to the publication of a supplement to this Prospectus, if required, the Company, the Selling\nShareholder and the Sole Bookrunner, on behalf of the Offering Banks, reserve the right to reduce the total\nnumber of Offer Shares, to increase or decrease the upper limit and/or the lower limit of the Price Range and/or\nto extend or shorten the Offer Period.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.625748502994012, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6775021385799829, "height": 0.0517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-12", "text": "          Reductions in the number of Offer Shares, changes to the Price Range or an extension or shortening of\nthe Offer Period will not invalidate any offers to purchase Offer Shares that have already been submitted. If such\nchanges require the publication of a supplement to this Prospectus, investors who submitted purchase orders\nprior to the publication of the supplement have the right to withdraw these offers to purchase within two\nbusiness days following the publication of the supplement (Section 16 para. 3 WpPG). Instead of withdrawing\ntheir offers to purchase placed prior to the publication of the supplement, investors may change their orders or\nplace new limited or unlimited offers to purchase within two business days following the publication of the\nsupplement.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6873396065012831, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7968349016253208, "height": 0.10949529512403766, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-75-13", "text": "", "page_number": 75, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-76-0", "text": "         Any changes to the terms of the Offering will be published by means of electronic media (such as\nReuters or Bloomberg) and, if required by the German Securities Trading Act (Wertpapierhandelsgesetz\n(\u201cWpHG\u201d)), the WpPG or Regulation (EU) no. 596/2014 of the European Parliament and of the Council of\nApril 16, 2014 on market abuse, as amended (\u201cMAR\u201d), as an ad-hoc release via an electronic information\ndissemination system, on the Company\u2019s website www.dermapharm.de under the \u201cInvestor Relations\u201d section\nand as a supplement to this Prospectus. Investors who have submitted offers to purchase will not be notified\nindividually. Under certain conditions, the Sole Bookrunner may terminate the underwriting agreement, entered\ninto between the Company, the Selling Shareholder and the Offering Banks on January 26, 2018 (the\n\u201cUnderwriting Agreement\u201d), even after commencement of trading (Aufnahme des Handels) of the Company\u2019s\nshares on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter\nWertpapierb\u00f6rse) (see \u201c19.5 Termination; Indemnification\u201d).\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-76-1", "text": "         The offer price for the Offering (the \u201cOffer Price\u201d) and the final number of Offer Shares placed in the\nOffering will be determined at the end of the bookbuilding process by the Company and the Selling Shareholder\nafter consultation with the Sole Bookrunner. The Offer Price will be set on the basis of the purchase orders\nsubmitted by investors during the Offer Period that have been collated in the order book prepared during a\nbookbuilding process. These orders will be evaluated according to the prices offered and the investment\nhorizons of the respective investors. This method of setting the number of Offer Shares that will be placed at the\nOffer Price is, in principle, aimed at maximizing proceeds. Consideration will also be given to whether the Offer\nPrice and the number of Offer Shares to be placed allow for the reasonable expectation that the share price will\ndemonstrate a steady performance in the secondary market given the demand for the Company\u2019s shares as\nreflected in the order book. Attention will be paid not only to the prices offered by investors and the number of\ninvestors interested in purchasing shares at a particular price, but also to the composition of the Company\u2019s\nshareholder structure that would result at a given price, and expected investor behavior. The Company and the\nSelling Shareholder will not specifically charge any expenses and taxes related to the Offering to investors.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.17835757057313942, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-76-2", "text": "          The Offer Price and the final number of Offer Shares placed in the Offering (i.e., the results of the\nOffering) are expected to be set on February 8, 2018. After the Offer Price has been set, the Offer Shares will be\nallotted to investors on the basis of the purchase offers then available. The Offer Price and the final number of\nOffer Shares (i.e., the results of the Offering) are expected to be published on or about February 8, 2018, by\nmeans of an ad-hoc release on an electronic information dissemination system and on the Company\u2019s website\nwww.dermapharm.de under the \u201cInvestor Relations\u201d section. Investors who have placed orders to purchase\nOffer Shares with the Sole Bookrunner can obtain information from the Sole Bookrunner about the Offer Price\nand the number of Offer Shares allotted to them on the business day following the setting of the Offer Price. As\ncommencement of trading (Aufnahme des Handels) of the Company\u2019s shares on the regulated market\n(regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) is expected to take place on\nthe business day following the setting of the Offer Price, investors may not have obtained information about the\nnumber of Offer Shares allotted to them when trading commences. Book-entry delivery of the allotted Offer\nShares against payment of the Offer Price is expected to take place two business days after commencement of\ntrading. Should the placement volume prove insufficient to satisfy all orders placed at the Offer Price, Sole\nBookrunner reserves the right to reject orders, or to only accept them in part.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6330196749358425, "height": 0.20573139435414878, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-76-3", "text": "", "page_number": 76, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-0", "text": "3.3   Expected Timetable for the Offering\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.3246674727932285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-1", "text": "         The following is the expected timetable of the Offering, which may be extended or shortened:\nJanuary 26, 2018 ................................................................\n                                                      Approval of the Prospectus by BaFin\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8107617896009673, "lower_right_y": 0.14884516680923868, "height": 0.03635585970915313, "width": 0.6898428053204353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-2", "text": "Publication of the approved Prospectus on the Company\u2019s website\nwww.dermapharm.de under the \u201cInvestor Relations\u201d section\n", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.15697177074422583, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18306244653550044, "height": 0.02609067579127461, "width": 0.4842805320435309}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-3", "text": "Notification of the approved Prospectus to the Luxembourg\nCommission for the Supervision of the Financial Sector (Commission\nde Surveillance du Secteur Financier (\u201cCSSF\u201d))\n", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.1911890504704876, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23139435414884515, "height": 0.04020530367835756, "width": 0.4842805320435309}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-4", "text": "January 29, 2018 ................................................................\n                                                      Commencement of the Offer Period\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12454655380894801, "top_left_y": 0.25962360992301114, "lower_right_x": 0.6432889963724304, "lower_right_y": 0.272027373823781, "height": 0.01240376390076986, "width": 0.5187424425634825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-5", "text": "Application for admission of the Company\u2019s shares to trading on the\nregulated market (regulierter Markt) of the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse) and simultaneous admission to the\nsub-segment of the regulated market with additional post admission\nobligations (Prime Standard) of the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse)\n", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3618477331052181, "height": 0.08169375534644996, "width": 0.4842805320435309}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-6", "text": "February 8, 2018 ................................................................\n                                                      Expiration of the Offer Period\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.3896492728828058, "lower_right_x": 0.6003627569528416, "lower_right_y": 0.4033361847733105, "height": 0.013686911890504694, "width": 0.47762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-7", "text": "Determination of the Offer Price and final number of shares to be", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.4101796407185629, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.010692899914456766, "width": 0.4842805320435309}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-8", "text": "Determin\nallocated\n", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.4238665526090676, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.4345594525235244, "height": 0.010692899914456822, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-9", "text": "Publication of the Offer Price in the form of an ad-hoc release on an\nelectronic information dissemination system and on the Company\u2019s\nwebsite www.dermapharm.de under the \u201cInvestor Relations\u201d section\n", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.041488451668092396, "width": 0.4842805320435309}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-10", "text": "Registration of the consummation of the IPO Capital Increase in the\ncommercial register of the local court (Amtsgericht) of Munich,\nGermany, and creation of the New Shares to be delivered at closing\n", "page_number": 77, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5337895637296834, "height": 0.04148845166809234, "width": 0.4842805320435309}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-11", "text": "                                                      Commencement of trading in the Company\u2019s shares on the Frankfurt\nFebruary 9, 2018 ................................................................\n                                                      Stock Exchange (Frankfurter Wertpapierb\u00f6rse)\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12212817412333736, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5885372112917023, "height": 0.027801539777587703, "width": 0.758162031438936}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-12", "text": "February 13, 2018 ..............................................................\n                                                     Book-entry delivery of the Offer Shares against payment of the Offer\n                                                     Price (closing)\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6432848588537211, "height": 0.027801539777587703, "width": 0.7575574365175333}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-13", "text": "         This Prospectus will be published on the Company\u2019s website at www.dermapharm.de under the\n\u201cInvestor Relations\u201d section. Printed copies of this Prospectus are available from the Company free of charge\nduring normal business hours at the following address: Dermapharm Holding SE, Lil-Dagover-Ring 7,\n82031 Gr\u00fcnwald, Germany.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7322497861420018, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-77-14", "text": "", "page_number": 77, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-0", "text": "3.4     Information on the Shares\n\n3.4.1   Voting Rights\n", "page_number": 78, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.1283147989734816, "height": 0.043199315654405476, "width": 0.2551390568319226}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-1", "text": "      Each share in the Company carries one vote at the Company\u2019s shareholders\u2019 meeting. All of the\nCompany\u2019s shares confer the same voting rights. There are no restrictions on voting rights.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17023096663815226, "height": 0.026946107784431128, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-2", "text": "3.4.2   Dividend and Liquidation Rights\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.4111245465538089, "lower_right_y": 0.19760479041916168, "height": 0.013259195893926434, "width": 0.2908101571946795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-3", "text": "         Each share in the Company carries full dividend rights since the Company\u2019s formation. However, the\nCompany will not pay a dividend with respect to the fiscal year ended December 31, 2017 (see \u201c6.2 Dividend\nPolicy and Earnings per Share\u201d).\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21171941830624466, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25278015397775877, "height": 0.04106073567151411, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-4", "text": "      In the event of the Company\u2019s liquidation, any proceeds will be distributed to the holders of the\nCompany\u2019s shares in proportion to their interest in the Company\u2019s share capital.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25962360992301114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28699743370402053, "height": 0.027373823781009388, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-5", "text": "3.4.3   Form, Certification of the Shares and Currency of the Securities Issue\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.31479897348160824, "height": 0.014114627887083009, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-6", "text": "         As of the date of this Prospectus, all of the Company\u2019s shares are bearer shares with no par value\n(St\u00fcckaktien). The Company\u2019s shares will be represented by one or more global share certificates, which will be\ndeposited with Clearstream Banking Aktiengesellschaft, Mergenthalerallee 61, 65760 Eschborn, Germany\n(\u201cClearstream\u201d). The global share certificate for the New Shares is expected to be delivered to Clearstream on\nFebruary 8, 2018.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39692044482463645, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-7", "text": "         Section 5 para. 3 of the Articles of Association excludes the shareholders\u2019 right to receive individual\nshare certificates to the extent permitted by law and unless mandated by the rules of a stock exchange to which\nthe shares are admitted. The Company\u2019s management board (Vorstand (the \u201cManagement Board\u201d)) determines\nthe form of the share certificates pursuant to Section 5 para. 3 of the Articles of Association. All shares of the\nCompany provide holders thereof with the same rights and no shares provide any additional rights or\nadvantages.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-8", "text": "The Company\u2019s shares are denominated in Euros.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4931565440547476, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.5064157399486741, "height": 0.013259195893926434, "width": 0.33857315598548965}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-9", "text": "3.4.4   Delivery and Settlement\n", "page_number": 78, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5230966638152267, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.5355004277159966, "height": 0.012403763900769915, "width": 0.23095525997581623}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-10", "text": "         Delivery of the Offer Shares against payment of the Offer Price is expected to take place on\nFebruary 13, 2018. The Offer Shares will be made available to investors as co-ownership interests in the global\nshare certificates.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5504704875962361, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5885372112917023, "height": 0.038066723695466265, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-11", "text": "          At the investor\u2019s option, the Offer Shares purchased in the Offering will be credited either to a\nsecurities deposit account maintained by a German bank with Clearstream or to a securities account of a\nparticipant in Euroclear Bank SA/NV, 1 Boulevard du Roi Albert II, 1210 Brussels, Belgium (\u201cEuroclear\u201d), as\nthe operator of the Euroclear system, or to Clearstream Banking S.A., 42 Avenue JF Kennedy,\nL-1855 Luxembourg, Luxembourg.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5983746792130026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6659538066723696, "height": 0.067579127459367, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-12", "text": "3.4.5   ISIN/WKN/Ticker Symbol\n", "page_number": 78, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6804961505560307, "lower_right_x": 0.36698911729141476, "lower_right_y": 0.6941830624465355, "height": 0.01368691189050475, "width": 0.250906892382104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-13", "text": "                                                                                                                   DE000A2GS5D8\nInternational Securities Identification Number (ISIN) .....................................................................\nGerman Securities Code (Wertpapierkennnummer (WKN)) .............................................................                       A2GS5D\nTicker Symbol ..................................................................................................................................\n                                                                                                                                        DMP\n", "page_number": 78, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7078699743370402, "lower_right_x": 0.8603385731559855, "lower_right_y": 0.7591958939264328, "height": 0.05132591958939259, "width": 0.7400241837968561}, "blob_type": "paragraph", "predictions": {}, "annotations": {"isin": ["....... E000A2GS5D8"], "ticker": [".......MP"]}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-78-14", "text": "", "page_number": 78, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-0", "text": "3.4.6   Identification of Target Market\n", "page_number": 79, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.28355501813784767}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-1", "text": "           Solely for the purpose of fulfilling the requirements of Article 24 para. 2 of Directive 2014/65/EU of\nthe European Parliament and of the Council of May 15, 2014 on markets in financial instruments, the following\ncriteria characterizing the target market for shares in the Company have been identified: (i) target clients include\nretail clients, professional clients and eligible counterparties, (ii) should be able and willing to carry losses of up\nto the total amounts invested, (iii) have a mid-term or long-term investment horizon, (iv) an investment strategy\nfocused on the overall accumulation of wealth and optimization of wealth, (v) possess basic knowledge and\nexperience with respect to financial instruments; and (vi) a sale strategy that includes execution only,\nnon-advisory services and investment advisory services. For the avoidance of doubt, this assessment does not\nconstitute an assessment of the suitability or appropriateness of an investment in shares of the Company, or a\nrecommendation to any investor to purchase, sell, or take any other action with respect to the Company\u2019s shares.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-2", "text": "3.5   Transferability of the Shares; Lock-up\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2660393498716852, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.2788708297690334, "height": 0.012831479897348175, "width": 0.3391777509068924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-3", "text": "         The Company\u2019s shares are freely transferable in accordance with the legal requirements for bearer\nshares. Except for the restrictions set forth in \u201c3.9 Lock-up Agreements and Limitations on Disposal\u201d, there are\nno prohibitions on disposals or restrictions with respect to the transferability of the Company\u2019s shares.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33404619332763047, "height": 0.04020530367835756, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-4", "text": "Selling Shareholder\n", "page_number": 79, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3485885372112917, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.36227544910179643, "height": 0.01368691189050475, "width": 0.14510278113663846}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-5", "text": "3.6\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3592814371257485, "height": 0.010692899914456822, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-6", "text": "         Immediately prior to the Offering, Themis Beteiligungs-Aktiengesellschaft holds 100.0% of the\nCompany\u2019s outstanding share capital. For a discussion of the ownership structure of the Selling Shareholder, see\n\u201c14. Information on the Selling Shareholder\u201d.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4170230966638152, "height": 0.04106073567151408, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-7", "text": "3.7\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4311377245508982, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.4414029084687767, "height": 0.010265183917878506, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-8", "text": "Allotment Criteria\n", "page_number": 79, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.4311377245508982, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.44268605645851156, "height": 0.01154833190761334, "width": 0.1396614268440145}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-9", "text": "         The allotment of Offer Shares to private investors and institutional investors will be decided by the\nCompany and the Selling Shareholder after consultation with the Sole Bookrunner. The decision ultimately rests\nwith the Company. Allotments will be made on the basis of the quality of individual investors (e.g., the expected\ninvestment horizon and trading behavior) as well as individual orders and other important allotment criteria to\nbe determined by the Company after consultation with the Sole Bookrunner.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5269461077844312, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-10", "text": "Stabilization Measures, Over-Allotments and Greenshoe Option\n", "page_number": 79, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5427715996578272, "lower_right_x": 0.6432889963724304, "lower_right_y": 0.5560307955517536, "height": 0.013259195893926434, "width": 0.464328899637243}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-11", "text": "3.8\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5436270316509837, "lower_right_x": 0.14389359129383314, "lower_right_y": 0.5538922155688623, "height": 0.010265183917878562, "width": 0.023579201934703753}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-12", "text": "         In connection with the placement of the Offer Shares, the Sole Bookrunner will act as the stabilization\nmanager and may, as stabilization manager, make over-allotments and take stabilization measures in accordance\nwith Article 5 paras. 4 and 5 MAR in conjunction with Articles 5 through 8 of Commission Delegated\nRegulation (EU) 2016/1052 of March 8, 2016, to provide support for the market price of the Company\u2019s shares,\nthus alleviating sales pressure generated by short-term investors and maintaining an orderly market in the\nCompany\u2019s shares.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5710008554319932, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6518391787852865, "height": 0.08083832335329333, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-13", "text": "         The Sole Bookrunner is under no obligation to take any stabilization measures. Therefore, no assurance\ncan be provided that any stabilization measures will be taken. Where stabilization measures are taken, these may\nbe terminated at any time without notice. Such measures may start from the date the Company\u2019s shares\ncommence trading on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter\nWertpapierb\u00f6rse) and must end no later than 30 calendar days thereafter (i.e., March 11, 2018 (the\n\u201cStabilization Period\u201d)).\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6599657827202737, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7408041060735672, "height": 0.08083832335329344, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-14", "text": "         Stabilization measures are intended to provide support for the price of the Company\u2019s shares during the\nStabilization Period. These measures may result in the market price of the Company\u2019s shares being higher than\nwould otherwise have been the case. Moreover, the market price may temporarily be at an unsustainable level.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7489307100085543, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7904191616766467, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-79-15", "text": "", "page_number": 79, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-0", "text": "         As a result of these stabilization measures, investors may, in addition to the Base Shares, be allocated\nup to 1,755,000 Over-Allotment Shares as part of the allocation of the Offer Shares (\u201cOver-Allotment\u201d). For\nthe purpose of such potential Over-Allotment, the Sole Bookrunner will be provided with 1,755,000\nOver-Allotment Shares from the holdings of the Selling Shareholder in the form of a securities loan. The total\nnumber of Over-Allotment Shares will not exceed 15% of the final number of Base Shares placed with\ninvestors. The Selling Shareholder will grant the Sole Bookrunner an option to acquire the Over-Allotment\nShares at the Offer Price, less agreed commissions (the \u201cGreenshoe Option\u201d). The Greenshoe Option may only\nbe exercised during the Stabilization Period and will terminate 30 calendar days after the commencement of\ntrading of the Company\u2019s shares.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.12360992301112063, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-1", "text": "         The Sole Bookrunner is entitled to exercise the Greenshoe Option to the extent Over-Allotment Shares\nwere allocated to investors in the Offering. The number of Over-Allotment Shares acquired under the Greenshoe\nOption is to be reduced by any shares of the Company held by the Sole Bookrunner when the Greenshoe Option\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.26732249786142004, "height": 0.05218135158254922, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-2", "text": "is exercised, if such shares were acquired by the Sole Bookrunner in the context of stabilization measures.\n          Public announcements regarding stabilization measures will be made (i) prior to the start of the\nOffering, (ii) by the end of the seventh daily market session following the date any stabilization were taken, and\n(iii) within one week after the end of the Stabilization Period.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2677502138579983, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.05047048759623607, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-3", "text": "         Within one week of the end of the Stabilization Period, the Sole Bookrunner will ensure adequate\npublic disclosure as to whether stabilization measures were taken, the date on which stabilization started and last\noccurred, and the price range within which stabilization measures were carried out, for each of the dates during\nwhich stabilization measures were carried out and the trading venue(s) on which the stabilization measures were\ncarried out, where applicable.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3246364414029085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39349871685201027, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-4", "text": "          Exercise of the Greenshoe Option will be disclosed to the public promptly, together with all appropriate\ndetails, including in particular the date of exercise of the Greenshoe Option and the number and nature of\nOver-Allotment Shares involved, in accordance with Article 8 (f) of the Commission Delegated Regulation\n(EU) 2016/1052 of March 8, 2016.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3999144568006843, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4550898203592814, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-5", "text": "Lock-up Agreements and Limitations on Disposal\n", "page_number": 80, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.47177074422583404, "lower_right_x": 0.535671100362757, "lower_right_y": 0.4846022241231822, "height": 0.012831479897348175, "width": 0.3573155985489722}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-6", "text": "3.9\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.47177074422583404, "lower_right_x": 0.14207980652962515, "lower_right_y": 0.48246364414029086, "height": 0.010692899914456822, "width": 0.021160822249093103}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-7", "text": "        In the Underwriting Agreement, the Company agreed with the Offering Banks that, during the period\ncommencing on January 26, 2018 and ending six months after the first day of trading of the Company\u2019s shares\non the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) (currently expected to take place on\nFebruary 9, 2018), to the extent legally permissible, without the prior written consent of the Sole Bookrunner,\nwhich may not be unreasonably withheld, the Company will not:\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4991445680068435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5667236954662105, "height": 0.067579127459367, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"lock-up_period": ["six months"]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-8", "text": "\uf0b7   announce or effect an increase of the share capital of the Company from authorized capital;\n", "page_number": 80, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8264812575574365, "lower_right_y": 0.5885372112917023, "height": 0.014114627887082953, "width": 0.6475211608222491}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-9", "text": "\uf0b7   propose to its shareholders\u2019 meeting an increase of the share capital; or\n\uf0b7   announce, effect or propose the issuance of securities with conversion or option rights on shares of\n    the Company or economically similar transactions.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6467065868263473, "height": 0.0517536355859709, "width": 0.6995163240628779}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-10", "text": "         The foregoing will not apply to any capital increase in connection with the Offering. Furthermore, the\nCompany may (i) issue or sell any shares or other securities to employees and members of executive bodies of\nthe Company or its subsidiaries under management participation plans and (ii) pursue any corporate actions\nundertaken by the Company for the purpose of entering into any agreement regarding, or resolve upon, the\nentering into any joint venture or the acquisition of any companies, provided that the parties to the joint venture\nor acquiring entity to which such shares will be issued agree towards the Sole Bookrunner to be bound by the\nsame lock-up undertaking as the Selling Shareholder.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7480752780153977, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-11", "text": "         In addition, for the period commencing on January 26, 2018 and ending twelve months after the first\nday of trading of the Company\u2019s shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse)\n(currently expected to take place on February 9, 2018), the Selling Shareholder has agreed that it will not,\nwithout the prior written consent of the Sole Bookrunner, which may not be unreasonably withheld:\n", "page_number": 80, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7557741659538066, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8100940975192472, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"lock-up_period": ["twelve months"]}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-12", "text": "\uf0b7   sell, market, transfer or otherwise dispose of, either directly or indirectly, any shares or other\n    securities in the Company; or\n\uf0b7   enter into any transaction economically equivalent to a sale of shares of the Company (e.g., the\n    issuance of options or conversion rights on shares of the Company).\n", "page_number": 80, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.8173652694610778, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8793840889649273, "height": 0.062018819503849465, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-80-13", "text": "", "page_number": 80, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-0", "text": "           The foregoing shall not apply to (i) transfers to affiliates or legal successors of the Selling Shareholder\nor to Mr. Wilhelm Beier, his spouse or his children, (ii) future pledges granted to the Sole Bookrunner or its\naffiliates having been agreed by the Sole Bookrunner, and (iii) any transfers of shares to the Sole Bookrunner or\nits affiliates pursuant to enforcement of any pledge entered into in accordance with (ii), provided in each case\nthat such transferee(s) agree(s) towards the Sole Bookrunner to be bound by the same lock-up undertaking.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.0688622754491018, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-1", "text": "Admission to the Frankfurt Stock Exchange and Commencement of Trading\n", "page_number": 81, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.16723695466210436, "lower_right_x": 0.7291414752116082, "lower_right_y": 0.18135158254918735, "height": 0.014114627887082981, "width": 0.5507859733978234}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-2", "text": "3.10\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16852010265183917, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.1804961505560308, "height": 0.011976047904191628, "width": 0.02962515114873035}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-3", "text": "         The Company expects to apply for the admission of its shares to trading on the regulated market\n(regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) and, simultaneously, to the\nsub-segment thereof with additional post-admission obligations (Prime Standard) on or about January 29, 2018.\nThe listing approval (admission decision) for the Company\u2019s shares is expected to be granted on February 8,\n2018. Trading in the Company\u2019s shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) is\nexpected to commence on February 9, 2018.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2788708297690334, "height": 0.08083832335329344, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-4", "text": "3.11   Designated Sponsors\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.30710008554319934, "height": 0.013259195893926434, "width": 0.21281741233373638}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-5", "text": "         Berenberg and ODDO BHF have been mandated as designated sponsors of the Company\u2019s shares\ntraded on the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse). Pursuant to the designated sponsor\nagreement expected to be concluded between the designated sponsors and the Company, the designated\nsponsors will, inter alia, place limited buy and sell orders for the Company\u2019s shares in the electronic trading\nsystem of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) during regular trading hours. This is\nintended to achieve greater liquidity in the market for the Company\u2019s shares.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40290846877673225, "height": 0.08169375534644996, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-6", "text": "Interests of Parties Participating in the Offering\n", "page_number": 81, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4170230966638152, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.4311377245508982, "height": 0.014114627887083009, "width": 0.3488512696493349}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-7", "text": "3.12\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4170230966638152, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.42728828058169377, "height": 0.010265183917878562, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-8", "text": "         Subject to the placement of the Existing Shares and the exercise of the Greenshoe Option, the Selling\nShareholder will receive the proceeds from the sale of the Existing Shares and the Over-Allotment Shares (after\ndeduction of fees and commissions). Accordingly, the Selling Shareholder has an interest in the success of the\nOffering at the best possible terms.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49957228400342174, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-9", "text": "        In connection with the Offering and the admission to trading of the Company\u2019s shares, the Offering\nBanks have formed a contractual relationship with the Company and the Selling Shareholder.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5337895637296834, "height": 0.02780153977758759, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-10", "text": "         Berenberg is acting for the Company and the Selling Shareholder on the Offering and on coordinating\nthe structuring and execution of the Offering. Upon successful completion of the Offering, Berenberg will\nreceive a commission and the size of this commission depends on the results of the Offering. As a result,\nBerenberg has a financial interest in the success of the Offering at the best possible terms.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5953806672369547, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-11", "text": "         ODDO BHF is acting as Co-Lead Manager and will receive a fixed fee for its services in connection\nwith the Offering. As a result, ODDO BHF has a financial interest in the success of the Offering.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6295979469632165, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-12", "text": "         The Offering Banks or their respective affiliates have, and may from time to time in the future continue\nto have, business relations with Dermapharm and the Selling Shareholder, including lending activities, or may\nperform services for Dermapharm or the Selling Shareholder in the ordinary course of business.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6775021385799829, "height": 0.04148845166809234, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-13", "text": "          Other than the interests described above, there are no material interests, in particular no material\nconflicts of interest, with respect to the Offering or the listing of the Company\u2019s shares.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6839178785286569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7117194183062446, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-81-14", "text": "", "page_number": 81, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-0", "text": "PROCEEDS AND COSTS OF THE OFFERING AND LISTING\n", "page_number": 82, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.46977025392986693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-1", "text": "4.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.23639661426844014, "top_left_y": 0.08597091531223268, "lower_right_x": 0.250906892382104, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.014510278113663871}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-2", "text": "         The Company will only receive the proceeds of the Offering resulting from the sale of the New Shares.\nThe Company will not receive any proceeds from the sale of the Existing Shares or the Over-Allotment Shares\nfrom the holdings of the Selling Shareholder.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-3", "text": "         Assuming that the maximum number of New Shares (i.e., 3,840,000 shares) is placed, the Company\nestimates that at the low end, mid-point and high end of the Price Range, gross proceeds attributable to the\nCompany would amount to approximately \u20ac99.8 million, \u20ac107.5 million or \u20ac115.2 million, respectively, and net\nproceeds would amount to approximately \u20ac96.0 million, \u20ac103.5 million and \u20ac111.0 million, respectively.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2155688622754491, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-4", "text": "         Assuming a placement of all 7,860,000 Existing Shares and full exercise of the Greenshoe Option\ntotaling 1,755,000 shares, the Company estimates that at the low end, mid-point and high end of the Price\nRange, gross proceeds attributable to the Selling Shareholder would amount to approximately \u20ac250.0 million,\n\u20ac269.2 million and \u20ac288.5 million, respectively, and net proceeds would amount to approximately\n\u20ac240.9 million, \u20ac259.6 million and \u20ac278.4 million, respectively.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2921300256629598, "height": 0.06672369546621046, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {"expected_gross_proceeds": ["\u20ac269.2 million"], "expected_net_proceeds": ["\u20ac259.6 million"]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-5", "text": "          The costs of the Company and the Selling Shareholder related to the Offering of the Offer Shares and\nlisting of the Company\u2019s entire share capital, including underwriting and placement commissions payable to the\nSole Bookrunner and the fixed fee payable to the Co-Lead Manager, are expected to total approximately\n\u20ac13.6 million at the mid-point of the Price Range (assuming placement of all Base Shares, full exercise of the\nGreenshoe Option and payment of the discretionary fee in full); of the total costs, the Selling Shareholder will\nbear approximately \u20ac9.6 million and the Company will bear the remaining amount of approximately\n\u20ac4.0 million.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39264328485885375, "height": 0.09880239520958084, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"offering_costs": ["\u20ac9.6 million"]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-6", "text": "         Assuming an Offer Price at the low end, mid-point and high end of the Price Range and that the\nmaximum number of Offer Shares is placed (i.e., the Greenshoe Option has been fully exercised) and assuming\nfurther payment in full of the discretionary fee of up to \u20ac3.5 million, \u20ac3.8 million and \u20ac4.0 million, at the low\nend, mid-point and high end of the Price Range, respectively; the commission payable to the Sole Bookrunner\nwould amount to \u20ac9.4 million, \u20ac10.2 million and \u20ac10.9 million, respectively. Thereof, \u20ac2.7 million, \u20ac2.9 million\nand \u20ac3.1 million, respectively, are attributable to the placement of the New Shares and will be borne by the\nCompany; \u20ac6.7 million, \u20ac7.3 million and \u20ac7.8 million, respectively, are attributable to the placement of the\nExisting Shares and the Over-Allotment Shares and will be borne by the Selling Shareholder (assuming in each\ncase placement of all Base Shares, full exercise of the Greenshoe Option and payment of the discretionary fee in\nfull).\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5372112917023096, "height": 0.13387510692899912, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-7", "text": "          Investors will not be charged expenses by the Company, the Selling Shareholder or the Offering Banks.\nInvestors will have to bear customary transaction and handling fees charged by their brokers or other financial\ninstitutions through which they hold their securities.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5868263473053892, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-82-8", "text": "39\n", "page_number": 82, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.009837467921300247, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-83-0", "text": "REASONS FOR THE OFFERING AND LISTING AND USE OF PROCEEDS\n", "page_number": 83, "bounding_box": {"top_left_x": 0.2460701330108827, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8119709794437727, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5659008464328901}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-83-1", "text": "5.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.18500604594921402, "top_left_y": 0.08597091531223268, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.013301088270858519}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-83-2", "text": "         The Company intends to pursue the Offering and list its shares on the regulated market (regulierter\nMarkt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) and, simultaneously, on the sub\nsegment with additional post admission obligations (Prime Standard) of the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse) to receive the net proceeds from the Offering attributable to the Company and to\ngain access to the capital markets.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.11248930710008555, "lower_right_x": 0.879081015719468, "lower_right_y": 0.1800684345594525, "height": 0.06757912745936696, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {"reasons_for_the_offering": ["The Company intends to pursue the Offering and list its shares on the regulated market (regulierterMarkt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) and, simultaneously, on the subsegment with additional post admission obligations (Prime Standard) of the Frankfurt Stock Exchange(Frankfurter Wertpapierb\u00f6rse) to receive the net proceeds from the Offering attributable to the Company and togain access to the capital markets."]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-83-3", "text": "The Selling Shareholder intends to pursue the Offering to receive the net proceeds from the Offering\n", "page_number": 83, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8681983071342201, "lower_right_y": 0.20958083832335328, "height": 0.021813515825491847, "width": 0.7430471584038694}, "blob_type": "paragraph", "predictions": {}, "annotations": {"shareholder_transaction": ["The Selling Shareholder intends to pursue the Offering to receive the net proceeds from the Offeringattributable to the Selling Shareholder and to diversify its investments."]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-83-4", "text": "         The Company currently intends to use the net proceeds attributable to the Company as follows:\napproximately \u20ac35 million are to be spent on in-house developments and an upgrade of Dermapharm\u2019s\nmanufacturing facilities in Brehna, Germany, and a new manufacturing facility in Neumarkt am Wallersee,\nAustria, approximately \u20ac20 million for Dermapharm\u2019s efforts to increase its international footprint (e.g., for\nfounding new enterprises in additional markets, hiring local sales managers and sales personnel and similar\ninvestments) and between approximately \u20ac40 million and \u20ac50 million on the partial refinancing of a loan\nprovided by Baden-W\u00fcrttembergische Bank to partially finance the acquisition of all shares in Trommsdorff\nGmbH & Co. KG and its sole general partner Cl. Lageman Gesellschaft mit beschr\u00e4nkter Haftung (together,\n\u201cTrommsdorff\u201d). The Company currently intends to spend any remaining net proceeds on general corporate\npurposes.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.13387510692899915, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-83-5", "text": "", "page_number": 83, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-0", "text": "6.   DIVIDEND POLICY; RESULTS AND DIVIDENDS PER SHARE; USE OF PROFITS\n", "page_number": 84, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8446191051995163, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.6904474002418379}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-1", "text": "General Provisions Relating to Profit Allocation and Dividend Payments\n", "page_number": 84, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.11548331907613345, "lower_right_x": 0.7013301088270859, "lower_right_y": 0.1270316509837468, "height": 0.011548331907613354, "width": 0.5223700120918985}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-2", "text": "6.1\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11591103507271172, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.12617621899059026, "height": 0.010265183917878534, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-3", "text": "           The shareholders\u2019 share of the Company\u2019s profits is determined based on their respective interests in\nthe Company\u2019s share capital. For a European company (Societas Europaea (SE)) with a two-tier management\nand control system under European and German law such as the Company, the distribution of dividends for any\ngiven fiscal year and the amount and payment date thereof, are resolved by the Company\u2019s shareholders\u2019\nmeeting (Hauptversammlung) of the subsequent fiscal year, based upon either a joint proposal by the\nManagement Board and the Company\u2019s supervisory board (Aufsichtsrat (the \u201cSupervisory Board\u201d)) or upon\nthe Management Board\u2019s or the Supervisory Board\u2019s proposal. The shareholders\u2019 meeting must be held within\nthe first six months of each fiscal year.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.24721984602224123, "height": 0.1039349871685201, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"dividend_policy": ["The shareholders\u2019 share of the Company\u2019s profits is determined based on their respective interests inthe Company\u2019s share capital. For a European company (Societas Europaea (SE)) with a two-tier managementand control system under European and German law such as the Company, the distribution of dividends for anygiven fiscal year and the amount and payment date thereof, are resolved by the Company\u2019s shareholders\u2019meeting (Hauptversammlung) of the subsequent fiscal year, based upon either a joint proposal by theManagement Board and the Company\u2019s supervisory board (Aufsichtsrat (the \u201cSupervisory Board\u201d)) or uponthe Management Board\u2019s or the Supervisory Board\u2019s proposal. The shareholders\u2019 meeting must be held withinthe first six months of each fiscal year."]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-4", "text": "         Dividends may only be distributed from the net retained profit (Bilanzgewinn) of the Company. The net\nretained profit is calculated based on the Company\u2019s individual financial statements prepared in accordance with\ngenerally accepted accounting principles of the German Commercial Code (Handelsgesetzbuch (\u201cHGB\u201d)).\nAccounting principles set forth in the HGB differ from IFRS in material respects.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25962360992301114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31308810949529514, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-5", "text": "          When determining the net retained profit, the net income or loss for the fiscal year\n(Jahres\u00fcberschuss/-fehlbetrag)        must      be   adjusted     for    retained    profit/loss  carryforwards\n(Gewinn-/Verlustvortr\u00e4ge) from the prior fiscal year and withdrawals from, or appropriations, to reserves\n(retained earnings). Certain reserves are required to be set up by law and must be deducted when calculating the\nnet retained profit available for distribution.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3135158254918734, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3887938408896493, "height": 0.0752780153977759, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-6", "text": "          The Management Board must prepare individual financial statements (statement of financial position,\nstatement of comprehensive income and notes to the individual financial statements) and a management report\nfor the previous fiscal year by the statutory deadline and present these to the Supervisory Board and the auditors\nimmediately after preparation. At the same time, the Management Board must present to the Supervisory Board\na proposal for the allocation of the Company\u2019s net retained profit pursuant to Article 61 of the Council\nRegulation (EC) no. 2157/2001 of October 8, 2001 on the statute for a European company (SE), as amended\n(the \u201cSE Regulation\u201d) in conjunction with Section 170 para. 2 of the German Stock Corporation Act\n(Aktiengesetz (\u201cAktG\u201d)). According to Article 61 of the SE Regulation in conjunction with Section 171 AktG,\nthe Supervisory Board must review the individual financial statements, the Management Board\u2019s management\nreport and the proposal for the allocation of the net retained profit and report to the shareholders\u2019 meeting in\nwriting on the results of such review.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5461933276304534, "height": 0.14970059880239517, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-7", "text": "          The shareholders\u2019 meeting\u2019s resolution on the allocation of the net retained profit requires a simple\nmajority of votes cast to be passed. Pursuant to Section 22 para. 2 of the Articles of Association, the\nshareholders\u2019 meeting may also resolve that the dividends be distributed partially or entirely in kind (e.g., as a\ndistribution of treasury shares if such shares are held by the Company at that time). Notifications of any\ndistribution of dividends resolved upon are published in the German Federal Gazette (Bundesanzeiger) without\nundue delay after the shareholders\u2019 meeting.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.635158254918734, "height": 0.08126603934987175, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-8", "text": "         Dividends resolved by the shareholders\u2019 meeting are due and payable in compliance with the rules of\nthe respective clearing system on the third business day following the relevant shareholders\u2019 meeting, unless a\nlater due date is specified in the dividend resolution or the Articles of Association. Since all of the Company\u2019s\ndividend entitlements will be evidenced by one or more global share certificates deposited with Clearstream,\nClearstream will transfer the dividends to the shareholders\u2019 custodian banks for crediting to their accounts.\nGerman custodian banks are under an obligation to distribute these funds to their customers. Shareholders using\na custodian bank located outside Germany must inquire at their respective bank about the terms and conditions\napplicable in their case. To the extent dividends can be distributed by the Company in accordance with the HGB\nand corresponding decisions are taken, there are no restrictions on shareholders\u2019 rights to receive such\ndividends.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.776732249786142, "height": 0.13387510692899907, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-9", "text": "         Generally, withholding tax (Kapitalertragsteuer) is withheld from dividends paid. For more\ninformation on the taxation of dividends, see \u201c20.2.1 Taxation of Dividend Income\u201d and \u201c21.2 Taxation of\nDividend Income\u201d.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7865697177074422, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8246364414029085, "height": 0.038066723695466265, "width": 0.7648125755743651}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-10", "text": "          Any dividends not claimed within three years become time-barred. Once the statute of limitations\napplies, the right to receive the relevant dividend payments passes to the Company.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.8344739093242087, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8614200171086399, "height": 0.026946107784431184, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-84-11", "text": "", "page_number": 84, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-0", "text": "6.2   Dividend Policy and Earnings per Share\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.348851269649335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-1", "text": "         The Company was founded on July 4, 2017 and did not conduct any business activities prior to the\ncontribution of Dermapharm AG on December 31, 2017. Therefore, the Company has not paid any dividends or\nmade any other distributions up to and including the date of this Prospectus.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-2", "text": "          The Company\u2019s ability and intention to pay dividends in the future will depend on its financial\nposition, results of operations, capital requirements, investment options and other factors that the Management\nBoard and the Supervisory Board deem relevant, and any proposals by the Management Board and Supervisory\nBoard regarding dividend payments will require the approval of Company\u2019s the shareholders\u2019 meeting. The\nprincipal sources of funding for the payment of dividends by the Company will be dividends and other\ndistributions received from the Company\u2019s current and future subsidiaries. Such subsidiaries may only pay\ndividends accordance with applicable laws and articles of association.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2566295979469632, "height": 0.0962360992301112, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-3", "text": "         On April 13, 2016, Dermapharm AG and the Selling Shareholder entered into a profit transfer\nagreement (Gewinnabf\u00fchrungsvertrag (the \u201cProfit Transfer Agreement\u201d)), pursuant to which\nDermapharm AG was required to transfer its entire profits, if any, to the Selling Shareholder, who in turn is\nrequired to assume Dermapharm AG\u2019s losses in any given fiscal year, if any (in each case, as determined by\nDermapharm AG\u2019s individual annual financial statements prepared in accordance with HGB). The Profit\nTransfer Agreement was terminated with effect from the end of December 31, 2017. Therefore,\nDermapharm AG is required to transfer its profits for the fiscal year ended December 31, 2017, if any, to the\nSelling Shareholder. However, Dermapharm AG has provided the Selling Shareholder with certain shareholder\nloans. Consequently, the claims of the Selling Shareholder under the Profit Transfer Agreement with respect to\nthe fiscal year ended December 31, 2017 will be offset against Dermapharm AG\u2019s claims under these\nshareholder loans and Dermapharm AG expects that its claims will exceed those of the Selling Shareholder by\nmore than \u20ac50 million.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4264328485885372, "height": 0.15996578272027373, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-4", "text": "         Given that Dermapharm AG is required to transfer its profits for the fiscal year ended December 31,\n2017 to the Selling Shareholder, the Company will not make any dividend payments with respect to the fiscal\nyear ended December 31, 2017.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4756201881950385, "height": 0.03806672369546621, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-5", "text": "         Starting with the fiscal year ending December 31, 2018, the Company intends to pay a dividend in the\nordinary course of business of 50% to 60% of Dermapharm\u2019s profits for the respective fiscal year calculated in\naccordance with IFRS. The Company aims to have a sustainable dividend policy that focuses on dividend\ncontinuity. However, the Company\u2019s ability to pay dividends in the future will depend on the amount of net\nretained profits available to the Company. There is no guarantee that sufficient net retained profits will be\navailable to the Company in the future to pay dividends in the envisaged amount, or at all. The results of\noperations set out in Dermapharm AG\u2019s audited consolidated financial statements and Dermapharm AG\u2019s\nunaudited consolidated interim financial statements may not be indicative of the Company\u2019s future dividend\npayments.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6073567151411463, "height": 0.12189905902480758, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-6", "text": "         In the fiscal years ended December 31, 2014, 2015 and 2016, Dermapharm AG made profit transfers\nunder the Profit Transfer Agreement to the Selling Shareholder in an amount of \u20ac33.0 million, \u20ac39.5 million and\n\u20ac59.9 million, respectively, as shown in the consolidated statement of comprehensive income in\nDermapharm AG\u2019s audited consolidated financial statements. In the nine-month period ended September 30,\n2017, Dermapharm AG made a profit transfer under the Profit Transfer Agreement in an amount of\n\u20ac46.4 million to the Selling Shareholder, as shown in the consolidated statement of comprehensive income in\nDermapharm AG\u2019s unaudited consolidated financial statements.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7100085543199316, "height": 0.09452523524379819, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-85-7", "text": "", "page_number": 85, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-0", "text": "CAPITALIZATION AND INDEBTEDNESS; STATEMENT ON WORKING CAPITAL\n", "page_number": 86, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.6438935912938331}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-1", "text": "7.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.08597091531223268, "lower_right_x": 0.16384522370012092, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.014510278113663844}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-2", "text": "        The following tables show Dermapharm AG\u2019s consolidated capitalization and indebtedness as of\nOctober 31, 2017 as adjusted for the contribution of Dermapharm AG and the completion of the Offering,\nassuming net proceeds of \u20ac103.5 million (i.e., assuming full placement of all New Shares at the mid-point of the\nPrice Range and payment of the discretionary fee in full), not taking into account any tax effects. Investors\nshould read these tables in conjunction with \u201c9. Selected Consolidated Financial Information\u201d,\n\u201c10. Management\u2019s Discussion and Analysis of Net Assets, Financial Condition and Results of Operations\u201d,\nDermapharm AG\u2019s consolidated financial statements, including the related notes thereto, contained in this\nProspectus, and additional financial information contained elsewhere in this Prospectus.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.22241231822070145, "height": 0.10992301112061591, "width": 0.7654171704957677}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-3", "text": "7.1   Capitalization\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.25149700598802394, "height": 0.01240376390076986, "width": 0.16505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-4", "text": "                                                                                              Effects of the\n                                                                            As of            contribution of\n                                                                         October 31,          Dermapharm              Effects of\n                                                                            2017                   AG              the Offering(1)   Total\n                                                                                                          (unaudited)\n                                                                                                         (in \u20ac million)\n Total current debt(2) ........................................................83.6                      \uf02d                    \uf02d         83.6\n Thereof guaranteed ...........................................................4.1                       \uf02d                    \uf02d          4.1\n Thereof secured ................................................................1.3                     \uf02d                    \uf02d          1.3\n Thereof unguaranteed/unsecured ......................................78.2                               \uf02d                    \uf02d         78.2\n Total non-current debt(3) ................................................          271.8               \uf02d                    \uf02d        271.8\n Thereof guaranteed ...........................................................      154.4               \uf02d                    \uf02d        154.4\n Thereof secured ................................................................60.9                    \uf02d                    \uf02d         60.9\n Thereof unguaranteed/unsecured ......................................56.5                               \uf02d                    \uf02d         56.5\n Total shareholder\u2019s equity .............................................71.2                            \uf02d                103.5        174.7\n Share capital(4) ..................................................................1.3               48.7                  3.8         53.8\n Legal reserve(5) .................................................................0.3                   \uf02d                 99.7        100.0\n Other reserves(6) ................................................................69.6             (48.7)                    \uf02d         20.9\n                                                                                     426.6\nTotal(7) ................................................................................                \uf02d                103.5        530.1\n", "page_number": 86, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26390076988879385, "lower_right_x": 0.879081015719468, "lower_right_y": 0.5243798118049615, "height": 0.26047904191616766, "width": 0.7587666263603385}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-5", "text": "(1) The adjustment reflects the expected gross proceeds from this Offering of \u20ac107.5 million (based on the issuance of\n    3,840,000 New Shares at a subscription price of \u20ac28.00 (i.e., assuming full placement of all New Shares at the\n    mid-point of the Price Range) and costs of the Offering relating to the placement of such New Shares of approximately\n    \u20ac4.0 million (assuming payment of the discretionary fee relating to the placement of the New Shares in full)). If the\n    consummation of the Contribution Capital Increase (see \u201c18.1.3 Contribution of all Shares in Dermapharm AG\u201d) had\n    occurred on October 31, 2017, this would not have affected Dermapharm AG\u2019s assets, liabilities and total shareholder\u2019s\n    equity.\n(2) Referred to as total current liabilities in the unaudited condensed consolidated interim financial statements of\n    Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(3) Referred to as total non-current liabilities in the unaudited condensed consolidated interim financial statements of\n    Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(4) Referred to as issued capital in the unaudited condensed consolidated interim financial statements of Dermapharm AG\n    as of and for the nine-month period ended September 30, 2017.\n(5) Referred to as capital reserves in the unaudited condensed consolidated interim financial statements of\n    Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(6) Referred to as retained earnings and other reserves in the unaudited condensed consolidated interim financial statements\n    of Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(7) Equals the sum of total equity, total current liabilities and total non-current liabilities, less non-controlling interests, in\n    each case as referred to in the unaudited condensed consolidated interim financial statements of Dermapharm AG as of\n    and for the nine-month period ended September 30, 2017.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5380667236954663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7869974337040205, "height": 0.24893071000855427, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-86-6", "text": "", "page_number": 86, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-0", "text": "7.2   Indebtedness\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.09837467921300257, "height": 0.013259195893926434, "width": 0.154776299879081}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-1", "text": "                                                                                               Effects of the\n                                                                          As of               contribution of\n                                                                       October 31,             Dermapharm              Effects of\n                                                                          2017                      AG               the Offering(1)   Total\n                                                                                                           (unaudited)\n                                                                                                          (in \u20ac million)\nA.   Cash(2) ......................................................................... 13.0                   \uf02d               103.5        116.5\nB.   Cash equivalents ......................................................... \uf02d                             \uf02d                   \uf02d            \uf02d\nC.   Trading securities ....................................................... \uf02d                             \uf02d                   \uf02d            \uf02d\nD.   Liquidity (A)+(B)+(C) .............................................. 13.0                                \uf02d               103.5        116.5\nE.   Current financial receivables(3) ...............................100.0                                    \uf02d                   \uf02d        100.0\nF.   Current bank debt(4) .................................................... 13.3                           \uf02d                   \uf02d         13.3\nG.   Current portion of non-current debt(5)......................... 21.6                                     \uf02d                   \uf02d         21.6\nH.   Other current financial debt(6) ..................................... 25.7                               \uf02d                   \uf02d         25.7\nI.   Current Financial Debt (F)+(G)+(H) ...................... 60.6                                           \uf02d                   \uf02d         60.6\nJ.   Net current financial indebtedness\n     (I)-(E)-(D) ..................................................................(52.4)                     \uf02d             (103.5)      (155.9)\nK.   Non-current bank loans(7) ...........................................235.3                               \uf02d                   \uf02d        235.3\nL.   Bonds issued ............................................................... \uf02d                           \uf02d                   \uf02d            \uf02d\nM.   Other non-current loans(8) ........................................... 5.2                               \uf02d                   \uf02d          5.2\nN.   Non-current financial liabilities\n     (K)+(L)+(M) ..............................................................240.5                          \uf02d                   \uf02d        240.5\nO.   Net financial indebtedness (J)+(N) ..........................188.1                                       \uf02d             (103.5)         84.6\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4251497005988024, "height": 0.3126603934987169, "width": 0.7642079806529625}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-2", "text": "(1) The adjustment reflects the expected gross proceeds from this Offering of \u20ac107.5 million (based on the issuance of\n    3,840,000 New Shares at a subscription price of \u20ac28.00 (i.e., assuming full placement of all New Shares at the\n    mid-point of the Price Range) and costs of the Offering relating to the placement of such New Shares of approximately\n    \u20ac4.0 million (assuming payment of the discretionary fee relating to the placement of the New Shares in full)). If the\n    consummation of the Contribution Capital Increase (see \u201c18.1.3 Contribution of all Shares in Dermapharm AG\u201d) had\n    occurred on October 31, 2017, this would not have affected Dermapharm AG\u2019s assets, liabilities and total shareholder\u2019s\n    equity.\n(2) Referred to as cash and cash equivalents in the unaudited condensed consolidated interim financial statements of\n    Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(3) Referred to as trade receivables and other current financial assets in the unaudited condensed consolidated interim\n    financial statements of Dermapharm AG as of and for the nine-month period ended September 30, 2017\n(4) Comprises bank loans in an amount of \u20ac13.3 million. Referred to as current financial liabilities in the unaudited\n    condensed consolidated interim financial statements of Dermapharm AG as of and for the nine-month period ended\n    September 30, 2017.\n(5) Comprises bank loans in an amount of \u20ac12.7 million, participation rights in an amount of \u20ac7.0 million and promissory\n    note loans in an amount of \u20ac1.8 million. Referred to as current financial liabilities in the unaudited condensed\n    consolidated interim financial statements of Dermapharm AG as of and for the nine-month period ended September 30,\n    2017.\n(6) Referred to as other current financial liabilities and trade accounts payable in the unaudited condensed consolidated\n    interim financial statements of Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(7) Referred to as non-current financial liabilities in the unaudited condensed consolidated interim financial statements of\n    Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n(8) Referred to as other non-current financial liabilities in the unaudited condensed consolidated interim financial\n    statements of Dermapharm AG as of and for the nine-month period ended September 30, 2017.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4414029084687767, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7378100940975193, "height": 0.2964071856287426, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-3", "text": "         As of September 30, 2017, Dermapharm recorded purchase commitments in connection with\ninventories in an amount of \u20ac40.6 million. Other than that, there were no contingent or indirect liabilities of\nDermapharm as of that date.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7921300256629598, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-4", "text": "7.3\n", "page_number": 87, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8071000855431993, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.8177929854576561, "height": 0.010692899914456766, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-5", "text": "Statement on Working Capital\n", "page_number": 87, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.8071000855431993, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.8212147134302823, "height": 0.014114627887082953, "width": 0.22309552599758162}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-6", "text": "        The Company is of the opinion that Dermapharm is in a position to meet the payment obligations that\nbecome due within the next twelve months from the date of this Prospectus.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8344739093242087, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8622754491017964, "height": 0.027801539777587703, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"working_capital_statement": ["The Company is of the opinion that Dermapharm is in a position to meet the payment obligations thatbecome due within the next twelve months from the date of this Prospectus."]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-87-7", "text": "", "page_number": 87, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-88-0", "text": "DILUTION\n", "page_number": 88, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5713422007255139, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.08827085852478839}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-88-1", "text": "8.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.42503022974607013, "top_left_y": 0.08597091531223268, "lower_right_x": 0.43893591293833134, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.013905683192261209}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-88-2", "text": "         According to Dermapharm AG\u2019s unaudited condensed consolidated interim financial statements as of\nand for the nine-month period ended September 30, 2017, Dermapharm\u2019s net book value (i.e., total assets less\ntotal non-current liabilities and total current liabilities) amounted to \u20ac69.5 million as of September 30, 2017, and\nwould amount to \u20ac1.39 per share of the Company based on 50,000,000 outstanding shares of the Company\nimmediately prior to the Offering. Dermapharm\u2019s net book value is shown as total equity in Dermapharm AG\u2019s\nunaudited condensed consolidated interim financial statements as of and for the nine-month period ended\nSeptember 30, 2017.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-88-3", "text": "          The dilutive effect of the Offering is illustrated in the table below, demonstrating the amount by which\nthe Offer Price exceeds the net book value per share after completion of the Offering and assuming the Offering\nhad been completed on September 30, 2017. In this respect, the net book value as of September 30, 2017 is\nadjusted for the effects of the successful completion of the Offering, assuming (i) the execution of the IPO\nCapital Increase for the maximum number of New Shares and (ii) an increase in the net book value by\n\u20ac103.5 million (assuming successful placement of all New Shares at the mid-point of the Price Range and not\ntaking into account any tax effects). The adjusted net book value is expressed as a per share figure, assuming\n53,840,000 shares of the Company outstanding upon completion of the Offering (this per share figure being\nreferred to as the \u201cPost-IPO Equity\u201d).\n", "page_number": 88, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33875106928999144, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-88-4", "text": "                                                                                                                                                 As of\n                                                                                                                                         September 30, 2017\n                                                                                                                                             (unaudited)\n                                                                                                                                             (in \u20ac, unless\n                                                                                                                                         otherwise specified)\n Net book value per share as of September 30, 2017(1) .............................................................                                    1.39\n Gross proceeds from the Offering attributable to the Company (in \u20ac million)(2) .....................                                                 107.5\n Estimated total costs of the Offering to be borne by the Company (in \u20ac million)(2)(3) .............                                                    4.0\n Total net proceeds from the Offering attributable to the Company (in \u20ac million) (2) ................                                                 103.5\n Post-IPO Equity per share(4) ....................................................................................................                     3.21\n Amount by which the offer price exceeds the Post-IPO Equity per share (immediate\n   dilution of new shareholders of the Company) ....................................................................                                  24.79\n Percentage by which the offer price exceeds the Post-IPO Equity per share (in %)...............                                                      771.5\n Amount by which the Post-IPO Equity per share exceeds the net book value per share\n   immediately prior to the Offering (immediate accretion to the existing shareholders of\n   the Company) ......................................................................................................................                  1.82\n Percentage by which the Post-IPO Equity per share exceeds the net book value per share\n   immediately prior to the Offering (in %) .............................................................................                             131.2\n\n(1) Based on 50,000,000 outstanding shares of the Company immediately prior to the Offering and a net book value of\n    Dermapharm in an amount of \u20ac69.5 million as of September 30, 2017. Shown as total equity in Dermapharm AG\u2019s\n    unaudited condensed consolidated interim financial statements as of and for the nine-month period ended September 30,\n    2017.\n(2) Assuming successful placement of 3,840,000 New Shares at the mid-point of the Price Range.\n(3) Including underwriting and placement commissions payable to the Sole Bookrunner as well as the fixed fee payable to\n    the Co-Lead Manager and assuming payment of the discretionary fee in full.\n(4) Based on 53,840,000 shares of the Company outstanding following completion of the Offering.\n\n            Each of the New Shares will have the same voting rights as the Company\u2019s existing shares.\n         Prior to the Offering, the Selling Shareholder held 100.0% of the voting rights in the Company. Upon\ncompletion of the Offering (assuming full exercise of the Greenshoe Option and issuance of all New Shares),\nthe aggregate voting rights held by the Selling Shareholder would amount to 75.0%.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34644995722840033, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7694610778443114, "height": 0.42301112061591106, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-88-5", "text": "", "page_number": 88, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-0", "text": "9.   SELECTED CONSOLIDATED FINANCIAL INFORMATION\n", "page_number": 89, "bounding_box": {"top_left_x": 0.2370012091898428, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.5223700120918985}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-1", "text": "          The financial information contained in the following tables is taken or derived from the audited\nconsolidated financial statements of Dermapharm AG, the former parent entity of Dermapharm, as of and for\nthe fiscal years ended December 31, 2016, 2015 and 2014, and the unaudited condensed consolidated interim\nfinancial statements of Dermapharm AG as of and for the nine-month period ended September 30, 2017 as well\nas the Company\u2019s audited individual financial statements as of September 30, 2017 and for the period from\nJuly 12, 2017 to September 30, 2017. Additional financial information relating to certain operational\ninformation is taken or derived from Dermapharm\u2019s accounting records or internal reporting system. The\naudited consolidated financial statements and the audited individual financial statements were prepared in\naccordance with IFRS. The unaudited condensed consolidated interim financial statements were prepared in\naccordance with IAS 34.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24850299401197604, "height": 0.13601368691189047, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-2", "text": "         Warth & Klein Grant Thornton AG Wirtschaftspr\u00fcfungsgesellschaft, Johannstra\u00dfe 39,\n40476 Dusseldorf, Germany (\u201cWarth & Klein Grant Thornton\u201d), has audited and issued an unqualified audit\nopinion with respect to Dermapharm AG\u2019s consolidated financial statements as of and for the fiscal years ended\nDecember 31, 2016, 2015 and 2014 as well as the Company\u2019s audited individual financial statements as of\nSeptember 30, 2017 and for the period from July 12, 2017 to September 30, 2017. The aforementioned audited\nfinancial statements and the independent audit opinions thereon, and Dermapharm AG\u2019s unaudited condensed\nconsolidated interim financial statements as of and for the nine-month period ended September 30, 2017 are\nincluded in this Prospectus.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.3661248930710009, "height": 0.10992301112061592, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-3", "text": "         Where financial information in the following tables is labelled \u201caudited\u201d, this means that it has been\ntaken from the audited consolidated financial statements mentioned above. The label \u201cunaudited\u201d is used in the\nfollowing tables to indicate financial information that has not been taken from the audited consolidated\nfinancial statements mentioned above, but was taken either from the unaudited condensed interim consolidated\nfinancial statements mentioned above, or Dermapharm\u2019s internal reporting system, or has been calculated\nbased on figures from the aforementioned sources.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37254063301967494, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4550898203592814, "height": 0.08254918733960648, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-4", "text": "         All of the financial information presented in the text and tables below is shown in millions of Euro (in\n\u20ac million), except as otherwise stated. Certain financial information (including percentages) in the following\ntables has been rounded according to established commercial standards. As a result, the aggregate amounts\n(sum totals or sub totals or differences or if numbers are put in relation) in the following tables may not\ncorrespond in all cases to the aggregate amounts of the underlying (unrounded) figures appearing elsewhere in\nthis Prospectus. Furthermore, these rounded figures may not add up exactly to the totals contained in the\nrelevant tables. Financial information presented in parentheses denotes the negative of such number presented.\nIn respect of financial information set out in this Prospectus, a dash (\u201c\u2013\u201d) signifies that the relevant figure is\nnot available, while a zero (\u201c0.0\u201d) signifies that the relevant figure is available but has been rounded to zero.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5851154833190761, "height": 0.12018819503849443, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-5", "text": "         The following selected consolidated financial information should be read together with the section\n\u201c10. Management\u2019s Discussion and Analysis of Net Assets, Financial Condition and Results of Operations\u201d, the\nconsolidated financial statements, including the related notes contained in this Prospectus, and additional\nfinancial information contained elsewhere in this Prospectus.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6484174508126604, "height": 0.05346449957228405, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-89-6", "text": "", "page_number": 89, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01874244256348251}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-0", "text": "Consolidated Statement of Comprehensive Income\n", "page_number": 90, "bounding_box": {"top_left_x": 0.18137847642079807, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.3651753325272068}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-1", "text": "9.1\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08597091531223268, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-2", "text": "                                                                                     For the fiscal year             For the nine-month period\n                                                                                    ended December 31,                 ended September 30,\n                                                                         2014               2015           2016        2016              2017\n                                                                                         (audited)                           (unaudited)\n                                                                                       (in \u20ac million)                       (in \u20ac million)\n Revenue ..................................................................................\n                                                                           391.3                 384.8      444.5        319.2          349.7\n Increase/decrease in finished goods and\n   work-in-process ...................................................................\n                                                                               8.3                  2.9        1.0          4.1            0.4\n Own work capitalized ..............................................................\n                                                                               8.5                  8.0        8.3          5.4            8.0\n Other operating income ...........................................................\n                                                                               6.2                  9.9        9.9          5.2            4.1\n Cost of material .......................................................................\n                                                                         (237.1)                (215.9)    (252.8)      (181.5)        (196.0)\n Personnel expenses ..................................................................\n                                                                           (57.7)                (55.7)     (58.7)       (42.0)         (46.5)\n Depreciation and amortization .................................................\n                                                                           (28.3)                (22.9)     (14.4)       (10.3)         (11.2)\n                                                                           (48.0)\n Other operating expenses .........................................................              (50.3)     (51.0)       (35.1)         (38.1)\n Operating income ..................................................................\n                                                                              43.3                 60.8       86.8         65.1           70.4\n Result from investments measured at\n   equity ...................................................................................\n                                                                               0.9                  1.0        1.5          1.1            1.2\n Financial income......................................................................\n                                                                               3.3                  9.4        7.3          4.1            3.3\n                                                                           (12.0)\n Financial expenses ...................................................................          (15.8)     (12.7)        (8.4)          (7.8)\n Earnings before taxes ............................................................\n                                                                              35.5                 55.3       82.9         61.8           67.2\n                                                                             (2.2)\n Income taxes ............................................................................        (2.9)      (5.9)        (6.0)          (4.3)\n                                                                              33.2\nProfit/loss for the period .........................................................               52.4       77.0         55.9           62.9\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41317365269461076, "height": 0.3006843455945252, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-3", "text": "Consolidated Statement of Financial Position\n", "page_number": 90, "bounding_box": {"top_left_x": 0.18137847642079807, "top_left_y": 0.44097519247219846, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.45124037639007697, "height": 0.010265183917878506, "width": 0.3264812575574365}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-4", "text": "9.2\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44097519247219846, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.45124037639007697, "height": 0.010265183917878506, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-5", "text": "                                                                                                   As of                            As of\n                                                                                               December 31,                    September 30,\n                                                                           2014                     2015        2016                 2017\n                                                                                                 (audited)                       (unaudited)\n                                                                                               (in \u20ac million)                   (in \u20ac million)\nAssets\n Intangible assets .......................................................................\n                                                                                  71.7                  68.0        70.0                129.7\n Goodwill ..................................................................................\n                                                                                  21.6                  16.4        17.0                 17.0\n Property, plant and equipment .................................................  56.5                  53.4        53.4                 52.9\n Investments measured at equity ...............................................     1.6                  2.7         3.2                  4.4\n Investments ..............................................................................\n                                                                                    0.5                  0.2         0.3                  0.2\n Other non-current financial assets ...........................................     9.2                 13.8        10.6                 22.4\n                                                                                    1.0\n Deferred tax assets ...................................................................                 0.0         0.2                  1.7\n Total non-current assets ........................................................\n                                                                                162.1                  154.6       154.7                228.3\n Inventories ...............................................................................\n                                                                                  71.5                  77.0        84.8                 81.9\n Trade accounts receivable........................................................22.8                  17.4        26.3                 34.7\n Other current financial assets ...................................................\n                                                                                  58.8                  42.5        40.0                 68.7\n Other current assets .................................................................\n                                                                                    3.0                  1.4         1.7                  2.0\n Income tax receivables \u2013 current .............................................     0.7                  1.0         0.4                  0.4\n Cash and cash equivalents .......................................................11.6                   2.8         3.8                 12.6\n                                                                                168.5\n Total current assets ...............................................................                  142.1       157.0                200.3\n                                                                                330.6\nTotal assets ...............................................................................           296.7       311.7                428.6\n\nEquity and liabilities\n Issued capital ...........................................................................\n                                                                                   1.3                    1.3            1.3               1.3\n Capital reserves .......................................................................\n                                                                                   0.3                    0.3            0.3               0.3\n Retained earnings ....................................................................\n                                                                                 28.6                    39.5           56.3              70.0\n Other reserves ..........................................................................\n                                                                                (1.9)                     0.1          (1.0)             (2.1)\n                                                                                   5.7\n Non-controlling interests .........................................................                      3.3            3.9                 \uf02d\n Total equity ............................................................................\n                                                                                 34.0                    44.4           60.8              69.5\n", "page_number": 90, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46663815226689476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8785286569717707, "height": 0.411890504704876, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-90-6", "text": "", "page_number": 90, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01874244256348251}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-0", "text": "                                                                                                As of                        As of\n                                                                                            December 31,                September 30,\n                                                                        2014                     2015        2016             2017\n                                                                                              (audited)                   (unaudited)\n                                                                                            (in \u20ac million)               (in \u20ac million)\n Defined benefit obligations and other\n   accrued employee benefits ...................................................\n                                                                               12.4                  12.1        13.3             13.3\n Other provisions ......................................................................\n                                                                                 0.1                    \uf02d           \uf02d                \uf02d\n Financial liabilities ..................................................................\n                                                                             161.5                  151.1        96.9            235.4\n Other non-current financial liabilities ......................................  9.9                 14.1        10.5              8.1\n Other non-current liabilities .....................................................\n                                                                               15.6                  13.3        11.5             10.4\n                                                                                   \uf02d\n Deferred tax liabilities .............................................................               0.2         3.4              5.8\n Total non-current liabilities ..................................................\n                                                                             199.6                  190.7       135.5            272.9\n Other provisions ......................................................................\n                                                                                 6.1                  6.4         7.0              6.0\n Financial liabilities ..................................................................\n                                                                               20.4                  24.9        65.9             43.4\n Trade accounts payable ...........................................................\n                                                                               27.4                  18.1        24.5             19.3\n Other current financial liabilities .............................................\n                                                                               30.6                   2.4         4.3              2.1\n Other current liabilities ............................................................\n                                                                               11.4                   8.2        11.0             11.5\n                                                                                 1.0\n Income tax liabilities ...............................................................               1.5         2.8              3.9\n                                                                               97.0\n Total current liabilities ..........................................................                61.6       115.4             86.2\n                                                                             330.6\nTotal equity and liabilities.......................................................                 296.7       311.7            428.6\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3729683490162532, "height": 0.28785286569717705, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-1", "text": "Consolidated Statement of Cash Flows\n", "page_number": 91, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.3999144568006843, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.41060735671514115, "height": 0.010692899914456822, "width": 0.279322853688029}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-2", "text": "9.3\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3999144568006843, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.41060735671514115, "height": 0.010692899914456822, "width": 0.024183796856106415}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-3", "text": "                                                                                                                      As of and for the\n                                                                        As of and for the fiscal year             nine-month period ended\n                                                                           ended December 31,                         September 30,(1)\n                                                                   2014             2015             2016           2016             2017\n                                                                                 (audited)                               (unaudited)\n                                                                               (in \u20ac million)                           (in \u20ac million)\nNet cash flows from operating activities .................................54.3               40.4       76.8           47.6           62.6\nNet cash flows used in investing activities ..............................\n                                                                        (21.9)              (0.9)     (12.3)         (11.7)         (84.9)\nNet cash from/used in financing activities ...............................  3.0            (55.6)     (55.9)         (47.9)           14.1\nNet increase/decrease in cash, cash\n  equivalents and bank overdrafts ......................................  35.3             (16.2)           8.6      (12.0)          (8.2)\nCash, cash equivalents and bank\n  overdrafts(2) ..........................................................................\n                                                                            6.5             (9.6)      (1.1)         (21.6)          (9.3)\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5953806672369547, "height": 0.17151411462788713, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-4", "text": "(1) Due to the termination of the Profit Transfer Agreement with effect from the end of December 31, 2017,\n    Dermapharm AG has changed the composition of its consolidated statement of cash flows, which is already reflected in\n    the financial information in the consolidated statement of cash flows shown in Dermapharm AG\u2019s unaudited condensed\n    consolidated interim financial statements for the nine-month period ended September 30, 2017. As a result, certain\n    comparable financial information with respect to the fiscal year ended December 31, 2016 shown in the consolidated\n    statement of cash flows in the consolidated financial statements for the fiscal year ended December 31, 2017 will differ\n    from the financial information shown in the consolidated statement of cash flows in Dermapharm AG\u2019s consolidated\n    financial statements for the fiscal years ended December 31, 2016, 2015 and 2014.\n(2) As at the end of the relevant period.\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.6065012831479898, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718562874251497, "height": 0.11206159110350722, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-5", "text": "Selected Financial Information of the Company\n", "page_number": 91, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.7318220701454234, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.7459366980325064, "height": 0.014114627887082953, "width": 0.34340991535671095}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-6", "text": "9.4\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7331052181351583, "lower_right_x": 0.14268440145102781, "lower_right_y": 0.7450812660393499, "height": 0.0119760479041916, "width": 0.021765417170495766}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-7", "text": "                                                                                          As of and for the period from July 12 to September 30\n                                                                                                                    2017\n                                                                                                             (audited and in \u20ac)\nTotal assets ...............................................................................                                          119,973.93\nTotal equity ..............................................................................                                           119,973.93\nNet loss.....................................................................................                                            (26.07)\nNet change in cash and cash equivalents .................................                                                              89,223.93\n", "page_number": 91, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7591958939264328, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.8520102651839179, "height": 0.09281437125748504, "width": 0.7496977025392986}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-91-8", "text": "", "page_number": 91, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01874244256348251}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-0", "text": "9.5   Other Operating Data and Financial Data\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.3633615477629988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-1", "text": "         The Management Board uses EBITDA as a key performance indicator in order to assess the success of\nDermapharm\u2019s business. In addition, Dermapharm believes that the working capital, leverage ratio and equity\nwill be helpful for investors when assessing the performance and financial position of Dermapharm.\n       The following table provides additional operating and financial information with respect to\nDermapharm for the periods and dates indicated:\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881950384944397, "height": 0.07570573139435414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-2", "text": "                                                                            As of and for the fiscal year          As of and for the nine-month\n                                                                               ended December 31,                  period ended September 30,\n                                                                       2014             2015              2016         2016             2017\n                                                                                   (audited and                             (unaudited)\n                                                                                    in \u20ac million,                          (in \u20ac million,\n                                                                            unless otherwise specified)             unless otherwise specified)\nRevenue ...................................................................................\n                                                                         391.3                384.8        444.5         319.2          349.7\nRevenue growth (unaudited and in %)(1) .................................        \uf02d              (1.7)        15.5             \uf02d            9.6\nEBIT (unaudited) .....................................................................\n                                                                           44.2                 61.7        88.3          66.1           71.7\nEBIT margin (unaudited and in %)(2) ...................................... 11.3                 16.0        19.9          20.7           20.5\nEBITDA (unaudited) ...............................................................\n                                                                           72.5                 84.6       102.7          76.4           82.9\nEBITDA margin (unaudited and in %)(3) .................................    18.5                 22.0        23.1          23.9           23.7\nWorking capital (unaudited)(4) .................................................\n                                                                           58.5                 69.5        77.3             \uf02d           87.8\nLeverage ratio (unaudited and in %)(4) ....................................\n                                                                         744.9                461.6        305.4             \uf02d          397.7\nEquity ratio (unaudited and in %)(4) ........................................8.6                13.9        18.3             \uf02d           16.2\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.19461077844311378, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39264328485885375, "height": 0.19803250641573997, "width": 0.7551390568319227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-3", "text": "(1)   Reflecting the percentage change between the relevant periods.\n(2)   Defined as the quotient of EBIT divided by revenues.\n(3)   Defined as the quotient of EBITDA divided by revenues.\n(4)   As at the end of the relevant period.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.40461933276304535, "lower_right_x": 0.5314389359129383, "lower_right_y": 0.4550898203592814, "height": 0.05047048759623607, "width": 0.41293833131801694}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-4", "text": "9.5.1     Performance Indicators and Working Capital\n\n9.5.1.1      EBITDA\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46834901625320785, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.5089820359281437, "height": 0.04063301967493588, "width": 0.3778718258766627}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-5", "text": "          Dermapharm defines earnings before interest, taxes depreciation and amortization (\u201cEBITDA\u201d) as\n(i) earnings before taxes, minus (ii) financial income, plus (iii) financial expenses, and plus (iv) depreciation and\namortization. EBITDA is not a performance indicator recognized under IFRS. The EBITDA reported by\nDermapharm is not necessarily comparable to performance figures published by other companies as EBITDA or\nthe like.\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.06544054747647565, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-6", "text": "The following table presents Dermapharm\u2019s EBITDA for the periods indicated:\n", "page_number": 92, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.6017964071856288, "lower_right_x": 0.7158403869407497, "lower_right_y": 0.6150556030795552, "height": 0.013259195893926434, "width": 0.5368802902055623}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-7", "text": "                                                                             For the fiscal year               For the nine-month period\n                                                                            ended December 31,                   ended September 30,\n                                                                    2014             2015            2016        2016              2017\n                                                                    (audited, unless otherwise specified)              (unaudited)\n                                                                                (in \u20ac million)                        (in \u20ac million)\n Earnings before taxes ............................................................\n                                                                        35.5               55.3         82.9         61.8           67.2\n Financial income......................................................................\n                                                                       (3.3)              (9.4)        (7.3)        (4.1)          (3.3)\n Financial expenses ...................................................................\n                                                                        12.0               15.8         12.7          8.4            7.8\n EBIT (unaudited) ...................................................................\n                                                                        44.2               61.7         88.3         66.1           71.7\n Depreciation and amortization .................................................\n                                                                        28.3               22.9         14.4         10.3           11.2\n                                                                        72.5\nEBITDA (unaudited) ...............................................................         84.6       102.7          76.4           82.9\n", "page_number": 92, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6206159110350727, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7681779298545766, "height": 0.14756201881950382, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-92-8", "text": "", "page_number": 92, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-0", "text": "9.5.1.2   Working Capital\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.19830713422007254}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-1", "text": "          Dermapharm defines working capital as (i) inventories, plus (ii) trade accounts receivable, plus\n(iii) other current assets, minus (iv) trade accounts payable, and minus (v) other current liabilities.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-2", "text": "The following table presents Dermapharm\u2019s working capital for the dates indicated:\n", "page_number": 93, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.1467065868263473, "lower_right_x": 0.7448609431680774, "lower_right_y": 0.16082121471343028, "height": 0.014114627887082981, "width": 0.5665054413542926}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-3", "text": "                                                                                               As of                                 As of\n                                                                                          December 31,                          September 30,\n                                                                           2014                 2015                2016              2017\n                                                                               (audited, unless otherwise specified)              (unaudited)\n                                                                                           (in \u20ac million)                        (in \u20ac million)\n Inventories ...............................................................................\n                                                                                  71.5              77.0                 84.8             81.9\n Trade accounts receivable........................................................22.8              17.4                 26.3             34.7\n Other current assets .................................................................\n                                                                                    3.0              1.4                  1.7              2.0\n Trade accounts payable ...........................................................\n                                                                               (27.4)             (18.1)               (24.5)           (19.3)\n Other current liabilities ............................................................\n                                                                               (11.4)              (8.2)               (11.0)           (11.5)\nWorking Capital (unaudited) .................................................     58.5              69.5                 77.3             87.8\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.16723695466210436, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31479897348160824, "height": 0.14756201881950387, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-4", "text": "9.5.2     Financial Indicators\n\n9.5.2.1      Leverage Ratio\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.369546621043627, "height": 0.04148845166809234, "width": 0.20314389359129384}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-5", "text": "         The following table presents Dermapharm\u2019s leverage ratio (i.e., the ratio of Dermapharm\u2019s net debt\ndivided by its equity attributable to owners of the company) for the dates indicated:\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38280581693755344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41060735671514115, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-6", "text": "                                                                                                  As of                                As of\n                                                                                             December 31,                         September 30,\n                                                                           2014                    2015              2016               2017\n                                                                                              (audited and                          (unaudited)\n                                                                                               in \u20ac million                        (in \u20ac million,\n                                                                                       unless otherwise specified)               unless otherwise\n                                                                                                                                     specified)\n Non-current financial liabilities ...............................................\n                                                                                161.5                 151.1               96.9            235.4\n Other non-current financial liabilities ......................................     9.9                 14.1              10.5               8.1\n Current financial liabilities ......................................................\n                                                                                  20.4                  24.9              65.9              43.4\n Other current financial liabilities .............................................30.6                   2.4               4.3               2.1\n Cash and cash equivalents .......................................................\n                                                                               (11.6)                  (2.8)             (3.8)            (12.6)\n Net debt...................................................................................\n                                                                                210.8                 189.7             173.8             276.4\n Total equity ..............................................................................\n                                                                                  34.0                  44.4              60.8              69.5\n                                                                                 (5.7)\n Non-controlling interests .........................................................                   (3.3)             (3.9)                 \uf02d\n Equity attributable to owners of the\n                                                                                  28.3\n   company..............................................................................               41.1              56.9              69.5\nLeverage ratio (unaudited and in %) .......................................     744.9                 461.6             305.4             397.7\n", "page_number": 93, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6569717707442259, "height": 0.23994867408041065, "width": 0.7642079806529626}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-7", "text": "9.5.2.2   Equity Ratio\n", "page_number": 93, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6839178785286569, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.6967493584260052, "height": 0.01283147989734823, "width": 0.16989117291414754}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-8", "text": "          The following table presents Dermapharm\u2019s equity ratio (i.e., the ratio of Dermapharm\u2019s equity\nattributable to owners of the company divided by its total assets) for the dates indicated:\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7386655260906758, "height": 0.027373823781009388, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-9", "text": "                                                                                                  As of                                   As of\n                                                                                             December 31,                            September 30,\n                                                                           2014                    2015              2016                  2017\n                                                                                              (audited and                             (unaudited)\n                                                                                               in \u20ac million                           (in \u20ac million,\n                                                                                       unless otherwise specified)                  unless otherwise\n                                                                                                                                        specified)\n Total equity ..............................................................................\n                                                                                  34.0                  44.4                 60.8              69.5\n                                                                                 (5.7)\n Non-controlling interests .........................................................                   (3.3)                (3.9)                 \uf02d\n Equity attributable to owners of the\n   company..............................................................................\n                                                                                  28.3                 41.1              56.9                 69.5\n Total assets .............................................................................\n                                                                                330.6                 296.7             311.7                428.6\nEquity ratio (unaudited and in %)............................................       8.6                13.9              18.3                 16.2\n", "page_number": 93, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.742087254063302, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9153122326775022, "height": 0.17322497861420016, "width": 0.7642079806529626}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-93-10", "text": "", "page_number": 93, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-0", "text": "10.   MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF NET ASSETS, FINANCIAL\n                CONDITION AND RESULTS OF OPERATIONS\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1596130592503023, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8409915356711004, "lower_right_y": 0.111633875106929, "height": 0.02651839178785287, "width": 0.6813784764207981}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-1", "text": "          The financial information contained in the following tables and discussion is taken or derived from the\naudited consolidated financial statements of Dermapharm AG, the former parent entity of Dermapharm, as of\nand for the fiscal years ended December 31, 2016, 2015 and 2014, and the unaudited condensed consolidated\ninterim financial statements of Dermapharm AG as of and for the nine-month period ended September 30, 2017.\nAdditional financial information relating to certain operational information is taken or derived from\nDermapharm\u2019s accounting records or internal reporting system. The audited consolidated financial statements\nwere prepared in accordance with IFRS. The unaudited condensed consolidated interim financial statements\nwere prepared in accordance with IAS 34. Additional financial information included in this discussion and\nanalysis is taken or derived from the Company\u2019s audited individual financial statements as of September 30,\n2017 and for the period from July 12, 2017 to September 30, 2017, which were prepared in accordance with\nIFRS.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12617621899059026, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.27587681779298545, "height": 0.1497005988023952, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-2", "text": "          Warth & Klein Grant Thornton has audited and issued unqualified audit opinions with respect to\nDermapharm AG\u2019s consolidated financial statements as of and for the fiscal years ended December 31, 2016,\n2015 and 2014 as well as the Company\u2019s audited individual financial statements as of September 30, 2017 and\nfor the period from July 12, 2017 to September 30, 2017. The aforementioned audited financial statements and\nas well as the independent audit opinions thereon, and Dermapharm AG\u2019s unaudited condensed consolidated\ninterim financial statements as of and for the nine-month period ended September 30, 2017 are included in this\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3661248930710009, "height": 0.08254918733960653, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-3", "text": "Prospectus.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.3798118049615056, "height": 0.010692899914456822, "width": 0.07799274486094315}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-4", "text": "          Where financial information in the following tables is labelled \u201caudited\u201d, this means that it has been\ntaken from the audited financial statements mentioned above. The label \u201cunaudited\u201d is used in the following\ntables to indicate financial information that has not been taken from the audited financial statements mentioned\nabove, but was taken either from the unaudited condensed interim consolidated financial statements mentioned\nabove, or Dermapharm\u2019s internal reporting system, or has been calculated based on figures from the\naforementioned sources.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38622754491017963, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46877673224978617, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-5", "text": "         All of the financial information presented in the text and tables below is shown in millions of Euro (in\n\u20ac million), except as otherwise stated. Certain financial information (including percentages) in the following\ntables has been rounded according to established commercial standards. As a result, the aggregate amounts\n(sum totals or sub totals or differences or if numbers are put in relation) in the following tables may not\ncorrespond in all cases to the aggregate amounts of the underlying (unrounded) figures appearing elsewhere in\nthis Prospectus. Furthermore, these rounded figures may not add up exactly to the totals contained in the\nrelevant tables. Financial information presented in parentheses denotes the negative of such number presented.\nIn respect of financial information set out in this Prospectus, a dash (\u201c\u2013\u201d) signifies that the relevant figure is\nnot available, while a zero (\u201c0.0\u201d) signifies that the relevant figure is available but has been rounded to zero.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4751924721984602, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5988023952095808, "height": 0.12360992301112056, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-6", "text": "         The following discussion and analysis should be read together with Dermapharm AG\u2019s consolidated\nfinancial statements, including the related notes, the Company\u2019s individual financial statements, and additional\nfinancial information contained elsewhere in this Prospectus, in particular in the section \u201c9. Selected\nConsolidated Financial Information\u201d.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6082121471343028, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.660393498716852, "height": 0.05218135158254922, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-94-7", "text": "", "page_number": 94, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-0", "text": "10.1   Overview\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.250906892382104, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.12998790810157196}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-1", "text": "         Dermapharm is a leader in branded pharmaceuticals for selected markets in Germany with an\nexpanding international footprint. It applies formulation and development expertise to the development,\nmanufacture and marketing of a broad assortment of branded pharmaceuticals that are no longer patent\nprotected, holding approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 200\nactive pharmaceutical ingredients (\u201cAPIs\u201d). Dermapharm also offers a growing portfolio of other healthcare\nproducts such as cosmetics, food supplements, dietary products and medical devices. In addition, Dermapharm\nleverages its direct marketing expertise by importing pharmaceuticals from other member states of the EEA\n(\u201cEEA Member States\u201d) for resale in the German market in order to profit from pricing differences between\nthese markets.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.23267750213858, "height": 0.12018819503849444, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"description_of_the_business": ["Dermapharm is a leader in branded pharmaceuticals for selected markets in Germany with anexpanding international footprint. It applies formulation and development expertise to the development,manufacture and marketing of a broad assortment of branded pharmaceuticals that are no longer patentprotected, holding approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 200active pharmaceutical ingredients (\u201cAPIs\u201d). Dermapharm also offers a growing portfolio of other healthcareproducts such as cosmetics, food supplements, dietary products and medical devices. In addition, Dermapharmleverages its direct marketing expertise by importing pharmaceuticals from other member states of the EEA(\u201cEEA Member States\u201d) for resale in the German market in order to profit from pricing differences betweenthese markets."], "industry": ["pharmaceuticals"]}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-2", "text": "           Dermapharm operates primarily in Germany, Europe\u2019s leading economy and, with aggregate sales of\n\u20ac36.7 billion in the fiscal year ended December 31, 2016 (based on ex-factory prices (Herstellerabgabepreise)),\nalso its largest pharmaceuticals market (source: IQVIA). Its German sales accounted for approximately 92.6% of\nDermapharm\u2019s revenues in the nine-month period ended September 30, 2017. Dermapharm is also active in\nAustria and Switzerland and sales in these countries accounted for approximately 4.9% of Dermapharm\u2019s\nrevenues in the same nine-month period. In the future, Dermapharm plans to introduce selected products from\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.325491873396065, "height": 0.08297690333618477, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-3", "text": "its existing product portfolio as well as new product developments to additional markets.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.32591958939264326, "lower_right_x": 0.7158403869407497, "lower_right_y": 0.33875106928999144, "height": 0.012831479897348175, "width": 0.5949214026602176}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-4", "text": "        Dermapharm also intends to continue its track record of successful acquisitions to further strengthen\ngrowth. Most recently, Dermapharm acquired the worldwide marketing rights for the medical devices bite\naway\u00ae and Herpotherm\u00ae as well as all shares in Bio-Di\u00e4t-Berlin Gesellschaft mit beschr\u00e4nkter Haftung and\nKr\u00e4uter K\u00fchne GmbH (together, \u201cBio-Di\u00e4t-Berlin\u201d). In December 2017 and January 2018, respectively,\nDermapharm furthermore acquired all shares in Strathmann GmbH & Co. KG, its sole general partner\nStrathmann Service GmbH and Biokirch GmbH Pharmaproduktion und \u00c4rzteservice (together, \u201cStrathmann\u201d)\nand Trommsdorff.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34516680923866555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.44011976047904194, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-5", "text": "Dermapharm operates in the following business areas:\n", "page_number": 95, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.45124037639007697, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.4644995722840034, "height": 0.013259195893926434, "width": 0.3681983071342201}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-6", "text": "\uf0b7   Pharmaceuticals and Other Healthcare Products: Dermapharm\u2019s pharmaceuticals and other\n    healthcare products cover multiple product areas with a broad assortment of products marketed\n    under well-known brands. Dermapharm focuses on the development, manufacture and marketing\n    of pharmaceuticals and other healthcare products for specifically targeted markets, in which\n    Dermapharm generally holds a significant market share and generates attractive margins. In the\n    nine-month period ended September 30, 2017, pharmaceuticals and other healthcare products\n    accounted for 46.8% of Dermapharm\u2019s revenues and 93.8% of its EBITDA.\n\uf0b7   Parallel Imports: Dermapharm\u2019s parallel import business, which operates under the well-known\n    \u201caxicorp\u201d brand, benefits from the statutory requirement that a minimum of 5% of all prescription\n    pharmaceuticals sold within the statutory healthcare system in Germany must be imported from\n    other EEA Member States to help reduce healthcare costs. Dermapharm covers the vast majority of\n    prescription pharmaceuticals available for sale in the German parallel import market and has\n    become the fourth largest parallel importer in Germany (source: INSIGHT Health). Parallel\n    imports, including certain non-prescription pharmaceuticals sold over the counter\n    (\u201cOTC\u201d) marketed by axicorp, accounted for 53.2% of Dermapharm\u2019s revenues and 6.1% of its\n    EBITDA in the nine-month period ended September 30, 2017.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.69803250641574, "height": 0.22626176218990596, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-7", "text": "        While Dermapharm has not reported any segments in Dermapharm AG\u2019s consolidated financial\nstatements in the past, it expects that going forward the Company will be required to report its pharmaceuticals\nand other healthcare products and parallel import business areas as segments in its consolidated financial\nstatements pursuant to IFRS 8. The details of such segment reporting may deviate from the information\nprovided in this Prospectus on the historical performance of Dermapharm\u2019s business areas.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.704448246364414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7733105218135158, "height": 0.06886227544910173, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-8", "text": "       In the fiscal year ended December 31, 2016, Dermapharm generated revenues of \u20ac444.5 million and\nEBITDA of \u20ac102.7 million. In the nine-month period ended September 30, 2017, Dermapharm\u2019s revenues\namounted to \u20ac349.7 million and its EBITDA totaled \u20ac82.9 million.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.77972626176219, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8195038494439693, "height": 0.0397775876817793, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-95-9", "text": "", "page_number": 95, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-0", "text": "10.2   Key Factors Affecting Dermapharm\u2019s Business\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.39661426844014513}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-1", "text": "         The key factors discussed below have significantly affected Dermapharm\u2019s results of operations,\nfinancial condition and cash flows during the periods for which financial information is included in this\nProspectus and Dermapharm believes that these factors will continue to affect it in the future:\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-2", "text": "10.2.1     Factors Affecting the Pharmaceuticals and Other Healthcare Products Business Area\n\n10.2.1.1      Price Restrictions for Prescription Pharmaceuticals\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.17065868263473055, "lower_right_x": 0.7738814993954051, "lower_right_y": 0.21086398631308811, "height": 0.04020530367835756, "width": 0.6535671100362757}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Price Restrictions for Prescription Pharmaceuticals"]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-3", "text": "         The German pharmaceuticals market is highly regulated, in particular with respect to prices for\nprescription pharmaceuticals (i.e., pharmaceuticals that require a doctor\u2019s prescription for distribution). Certain\nprescription pharmaceuticals are subject to a reference price, which is the maximum price for which patients are\nreimbursed by statutory health insurance (\u201cSHI\u201d) providers. All other prescription pharmaceuticals are subject\nto a mandatory manufacturer rebate, which, in the case of patent-free pharmaceuticals, amounts to 6%. In\naddition, manufacturers of patent-free pharmaceuticals such as Dermapharm are generally required to offer a\nmandatory rebate of 10% on the ex-factory price of their prescription pharmaceuticals. Furthermore, a price\nmoratorium (Preismoratorium) is applicable to all prescription pharmaceuticals without a reference price,\nlimiting the benefits from price increases for such pharmaceuticals. In the nine-month period ended\nSeptember 30, 2017, pharmaceuticals manufacturers reimbursed German SHI providers for mandatory rebates\nin an amount of \u20ac1.2 billion (source: Pro Generika \u2013 Q3 2017).\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37553464499572287, "height": 0.1501283147989735, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-4", "text": "          In addition, SHI providers seek to further reduce prices for most high-volume patent-free\npharmaceuticals by entering into individual rebate agreements with manufacturers. Given that Dermapharm\u2019s\nselected markets are generally limited in terms of size and number of competitors and therefore oftentimes not\nsuitable for rebate agreements, Dermapharm only selectively enters into such agreements. As a result, the share\nof revenues for Dermapharm\u2019s pharmaceuticals and other healthcare products that are subject to rebate\nagreements fell from 15% in the fiscal year ended December 31, 2014 to 12% in the nine-month period ended\nSeptember 30, 2017.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38280581693755344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47818648417450815, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-5", "text": "           Overall, approximately 47% of Dermapharm\u2019s revenues from pharmaceuticals and other healthcare\nproducts were subject to pricing restrictions or rebate agreements in the nine-month period ended September 30,\n2017 (sources: INSIGHT Health; Company information). Dermapharm accounts for mandatory rebates and\nrebate agreements as deductions from revenues in the consolidated statement of comprehensive income\n(i.e., revenues are stated net of discounts, rebates and returns. Adjustments to deductions made in prior periods\nfor accruals of rebates are recognized as a decrease or increase of revenues subsequent periods, as the case may\nbe.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5782720273738238, "height": 0.09281437125748504, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-6", "text": "10.2.1.2   Sales to Direct Payers and Sales of OTC and other Healthcare Products\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.6090675791274593, "height": 0.014114627887082953, "width": 0.5761789600967352}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Sales to Direct Payers and Sales of OTC and other Healthcare Products"]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-7", "text": "          Revenues from sales to direct payers and/or hospitals are generally not affected by the pricing\nrestrictions (i.e., reference prices, mandatory rebates and/or the price moratorium) that apply to sales of\nprescription pharmaceuticals covered by SHI providers and private health insurance providers. The same holds\ntrue for sales of OTC and other healthcare products. Due to the absence of pricing restrictions, Dermapharm is\nable to generate higher margins from the sale of prescription pharmaceuticals to direct payers and hospitals and\nfrom the sale of OTC and other healthcare products.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7048759623609923, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-8", "text": "         Dermapharm seeks to actively increase the share of sales of its prescription pharmaceuticals to direct\npayers through its careful selection of attractive markets and by focussing on products, for which such direct\npayers form a significant customer group. In addition, Dermapharm has intensified its marketing efforts with\nrespect to OTC and other healthcare products, employing specialized sales representatives as well as direct\nmarketing efforts through its call center. As a result of this focus, the share of sales of prescription\npharmaceuticals to direct payers and hospitals as well as sales of OTC and other healthcare products has\nincreased during the periods for which financial information is included in this Prospectus, starting from 37% of\nDermapharm\u2019s revenues from pharmaceuticals and other healthcare products in the fiscal year ended\nDecember 31, 2014 and increasing to 43% in the nine-month period ended September 30, 2017, thereby\nreducing the effects of pricing pressure from SHI providers on Dermapharm\u2019s revenues and margins.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8485885372112917, "height": 0.13729683490162525, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-96-9", "text": "", "page_number": 96, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-0", "text": "10.2.1.3   Demand for Dermapharm\u2019s Key Products\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4909310761789601, "lower_right_y": 0.09880239520958084, "height": 0.013686911890504708, "width": 0.3730350665054414}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["10.2.1.3Demand for Dermapharm\u2019s Key Products"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-1", "text": "         Dermapharm derives a substantial portion of its revenues and operating income from sales of a limited\nnumber of key products, in particular Dermapharm\u2019s flagship product Dekristol \u00ae 20,000 I.E., a vitamin D\npreparation. In recent years, sales of Dekristol\u00ae 20,000 I.E. have greatly benefited from the wide acceptance of\nmedical studies demonstrating the adverse health consequences of vitamin D deficiency and the increasing\nrecognition of its prevalence among the general population. Dekristol \u00ae 20,000 I.E. has benefited from this\ndevelopment and also attracted a significant number of direct payers, who account, based on Company\nestimates, for almost half of Dermapharm\u2019s Dekristol\u00ae 20,000 I.E. sales. As a result, revenues from the sale of\nDekristol\u00ae 20,000 I.E. almost doubled from approximately \u20ac17.0 million in the fiscal year ended December 31,\n2014 to approximately \u20ac32.9 million in the fiscal year ended December 31, 2016, while the number of packages\nsold increased from approximately 1.9 million packages by approximately 53% to approximately 2.9 million\npackages in that same period. This makes Dekristol\u00ae 20,000 I.E. Dermapharm\u2019s product with the highest\nrevenues and it accounted for 7.7% of Dermapharm\u2019s revenues and an even larger share of its EBITDA in the\nnine-month period ended September 30, 2017.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.17792985457656116, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-2", "text": "          Other key products of Dermapharm include Ampho-Moronal\u00ae, Dienovel\u00ae and Prednisolut\u00ae, which\nform part of Dermapharm\u2019s product offering for its key product areas dermatologicals, systemic corticoids and\nwomen\u2019s healthcare products. While revenues of these products have not grown as strongly as revenues of\nDekristol\u00ae 20,000 I.E., Ampho-Moronal\u00ae, Dienovel\u00ae and Prednisolut\u00ae have steadily provided a substantial\nportion of Dermapharm\u2019s revenues during the periods for which financial information is included in this\nProspectus. Revenues from Ampho-Moronal\u00ae, Dienovel\u00ae and Prednisolut\u00ae amounted to \u20ac23.4 million in the\nfiscal year ended December 31, 2014 and increased 3.8% to \u20ac24.3 million in the fiscal year ended December 31,\n2016. Dermapharm expects that sales of Dekristol\u00ae 20,000 I.E., Ampho-Moronal\u00ae, Dienovel\u00ae and Prednisolut\u00ae,\nwhich together accounted for 27.8% of Dermapharm\u2019s revenues from pharmaceuticals and other healthcare\nproducts in the nine-month period ended September 30, 2017, will continue to boost Dermapharm\u2019s revenues\nand operating income.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.29726261762189904, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4482463644140291, "height": 0.15098374679213006, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-3", "text": "Development of Additional Pharmaceuticals and Other Healthcare Products\n", "page_number": 97, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.4649272882805817, "lower_right_x": 0.7249093107617895, "lower_right_y": 0.4773310521813516, "height": 0.01240376390076986, "width": 0.5223700120918984}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["10.2.1.4Development of Additional Pharmaceuticals and Other Healthcare Products"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-4", "text": "10.2.1.4\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4649272882805817, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.47604790419161674, "height": 0.011120615911035026, "width": 0.060459492140266025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-5", "text": "         Pharmaceuticals in Dermapharm\u2019s broad product offering are no longer patent protected and have often\nbeen in the market for many years. Revenues from such patent-free pharmaceuticals typically decline over time,\nwhich has become an increasing issue for manufacturers of high-volume generics. While Dermapharm\u2019s key\nproduct areas (i.e., vitamins/minerals/enzymes, dermatologicals, systemic corticoids, women\u2019s healthcare\nproducts and ophthalmologicals) are less affected by such developments due to the limited size of the relevant\nmarkets, Dermapharm seeks to develop and introduce additional patent-free pharmaceuticals and other\nhealthcare products to offset such declining revenues for older products, grow its overall revenues and further\ndiversify its product portfolio. In the fiscal year ended December 31, 2016, Dermapharm spent \u20ac4.8 million\n(\u20ac4.6 million in the fiscal year ended December 31, 2015) on development activities, employing an average of\n58 employees in its development department (in the fiscal year ended December 31, 2015: 52 employees).\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6278870829769033, "height": 0.13558597091531222, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-6", "text": "         The time required for the development of new pharmaceuticals and other healthcare products strongly\ndepends on the type of product: for new pharmaceuticals, development usually takes about five years in total,\nwhile Dermapharm has been able to flexibly introduce healthcare products with oftentimes less than a year\nelapsing between the start of development and the market introduction of such products. If Dermapharm is able\nto successfully develop additional pharmaceuticals and other healthcare products and to obtain the marketing\nauthorizations, which are required in case of pharmaceuticals, such new product introductions will generally\nhelp increase Dermapharm\u2019s revenues and operating income.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7309666381522669, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-7", "text": "       Under IAS 38, Dermapharm is generally required to capitalize development costs for its\npharmaceuticals and other healthcare products as intangible assets, if the following criteria are met:\n", "page_number": 97, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7386655260906758, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7651839178785287, "height": 0.02651839178785287, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-8", "text": "\uf0b7   newly developed products are identifiable assets;\n\uf0b7   completing the intangible asset is technically feasible so that it will be available for use;\n\uf0b7   management intends to complete and use the relevant product;\n\uf0b7   it is probable that the product will generate future economic benefits;\n\uf0b7   adequate technical, financial, and other resources are available so that the development can be\n    completed and the product can be used; and\n\uf0b7   the expenditure during development can be reliably measured.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9088964927288281, "height": 0.13601368691189053, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-97-9", "text": "", "page_number": 97, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-0", "text": "         Once a project meets the criteria of IAS 38, the relevant costs are capitalized. Only those costs\ndirectly attributable to the development project, including personnel costs for members of staff involved in\nthe development process, an appropriate part of the corresponding directly attributable overhead costs and\ncosts for external resources, are used. Other development expenditures that do not meet the criteria of\nIAS 38 are recognized as an expense as incurred. Capitalized development costs as recorded on\nDermapharm AG\u2019s consolidated statement of financial position amounted to \u20ac7.8 million, \u20ac15.2 million,\n\u20ac22.4 million and \u20ac30.2 million as of December 31, 2014, 2015 and 2016 and September 30, 2017,\nrespectively.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-1", "text": "         Intangible assets from capitalized development costs are amortized on a straight-line basis over the\nperiod of expected future benefit, generally 15 years. Amortization begins when development is complete\nand the asset is available for use, which is normally the release of the developed product to mass\nproduction. In addition, Dermapharm is required to regularly test intangible assets from capitalized\ndevelopment costs for impairments in accordance with IAS 36 (IAS 38.111) at each balance sheet date. If\nsuch assets are no longer recoverable, the intangible asset is reduced accordingly and impairment charges\nare recorded on the consolidated statement of comprehensive income. As a result of the required\nimpairment testing, Dermapharm incurred impairment charges on capitalized development costs in an\namount of \u20ac4.7 million in the fiscal year ended December 31, 2014 in connection with the development of\na spray for the treatment of asthma and chronic obstructive pulmonary disease, which Dermapharm\ndecided to discontinue.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34901625320787, "height": 0.14756201881950387, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-2", "text": "Fluctuations of Raw Material Prices\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36569717707442256, "lower_right_x": 0.466142684401451, "lower_right_y": 0.3798118049615056, "height": 0.014114627887083009, "width": 0.3458282950423216}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Fluctuations of Raw Material Prices"]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-3", "text": "          The raw materials used in the manufacturing of Dermapharm\u2019s products consist of chemicals in various\nforms, which Dermapharm purchases from various sources, in particular from suppliers in China and India. In\nthe nine-month period ended September 30, 2017, Dermapharm purchased approximately one third of its APIs\ndirectly from the relevant producers, thereby avoiding intermediaries and agents. Fluctuations of raw material\nprices affect Dermapharm\u2019s cost of material and may adversely affect its operating margin, in particular since\npricing restrictions for prescription pharmaceuticals may limit Dermapharm\u2019s ability to pass on rising raw\nmaterial prices. At the same time, Dermapharm benefits from rising sales of products with comparably low raw\nmaterial costs, in particular Dekristol\u00ae 20,000 I.E., which have allowed Dermapharm to reduce its cost of\nmaterial for the manufacture of Dermapharm\u2019s pharmaceuticals and other healthcare products from\n\u20ac45.7 million in the fiscal year ended December 31, 2014 by 8.8% to \u20ac41.7 million in the fiscal year ended\nDecember 31, 2016, while revenues from pharmaceuticals and other healthcare products increased by 12.7% in\nthat same period.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3960650128314799, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5577416595380668, "height": 0.16167664670658688, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-4", "text": "10.2.2   Factors Affecting the Parallel Import Business Area\n\n            Composition of Dermapharm\u2019s Product Offering\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5744225834046194, "lower_right_x": 0.5532043530834341, "lower_right_y": 0.6159110350727117, "height": 0.04148845166809234, "width": 0.43288996372430466}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Composition of Dermapharm\u2019s Product Offering"]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-5", "text": "          While Dermapharm\u2019s parallel import business is a low-margin, high-volume business overall, margins\nfor individual pharmaceuticals may vary considerably. In general, demand from customers for high-margin\nimports is low, while demand for low-margin pharmaceuticals, for which there is only a limited offering from\nparallel importers, is considerably higher. In order to generate an attractive margin from its parallel import\nbusiness, Dermapharm tries to ensure that each customer purchases a mixed basket of products\n(i.e., Dermapharm will offer customers a selection of attractive low-margin pharmaceuticals, while also\nrequiring them to purchase lower-demand pharmaceuticals that generate a considerably higher margin for\nDermapharm).\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7386655260906758, "height": 0.10949529512403766, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-6", "text": "         Fluctuations in the product mix for Dermapharm\u2019s parallel import business affect the margins\nDermapharm can achieve in this business area and consequently its operating income. While it may temporarily\ndecide to accept a decline of its EBITDA margin (i.e., the ratio of EBITDA to revenues) in order to boost its\nmarket share, Dermapharm generally seeks to maintain a stable margin from the sale of its imported\npharmaceuticals. These efforts were successful during the periods for which financial information is included in\nthis Prospectus, with the EBITDA margin for Dermapharm\u2019s parallel import business almost doubling from\n1.7% in the fiscal year ended December 31, 2014 to 2.8% in the nine-month period ended September 30, 2017.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7455089820359282, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8413173652694611, "height": 0.09580838323353291, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-98-7", "text": "", "page_number": 98, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-0", "text": "10.2.2.2   Patent Expirations\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3343409915356711, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.21342200725513905}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Patent Expirations"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-1", "text": "         Many of the pharmaceuticals imported as part of Dermapharm\u2019s parallel import business are originator\npharmaceuticals that still enjoy patent protection. However, the duration of this protection is limited and\ngenerally expires after 15 years. In the fiscal year ended December 31, 2017, patent protection is expected to\nexpire for 31 originator pharmaceuticals with aggregate revenues of approximately \u20ac617 million in the fiscal\nyear ended December 31, 2016 (source: INSIGHT Health \u2013 Patent Expirations). Following such expiration,\nmanufacturers often introduce competing patent-free versions of the originator product, leading to pricing\npressure and loss of market share for the originator pharmaceutical. In some cases, however, prices for the\noriginator pharmaceutical may be slow to decline following the expiration of patent protection, in particular\nwhere no competing patent-free pharmaceuticals have been introduced.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1236099230111206, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-2", "text": "         Dermapharm closely monitors patent expirations and the expected impact on prices and demand for its\nimported pharmaceuticals, seeking to market the relevant pharmaceutical for as long as possible. Should it\ndecide to cease sourcing a certain pharmaceutical, this will reduce the revenues and operating income it can\ngenerate from sales of this pharmaceutical. At the same time, should Dermapharm misjudge the effects of the\nexpiration of patent protection for a certain pharmaceutical, there may not be sufficient demand for such\npharmaceutical and Dermapharm may be required to incur operating losses from the sale of the relevant\npharmaceutical or write down the relevant inventories, resulting in impairment charges, which are generally\nrecorded as an increase of cost of material.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35115483319076135, "height": 0.10863986313088111, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-3", "text": "New Product Introductions\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.3798118049615056, "height": 0.010692899914456822, "width": 0.2805320435308344}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["New Product Introductions"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-4", "text": "          Dermapharm constantly reviews the European pharmaceuticals market in order to identify attractive\npharmaceuticals that would complement and expand its parallel import product offering. In the nine-month\nperiod ended September 30, 2017, Dermapharm was able to successfully introduce 194 new pharmaceuticals to\nits parallel import product offering. Dermapharm generally seeks to be either the first or second parallel\nimporter when it comes to introducing a new pharmaceutical to the German market. Such introductions lead to\nadditional sales of imported pharmaceuticals and help increase Dermapharm\u2019s revenues and operating income,\nin particular if the relevant pharmaceutical is a high-margin import.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4914456800684346, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-5", "text": "Fluctuations in the Costs of Imported Pharmaceuticals\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.5192472198460223, "height": 0.013259195893926434, "width": 0.47460701330108823}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Fluctuations in the Costs of Imported Pharmaceuticals"]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-6", "text": "         While pricing restrictions generally limit the fluctuations of pharmaceutical prices in Germany, many\nof the 25 EEA Member States from which Dermapharm sources its pharmaceuticals for parallel imports are not\nsubject to similar pricing restrictions or any pricing restrictions at all. As a result, prices for pharmaceuticals in\nthese EEA Member States may be subject to stronger fluctuations than in Germany, which may increase or\ndecrease the margin Dermapharm can generate from sales of its parallel imports. Costs of material for parallel\nimports, which primarily comprise the purchase price paid by Dermapharm for imported pharmaceuticals,\nincreased from \u20ac190.3 million in the fiscal year ended December 31, 2014 by 10.9% to \u20ac211.1 million in the\nfiscal year ended December 31, 2016, while revenues from parallel imports increased by 14.3% in that same\nperiod.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5333618477331052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6565440547476475, "height": 0.1231822070145423, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-7", "text": "10.2.3     Other Factors affecting Dermapharm\n\n10.2.3.1      External Growth through Acquisitions\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6702309666381523, "lower_right_x": 0.466142684401451, "lower_right_y": 0.7117194183062446, "height": 0.04148845166809234, "width": 0.3458282950423216}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["External Growth through Acquisitions"]}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-8", "text": "         Following its foundation in 1991, Dermapharm has continuously expanded its product offering through\nsuccessful acquisitions, in particular several entities operating under the \u201cH\u00fcbner\u201d brand in 2010, which\ncontributed substantially to Dermapharm\u2019s other healthcare product offering, and axicorp GmbH in 2012, which\nenabled Dermapharm to enter the parallel import business. In the fiscal years ended December 31, 2014, 2015\nand 2016, Dermapharm made a number of smaller acquisitions, including:\n", "page_number": 99, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7938408896492729, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-9", "text": "\uf0b7   Naturwohl Vertriebs GmbH, which holds the right to market the OTC product LactoStop \u00ae;\n\uf0b7   Remedix GmbH;\n\uf0b7   the remaining 15%-stake in axicorp GmbH; and\n\uf0b7   the remaining 25%-stake in Austrian-based Melasan Produktions & Vertriebsgesellschaft m.b.H.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.800256629597947, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.8828058169375534, "height": 0.08254918733960648, "width": 0.6862152357920194}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-99-10", "text": "", "page_number": 99, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-0", "text": "         In the nine-month period ended September 30, 2017, Dermapharm completed two key acquisitions: On\nSeptember 4, 2017, Dermapharm entered into an agreement for the acquisition of the assets pertaining to the\nhyperthermic medical devices division of Riemser Pharma GmbH. On September 21, 2017, Dermapharm\nentered into an agreement for the acquisition of all shares in Bio-Di\u00e4t. The acquisitions were completed on\nSeptember 20, 2017 and October 1, 2017, respectively. The acquired businesses include medical devices,\nincluding bite away\u00ae, a device selectively targeting mosquito and insect stings, and Herpotherm \u00ae, which is used\nfor the treatment of herpes blisters as well as phytopharmaceuticals (herbal medicines), homoeopathics and\nnatural cosmetics.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19161676646706588, "height": 0.10650128314798975, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-1", "text": "         Dermapharm seeks to continue to grow through future acquisitions and to this end constantly screens\nselective growth opportunities, including acquisitions of new marketing authorizations, products and businesses.\nTo this end, it acquired all shares in Strathmann in December 2017, which distributes a broad product offering\nprimarily comprising OTC products, which complement Dermapharm\u2019s existing product portfolio, in particular\nwith respect to the dermatologicals, women\u2019s healthcare and vitamins/minerals/enzymes product areas.\nFurthermore, in January 2018 Dermapharm acquired all shares in Trommsdorff, which manufactures and\nmarkets 23 different prescription pharmaceuticals and OTC products, in particular Keltican\u00ae forte, a dietary\nproduct for the treatment of back pain, and Tromcardin \u00ae complex, which combines certain minerals and\nvitamins for the treatment of cardiac arrhythmia. Trommsdorff also serves its former parent group as a toll\nmanufacturer.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3361847733105218, "height": 0.1347305389221557, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-2", "text": "         Historically, Dermapharm\u2019s acquisitions have been immediately accretive to its operating income,\nalthough transaction costs have increased Dermapharm\u2019s other operating expenses during the periods in which\nthe acquisitions occurred. Dermapharm\u2019s past acquisitions were generally financed through cash flows from\noperations. However, in connection with the acquisitions completed in the nine-month period ended\nSeptember 30, 2017, Dermapharm obtained various loans to fund these acquisitions. In the future, Dermapharm\nplans to continue to finance acquisitions through cash flows from operations, but may also decide to take on\nadditional debt financing, which would increase its financial liabilities accordingly.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34516680923866555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4414029084687767, "height": 0.09623609923011117, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-3", "text": "           In addition, acquisitions of businesses may lead to the recognition of goodwill. Goodwill represents the\nexcess of the consideration transferred over Dermapharm\u2019s interest in the net fair value of the identifiable assets,\nliabilities and contingent liabilities of a newly acquired business. If the consideration is lower (negative\ngoodwill), it is recognized in profit or loss. As of September 30, 2017, goodwill recorded on Dermapharm AG\u2019s\nconsolidated statement of financial position amounted to \u20ac17.0 million. Capitalized goodwill is not subject to\namortization. It is, however, assessed annually for impairment and can be assessed more frequently if there is\nany indication for impairments during the year (impairment-only approach) Dermapharm incurred impairment\ncharges on goodwill of \u20ac5.1 million allocated to Farmal d.d. (\u201cFarmal\u201d) in the fiscal year ended\nDecember 31, 2015 and \u20ac5.2 million allocated to Cancernova GmbH onkologische Arzneimittel in the fiscal\nyear ended December 31, 2014.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44781864841745084, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5851154833190761, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-4", "text": "10.2.3.2   Exchange Rate Fluctuations\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5983746792130026, "lower_right_x": 0.3984280532043531, "lower_right_y": 0.6129170230966638, "height": 0.014542343883661268, "width": 0.2805320435308344}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["10.2.3.2Exchange Rate Fluctuations"]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-5", "text": "           Dermapharm conducts its business in various countries, including countries from which it sources\npharmaceuticals for its parallel import business. The exchange rates between these currencies and the Euro,\nDermapharm\u2019s reporting currency, remain volatile and changes in these exchange rates affect Dermapharm\u2019s\nreported revenues, costs and earnings as expressed in Euro, and in the reported value of Dermapharm\u2019s assets,\nliabilities and cash flows. The most important foreign currencies for Dermapharm are the U.S. Dollar, the\nBritish Pound, the Swiss Franc, the Croatian Kuna and the Norwegian Krone.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7095808383233533, "height": 0.08041060735671512, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-6", "text": "         Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the\ndate of the transaction. Non-monetary items that are measured in terms of historical cost in a foreign currency\nare not retranslated. Monetary items (i.e., cash and cash equivalents, receivables and liabilities) denominated in\nforeign currencies are translated into the functional currency at closing rates. The resulting exchange rate gains\nand losses are recognized through profit and loss under net foreign exchange gains and losses.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7852865697177075, "height": 0.0671514114627888, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-7", "text": "           To the extent that cash outflows in any one foreign currency are not offset by cash inflows resulting\nfrom operational business in such currency, the remaining net foreign currency exposure is generally hedged in\nline with the existing hedging strategy for the net exposure of the next twelve months, using derivative financial\ninstruments, in particular forward exchange contracts and interest-rate swaps. Depending on whether the market\nvalue of the derivatives is positive or negative, they are recognized as other financial assets or other financial\nliabilities. Dermapharm does not apply hedge accounting.\n", "page_number": 100, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8746792130025663, "height": 0.08126603934987175, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-100-8", "text": "", "page_number": 100, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-0", "text": "         In the future, Dermapharm may be adversely affected by exchange rate fluctuations and hedging\nagainst such fluctuations (see \u201c1.1.30 Exchange rate fluctuations and related hedges may adversely affect\nDermapharm\u2019s results and the value of some of its assets.\u201d).\n", "page_number": 101, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-1", "text": "          In addition, Dermapharm AG entered into certain currency related swap transactions with UniCredit\nBank AG (\u201cUniCredit\u201d) between 2006 and 2010, with the relevant reference currency being the Swiss Franc.\nDue to the adverse development of the value of these currency related swap transactions, Dermapharm accounts\nfor future payment obligations due to these swaps as a financial liability, which as of September 30, 2017\namounted to \u20ac7.4 million. However, Dermapharm AG has also entered into the Indemnification Agreement with\nthe Selling Shareholder (see \u201c18.1.2 Indemnification Agreement with respect to UniCredit Litigation\u201d), pursuant\nto which the Selling Shareholder has agreed to indemnify Dermapharm for certain claims in connection with\nthese swap transactions. Therefore, Dermapharm recorded a corresponding \u20ac7.4 million financial asset,\nreflecting its future indemnification claims against the Selling Shareholder. Future fluctuations of the Swiss\nFranc would affect both Dermapharm\u2019s financial liabilities in connection with the currency swap transactions\nwith UniCredit as well as its financial assets in connection with the Indemnification Agreement. As a result, the\nCompany does not expect any effects from the currency related swap transactions with UniCredit with respect to\nits consolidated statement of comprehensive income.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1330196749358426, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.17835757057313945, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-2", "text": "        In December 2011, Dermapharm AG filed a lawsuit against UniCredit, demanding the rescission of the\ncurrency related swap transactions between Dermapharm and UniCredit (see \u201c12.12 Litigation\u201d). Under the\nIndemnification Agreement, Dermapharm has assigned any claims against UniCredit to the Selling Shareholder.\nShould Dermapharm\u2019s lawsuit be successful, UniCredit\u2019s potential claims as well as Dermapharm\u2019s potential\nindemnification claims against the Selling Shareholder would no longer be recorded in the Company\u2019s\nconsolidated statement of financial position.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40034217279726264, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-3", "text": "10.2.3.3   Changes in Tax Rates\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.41402908468776733, "lower_right_x": 0.3555018137847642, "lower_right_y": 0.42771599657827203, "height": 0.013686911890504694, "width": 0.23397823458282951}, "blob_type": "headline", "predictions": {}, "annotations": {"key_factor_affecting_results": ["Changes in Tax Rates"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-4", "text": "          Dermapharm operates in various countries and is required to pay income taxes in each relevant tax\njurisdiction. In order to calculate Dermapharm\u2019s income tax provisions and the deferred tax liabilities, the\nexpected income tax as well as the temporary differences resulting from the different treatment of certain\nbalance sheet items pursuant to IFRS and their accounting in accordance with applicable tax laws must be\ndetermined on the basis of assumptions. If the final taxation imposed deviates from the assumed values, this has\na corresponding effect on current and deferred taxes and consequently on Dermapharm\u2019s net assets, financial\nposition and results of operations in the respective period.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5389221556886228, "height": 0.09452523524379813, "width": 0.7605804111245467}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-5", "text": "        The effective income tax rates amounted to 6.32%, 5.28% and 7.08%, for the fiscal years ended\nDecember 31, 2014, 2015 and 2016, respectively. These comparably low effective income tax rates resulted\nfrom the tax group formed with the Selling Shareholder, which was the taxpaying entity of the tax group.\nFollowing the termination of the Profit Transfer Agreement on December 31, 2017 (see \u201c18.1.1 Profit Transfer\nAgreement\u201d), Dermapharm expects that its effective income tax rate will increase significantly.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6142001710863987, "height": 0.0671514114627888, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-101-6", "text": "", "page_number": 101, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-0", "text": "10.3   Results of Operations\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.21765417170495766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-1", "text": "             The following table presents Dermapharm\u2019s results of operations for the periods indicated:\n                                                                                     For the fiscal year             For the nine-month period\n                                                                                    ended December 31,                 ended September 30,\n                                                                         2014               2015           2016        2016              2017\n                                                                                         (audited)                           (unaudited)\n                                                                                       (in \u20ac million)                       (in \u20ac million)\n Revenue ..................................................................................\n                                                                           391.3                 384.8      444.5        319.2          349.7\n Increase/decrease in finished goods and\n   work-in-process ...................................................................\n                                                                               8.3                  2.9        1.0          4.1            0.4\n Own work capitalized ..............................................................\n                                                                               8.5                  8.0        8.3          5.4            8.0\n Other operating income ...........................................................\n                                                                               6.2                  9.9        9.9          5.2            4.1\n Cost of material .......................................................................\n                                                                         (237.1)                (215.9)    (252.8)      (181.5)        (196.0)\n Personnel expenses ..................................................................\n                                                                           (57.7)                (55.7)     (58.7)       (42.0)         (46.5)\n Depreciation and amortization .................................................\n                                                                           (28.3)                (22.9)     (14.4)       (10.3)         (11.2)\n                                                                           (48.0)\n Other operating expenses .........................................................              (50.3)     (51.0)       (35.1)         (38.1)\n Operating income ..................................................................\n                                                                              43.3                 60.8       86.8         65.1           70.4\n Result from investments measured at\n   equity ...................................................................................\n                                                                               0.9                  1.0        1.5          1.1            1.2\n Financial income......................................................................\n                                                                               3.3                  9.4        7.3          4.1            3.3\n                                                                           (12.0)\n Financial expenses ...................................................................          (15.8)     (12.7)        (8.4)          (7.8)\n Earnings before taxes ............................................................\n                                                                              35.5                 55.3       82.9         61.8           67.2\n                                                                             (2.2)\n Income taxes ............................................................................        (2.9)      (5.9)        (6.0)          (4.3)\n                                                                              33.2\nProfit/loss for the period .........................................................               52.4       77.0         55.9           62.9\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11377245508982035, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4341317365269461, "height": 0.3203592814371257, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-2", "text": "10.3.1   Revenues\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46150556030795553, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.47177074422583404, "height": 0.010265183917878506, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-3", "text": "         Revenues from Dermapharm\u2019s pharmaceuticals and other healthcare products business area comprise\nrevenues from the sale of prescription pharmaceuticals as well as OTC and other healthcare products. Revenues\nfrom Dermapharm\u2019s parallel import business area comprise revenues from the sale of prescription\npharmaceuticals imported and resold in Germany as well as revenues from certain OTC products marketed by\naxicorp.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4888793840889649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5568862275449101, "height": 0.06800684345594521, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-4", "text": "         The following table provides an overview of Dermapharm\u2019s revenues from its two business areas for\nthe periods indicated:\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5641573994867408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5898203592814372, "height": 0.02566295979469635, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-5", "text": "                                                                                   For the fiscal year              For the nine-month period\n                                                                                  ended December 31,                  ended September 30,\n                                                                          2014             2015           2016        2016              2017\n                                                                          (audited, unless otherwise specified)             (unaudited)\n                                                                                      (in \u20ac million)                       (in \u20ac million)\n Prescription pharmaceuticals (unaudited) ................................  119.2                126.6      135.3         97.9         106.1\n OTC and other healthcare products\n   (unaudited) ...........................................................................\n                                                                              50.6                53.6       56.5         42.6           43.3\n SLG(1) ......................................................................................\n                                                                                6.0                  \uf02d          \uf02d            \uf02d              \uf02d\n Balance (unaudited)(2) ..............................................................\n                                                                                9.2                9.7       16.7         13.9           14.2\n Pharmaceuticals and other healthcare\n   products (unaudited)(2) ......................................................\n                                                                            185.0                189.9      208.5       154.4          163.6\n Parallel imports (unaudited) (3) ..............................................\n                                                                            206.3                195.0      235.9       164.8          186.1\n                                                                            391.3\nTotal revenue ...........................................................................        384.8      444.5       319.2          349.7\n", "page_number": 102, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5953806672369547, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7857142857142857, "height": 0.190333618477331, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-6", "text": "(1) Comprises sales by SLG Service Logistik G\u00fcnthersdorf GmbH (\u201cSLG\u201d), which was divested on December 31, 2015.\n(2) Comprises sales by Melasan GmbH, Melasan Produktions & Vertriebsgesellschaft m.b.H., Sun-Farm Sp.z o.o., Farmal\n    and Mibe Pharmaceuticals d.o.o. as well as other income, the effects of discounts and certain rebates, all of which\n    cannot be allocated to prescription pharmaceuticals and OTC and other healthcare products, respectively, for accounting\n    reasons.\n(2) Excludes certain OTC products marketed by axicorp.\n(3) Includes certain OTC products marketed by axicorp.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7972626176218991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8862275449101796, "height": 0.08896492728828054, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-102-7", "text": "", "page_number": 102, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-0", "text": "         The following table provides an overview of Dermapharm\u2019s revenues by region for the periods\nindicated:\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11120615911035073, "height": 0.026090675791274595, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-1", "text": "                                                                                 For the fiscal year             For the nine-month period\n                                                                                ended December 31,                 ended September 30,\n                                                                      2014              2015            2016       2016              2017\n                                                                                     (audited)                           (unaudited)\n                                                                                   (in \u20ac million)                       (in \u20ac million)\n Germany ..................................................................................\n                                                                             370.8              360.9    413.1       295.7          323.8\n Austria and Switzerland ...........................................................\n                                                                               13.9              18.8     20.1        15.2           17.0\n Other ........................................................................................\n                                                                                 6.6              5.1     11.3         8.3            8.9\n                                                                             391.3\nTotal revenue ...........................................................................       384.8    444.5       319.2          349.7\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1193327630453379, "lower_right_x": 0.875453446191052, "lower_right_y": 0.23609923011120615, "height": 0.11676646706586825, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-2", "text": "10.3.1.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.2630453378956373, "lower_right_x": 0.720677146311971, "lower_right_y": 0.2771599657827203, "height": 0.014114627887083009, "width": 0.5991535671100363}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-3", "text": "         In the nine-month period ended September 30, 2017, revenues increased from \u20ac319.2 million in the\nnine-month period ended September 30, 2016 by \u20ac30.5 million, or 9.6%, to \u20ac349.7 million, reflecting the\nincrease in sales for both pharmaceuticals and other healthcare products as well as parallel imports.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33361847733105215, "height": 0.03977758768177925, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-4", "text": "         Revenues from pharmaceuticals and other healthcare products increased by \u20ac9.2 million, or 6.0%, in\nthe nine-month period ended September 30, 2017, driven by successful new product introductions, in particular\nin the dermatologicals and vitamins/minerals/enzymes product areas. Revenues from prescription\npharmaceuticals strongly contributed to this development, increasing by 8.3% during that same period as a result\nof a strong increase of sales for Solacutan\u00ae, Fusicutan\u00ae, an ointment for the treatment of bacterial skin\ninfections, and Dekristol\u00ae 20,000 I.E. By comparison, revenues from OTC and other healthcare products rose at\na more modest 1.6% in the nine-month period ended September 30, 2017, driven by rising sales of Dekristolvit\u00ae\nand the introduction of VITA aktiv B12, an OTC vitamin B12 direct stick for self-medication of vitamin B12\ndeficiency.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34174508126603936, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46407185628742514, "height": 0.12232677502138578, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-5", "text": "         For Dermapharm\u2019s parallel import business area, revenues increased by \u20ac21.3 million, or 12.9%, aided\nby a growing overall parallel imports market. However, Dermapharm was able to actually surpass this market\ngrowth through the continued optimization of its product mix as well as the success of its direct marketing\nefforts.\n\n10.3.1.2    Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5543199315654406, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-6", "text": "        Revenues increased from \u20ac384.8 million in the fiscal year ended December 31, 2015 by \u20ac59.7 million,\nor 15.5%, to \u20ac444.5 million in the fiscal year ended December 31, 2016, due to rising sales of both\npharmaceuticals and other healthcare products as well as parallel imports.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6086398631308811, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-7", "text": "         For Dermapharm\u2019s pharmaceuticals and other healthcare products business area, revenues increased by\n\u20ac18.6 million, or 9.8%, in the fiscal year ended December 31, 2016, reflecting the introduction of additional\nproducts complementing Dermapharm\u2019s product offering, for which Dermapharm was able to obtain 28 new\nmarketing authorizations. Revenues from prescription pharmaceuticals, which increased by 6.9%, strongly\ncontributed to the positive developments in the fiscal year ended December 31, 2016, in particular sales of\nDekristol\u00ae 20,000 I.E., which rose by 38.2% and due in part to Dermapharm\u2019s decision to implement a price\nincrease for Dekristol\u00ae 20,000 I.E. in the fiscal year ended December 31, 2016. Revenues from OTC and other\nhealthcare products also increased, albeit at a more modest 5.4%, such growth being primarily driven by the\nintroduction of additional healthcare products, primarily vitamin D preparations, sikapur\u00ae and silicea products.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.739093242087254, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-8", "text": "          For its parallel import business area, Dermapharm was able to increase revenues by \u20ac40.9 million, or\n21.0%, through the careful optimization of its product portfolio, even as the overall parallel imports market\ndecreased by 1.9% (source: INSIGHT Health). In particular, Dermapharm introduced 306 new products to its\nparallel import offering in the fiscal year ended December 31, 2016. The parallel import business also benefited\nfrom the acquisition of a 75.1%-stake in Remedix GmbH, which closed on February 29, 2016, and contributed\n\u20ac5.7 million to Dermapharm\u2019s revenues in the fiscal year ended December 31, 2016.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7455089820359282, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8280581693755347, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-103-9", "text": "", "page_number": 103, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-0", "text": "10.3.1.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-1", "text": "          In the fiscal year ended December 31, 2015, revenues decreased slightly from \u20ac391.3 million in the\nfiscal year ended December 31, 2014 by \u20ac6.5 million, or 1.7%, to \u20ac384.8 million, as an increase of sales of\npharmaceuticals and other healthcare products was more than offset by the decrease in revenues from\nDermapharm\u2019s parallel import business. In addition, the disposal of SLG, which had contributed revenues of\n\u20ac6.0 million in the fiscal year ended December 31, 2014, adversely affected Dermapharm\u2019s revenues in the\nfiscal year ended December 31, 2015.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-2", "text": "         Revenues from pharmaceuticals and other healthcare products rose by \u20ac4.9 million, or 2.6%, in the\nfiscal year ended December 31, 2015 due to an expansion of Dermapharm\u2019s product portfolio, where\nDermapharm obtained 21 new marketing authorizations. Revenues from prescription pharmaceuticals increased\nby 6.2% due to growing sales across Dermapharm\u2019s broad product offering. In addition, revenues from\nOTC and other healthcare products, which increased by 5.9%, benefited from increased sales of vitamin D\npreparations, Ketozolin\u00ae 2% shampoo and Amorocutan\u00ae nail polish.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2840034217279726, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-3", "text": "         The overall decrease in revenues was the result of decreasing revenues for Dermapharm\u2019s parallel\nimport business area, which fell by \u20ac11.3 million, or 5.5%, in the fiscal year ended December 31, 2015 due to a\ncareful optimization of Dermapharm\u2019s parallel import portfolio, during the course of which Dermapharm\ndecided to discontinue the import of certain low-margin pharmaceuticals in favor of pharmaceuticals with\nhigher margins.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.0654405474764756, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-4", "text": "10.3.2   Increase/Decrease in Finished Goods and Work-in-process\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.3887938408896493, "height": 0.012831479897348175, "width": 0.46977025392986693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-5", "text": "       Increase/decrease in finished goods and work-in-process reflects the increase/decrease of the value of\nDermapharm\u2019s inventories during the respective period as accounted for under the total cost method\n(Gesamtkostenverfahren).\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4439692044482464, "height": 0.04063301967493588, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-6", "text": "        In the nine-month period ended September 30, 2017, increase/decrease in finished goods and\nwork-in-process decreased significantly by \u20ac3.7 million, or 90.2%, from \u20ac4.1 million in the nine-month period\nended September 30, 2016 to \u20ac0.4 million as a result of the strong increase in sales of parallel imports.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49187339606501285, "height": 0.04063301967493588, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-7", "text": "         Increase/decrease in finished goods and work-in-process decreased from \u20ac2.9 million in the fiscal year\nended December 31, 2015 by \u20ac1.9 million, or 65.5%, to \u20ac1.0 million in the fiscal year ended December 31,\n2016, reflecting the increase of Dermapharm\u2019s inventories as well as valuation gains on existing inventories.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4991445680068435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5402053036783576, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-8", "text": "         In the fiscal year ended December 31, 2015, increase/decrease in finished goods and work-in-process\nsaw a strong decrease by \u20ac5.4 million, or 65.1%, from \u20ac8.3 million in the fiscal year ended December 31, 2014\nto \u20ac2.9 million caused by the increase of Dermapharm\u2019s inventories in connection with rising demand for its\npharmaceuticals and other healthcare products as well as valuation gains.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.602224123182207, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-9", "text": "10.3.3   Own Work Capitalized\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.33796856106408707, "lower_right_y": 0.6295979469632165, "height": 0.014114627887083064, "width": 0.21765417170495768}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-10", "text": "        Own work capitalized comprises the capitalized development costs resulting from Dermapharm\u2019s\ndevelopment activities during the respective period as accounted for under the total cost method.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6706586826347305, "height": 0.02780153977758759, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-11", "text": "          In the nine-month period ended September 30, 2017, own work capitalized increased from \u20ac5.4 million\nin the nine-month period ended September 30, 2016 by \u20ac2.6 million, or 48.1%, to \u20ac8.0 million due to additional\nspending on clinical studies during that period.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718562874251497, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-12", "text": "         Own work capitalized increased from \u20ac8.0 million in the fiscal year ended December 31, 2015 by\n\u20ac0.3 million, or 3.8%, to \u20ac8.3 million in the fiscal year ended December 31, 2016 as a result of Dermapharm\u2019s\nincreased development activities, in particular additional spending on clinical studies.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.04148845166809245, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-13", "text": "          In the fiscal year ended December 31, 2015, own work capitalized decreased from \u20ac8.5 million in the\nfiscal year ended December 31, 2014 by \u20ac0.5 million, or 5.9%, to \u20ac8.0 million due to slightly reduced spending\non development efforts, in particular reflecting the fact that Dermapharm was engaged in development efforts\nwhich required less spending on clinical studies in the fiscal year ended December 31, 2015.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8280581693755347, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-104-14", "text": "", "page_number": 104, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-0", "text": "10.3.4   Other Operating Income\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.23276904474002416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-1", "text": "         Other operating income comprises income from government grants, insurance refunds and damage\ncompensation, reversal of provisions, including provisions on impairment of trade receivables, income from\ndisposals, foreign exchange gains and miscellaneous other operating income.\n         The following table provides a breakdown of Dermapharm\u2019s other operating income for the periods\nindicated:\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18776732249786143, "height": 0.07527801539777589, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-2", "text": "                                                                                  For the fiscal year                For the nine-month period\n                                                                                 ended December 31,                    ended September 30,\n                                                                       2014              2015           2016           2016              2017\n                                                                                      (audited)                              (unaudited)\n                                                                                    (in \u20ac million)                          (in \u20ac million)\n Government grants ..................................................................\n                                                                            2.4              3.4               2.2          1.7            1.3\n Insurance refunds and damage\n   compensation .......................................................................\n                                                                            0.1              0.1               1.7          1.7            0.1\n Reversal of provisions, including\n   provisions on impairment of trade\n   receivables ...........................................................................\n                                                                            0.3              0.7               0.7          0.6            0.5\n Income from disposals .............................................................\n                                                                            0.2              0.6               0.4          0.2            0.1\n Foreign exchange gains ...........................................................\n                                                                            0.8              0.5               0.2          0.1            1.1\n Miscellaneous ..........................................................................\n                                                                            2.4              4.7               4.7          0.9            1.0\n                                                                            6.2\nTotal other operating income .................................................               9.9               9.9          5.2            4.1\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.19461077844311378, "lower_right_x": 0.875453446191052, "lower_right_y": 0.3964927288280582, "height": 0.20188195038494441, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-3", "text": "10.3.4.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.720677146311971, "lower_right_y": 0.43669803250641576, "height": 0.012831479897348175, "width": 0.6003627569528416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-4", "text": "          In the nine-month period ended September 30, 2017, other operating income decreased from\n\u20ac5.2 million in the nine-month period ended September 30, 2016 by \u20ac1.1 million, or 21.1%, to \u20ac4.1 million,\nreflecting the fact that Dermapharm received \u20ac1.6 million less insurance refunds and damage compensation as a\nresult of fewer insurance events settled during that period. This development was partially offset by an increase\nof foreign exchange gains by \u20ac1.0 million in the nine-month period ended September 30, 2017, reflecting\nfavorable developments of foreign currencies, in particular the Swiss Franc.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5329341317365269, "height": 0.08169375534644996, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-5", "text": "10.3.4.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.5598802395209581, "height": 0.01283147989734823, "width": 0.5471584038694075}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-6", "text": "          Other operating income remained unchanged at \u20ac9.9 million in the fiscal year ended December 31,\n2016. An increase of insurance refunds and damage compensation by \u20ac1.6 million in the fiscal year ended\nDecember 31, 2016, of which \u20ac1.0 million was attributable to damages awarded to Mibe GmbH Arzneimittel\n(\u201cMibe\u201d) as part of a settlement with a competitor, more than offset the reduction of income from the reversal of\ngovernment grants in connection with Dermapharm\u2019s Brehna facility, which was \u20ac1.2 million lower compared\nto the fiscal year ended December 31, 2015.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6569717707442259, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-7", "text": "10.3.4.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6702309666381523, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.6839178785286569, "height": 0.013686911890504638, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-8", "text": "          In the fiscal year ended December 31, 2015, other operating income increased from \u20ac6.2 million in the\nfiscal year ended December 31, 2014 by \u20ac3.7 million, or 59.7%, to \u20ac9.9 million, primarily driven by an increase\nof miscellaneous other operating income by \u20ac2.3 million, which comprised various smaller items. Higher\ngovernment grants in connection with Dermapharm\u2019s Brehna facility contributed \u20ac1.0 million to the increase in\nother operating income in the fiscal year ended December 31, 2015.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-105-9", "text": "", "page_number": 105, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-0", "text": "10.3.5   Cost of Material\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.1747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-1", "text": "        Cost of material comprises (i) the costs of raw materials required for Dermapharm\u2019s pharmaceuticals\nand other healthcare products business area and (ii) the costs of imported pharmaceuticals as part of\nDermapharm\u2019s parallel import business.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-2", "text": "           In the nine-month period ended September 30, 2017, cost of material increased from \u20ac181.5 million in\nthe nine-month period ended September 30, 2016 by \u20ac14.5 million, or 8.0%, to \u20ac196.0 million, primarily\nreflecting rising sales in Dermapharm\u2019s parallel import business area, where costs of material, which primarily\ncomprise the purchase price paid by Dermapharm for imported pharmaceuticals, are considerably higher than\nfor Dermapharm\u2019s pharmaceuticals and other healthcare products business area. Dermapharm\u2019s gross profit\n(i.e., the difference between revenues and cost of material) increased by \u20ac16.0 million, or 11.6%, from\n\u20ac137.7 million in the nine-month period ended September 30, 2016 to \u20ac153.7 million in the nine-month period\nended September 30, 2017.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.1099230111206159, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-3", "text": "         Cost of material increased from \u20ac215.9 million in the fiscal year ended December 31, 2015 by\n\u20ac36.9 million, or 17.1%, to \u20ac252.8 million in the fiscal year ended December 31, 2016, primarily due to the\nstrong increase of revenues from Dermapharm\u2019s parallel import business area with comparably higher costs of\nmaterial. Gross profit (i.e., the difference between revenues and cost of material) increased by \u20ac22.8 million, or\n13.5%, from \u20ac168.9 million in the fiscal year ended December 31, 2015 to \u20ac191.7 million in the fiscal year\nended December 31, 2016.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.07912745936698035, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-4", "text": "          In the fiscal year ended December 31, 2015, cost of material decreased from \u20ac237.1 million in the\nfiscal year ended December 31, 2014 by \u20ac21.2 million, or 8.9%, to \u20ac215.9 million, primarily due to the portfolio\noptimization for Dermapharm\u2019s parallel import business area, where Dermapharm decided to discontinue the\nimport of certain low-margin pharmaceuticals. Dermapharm\u2019s efforts to centralize production at its facility in\nBrehna and its investments in specialized production capacities, which improved the utilization rate for\nDermapharm\u2019s operations and led to a reduction in material usage, also contributed to the decrease of cost of\nmaterial. In addition, Dermapharm was able to centralize purchasing for its pharmaceuticals and other\nhealthcare products business area, which led to additional savings of material costs. Gross profit (i.e., the\ndifference between revenues and cost of material) increased by \u20ac14.7 million, or 9.5%, from \u20ac154.2 million in\nthe fiscal year ended December 31, 2014 to \u20ac168.9 million in the fiscal year ended December 31, 2015.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5029940119760479, "height": 0.13387510692899912, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-5", "text": "10.3.6   Personnel Expenses\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5196749358426005, "lower_right_x": 0.3216444981862152, "lower_right_y": 0.5325064157399487, "height": 0.01283147989734823, "width": 0.20133010882708582}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-6", "text": "       Personnel expenses comprise wages and salaries, social security expenses and termination benefits.\n         The following table provides a breakdown of Dermapharm\u2019s personnel expenses for the periods\nindicated:\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.04491017964071864, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-7", "text": "                                                                              For the fiscal year             For the nine-month period\n                                                                             ended December 31,                 ended September 30,\n                                                                    2014             2015           2016        2016              2017\n                                                                                  (audited)                           (unaudited)\n                                                                                (in \u20ac million)                       (in \u20ac million)\n Wages and salaries...................................................................\n                                                                      48.5               46.7          49.8         36.0           39.8\n Social security expenses ..........................................................\n                                                                        9.1               9.0           8.8          5.9            6.5\n Termination benefits ................................................................\n                                                                        0.1               0.0           0.2          0.1            0.2\n                                                                      57.7\nTotal personnel expenses .........................................................       55.7          58.7         42.0           46.5\n", "page_number": 106, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5988023952095808, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7198460222412318, "height": 0.12104362703165106, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-106-8", "text": "", "page_number": 106, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-0", "text": "         The following table provides a breakdown of Dermapharm\u2019s average number of full-time employees\nby function for the periods indicated:\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-1", "text": "                                                                                For the fiscal year            For the nine-month period\n                                                                               ended December 31,                ended September 30,\n                                                                     2014             2015            2016       2016            2017\n                                                                                   (unaudited)                        (unaudited)\n Sales & Marketing ...................................................................\n                                                                              267               265      258         256            257\n Production................................................................................\n                                                                              432               407      398         388            398\n Administration .........................................................................\n                                                                              248               255      287         289            302\n Development............................................................................\n                                                                                42               52       58          56             59\n Logistics ..................................................................................\n                                                                              118               115      111         108            108\n                                                                           1,107\nTotal employees........................................................................       1,094    1,112       1,097          1,124\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1193327630453379, "lower_right_x": 0.875453446191052, "lower_right_y": 0.2549187339606501, "height": 0.13558597091531222, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-2", "text": "        In addition, Dermapharm also employed an average of 78 part-time employees in the fiscal year ended\nDecember 31, 2016 (fiscal year ended December 31, 2015: 63; fiscal year ended December 31, 2014: 109). In\nthe nine-month period ended September 30, 2017, Dermapharm employed an average of 95 part-time\nemployees.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.334901625320787, "height": 0.05474764756201883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-3", "text": "Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 107, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.3485885372112917, "lower_right_x": 0.720677146311971, "lower_right_y": 0.3627031650983747, "height": 0.014114627887083009, "width": 0.5181378476420798}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-4", "text": "10.3.6.1\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.3485885372112917, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.36142001710863986, "height": 0.012831479897348175, "width": 0.05139056831922613}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-5", "text": "         In the nine-month period ended September 30, 2017, personnel expenses increased from \u20ac42.0 million\nin the nine-month period ended September 30, 2016 by \u20ac4.5 million, or 10.7%, to \u20ac46.5 million, driven by an\nincrease in wages and salaries by \u20ac3.8 million, which was primarily due to the addition of administrative\npersonnel, where Dermapharm hired 13 average of full-time employees in the nine-month period ended\nSeptember 30, 2017.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3793840889649273, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.44568006843455943, "height": 0.06629597946963212, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-6", "text": "Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 107, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.46150556030795553, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.4743370402053037, "height": 0.012831479897348175, "width": 0.46493349455864574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-7", "text": "10.3.6.2\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46150556030795553, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.47177074422583404, "height": 0.010265183917878506, "width": 0.058041112454655375}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-8", "text": "        Personnel expenses slightly increased from \u20ac55.7 million in the fiscal year ended December 31, 2015\nby \u20ac3.0 million, or 5.4%, to \u20ac58.7 million in the fiscal year ended December 31, 2016. Higher personnel\nexpenses correspond to the increase in the average number of full-time employees by 18 employees. At the\nsame time, the average number of part-time employees increased by 15 employees The increase in the\nworkforce reflects Dermapharm\u2019s expansion of its development and administration capacities, while\nDermapharm was able to reduce the number of production as well as sales and marketing personnel required.\nThe share of personnel expenses compared to revenues continued to decrease, falling from 14.5% in the fiscal\nyear ended December 31, 2015 to 13.2% in the fiscal year ended December 31, 2016.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4888793840889649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5988023952095808, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-9", "text": "10.3.6.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6120615911035072, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.6248930710008554, "height": 0.01283147989734823, "width": 0.5471584038694075}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-10", "text": "         In the fiscal year ended December 31, 2015, personnel expenses decreased from \u20ac57.7 million in the\nfiscal year ended December 31, 2014 by \u20ac2.0 million, or 3.5%, to \u20ac55.7 million. This decrease reflects the\nreduced average number of full-time employees of Dermapharm, which decreased by 13 employees, and the\nlower number of part-time employees, which decreased by 46 employees. The reduction of the workforce was\nthe primarily result of a lower number of employees needed in Dermapharm\u2019s production functions. At the same\ntime, Dermapharm\u2019s commitment to continuous development was evidenced by an increase of its development\npersonnel. The share of personnel expenses compared to revenues decreased from 14.7% in the fiscal year\nended December 31, 2014 to 14.5% in the fiscal year ended December 31, 2015.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6394354148845167, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7493584260051326, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-107-11", "text": "", "page_number": 107, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-0", "text": "10.3.7   Depreciation and Amortization\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-1", "text": "        Depreciation and amortization comprises depreciation on property, plant and equipment as well as\namortization and impairment write-offs of revenue generating assets.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-2", "text": "         In the nine-month period ended September 30, 2017, depreciation and amortization increased from\n\u20ac10.3 million in the nine-month period ended September 30, 2016 by \u20ac0.9 million, or 8.7%, to \u20ac11.2 million,\nprimarily due to impairment charges in connection with the termination of certain concessions.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881950384944397, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-3", "text": "        Depreciation and amortization decreased from \u20ac22.9 million in the fiscal year ended December 31,\n2015 by \u20ac8.5 million, or 37.1%, to \u20ac14.4 million in the fiscal year ended December 31, 2016, given that\nDermapharm did not incur any impairment charges, compared to impairment charges of \u20ac5.1 million and\nimpairment of inventories of \u20ac2.8 million in the fiscal year ended December 31, 2015.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25149700598802394, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-4", "text": "         In the fiscal year ended December 31, 2015, depreciation and amortization decreased from\n\u20ac28.3 million in the fiscal year ended December 31, 2014 by \u20ac5.4 million, or 19.1%, to \u20ac22.9 million. While\nDermapharm incurred impairment charges of \u20ac5.1 million and impairment of inventories of \u20ac2.8 million in the\nfiscal year ended December 31, 2015, impairment charges were considerably higher in the fiscal year ended\nDecember 31, 2014, amounting to \u20ac9.9 million during that period.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25192472198460225, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32677502138579984, "height": 0.07485029940119758, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-5", "text": "10.3.8   Other Operating Expenses\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34174508126603936, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.3550042771599658, "height": 0.013259195893926434, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-6", "text": "         Other operating expenses comprise marketing and advertising expenses, research and development\ncosts, contributions, fees and charges, warehousing and freight expenses, rent, building, land and fixtures\nmaintenance expenses, maintenance expenses, legal, consulting and audit fees, selling costs, third-party services\nexpenses, losses from disposals, bank charges, foreign exchange losses, expenses from write-downs and\nmiscellaneous other operating expenses.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4375534644995723, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-7", "text": "         The following table provides a breakdown of Dermapharm\u2019s other operating expenses for the periods\nindicated:\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46877673224978617, "height": 0.024379811804961515, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-8", "text": "                                                                                    For the fiscal year                For the nine-month period\n                                                                                   ended December 31,                    ended September 30,\n                                                                        2014               2015           2016           2016              2017\n                                                                                        (audited)                              (unaudited)\n                                                                                      (in \u20ac million)                          (in \u20ac million)\n Marketing and advertising .......................................................\n                                                                              7.1               7.3              7.3          5.6            5.1\n Research and development ......................................................\n                                                                              7.3               4.6              4.8          2.8            5.2\n Contributions, fees and charges ...............................................\n                                                                              3.9               3.8              4.7          3.3            3.3\n Warehousing and freight..........................................................\n                                                                              5.5               3.8              4.6          3.3            3.5\n Rent, building, land and fixtures\n   maintenance .........................................................................\n                                                                              3.8               4.0           4.6             3.6            3.2\n Maintenance expenses .............................................................\n                                                                              2.9               3.2           3.3             2.6            3.0\n Legal, consulting and audit fees ..............................................\n                                                                              3.0               3.5           3.2             2.4            3.7\n Selling costs .............................................................................\n                                                                              2.3               2.7           2.9             3.2            2.3\n Third-party services .................................................................\n                                                                              0.6               0.8           1.2             0.9            0.8\n Losses from disposals ..............................................................\n                                                                              0.4               3.6           0.8             0.3            0.5\n Bank charges ...........................................................................\n                                                                              0.1               0.3           0.3             0.2            0.2\n Foreign exchange losses ..........................................................\n                                                                              0.8               1.8           0.2             0.2            0.1\n Expenses from write-downs ....................................................\n                                                                              0.8               2.5           0.2             0.1            0.0\n Miscellaneous ..........................................................................\n                                                                              9.4               8.6          12.7             6.6            7.2\n                                                                            48.0\nTotal other operating expenses ...............................................                 50.3          51.0            35.1           38.1\n", "page_number": 108, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4756201881950385, "lower_right_x": 0.875453446191052, "lower_right_y": 0.760906757912746, "height": 0.2852865697177075, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-108-9", "text": "", "page_number": 108, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-0", "text": "10.3.8.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7200725513905684, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5991535671100363}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-1", "text": "         In the nine-month period ended September 30, 2017, other operating expenses increased from\n\u20ac35.1 million in the nine-month period ended September 30, 2016 by \u20ac3.0 million, or 8.5%, to \u20ac38.1 million,\nprimarily due to an increase of research and development expenses by \u20ac2.4 million, reflecting increased\ndevelopment efforts of Dermapharm in that period. In addition, legal, consulting and audit fees increased by\n\u20ac1.3 million in the nine-month period ended September 30, 2017, driven by additional costs incurred by\nDermapharm in connection with the preparation of this Offering. These developments were only partly offset by\na decrease of selling costs by \u20ac1.1 million in the nine-month period ended September 30, 2017, due to changes\nto how intra-group selling costs were accounted for.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-2", "text": "10.3.8.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.25021385799828916, "height": 0.011120615911035081, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-3", "text": "         Other operating expenses increased from \u20ac50.3 million in the fiscal year ended December 31, 2015 by\n\u20ac0.7 million, or 1.4%, to \u20ac51.0 million in the fiscal year ended December 31, 2016, driven by various factors:\nWarehousing and freight expenses rose by \u20ac1.2 million due to increased sales, while contributions, fees and\ncharges increased by \u20ac0.9 million, resulting from higher fees for the renewal of marketing authorizations for\nDermapharm\u2019s parallel import product offering. In addition, expenses on rent, building, land and fixtures\nmaintenance increased by \u20ac0.6 million, reflecting increased spending on Dermapharm\u2019s growing operations.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34773310521813516, "height": 0.0812660393498717, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-4", "text": "10.3.8.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.36227544910179643, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.37553464499572287, "height": 0.013259195893926434, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-5", "text": "          In the fiscal year ended December 31, 2015, other operating expenses increased from \u20ac48.0 million in\nthe fiscal year ended December 31, 2014 by \u20ac2.3 million, or 4.8%, to \u20ac50.3 million, primarily resulting from the\nrealized loss in the course of the sale of a 75.1%-stake in Centuere Beteiligungs-Aktiengesellschaft i.L.\n(\u201cCentuere\u201d) and realized losses from the disposal of certain drug licenses held by Mibe, which amounted to\n\u20ac1.7 million in aggregate and were recorded under losses from disposals. In addition, expenses from\nwrite-downs, which primarily include losses on bad debts, contributed \u20ac1.7 million to other operating expenses.\nDue to adverse developments of exchange rates, Dermapharm also incurred an additional \u20ac1.0 million of foreign\nexchange losses. These additional other operating expenses were partially offset by lower research and\ndevelopment expenses, which decreased by \u20ac2.7 million in the fiscal year ended December 31, 2015, reflecting\nordinary fluctuations with respect to the duration of clinical studies conducted in the respective periods. In\naddition, warehousing and freight expenses decreased by \u20ac1.7 million, primarily due to the disposal of SLG.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5402053036783576, "height": 0.1505560307955518, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-6", "text": "10.3.9   Operating Income\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5538922155688623, "lower_right_x": 0.309552599758162, "lower_right_y": 0.5680068434559452, "height": 0.014114627887082953, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-7", "text": "         In the nine-month period ended September 30, 2017, Dermapharm\u2019s operating income increased from\n\u20ac65.1 million in the nine-month period ended September 30, 2016 by \u20ac5.3 million, or 8.1%, to \u20ac70.4 million.\nDermapharm\u2019s pharmaceuticals and other healthcare products business area, where operating income increased\nfrom \u20ac60.7 million in the nine-month period ended September 30, 2016 by \u20ac5.6 million, or 9.2%, to\n\u20ac66.3 million in the nine-month period ended September 30, 2017 as a result of rising sales, was primarily\nresponsible for this increase. By comparison, operating income from Dermapharm\u2019s parallel import business\narea increased, from \u20ac4.4 million in the nine-month period ended September 30, 2017 by \u20ac0.2 million, or 4.5%,\nto \u20ac4.2 million the nine-month period ended September 30, 2016, resulting from the greater focus on gaining\nmarket share by Dermapharm\u2019s parallel import business area.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.58169375534645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7048759623609923, "height": 0.1231822070145423, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-8", "text": "          Dermapharm\u2019s operating income increased from \u20ac60.8 million in the fiscal year ended December 31,\n2015 by \u20ac26.0 million, or 42.8%, to \u20ac86.8 million in the fiscal year ended December 31, 2016. For its\npharmaceuticals and other healthcare products business area, Dermapharm saw a slightly lower increase of\noperating income, which rose from \u20ac58.7 million in the fiscal year ended December 31, 2015 by \u20ac23.2 million,\nor 39.5%, to \u20ac81.9 million in the fiscal year ended December 31, 2016, mainly as a result of high-margin sales\nof Dekristol\u00ae 20,000 I.E., and Dermapharm\u2019s ability to increase the share of sales that were not subject to\npricing restrictions or rebate agreements. In addition, the successful integration of past acquisitions added to a\nreduction of operating expenses. Due an improvement of the product mix for Dermapharm\u2019s parallel import\nproduct offering and the increase in revenues resulting therefrom, operating income from Dermapharm\u2019s\nparallel import business area, increased even stronger from \u20ac2.8 million in the fiscal year ended December 31,\n2015 by \u20ac2.1 million, or 72.4%, to \u20ac4.8 million in the fiscal year ended December 31, 2016, nevertheless still\ngenerating far lower margins than the pharmaceuticals and other healthcare products business area.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8759623609923011, "height": 0.16467065868263464, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-109-9", "text": "66\n", "page_number": 109, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9443969204448246, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.016928657799274494}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-0", "text": "          In the fiscal year ended December 31, 2015, Dermapharm\u2019s operating income increased from\n\u20ac43.3 million in the fiscal year ended December 31, 2014 by \u20ac17.5 million, or 40.4%, to \u20ac60.8 million,\nreflecting the increase of Dermapharm\u2019s gross profits. This increase was fueled by sales of Dermapharm\u2019s\npharmaceuticals and other healthcare products and operating income in this business area rose from\n\u20ac40.3 million in the fiscal year ended December 31, 2014 by \u20ac18.4 million, or 45.7%, to \u20ac58.7 million in the\nfiscal year ended December 31, 2015, primarily due to a growing share of sales that were not subject to pricing\nrestrictions or rebate agreements. Furthermore, Dermapharm was able to continue the integration of past\nacquisitions into its existing operations, thereby further improving overall profitability. By comparison,\noperating income from Dermapharm\u2019s parallel import business area decreased from \u20ac3.0 million in the fiscal\nyear ended December 31, 2014 by \u20ac0.9 million, or 30.0%, to \u20ac2.1 million in the fiscal year ended December 31,\n2015, reflecting the reduction in revenues in connection with the optimization of Dermapharm\u2019s parallel import\nproduct offering as well as costs for the restructuring of the sourcing systems.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-1", "text": "10.3.10 Financial Result\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2634730538922156, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.27587681779298545, "height": 0.01240376390076986, "width": 0.1789600967351874}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-2", "text": "         Financial result is the difference between financial income and result from investments measured at\nequity on the one hand, and financial expenses on the other hand. Result from investments measured at equity\nreflects Dermapharm\u2019s share in the profits or losses of entities accounted for under the equity method. The\nmaterial group entities of Dermapharm accounted for under the equity method in the fiscal years ended\nDecember 31, 2014, 2015 and 2016 as well as the nine-month period ended September 30, 2017 were Hasan\nDermapharm Co. Ltd., in which Dermapharm holds a 30.0%-stake, and Gynial GmbH, in which Dermapharm\nholds a 25.1%-stake.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3853721129170231, "height": 0.0915312232677502, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-3", "text": "The following table provides a breakdown of Dermapharm\u2019s financial results for the periods indicated:\n", "page_number": 110, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.40889649272882805, "height": 0.01240376390076986, "width": 0.6916565900846433}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-4", "text": "                                                                                 For the fiscal year             For the nine-month period\n                                                                                ended December 31,                 ended September 30,\n                                                                      2014              2015           2016        2016              2017\n                                                                                     (audited)                           (unaudited)\n                                                                                   (in \u20ac million)                       (in \u20ac million)\n Result from investments measured at\n   equity ...................................................................................\n                                                                               0.9               1.0       1.5          1.1            1.2\n Financial income......................................................................\n                                                                               3.3               9.4       7.3          4.1            3.3\n Financial expenses ...................................................................\n                                                                          (12.0)              (15.8)    (12.7)        (8.4)          (7.8)\n                                                                            (7.8)\nFinancial result ........................................................................      (5.4)     (3.9)        (3.2)          (3.3)\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4136013686911891, "lower_right_x": 0.875453446191052, "lower_right_y": 0.5453378956372968, "height": 0.13173652694610777, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-5", "text": "10.3.10.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5744225834046194, "lower_right_x": 0.720677146311971, "lower_right_y": 0.5872540633019675, "height": 0.01283147989734812, "width": 0.6003627569528416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-6", "text": "         In the nine-month period ended September 30, 2017, Dermapharm\u2019s financial result remained almost\nunchanged, deteriorating by \u20ac0.1 million, or 3.1%, from a net financial expense of \u20ac3.2 million in the\nnine-month period ended September 30, 2016 to a net financial expense of \u20ac3.3 million. While Dermapharm\nfinancial expenses decreased by \u20ac0.6 million due to lower payments in connection with currency swap\ntransactions entered into with UniCredit in the nine-month period ended September 30, 2017, Dermapharm\u2019s\nfinancial income also decreased from \u20ac4.1 million in the nine-month period ended September 30, 2016 to\n\u20ac3.3 million the nine-month period ended September 30, 2017, reflecting lower payments by the Selling\nShareholder under the Indemnification Agreement (see \u201c10.2.3.2 Exchange Rate Fluctuations\u201d).\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7117194183062446, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-7", "text": "10.3.10.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7249786142001711, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.739093242087254, "height": 0.014114627887082953, "width": 0.5471584038694075}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-8", "text": "         Dermapharm\u2019s financial result improved from a net financial expense of \u20ac5.4 million in the fiscal year\nended December 31, 2015 by \u20ac1.5 million, or 27.8%, to a net financial expense of \u20ac3.9 million in the fiscal year\nended December 31, 2016, despite a decrease of interest and other expenses, reflecting successful refinancings\nby Dermapharm through loans with variable interest rates, allowing Dermapharm to benefit from the positive\nmarket interest rates.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8177929854576561, "height": 0.06544054747647565, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-110-9", "text": "67\n", "page_number": 110, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9443969204448246, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.016928657799274494}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-0", "text": "10.3.10.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-1", "text": "         In the fiscal year ended December 31, 2015, Dermapharm\u2019s financial result improved from a net\nfinancial expense of \u20ac7.8 million in the fiscal year ended December 31, 2014 by \u20ac2.4 million, or 30.8%, to a net\nfinancial expense of \u20ac5.4 million. Expenses from fair value measurements increased due to the currency swap\ntransactions entered into with UniCredit, yet due to the Indemnification Agreement with the Selling\nShareholder, this led to a corresponding increase of income from fair value measurements\n(see \u201c10.2.3.2 Exchange Rate Fluctuations\u201d).\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-2", "text": "10.3.11 Income Taxes\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21171941830624466, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.2219846022241232, "height": 0.010265183917878534, "width": 0.1596130592503023}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-3", "text": "         Income taxes comprise current income taxes as well as deferred taxes from temporary differences and\nfrom tax losses carried forward.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2630453378956373, "height": 0.0239520958083832, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-4", "text": "The following table provides a breakdown of Dermapharm\u2019s income taxes for the periods indicated:\n", "page_number": 111, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.27331052181351584, "lower_right_x": 0.8530834340991535, "lower_right_y": 0.2865697177074423, "height": 0.013259195893926434, "width": 0.6741233373639661}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-5", "text": "                                                                                   For the fiscal year                For the nine-month period\n                                                                                  ended December 31,                    ended September 30,\n                                                                        2014              2015           2016           2016              2017\n                                                                                       (audited)                              (unaudited)\n                                                                                     (in \u20ac million)                          (in \u20ac million)\n Current income taxes ...............................................................\n                                                                             2.4              1.9               3.4          3.7            3.3\n Deferred taxes from temporary differences .............................  (0.2)               1.0               2.0          2.3            1.0\n Deferred taxes from tax losses carried\n                                                                                \uf02d\n   forward ................................................................................     \uf02d               0.4            \uf02d              \uf02d\n                                                                             2.2\nTotal income taxes ...................................................................        2.9               5.9          6.0            4.3\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.290846877673225, "lower_right_x": 0.875453446191052, "lower_right_y": 0.42130025662959797, "height": 0.130453378956373, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-6", "text": "10.3.11.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.44781864841745084, "lower_right_x": 0.720677146311971, "lower_right_y": 0.4619332763045338, "height": 0.014114627887082953, "width": 0.5991535671100363}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-7", "text": "         In the nine-month period ended September 30, 2017, income taxes decreased by \u20ac1.7 million, or\n28.3%, from a tax charge of \u20ac6.0 million in the nine-month period ended September 30, 2016 to a tax charge of\n\u20ac4.3 million, reflecting the decrease of deferred taxes from temporary differences by \u20ac1.3 million and the\ndecrease of current income taxes by \u20ac0.4 million due to a reduction of the effective income tax rate.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5320786997433704, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-8", "text": "10.3.11.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5470487596236099, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.5603079555175363, "height": 0.013259195893926434, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-9", "text": "          Income taxes more than doubled, with the tax charge of \u20ac2.9 million in the fiscal year ended\nDecember 31, 2015 increasing by \u20ac3.0 million, or 103.4%, to a tax charge of \u20ac5.9 million in the fiscal year\nended December 31, 2016, primarily due to the increase of current income taxes resulting from Dermapharm\u2019s\nrising sales as well as an increase of the effective income tax rate from 5.28% in the fiscal year ended\nDecember 31, 2015 to 7.08% in the fiscal year ended December 31, 2016. These comparably low effective\nincome tax rates resulted from the tax group formed with the Selling Shareholder, which was the taxpaying\nentity of the tax group, and are expected to increase following the termination of the Profit Transfer Agreement\n(see \u201c10.2.3.3 Changes in Tax Rates\u201d).\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6834901625320787, "height": 0.10906757912745935, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-10", "text": "10.3.11.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.7117194183062446, "height": 0.014114627887082953, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-11", "text": "         In the fiscal year ended December 31, 2015, Dermapharm\u2019s income taxes increased from a tax charge\nof \u20ac2.2 million in the fiscal year ended December 31, 2014 by \u20ac0.7 million, or 31.8%, to a tax charge of\n\u20ac2.9 million, primarily caused by the increase of deferred taxes from temporary differences, which mainly arose\nfrom capitalized development costs. At the same time, the effective income tax rate of Dermapharm decreased\nfrom 6.32% in the fiscal year ended December 31, 2015 to 5.28% in the fiscal year ended December 31, 2016.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7938408896492729, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-111-12", "text": "", "page_number": 111, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.016928657799274494}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-0", "text": "10.3.12 Profit/loss for the Period\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.23276904474002416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-1", "text": "         In the nine-month period ended September 30, 2017, Dermapharm\u2019s profit for the period increased by\n\u20ac7.0 million, or 12.5%, from a profit of \u20ac55.9 million in the nine-month period ended September 30, 2016 to a\nprofit of \u20ac62.9 million, due to the strong increase of profitable sales for both business areas. As a result,\nDermapharm\u2019s net profit margin increased from 17.5% in the nine-month period ended September 30, 2016 to\n18.0% in the nine-month period ended September 30, 2017.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-2", "text": "         Dermapharm\u2019s profit for the period increased from \u20ac52.4 million in the fiscal year ended December 31,\n2015 by \u20ac24.6 million, or 46.9%, to \u20ac77.0 million in the fiscal year ended December 31, 2016, primarily due to\nthe significant increase in Dermapharm\u2019s operating income. Consequently, Dermapharm\u2019s net profit margin\nincreased from 13.6% in the fiscal year ended December 31, 2015 to 17.3% in the fiscal year ended\nDecember 31, 2016.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2566295979469632, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-3", "text": "         In the fiscal year ended December 31, 2015, Dermapharm\u2019s profit for the period increased from\n\u20ac33.2 million in the fiscal year ended December 31, 2014 by \u20ac19.2 million, or 57.8%, to \u20ac52.4 million, driven\nby Dermapharm\u2019s strong operating performance. Dermapharm\u2019s net profit margin also increased strongly from\n8.5% in the fiscal year ended December 31, 2014 to 13.6% in the fiscal year ended December 31, 2015.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31993156544054746, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-4", "text": "10.4     Assets, Equity and Liabilities\n\n10.4.1   Assets\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.334901625320787, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.3729683490162532, "height": 0.03806672369546621, "width": 0.2714631197097944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-5", "text": "The following table provides an overview of Dermapharm\u2019s assets as of the dates indicated:\n", "page_number": 112, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3896492728828058, "lower_right_x": 0.7968561064087062, "lower_right_y": 0.4033361847733105, "height": 0.013686911890504694, "width": 0.6178960096735188}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-6", "text": "                                                                                                   As of                        As of\n                                                                                               December 31,                September 30,\n                                                                           2014                     2015        2016             2017\n                                                                                                 (audited)                   (unaudited)\n                                                                                               (in \u20ac million)               (in \u20ac million)\n Intangible assets .......................................................................\n                                                                                  71.7                  68.0        70.0            129.7\n Goodwill ..................................................................................\n                                                                                  21.6                  16.4        17.0             17.0\n Property, plant and equipment .................................................  56.5                  53.4        53.4             52.9\n Investments measured at equity ...............................................     1.6                  2.7         3.2              4.4\n Investments ..............................................................................\n                                                                                    0.5                  0.2         0.3              0.2\n Other non-current financial assets ...........................................     9.2                 13.8        10.6             22.4\n                                                                                    1.0\n Deferred tax assets ...................................................................                 0.0         0.2              1.7\n Total non-current assets ........................................................\n                                                                                162.1                  154.6       154.7            228.3\n Inventories ...............................................................................\n                                                                                  71.5                  77.0        84.8             81.9\n Trade accounts receivable........................................................22.8                  17.4        26.3             34.7\n Other current financial assets ...................................................\n                                                                                  58.8                  42.5        40.0             68.7\n Other current assets .................................................................\n                                                                                    3.0                  1.4         1.7              2.0\n Income tax receivables \u2013 current .............................................     0.7                  1.0         0.4              0.4\n Cash and cash equivalents .......................................................11.6                   2.8         3.8             12.6\n                                                                                168.5\n Total current assets ...............................................................                  142.1       157.0            200.3\n                                                                                330.6\nTotal assets ...............................................................................           296.7       311.7            428.6\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.40889649272882805, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.693327630453379, "height": 0.2844311377245509, "width": 0.7587666263603385}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-7", "text": "10.4.1.1   Comparison of December 31, 2016 and September 30, 2017\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7215568862275449, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.7356715141146278, "height": 0.014114627887082953, "width": 0.49274486094316805}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-8", "text": "         In the nine-month period ended September 30, 2017, Dermapharm\u2019s total assets increased from\n\u20ac311.7 million as of December 31, 2016 by \u20ac116.9 million, or 37.5%, to \u20ac428.6 million as of September 30,\n2017. Intangible assets increased by \u20ac59.7 million in the nine-month period ended September 30, 2017,\nprimarily due to the acquisition of the assets pertaining to the hyperthermic medical devices division of Riemser\nPharma GmbH (see \u201c12.13.3.1 Asset Purchase Agreement for bite away\u00ae and Herpotherm\u00ae\u201d). In addition, other\nnon-current financial assets increased by \u20ac11.8 million during that same period, reflecting prepayments on the\nacquisition of Bio-Di\u00e4t-Berlin in an amount of \u20ac14.5 million, which were only partly offset by a reduction of\nfuture claims against the Selling Shareholder in connection with the Indemnification Agreement. Furthermore,\nother current financial assets rose by \u20ac28.7 in the nine-month period ended September 30, 2017 due to loans\nprovided by Dermapharm to the Selling Shareholder.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7489307100085543, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8862275449101796, "height": 0.13729683490162536, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-112-9", "text": "", "page_number": 112, "bounding_box": {"top_left_x": 0.49032648125755746, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.017533252720677128}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-0", "text": "10.4.1.2   Comparison of December 31, 2015 and December 31, 2016\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4885126964933495}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-1", "text": "          Dermapharm\u2019s total assets increased from \u20ac296.7 million as of December 31, 2015 by \u20ac15.0 million, or\n5.1%, to \u20ac311.7 million as of December 31, 2016 in the fiscal year ended December 31, 2016. This increase was\nprimarily caused by higher trade accounts receivable, which increased by \u20ac8.9 million, reflecting the strong\nincrease of Dermapharm\u2019s revenues. In addition, inventories increased by \u20ac7.8 million, which reflects the need\nto hold additional raw materials and finished products in stock to ensure that Dermapharm can continue to avoid\ndelivery shortages despite constantly increasing demand for its pharmaceuticals and other healthcare products as\nwell as Dermapharm\u2019s parallel imports. As of December 31 2016, intangible assets, primarily consisting of\nmedical licenses, with a carrying amount of \u20ac2.2 million were pledged to different banks in order to provide\ncollateral for bank loans (as of December 31, 2015: \u20ac2.5 million).\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1236099230111206, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-2", "text": "Comparison of December 31, 2014 and December 31, 2015\n", "page_number": 113, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.25278015397775877, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.26390076988879385, "height": 0.011120615911035081, "width": 0.40689238210399037}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-3", "text": "10.4.1.3\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.262617621899059, "height": 0.009837467921300247, "width": 0.053808948004836765}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-4", "text": "          In the fiscal year ended December 31, 2015, Dermapharm\u2019s total assets decreased from \u20ac330.6 million\nas of December 31, 2014 by \u20ac33.9 million, or 10.3%, to \u20ac296.7 million due to a reduction of intangible assets\nand goodwill in an aggregate amount of \u20ac8.9 million, caused by amortization and an impairment loss of\n\u20ac5.1 million on the goodwill allocated to Farmal due to provisions for an indictment filed against the company.\nBy comparison, inventories increased by \u20ac5.5 million in the fiscal year ended December 31, 2015, since\nDermapharm increased its stock to ensure delivery reliability. As of December 31 2015, intangible assets,\nprimarily consisting of medical licenses, with a carrying amount of \u20ac2.5 million were pledged to different banks\nin order to provide collateral for bank loans (as of December 31, 2014: \u20ac2.4 million).\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3887938408896493, "height": 0.10863986313088114, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-5", "text": "10.4.2   Equity\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.22551390568319227, "lower_right_y": 0.4170230966638152, "height": 0.013686911890504694, "width": 0.10519951632406288}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-6", "text": "The following table provides an overview of Dermapharm\u2019s equity as of the dates indicated:\n", "page_number": 113, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.43071000855431996, "lower_right_x": 0.8022974607013301, "lower_right_y": 0.44439692044482465, "height": 0.013686911890504694, "width": 0.6233373639661427}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-7", "text": "                                                                                                  As of                            As of\n                                                                                              December 31,                    September 30,\n                                                                          2014                     2015        2016                 2017\n                                                                                                (audited)                       (unaudited)\n                                                                                              (in \u20ac million)                   (in \u20ac million)\n Issued capital ...........................................................................\n                                                                                   1.3                   1.3            1.3               1.3\n Capital reserves .......................................................................\n                                                                                   0.3                   0.3            0.3               0.3\n Retained earnings ....................................................................\n                                                                                 28.6                   39.5           56.3              70.0\n Other reserves ..........................................................................\n                                                                                (1.9)                    0.1          (1.0)             (2.1)\n                                                                                   5.7\n Non-controlling interests .........................................................                     3.3            3.9                 \uf02d\n                                                                                 34.0\nTotal equity ..............................................................................             44.4           60.8              69.5\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44781864841745084, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5975192472198461, "height": 0.14970059880239522, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-8", "text": "10.4.2.1   Comparison of December 31, 2016 and September 30, 2017\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.6223267750213858, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.6364414029084687, "height": 0.014114627887082953, "width": 0.4921402660217654}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-9", "text": "          In the nine-month period ended September 30, 2017, Dermapharm\u2019s total equity increased from\n\u20ac60.8 million as of December 31, 2016 by \u20ac8.7 million, or 14.3%, to \u20ac69.5 million as of September 30, 2017.\nThis increase was driven by the increase of retained earnings resulting from Dermapharm\u2019s strong operating\nperformance and profits in the nine-month period ended September 30, 2017. The decrease in non-controlling\ninterests to zero reflects the acquisition of the remaining 15%-stake in axicorp GmbH and the remaining\n24.9%-stake in Remedix GmbH, making these two entities wholly owned subsidiaries of Dermapharm.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7339606501283148, "height": 0.08083832335329344, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-10", "text": "10.4.2.2   Comparison of December 31, 2015 and December 31, 2016\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7489307100085543, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.760906757912746, "height": 0.011976047904191711, "width": 0.48911729141475213}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-11", "text": "          In the fiscal year ended December 31, 2016, Dermapharm\u2019s total equity increased from \u20ac44.4 million\nas of December 31, 2015 by \u20ac16.4 million, or 36.9%, to \u20ac60.8 million as of December 31, 2016, primarily due\nto the increase in retained earnings, which reflects Dermapharm\u2019s strong profits. The increase of non-controlling\ninterests primarily reflects the outside shareholders of Remedix GmbH, in which Dermapharm acquired a\n75.1%-stake.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7763045337895638, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8417450812660393, "height": 0.06544054747647554, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-113-12", "text": "", "page_number": 113, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-0", "text": "10.4.2.3   Comparison of December 31, 2014 and December 31, 2015\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4885126964933495}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-1", "text": "         In the fiscal year ended December 31, 2015, Dermapharm\u2019s total equity increased from \u20ac34.0 million\nas of December 31, 2015 by \u20ac10.4 million, or 30.6%, to \u20ac44.4 million as of December 31, 2016, with the main\ncontribution coming from Dermapharm\u2019s profits for the fiscal year ended December 31, 2015. By comparison,\nnon-controlling interests decreased by \u20ac2.4 million due to the acquisition of the remaining 25.0%-stake in\nMelasan Produktions & Vertriebsgesellschaft m.b.H. and the remaining 2.9% in Farmal.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-2", "text": "10.4.3   Liabilities\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.20829769033361847, "height": 0.010265183917878534, "width": 0.13119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-3", "text": "The following table provides an overview of Dermapharm\u2019s liabilities as of the dates indicated:\n", "page_number": 114, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.23823781009409753, "height": 0.012831479897348175, "width": 0.6432889963724304}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-4", "text": "                                                                                            As of                                As of\n                                                                                       December 31,                         September 30,\n                                                                        2014                 2015                2016             2017\n                                                                            (audited, unless otherwise specified)             (unaudited)\n                                                                                        (in \u20ac million)                       (in \u20ac million)\n Defined benefit obligations and other\n   accrued employee benefits ...................................................\n                                                                               12.4              12.1                13.3             13.3\n Other provisions ......................................................................\n                                                                                 0.1                \uf02d                   \uf02d                \uf02d\n Financial liabilities ..................................................................\n                                                                             161.5              151.1                96.9            235.4\n Other non-current financial liabilities ......................................  9.9             14.1                10.5              8.1\n Other non-current liabilities .....................................................\n                                                                               15.6              13.3                11.5             10.4\n                                                                                   \uf02d\n Deferred tax liabilities .............................................................           0.2                 3.4              5.8\n Total non-current liabilities ..................................................\n                                                                             199.6              190.7               135.5            272.9\n Other provisions ......................................................................\n                                                                                 6.1              6.4                 7.0              6.0\n Financial liabilities ..................................................................\n                                                                               20.4              24.9                65.9             43.4\n Trade accounts payable ...........................................................\n                                                                               27.4              18.1                24.5             19.3\n Other current financial liabilities .............................................\n                                                                               30.6               2.4                 4.3              2.1\n Other current liabilities ............................................................\n                                                                               11.4               8.2                11.0             11.5\n                                                                                 1.0\n Income tax liabilities ...............................................................           1.5                 2.8              3.9\n                                                                               97.0\n Total current liabilities ..........................................................            61.6               115.4             86.2\n                                                                             296.6\nTotal liabilities (unaudited) .....................................................             252.3               250.9            359.1\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5316509837467921, "height": 0.2891360136869119, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-5", "text": "10.4.3.1   Comparison of December 31, 2016 and September 30, 2017\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.5573139435414884, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.5714285714285714, "height": 0.014114627887082953, "width": 0.4921402660217654}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-6", "text": "          In the nine-month period ended September 30, 2017, Dermapharm\u2019s total liabilities increased from\n\u20ac250.9 million as of December 31, 2016 by \u20ac108.2 million, or 43.1%, to \u20ac359.1 million as of September 30,\n2017, driven by an increase of financial liabilities by \u20ac116.0 million, primarily due to the acquisition financing\nrequired for the acquisition of the assets pertaining to the hyperthermic medical devices division of Riemser\nPharma GmbH (see \u201c12.13.3.1 Asset Purchase Agreement for bite away\u00ae and Herpotherm\u00ae\u201d) and all shares in\nBio-Di\u00e4t-Berlin (see \u201c12.13.3.2 Share Purchase Agreement for Bio-Di\u00e4t-Berlin\u201d). Overall, Dermapharm was\nable to enter into various new loan agreements (see \u201c12.13.2.2 Loan Agreements of Dermapharm AG\u201d),\nincluding for the refinancing of existing loans, resulting in a shift from current financial liabilities to non-current\nfinancial liabilities in the nine-month period ended September 30, 2017. The increase in financial liabilities was\npartly offset by a decrease of trade accounts payable by \u20ac5.2 million during that same period, reflecting\nfluctuations in Dermapharm\u2019s working capital in the ordinary course of business.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.588109495295124, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7356715141146278, "height": 0.14756201881950382, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-7", "text": "Comparison of December 31, 2015 and December 31, 2016\n", "page_number": 114, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.7523524379811805, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.7651839178785287, "height": 0.01283147989734823, "width": 0.40689238210399037}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-8", "text": "10.4.3.2\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.762617621899059, "height": 0.010265183917878562, "width": 0.058041112454655375}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-9", "text": "         Dermapharm\u2019s total liabilities decreased in the fiscal year ended December 31, 2016, from\n\u20ac252.3 million as of December 31, 2015 by \u20ac1.4 million, or 0.6%, to \u20ac250.9 million as of December 31, 2016,\ndriven by a strong reduction of financial liabilities by \u20ac13.2 million, reflecting the repayment of some of\nDermapharm\u2019s bank loans and a portion of its promissory note loans. However, the maturity of Dermapharm\u2019s\nfinancial liabilities decreased as loan agreements matured, resulting in a shift from non-current to current\nfinancial liabilities. Trade accounts payable increased by 35.4%, thereby almost twice as fast as Dermapharm\u2019s\nrevenues as a result of increased market introductions of new originator pharmaceuticals, which Dermapharm\nincluded in its parallel import product offering and for which it had to build up additional inventories.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.77972626176219, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8887938408896493, "height": 0.10906757912745935, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-114-10", "text": "", "page_number": 114, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-0", "text": "10.4.3.3   Comparison of December 31, 2014 and December 31, 2015\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4885126964933495}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-1", "text": "           In the fiscal year ended December 31, 2015, Dermapharm\u2019s total liabilities decreased from\n\u20ac296.6 million as of December 31, 2014 by \u20ac44.3 million, or 14.9%, to \u20ac252.3 million as of December 31,\n2015, aided by a reduction of trade accounts payable by \u20ac9.3 million resulting from fluctuations of\nDermapharm\u2019s working capital in the ordinary course of business. At the same time, there was a slight shift\nfrom current to non-current financial liabilities, in particular due to the strong reduction of Dermapharm\u2019s other\ncurrent financial liabilities by \u20ac28.2 million, primarily as a result of the disposal of SLG, which had been\nprovided with a loan in an amount of \u20ac23.8 million by the Selling Shareholder that no longer had to be recorded\non Dermapharm\u2019s consolidated statement of financial position following the disposal. Overall, financial\nliabilities decreased by \u20ac5.9 million, as Dermapharm made payments under its bank loans.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1236099230111206, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-2", "text": "Liquidity and Capital Resources\n", "page_number": 115, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.25278015397775877, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.26518391787852863, "height": 0.01240376390076986, "width": 0.23760580411124546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-3", "text": "10.5\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.2630453378956373, "height": 0.010265183917878506, "width": 0.02962515114873035}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-4", "text": "10.5.1\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.290846877673225, "height": 0.010692899914456822, "width": 0.044135429262394194}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-5", "text": "Cash Flows\n", "page_number": 115, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.2805816937553465, "lower_right_x": 0.2642079806529625, "lower_right_y": 0.290846877673225, "height": 0.010265183917878506, "width": 0.08585247883917776}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-6", "text": "The following table provides a breakdown of Dermapharm\u2019s cash flows for the periods indicated:\n", "page_number": 115, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8349455864570737, "lower_right_y": 0.32078699743370404, "height": 0.013259195893926434, "width": 0.6559854897218863}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-7", "text": "                                                                                 For the fiscal year                 For the nine-month period\n                                                                                ended December 31,                    ended September 30,(1)\n                                                                      2014              2015            2016           2016              2017\n                                                                                     (audited)                               (unaudited)\n                                                                                   (in \u20ac million)                           (in \u20ac million)\nProfit or loss for the period ......................................................\n                                                                                0.2              12.9      17.1            55.9           62.9\nAmortization of intangible assets ............................................ 13.5               9.9       9.2             6.7            7.2\nAmortization of intangible assets \u2013\n   impairment charges..............................................................\n                                                                                9.9               5.1           \uf02d             \uf02d              \uf02d\nDepreciation of property, plant and\n   equipment ............................................................................\n                                                                                4.9               5.2          4.9          3.6            3.7\nIncrease/decrease in other accrued\n   employee benefits ................................................................\n                                                                                0.2               0.1          0.1          0.0            0.0\nIncrease/decrease in other non-current\n   provisions ............................................................................\n                                                                                0.0             (0.1)           \uf02d             \uf02d              \uf02d\nIncrease/decrease in other current\n   provisions ............................................................................\n                                                                                0.6               0.3       0.5           (0.7)          (1.0)\nOther non-cash expenses/income items ...................................       40.4              33.7      39.5           (5.3)            0.1\nIncrease/decrease in inventories ..............................................\n                                                                              (3.3)             (5.4)     (6.1)          (10.7)            2.8\nIncrease/decrease in trade receivables .....................................  (0.4)               5.4     (8.7)          (11.8)          (8.4)\nIncrease/decrease in other assets .............................................24.9            (19.0)       6.3             1.8            1.3\nIncrease/decrease in trade payables .........................................   2.1             (9.1)       5.5             4.7          (5.2)\nIncrease/decrease in other liabilities ........................................\n                                                                            (46.8)              (7.1)     (0.2)           (2.7)          (5.3)\nShare of profit of equity-accounted\n   investees, net of tax .............................................................\n                                                                              (0.9)             (1.0)     (1.5)           (1.1)          (1.2)\nNet gain/loss on disposal of intangible\n   assets ....................................................................................\n                                                                                2.4               2.6          1.6          0.1            0.3\nNet gain/loss on disposal of property,\n   plant and equipment.............................................................\n                                                                                0.1               0.0     (0.0)           (0.0)            0.0\nNet gain/loss on sale of investments ........................................      \uf02d              0.1         \uf02d               \uf02d              \uf02d\nInterest expenses/income .........................................................\n                                                                                6.5               5.4       4.2             2.9            3.2\nIncrease/decrease in income tax payables\n   and deferred tax liabilities ...................................................\n                                                                                2.4               3.1       4.3             5.0            3.3\nIncome tax paid/received .........................................................\n                                                                              (2.4)             (1.8)     (0.0)           (0.8)          (1.2)\nNet cash flows from operating activities ..............................        54.3              40.4      76.8            47.6           62.6\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.32677502138579984, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7989734816082121, "height": 0.4721984602224123, "width": 0.7551390568319227}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-115-8", "text": "", "page_number": 115, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-116-0", "text": "                                                                                       For the fiscal year                For the nine-month period\n                                                                                      ended December 31,                   ended September 30,(1)\n                                                                           2014               2015           2016           2016              2017\n                                                                                           (audited)                              (unaudited)\n                                                                                         (in \u20ac million)                          (in \u20ac million)\n Proceeds from sale of intangible assets ...................................     0.2                3.1             2.4          2.4            0.2\n Proceeds from sale of property, plant and\n    equipment ............................................................................\n                                                                                 2.0                0.4             0.3          0.1            0.2\n Proceeds from sale of investments...........................................       \uf02d               6.8             0.0            \uf02d              \uf02d\n Acquisition of subsidiary, net of cash\n                                                                                    \uf02d\n    acquired ...............................................................................           \uf02d       (1.4)           (1.4)              \uf02d\n Purchase of intangible assets ...................................................\n                                                                             (22.2)               (11.7)      (12.7)           (8.7)         (67.4)\n Purchase of property, plant and equipment..............................       (6.3)               (3.2)       (5.1)           (4.2)          (3.4)\n Payments for investment in financial\n                                                                                    \uf02d\n    assets ....................................................................................    (1.1)       (0.1)           (0.1)         (14.5)\n Dividends from equity-accounted\n    investees ..............................................................................\n                                                                                 2.0                1.0             0.9            \uf02d              \uf02d\n Interest received .......................................................................\n                                                                                 2.3                3.8             3.3          0.1            0.0\n Net cash flows used in investing\n    activities ..............................................................................\n                                                                             (21.9)                (0.9)      (12.3)          (11.7)         (84.9)\n Payment/prepayment of profit transfers\n    due to profit transfer agreements .........................................\n                                                                             (39.9)               (33.0)      (39.5)          (39.5)         (66.9)\n Acquisition of non-controlling interests ..................................   (0.0)               (0.1)       (1.9)           (1.9)          (6.6)\n Dividends paid .........................................................................\n                                                                               (5.6)               (0.1)           \uf02d               \uf02d              \uf02d\n Payments for financial receivables ..........................................      \uf02d                  \uf02d           \uf02d               \uf02d          (8.2)\n Proceeds from financial liabilities ...........................................74.3                 9.8         6.1             2.8         151.8\n Repayment of financial liabilities ............................................\n                                                                             (16.7)               (22.6)      (12.5)           (6.2)         (52.8)\n Payment of finance lease liabilities .........................................(0.3)               (0.4)       (0.6)           (0.2)          (0.1)\n Interest paid .............................................................................\n                                                                               (8.8)               (9.2)       (7.5)           (3.0)          (3.2)\n Net cash flows from/used in financing\n                                                                                 3.0\n    activities ..............................................................................     (55.6)      (55.9)          (47.9)           14.1\nNet increase in cash, cash equivalents\n                                                                                35.3\nand bank overdrafts ................................................................              (16.2)            8.6       (12.0)          (8.2)\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5312232677502139, "height": 0.44610778443113774, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-116-1", "text": "(1) Due to the termination of the Profit Transfer Agreement with effect from the end of December 31, 2017,\n    Dermapharm AG has changed the composition of its consolidated statement of cash flows, which is already reflected in\n    the financial information in the consolidated statement of cash flows shown in Dermapharm AG\u2019s unaudited condensed\n    consolidated interim financial statements for the nine-month period ended September 30, 2017. As a result, certain\n    comparable financial information with respect to the fiscal year ended December 31, 2016 shown in the consolidated\n    statement of cash flows in the consolidated financial statements for the fiscal year ended December 31, 2017 will differ\n    from the financial information shown in the consolidated statement of cash flows in Dermapharm AG\u2019s consolidated\n    financial statements for the fiscal years ended December 31, 2016, 2015 and 2014. The change in composition of the\n    consolidated statement of cash flows affects the line items profit or loss for the period, other non-cash expenses/income\n    items, increase/decrease in other assets, payment/prepayment of profit transfers due to profit transfer agreements and\n    payments for financial receivables.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.544054747647562, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6830624465355004, "height": 0.1390076988879384, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-116-2", "text": "10.5.1.1     Net Cash Flows from Operating Activities\n\n10.5.1.1.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.720677146311971, "lower_right_y": 0.739093242087254, "height": 0.04148845166809234, "width": 0.6003627569528416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-116-3", "text": "          In the nine-month period ended September 30, 2017, net cash flows from operating activities improved\nfrom \u20ac47.6 million in the nine-month period ended September 30, 2016 by \u20ac15.0 million, or 31.5%, to\n\u20ac62.6 million, particularly due to the decrease in inventories caused by fluctuations of Dermapharm\u2019s working\ncapital in the ordinary course of business, which led to a cash inflow of \u20ac2.8 million in the nine-month period\nended September 30, 2017, compared to a cash outflow of \u20ac10.7 million in the nine-month period ended\nSeptember 30, 2016 caused by the increase in inventories required to secure Dermapharm\u2019s delivery reliability.\nIn addition, there were lower adjustments for non-cash items in the nine-month period ended September 30,\n2017. These developments were partly offset by the decrease of trade payables, which resulted in a cash outflow\nof \u20ac5.2 million in the nine-month period ended September 30, 2017, compared to a cash inflow of \u20ac4.7 million\ndue to an increase of trade payables in the nine-month period ended September 30, 2016. The change in trade\npayables was predominantly caused by the different timing of payments to suppliers in different periods.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9033361847733106, "height": 0.1509837467921301, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-116-4", "text": "", "page_number": 116, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-0", "text": "10.5.1.1.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-1", "text": "         Dermapharm\u2019s net cash flow from operating activities improved from \u20ac40.4 million in the fiscal year\nended December 31, 2015 by \u20ac36.4 million, or 90.1%, to \u20ac76.8 million in the fiscal year ended December 31,\n2016, primarily driven by lower cash outflows from changes in working capital. An increase in trade payables\ngenerated a cash inflow of \u20ac5.5 million compared to the cash outflow of \u20ac9.1 million from a decrease of trade\npayables in the fiscal year ended December 31, 2015. This development was only partly offset by the increase in\ntrade receivables that resulted in a cash outflow of \u20ac8.7 million in the fiscal year ended December 31, 2016,\ncompared to a cash inflow of \u20ac5.4 million caused by the decrease in trade receivables in the fiscal year ended\nDecember 31, 2015. These changes in trade payables and trade receivables were predominantly caused by the\ndifferent timing of payments to suppliers and payments by customers, respectively, in different periods. With\nrespect to decreases and increases of other assets and other liabilities, these primarily reflect the adjustments for\nnon-cash effective changes in the value of currency related swaps with UniCredit and the corresponding\nreceivable against the Selling Shareholder (see \u201c10.2.3.2 Exchange Rate Fluctuations\u201d).\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2771599657827203, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-2", "text": "10.5.1.1.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.30624465355004277, "height": 0.01240376390076986, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-3", "text": "          In the fiscal year ended December 31, 2015, Dermapharm\u2019s net cash flow from operating activities\ndecreased from \u20ac54.3 million in the fiscal year ended December 31, 2014 by \u20ac13.9 million, or 25.6%, to\n\u20ac40.4 million, mainly due to higher cash outflows from changes in working capital. A decrease in trade payables\nled to a cash outflow of \u20ac9.1 million in the fiscal year ended December 31, 2015, compared to a cash inflow of\n\u20ac2.1 million from the increase of trade payables in the fiscal year ended December 31, 2014. This development\nwas only partly offset by a decrease in trade receivables. The changes in trade payables and trade receivables\nwere predominantly caused by the different timing of payments to suppliers and payments by customers,\nrespectively, in different periods. With respect to decreases and increases of other assets and other liabilities,\nthese primarily reflect the adjustments for non-cash effective changes in the value of currency related swaps\nwith UniCredit and the corresponding receivable against the Selling Shareholder (see \u201c10.2.3.2 Exchange Rate\nFluctuations\u201d).\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4704875962360992, "height": 0.1492728828058169, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-4", "text": "10.5.1.2     Net Cash Flows used in Investing Activities\n\n10.5.1.2.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.7200725513905684, "lower_right_y": 0.5265183917878529, "height": 0.04106073567151414, "width": 0.599758162031439}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-5", "text": "         In the nine-month period ended September 30, 2017, net cash flows used in investing activities\nincreased significantly from a cash outflow of \u20ac11.7 million in the nine-month period ended September 30, 2016\nto a cash outflow of \u20ac84.9 million, primarily driven by increasing cash outflows for purchases of intangible\nassets of \u20ac67.4 million in the nine-month period ended September 30, 2017, inter alia, reflecting the funds\ninvested for the acquisition of the assets pertaining to the hyperthermic medical devices division of Riemser\nPharma GmbH (see \u201c12.13.3.1 Asset Purchase Agreement for bite away\u00ae and Herpotherm\u00ae\u201d). In addition,\ninvestments in financial assets in connection with a prepayment for the acquisition of Bio-Di\u00e4t-Berlin\n(see \u201c12.13.3.2 Share Purchase Agreement for Bio-Di\u00e4t-Berlin\u201d) led to a cash outflow of \u20ac14.5 million in the\nnine-month period ended September 30, 2017.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6638152266894782, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-6", "text": "10.5.1.2.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6770744225834047, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.6911890504704876, "height": 0.014114627887082953, "width": 0.5465538089480049}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-7", "text": "          Dermapharm\u2019s net cash flows used in investing activities increased from a cash outflow of \u20ac0.9 million\nin the fiscal year ended December 31, 2015 by \u20ac11.4 million to a cash outflow of \u20ac12.3 million in the fiscal year\nended December 31, 2016. Purchases of intangible assets of \u20ac12.7 million were the most significant cause of\ncash outflows, in particular reflecting Dermapharm\u2019s spending on capitalized development projects as part of its\ndevelopment efforts as well as on the acquisition of licenses, patents and similar rights. In addition, the\nacquisition of a 75.1%-stake in Remedix GmbH contributed to a cash outflow of \u20ac1.4 million recorded under\nacquisitions of subsidiaries, net of cash acquired.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.704448246364414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8006843455945253, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-8", "text": "10.5.1.2.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.8139435414884517, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.8280581693755347, "height": 0.014114627887082953, "width": 0.5459492140266022}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-9", "text": "         In the fiscal year ended December 31, 2015, Dermapharm\u2019s net cash flows used in investing activities\ndecreased strongly from a cash outflow of \u20ac21.9 million in the fiscal year ended December 31, 2014 by\n\u20ac21.0 million to a cash outflow of \u20ac0.9 million, reflecting the fact that Dermapharm significantly reduced its\npurchases of intangible assets, while at the same time generating proceeds from the sale of investments of\n\u20ac6.8 million, primarily from the sale of Centuere.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8447390932420873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.911890504704876, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-117-10", "text": "", "page_number": 117, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-0", "text": "10.5.1.3     Net Cash Flows from/used in Financing Activities\n\n10.5.1.3.1   Comparison of the Nine-month Periods ended September 30, 2016 and 2017\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.720677146311971, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.599758162031439}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-1", "text": "          In the nine-month period ended September 30, 2017, Dermapharm\u2019s net cash flows from financing\nactivities improved from a cash outflow of \u20ac47.9 million in the nine-month period ended September 30, 2016 to\na cash inflow of \u20ac14.1 million, driven by cash inflows due to proceeds from financial liabilities in an amount of\n\u20ac151.8 million resulting from new loans taken out by Dermapharm in the nine-month period ended September\n30, 2017 (see \u201c12.13.2.2 Loan Agreements of Dermapharm AG\u201d). However, parts of these proceeds were used\nto refinance existing loans, resulting in cash outflows in connection with the repayment of financial liabilities in\nan amount of \u20ac52.8 million in the nine-month period ended September 30, 2017. In addition, Dermapharm\nrecorded cash outflows of \u20ac66.9 million due to payments to the Selling Shareholder under the Profit Transfer\nAgreement in that amount.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.26390076988879385, "height": 0.12061591103507271, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-2", "text": "10.5.1.3.2   Comparison of the Fiscal Years ended December 31, 2015 and 2016\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.29298545765611633, "height": 0.012831479897348175, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-3", "text": "        Dermapharm\u2019s net cash flows used in financing activities increased only slightly from a cash outflow\nof \u20ac55.6 million in the fiscal year ended December 31, 2015 by \u20ac0.3 million, or 0.5%, to a cash outflow of\n\u20ac55.9 million in the fiscal year ended December 31, 2016. Payments under the Profit Transfer Agreement in an\namount of \u20ac39.5 million were responsible for the most significant cash outflows. In addition, Dermapharm made\nrepayments in order to further reduce its financial liabilities, in particular promissory loan notes, leading to\npayments of principal in an amount of \u20ac12.5 million and interest of \u20ac7.5 million. At the same time, Dermapharm\nrecorded cash inflows of \u20ac6.1 million from new bank loans.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40034217279726264, "height": 0.09281437125748504, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-4", "text": "10.5.1.3.3   Comparison of the Fiscal Years ended December 31, 2014 and 2015\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.43071000855431996, "height": 0.01368691189050475, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-5", "text": "         In the fiscal year ended December 31, 2015, Dermapharm\u2019s net cash flows used in financing activities\ndeteriorated from a cash inflow of \u20ac3.0 million in the fiscal year ended December 31, 2014 by \u20ac58.6 million to a\ncash outflow of \u20ac55.6 million, Payments under the Profit Transfer Agreement in an amount of \u20ac33.0 million\nwere responsible for the most significant cash outflows. By refinancing bank loans through the issuance of\npromissory note loans, Dermapharm was able to generate cash inflows of \u20ac9.8 million, while spending\n\u20ac22.6 million on the repayment of financial liabilities.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5269461077844312, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-6", "text": "10.5.2   Cash, Cash Equivalents and Bank Overdrafts\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.5543199315654406, "height": 0.014114627887082953, "width": 0.3778718258766627}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-7", "text": "          The following table provides an overview of Dermapharm\u2019s cash, cash equivalents and bank overdrafts\nas of the dates indicated:\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5945252352437981, "height": 0.026946107784431073, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-8", "text": "                                                                                     As of                            As of\n                                                                                 December 31,                    September 30,\n                                                                   2014               2015          2016      2016             2017\n                                                                                   (audited)                       (unaudited)\n                                                                                 (in \u20ac million)                   (in \u20ac million)\n Cash and cash equivalents .......................................................\n                                                                          11.6                2.8       3.8       4.2            12.6\n                                                                         (5.2)\n Bank overdrafts .......................................................................   (12.4)     (4.9)    (25.8)          (21.9)\nCash, cash equivalents and bank\n                                                                            6.5\n  overdrafts .............................................................................  (9.6)     (1.1)    (21.6)            (9.3)\n", "page_number": 118, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.602224123182207, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7164242942686057, "height": 0.11420017108639868, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-118-9", "text": "", "page_number": 118, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-0", "text": "10.5.3   Capital Expenditures\n\n         The following table presents Dermapharm\u2019s capital expenditures for the periods indicated:\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.788391777509069, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.6680773881499396}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-1", "text": "                                                                                   For the fiscal year              For the nine-month period\n                                                                                  ended December 31,                  ended September 30,\n                                                                          2014             2015           2016        2016              2017\n                                                                          (audited, unless otherwise specified)             (unaudited)\n                                                                                      (in \u20ac million)                       (in \u20ac million)\n Acquisition of subsidiaries, net of cash\n                                                                                   \uf02d\n   acquired ...............................................................................         \uf02d         1.4          1.4              \uf02d\n Purchase of intangible assets ...................................................\n                                                                              22.2               11.7        12.7          8.7           67.4\n Purchase of property, plant and equipment..............................        6.3               3.2         5.1          4.2            3.4\n Payments for investments in financial\n                                                                                   \uf02d\n   assets ....................................................................................    1.1         0.1          0.1           14.5\nTotal capital expenditures (unaudited) ..................................     28.5               16.0        19.2         14.3           85.3\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.1330196749358426, "lower_right_x": 0.875453446191052, "lower_right_y": 0.2938408896492729, "height": 0.1608212147134303, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-2", "text": "10.5.3.1   Future and Planned Principal Capital Expenditures\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.3331907613344739, "height": 0.0119760479041916, "width": 0.43591293833131795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-3", "text": "         As of the date of this Prospectus, the Management Board has made commitments on several future\ncapital expenditures in an aggregate amount of approximately \u20ac60.0 million for the fiscal years ending\nDecember 31, 2018, 2019 and 2020. These capital expenditures include:\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38922155688622756, "height": 0.04063301967493588, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-4", "text": "           \uf0b7   the construction of a new logistics center with approximately 6,000 new pallet places as well as an\n               expansion of manufacturing capacities in Brehna, with the total investment volume amounting to\n               approximately \u20ac8.0 million;\n           \uf0b7   the construction of a new manufacturing facility in Neumarkt am Wallersee for Austrian-based\n               Melasan Produktions & Vertriebsgesellschaft m.b.H., with the total investment volume amounting\n               to approximately \u20ac7.0 million;\n           \uf0b7   capital expenditures on future pharmaceuticals and other healthcare product developments in an\n               amount of \u20ac11.0 million per annum in the fiscal years ending December 31, 2018, 2019 and 2020;\n               and\n           \uf0b7   acquisitions of product portfolios, marketing rights and similar expansions in an aggregate amount\n               of \u20ac12.0 million.\n\n10.5.3.2       Principal Capital Expenditures since December 31, 2016 and Principal Ongoing Capital\n               Expenditures\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6124893071000855, "height": 0.21599657827202734, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-5", "text": "         In the nine-month period ended September 30, 2017, Dermapharm\u2019s capital expenditures amounted to\n\u20ac85.3 million, primarily consisting of payments for the acquisition of the remaining 15%-stake in axicorp\nGmbH, the purchase of the marketing rights for medical devices bite away\u00ae and Herpotherm\u00ae as well as the\nacquisition of all shares in Bio-Di\u00e4t-Berlin.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.625748502994012, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6809238665526091, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-6", "text": "       Between September 30, 2017 and the date of this Prospectus, Dermapharm\u2019s capital expenditures\namounted to \u20ac114.1 million, comprising the costs and purchase prices for the acquisitions of Strathmann and\nTrommsdorff as well as development costs in connection with Dermapharm\u2019s ongoing development efforts.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6873396065012831, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7288280581693756, "height": 0.04148845166809245, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-7", "text": "        Dermapharm\u2019s capital expenditures between December 31, 2016 and the date of this Prospectus were\nfinanced from Dermapharm\u2019s net cash flows from operating activities as well as a loan from\nCOMMERZBANK Aktiengesellschaft in an amount of \u20ac50.0 million (see \u201c12.13.2.2.2 Loan Agreement with\nCOMMERZBANK Aktiengesellschaft\u201d) and a loan from Baden-W\u00fcrttembergische Bank in an amount of\n\u20ac80.0 million (see \u201c12.13.2.2.5 Loan Agreement with Baden-W\u00fcrttembergische Bank\u201d).\n", "page_number": 119, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7352437981180496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8041060735671514, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-119-8", "text": "", "page_number": 119, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01874244256348251}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-0", "text": "10.5.3.3   Principal Capital Expenditures in the Fiscal Years ended December 31, 2014, 2015 and 2016\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8367593712212817, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-1", "text": "         In the fiscal year ended December 31, 2016 Dermapharm\u2019s capital expenditures amounted to\n\u20ac19.2 million, which primarily consisted of investments in the expansion and optimization of Dermapharm\u2019s\nproduction capacities for its prescription pharmaceuticals and other healthcare products business area as well as\nfunds for the acquisition of a 75.1%-stake in Remedix GmbH.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.055175363558597076, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-2", "text": "         In the fiscal year ended December 31, 2015 Dermapharm\u2019s capital expenditures amounted to\n\u20ac16.0 million, comprising the acquisition of the remaining 25%-stake in Austrian-based Melasan Produktions &\nVertriebsgesellschaft m.b.H. as well as investments in the expansion of Dermapharm\u2019s product portfolio for\npharmaceuticals and other healthcare products.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2292557741659538, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-3", "text": "        In the fiscal year ended December 31, 2014 Dermapharm\u2019s capital expenditures amounted to\n\u20ac28.5 million, comprising funds spent to acquire Naturwohl Vertriebs GmbH, which holds the right to market\nthe OTC product LactoStop\u00ae, as well as investments in the expansion of Dermapharm\u2019s production capacities\nand machinery for its Brehna facility.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2917023096663815, "height": 0.05260906757912742, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-4", "text": "and machinery for its Brehna facility.\n         All of Dermapharm\u2019s investments in the fiscal years ended December 31, 2014, 2015 and 2016,\nrespectively, were financed from Dermapharm\u2019s net cash flows from operating activities as well as the\n2014 Promissory Notes (see \u201c12.13.2.1.1 2014 Promissory Notes\u201d).\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2921300256629598, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34046193327630453, "height": 0.048331907613344716, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-5", "text": "10.5.4   Financial Liabilities\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35543199315654406, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.3661248930710009, "height": 0.010692899914456822, "width": 0.20374848851269647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-6", "text": "         The following table provides an overview of Dermapharm\u2019s financial liabilities as of the dates\nindicated:\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.38280581693755344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40718562874251496, "height": 0.024379811804961515, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-7", "text": "                                                                                              As of                                As of\n                                                                                         December 31,                         September 30,\n                                                                          2014                 2015                2016             2017\n                                                                              (audited, unless otherwise specified)             (unaudited)\n                                                                                          (in \u20ac million)                       (in \u20ac million)\n Bank loans ...............................................................................\n                                                                                 22.2              12.5                 2.7            147.5\n Promissory note loans ..............................................................\n                                                                               128.0              127.5                87.7             87.7\n Leasing liabilities .....................................................................\n                                                                                   0.3              0.1                 0.1              0.2\n                                                                                 11.0\n Participation rights ...................................................................          11.0                 6.4                \uf02d\n Non-current financial liabilities ............................................161.5              151.1                96.9            235.4\n Bank loans ...............................................................................\n                                                                                 13.1              10.0                14.7             12.9\n Promissory note loans ..............................................................\n                                                                                   0.6              0.9                40.4              1.5\n Leasing liabilities .....................................................................\n                                                                                   0.2              0.2                 0.1              0.1\n Participation rights ...................................................................\n                                                                                   1.3              1.3                 5.8              6.9\n Bank overdrafts .......................................................................\n                                                                                   5.2             12.4                 4.9             21.9\n Current financial liabilities ...................................................\n                                                                                 20.4              24.9                65.9             43.4\n Other non-current financial liabilities .................................         9.9             14.1                10.5             10.4\n Other current financial liabilities .........................................   30.6               2.4                 4.3              2.1\nTotal financial liabilities (unaudited) .....................................  222.4              192.5               177.6            291.3\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4136013686911891, "lower_right_x": 0.875453446191052, "lower_right_y": 0.6775021385799829, "height": 0.2639007698887938, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-8", "text": "         For further information   on   Dermapharm\u2019s   liabilities,   see   \u201d10.7.3 Liquidity   Risks\u201d   and\n\u201c12.13.2 Financing Agreements\u201d.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7010265183917879, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7288280581693756, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-120-9", "text": "", "page_number": 120, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01874244256348251}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-0", "text": "10.5.5   Maturity Profile\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.1747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-1", "text": "          The following table shows Dermapharm\u2019s financial liabilities according to class of maturity, based on\nthe remaining maturity as of the dates indicated and related to the contractually agreed, non-discounted cash\nflows. Financial liabilities payable at any time are allocated to the earliest possible time of payment. Variable\ninterest payments from the financial instruments, where applicable, were calculated on the basis of respective\nforward rates as of the relevant date:\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1800684345594525, "height": 0.06757912745936696, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-2", "text": "                                                                                                           As of\n                                                                                                     December 31, 2016\n                                                                                                         (audited)\n                                                                                                       (in \u20ac million)\n                                                                                                     Due between one\n                                                                      Due within one year             and five years     Due after five years\nInterest ..................................................................................... 8.1                 5.4                      \uf02d\nRepayment ...............................................................................65.1                     96.1                    0.0\nExpected cash flows from trade payables ................................24.5                                         \uf02d                      \uf02d\nExpected cash flows from other liabilities ............................... 4.3                                       \uf02d                      \uf02d\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1275695284159613, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8766626360338573, "lower_right_y": 0.3143712574850299, "height": 0.1266039349871685, "width": 0.7490931076178959}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-3", "text": "As of the date indicated, proceeds and payments from derivatives were expected as follows:\n", "page_number": 121, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.34174508126603936, "lower_right_x": 0.7980652962515115, "lower_right_y": 0.35457656116338754, "height": 0.012831479897348175, "width": 0.6197097944377267}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-4", "text": "                                                                                                           As of\n                                                                                                     December 31, 2016\n                                                                                                         (audited)\n                                                                                                       (in \u20ac million)\n                                                                                                     Due between one\n                                                                      Due within one year             and five years      Due after five years\nInterest ..................................................................................... 3.3                  6.9                      \uf02d\nRepayment ...............................................................................   (3.7)                 (7.0)                      \uf02d\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12696493349455865, "top_left_y": 0.3627031650983747, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4576561163387511, "height": 0.0949529512403764, "width": 0.752720677146312}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-5", "text": "10.5.6   Other Financial Obligations and Contingent Liabilities\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.562273276904474, "lower_right_y": 0.49871685201026517, "height": 0.013259195893926434, "width": 0.4419588875453446}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-6", "text": "       There were no material guarantees or contingent liabilities with respect to Dermapharm as of\nDecember 31, 2016, 2015 and 2014.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5128314798973481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5389221556886228, "height": 0.026090675791274665, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-7", "text": "         As of December 31, 2016, Dermapharm\u2019s purchase commitments for inventories, which comprised\noutstanding orders of pharmaceuticals for Dermapharm\u2019s parallel import business area, amounted to\n\u20ac73.0 million (as of December 31, 2015: \u20ac89.0 million; as of December 31, 2014: \u20ac65.4 million).\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.588109495295124, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-8", "text": "Additional Information from the Individual Financial Statements of the Company\n", "page_number": 121, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.6017964071856288, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.6159110350727117, "height": 0.014114627887082953, "width": 0.5900846432889963}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-9", "text": "10.6\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.602224123182207, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.6124893071000855, "height": 0.010265183917878562, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-10", "text": "          The Company was formed as a as a European company (Societas Europaea (SE)) under European law\nby articles of association dated July 4, 2017. The Company has prepared audited individual financial statements\nas of September 30, 2017 and for the period from July 12, 2017 to September 30, 2017 in accordance with\nIFRS.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6822070145423439, "height": 0.05303678357570574, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-11", "text": "         The Company has prepared the audited individual financial statements as of September 30, 2017 and\nfor the period from July 12, 2017 to September 30, 2017 on a voluntary basis for purposes of this Prospectus.\nWith respect to the fiscal year ended December 31, 2017, the Company will prepare individual financial\nstatements in accordance with generally accepted accounting principles of the HGB for the short fiscal year\nended December 31, 2017. Accounting principles set forth in the HGB differ from IFRS in material respects.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6907613344739093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7596236099230111, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-12", "text": "          According to the Company\u2019s audited statement of comprehensive income for the period from July 12,\n2017 to September 30, 2017, the Company incurred other operating expenses of \u20ac26.07 and a corresponding net\nloss in that period.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8075278015397775, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-13", "text": "        According to the Company\u2019s audited statement of financial position as of September 30, 2017, the\nCompany\u2019s issued capital amounted to \u20ac120,000.00 as of that date. As of September 30, 2017, the Company\nrecorded cash and cash equivalents in an amount of \u20ac119,973.93 and a net loss of \u20ac26.07.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8139435414884517, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8554319931565441, "height": 0.04148845166809234, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-14", "text": "        For further information on the Company\u2019s audited individual financial statements prepared in\naccordance with IFRS, see pages F-92 et seq. of this Prospectus.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8618477331052181, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8896492728828058, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-121-15", "text": "", "page_number": 121, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01874244256348251}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-0", "text": "10.7   Qualitative Disclosure on Financial Risks\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.35792019347037485}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-1", "text": "         Dermapharm is exposed to a number of financial risks arising from the ordinary course of business,\nincluding market risks, credit risks and liquidity risks.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-2", "text": "10.7.1   Market Risks\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15697177074422583, "lower_right_x": 0.27267230955259975, "lower_right_y": 0.16723695466210436, "height": 0.010265183917878534, "width": 0.15235792019347036}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-3", "text": "         Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and\nequity prices, will affect Dermapharm\u2019s income or the value of its holdings of financial instruments. The\nobjective of market risk management is to manage and control market risk exposures within acceptable\nparameters, while optimizing the return.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23823781009409753, "height": 0.053892215568862284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-4", "text": "10.7.1.1\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.2634730538922156, "height": 0.010692899914456822, "width": 0.0532043530834341}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-5", "text": "Currency Risks\n", "page_number": 122, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.25278015397775877, "lower_right_x": 0.309552599758162, "lower_right_y": 0.2668947818648417, "height": 0.014114627887082953, "width": 0.10701330108827084}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-6", "text": "         Currency risk arises from future commercial transactions, recognized assets and liabilities and net\ninvestments in foreign operations. The foreign exchange risk can be split into two types: translation risk and\ntransaction risk.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.03806672369546621, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-7", "text": "          The translation risk describes the risk from changes to the statement of financial position and statement\nof comprehensive income items of a subsidiary due to changes to the exchange rates when converting local\nindividual financial statements into Dermapharm\u2019s presentation currency, the Euro. The changes caused by\ncurrency fluctuations when translating statement of financial position line items were recognized in equity.\nDermapharm is currently exposed to currency risks with six subsidiaries, though this risk is minimal due to the\nsize of these companies.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4101796407185629, "height": 0.08212147134302822, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-8", "text": "          Transaction risk is the risk that the value of future foreign currency payments may change due to\nexchange rate fluctuations. Dermapharm operates internationally and is exposed to foreign exchange risks\narising from various currency exposures, primarily with respect to Euros.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4585115483319076, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-9", "text": "         Dermapharm does not account for any fixed rate financial assets or liabilities at fair value through\nprofit or loss, and it does not designate derivatives (interest swap rates) as hedging instruments under a fair\nvalue hedge accounting model. Therefore, a change in interest rates at the reporting date does not affect\nDermapharm\u2019s profits or losses.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5201026518391788, "height": 0.05517536355859709, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-10", "text": "The following table shows the effects of an appreciation or depreciation of the Euro by 10%:\n", "page_number": 122, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8022974607013301, "lower_right_y": 0.5406330196749358, "height": 0.014114627887082953, "width": 0.6233373639661427}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-11", "text": "                                                                                     For the fiscal year ended December 31, 2016\n                                                                                                        (audited)\n                                                                                                      (in \u20ac million)\n                                                                             \u20ac appreciates by 10%                    \u20ac depreciates by 10%\n Total Changes in Fair Value ....................................................                  (0.2)                                    0.1\nProfit/Loss ................................................................................       (0.2)                                    0.1\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6261762189905903, "height": 0.0791274593669804, "width": 0.7593712212817412}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-12", "text": "         To reflect market risks, IFRS 7 requires sensitivity analyses that demonstrate the effects of hypothetical\nchanges of relevant risk variables on the profit for the period as well as equity. The following observation is\none-dimensional and does not take into account the effect of taxes. The table shows the positive and negative\neffects had the Euro depreciated or appreciated by 5% in comparison to Swiss Francs and Polish Zloty, provided\nthat all other variables had remained constant. Here, currency gains and losses from foreign currency\ndenominated financial assets and financial liabilities equally impact Dermapharm\u2019s profits and equity. Apart\nfrom changes to Dermapharm\u2019s profits, there are no other effects on equity resulting from changes in exchange\nrates.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7591958939264328, "height": 0.10607356715141147, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-13", "text": "         The following table shows the effects of an appreciation or depreciation of the Euro against the Swiss\nFranc and Polish Zloty, assuming that all other variables, in particular interest rates, remain constant and not\ntaking into account any impact of forecast sales and purchases:\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7694610778443114, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8100940975192472, "height": 0.04063301967493582, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-14", "text": "                                                                              As of and for the fiscal year ended December 31, 2016\n                                                                                                      (audited)\n                                                                                                    (in \u20ac million)\n                                                                                              Impact on profit/loss     Impact on profit/loss\n                                                                          Balance              \u20ac appreciates by 5%      \u20ac depreciates by 5%\nSwiss Franc ..............................................................................15.5                (0.7)                       0.8\nPolish Zloty .............................................................................\n                                                                                        (0.3)                 (0.0)                       0.0\n", "page_number": 122, "bounding_box": {"top_left_x": 0.12636033857315598, "top_left_y": 0.8173652694610778, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8999144568006844, "height": 0.08254918733960659, "width": 0.7575574365175333}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-122-15", "text": "", "page_number": 122, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-0", "text": "10.7.1.2   Interest Rate Risks\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-1", "text": "         The interest rate risk includes the effect of positive and negative changes to interest rates on profits,\nequity, or cash flows in the current or a future reporting period. Interest rate risks from financial instruments can\narise within Dermapharm mainly in connection with financial liabilities.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-2", "text": "         The following table shows Dermapharm\u2019s expenses from interest rate swaps, assuming a decrease and\nincrease, respectively, of the Euro Interbank Offered Rate (\u201cEURIBOR\u201d) by 50 basis points:\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881950384944397, "height": 0.027801539777587675, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-3", "text": "                                                                          As of and for the fiscal year ended December 31, 2016\n                                                                                                  (audited)\n                                                                                                (in \u20ac million)\nEURIBOR decreases by 50 basis points ..................................                          (0.4)\nCurrent swap expense ..............................................................              (0.3)\nEURIBOR increases by 50 basis points ..................................                          (0.3)\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12636033857315598, "top_left_y": 0.19461077844311378, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.27245508982035926, "height": 0.07784431137724548, "width": 0.7442563482466747}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-4", "text": "         The following table shows Dermapharm\u2019s interest expenses for variable rate loans, assuming a\ndecrease and increase, respectively, of the EURIBOR by 50 basis point:\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.29726261762189904, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32506415739948674, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-5", "text": "", "page_number": 123, "bounding_box": {"top_left_x": 0.5036275695284159, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8065296251511487, "lower_right_y": 0.33575705731394356, "height": 0.004277159965782762, "width": 0.30290205562273276}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-6", "text": "                                                                          As of and for the fiscal year ended December 31, 2016\n                                                                                                  (audited)\n                                                                                                (in \u20ac million)\nEURIBOR decreases by 50 basis points ..................................                           0.3\nCurrent interest expense ..........................................................               0.5\nEURIBOR increases by 50 basis points ..................................                           0.6\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.3361847733105218, "lower_right_x": 0.8627569528415961, "lower_right_y": 0.40889649272882805, "height": 0.07271171941830623, "width": 0.7370012091898428}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-7", "text": "10.7.2   Credit Risks\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4341317365269461, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.4473909324208725, "height": 0.013259195893926434, "width": 0.1457073760580411}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-8", "text": "         Credit risk is the risk of financial loss arising from a counterparty\u2019s inability to repay or service debt in\naccordance with the contractual terms. Credit risk includes both the direct risk of default and the risk of a\ndeterioration of creditworthiness as well as concentration risk.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46150556030795553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.501710863986313, "height": 0.04020530367835751, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-9", "text": "          Credit risk is managed at the group level, except for credit risk relating to accounts receivable balances.\nEach local entity of Dermapharm is responsible for managing and analyzing the credit risk for each of their new\nclients before standard payment and delivery terms and conditions are offered.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5128314798973481, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5526090675791274, "height": 0.0397775876817793, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-10", "text": "         The extent of this credit risk for Dermapharm corresponds to the sum of trade receivables, other\nfinancial assets and cash or cash equivalents. The maximum credit risk in case of a counterparty defaulting\ncorresponds for all classes of financial assets to the book value on the balance sheet date in each case. No\nsignificant concentration risks for Dermapharm existed as of September 30, 2017 or for previous periods.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6142001710863987, "height": 0.05346449957228405, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-11", "text": "         Risks of default mainly arise from trade receivables from customers. Credit risks from financial\ntransactions are managed centrally by Dermapharm\u2019s finance department. To minimize risks, financial\ntransactions are only conducted within short defined terms of payments and with banks and other partners that\npreferably have investment-grade ratings. In the past, no major impairments of trade receivables were necessary.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.676218990590248, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-12", "text": "         In addition, there exists a risk of default for cash and cash equivalents if financial institutions can no\nlonger fulfil their obligations. Dermapharm limits this risk by investing only with various banking institutions\nwith good ratings.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.6839178785286569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7249786142001711, "height": 0.04106073567151414, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-13", "text": "10.7.3   Liquidity Risks\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7386655260906758, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.7523524379811805, "height": 0.013686911890504638, "width": 0.16505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-14", "text": "         Liquidity risk includes the risk that Dermapharm is unable to settle its assumed financial liabilities\nupon maturity. This is why a significant aim of the liquidity management is to ensure that payment is possible at\nall times. Dermapharm\u2019s management constantly monitors the risk of liquidity shortfalls by using the liquidity\nplanning capabilities of its ERP-System, which takes account of payments in and out of the financial assets and\nfinancial liabilities as well as expected cash flows from business activities.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8344739093242087, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-15", "text": "         Dermapharm seeks to maintain a balance between continuously covering the required financial\nresources and ensuring flexibility by using bank credit facilities. Any remaining short-term liquidity requirement\npeaks are balanced out by using those credit facilities.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8413173652694611, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8828058169375534, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-123-16", "text": "", "page_number": 123, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-0", "text": "         As of the date indicated, Dermapharm had access to the following lines of credit as of the dates\nindicated:\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11120615911035073, "height": 0.026090675791274595, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-1", "text": "                                                                                            As of December 31,\n                                                                        2014                        2015          2016\n                                                                                                 (audited)\n                                                                                               (in \u20ac million)\nAggregate line of credit ...........................................................72.8                   76.5          75.5\nAvailable line of credit ............................................................67.6                  64.1          70.6\nNumber of banks ..................................................................... 17                     17            16\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1293833131801693, "top_left_y": 0.12959794696321641, "lower_right_x": 0.875453446191052, "lower_right_y": 0.21642429426860565, "height": 0.08682634730538924, "width": 0.7460701330108828}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-2", "text": "Critical Accounting Policies and Use of Estimates and Assumptions\n", "page_number": 124, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.24593669803250642, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.25962360992301114, "height": 0.013686911890504722, "width": 0.48246674727932287}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-3", "text": "10.8\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.24593669803250642, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.2566295979469632, "height": 0.010692899914456794, "width": 0.028415961305925025}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-4", "text": "         The preparation of consolidated financial statements under IFRS requires assumptions and estimates\nthat have an impact on the recognition of assets and liabilities on the consolidated statement of financial\nposition, on income and expenses in the consolidated statement of comprehensive income and on disclosures\nconcerning the existence of contingent liabilities. Actual results may differ from Dermapharm\u2019s estimates.\nDermapharm has identified the accounting policies discussed below as critical to its business and results of\noperations.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.27331052181351584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35457656116338754, "height": 0.0812660393498717, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-5", "text": "         The following accounting policies are important to the amounts of expenses, assets and liabilities\nreported and to the disclosure of contingent liabilities at the reporting date and require the most subjective or\ncomplex judgments and the use of assumptions from Dermapharm\u2019s management, often as a result of the need\nto estimate the effects of matters that are inherently uncertain and susceptible to change. Management bases its\nestimates and assumptions on historical experience, where applicable, and other factors believed to be\nreasonable under the circumstances. However, uncertainty about these assumptions and estimates could result in\noutcomes that could require a material adjustment to the carrying amounts of assets or liabilities affected in the\nfuture. Dermapharm\u2019s management cannot offer any assurance that the actual results will be consistent with\nthese estimates and assumptions, and these critical accounting estimates or assumptions could change from\nperiod to period, or could involve estimates where management could have reasonably used another estimate in\nthe relevant accounting period. The most critical accounting policies, which reflect significant management\nestimates and judgment are as follows:\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5269461077844312, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-6", "text": "10.8.1   Business Combinations\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.343409915356711, "lower_right_y": 0.5543199315654406, "height": 0.014114627887082953, "width": 0.22309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-7", "text": "        Various valuation methods are used in the context of purchase price allocations in business\ncombinations that are primarily based on estimates and assumptions.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5953806672369547, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-8", "text": "10.8.2   Goodwill Impairment Test\n\n         The Company tests any capitalized goodwill for impairment at least once a year.\n\n10.8.3   Impairment of other assets\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6103507271171942, "lower_right_x": 0.720677146311971, "lower_right_y": 0.6809238665526091, "height": 0.07057313943541488, "width": 0.6003627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-9", "text": "         For items of property, plant and equipment and intangible assets, the expected useful lives and\nassociated amortization or depreciation expenses are determined on the basis of management expectations and\nassessments. Dermapharm assesses whether there are any indications of impairment for all non-financial assets\nat each reporting date. In particular, with respect to impairment tests for yet unused approvals, the growth rates\napplied for the test as well as the price and cost development of active pharmaceutical ingredients are based on\nbest possible estimates.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6941830624465355, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7763045337895638, "height": 0.08212147134302827, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-10", "text": "10.8.4   Development Costs\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7899914456800684, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.8041060735671514, "height": 0.014114627887082953, "width": 0.19347037484885124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-11", "text": "         Development costs are capitalized based on the assessment of whether the capitalization requirements\nof IAS 38 are met. Planning calculations are necessary to determine the future economic benefit, which are by\nnature subject to estimates and may therefore deviate from actual results in the future.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8173652694610778, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8588537211291702, "height": 0.04148845166809245, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-124-12", "text": "", "page_number": 124, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-0", "text": "10.8.5   Taxation\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.24425634824667472, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.12394195888754533}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-1", "text": "          Dermapharm operates in various countries and is required to pay the respective income taxes in each\ntax jurisdiction. In order to calculate the income tax provisions and the deferred tax liabilities of Dermapharm,\nthe expected income tax as well as the temporary differences resulting from the different treatment of certain\nbalance sheet items pursuant to IFRS and their accounting in accordance with tax laws must each be determined\non the basis of assumptions. If the final taxation imposed deviates from the assumed values, this has a\ncorresponding effect on current and deferred taxes and thus on the net assets, financial position and results of\noperations of Dermapharm in the respective period.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-2", "text": "10.8.6   Fair Value of Financial Assets and Liabilities\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.23823781009409753, "height": 0.012831479897348175, "width": 0.3778718258766627}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-3", "text": "          When determining the fair values of derivatives and other financial instruments, for which no market\nprice in an active market is available, valuation models based on input parameters observable in the market are\napplied. The cash flows, which are already fixed or calculated by means of the current yield curve using\nso-called \u201cforward rates\u201d, are discounted to the measurement date with the discount factors determined by the\nyield curve applicable on the reporting date.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3203592814371258, "height": 0.067579127459367, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-4", "text": "          Trade receivables and other receivables, cash and cash equivalents, trade payables and other payables,\ncurrent liabilities to banks, current leasing liabilities and other current financial liabilities generally have a short\nmaturity. The carrying amounts, less allowances, if any, approximate the fair values.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36826347305389223, "height": 0.04020530367835756, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-5", "text": "10.8.7   Pension and Other Post-employment Benefits\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38280581693755344, "lower_right_x": 0.49758162031438935, "lower_right_y": 0.3964927288280582, "height": 0.01368691189050475, "width": 0.37726723095525994}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-6", "text": "          The carrying amounts of defined benefit pension plans and other post-employment benefits are based\non actuarial valuations. The actuarial valuations involved making assumptions about discount rates, expected\nrates of return on plan assets, future salary increases, mortality rates and future pension increases. Due to the\nlong-term nature of these plans, such estimates are subject to significant uncertainty.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46535500427716, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-7", "text": "10.8.8   Other Provisions\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.49101796407185627, "height": 0.01240376390076986, "width": 0.1795646916565901}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-8", "text": "         Other provisions are recognized when it is considered probable that economical, legal, ecological and\ndecommissioning obligations will result in future cash outflows, when the costs can be estimated reliably and\nthe measures in question are not expected to result in future cash inflows. The estimate of future costs is subject\nto many uncertainties, including legal uncertainties based on the applicable laws and regulations and with\nuncertainties regarding the actual conditions in the different countries and operating locations. In particular,\nestimates of costs are based on previous experiences in similar cases, the conclusions of expert opinions\ncommissioned by Dermapharm, current costs and new developments that have a bearing on the costs. Any\nchanges to these estimates could have an impact on Dermapharm\u2019s future results.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6159110350727117, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-125-9", "text": "", "page_number": 125, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-0", "text": "11.   MARKETS AND COMPETITION\n", "page_number": 126, "bounding_box": {"top_left_x": 0.343409915356711, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.09880239520958084, "height": 0.013686911890504708, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-1", "text": "11.1   Markets\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11591103507271172, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.12660393498716851, "height": 0.010692899914456794, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-2", "text": "         Dermapharm develops, manufactures and markets branded pharmaceuticals that are no longer patent\nprotected for selected markets primarily in Germany. It also offers a growing portfolio of other healthcare\nproducts such as cosmetics, food supplements, dietary products and medical devices. In addition, Dermapharm\nimports pharmaceuticals from other EEA Member States for resale in the German market.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19674935842600513, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-3", "text": "11.1.1   European Pharmaceuticals Market\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21171941830624466, "lower_right_x": 0.42503022974607013, "lower_right_y": 0.2249786142001711, "height": 0.013259195893926434, "width": 0.3047158403869408}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-4", "text": "          The European pharmaceuticals market is steadily growing. In the fiscal year ended December 31, 2015,\nthe total European pharmaceuticals market accounted for revenues of \u20ac169 billion, up by approximately 5.3%\ncompared to the fiscal year ended December 31, 2014. For the fiscal year ending December 31, 2022, the\nmarket size of the European pharmaceuticals market is projected to increase to \u20ac206 billion, up by\napproximately 21.9% compared to the fiscal year ended December 31, 2015. This growth corresponds to a\ncompound annual growth rate (\u201cCAGR\u201c) of approximately 3.1% between 2016 and 2020 (source: Evaluate \u2013\nEurope).\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33447390932420873, "height": 0.09538066723695465, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-5", "text": "11.1.2   German Pharmaceuticals Market\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.4153567110036276, "lower_right_y": 0.3592814371257485, "height": 0.010692899914456822, "width": 0.2950423216444982}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-6", "text": "         Germany, Dermapharm\u2019s primary market, is Europe\u2019s leading economy with a population of\napproximately 82.8 million as of December 31, 2016 and a gross domestic product of \u20ac3,144.1 billion in the\nfiscal year ended December 31, 2016 (source: Destatis). Germany has a highly developed healthcare system,\nwith 152,000 registered physicians and 20,023 licensed pharmacies (source: ABDA) and 1,951 hospitals as of\nDecember 31, 2016 (source: Destatis), and spending a greater portion of its gross domestic product on\nhealthcare than any other country in the European Union, having the second highest healthcare spending per\ncapita, while also recording the highest share in terms of healthcare spending covered through public funding in\nthe European Union (source: OECD Germany 2017).\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-7", "text": "         In recent years, revenues in the German pharmaceuticals market have increased by 8.3%, from\n\u20ac33.9 billion in the fiscal year ended December 31, 2014 to \u20ac36.7 billion in the fiscal year ended December 31,\n2016 (based on ex-factory prices (Herstellerabgabepreise)) (source: IQVIA). In the nine-month period ended\nSeptember 30, 2017, revenues in the German pharmaceuticals market, excluding rebates under rebate\nagreements, amounted to \u20ac29.2 billion (source: Pro Generika \u2013 Q3 2017).\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.561163387510693, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-8", "text": "         Patent-free pharmaceuticals, including patent-free originator products, accounted for 41.3% of all\nrevenues in the German pharmaceuticals market in the fiscal year ended December 31, 2016, a decrease\ncompared to a share of 44.1% in the fiscal year ended December 31, 2014 (based on pharmacy retail prices\n(Apothekenverkaufspreise)). This share remained relatively unchanged at 41.1% in the nine-month period ended\nSeptember 30, 2017 (sources: Pro Generika \u2013 2014; Pro Generika \u2013 2016; Pro Generika \u2013 Q3 2017). The high\nshare of patent-free pharmaceuticals makes Germany one of the countries with the highest share of generics in\nEurope (source: OECD Germany 2017).\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6638152266894782, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-9", "text": "         The German healthcare system is funded by a statutory contribution system, which ensures free\nhealthcare via SHI providers. The German SHI scheme is the oldest nationwide healthcare scheme in the world.\nParticipation in the SHI system is generally compulsory. However, citizens with a monthly gross income of at\nleast \u20ac4,462.50 may decide to opt out of the SHI system and obtain coverage from private health insurance\nproviders instead, or stay within the SHI system and obtain additional coverage from such private health\ninsurance providers. In 2017, 88% of the German population was covered by SHI providers, which financed\napproximately 58% the total healthcare expenditures in Germany. Together with coverage from private health\ninsurance providers, Germany has achieved near universal levels of coverage (source: OECD Germany 2017).\n", "page_number": 126, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6702309666381523, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7801539777587682, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-126-10", "text": "", "page_number": 126, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-0", "text": "11.1.2.1   Key Trends\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.16444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-1", "text": "         The German pharmaceuticals market is currently impacted by a number of key trends, which together\ninfluence the performance of individual pharmaceuticals manufacturers, in particular:\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-2", "text": "11.1.2.1.1\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15697177074422583, "lower_right_x": 0.18863361547763, "lower_right_y": 0.16723695466210436, "height": 0.010265183917878534, "width": 0.06831922611850061}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-3", "text": "Demographic Developments and Chronification of Diseases\n", "page_number": 127, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.15697177074422583, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.169803250641574, "height": 0.012831479897348175, "width": 0.4111245465538089}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-4", "text": "         While the global population is growing rapidly, there is a significant disparity between developing\ncountries and the most highly developed countries, including Germany, where birth rates are at best stable. At\nthe same time, the average life span is increasing, leading to a growing share of elderly people. In 2015, the\nGerman population was already significantly older than the average of OECD countries, with 21% of the\npopulation being 65 years and older, while 6% were 80 years and older. Until 2050, the share of elderly people\nin Germany is expected to increase even further, with more than 30% expected to be 65 years and older, while\nalmost 15% are expected to be 80 years and older (source: OECD \u2013 Health at a Glance 2017).\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27929854576561164, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-5", "text": "         The ageing of the population also increases the prevalence of various age-related diseases and\nconditions. On average, elderly people are more likely to administer several pharmaceuticals at the same time,\nwith the likelihood increasing at a growing age (source: DEGS). Only 47% of the German population does not\nadminister any pharmaceuticals, while 23% administer three or more pharmaceuticals simultaneously\n(source: ABDA).\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28699743370402053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3541488451668092, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-6", "text": "         In addition, medical advances increase the total number of conditions and diseases that can be\naddressed with appropriate medication, with originator manufacturers introducing 30 pharmaceuticals with new\nAPIs in the fiscal year ended December 31, 2016 (source: vfa). Dermapharm believes that the ageing of the\npopulation and the corresponding trend towards polypharmacy will positively affect demand for its\npharmaceuticals and other healthcare products.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43028229255774164, "height": 0.06800684345594521, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-7", "text": "11.1.2.1.2   Increased Health Awareness and Self-Medication\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.455945252352438, "height": 0.01154833190761334, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-8", "text": "         Increased availability and access to medical information lead to increasing health awareness. The\nnumber of people actively utilizing the Internet to gather information on diseases and medical conditions is\nconstantly growing. Through online research, patients can easily access various data on diseases, treatment\noptions, relevant pharmaceuticals, pharmaceuticals manufacturers as well as patient reviews. The increased\nimportance of the Internet also affects roads to market for pharmaceuticals. While mail-order pharmacies\naccounted for less than 2% of revenues for prescription pharmaceuticals in the fiscal year ended December 31,\n2016, the share of these pharmacies already accounted for almost 13% of revenues of OTC products\n(source: ABDA). In addition, growth rates of mail-order pharmacies for sales of OTC and other healthcare\nproducts far exceeded revenue growth of stationary pharmacies in the fiscal years ended December 31, 2014,\n2015 and 2016 (sources: B.A.H. 2014; B.A.H. 2015; B.A.H. 2016).\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6086398631308811, "height": 0.1368691189050471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-9", "text": "          Increased health awareness drives a general trend towards self-medication (i.e., patients administering\nOTC and other healthcare products for actual or perceived diseases and conditions, for preventive treatment as\nwell as to increase their general well-being themselves). This trend has resulted in growing demand for such\nOTC and other healthcare products (e.g., dietary products and food supplements), with revenues increasing from\n\u20ac7.9 billion in the fiscal year ended December 31, 2014 to \u20ac9.5 billion in the fiscal year ended December 31,\n2016, corresponding to a CAGR of 10.1% (sources: B.A.H. 2014; B.A.H. 2016). Dermapharm believes that\nincreased health awareness and a trend towards self-medication will positively affect demand for its OTC and\nother healthcare products.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7241231822070145, "height": 0.10863986313088114, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-10", "text": "11.1.2.2   Pharmaceuticals and Other Healthcare Products\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7386655260906758, "lower_right_x": 0.5362756952841596, "lower_right_y": 0.7510692899914457, "height": 0.012403763900769915, "width": 0.4153567110036276}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-11", "text": "          Given that specific pharmaceuticals and other healthcare products are used for the treatment of\nindividual conditions and diseases, the relevant markets for Dermapharm\u2019s products depend on the APIs used\nfor the treatment of such conditions and diseases. Therefore, Dermapharm defines the relevant markets for its\nkey product areas based on the APIs offered by Dermapharm for such product areas.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8212147134302823, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-127-12", "text": "", "page_number": 127, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-0", "text": "11.1.2.2.1   Vitamins, Minerals and Enzymes\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-1", "text": "        Between 2011 and 2016, the market for vitamins, minerals and enzymes containing APIs offered by\nDermapharm grew from \u20ac371 million in the fiscal year ended December 31, 2011 by \u20ac112 million, or 30.2%, to\n\u20ac483 million in the fiscal year ended December 31, 2016, corresponding to a CAGR of 5.4%. By comparison,\nDermapharm\u2019s revenues grew at a far higher CAGR of 28.3% in that same time period (sources: INSIGHT\nHealth; Company information).\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-2", "text": "11.1.2.2.2   Dermatologicals\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.21043627031650983, "height": 0.012403763900769887, "width": 0.19891172914147523}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-3", "text": "         Between 2011 and 2016, the market for dermatologicals containing APIs offered by Dermapharm grew\nfrom \u20ac358 million in the fiscal year ended December 31, 2011 by \u20ac8 million, or 2.2%, to \u20ac366 million in the\nfiscal year ended December 31, 2016, corresponding to a CAGR of 0.5%. By comparison, Dermapharm\u2019s\nrevenues grew at a CAGR of 4.8% in that same time period (sources: INSIGHT Health; Company information).\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27929854576561164, "height": 0.053892215568862284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-4", "text": "11.1.2.2.3   Systemic Corticoids\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.2938408896492729, "lower_right_x": 0.343409915356711, "lower_right_y": 0.30710008554319934, "height": 0.013259195893926434, "width": 0.22249093107617895}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-5", "text": "          Between 2011 and 2016, the market for systemic corticoids containing APIs offered by Dermapharm\ngrew from \u20ac95 million in the fiscal year ended December 31, 2011 by \u20ac7 million, or 7.4%, to \u20ac102 million in\nthe fiscal year ended December 31, 2016, corresponding to a CAGR of 1.5%. By comparison, Dermapharm\u2019s\nrevenues grew at a CAGR of 2.2% in that same time period (sources: INSIGHT Health; Company information).\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3759623609923011, "height": 0.05474764756201883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-6", "text": "11.1.2.2.4   Women\u2019s Healthcare\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3896492728828058, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.4016253207869974, "height": 0.0119760479041916, "width": 0.22732769044740025}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-7", "text": "         Between 2011 and 2016, the market for women\u2019s healthcare products containing APIs offered by\nDermapharm shrunk from \u20ac357 million in the fiscal year ended December 31, 2011 by \u20ac111 million, or 31.1%,\nto \u20ac246 million in the fiscal year ended December 31, 2016, corresponding to a CAGR of minus 7.2%. By\ncomparison, Dermapharm\u2019s revenues increased at a CAGR of 48.6% in that same time period\n(sources: INSIGHT Health; Company information).\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-8", "text": "11.1.2.2.5   Ophthalmologicals\n", "page_number": 128, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.4991445680068435, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.5132591958939264, "height": 0.014114627887082953, "width": 0.21221281741233378}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-9", "text": "Between 2011 and 2016, the market for ophthalmologicals containing APIs offered by Dermapharm grew from\n\u20ac128 million in the fiscal year ended December 31, 2011 by \u20ac16 million, or 12.5%, to \u20ac144 million in the fiscal\nyear ended December 31, 2016, corresponding to a CAGR of 2.3%. Dermapharm\u2019s revenues increased even\nfaster at a CAGR of 8.0% in that same time period (sources: INSIGHT Health; Company information).\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5299401197604791, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.583404619332763, "height": 0.05346449957228394, "width": 0.7503022974607013}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-10", "text": "11.1.2.3   Parallel Import Market\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5983746792130026, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.6112061591103507, "height": 0.01283147989734812, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-11", "text": "          While statutory requirements provide that a minimum of 5% of all prescription pharmaceuticals sold\nwithin the statutory healthcare system in Germany must be imported from other EEA Member States\n(see \u201c13.1.9 Parallel Imports\u201d), parallel imports accounted for more than this share of the German\npharmaceuticals market in the fiscal years ended December 31, 2014, 2015 and 2016. However, revenues in the\nparallel import market have constantly declined over this period, from \u20ac4.2 billion in the fiscal year ended\nDecember 31, 2014 to \u20ac3.9 billion in the fiscal year ended December 31, 2015, decreasing further to \u20ac3.7 billion\nin the fiscal year ended December 31, 2016 (sources: B.A.H. 2014; B.A.H. 2015; B.A.H. 2016).\n", "page_number": 128, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.625748502994012, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7219846022241232, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-128-12", "text": "", "page_number": 128, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-0", "text": "11.1.3     Austrian and Swiss Pharmaceuticals Markets\n\n11.1.3.1      Austrian Pharmaceuticals Market\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.3778718258766627}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-1", "text": "         Austria has a well-developed healthcare system, having the second highest number of hospital beds and\nfifth highest number of doctors relative to its population amongst all OECD countries (source: OECD\nAustria 2017). In recent years, revenues in the Austrian pharmaceuticals market increased from \u20ac3.4 billion in\nthe fiscal year ended December 31, 2014 to \u20ac3.7 billion in the fiscal year ended December 31, 2016,\ncorresponding to a CAGR of 4.4% (source: IQVIA).\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21000855431993157, "height": 0.06672369546621043, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-2", "text": "11.1.3.2   Swiss Pharmaceuticals Market\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.23609923011120615, "height": 0.010692899914456794, "width": 0.2956469165659008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-3", "text": "         In the fiscal year ended December 31, 2016, revenues in the Swiss pharmaceuticals market amounted\nto approximately CHF 5.6 billion, up by 4.6% compared to the fiscal year ended December 31, 2015 (based on\nex-factory prices). Approximately CHF 4.7 billion in revenues were attributable to prescription pharmaceuticals\nin the fiscal year ended December 31, 2016, with the remaining CHF 0.8 billion being attributable to\nOTC products. With respect to patent-free pharmaceuticals, such pharmaceuticals generated revenues\namounting to approximately CHF 0.7 billion or 12.5% of the overall market in the fiscal year ended\nDecember 31, 2016 (source: Interpharma).\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3481608212147134, "height": 0.09538066723695465, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-4", "text": "11.2       Competition\n\n11.2.1     Pharmaceuticals and Other Healthcare Products\n\n         For its pharmaceuticals and other healthcare products business area, Dermapharm competes with\nvarious competitors for each of its key product areas:\n\n11.2.1.1      Vitamins, Minerals and Enzymes\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4721984602224123, "height": 0.10992301112061587, "width": 0.7593712212817412}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-5", "text": "       In the field of vitamins, minerals and enzymes, Dermapharm\u2018s main competitors (in alphabetic order)\nare Merck Serono GmbH, Pfizer Deutschland GmbH, Protina Pharmazeutische GmbH and Verla-Pharm\nArzneimittel GmbH & Co. KG.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4888793840889649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5260906757912746, "height": 0.037211291702309635, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-6", "text": "11.2.1.2   Dermatologicals\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5436270316509837, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.5568862275449101, "height": 0.013259195893926434, "width": 0.19830713422007257}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-7", "text": "         In the field of dermatologicals, Dermapharm\u2018s main competitors (in alphabetic order) are\nAlmirall S.A., Bayer AG, Galderma S.A., GALENpharma GmbH, LEO Pharma A/S and Zentiva Group, a.s.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5710008554319932, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5988023952095808, "height": 0.02780153977758759, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-8", "text": "11.2.1.3   Systemic Corticoids\n\n     In the field of systemic corticoids, Dermapharm\u2018s main competitors (in alphabetic order) are\nGALENpharma GmbH, Merck Serono GmbH, Shire plc and Zentiva Group, a.s.\n\n11.2.1.4   Women\u2019s Health\n\n        In the field of women\u2019s health, Dermapharm\u2018s main competitors (in alphabetic order) are Aristo\nPharma GmbH, Exeltis Germany GmbH, Gedeon Richter Pharma GmbH, Hexal AG and Jenapharm GmbH &\nCo. KG.\n\n11.2.1.5   Ophthalmologicals\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6120615911035072, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7801539777587682, "height": 0.16809238665526094, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-9", "text": "      In the field of ophthalmologicals, Dermapharm\u2018s main competitors (in alphabetic order) are Bayer AG,\nMAAN Pharmaceuticals Ltd., Pfizer Deutschland GmbH, Pharm-Allergan GmbH and Th\u00e9a Pharma GmbH.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.8203592814371258, "height": 0.026946107784431184, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-129-10", "text": "", "page_number": 129, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-130-0", "text": "11.2.2   Parallel Imports\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.1747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-130-1", "text": "        Dermapharm\u2019s parallel import business area competes in a fragmented market. The following table\nprovides an overview of Dermapharm\u2019s ten largest parallel import competitors based on gross revenues\ngenerated in the fiscal year ended December 31, 2016:\n", "page_number": 130, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-130-2", "text": "Competitor                                                                   Gross revenues in the fiscal year ended December 31, 2016\n                                                                                                    (in \u20ac million)\n kohlpharma GmbH ...........................................................                                                             655\n EMRAmed Arzneimittel GmbH .......................................                                                                       415\n EurimPharm Arzneimittel GmbH .....................................                                                                      332\n Orifarm GmbH .................................................................                                                          243\n cc pharma gmbh................................................................                                                          173\n ABACUS MEDICINE Berlin GmbH ...............................                                                                              99\n ACA M\u00fcller ADAG Pharma AG......................................                                                                          96\n HAEMATO AG ...............................................................                                                               84\n BERAGENA Arzneimittel GmbH ...................................                                                                           65\n Pharma Gerke Arzneimittelvertriebs GmbH ....................                                                                             41\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.16381522668947818, "lower_right_x": 0.875453446191052, "lower_right_y": 0.32164242942686055, "height": 0.15782720273738238, "width": 0.7569528415961306}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-130-3", "text": "Source: INSIGHT Health.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.3361847733105218, "lower_right_x": 0.2914147521160822, "lower_right_y": 0.3485885372112917, "height": 0.01240376390076986, "width": 0.1729141475211608}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-130-4", "text": "", "page_number": 130, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-0", "text": "12.   BUSINESS DESCRIPTION\n", "page_number": 131, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.2666263603385732}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-1", "text": "12.1\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11591103507271172, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.12660393498716851, "height": 0.010692899914456794, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-2", "text": "Overview\n", "page_number": 131, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.11591103507271172, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.12660393498716851, "height": 0.010692899914456794, "width": 0.07255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-3", "text": "         Dermapharm is a leader in branded pharmaceuticals for selected markets in Germany with an\nexpanding international footprint. It applies formulation and development expertise to the development,\nmanufacture and marketing of a broad assortment of branded pharmaceuticals that are no longer patent\nprotected, holding approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than\n200 APIs. Dermapharm also offers a growing portfolio of other healthcare products such as cosmetics, food\nsupplements, dietary products and medical devices. In addition, Dermapharm leverages its direct marketing\nexpertise by importing pharmaceuticals from other EEA Member States for resale in the German market in\norder to profit from pricing differences between these markets.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.24764756201881952, "height": 0.10436270316509838, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {"description_of_the_business": ["Dermapharm is a leader in branded pharmaceuticals for selected markets in Germany with anexpanding international footprint. It applies formulation and development expertise to the development,manufacture and marketing of a broad assortment of branded pharmaceuticals that are no longer patentprotected, holding approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than200 APIs. Dermapharm also offers a growing portfolio of other healthcare products such as cosmetics, foodsupplements, dietary products and medical devices. In addition, Dermapharm leverages its direct marketingexpertise by importing pharmaceuticals from other EEA Member States for resale in the German market inorder to profit from pricing differences between these markets."]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-4", "text": "          Dermapharm operates primarily in Germany, Europe\u2019s leading economy and, with aggregate sales of\n\u20ac36.7 billion in the fiscal year ended December 31, 2016 (based on ex-factory prices (Herstellerabgabepreise)),\nalso its largest pharmaceuticals market (source: IQVIA). The German pharmaceuticals market benefits from\ncertain general trends, including the ageing of the population, chronification of diseases, increasing health\nawareness and higher spending on OTC and other healthcare products, reflecting increased self-medication.\nDermapharm believes that it benefits from these trends and will continue to do so in the future. Dermapharm\u2019s\nsales in Germany accounted for approximately 92.6% of Dermapharm\u2019s revenues in the nine-month period\nended September 30, 2017. Dermapharm is also active in Austria and Switzerland and sales in these countries\naccounted for approximately 4.9% of Dermapharm\u2019s revenues in the same nine-month period. In the future,\nDermapharm plans to introduce selected products from its existing product portfolio as well as new product\ndevelopments to additional markets.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25962360992301114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40889649272882805, "height": 0.1492728828058169, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-5", "text": "Dermapharm operates in the following business areas:\n", "page_number": 131, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4170230966638152, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.4294268605645851, "height": 0.012403763900769915, "width": 0.3681983071342201}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-6", "text": "\uf0b7   Pharmaceuticals and Other Healthcare Products: Dermapharm\u2019s pharmaceuticals and other\n    healthcare products cover multiple product areas with a broad assortment of products marketed\n    under well-known brands. Dermapharm focuses on the development, manufacture and marketing\n    of pharmaceuticals and other healthcare products for specifically targeted markets, in which\n    Dermapharm generally holds a significant market share and generates attractive margins.\n    Dermapharm is the German market leader in prescription vitamins through its vitamin D\n    preparation Dekristol\u00ae 20,000 I.E. (based on number of prescriptions and revenues, excluding\n    hospital sales (sources: INSIGHT Health; Company information)). Its broad product assortment\n    has also made Dermapharm the German market leader for prescription dermatologicals and\n    systemic corticoids (in each case based on number of prescriptions and revenues for APIs offered\n    by Dermapharm, excluding hospital sales (sources: INSIGHT Health; Company information)).\n    With regard to OTC products, Dermapharm is able to leverage its development and manufacturing\n    know-how with prescription pharmaceuticals to obtain required marketing authorizations quickly\n    and cost-efficiently. Other healthcare products may be sold without marketing authorizations and\n    benefit from Dermapharm\u2019s long-standing relationships with pharmacies based on its\n    pharmaceuticals business and well-known brands. In the nine-month period ended September 30,\n    2017, pharmaceuticals and other healthcare products accounted for 46.8% of Dermapharm\u2019s\n    revenues and 93.8% of its EBITDA.\n\uf0b7   Parallel Imports: Dermapharm\u2019s parallel import business, which operates under the well-known\n    \u201caxicorp\u201d brand, benefits from the statutory requirement that a minimum of 5% of all prescription\n    pharmaceuticals sold within the statutory healthcare system in Germany must be imported from\n    other EEA Member States to help reduce healthcare costs. The actual market share of parallel\n    imports in Germany exceeds this quota and amounted to approximately 8.6% in the fiscal year\n    ended December 31, 2016 (source: INSIGHT Health). In the same fiscal year, Dermapharm\n    covered approximately 89% of prescription pharmaceuticals available for sale in the German\n    parallel import market and was the fourth largest parallel importer in Germany (source: INSIGHT\n    Health). Its strong market expertise and stringent planning, which is continuously driven forward\n    by both sales and sourcing experts, allow Dermapharm to ensure an appropriate product mix and\n    thereby maintain its targeted profit margin. Parallel imports, including certain OTC products\n    marketed by axicorp, accounted for 53.2% of Dermapharm\u2019s revenues and 6.1% of its EBITDA in\n    the nine-month period ended September 30, 2017.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4298545765611634, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8691189050470488, "height": 0.4392643284858854, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-131-7", "text": "", "page_number": 131, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019347037484885143}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-132-0", "text": "          The German pharmaceuticals market is highly regulated, requiring manufacturers to obtain marketing\nauthorizations before introducing a new product for sale. While manufacturers of patent-free pharmaceuticals\nsuch as Dermapharm do not engage in expensive basic research, they still require considerable expertise to\nobtain such marketing authorizations, as they are required to prove bioequivalence to already authorized\npharmaceuticals and in many cases even have to conduct additional clinical studies. Dermapharm believes that\nits positioning in selected markets with a limited size affords it significant protection from competing\npharmaceuticals manufacturers since competitors are unlikely to introduce competing pharmaceuticals in light\nof the costs and know-how required to obtain the relevant marketing authorizations and the relatively low\nrevenue potential.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.12360992301112063, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-132-1", "text": "          Extensive regulation also affects prices for prescription pharmaceuticals (i.e., pharmaceuticals that\nrequire a doctor\u2019s prescription for distribution) in Germany. Certain prescription pharmaceuticals, in particular\nthose with high volumes, are subject to a reference price, which is the maximum price for which patients are\nreimbursed by SHI providers. All other prescription pharmaceuticals (i.e., those without a reference price) are\nsubject to a mandatory manufacturer rebate, which, in the case of patent-free pharmaceuticals, amounts to 6%,\nas well as a price moratorium (Preismoratorium), which was recently extended until 2022. Under this\nmoratorium, pharmaceuticals manufacturers are required to compensate SHI providers and private health\ninsurance providers for any price increases, limiting the benefits from price increases for prescription\npharmaceuticals. In addition, manufacturers of patent-free pharmaceuticals such as Dermapharm are generally\nrequired to offer a mandatory rebate of 10% on the ex-factory price of their prescription pharmaceuticals. For\nmost high-volume patent-free pharmaceuticals, SHI providers seek to further reduce prices by entering into\nindividual rebate agreements with manufacturers, which are awarded through public tenders, generally to the\nmanufacturer offering the largest rebate. Under these agreements, patients insured by the relevant SHI provider\nonly receive reimbursement for the pharmaceutical manufactured by the winner of the public tender, who thus\nsacrifices higher margins to lock in higher sales volumes.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.20573139435414883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-132-2", "text": "         Dermapharm seeks to limit the impact of these pricing restrictions by focusing on prescription\npharmaceuticals for selected markets, which meet the following market criteria: limited competition and the\nopportunity for Dermapharm to achieve a strong market position, absence of rebate agreements and reference\nprices, with a substantial share of sales that can be generated from direct payers (i.e., patients who bear\npharmaceutical costs themselves) and/or hospitals. Sales of prescription pharmaceuticals to such direct payers\nand hospitals are generally not affected by the aforementioned pricing restrictions. In addition, Dermapharm\nintends to increase its revenues from OTC and other healthcare products, making Dermapharm even more\nindependent from restrictions applicable to prescription pharmaceuticals. In the nine-month period ended\nSeptember 30, 2017, sales to direct payers and patients receiving reimbursements from private health insurance\nproviders, hospital sales and sales of OTC and other healthcare products together accounted for approximately\n53% of Dermapharm\u2019s revenues from pharmaceuticals and other healthcare products (sources: INSIGHT\nHealth; Company information).\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-132-3", "text": "         Dermapharm uses a broad range of distribution channels and employs a large salesforce to maintain\nand further expand its strong market position. Doctors represent Dermapharm\u2019s most important target group for\npharmaceuticals as they directly recommend and prescribe Dermapharm\u2019s pharmaceuticals to patients.\nDistribution of such pharmaceuticals takes place via pharmaceutical wholesalers or directly to pharmacies,\nwhile hospitals also represent an important distribution channel. Dermapharm\u2019s other healthcare products are\nsold in pharmacies, health stores and drugstores, many of whom purchase such products through wholesalers.\nWith respect to its parallel import business, Dermapharm resells the imported products to pharmaceutical\nwholesalers and directly to pharmacies.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5983746792130026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7082976903336184, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-132-4", "text": "          Dermapharm\u2019s business operations cover the entire value chain for its pharmaceuticals and other\nhealthcare products, starting with the development of new products, including designing and sponsoring any\nclinical studies required for Dermapharm\u2019s pharmaceuticals. Based on the number of packages, approximately\n90% of Dermapharm\u2019s pharmaceuticals and other healthcare products were manufactured in-house in the\nnine-month period ended September 30, 2017 (including packages made from bulk products manufactured by\nthird parties), using Dermapharm\u2019s state-of-the-art equipment. This enables Dermapharm to manufacture at the\ngood manufacturing practice (\u201cGMP\u201d) standard, a standard widely recognized in the pharmaceuticals industry,\nand makes it less dependent on third-party service providers. Following manufacture, Dermapharm distributes\nits products directly from its logistics centers to its various customers. To achieve this level of control over the\nwhole value chain, Dermapharm operates a highly integrated development, manufacturing and distribution\nfacility in Brehna, Saxony-Anhalt, Germany.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7147134302822925, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8656971770744226, "height": 0.1509837467921301, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-132-5", "text": "", "page_number": 132, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.019951632406287778}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-133-0", "text": "          Dermapharm\u2019s business, which was established in 1991, initially focused on prescription\npharmaceuticals for the dermatology market, and Dermapharm continues to benefit from its long-standing\nexperience in this product area. Over the years, Dermapharm expanded its business through various\nacquisitions: Dermapharm\u2019s first expansions focussed on the dermatology market, including the acquisition of\nkey dermatology products from Bristol-Myers Squibb in 2002. Beginning in 2003, Dermapharm broadened its\nproduct range to encompass additional product areas, including through the acquisition of Jenapharm GmbH &\nCo. KG\u2019s therapeutic drugs division, which owned the marketing authorization for Dermapharm\u2019s current\nflagship product Dekristol\u00ae 20,000 I.E. Since 2009, Dermapharm has increasingly focused on other healthcare\nproducts, in particular acquiring several entities operating under the \u201cH\u00fcbner\u201d brand in 2010, which\nmanufacture supplements, dietary products and organic pharmaceuticals. In 2012, Dermapharm entered the\nparallel import business to complement its other business areas by acquiring axicorp GmbH (together with its\ndirect and indirect subsidiaries, \u201caxicorp\u201d). In September 2017, Dermapharm further expanded its product\noffering by acquiring the right to market medical devices bite away\u00ae for the external treatment of bites and\nstings from insects and Herpotherm\u00ae for the treatment of herpes symptoms as well as Bio-Di\u00e4t-Berlin, which\ndevelops, produces and markets OTC and other healthcare products, in particular food supplements for the\ntreatment of respiratory diseases and muscle aches. In December 2017 and January 2018, respectively,\nDermapharm furthermore acquired all shares in Strathmann and Trommsdorff.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.23310521813515822, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-133-1", "text": "       In the fiscal year ended December 31, 2016, Dermapharm generated revenues of \u20ac444.5 million and\nEBITDA of \u20ac102.7 million. In the nine-month period ended September 30, 2017, Dermapharm\u2019s revenues\namounted to \u20ac349.7 million and its EBITDA totaled \u20ac82.9 million.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3246364414029085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36398631308810947, "height": 0.03934987168520099, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-133-2", "text": "12.2     Strengths\n\n         Dermapharm believes that the development of its business is supported by the following strengths:\n\n12.2.1   Leading pharmaceuticals manufacturer in attractive, selected product areas with a broad product\n         diversification\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.3806672369546621, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.4627887082976903, "height": 0.08212147134302822, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"competitive_strength": ["12.2.1Leading pharmaceuticals manufacturer in attractive, selected product areas with a broad productdiversification"]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-133-3", "text": "         Dermapharm\u2019s pharmaceuticals predominantly cover selected markets, which Dermapharm targets by\nmarketing its products under well-known brands. Although these markets are relatively small when compared to\nother pharmaceuticals markets, they also contain limited competition with high barriers to entry for further\ncompetition due to the costs and complexity of obtaining the required marketing approvals as well as the\nmanufacturing expertise required to successfully introduce new pharmaceuticals to these markets. As a result,\nDermapharm holds a significant market share in the vast majority of its selected markets. In addition,\nDermapharm believes that its product offering is sufficiently diversified with a mix of high-growth products and\nproducts which provide for stable revenues. In the nine-month period ended September 30, 2017, no product\narea accounted for more than 30.3% of Dermapharm\u2019s revenues from pharmaceuticals and other healthcare\nproducts.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6150556030795552, "height": 0.1364414029084688, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-133-4", "text": "         Dermapharm is the German market leader in prescription vitamins through its vitamin D preparation\nDekristol\u00ae 20,000 I.E. (based on number of prescriptions and revenues, excluding hospital sales\n(sources: INSIGHT Health; Company information)). In recent years, sales of Dekristol\u00ae 20,000 I.E. have greatly\nbenefited from the wide acceptance of medical studies demonstrating the adverse health consequences of\nvitamin D deficiency and the increasing recognition of its prevalence among the general population. As the only\nhigh-dosage vitamin D prescription pharmaceutical with a marketing authorization for this particular\ncombination of dosage and packaging size (Verpackungsgr\u00f6\u00dfe) in Germany, Dekristol\u00ae 20,000 I.E. has actually\noutperformed the growing vitamin D market. In addition, Dekristol\u00ae 20,000 I.E. has attracted a significant\nnumber of direct payers, who account for almost half of Dermapharm\u2019s Dekristol \u00ae 20,000 I.E. sales, based on\nCompany estimates. As a result of these developments, revenues from the sale of Dekristol \u00ae 20,000 I.E. almost\ndoubled from approximately \u20ac17.0 million in the fiscal year ended December 31, 2014 to approximately\n\u20ac32.9 million in the fiscal year ended December 31, 2016, while the number of packages sold increased from\napproximately 1.9 million packages by approximately 53% to approximately 2.9 million packages in that same\nperiod.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.19204448246364414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-133-5", "text": "", "page_number": 133, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-0", "text": "         Dermapharm is also the market leader for prescription dermatologicals and systemic corticoids in\nGermany (in each case based on number of prescriptions and revenues for APIs offered by Dermapharm,\nexcluding hospital sales (sources: INSIGHT Health; Company information)). In these product areas,\nDermapharm\u2019s market leadership is based on its broad assortment of branded pharmaceuticals and its ability to\ndevelop and manufacture multiple strengths and dosage forms. Dermapharm\u2019s prescription dermatologicals\ninclude Ampho-Moronal\u00ae, one of Dermapharm\u2019s best-selling antifungals, which is used for the treatment of\ndiseases in the mouth and throat area as well as gastrointestinal diseases. In addition, Prednisolut\u00ae, a systemic\ncorticoid, is one of only two such prescription pharmaceuticals for which a marketing authorization has been\napproved in Germany. Dermapharm\u2019s ability to offer over 200 APIs in a broad variety of strengths and dosage\nforms enables it to provide doctors and pharmacies with solutions to varying medical needs.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-1", "text": "         Dermapharm\u2019s strong market positions and broad product offering in its vitamins/minerals/enzymes,\ndermatologicals and systemic corticoids product areas, which together accounted for approximately 90% of\nDermapharm\u2019s revenues from pharmaceuticals and other healthcare products in the fiscal year ended\nDecember 31, 2016, as well as its attractive offering in other selected markets enable Dermapharm to generate\nhigh margins as well as stable returns. This product portfolio has been very stable. While Dermapharm\ncontinuously reviews its pharmaceuticals and other healthcare product offering for any products which can no\nlonger be marketed profitably, it has rarely identified such products. Dermapharm believes that this evidences\nthe success of its strategic decision to focus on particularly attractive products in selected product areas.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33875106928999144, "height": 0.1099230111206159, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-2", "text": "12.2.2   Strategic focus on selected markets with particularly attractive margins\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.35201026518391787, "lower_right_x": 0.6771463119709794, "lower_right_y": 0.36655260906757914, "height": 0.014542343883661268, "width": 0.5592503022974606}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["12.2.2Strategic focus on selected markets with particularly attractive margins"]}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-3", "text": "          Dermapharm offers a broad product assortment of branded pharmaceuticals with approximately\n900 marketing authorizations for more than 200 APIs. Due to Dermapharm\u2019s careful selection of attractive\nmarkets, a growing share of Dermapharm\u2019s revenues for prescription pharmaceuticals is derived from direct\npayers, sales to whom are not subject to regulatory pricing restrictions, which increases Dermapharm\u2019s\nresilience to rebate agreements and regulatory initiatives. In addition, sales of prescription pharmaceuticals to\nhospitals are also not subject to pricing restrictions. Furthermore, sales of Dermapharm\u2019s OTC and other\nhealthcare products are not subject to any form of pricing restrictions. In the nine-month period ended\nSeptember 30, 2017, the share of Dermapharm\u2019s revenues from pharmaceuticals and other healthcare products\nthat was subject to pricing restrictions amounted to approximately 47% and the Company believes that this is\nsignificantly lower than the industry average (sources: INSIGHT Health; Company information).\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38280581693755344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5166809238665526, "height": 0.13387510692899918, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-4", "text": "         Unlike other manufacturers of patent-free pharmaceuticals Dermapharm does not depend on\nhigh-volume and low-margin rebate agreements with SHI providers, as Dermapharm\u2019s high quality products in\nselected markets are generally not subject to tender processes. Revenues derived from exclusive or\nsemi-exclusive rebate agreements only accounted for 12% of Dermapharm\u2019s revenues from pharmaceuticals and\nother healthcare products in the nine-month period ended September 30, 2017 (sources: INSIGHT Health;\nCompany information), compared to more than 50% for the generics market in Germany overall during that\nperiod (source: Pro Generika \u2013 Q3 2017). While Dermapharm may selectively choose to participate in such\ntender processes in the future (e.g., when it believes that winning the respective rebate agreement will lead to\nfollow-on sales to direct payers), a growing degree of independence from SHI providers ensures that\nDermapharm\u2019s attractive margins enjoy a high degree of protection against pricing pressure.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.660393498716852, "height": 0.13387510692899918, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-5", "text": "12.2.3   Successful track record of product developments underpinned by operational excellence and \u201call\n         under one roof\u201d approach\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7048759623609923, "height": 0.02780153977758759, "width": 0.7605804111245466}, "blob_type": "paragraph", "predictions": {}, "annotations": {"competitive_strength": ["Successful track record of product developments underpinned by operational excellence and \u201callunder one roof\u201d approach"]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-6", "text": "         Dermapharm has a strong track record in developing and introducing new pharmaceuticals and other\nhealthcare products. Between January 1, 2012, and the date of this Prospectus, Dermapharm has obtained\nmarketing authorizations for over 200 pharmaceuticals developed by its highly educated and experienced\ndevelopment personnel, including marketing authorizations for markets outside Germany. For example,\nDermapharm recently introduced Solacutan\u00ae, a prescription pharmaceutical which includes diclofenac sodium\nand is applied to the face or scalp to treat mild to moderate cornification disorders of the skin, including actinic\nkeratosis, which, if left untreated, may become cancerous. Dermapharm believes that it is the first manufacturer\nto receive a marketing authorization for a patent-free pharmaceutical for this formula in Europe.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8272027373823782, "height": 0.10906757912745946, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-134-7", "text": "", "page_number": 134, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-0", "text": "          Dermapharm constantly screens the product areas covered by its product offering. Once it has\nidentified a potentially attractive pharmaceutical, Dermapharm is able to handle the key stages of the approval\nprocess in-house, including the designing and sponsoring of clinical studies required for the market introduction\nof new patent-free pharmaceuticals (e.g., setting criteria for patient selection, determining the relevant dosage\nregime and analyzing data obtained in clinical studies) and the manufacture of clinical batches. While\nDermapharm contracts third-party service providers to conduct the actual clinical studies, Dermapharm believes\nthat its deep know-how and control over key stages of the development process make it less dependent on such\nthird-party service providers compared to most of its competitors and ensure stringent cost control when\nconducting clinical studies. In addition, Dermapharm has the necessary regulatory expertise to conduct the filing\nprocess for marketing authorizations. In doing so, it can draw on the particular expertise of its research experts,\nsome of whom have more than 25 years of experience in developing patent-free pharmaceuticals.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-1", "text": "         Once Dermapharm has successfully completed the development process, Dermapharm benefits from\ncontrolling and operating its own manufacturing facility in Brehna, which provides the necessary flexibility and\nfree capacity to manufacture newly launched products in-house. As a result, Dermapharm has regularly been\nable to avoid problems in the transition from product development to actual manufacture, which provides\nDermapharm with a key advantage when trying to introduce new pharmaceuticals as soon as possible and at\ncomparatively limited cost. Dermapharm\u2019s decision to centralize operations in Brehna, together with the\nexpertise required to manufacture almost all relevant dosage forms at this facility, allowed for approximately\n90% of packages for Dermapharm\u2019s pharmaceuticals and other healthcare products to be manufactured in-house\nand marketed as \u201cMade in Germany\u201d in the nine-month period ended September 30, 2017 (including packages\nmade from bulk products manufactured by third parties). At the same time, Dermapharm has been able to limit\nthe number of product defects to a level which Dermapharm considers very low compared to its competitors\nthrough use of state-of-the-art equipment.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40718562874251496, "height": 0.16467065868263472, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-2", "text": "         The Brehna facility also houses Dermapharm\u2019s procurement division and main logistics center.\nDermapharm\u2019s integrated approach enables it to fully control its supply chain, thereby limiting the risk of\ninventory shortages and manufacturing issues, while at the same time enabling Dermapharm to optimize\nmargins by reducing manufacturing costs. In addition, Dermapharm\u2019s integrated approach to logistics includes\ncapacity backup solutions, has effectively prevented any delivery shortages in recent years and allows for a\n24-hour delivery service to pharmacies and hospitals. Dermapharm believes that its deep understanding of\nDermapharm\u2019s different product areas, combined with its ability to cover all steps of the value chain, provide it\nwith the flexibility to quickly react to market changes and new opportunities.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4136013686911891, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.523524379811805, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-3", "text": "12.2.4   Effective sales organization\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5367835757057314, "lower_right_x": 0.37484885126964934, "lower_right_y": 0.5513259195893926, "height": 0.014542343883661157, "width": 0.25453446191052}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Effective sales organization"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-4", "text": "         Dermapharm considers its sales and marketing capabilities to be particularly strong. As of the date of\nthis Prospectus, Dermapharm\u2019s German salesforce comprises 72 general sales representatives responsible for\nDermapharm\u2019s most important customers, doctors and pharmacies, as well as seven hospital sales\nrepresentatives, whose performance is constantly monitored at Dermapharm\u2019s headquarters. Members of\nDermapharm\u2019s salesforce are specially trained with respect to the product areas that Dermapharm covers and\nDermapharm believes that the low level of fluctuation of sales representatives is proof of their strong\ncommitment and identification with Dermapharm\u2019s high-quality products. Dermapharm believes that the recent\nacquisition of Trommsdorff, which employs its own sales organization comprising around 60 sales\nrepresentatives, will further boost its marketing capacities for pharmaceuticals and other healthcare products.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6877673224978614, "height": 0.12018819503849443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-5", "text": "         Dermapharm\u2019s sales representatives engage with Dermapharm\u2019s customers on a regular basis, and have\ndone so for many years, drawing on longstanding relationships and the deep trust that Dermapharm has built\nwith doctors, pharmacists and other key customer groups, which also helps Dermapharm to better understand\nand anticipate their demands. In the twelve-month period ended November 30, 2017, Dermapharm\u2019s German\ngeneral sales representatives paid approximately 29,000 visits to dermatologists, approximately 22,000 visits to\ngynecologists and approximately 35,000 visits to German pharmacies. Dermapharm believes that this efficient\nand highly-qualified sales organization will ensure that its products are successfully placed with its customers\nand further enhance its reputation.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8058169375534645, "height": 0.10821214713430283, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-135-6", "text": "", "page_number": 135, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-0", "text": "12.2.5   Broad parallel import product offering sourced and marketed by a highly integrated organization\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8548972188633616, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.7333736396614269}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["12.2.5Broad parallel import product offering sourced and marketed by a highly integrated organization"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-1", "text": "          Dermapharm\u2019s parallel import business offers a broad product assortment of pharmaceuticals with over\n1,500 product codes (Artikelnummern) imported from other EEA Member States (as of September 30, 2017).\nDermapharm constantly reviews the European pharmaceuticals market in order to identify attractive\npharmaceuticals that would complement and expand its parallel import product offering. In doing so, it can\nleverage its extensive database which comprises both public market sources as well as feedback from suppliers,\ngiving Dermapharm deep insight into developments and opportunities in the European pharmaceuticals market.\nIn addition, Dermapharm\u2019s sales department provides feedback from customers to ensure that Dermapharm can\nidentify areas with unsatisfied market demand. In the nine-month period ended September 30, 2017,\nDermapharm has been able to successfully introduce 194 new pharmaceuticals to its parallel import product\noffering.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-2", "text": "         Dermapharm believes that the close cooperation and communication between its sales and purchasing\ndepartments are key factors for its continued growth and success in the parallel import market. The extensive\nmarket knowledge and strong business relationships with suppliers enable Dermapharm\u2019s purchasing experts to\nsource more than 98% of the volume agreed with the sales department in the final purchasing schedule (based\non sourcing volumes). This close cooperation also ensures that almost all pharmaceuticals imported by\nDermapharm are successfully resold by the sales department. Dermapharm\u2019s sales operations benefit from\nwell-established relationships with pharmaceutical wholesalers and a separate salesforce comprising 18 sales\nrepresentatives. In the fiscal year ended December 31, 2016, Dermapharm\u2019s salesforce conducted approximately\n183,000 phone calls to pharmacies, covering approximately 95% of the 20,023 licensed pharmacies in Germany\nas of December 31, 2016 (source: ABDA). Its highly qualified and motivated salesforce has helped Dermapharm\nto become the second largest player in the German market for the direct resale of parallel imports to pharmacies\n(source: INSIGHT Health).\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.1646706586826347, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-3", "text": "12.2.6   Strong profitability with credible cash flow generation and significant dividend capacity\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.43498716852010266, "lower_right_x": 0.7902055622732769, "lower_right_y": 0.45038494439692045, "height": 0.015397775876817787, "width": 0.6698911729141475}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Strong profitability with credible cash flow generation and significant dividend capacity"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-4", "text": "          In the fiscal year ended December 31, 2016, Dermapharm\u2019s EBITDA amounted to \u20ac102.7 million,\ncorresponding to an EBITDA margin of 23.1%. Dermapharm\u2019s profitability has increased even further in the\nnine-month period ended September 30, 2017, with its EBITDA margin increasing by 33 basis points to 23.7%.\nThis high profitability has also contributed to strong net cash flows from operating activities of \u20ac76.8 million in\nthe fiscal year ended December 31, 2016 and \u20ac62.6 million in the nine-month period ended September 30, 2017.\nWhile the Company will not pay a dividend with respect to the fiscal year ended December 31, 2017 (see\n\u201c6.2 Dividend Policy and Earnings per Share\u201d), the Company believes that its strong profitability and free cash\nflow provide significant dividend capacity and it intends to pay a dividend in the ordinary course of business of\n50% to 60% of Dermapharm\u2019s profits for the respective fiscal year calculated in accordance with IFRS starting\nwith the fiscal year ending December 31, 2018.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6009409751924722, "height": 0.13601368691189053, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-5", "text": "12.2.7   Highly experienced and committed management team with a proven track recor\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.7285368802902056, "lower_right_y": 0.6295979469632165, "height": 0.014114627887083064, "width": 0.6082224909310762}, "blob_type": "headline", "predictions": {}, "annotations": {"competitive_strength": ["Highly experienced and committed management team with a proven track record"]}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-6", "text": "        The four members of the Management Board, Dr. Hans-Georg Feldmeier, Stefan H\u00fcmer, Stefan\nGrieving and Karin Samusch have 30 years, 20 years, 26 years and 29 years, respectively, of experience in the\npharmaceuticals industry.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6839178785286569, "height": 0.041060735671514026, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-7", "text": "         Dermapharm\u2019s Chief Executive Officer Dr. Feldmeier, who joined Dermapharm in 2003, started his\ncareer with VEB Berlin Chemie in the former German Democratic Republic as a junior scientist in 1987. Since\nthen, he obtained extensive experience in modernizing and restructuring pharmaceutical manufacturing facilities\nand also served as Head of Supply Center with Schering Aktiengesellschaft, Berlin, in 2002. Dermapharm\u2019s\nChief Financial Officer Mr. H\u00fcmer started his career with Hexal Aktiengesellschaft as a participation controller\n(Beteiligungscontroller) in 2001. Following the merger between Hexal Aktiengesellschaft and Sandoz Group in\nOctober 2005, Mr. H\u00fcmer joined Sandoz where he became International Head of Controlling in the research and\ndevelopment department. In June 2006, Mr. H\u00fcmer joined Dermapharm as Head of Controlling and Finance.\nDermapharm\u2019s Chief Marketing Officer Mr. Grieving joined Dermapharm in 2010. He started his career with\nPharmacia as a medical representative. Since then, Mr. Grieving worked in various sales functions in the\npharmaceuticals industry, including as Head of Marketing & Sales and later General Manager OTC and\nGenerics Germany for STADA Arzneimittel Aktiengesellschaft and Head of Marketing & Sales and later\nGeneral Manager for TAD Pharma (KRKA group). Dermapharm\u2019s Chief Business Development Officer\nMs. Samusch has been with Dermapharm since 1991 and since then held responsibility for business\ndevelopment, international affairs as well as regulatory affairs and pharmacovigilance.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6907613344739093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8960650128314799, "height": 0.20530367835757057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-136-8", "text": "", "page_number": 136, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-0", "text": "For more information, see \u201c17.2.1 Members of the Management Board\u201d.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.48911729141475213}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-1", "text": "12.3   Strategy\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11591103507271172, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.1283147989734816, "height": 0.012403763900769887, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-2", "text": "         Dermapharm believes that its strong position in both the German pharmaceuticals and parallel imports\nmarkets will allow to further expand its business. Dermapharm seeks to capitalize on both organic and external\ngrowth opportunities to become the leading European pharmaceuticals manufacturer in its selected markets as\nwell as a key player in the German parallel imports industry. To achieve this aim, Dermapharm has identified\nthe following key elements of its strategy:\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21043627031650983, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-3", "text": "12.3.1   Expand product portfolio through the introduction of new products developed in-house\n", "page_number": 137, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.22540633019674935, "lower_right_x": 0.786577992744861, "lower_right_y": 0.2386655260906758, "height": 0.013259195893926434, "width": 0.6686819830713422}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["12.3.1Expand product portfolio through the introduction of new products developed in-house"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-4", "text": "         Dermapharm constantly seeks to develop and introduce additional pharmaceuticals and other\nhealthcare products. In the fiscal year ended December 31, 2016, it spent \u20ac4.8 million on such development\nefforts. As of the date of this Prospectus, Dermapharm\u2019s product pipeline comprises more than 40 ongoing\ndevelopment projects with new products for all of Dermapharm\u2019s product areas, including\nsix vitamins/minerals/enzymes, 20 dermatologicals, one systemic corticoid, two women\u2019s healthcare products\nand two ophthalmologicals. This pipeline includes 28 pharmaceuticals and other healthcare products, in\nparticular dermatologicals, women\u2019s healthcare products and food supplements, which are expected to be\nmarketable by 2023 and target markets where the aggregate revenues from existing products marketed by\ncompetitors in Germany amounted to approximately \u20ac345 million in the fiscal year ended December 31, 2016\n(source: INSIGHT Health). Dermapharm plans to leverage its existing development, manufacturing and\nmarketing capabilities to introduce new products, which will be marketed through Dermapharm\u2019s established\nsales organization.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41659538066723695, "height": 0.16381522668947818, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-5", "text": "          For the development of new pharmaceuticals, Dermapharm harnesses its longstanding experience in\ndeveloping such pharmaceuticals and completing the required approval processes in-house. Where feasible,\nDermapharm seeks to introduce value-added variations of existing originator pharmaceuticals (e.g., new dosage\nforms). For the development of other healthcare products, in particular food supplements and dietary products,\nDermapharm expects to benefit from the fact that such products do not require any approvals, further reducing\nthe time between development and market introduction. As a result, Dermapharm has been able to flexibly\nintroduce healthcare products such as supplements and cosmetics, usually requiring less than a year for the\ndevelopment of such products. In addition, the successful introduction of new products is aided by\nDermapharm\u2019s well-established marketing and distribution channels. Dermapharm believes that its constant\nsearch for new development opportunities as well as its proven development expertise will enable it to introduce\nnew pharmaceuticals and other healthcare products that capture significant market shares from existing products\nin attractive markets.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5851154833190761, "height": 0.16124893071000856, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-6", "text": "12.3.2   Increase Dermapharm\u2019s international footprint\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.6159110350727117, "height": 0.014114627887082953, "width": 0.39238210399032647}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["Increase Dermapharm\u2019s international footprint"]}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-7", "text": "         In the future, Dermapharm plans to introduce selected products from its existing product portfolio as\nwell as new product developments to additional markets. In a first phase, Dermapharm intends to enter attractive\nadjacent markets in Italy, Spain and the United Kingdom due to the large addressable markets for\nDermapharm\u2019s product areas in these countries. In the fiscal year ended December 31, 2016, the overall size of\nthe pharmaceuticals markets in Italy, Spain and the United Kingdom amounted to \u20ac25.9 billion, \u20ac18.9 billion\nand \u20ac21.5 billion, respectively (source: IQVIA).\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7117194183062446, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-8", "text": "         In a second phase, Dermapharm intends to also enter markets in the Benelux countries, the Czech\nRepublic and Slovakia, as it believes it will be able to compete in these markets with only limited additional\ninvestments in Dermapharm\u2019s existing platform. With respect to medical devices bite away\u00ae and Herpotherm\u00ae,\nfor which Dermapharm recently acquired the worldwide marketing rights, Dermapharm intends to market these\ndevices globally. Through all of these expansion efforts, Dermapharm will make opportunistic judgements,\ntargeting those foreign markets it considers particularly attractive at the time.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8006843455945253, "height": 0.08254918733960659, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-9", "text": "          To support its expansion efforts, Dermapharm has already obtained marketing authorizations for some\nof its recently developed pharmaceuticals in these markets (e.g., for Solacutan\u00ae). With respect to new product\nlaunches, Dermapharm plans to obtain marketing authorizations for several target markets faster and more cost\nefficient by conducting one combined approval process for several countries.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8071000855431993, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8622754491017964, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-137-10", "text": "", "page_number": 137, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-138-0", "text": "          In order to establish a functioning sales infrastructure in the adjacent regional markets targeted by\nDermapharm, it will opportunistically decide whether to hire new management personnel and sales\nrepresentatives and/or acquire existing businesses in these markets. Dermapharm expects that it will take\nbetween eight and twelve weeks after completion of the relevant market research and analysis by local\npersonnel to establish its initial operations and commence distribution in new markets. When entering these new\nmarkets, Dermapharm can rely on its extensive expertise with the establishment of strong sales capacities and\nthe successful integration of acquisitions, helping to ensure that Dermapharm will be able to quickly integrate\noperations in foreign markets into its overall business. For example, Dermapharm has recently established\nsubsidiaries in Italy and the United Kingdom and hired sales managers, who are tasked with establishing\nsalesforces and introducing relevant pharmaceuticals and other healthcare products from Dermapharm\u2019s product\noffering to these markets, which Dermapharm considers particularly attractive.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-138-1", "text": "12.3.3   Continue track record of successful acquisitions to further strengthen growth and profitability\n", "page_number": 138, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.24935842600513258, "lower_right_x": 0.8349455864570737, "lower_right_y": 0.2634730538922156, "height": 0.014114627887083009, "width": 0.717049576783555}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["12.3.3Continue track record of successful acquisitions to further strengthen growth and profitability"]}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-138-2", "text": "          Dermapharm constantly screens and seeks to capitalize on selective growth opportunities, including\nacquisitions of new marketing authorizations, products and businesses. In doing so, Dermapharm particularly\nseeks opportunities that meet its existing or complementary business areas, with a potential for additional\norganic growth following acquisition (including growth through cross-selling of Dermapharm\u2019s existing product\nportfolio), an acquisition price that fits Dermapharm\u2019s generally conservative approach to external growth and\nthe potential of a swift integration into Dermapharm\u2019s existing operations structure. If it can identify suitable\ntargets, Dermapharm may selectively rely on acquisitions to increase its international footprint.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3729683490162532, "height": 0.09281437125748504, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-138-3", "text": "         For external growth, Dermapharm relies on its long-term market experience and track-record of\nsuccessful acquisition and integration of new businesses. Following its foundation in 1991, Dermapharm has\ncontinuously expanded its product offering through successful acquisitions, in particular several entities\noperating under the \u201cH\u00fcbner\u201d brand in 2010, which contributed substantially to Dermapharm\u2019s other healthcare\nproduct offering, and axicorp GmbH in 2012, which enabled Dermapharm to enter the parallel import business.\nIn September 2017, Dermapharm acquired the marketing rights for medical devices bite away\u00ae for the external\ntreatment of bites and stings from insects and Herpotherm\u00ae for the treatment of herpes symptoms. Furthermore,\nDermapharm acquired Bio-Di\u00e4t-Berlin in September 2017, which, inter alia, manufactures and markets\nwell-known OTC products, in particular China-Oel oils, capsules and lozenges. In December 2017,\nDermapharm further expanded its product offering by acquiring all shares in Strathmann, which distributes a\nbroad product offering primarily comprising OTC products, which complement Dermapharm\u2019s existing product\nportfolio, in particular with respect to the dermatologicals, women\u2019s healthcare and vitamins/minerals/enzymes\nproduct areas. In addition, Strathmann recently obtained a marketing authorization for a prescription\npharmaceutical for the treatment of muscle spasms and muscle aches and Dermapharm believes that this new\nproduct offers significant market potential. Furthermore, in January 2018 Dermapharm acquired all shares in\nTrommsdorff, which manufactures and markets 23 different prescription pharmaceuticals and OTC products, in\nparticular Keltican\u00ae forte, a dietary product for the treatment of back pain, and Tromcardin \u00ae complex, which\ncombines certain minerals and vitamins for the treatment of cardiac arrhythmia.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.38280581693755344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6261762189905903, "height": 0.24337040205303684, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-138-4", "text": "         Following closing of past acquisitions, Dermapharm has consistently managed to utilize its\nmanufacturing, distribution and administrative platform to improve cost efficiency and increase revenues as well\nas margins in connection with the integration of the acquired products and companies. For example entities\noperating under the \u201cH\u00fcbner\u201d brand in 2010, the logistics operations of these entities were transferred to\nDermapharm\u2019s Brehna facilities. In addition, Dermapharm was able to create synergies by transferring the\nmanufacturing of ointments and capsules for certain healthcare products to Brehna. Dermapharm expects to\nhave a similar success with respect to Trommsdorff, which operates a manufacturing facility in Alsdorf,\nHamburg, Germany. Dermapharm plans to transfer the manufacturing of ibutop\u00ae, which is currently\nmanufactured by third parties, to the Alsdorf facility, thereby increasing the share of products manufactured\nunder Dermapharm\u2019s direct control. At the same time, the current logistics operations of Strathmann and\nTrommsdorff will be transferred to Dermapharm\u2019s central logistics hub in Brehna, helping to optimize logistics\nprocesses and the integration of these businesses. In the future, Dermapharm plans to further expand its product\nrange and geographic reach through selective value-adding acquisitions.\n", "page_number": 138, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8109495295124037, "height": 0.1749358426005132, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-138-5", "text": "95\n", "page_number": 138, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-0", "text": "12.3.4   Increase sales of OTC and other healthcare products through focused marketing efforts\n", "page_number": 139, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7914147521160823, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.6735187424425635}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["12.3.4Increase sales of OTC and other healthcare products through focused marketing efforts"]}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-1", "text": "          In order to grow its revenues from OTC and other healthcare products, Dermapharm plans to focus on\nthe marketing efforts with respect to these products, aiming to exploit sales channels that Dermapharm considers\nunderutilized by its competitors. To this end, 13 of Dermapharm\u2019s 72 German general sales representatives\nprimarily focus on directly marketing OTC and other healthcare products through visits with pharmacies and\nhealth stores which Dermapharm has identified as particularly relevant for such products. Dermapharm believes\nthat this salesforce will help it to better market its OTC and other healthcare products, further decreasing the\nportion of revenues that is subject to pricing restrictions.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-2", "text": "          With respect to certain high-volume, low-margin OTC products, Dermapharm plans to utilize axicorp\u2019s\ndirect marketing and call center expertise by employing direct calls to pharmacies in order to better market such\nproducts. To this end, axicorp has built a salesforce of five call center employees, and Dermapharm has handed\nthe marketing of the relevant low-margin OTC products, in particular ibutop\u00ae, a pain-relieving medication\nadministered in the form of gels or tablets, and Cetirizin-dihydrochlorid axicorp\u00ae, which helps to alleviate\nallergies and related symptoms, to axicorp. Dermapharm\u2019s call center salesforce specifically targets pharmacies\nDermapharm considers underserved by major manufacturers of OTC products and other competitors in order to\nsomewhat avoid pricing pressure for the relevant high-volume, low-margin OTC products. Dermapharm expects\nthat by the end of December 31, 2018, it will successfully have transferred the marketing of three additional\nOTC products to axicorp and that this will positively affect future revenues from these products.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35243798118049613, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-3", "text": "12.3.5   Further optimize operations and market analysis for Dermapharm\u2019s parallel import business\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8258766626360339, "lower_right_y": 0.3819503849443969, "height": 0.012831479897348175, "width": 0.7055622732769045}, "blob_type": "headline", "predictions": {}, "annotations": {"key_element_strategy": ["Further optimize operations and market analysis for Dermapharm\u2019s parallel import business"]}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-4", "text": "          Dermapharm\u2019s clearly defined approach to analyzing the European pharmaceuticals market and ability\nto identify attractive opportunities have made Dermapharm the fastest growing player amongst the five largest\nparallel importers in the German pharmaceuticals import market with a market share of 10.8% in the fiscal year\nended December 31, 2016 (source: INSIGHT Health). Dermapharm seeks to further optimize its data gathering\nand analysis processes by reducing the amount of manual input required to maintain Dermapharm\u2019s extensive\ndatabase. In addition, it intends to increase connectivity between different information technology systems and\nits database, allowing its purchasing and sales departments faster access to even more extensive and\nbetter-prepared data. Dermapharm believes that these improvements to its data gathering and analysis processes\nwill help it to further grow its parallel import business by identifying attractive pharmaceuticals ahead of\ncompetitors and at the same time support Dermapharm\u2019s margins from parallel imports by lowering its\noperating costs.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5461933276304534, "height": 0.14970059880239517, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-5", "text": "12.4   Business Areas\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5607356715141146, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.5714285714285714, "height": 0.010692899914456766, "width": 0.16928657799274488}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-6", "text": "        Dermapharm is a leading independent developer, manufacturer and distributor of branded\npharmaceuticals that are no longer patent protected as well as other healthcare products in the German market.\nThrough its parallel import business, Dermapharm also leverages its direct marketing expertise in Germany by\nimporting pharmaceuticals from other member states of the European Union for resale in Germany.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.588109495295124, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6428571428571429, "height": 0.054747647562018886, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-7", "text": "         The following table provides additional information on Dermapharm\u2019s two business areas for the\nperiods indicated:\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6497005988023952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6770744225834047, "height": 0.0273738237810095, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-8", "text": "                                                                              For the fiscal year            For the nine-month period\n                                                                             ended December 31,                ended September 30,\n                                                                   2014              2015           2016       2016              2017\n                                                                                 (unaudited)                         (unaudited)\n                                                                                (in \u20ac million)                      (in \u20ac million)\nPharmaceuticals and other healthcare\n  products\n Revenues..................................................................................\n                                                                         185.0              189.9    208.5       154.4          163.6\n EBITDA ..................................................................................\n                                                                           68.8              80.6     96.4        71.4           77.7\n EBITDA margin .......................................................................\n                                                                           37.2              42.4     46.2        46.2           47.5\nParallel imports(1)\n Revenues..................................................................................\n                                                                         206.3              195.0    235.9       164.8          186.1\n EBITDA ..................................................................................\n                                                                             3.6              4.1      6.3         5.1            5.2\n EBITDA margin .......................................................................\n                                                                             1.7              2.1      2.7         3.1            2.8\n", "page_number": 139, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6804961505560307, "lower_right_x": 0.875453446191052, "lower_right_y": 0.8652694610778443, "height": 0.18477331052181356, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-9", "text": "(1) Includes certain OTC products marketed by axicorp.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8755346449957229, "lower_right_x": 0.46856106408706166, "lower_right_y": 0.8922155688622755, "height": 0.01668092386655262, "width": 0.3524788391777509}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-139-10", "text": "", "page_number": 139, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.01571946795646917}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-0", "text": "12.4.1   Pharmaceuticals and Other Healthcare Products\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.40205562273276907}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-1", "text": "          Pharmaceuticals comprise prescription pharmaceuticals (i.e., pharmaceuticals that may only be\nobtained by patients if prescribed by a doctor) and OTC products. All pharmaceuticals may only be distributed\nafter obtaining a marketing authorization with respect to each combination of dosage form and packaging, and\nDermapharm develops, manufactures and sells branded pharmaceuticals in a variety of dosage forms, including\ntablets, capsules, injectables, drops, liquids, sprays, ointments and creams. Dermapharm\u2019s other healthcare\nproducts such as cosmetics, food supplements and dietary products may be sold without a marketing\nauthorization.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20744225834046193, "height": 0.09495295124037638, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-2", "text": "       The following table provides a breakdown of Dermapharm\u2019s revenues from prescription\npharmaceuticals as well as OTC and other healthcare products for the periods indicated:\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-3", "text": "                                                                                For the fiscal year             For the nine-month period\n                                                                               ended December 31,                 ended September 30,\n                                                                     2014              2015            2016       2016              2017\n                                                                                   (unaudited)                          (unaudited)\n                                                                                  (in \u20ac million)                       (in \u20ac million)\nPrescription pharmaceuticals ...................................................\n                                                                            119.2              126.6    135.3        97.9          106.1\nOTC and other healthcare products(2) ......................................   50.6              53.6     56.5        42.6           43.3\nSLG(1) ......................................................................................\n                                                                                6.0                \uf02d        \uf02d           \uf02d              \uf02d\nBalance(3) .................................................................................\n                                                                                9.2              9.7     16.7        13.9           14.2\n                                                                            185.0\nTotal(2) ..................................................................................... 189.9    208.5       154.4          163.6\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.24935842600513258, "lower_right_x": 0.875453446191052, "lower_right_y": 0.38109495295124035, "height": 0.13173652694610777, "width": 0.7503022974607014}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-4", "text": "(1) Comprises sales by SLG, which was divested on December 31, 2015.\n(2) Excludes certain OTC products marketed by axicorp.\n(3) Comprises sales by Melasan GmbH, Melasan Produktions & Vertriebsgesellschaft m.b.H., Sun-Farm Sp.z o.o., Farmal\n    and Mibe Pharmaceuticals d.o.o. as well as other income, the effects of discounts and certain rebates, all of which\n    cannot be allocated to prescription pharmaceuticals and OTC and other healthcare products, respectively, for accounting\n    reasons.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.3943541488451668, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46877673224978617, "height": 0.07442258340461938, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-5", "text": "12.4.1.1\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.49615055603079555, "height": 0.010692899914456822, "width": 0.0532043530834341}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-6", "text": "Product Areas\n", "page_number": 140, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.48545765611633873, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.49700598802395207, "height": 0.01154833190761334, "width": 0.1021765417170496}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-7", "text": "          Dermapharm\u2019s portfolio of pharmaceuticals and other healthcare products covers the following product\nareas: (i) vitamins/minerals/enzymes, (ii) dermatologicals, (iii) systemic corticoids, (iv) women\u2019s healthcare and\n(v) ophthalmologicals.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5128314798973481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5543199315654406, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-8", "text": "         The following table provides a breakdown of Dermapharm\u2019s revenues from pharmaceuticals and other\nhealthcare products by product areas for the periods indicated:\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5885372112917023, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-9", "text": "                                                                                  For the fiscal year             For the nine-month period\n                                                                                 ended December 31,                 ended September 30,\n                                                                       2014              2015            2016       2016              2017\n                                                                                     (unaudited)                          (unaudited)\n                                                                                    (in \u20ac million)                       (in \u20ac million)\n Vitamins/minerals/enzymes ......................................................\n                                                                                41.8              50.4     60.3        42.0           47.7\n Dermatologicals ........................................................................\n                                                                                54.5              58.1     60.2        45.4           49.5\n Systemic corticoids ...................................................................\n                                                                                25.6              28.4     27.2        20.4           20.5\n Women\u2019s healthcare .................................................................\n                                                                                  6.2              9.0     10.9         8.0            8.7\n Ophthalmologicals ....................................................................\n                                                                                  3.4              3.9      4.9         3.6            4.2\n         (1)\n                                                                                38.3\n Others ....................................................................................      30.5     28.2        21.0           18.7\n Subtotal....................................................................................\n                                                                              169.8              180.3    191.7       140.5          149.4\n SLG(2) .......................................................................................\n                                                                                  6.0                \uf02d        \uf02d           \uf02d              \uf02d\n Balance(3) ..................................................................................\n                                                                                  9.2              9.7     16.7        13.9           14.2\n                                                                              185.0\nTotal(1) ....................................................................................... 189.9    208.5       154.4          163.6\n", "page_number": 140, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5949529512403764, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7959794696321643, "height": 0.20102651839178787, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-10", "text": "(1) Excludes certain OTC products marketed by axicorp.\n(2) Comprises sales by SLG, which was divested on December 31, 2015.\n(3) Comprises sales by Melasan GmbH, Melasan Produktions & Vertriebsgesellschaft m.b.H., Sun-Farm Sp.z o.o., Farmal\n    and Mibe Pharmaceuticals d.o.o. as well as other income, the effects of discounts and certain rebates, all of which\n    cannot be allocated to prescription pharmaceuticals and OTC and other healthcare products, respectively, for accounting\n    reasons.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8109495295124037, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8828058169375534, "height": 0.07185628742514971, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-140-11", "text": "", "page_number": 140, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01571946795646917}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-0", "text": "12.4.1.1.1   Vitamins/Minerals/Enzymes\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.28053204353083433}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-1", "text": "         Dermapharm\u2019s vitamins/minerals/enzymes product area comprises products with 25 APIs offered in\n251 different articles (each as of September 30, 2017). These products are used to treat a variety of diseases\nfrom bone ailments to nutrition deficits. The vitamins/minerals/enzymes product area includes Dermapharm\u2019s\nflagship product Dekristol\u00ae 20,000 I.E., a unique high-dosage vitamin D preparation and the product of\nDermapharm with the highest annual revenues. Vitamin D improves the absorption and use of calcium, which\npositively affects calcium levels in the blood, improves dental and bone health and benefits muscular functions\nas well as the overall immune system. Dekristol\u00ae 20,000 I.E. is used to treat or prevent many conditions caused\nby a lack of vitamin D, especially conditions of the skin or bones.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-2", "text": "          In addition, Dermapharm markets vitamin D drops as well as various silicea healthcare products under\nits \u201cH\u00fcbner\u201d brand, including food supplement sikapur \u00ae, a mineral silicon in gel form, which helps strengthen\nthe skin, hair and nails.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.04148845166809237, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-3", "text": "12.4.1.1.2   Dermatologicals\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28699743370402053, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.2994011976047904, "height": 0.01240376390076986, "width": 0.19891172914147523}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-4", "text": "         In its dermatologicals product area, Dermapharm markets a broad range of products with 63 APIs\noffered in 595 different articles (each as of September 30, 2017) for the treatment of skin diseases (e.g., fungal\ninfections and diseases, rash, itchiness or reddening and other skin diseases as well as hair loss). Dermapharm\nconsiders itself the pharmaceuticals manufacturer in the German market with the broadest assortment of topical\ncorticoids. Its longstanding expertise with dermatologicals has made Dermapharm the market leader for\nprescription dermatologicals in Germany (based on number of prescriptions and revenues for APIs offered by\nDermapharm, excluding hospital sales (sources: INSIGHT Health; Company information)).\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3143712574850299, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4093242087254063, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-5", "text": "         Dermapharm\u2019s dermatologicals include Ampho-Moronal\u00ae, a specialty pharmaceutical and one of\nDermapharm\u2019s best-selling prescription antifungals, which is used for the treatment of diseases in the mouth and\nthroat area as well as gastrointestinal diseases. In addition, Dermapharm recently introduced Solacutan\u00ae, a\nprescription pharmaceutical which includes diclofenac sodium and is applied to the face or scalp to treat mild to\nmoderate cornification disorders of the skin, including actinic keratosis, which, if left untreated, may become\ncancerous. Dermapharm considers itself the first manufacturer to receive a marketing authorization for a\npatent-free pharmaceutical for this formula in Europe. In addition, Dermapharm markets a nail varnish under the\nCiclocutan\u00ae trademark, which reduces nail fungus. In 2017, Dermapharm introduced Minoxicutan \u00ae, an\nOTC product in the form of a dissolution that is applied to the skin in order to combat hereditary hair loss in\nmen or women.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.41402908468776733, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5504704875962361, "height": 0.13644140290846873, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-6", "text": "         In September 2017, Dermapharm further expanded its dermatologicals offering by acquiring the\nworldwide marketing rights for medical devices bite away\u00ae for the external treatment of bites and stings from\ninsects and Herpotherm\u00ae for the treatment of herpes symptoms.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6013686911890505, "height": 0.04063301967493582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-7", "text": "12.4.1.1.3   Systemic Corticoids\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.343409915356711, "lower_right_y": 0.6291702309666382, "height": 0.01368691189050475, "width": 0.22309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-8", "text": "         In its systemic corticoids product area, Dermapharm markets products with seven APIs offered in\n224 different articles (each as of September 30, 2017) for the treatment of allergic reactions, skin diseases,\ninflammations and other skin disorders (e.g., eczema, vesicles and crusts). All of these products are prescription\npharmaceuticals and include Prednisolut\u00ae, which, depending on the respective dosage, is used as a standard\ntherapy to treat a wide range of adverse physical reactions ranging from seasonal allergic reactions to\nanaphylactic shocks and other acute symptoms. To the Company\u2019s knowledge, Prednisolut \u00ae is one of only two\nsuch prescription corticoids for which a marketing authorization has been approved in Germany. Its broad\nproduct offering has made Dermapharm the German market leader for prescription pharmaceuticals in the\nGerman systemic corticoids market (based on number of prescriptions and revenues for APIs offered by\nDermapharm, excluding hospital sales (sources: INSIGHT Health; Company information)).\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7801539777587682, "height": 0.13729683490162525, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-9", "text": "12.4.1.1.4   Women\u2019s healthcare\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7934131736526946, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.806672369546621, "height": 0.013259195893926434, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-10", "text": "         Dermapharm\u2019s women\u2019s healthcare product area markets a broad range of contraceptives and other\nwomen\u2019s healthcare products with 13 APIs offered in 103 different articles (each as of September 30, 2017).\nOne of the most successful prescription contraceptives is Dienovel\u00ae, a hormonal oral contraceptive for the\nprevention of pregnancy as well as the treatment of acne. In addition, women\u2019s healthcare product Lactofem \u00ae is\napplied in the form of suppositories and gels and used for the maintenance and restoration of natural pH levels\nin the vagina by acidification with lactic acid.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.820786997433704, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9033361847733106, "height": 0.08254918733960659, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-141-11", "text": "", "page_number": 141, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.507255139056832, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.01571946795646917}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-0", "text": "12.4.1.1.5   Ophthalmologicals\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-1", "text": "         Dermapharm\u2019s ophthalmologicals products area markets products with eleven APIs offered in\n30 different articles (each as of September 30, 2017) for the treatment of various disorders and diseases of the\neye. These products include Panthenol-Augensalbe JENAPHARM\u00ae, an OTC product in the form of an eye\nointment used for the treatment of acute or chronic bacterial infections of the anterior eye segment, caused by\nconjunctivitis, blepharitis or corneal ulcers as complications of keratitis resulting from corrosive injuries or\nburns. Dermapharm believes that Panthenol-Augensalbe JENAPHARM\u00ae is the only product currently\ncompeting in this particular market in Germany alongside well-known originator product Bepanthen\u00ae.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-2", "text": "12.4.1.1.6   Others\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.2352437981180496, "height": 0.009837467921300247, "width": 0.13119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-3", "text": "          In addition to the aforementioned product areas, Dermapharm markets a broad range of other\npharmaceuticals and healthcare products with 102 APIs offered in 469 different articles (each as of\nSeptember 30, 2017), including bone metabolism regulators and pharmaceuticals for the treatment of\ncardiovascular diseases or diseases of the central nervous system. For example, Suxilep \u00ae is a prescription\nanti-epileptic pharmaceutical used to treat absence seizures. Furthermore, Dermapharm markets Temagin\u00ae pac,\nan OTC painkiller in tablet form with the same APIs and dosage as well-known originator product\nThomapyrin\u00ae.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34901625320787, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-4", "text": "12.4.1.2     Sales and Distribution Channels\n\n12.4.1.2.1   Doctors\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.4007698887938409, "height": 0.03849443969204447, "width": 0.3053204353083434}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-5", "text": "         Doctors in private practice are Dermapharm\u2019s most important target group for prescription\npharmaceuticals. Prescription pharmaceuticals may only be obtained by patients if prescribed by a doctor. If the\nprescription notes a specific product and expressly excludes any substitution thereof, pharmacies are legally\nrequired to dispense only the specifically prescribed pharmaceutical. Consequently, doctors have a strong\ninfluence over the market penetration of prescription pharmaceuticals in their respective practice area. As of the\ndate of this Prospectus, Dermapharm employs 60 German sales representatives who regularly visit doctors\nrelevant for Dermapharm\u2019s product areas. Dermapharm believes that the recent acquisition of Trommsdorff,\nwhich employs its own sales organization comprising around 60 sales representatives, will further boost its\nmarketing capacities for pharmaceuticals and other healthcare products.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5406330196749358, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-6", "text": "         In the twelve-month period ended November 30, 2017, Dermapharm\u2019s German general sales\nrepresentatives paid approximately 29,000 visits to dermatologists and approximately 22,000 visits to\ngynecologists. These efforts have led to considerable success, particularly in the field of dermatology, in which\nDermapharm already ranked first in dermatological prescriptions in Germany in the fiscal year ended\nDecember 31, 2016 as dermatologists issued 1.4 million prescriptions noting pharmaceuticals marketed under\nDermapharm\u2019s various brands (sources: INSIGHT Health; Company information).\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6295979469632165, "height": 0.08254918733960659, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-7", "text": "12.4.1.2.2   Pharmacies and Pharmaceutical Wholesalers\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6428571428571429, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.6569717707442259, "height": 0.014114627887082953, "width": 0.38694074969770254}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-8", "text": "        Pharmacies, including online pharmacies, are an important distribution channel for Dermapharm\u2019s\npharmaceuticals, as they directly distribute these pharmaceuticals to patients. In addition, a large number of\nDermapharm\u2019s other healthcare products are also offered by pharmacies. Pharmacies purchase Dermapharm\u2019s\npharmaceuticals and other healthcare products primarily through pharmaceutical wholesalers, but may also\npurchase such products directly from Dermapharm. In the fiscal year ended December 31, 2016, 80% of\nDermapharm\u2019s revenues from pharmaceuticals and other healthcare products were derived from sales to\npharmaceutical wholesalers, while 20% of such revenues were derived from direct sales to pharmacies.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6702309666381523, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-9", "text": "         If an exchange with a similar pharmaceutical is not expressly excluded in the relevant prescription and\nthere is no existing rebate agreement between the patient\u2019s SHI provider for such product, the pharmacy is\nrequired to distribute one of the three cheapest comparable pharmaceuticals. If the prescribed pharmaceutical is\namongst the three cheapest pharmaceuticals on offer, the pharmacy may not distribute a higher priced\npharmaceutical. In addition, if the doctor has only prescribed certain APIs and there is no existing rebate\nagreement between the patient\u2019s SHI provider for such product, the pharmacy is required to distribute one of\nthree cheapest pharmaceuticals containing the relevant APIs.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8691189050470488, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-142-10", "text": "", "page_number": 142, "bounding_box": {"top_left_x": 0.4915356711003628, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.016324062877871803}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-0", "text": "         Therefore, pharmacies not only purchase Dermapharm\u2019s pharmaceuticals, but also have significant\ninfluence on Dermapharm\u2019s success by determining the composition and pricing of their product assortment and\nchoosing Dermapharm\u2019s products over those of its competitors. Dermapharm regularly enters into annual rebate\nand sales agreements with its pharmacies (but not with wholesalers). In the twelve-month period ended\nNovember 30, 2017, Dermapharm\u2019s German general sales representatives paid approximately 35,000 visits to\nGerman pharmacies.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-1", "text": "         As of the date of this Prospectus, Dermapharm employs 14 German sales representatives who primarily\nfocus on directly marketing Dermapharm\u2019s OTC and other healthcare products through visits with pharmacies\nand health stores which Dermapharm has identified as particularly relevant for such products. With respect to\ncertain high-volume, low-margin OTC products, Dermapharm plans to utilize axicorp\u2019s direct marketing and\ncall center expertise by employing direct calls to pharmacies in order to better market such products. To this\nend, axicorp has built a salesforce of five call center employees, and Dermapharm has handed the marketing of\nthe relevant low-margin OTC products, in particular ibutop\u00ae, a pain-relieving medication administered in the\nform of gels or tablets, and Cetirizin-dihydrochlorid axicorp\u00ae, which helps to alleviate allergies and related\nsymptoms, to axicorp. Dermapharm\u2019s call center salesforce specifically targets pharmacies Dermapharm\nconsiders underserved by major manufacturers of OTC products and other competitors in order to somewhat\navoid pricing pressure for the relevant high-volume, low-margin OTC products. Dermapharm expects that by\nthe end of December 31, 2018, it will successfully have transferred the marketing of three additional\nOTC products to axicorp and that this will positively affect future revenues from these products.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35243798118049613, "height": 0.17835757057313942, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-2", "text": "12.4.1.2.3   SHI Providers\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.3661248930710009, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.37852865697177074, "height": 0.01240376390076986, "width": 0.18198307134220076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-3", "text": "          SHI providers often initiate tender processes for specific types of prescription pharmaceuticals, in\nwhich manufacturers of the relevant pharmaceutical compete for exclusive or semi-exclusive rebate agreements\nwith the relevant provider. Such contracts are generally awarded to the manufacturer offering the lowest price\nand may include significant discounts to market prices. In the case of an existing rebate agreement with the\nrelevant patient\u2019s SHI provider relating to the pharmaceutical prescribed by the doctor, pharmacies are required\nto distribute the specific product referenced in the rebate agreement rather than the prescribed pharmaceutical,\nso long as the specific product is equivalent to the prescribed drug with respect to the APIs, amount and form of\ndosage, unless such exchange is expressly excluded on the prescription. Furthermore, a patient may choose to\nobtain a different pharmaceutical than the one provided by the rebate agreement, if such patient covers the price\ndifference himself.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5303678357570573, "height": 0.13387510692899907, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-4", "text": "         Such rebate agreements remain an important distribution channel for Dermapharm\u2019s pharmaceuticals,\naccounting for approximately 12% of Dermapharm\u2019s revenues from pharmaceuticals and other healthcare\nproducts in the nine-month period ended September 30, 2017 (sources: INSIGHT Health; Company\ninformation). However, due to the decrease in margins and strong competition in tender offers for rebate\nagreements with SHI providers, which are typically decided in favor of the lowest offered price, Dermapharm\nseeks to further its independence from the tender business by focusing on attractive markets and products that\nare not covered, or only partially covered, by SHI providers or where such SHI providers do not initiate tender\nprocesses.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6471343028229256, "height": 0.106928999144568, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-5", "text": "12.4.1.2.4   Hospitals\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6633875106928999, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.676218990590248, "height": 0.01283147989734812, "width": 0.1505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-6", "text": "          Dermapharm also sells its pharmaceuticals directly to hospitals, which constitute a completely\nindependent distribution channel and accounted for 11% of Dermapharm\u2019s revenues from pharmaceuticals and\nother healthcare products in the nine-month period ended September 30, 2017. Statutory pricing restrictions and\nrebate agreements with SHI providers do not apply to pharmaceuticals that are distributed to patients at\nhospitals. Dermapharm has entered into various types of purchase co-operations with large hospital operators\nsuch as Helios, Sana and the Pharmaceutical Benefit Management Group, a cooperation for hospitals.\nDermapharm considers regular personal contacts with relevant hospitals and service as key elements to generate\nrevenues in the hospital market. Dermapharm employs seven hospital sales representatives in Germany, who are\nin close contact with key accounts at major hospital chains and large hospitals.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6907613344739093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8135158254918734, "height": 0.1227544910179641, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-7", "text": "12.4.1.2.5   Health Stores, Drug Stores and Healthcare Wholesalers\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8276304533789564, "lower_right_x": 0.5785973397823458, "lower_right_y": 0.8404619332763046, "height": 0.01283147989734823, "width": 0.45828295042321643}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-8", "text": "         In addition to pharmacies, Dermapharm\u2019s other healthcare products are sold in health stores and\ndrugstores, many of whom purchase such products through wholesalers. Dermapharm considers a strong\ncustomer focus, regular personal contact and excellent brand recognition, in particular with respect to its\n\u201cH\u00fcbner\u201d brand, as key drivers for the sale of such healthcare products.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8550042771599657, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9101796407185628, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-143-9", "text": "100", "page_number": 143, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-0", "text": "12.4.1.2.6   Distribution Partners\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-1", "text": "         Dermapharm\u2019s healthcare products marketed under the \u201cH\u00fcbner\u201d brand are also distributed through\n34 third-party distribution partners, who purchase these products from Dermapharm for resale in 31 countries\noutside of Germany.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-2", "text": "12.4.1.2.7   Online Shops\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.17065868263473055, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.18306244653550044, "height": 0.012403763900769887, "width": 0.1795646916565901}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-3", "text": "         Dermapharm\u2019s medical devices bite away\u00ae and Herpotherm\u00ae are marketed through various online\nshops, in particular the online platform operated by Amazon EU S.\u00e0 r.l. As of the date of this Prospectus, these\nmedical devices had comparably high average user ratings and in the nine-month period ended September 30,\n2017, approximately 288,000 units of bite away\u00ae and Herpotherm\u00ae were sold through such online shops.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19461077844311378, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25192472198460225, "height": 0.05731394354148847, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-4", "text": "12.4.1.3   Development\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.26646706586826346, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.2797262617621899, "height": 0.013259195893926434, "width": 0.17412333736396612}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-5", "text": "          In the fiscal year ended December 31, 2016, Dermapharm spent \u20ac4.8 million (\u20ac4.6 million in the fiscal\nyear ended December 31, 2015) on development activities, employing an average of 58 employees in its\ndevelopment department (in the fiscal year ended December 31, 2015: 52 employees). Given its exclusive focus\non pharmaceuticals that are no longer patent protected and for which it has the required know-how to develop\nall relevant dosage forms, Dermapharm does not conduct any basic medical research (Grundlagenforschung).\nAs a result, Dermapharm\u2019s development costs are comparably low, with average development costs of between\n\u20ac330,000 and \u20ac1.5 million for new pharmaceuticals.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3896492728828058, "height": 0.09580838323353291, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-6", "text": "         Dermapharm\u2019s development efforts relate to all of Dermapharm\u2019s product areas and if it were to\nexpand into additional product areas in the future, Dermapharm would likely seek to develop new\npharmaceuticals and other healthcare products to complement its offering in these product areas as well.\nDermapharm constantly screens the product areas covered by its product offering in order to identify attractive\ndevelopment opportunities meeting the following criteria: they are part of a product area covered by\nDermapharm\u2019s portfolio, in case of prescription pharmaceuticals, there is limited pricing pressure from\nSHI providers or a high share of direct payers for the relevant product and competition for the relevant\ncustomers is expected to be limited, the relevant product can be developed by primarily utilizing Dermapharm\u2019s\nexisting development expertise and manufacture will be possible at existing manufacturing facilities.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5201026518391788, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-7", "text": "         Once Dermapharm has identified a suitable candidate, the duration of development strongly depends on\nthe type of product: for new pharmaceuticals, development usually takes about five years in total, with between\none and two years required to develop new formulations, followed by between six months and two years to\nconduct the relevant clinical studies and between six months and 18 months in order to obtain the required\nmarketing authorization and prepare the market introduction of the new pharmaceutical. By comparison,\nDermapharm has been able to flexibly introduce healthcare products with oftentimes less than a year elapsing\nbetween the start of development and the market introduction of such products. For food supplements,\nDermapharm has even been able to introduce new products within just four months after the start of the\ndevelopment process.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6497005988023952, "height": 0.1231822070145423, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-8", "text": "         Dermapharm is able to handle the key stages of the approval process in-house, including the designing\nand sponsoring of clinical studies (i.e., usually Phase I and Phase III studies) required for the market\nintroduction of new patent-free pharmaceuticals (e.g., setting criteria for patient selection, determining the\nrelevant dosage regime and analyzing data obtained in clinical studies) and the manufacture of clinical batches.\nDermapharm\u2019s development department is fully integrated with the other corporate functions material for the\ndevelopment of new products (e.g., sourcing and purchasing, quality control, packaging and design). The\ndepartment intensively cooperates with the regulatory affairs department and is supervised by quarterly\nmanagement meetings. Additionally, the development department has the required know-how to conduct the\napplication process for new marketing authorizations in-house. While Dermapharm\u2019s development department\nis able to design and sponsor clinical studies itself, it outsources the conduct of such studies to third-party\nservice providers. Between January 1, 2012 and September 30, 2017, Dermapharm conducted a total of\n26 clinical studies, including five clinical studies still pending as of the date of this Prospectus. Dermapharm\nconsiders the areas of complex microbiological investigations, clinical dermatology, the development of low\ndosage formulations, complex disperse systems and differentiated in-vitro testing as the core competencies of its\ndevelopment department. In addition, Dermapharm occasionally enters into development cooperation\nagreements with selected third-party research institutions (e.g., Proinnovera Gesellschaft f\u00fcr Beratung, Planung\nund Durchf\u00fchrung zur Entwicklung neuer pharmazeutischer Produkte mbH and CCDRD Cooperative Clinical\nDrug Research and Development Aktiengesellschaft).\n", "page_number": 144, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9029084687767323, "height": 0.2463644140290847, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-144-9", "text": "101", "page_number": 144, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-0", "text": "         Dermapharm\u2019s most important development center is located in Brehna and uses state-of-the-art\nequipment providing full GMP-compliance, while also holding an authorization for research on hormone\npreparations. The analytical and pharmaceutical development facilities include a laboratory explicitly designed\nfor analytical development with a total size of 550 square meters (\u201csqm\u201d), a microbiological laboratory, a\nlaboratory and pilot scale for pharmaceutical development with a total size of 750 sqm and eleven\npharmaceutical climate chambers with a total usable area of 150 sqm. Additionally, the pharmaceutical\ndevelopment division has bulk manufacturing expertise. Together, Dermapharm\u2019s development, clinical\nresearch and regulatory affairs departments are able to quickly and cost-efficiently develop new pharmaceuticals\nand other healthcare products.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20786997433704021, "height": 0.12275449101796408, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-1", "text": "          Dermapharm also conducts a special part of its development activities for healthcare products at its\nfacilities in Ehrenkirchen. These efforts focus on searching for new trends in the healthcare market, renewing\nDermapharm\u2019s existing portfolio of such products marketed under the \u201cH\u00fcbner\u201d brand, improving silicea\ncompetence, and developing capsules, sticks, liquids and semi-solids.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2677502138579983, "height": 0.05260906757912748, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-2", "text": "competence, and developing capsules, sticks, liquids and semi-solids.\n         Dermapharm\u2019s most recent acquisition Strathmann operates its own development department with a\nparticular expertise for OTC products and Dermapharm believes that these capacities will complement and\nenhance its existing development operations.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26817792985457656, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.05004277159965781, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-3", "text": "12.4.1.4   Manufacture and Logistics\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.3314798973481608, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.3455945252352438, "height": 0.014114627887083009, "width": 0.26541717049576785}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-4", "text": "         Dermapharm pursues an \u201call under one roof\u201d approach with respect to manufacture and logistics,\nfocusing on integration of its manufacturing sites, a flexible plant organization with flexible production lines,\nlean supply chains and state-of-the-art equipment. Based on the number of packages, approximately 90% of\nDermapharm\u2019s pharmaceuticals and other healthcare products were manufactured in-house in the nine-month\nperiod ended September 30, 2017 (including packages made from bulk products manufactured by third parties).\nDermapharm operates five manufacturing facilities, with three of these facilities being located in Germany and\nthe other two located in Poland and Austria, respectively.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.45551753635585973, "height": 0.0932420872540633, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-5", "text": "         The raw materials used in the manufacturing of Dermapharm\u2019s pharmaceuticals and other healthcare\nproducts consist of chemicals in various forms that are generally available from several sources. Dermapharm\nhas established a global sourcing strategy, including by employing its own representatives in China and India,\nDermapharm\u2019s most important sourcing countries with respect to raw materials for its pharmaceuticals and other\nhealthcare products. Dermapharm has long-established direct contacts with many of its key suppliers and agents.\nThis also makes it easier for Dermapharm to monitor compliance with relevant quality standards. Dermapharm\nplaces a high focus on quality control and vigilance, reviewing each shipment of raw materials received at its\nmain manufacturing facility in Brehna. Dermapharm favors a just in time investigation approach with respect to\nbulk materials and state-of-the-art processes to ensure that relevant raw materials comply with the standards laid\ndown in pharmacopeias. In addition, Dermapharm benefits from utilizing its various laboratories in Brehna\nwhen investigating special substances.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6142001710863987, "height": 0.14927288280581696, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-6", "text": "         The majority of Dermapharm\u2019s pharmaceuticals, including almost all application forms (e.g., ointments\nand creams, liquids and nasal sprays, powders and eye ointments/drops, capsules, freeze drying products, tablets\nand coated tablets, syringes fillings and ampules and vials), are manufactured and packaged at Dermapharm\u2019s\nmain manufacturing facility located in Brehna. In the fiscal year ended December 31, 2016, 36 million packages\nof pharmaceuticals were manufactured in Brehna. However, the soft capsules for Dermapharm\u2019s\nDekristol\u00ae 20,000 I.E. vitamin D preparation, its most significant product, are supplied by two European\nthird-party suppliers and merely repackaged by Dermapharm. In addition medical devices bite away\u00ae and\nHerpotherm\u00ae are manufactured by Riemser Pharma GmbH.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7309666381522669, "height": 0.10863986313088114, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-7", "text": "         Dermapharm\u2019s Brehna facilities also serve as Dermapharm\u2019s hub and logistical center. These facilities\nprovide for inbound logistics, with a warehouse containing over 2,500 consignment spaces and a storage system\nwith approximately 21,000 pallet places as well as an information technology system that manages sourcing,\nreporting and outbound logistics. Dermapharm\u2019s entire domestic product portfolio is distributed directly from\nthe Brehna facilities through third-party logistics providers to national and international consumers, allowing for\na worldwide distribution scope. In January 2017, Dermapharm initiated a program to review and further\nstreamline its integrated operations and processes in Brehna. This program is aimed at implementing operating\nstandards for each step of the manufacturing process for every single one of Dermapharm\u2019s products. When\nimplementing these standards, Dermapharm particularly focusses on the potential for cost reductions.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7386655260906758, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8609923011120616, "height": 0.12232677502138578, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-145-8", "text": "102", "page_number": 145, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-0", "text": "           Dermapharm\u2019s second German manufacturing site is located in Ehrenkirchen, Baden-Wuerttemberg,\nGermany, and focuses on natural healthcare products in liquid and gel form marketed under the \u201cH\u00fcbner\u201d brand.\nMost of these products are sold in pharmacies, health stores as well as drugstores in Germany, while\napproximately one third was sold to international third-party distribution partners in the fiscal year ended\nDecember 31, 2016. Such distribution partners resell Dermapharm\u2019s products marketed under the \u201cH\u00fcbner\u201d\nbrand in 31 countries outside Germany. In addition, the facility in Ehrenkirchen includes a silicea production\nline, a liquid production line (preservative free filling) as well as sachets filling and sealing machinery for liquid\nproducts. In the fiscal year ended December 31, 2016, the Ehrenkirchen facility manufactured 1.4 million units\nof silicea products and 1.2 million units of liquids.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.12360992301112063, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-1", "text": "         Dermapharm\u2019s most recent acquisition Strathmann operates the third German manufacturing facility in\nSeevetal, Lower-Saxony, Germany, which manufactures products for Strathmann\u2019s broad product offering\nprimarily comprising OTC products, in particular with respect to the dermatologicals, women\u2019s healthcare and\nvitamins/minerals/enzymes product areas. In the fiscal year ended December 31, 2016, the Seevetal facility\nmanufactured approximately 6.1 million units. Dermapharm plans to transfer the logistics operations of\nStrathmann to its central logistics hub in Brehna, helping to optimize logistics processes and the integration of\nStrathmann.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3092386655260907, "height": 0.09409751924721987, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-2", "text": "          In addition, Dermapharm\u2019s Polish manufacturing site, located near Warsaw, is dedicated to\nSun-Farm Sp. z o.o., a small-sized manufacturer with a local work force, specializing in food supplements. The\nplant also serves as a manual packaging site for Dermapharm.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-3", "text": "         Dermapharm\u2019s Austrian manufacturing site, located in Eugendorf near Salzburg, is dedicated to the\nAustrian Dermapharm entity Melasan GmbH, a company specialized in the development and manufacturing of\nfood supplements, in particular capsules, which are customized for Austrian pharmacies. Melasan GmbH\u2019s\noperations are increasingly utilized to achieve synergies in combination with Dermapharm\u2019s other entities.\nDermapharm has already made plans to replace the manufacturing facility in Eugendorf with a new facility in\nNeumarkt am Wallersee. The total investment volume for the new facility is expected to amount to\napproximately \u20ac7.0 million. The construction is expect to be completed by the end of the fiscal year ending\nDecember 31, 2019.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36569717707442256, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4756201881950385, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-4", "text": "           With respect to Trommsdorff, which operates a manufacturing facility in Alsdorf, Dermapharm plans\nto transfer the manufacturing of ibutop\u00ae, which is currently manufactured by third parties, to the Alsdorf\nfacility, thereby increasing the share of products manufactured under Dermapharm\u2019s direct control. At the same\ntime, the current logistics operations of Trommsdorff will be transferred to Dermapharm\u2019s central logistics hub\nin Brehna, helping to optimize logistics processes and the integration of Trommsdorff.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4820359281437126, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5508982035928144, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-5", "text": "          Dermapharm works strategically with its supplier base in order to meet cost, supply certainty and\nquality targets on a sustainable basis in keeping with its procurement organization. A significant portion of the\nraw materials required for the manufacture of Dermapharm\u2019s pharmaceuticals and other healthcare products is\npurchased outside Europe, in particular in China and India.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5573139435414884, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6124893071000855, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-6", "text": "12.4.2   Parallel Imports\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.6407185628742516, "height": 0.011548331907613396, "width": 0.1747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-7", "text": "         Dermapharm\u2019s parallel import business operates under the \u201caxicorp\u201d brand and leverages\nDermapharm\u2019s direct sales expertise in Germany by importing pharmaceuticals from other EEA Member States\nfor resale to pharmaceutical wholesalers and pharmacies in the German market, including reimports of\npharmaceuticals previously exported from Germany. Economically, Dermapharm benefits from selling the\nimported pharmaceuticals in Germany at a premium over the price of the respective pharmaceutical in the\nsourcing market. As of September 30, 2017, Dermapharm listed pharmaceuticals with over 1,500 product codes\n(Artikelnummern) in its parallel import product portfolio.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7514970059880239, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-8", "text": "         In the fiscal year ended December 31, 2016, Dermapharm covered approximately 89% of prescription\npharmaceuticals available for sale in the German parallel import market and was the fourth largest parallel\nimporter in Germany with a market share of 10.8% (source: INSIGHT Health). Moreover, Dermapharm\u2019s\nclearly defined approach to analyzing the European pharmaceuticals market and its ability to identify attractive\nopportunities have also made Dermapharm the fastest growing player amongst the five largest parallel importers\nin the German pharmaceuticals import market in the fiscal year ended December 31, 2016 (source: INSIGHT\nHealth).\n", "page_number": 146, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7591958939264328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8520102651839179, "height": 0.09281437125748504, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-146-9", "text": "103", "page_number": 146, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-0", "text": "         The following table provides additional information on Dermapharm\u2019s parallel import business for the\nperiods indicated:\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-1", "text": "                                                                           For the fiscal year              For the nine-month period\n                                                                          ended December 31,                  ended September 30,\n                                                                  2014            2015             2016       2016             2017\n                                                                               (unaudited)                         (unaudited)\n                                                                              (in \u20acmillion,                    (in \u20acmillion, unless\n                                                                       unless otherwise specified)             otherwise specified)\nRevenues(1)...............................................................................\n                                                                        206.3              195.0    235.9       164.8          186.1\nMarket share (in %)(2) ..............................................................\n                                                                            7.4              7.9      9.2         8.4            9.3\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.1193327630453379, "lower_right_x": 0.875453446191052, "lower_right_y": 0.21685201026518391, "height": 0.09751924721984602, "width": 0.7503022974607014}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-2", "text": "(1) Includes certain OTC products marketed by axicorp.\n(2) Source: INSIGHT Health.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2292557741659538, "lower_right_x": 0.4667472793228537, "lower_right_y": 0.25620188195038496, "height": 0.026946107784431156, "width": 0.3512696493349456}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-3", "text": "12.4.2.1   Sales and Relevant Customers\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26988879384088965, "lower_right_x": 0.4105199516324063, "lower_right_y": 0.281437125748503, "height": 0.01154833190761334, "width": 0.2902055622732769}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-4", "text": "         Pursuant to the Framework Agreement on Drug Provision according to Section 129 of the German\nSocial Code, Book V (Rahmenvertrag \u00fcber die Arzneimittelversorgung nach \u00a7 129 Abs. 2 Sozialgesetzbuch V\n(the \u201cFramework Agreement\u201d)), at least 5% of all prescription pharmaceuticals sold within the statutory\nhealthcare system in Germany must be brought into the market through parallel imports from other\nEEA Member States. According to Section 129 para. 1 no. 2 of the German Social Code, Book V\n(Sozialgesetzbuch F\u00fcnftes Buch (the \u201cSocial Code V\u201d)), only parallel imports with prices that are at least \u20ac15.00\nor 15% lower than the price of the German original pharmaceutical, taking into account any mandatory rebates,\ncount towards the 5% import quota. The actual market share of parallel imports in Germany exceeds this quota\nand amounted to approximately 8.6% in the fiscal year ended December 31, 2016 (source: INSIGHT Health).\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.29726261762189904, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-5", "text": "          While the parallel import business is a low-margin, high-volume business overall, margins for\nindividual pharmaceuticals may vary considerably. In general, demand from customers for high-margin imports\nis low, while demand for low-margin pharmaceuticals, for which there is only a limited offering from parallel\nimporters, is considerably higher. Dermapharm has divided its product offering into five product categories\nbased on the expected margin of each individual pharmaceutical. In order to generate an attractive margin from\nits parallel import business, Dermapharm tries to ensure that each customer purchases a mixed basket with\npharmaceuticals from different product categories (i.e., Dermapharm will offer customers a selection of\nattractive low-margin pharmaceuticals, while also requiring them to purchase lower-demand pharmaceuticals\nthat generate a considerably higher margin for Dermapharm).\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42728828058169377, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5508982035928144, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-6", "text": "         In addition, Dermapharm constantly reviews its product offering in order to identify new\npharmaceuticals that it can introduce to its parallel import product offering (see \u201c12.4.2.3 New Introductions of\nParallel Imports\u201d) or products that are no longer relevant for its offering. In this context, Dermapharm benefits\nfrom the close cooperation between the sourcing and sales departments for its parallel import business area\n(see \u201c12.4.2.2 Sourcing and Logistics\u201d).\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5573139435414884, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6261762189905903, "height": 0.06886227544910184, "width": 0.7605804111245466}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-7", "text": "12.4.2.1.1   Pharmaceutical Wholesalers\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6394354148845167, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.6535500427715997, "height": 0.014114627887082953, "width": 0.27569528415961303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-8", "text": "         Pharmaceutical wholesalers are key customers for Dermapharm\u2019s parallel import business and sales to\n11 different wholesalers accounted for approximately 70% of the revenues from parallel import in the fiscal year\nended December 31, 2016. Dermapharm employs three sales representatives who are constantly in personal\ncontact with these key customers and together plan the prospective demand of these customers for extended\nperiods of time. While pharmaceutical wholesalers will purchase a large part of Dermapharm\u2019s broad parallel\nimport product offering, Dermapharm\u2019s salesforce focusses on ensuring that each individual wholesaler\npurchases a mixed basket of pharmaceuticals from its five margin-related product categories.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6672369546621043, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7630453378956373, "height": 0.09580838323353302, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-9", "text": "          Due to the large number of pharmaceutical wholesalers with whom it has established close business\nrelationships, Dermapharm is not overly dependent on any one customer. At the same time, Dermapharm is\nopen to further intensifying such relationships and to this end entered into an agreement with\nPHOENIX Pharma-Einkauf GmbH, a member of the largest pharmaceutical wholesaler group in Germany, in\nJuly 2017, pursuant to which PHOENIX Pharma-Einkauf GmbH will give preferential treatment to the\ndistribution of Dermapharm\u2019s parallel imports for certain of PHOENIX Pharma-Einkauf GmbH\u2019s customers,\nreceiving a commission with respect to these pharmaceuticals. Dermapharm believes that this agreement\nevidences the strong market position obtained by its parallel import business and will help secure stable demand\nfor its parallel import business.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.893071000855432, "height": 0.12018819503849443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-147-10", "text": "104", "page_number": 147, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-0", "text": "12.4.2.1.2   Pharmacies\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.16444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-1", "text": "         Dermapharm also sells its imported pharmaceuticals directly to pharmacies, including online\npharmacies, and such sales accounted for approximately 30% of Dermapharm\u2019s revenues from its parallel\nimport business in the fiscal year ended December 31, 2016. Sales to pharmacies are handled by a separate\nsalesforce comprising 18 sales representatives, who operate from a call center in Friedrichsdorf, Hesse,\nGermany. In the fiscal year ended December 31, 2016, Dermapharm\u2019s salesforce conducted approximately\n183,000 phone calls to pharmacies, covering approximately 95% of the 20,023 licensed pharmacies in Germany\nas of December 31, 2016 (source: ABDA). This has helped Dermapharm to become the second largest player in\nthe German market for the direct resale of parallel imports to pharmacies (source: INSIGHT Health).\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-2", "text": "         Dermapharm has allocated each sales representative an individual distribution area with between\n300 and 500 pharmacies and incentivizes its sales representatives to ensure that their sales comply with the\nbasket mix required to achieve the envisaged overall margin for Dermapharm\u2019s parallel import business. Due to\nthe low fluctuation of its salesforce, Dermapharm benefits from long-established customer relationships of its\nindividual sales representatives, who also generate a significant share of inbound calls (i.e., requests from\npharmacies with respect to specific pharmaceuticals they want to purchase from Dermapharm). In order to retain\nthe most attractive pharmacy customers, Dermapharm has introduced a partnership program with several\npartnership levels, offering such customers various benefits (e.g., billing simplifications, free delivery and a\nmore generous policy with respect to returns).\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35243798118049613, "height": 0.12360992301112059, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-3", "text": "        In the fiscal year ended December 31, 2016, Dermapharm\u2019s parallel import business had approximately\n5,000 pharmacies as regular customers, thereby covering approximately 25% of the 20,023 licensed pharmacies\nin Germany as of December 31, 2016 (source: ABDA).\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35885372112917024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40034217279726264, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-4", "text": "12.4.2.2   Sourcing and Logistics\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.42857142857142855, "height": 0.01154833190761334, "width": 0.24244256348246676}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-5", "text": "         Dermapharm sources its imported pharmaceuticals from 25 EEA Member States, with the importance\nof any of these national markets constantly fluctuating (e.g., due to pricing changes and changes in the available\nvolume of attractive pharmaceuticals). Due to its ability to target all relevant sourcing markets, Dermapharm is\ncapable of ensuring that its sourcing is not overly dependent on any one of these countries. The sourcing itself is\nhandled by five purchasing representatives, each of whom is responsible for certain sourcing countries.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5119760479041916, "height": 0.06757912745936695, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-6", "text": "        The following chart provides an overview of the split of sourcing volume with respect to relevant\nsourcing countries for Dermapharm\u2019s parallel import business in the nine-month period ended September 30,\n2017:\n", "page_number": 148, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5577416595380668, "height": 0.038066723695466265, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-7", "text": "K\n@.", "page_number": 148, "bounding_box": {"top_left_x": 0.36577992744860943, "top_left_y": 0.5804106073567151, "lower_right_x": 0.6275695284159613, "lower_right_y": 0.7660393498716852, "height": 0.18562874251497008, "width": 0.2617896009673518}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-8", "text": "= Romania = UnitedKingdom = France Belgium Poland s=Norway mAustria mBulgaria mNetherlands mGreece \u00a9 Other", "page_number": 148, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.7899914456800684, "lower_right_x": 0.875453446191052, "lower_right_y": 0.8006843455945253, "height": 0.010692899914456877, "width": 0.7503022974607014}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-148-9", "text": "105", "page_number": 148, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-0", "text": "          Dermapharm believes that the close cooperation and communication between its sales and purchasing\ndepartments are key factors for its continued growth and success in the parallel import market. This cooperation\nis, in particular, reflected in the planning for Dermapharm\u2019s parallel import business, which is renewed every\nmonth for the upcoming three-month period. Initially, the sales department draws up a schedule of\npharmaceuticals that it deems attractive and likely marketable to customers. This list is reviewed, taking into\naccount the relevant volumes likely to be available and risks associated with individual pharmaceuticals. For\nthis analysis, Dermapharm relies on a broad product database on its 25 sourcing markets, which includes\ninformation obtained through public market sources as well as offers and feedback from local suppliers.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-1", "text": "         Once a purchasing schedule has been agreed upon, product contingents are allocated to individual\npurchasing representatives based on the likely availability of the relevant pharmaceuticals in different countries.\nDermapharm\u2019s purchasing department proceeds to contact selected local suppliers, with whom it has established\nstrong business relationships, enabling Dermapharm\u2019s purchasing experts to source more than 98% of the\nvolume agreed in the final purchasing schedule (based on sourcing volumes). In the nine-month period ended\nSeptember 30, 2017, Dermapharm purchased pharmaceuticals for its parallel import business from 159 different\nlocal suppliers. The close cooperation between the sales and purchasing departments, combined with\nDermapharm\u2019s extensive market knowledge on a multitude of sourcing countries, enable the sales department to\nsuccessfully resell almost all imported pharmaceuticals within a relatively short period of time. For the fiscal\nyear ended December 31, 2016, Dermapharm achieved an average inventory turnover duration of approximately\n1.5 months per package.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35243798118049613, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-2", "text": "          Imported pharmaceuticals arrive at the logistics and storage center for Dermapharm\u2019s parallel import\nbusiness located in Friedrichsdorf, where these pharmaceuticals are repackaged. Dermapharm is specialized on\nthe repackaging of smaller lot sizes (i.e., lots with 100 packs per lot), which allows for the introduction of lower\nvolume pharmaceuticals and provides Dermapharm with additional flexibility. To ensure delivery reliability,\nDermapharm only offers pharmaceuticals for resale once the relevant imports have arrived at its logistics\nfacility. Dermapharm is often able to offer imported pharmaceuticals in a packaging form that is almost identical\nto the original product, increasing the appeal of such pharmaceuticals to patients. The location of Friedrichsdorf\nnear Frankfurt am Main places Dermapharm\u2019s parallel import business at the heart of Europe, reducing shipping\ncosts and times when sourcing and redistributing imported pharmaceuticals.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35885372112917024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48246364414029086, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-3", "text": "New Introductions of Parallel Imports\n", "page_number": 149, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.4957228400342173, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.5098374679213002, "height": 0.014114627887082953, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-4", "text": "12.4.2.3\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.4965782720273738, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.5085543199315654, "height": 0.0119760479041916, "width": 0.05139056831922613}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-5", "text": "          Dermapharm constantly reviews the European pharmaceuticals market in order to identify attractive\npharmaceuticals that would complement and expand its parallel import product offering. In doing so, it can\nleverage its extensive database, which comprises both public market sources as well as feedback from suppliers,\ngiving Dermapharm deep insight into developments and opportunities in the European pharmaceuticals market.\nIn addition, Dermapharm\u2019s sales department provides feedback from customers to ensure that Dermapharm can\nidentify areas with unsatisfied market demand. Dermapharm generally seeks to be either the first or second\nparallel importer when it comes to introducing a new pharmaceutical to the German market.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.621043627031651, "height": 0.09452523524379808, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-6", "text": "         When making a decision on whether to include new pharmaceuticals in its parallel import product\noffering, Dermapharm focuses on those products with the highest expected margin and will only chose\nlow-margin pharmaceuticals with a high strategic benefit (i.e., if Dermapharm expects that these\npharmaceuticals will add to the attractiveness of Dermapharm\u2019s product baskets and allow it to better market\nother, high-margin pharmaceuticals). In the fiscal year ended December 31, 2016, Dermapharm was able to\nsuccessfully introduce 306 new pharmaceuticals to its parallel import product offering, with an additional\n194 new pharmaceuticals having been introduced in the nine-month period ended September 30, 2017.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7236954662104362, "height": 0.09452523524379808, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-7", "text": "194 new pharmaceuticals having been introduced in the nine-month period ended September 30, 2017.\n         Once Dermapharm has identified an attractive pharmaceutical and decided to introduce it to its product\nportfolio, it applies for the relevant authorizations allowing marketing in Germany. Pharmaceuticals that are\nsubject to a centralized European marketing authorization only require Dermapharm to notify the European\nMedicines Agency (\u201cEMA\u201d) by means of an EMA Parallel Import Notification. This allows Dermapharm to\nintroduce the relevant pharmaceutical almost immediately. If the imported pharmaceutical is only distributed\nbased on a German marketing authorization, Dermapharm requires a corresponding authorization\n(Bezugszulassung). Obtaining a corresponding authorization is less expensive and requires limited\ndocumentation compared to a marketing authorization, in particular since no additional clinical studies are\nneeded. The process may, however, take between eight and 15 months, at the end of which Dermapharm again\nreviews whether the relevant pharmaceutical is still sufficiently attractive to warrant introduction into its parallel\nimport product offering.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7241231822070145, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8810949529512404, "height": 0.15697177074422586, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-149-8", "text": "106", "page_number": 149, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-0", "text": "12.5   Information Technology\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3573155985489722, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.23639661426844016}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-1", "text": "         The information technology employed by Dermapharm\u2019s pharmaceuticals and other healthcare\nproducts business is managed centrally at its main facility in Brehna, which also serves as the maintenance\ncenter for Dermapharm\u2019s information technology infrastructure. Information technology is an important part of\nthese operations in order to optimize Dermapharm\u2019s processed and thereby increase productivity. Dermapharm\nemploys scarabPLUS \u2013 PHARMA-ERP-System, a software specialized on pharmaceutical merchandise and\nproduction management, which covers business processes (e.g., material and supply chain management), the\nplanning and execution of manufacturing and quality control processes, sales, distribution and logistics as well\nas maintenance. In addition, Dermapharm relies on specialized software for different aspects of its operations\n(e.g., a marketing information system developed by QuintilesIMS, which supports Dermapharm\u2019s customer\nrelationship management and salesforce management). Dermapharm mainly uses products of Microsoft\nCorporation for basic business applications and Microsoft Dynamics NAV 2013 for its accounting system.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2634730538922156, "height": 0.15098374679213006, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-2", "text": "         For Dermapharm\u2019s parallel import business, the relevant information technology is managed centrally\nin Friedrichsdorf. Dermapharm uses a proprietary and customized ERP-System to store and analyze the relevant\nmarket data. In addition, it utilizes ADDIS\u00ae-CRM developed by IDV GmbH, which provides Dermapharm with\ndetailed information on German pharmacies and their individual pharmaceutical demand. Dermapharm mainly\nuses products of Microsoft Corporation for basic business applications\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26988879384088965, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33875106928999144, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-3", "text": "          To ensure data safety and protection from outages, Dermapharm has implemented a number of\nprotective measures, including duplicate systems at different locations, firewalls, antivirus software, patches,\ndata encryption, log monitors, routine backups with offsite retention of storage media, system audits, data\npartitioning, routine password modifications and disaster recovery procedures.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34516680923866555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40034217279726264, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-4", "text": "12.6   Intellectual Property\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.4298545765611634, "height": 0.012831479897348175, "width": 0.21342200725513907}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-5", "text": "         As of the date of this Prospectus, Dermapharm\u2019s portfolio of trademarks consists of more than\n1,800 registered word marks, figurative marks and word-figurative marks and applications, and Dermapharm\nbelieves it is one of the most active trademark holders in Germany.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48502994011976047, "height": 0.04063301967493582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-6", "text": "          Most of its trademarks are German registrations, international and European trademarks, as the vast\nmajority of trademarks is attributable to Dermapharm\u2019s German entities. To the extent these trademarks are also\nheld by Dermapharm\u2019s foreign entities, such trademarks are also registered in the respective national trademark\nregisters. Dermapharm\u2019s most important protected trademarks are those related to its products, in particular\nDekristol\u00ae 20,000 I.E., bite away\u00ae, Herpotherm\u00ae, sikapur\u00ae, Ampho-Moronal\u00ae, Solacutan\u00ae, Ciclocutan\u00ae,\nMinoxicutan\u00ae, Prednisolut\u00ae, Dienovel\u00ae, Lactofem\u00ae, Finapil\u00ae, Panthenol-Augensalbe JENAPHARM\u00ae and\nSuxilep\u00ae.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5876817792985458, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-7", "text": "         Dermapharm has various registered domain names, mostly with respect to its different group entities, in\nparticular dermapharm.de, axicorp.de, mibe.de, acis.de, huebner-vital.de and huebner-naturarzneimittel.de.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6218990590248076, "height": 0.026946107784431184, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-8", "text": "       In addition, it holds patents for the medical devices bite away\u00ae and Herpotherm\u00ae as well as two\nGerman utility models.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6565440547476475, "height": 0.03421727972626176, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-9", "text": "          Dermapharm constantly monitors its intellectual property to ensure that all material rights remain in\nfull force and effect. In addition, it has engaged a third-party service provider with alerting Dermapharm to any\npotential violations of its intellectual property. Where such violations are identified, Dermapharm hires\nspecialized counsel in order to effectively assert Dermapharm\u2019s rights with respect to any infringements.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6633875106928999, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7181351582549187, "height": 0.054747647562018775, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-150-10", "text": "107", "page_number": 150, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-0", "text": "12.7   Real Property\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.16444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-1", "text": "         Dermapharm uses offices, manufacturing facilities and logistic facilities in all geographic areas where\nit operates, which are either owned or leased by Dermapharm. Dermapharm\u2019s headquarters are located in\nGr\u00fcnwald, Bavaria, Germany. Its manufacturing facilities are located in Brehna, Germany, Ehrenkirchen,\nGermany, Seevetal, Germany, Eugendorf, Austria, and Warsaw, Poland.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.055175363558597076, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-2", "text": "          The following table provides an overview of all real estate leased or owned by Dermapharm in order of\nthe size of the relevant property:\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2018819503849444, "height": 0.027801539777587675, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-3", "text": "Location                                                                                   Size of property                     Size of effective area\n                                                                                                                     (unaudited)\n                                                                                                                        (in sqm)\n Brehna, Germany(1) ..............................................................................................................\n                                                                                                        80,000                            38,000\n Alsdorf, Germany(1) .............................................................................................................\n                                                                                                        39,849                            12,106\n Ehrenkirchen, Germany(1) ...................................................................................................\n                                                                                                          6,900                            7,300\n Friedrichsdorf, Germany(2) ..................................................................................................\n                                                                                                            N/A                            6,097\n Seevetal, Germany(1) ...........................................................................................................\n                                                                                                        14,530                             7,998\n Gr\u00fcnwald, Germany(3) .........................................................................................................\n                                                                                                          4,862                            5,200\n Warsaw, Poland(1)................................................................................................................\n                                                                                                          6,512                            3,383\n Ludbreg, Croatia(1)...............................................................................................................\n                                                                                                        11,878                             3,114\n Berlin, Germany(1) ...............................................................................................................\n                                                                                                          2,044                            2,679\n Eugendorf, Austria(2) ...........................................................................................................\n                                                                                                            N/A                            2,000\n H\u00fcnenburg, Switzerland(2) ...................................................................................................\n                                                                                                            N/A                              876\n Vienna, Austria(2) ................................................................................................................\n                                                                                                            N/A                              303\n Zagreb, Croatia(2) .................................................................................................................\n                                                                                                            N/A                              216\n Kiev, Ukraine(2) ...................................................................................................................\n                                                                                                            N/A                              180\n", "page_number": 151, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.20915312232677502, "lower_right_x": 0.8700120918984281, "lower_right_y": 0.4345594525235244, "height": 0.22540633019674938, "width": 0.7509068923821041}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-4", "text": "(1) Wholly owned by Dermapharm.\n(2) Leased by Dermapharm.\n(3) Dermapharm holds a heritable building right with a term extending until 2073.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.44568006843455943, "lower_right_x": 0.6287787182587666, "lower_right_y": 0.48502994011976047, "height": 0.03934987168520104, "width": 0.5102781136638452}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-5", "text": "         As of the date of this Prospectus, Dermapharm has granted a land charge over its property in Brehna,\nsecuring an amount of \u20ac12.9 million. Besides this land charge, no other property owned by Dermapharm is\nencumbered with land charges or other encumbrances (dingliche Belastungen).\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4991445680068435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5397775876817793, "height": 0.04063301967493582, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-6", "text": "12.8   Employees\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5538922155688623, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.5680068434559452, "height": 0.014114627887082953, "width": 0.1402660217654172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-7", "text": "        As of the date of this Prospectus, Dermapharm employs a total of 1,269 employees.\n         The following table provides an overview of Dermapharm\u2019s average number of full-time employees by\nfunctions for the periods indicated:\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6295979469632165, "height": 0.04833190761334483, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-8", "text": "                                                                                                                                  For the\n                                                                                                                                nine-month\n                                                                                             For the fiscal year               period ended\n                                                                                            ended December 31,                 September 30,\n                                                                           2014(1)                2015(1)          2016(1)        2017(1)\n                                                                                                (unaudited)                     (unaudited)\n Sales & Marketing ....................................................... 267                          265              258            257\n Production.................................................................... 432                     407              398            398\n Administration ............................................................. 248                       255              287            302\n Development................................................................ 42                          52               58             59\n Logistics ...................................................................... 118                   115              111            108\nTotal ..............................................................................1,107             1,094            1,112          1,124\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8772672309552599, "lower_right_y": 0.7938408896492729, "height": 0.15782720273738238, "width": 0.7569528415961305}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-9", "text": "        In addition, Dermapharm also employed an average of 78 part-time employees in the fiscal year ended\nDecember 31, 2016 (fiscal year ended December 31, 2015: 63; fiscal year ended December 31, 2014: 109). In\nthe nine-month period ended September 30, 2017, Dermapharm employed an average of 95 part-time\nemployees.\n       Nearly all of Dermapharm\u2019s employees either have SHI or can obtain health insurance through\nDermapharm.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.820786997433704, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9084687767322498, "height": 0.08768177929854581, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-151-10", "text": "108", "page_number": 151, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-0", "text": "12.9   Sustainability, Safety and the Environment\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.49274486094316805, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.371825876662636}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-1", "text": "          Dermapharm pursues a strict safety policy in relation to its products. In 2003, the Regional\nAdministrative Department (Landesverwaltungsamt) of the state of Saxony-Anhalt first awarded Dermapharm\u2019s\nmain manufacturing site in Brehna the Certificate of Good Manufacturing Practice (GMP) following an\ninspection in accordance with Article 111 para. 5 of Directive 2001/83/EC of the European Parliament and of\nthe Council of November 6, 2001 on the community code relating to medicinal products for human use (the\n\u201cMedicinal Products Directive\u201d) in conjunction with Article 15 of Directive 2001/20/EC of the European\nParliament and of the Council of April 4, 2001 on the approximation of the laws, regulations and administrative\nprovisions of the member states relating to the implementation of good clinical practice in the conduct of\nclinical studies on medicinal products for human use. This certificate has been periodically renewed over the\nyears.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-2", "text": "         In relation to its products, Dermapharm assures full GMP conformity, kosher/halal certification and\ncompliance with applicable medical regulations and industry standards (e.g., hazard analysis and critical control\npoints (\u201cHACCP\u201d) standards).\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29769033361847735, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-3", "text": "         In order to ensure a high safety standard, Dermapharm runs its own quality control laboratories which\nare also located at its Brehna facility. All materials used in the manufacturing processes are previously\ninvestigated, using state-of-the-art processes to ensure that relevant raw materials confirm to, and comply with,\nthe standards laid down in pharmacopeias. For finished products, every single batch is carefully reviewed before\nrelease and all of Dermapharm\u2019s pharmaceuticals and other healthcare products are subject to permanent quality\nmonitoring in order to avoid any product defects.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3866552609067579, "height": 0.07912745936698029, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-4", "text": "         Dermapharm pays particular attention to fulfilling its commitment to environmentally friendly\nmanufacture. Dermapharm conducts the development and manufacturing of products as well as the construction\nand utilization of the required facilities in strict compliance with applicable environmental regulations.\nFurthermore, Dermapharm cooperates with local authorities in monitoring the sewage water around its\nmanufacturing sites. Any disposals are subject to full documentation and any other sources of possible ground\nand water contamination are continuously controlled. Dermapharm believes that its manufacturing facilities are\nnot exposed to particular risks compared to other facilities in the pharmaceuticals and healthcare industries.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4893071000855432, "height": 0.09281437125748498, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-5", "text": "Compliance Management\n", "page_number": 152, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.5059880239520959, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.518819503849444, "height": 0.01283147989734812, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-6", "text": "12.10\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.5166809238665526, "height": 0.010692899914456766, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-7", "text": "         Dermapharm has established a compliance management system aimed at ensuring lawful and ethical\nconduct by its employees. It is designed to identify potential violations in advance and systematically prevent\ntheir occurrence. The compliance management system is supervised by Dermapharm\u2019s compliance officers and\ncontributes significantly to the integration of compliance into Dermapharm\u2019s operations and processes. It\ncomprises, inter alia, compliance audits of the relevant entities of Dermapharm, a compliance manual that\nincludes Dermapharm\u2019s mandatory compliance policies, regular training courses on relevant compliance risks\nand measures as well as adequate measures to allow employees to report potential compliance violations.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5333618477331052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6287425149700598, "height": 0.0953806672369546, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-8", "text": "         With respect to the advertising of its pharmaceuticals, Dermapharm has adopted the code of conduct of\nthe members of the Pharmaceuticals and Cooperation in the Healthcare System Association (Arzneimittel und\nKooperation im Gesundheitswesen e.V. (\u201cAKG\u201d)), as amended. The code of conduct promulgated by the AKG\naims to ensure that all measures used in the conveyance of information and in collaboration with healthcare\nprofessionals are carried out within the limits of applicable laws. This code was recognized as rules of\ncompetition by the German Federal Cartel Office (Bundeskartellamt) on September 25, 2014.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718562874251497, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-9", "text": "12.11   Insurance\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7318220701454234, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.7425149700598802, "height": 0.010692899914456766, "width": 0.1348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-10", "text": "         Dermapharm has taken out insurance policies it considers customary and necessary in the\npharmaceutical industry, including pharmaceuticals product liability insurance as required by Section 94 para. 1\nof the German Pharmaceuticals Act (Arzneimittelgesetz (\u201cAMG\u201d)), general product liability insurance, property\ninsurance combined with business interruption and loss of revenue insurance, transport insurance,\nenvironmental insurance and casualty insurance. These insurance policies are usually entered into by\nDermapharm AG, but also cover various other entities of Dermapharm, though usually not all German or\nforeign subsidiaries. Various foreign entities of Dermapharm have taken out individual insurance policies.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7591958939264328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8554319931565441, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-152-11", "text": "109", "page_number": 152, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-0", "text": "         Dermapharm\u2019s insurance policies contain market-standard exclusions and deductibles. Dermapharm\nregularly reviews the adequacy of its insurance coverage. Dermapharm believes that its insurance coverage is in\nline with market standards in the industry. There is, however, no guarantee that it will not suffer any losses for\nwhich no insurance coverage is available or that the losses will not exceed the amount of insurance coverage\nunder existing insurance policies.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-1", "text": "         Dermapharm has also taken out a directors and officers (\u201cD&O\u201d) insurance policy that covers the\ncurrent and future members of the Management Board and Supervisory Board as well as equivalent bodies of\nother entities of Dermapharm, with a total coverage of up to \u20ac40.0 million in total per year and various sublimits\ndepending on the specific nature of claims. The D&O insurance provides for a deductible for all of the members\nof the Management Board in line with the AktG.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2292557741659538, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-2", "text": "12.12   Litigation\n", "page_number": 153, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24593669803250642, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.2570573139435415, "height": 0.011120615911035053, "width": 0.13542926239419587}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-3", "text": "         In the course of its business activities, Dermapharm is regularly exposed to numerous legal risks,\nparticularly in the areas of product liability, competition, intellectual property disputes and tax matters\n(see \u201c1.2.4 Dermapharm may become involved in various legal proceedings, including patent litigation, which\nmay expose Dermapharm to substantial liability or adversely impact its business.\u201d).\n", "page_number": 153, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.27331052181351584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32677502138579984, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-4", "text": "       The following legal disputes are the only proceedings with a value exceeding \u20ac1.0 million that\nDermapharm is currently involved in or was involved in during the past twelve months:\n", "page_number": 153, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.334901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36142001710863986, "height": 0.02651839178785287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-5", "text": "\uf0b7   In 2009, Israel-based SuperMedic (MediLight) Ltd. and various related parties (together\n    \u201cSuperMedic\u201d) asserted claims for damages and infringement of intellectual property in an\n    aggregate amount of approximately \u20ac9.7 million against Anton H\u00fcbner GmbH & Co. KG relating\n    to the termination of a distribution agreement between the parties concerning certain products and\n    an alleged trademark infringement concerning the \u201cTannenblut\u201d trademark in Israel. At the time,\n    Anton H\u00fcbner GmbH & Co. KG was owned by Nordzucker AG and filed a counterclaim against\n    SuperMedic for infringement of this trademark, seeking to cancel SuperMedic\u2019s registration as\n    owner of the \u201cTannenblut\u201d trademark in Israel before the Israeli Trademark Office. According to\n    the share purchase agreement between Dermapharm AG and Nordzucker AG dated December 8,\n    2010, Nordzucker AG was required to bear all financial risks arising from SuperMedic\u2019s lawsuit.\n    In May 2017, Anton H\u00fcbner GmbH & Co. KG and SuperMedic settled the dispute. SuperMedic\n    agreed to pay compensation in an amount of 100,000 Israeli Shekel (approximately \u20ac24,000.00)\n    and to recognize the trademarks asserted by Anton H\u00fcbner GmbH & Co. KG, in particular the\n    \u201cTannenblut\u201d trademark.\n\uf0b7   In February 2015, several private health insurance providers filed a class action lawsuit against\n    AxiCorp Pharma GmbH and axicorp Pharma B.V., suing the defendants for payment of the\n    mandatory manufacturer rebate. Like other major importers of pharmaceuticals, Dermapharm\n    disputes the position of private health insurance providers that Dermapharm should offer this\n    manufacturer rebate on its imported pharmaceuticals, since it considers this a violation of the\n    German constitution. In December 2016, AxiCorp Pharma GmbH settled the claims brought\n    against it by paying an aggregate amount of approximately \u20ac1.7 million (including interest\n    payments) to the relevant private health insurance providers after a parallel case had been ruled in\n    favor of the private health insurance providers. In November 2017, axicorp Pharma B.V. also\n    settled claims brought against it in respect of rebates in an aggregate amount of approximately\n    \u20ac1.2 million. Furthermore, it paid \u20ac1.9 million, plus interest in an amount of \u20ac0.2 million, in\n    respect of rebates to private health insurance providers for which Dermapharm had already\n    received invoices, but which had not yet been claimed by these private health insurance providers\n    in court. Both AxiCorp Pharma GmbH and axicorp Pharma B.V. have expressly reserved the right\n    to reclaim the amounts paid by them, should the German Federal Supreme Court\n    (Bundesgerichtshof) rule in favor of pharmaceutical importers. The plaintiff in the case against\n    axicorp Pharma B.V. has, however, refused to accept such reservation. In its attempt to reclaim its\n    payments, axicorp Pharma B.V. already has an appeal against denial of leave to appeal\n    (Nichtzulassungsbeschwerde) pending with the German Federal Supreme Court\n    (Bundesgerichtshof) with respect to a case, which Dermapharm believes may serve as a relevant\n    precedent.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8545765611633875, "height": 0.4854576561163388, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-153-6", "text": "110", "page_number": 153, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-0", "text": "\uf0b7   In December 2011, Dermapharm AG filed a lawsuit against UniCredit with the regional court\n    (Landgericht) of Munich. Dermapharm demands the rescission of certain currency related swap\n    transactions entered into between Dermapharm AG and UniCredit between 2006 and 2010 as well\n    as compensation for all damages incurred in connection with these swaps. The relevant reference\n    currency for these swaps is the Swiss Franc. Dermapharm is of the opinion that UniCredit has\n    violated its obligation to properly advise Dermapharm on the risks associated with these\n    transactions. As of September 30, 2017, the negative value of swap transactions with UniCredit\n    (i.e., Dermapharm\u2019s assumed future payment obligations as of that date) amounted to \u20ac7.4 million\n    and was recorded under other financial liabilities on Dermapharm AG\u2019s consolidated statement of\n    financial position. The lawsuit was dismissed in the first two instances. Dermapharm has filed an\n    appeal against denial of leave to appeal (Nichtzulassungsbeschwerde) with the German Federal\n    Supreme Court (Bundesgerichtshof) and currently expects that a ruling on this appeal will be\n    announced during the first quarter of the fiscal year ending December 31, 2018. On December 21,\n    2015, Dermapharm AG and the Selling Shareholder entered into the Indemnification Agreement,\n    pursuant to which Dermapharm assigned its claims against UniCredit to the Selling Shareholder.\n    In turn, the Selling Shareholder has agreed to assume any payments required from Dermapharm to\n    UniCredit under the currency related swap transactions as well as attorneys\u2019 fees in connection\n    with the proceedings at the regional court of Munich, unless Dermapharm AG has set up a\n    provision for such costs in its consolidated statement of financial position as of December 31, 2015\n    (see \u201c18.1.2 Indemnification Agreement with respect to UniCredit Litigation\u201d).\n", "page_number": 154, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.2707442258340462, "width": 0.7001209189842805}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-1", "text": "          Apart from the proceedings described above, Dermapharm is not aware of any governmental, legal or\narbitration proceedings (whether pending or threatened) which may have, or have had, a significant effect on\nDermapharm\u2019s financial position or profitability during the past twelve months.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36569717707442256, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40718562874251496, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-2", "text": "12.13   Material Agreements\n\n12.13.1 Enterprise Agreements\n", "page_number": 154, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.33978234582829503, "lower_right_y": 0.46535500427716, "height": 0.041488451668092396, "width": 0.21946795646916564}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-3", "text": "         Various entities of Dermapharm have entered into profit transfer agreements\n(Gewinnabf\u00fchrungsvertr\u00e4ge) to create fiscal units for tax purposes. Dermapharm AG as the controlling entity\nhas entered into profit transfer agreements with the following subsidiaries:\n", "page_number": 154, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5196749358426005, "height": 0.04106073567151408, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-4", "text": "\uf0b7   Mibe;\n\uf0b7   Mibe Vertrieb GmbH; and\n\uf0b7   H\u00fcbner Naturarzneimittel GmbH.\nIn addition, the following other entities of Dermapharm have entered into profit transfer agreements:\n\uf0b7   Mibe (as parent company) and acis Arzneimittel GmbH;\n\uf0b7   axicorp GmbH (as parent company) and AxiCorp Pharma GmbH; and\n\uf0b7   axicorp GmbH (as parent company) and Podolux GmbH.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8561064087061668, "lower_right_y": 0.6706586826347305, "height": 0.14414029084687763, "width": 0.677750906892382}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-5", "text": "         Under the aforementioned profit transfer agreements, the respective subsidiary is required to transfer its\nentire profits, if any, to the respective parent company, which in turn is required to assume the subsidiary\u2019s\nlosses in any given fiscal year, if any (in each case, as determined by the respective subsidiary\u2019s individual\nannual financial statements prepared in accordance with HGB).\n", "page_number": 154, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6839178785286569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.739093242087254, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-6", "text": "          All of the aforementioned profit transfer agreements have a minimum term of five years and may\ngenerally be terminated with a six-month notice period and with effect from the end of the respective fiscal year,\nexcept for the profit transfer agreement between Dermapharm AG and H\u00fcbner Naturarzneimittel GmbH, which\nprovides for a three-month notice period. The right of the respective parties to terminate the relevant profit\ntransfer agreement for due cause without prior notice remains unaffected.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8212147134302823, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-154-7", "text": "111", "page_number": 154, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-0", "text": "12.13.2 Financing Agreements\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.34280532043530837, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.22249093107617898}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-1", "text": "           Dermapharm has entered into various loan agreements, with the largest loans having been entered into\nby Dermapharm AG as the borrower. Material loans were also granted to Mibe. In addition to the loan\nagreements described in detail below, Dermapharm has entered into various other loan agreements and overdraft\nfacilities for smaller amounts.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16638152266894782, "height": 0.05389221556886227, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-2", "text": "          Many of Dermapharm\u2019s loan agreements provide for a joint liability of either Dermapharm AG or the\nSelling Shareholder or as contractual co-debtors or guarantors. Therefore, generally no further in rem security\nrights are required. However, in relation to a loan granted to Dermapharm in 2008, a land charge was registered\non the heritable building right Dermapharm owns with respect to its headquarters in Gr\u00fcnwald. As of\nSeptember 30, 2017, the outstanding amounts under this loan amounted to \u20ac0.6 million.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.06886227544910181, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-3", "text": "Promissory Notes of Dermapharm AG\n", "page_number": 155, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.25962360992301114, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.26988879384088965, "height": 0.010265183917878506, "width": 0.2617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-4", "text": "12.13.2.1\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25962360992301114, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.26988879384088965, "height": 0.010265183917878506, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-5", "text": "12.13.2.1.1 2014 Promissory Notes\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.28699743370402053, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.30025662959794697, "height": 0.013259195893926434, "width": 0.24667472793228534}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-6", "text": "         On November 20, 2014, Dermapharm AG, as borrower, and Bayerische Landesbank, as lender and\narranger, entered into promissory note agreements (Schuldscheindarlehen), of which an aggregate amount of\n\u20ac71.5 million is still outstanding as of the date of this Prospectus (the \u201c2014 Promissory Notes\u201d). The amounts\nborrowed under the 2014 Promissory Notes were applied towards a refinancing of Dermapharm and general\ncorporate purposes.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3143712574850299, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38280581693755344, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-7", "text": "         The terms of the 2014 Promissory Notes were amended by an amendment agreement dated October 4,\n2017, entered into between Dermapharm AG as borrower, Bayerische Landesbank as original lender and agent,\nthe investors holding commitments under the 2014 Promissory Notes, the Selling Shareholder as original\nguarantor and the Company as new guarantor. The amendments, inter alia, relate, to financial covenants and the\nreplacement of the Selling Shareholder as guarantor by the Company. In addition, the investors declared their\nconsent to the termination of the Profit Transfer Agreement.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47177074422583404, "height": 0.08212147134302822, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-8", "text": "         An amount of \u20ac43.5 million under the 2014 Promissory Notes will expire on November 20, 2019,\nwhile the remaining \u20ac28.0 million will expire on November 20, 2021. The amounts borrowed under the\n2014 Promissory Notes must be repaid on the respective due dates in full. Early repayments or a prior\ntermination of the 2014 Promissory Notes is generally not permissible.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5333618477331052, "height": 0.05474764756201883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-9", "text": "        2014 Promissory Notes in an amount of \u20ac43.5 million bear a fixed interest rate of 177 basis points\n(\u201cBPs\u201d) per annum, while 2014 Promissory Notes in an amount of \u20ac28.0 million bear a fixed interest rate of\n220 BPs per annum. Depending on Dermapharm\u2019s equity ratio, the interest rate for the 2014 Promissory Notes\nmay increase by 50 BPs. Interest is payable on an annual basis on November 20 of each calendar year.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5953806672369547, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-10", "text": "          All sums payable under the 2014 Promissory Notes are guaranteed by the Company. No further\nsecurities are required under the 2014 Promissory Notes.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6295979469632165, "height": 0.027801539777587703, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-11", "text": "         The 2014 Promissory Notes entitle Bayerische Landesbank to transfer its rights and obligations to\ncredit institutions, pension funds or insurance companies in partial amounts of \u20ac500,000.00 or a multiple\nthereof, without any further consultations with Dermapharm. This also applies to any new lender who acquired\nrights and obligations under the 2014 Promissory Notes pursuant to these stipulations.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6911890504704876, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-12", "text": "         The 2014 Promissory Notes contain a number of covenants with regards to Dermapharm AG and\ncertain of its subsidiaries, including a negative pledge and pari passu clause, restrictions on substantial changes\nto the core business, a limitation on the disposal of assets and financial covenants relating to the leverage of\nDermapharm.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7523524379811805, "height": 0.054747647562018775, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-13", "text": "          Upon the occurrence of a change-of-control, Bayerische Landesbank is entitled to terminate each\n2014 Promissory Note. A change-of-control under the 2014 Promissory Notes occurs if any person or any group\nof persons acting in concert pursuant to Section 22 para. 2 WpHG acquires at any point in time, directly or\nindirectly, the majority of the voting rights in the share capital of Dermapharm AG.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7591958939264328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-14", "text": "         Furthermore, the 2014 Promissory Notes provide for customary events of default, including the\nnon-payment of debts or default under any other financial indebtedness by Dermapharm AG or certain of its\nsubsidiaries (cross-default).\n", "page_number": 155, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.820786997433704, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8622754491017964, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-155-15", "text": "112", "page_number": 155, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-0", "text": "12.13.2.1.2 2012 Promissory Notes\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.24667472793228534}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-1", "text": "         On September 19, 2012, Dermapharm AG, as borrower, and Bayerische Landesbank, as lender and\narranger, entered into promissory note agreements (Schuldscheindarlehen), of which an aggregate amount of\n\u20ac10.0 million is still outstanding as of the date of this Prospectus (the \u201c2012 Promissory Notes\u201d).\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-2", "text": "          The terms of the 2012 Promissory Notes were amended by an amendment agreement dated October 4,\n2017, entered into between Dermapharm AG as borrower, Bayerische Landesbank as original lender and agent,\nOberbank Aktiengesellschaft as the sole investor holding 2012 Promissory Notes, the Selling Shareholder as\noriginal guarantor and the Company as new guarantor. The terms of the amendment agreement are similar to\nthose of the amendment agreement with respect to the 2014 Promissory Notes.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2292557741659538, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-3", "text": "         The 2012 Promissory Notes will expire on September 19, 2019. The 2012 Promissory Notes bear a\nfixed interest rate of 284 BPs per annum. Depending on Dermapharm\u2019s equity ratio, the interest rate for the\n2014 Promissory Notes may increase by 50 BPs. Interest is payable on an annual basis on September 19 of each\ncalendar year. The remaining terms of the 2012 Promissory Notes are essentially similar to those of the\n2014 Promissory Notes.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3058169375534645, "height": 0.06672369546621043, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-4", "text": "12.13.2.2   Loan Agreements of Dermapharm AG\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.33404619332763047, "height": 0.012831479897348175, "width": 0.3440145102781137}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-5", "text": "12.13.2.2.1 Loan Agreement with Bayerische Landesbank\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3485885372112917, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.3618477331052181, "height": 0.013259195893926434, "width": 0.39661426844014513}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-6", "text": "         On September 8, 2017, Dermapharm AG, as borrower, and Bayerische Landesbank, as lender, entered\ninto a \u20ac60.0 million loan agreement. The funds were utilized to finance the acquisition of the assets pertaining to\nthe hyperthermic medical devices division of Riemser Pharma GmbH (see \u201c12.13.3.1 Asset Purchase\nAgreement for bite away\u00ae and Herpotherm\u00ae\u201d). The loan expires on September 8, 2022.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3759623609923011, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43071000855431996, "height": 0.05474764756201883, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-7", "text": "          The loan is to be repaid in quarterly instalments of \u20ac0.95 million, beginning on December 31, 2017,\nplus one final instalment for any outstanding amounts at the end of the term. The loan bears interest at the\naggregate of the EURIBOR on a three-month or six-month basis (depending on the relevant interest period), but\nat least 0.0%, plus a margin of 130 BPs per annum on any outstanding amounts. Interest becomes due and\npayable at the end of the relevant interest period, which may be either three months or six months.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5064157399486741, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-8", "text": "         The loan agreement provides for joint liability of the Company, Mibe and axicorp with respect to all\nclaims and liabilities arising from the loan. In addition, Dermapharm AG is required to ensure that any of its\nsubsidiaries that are regarded material subsidiaries as defined in the loan agreement accede to the loan\nagreement as co-debtors. Furthermore, the loan agreement provides for the assignment of all claims\nDermapharm AG may have under the agreement for the acquisition of the assets pertaining to the hyperthermic\nmedical devices division of Riemser Pharma GmbH in order to secure the claims of Bayerische Landesbank\nunder the loan.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5128314798973481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6056458511548332, "height": 0.09281437125748504, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-9", "text": "         Upon a change-of-control, any outstanding amounts under the loan immediately become due and\npayable. A change-of-control occurs if any person, other than the Selling Shareholder, directly or indirectly\nholds 50% or more of the share capital or voting rights in Dermapharm AG.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6569717707442259, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-10", "text": "       The loan agreement contains a number of covenants, including negative pledges, a maximum leverage\nof Dermapharm and an obligation not to terminate the profit transfer agreement between Dermapharm AG and\nMibe.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6633875106928999, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7014542343883661, "height": 0.038066723695466154, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-11", "text": "12.13.2.2.2 Loan Agreement with COMMERZBANK Aktiengesellschaft\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7181351582549187, "lower_right_x": 0.619105199516324, "lower_right_y": 0.7322497861420018, "height": 0.014114627887083064, "width": 0.498186215235792}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-12", "text": "         On September 14, 2017, Dermapharm AG, as borrower, and COMMERZBANK Aktiengesellschaft, as\nlender, entered into a \u20ac50.0 million loan agreement. The funds were utilized to finance the acquisition of\nBio-Di\u00e4t-Berlin (see \u201c12.13.3.2 Share Purchase Agreement for Bio-Di\u00e4t-Berlin\u201d). The loan expires on\nSeptember 30, 2022.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7455089820359282, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8006843455945253, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-13", "text": "          The loan is to be repaid in quarterly instalments of \u20ac625,000.00, beginning on December 30, 2017, plus\none final instalment for any outstanding amounts at the end of the term. The loan bears interest at the aggregate\nof the EURIBOR on a three-month basis, but at least 0.0%, plus a margin of 120 BPs per annum on the\noutstanding amounts. Depending on Dermapharm\u2019s equity ratio, the margin may increase by 50 BPs per annum.\nInterest becomes due and payable at the end of each three-month period.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8105218135158255, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8768177929854577, "height": 0.06629597946963217, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-14", "text": "Interest becomes due and payable at the end of each three-month period.\n          The loan agreement provides for joint liability of the Company with respect to all claims and liabilities\narising from the loan.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8772455089820359, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9106073567151411, "height": 0.03336184773310524, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-156-15", "text": "113", "page_number": 156, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-0", "text": "          Upon a change-of-control, COMMERZBANK Aktiengesellschaft may terminate the loan immediately\nand without observing any notice period, in which case any outstanding amounts become due and payable.\nA change-of-control occurs if any person, other than the Selling Shareholder, holds 50% or more of the voting\nrights in the Company.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13986313088109495, "height": 0.05474764756201882, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-1", "text": "       The loan agreement contains a number of covenants, including negative pledges, a maximum leverage\nof Dermapharm and an obligation not to terminate any of the existing profit transfer agreements between\nDermapharm AG and its subsidiaries.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1881950384944397, "height": 0.041488451668092396, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-2", "text": "12.13.2.2.3 Loan Agreement with Raiffeisen Landesbank Ober\u00f6sterreich\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.20145423438836613, "lower_right_x": 0.6185006045949214, "lower_right_y": 0.2155688622754491, "height": 0.014114627887082981, "width": 0.4969770253929867}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-3", "text": "         On September 14, 2017, Dermapharm AG, as borrower, and Raiffeisen Landesbank Ober\u00f6sterreich, as\nlender, entered into a \u20ac20.0 million loan agreement. Dermapharm AG utilized the funds to refinance a portion of\nits promissory notes issued in 2011, which became due and payable on September 19, 2017. The loan expires on\nSeptember 30, 2022.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2322497861420017, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2848588537211292, "height": 0.05260906757912748, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-4", "text": "          The loan is to be repaid in quarterly instalments of \u20ac250,000.00, beginning on December 31, 2017, plus\none final instalment for any outstanding amounts at the end of the term. The loan bears interest at the aggregate\nof the EURIBOR on a three-month basis, but at least 0.0%, plus a margin of 140 BPs per annum on any\noutstanding amounts. Depending on Dermapharm\u2019s equity ratio, the margin may increase by 50 BPs per annum.\nInterest becomes due and payable at the end of each three-month period.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36142001710863986, "height": 0.06757912745936695, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-5", "text": "The Company has acceded to the loan agreement as a co-debtor.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.36911890504704875, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.3819503849443969, "height": 0.012831479897348175, "width": 0.43591293833131795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-6", "text": "          Upon a change-of-control, Raiffeisen Landesbank Ober\u00f6sterreich may terminate the loan immediately\nand without observing any notice period, in which case any outstanding amounts become due and payable.\nA change-of-control occurs if any person or any group of persons acting in concert acquire(s), directly or\nindirectly, the majority of the share capital and/or voting rights in Dermapharm AG.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4439692044482464, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-7", "text": "         The loan agreement contains a number of covenants, including negative pledges and a maximum\nleverage of Dermapharm.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47818648417450815, "height": 0.026946107784431184, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-8", "text": "12.13.2.2.4 Loan Agreement with Deutsche Postbank AG\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.5064157399486741, "height": 0.014114627887082953, "width": 0.396614268440145}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-9", "text": "         On September 14, 2017, Dermapharm AG, as borrower, and Deutsche Postbank AG, as lender, entered\ninto a \u20ac20.0 million loan agreement. Dermapharm AG utilized the funds to refinance a portion of its promissory\nnotes issued in 2011, which became due and payable on September 19, 2017. The loan expires on September 19,\n2022.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5714285714285714, "height": 0.0517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-10", "text": "         Any amounts outstanding under the loan agreement must be repaid in full on September 19, 2022. In\ngeneral, early repayments are not permitted. The loan bears interest at the aggregate of the EURIBOR on a\nsix-month basis, but at least 0.0%, plus a margin of 85 BPs per annum on any outstanding amounts. Depending\non Dermapharm\u2019s equity ratio, the margin may increase by 50 BPs per annum. Interest becomes due and\npayable at the end of each six-month period.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6501283147989735, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-11", "text": "The loan agreement provides for a joint liability of the Selling Shareholder.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.6565440547476475, "lower_right_x": 0.6862152357920194, "lower_right_y": 0.6706586826347305, "height": 0.014114627887082953, "width": 0.507255139056832}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-12", "text": "          Upon a change-of-control, Deutsche Postbank AG may terminate the loan immediately and without\nobserving any notice period, in which case any outstanding amounts become due and payable. A\nchange-of-control occurs if any person, other than the Selling Shareholder, holds 50% or more of the voting\nrights in Dermapharm AG.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7322497861420018, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-13", "text": "         The loan agreement contains a number of covenants, including negative pledges and a maximum\nleverage of Dermapharm.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.7386655260906758, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.027801539777587703, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-157-14", "text": "114", "page_number": 157, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-0", "text": "12.13.2.2.5 Loan Agreement with Baden-W\u00fcrttembergische Bank\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4498186215235792}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-1", "text": "         On December 4, 2017, Dermapharm AG, as borrower, and Baden-W\u00fcrttembergische Bank, as lender,\nentered into a \u20ac80.0 million loan agreement. Dermapharm AG will utilize the funds from the loan agreement as\nbridge financing to partially finance its future capital expenditures, in particular the acquisition of Trommsdorff\n(see \u201c10.5.3.2 Principal Capital Expenditures since December 31, 2016 and Principal Ongoing Capital\nExpenditures\u201d). As of the date of this Prospectus, loan by Baden-W\u00fcrttembergische Bank is fully drawn.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-2", "text": "          Any amounts drawn under the loan agreement must be repaid by November 30, 2018 and will bear\ninterest an interest rate which is the aggregate of the EURIBOR on a three-month basis, but no less than 0.0%,\nand a margin of 75 BPs per annum.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2292557741659538, "height": 0.04148845166809237, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-3", "text": "The loan agreement provides for\n", "page_number": 158, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.23909324208725408, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.25192472198460225, "height": 0.012831479897348175, "width": 0.22249093107617895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-4", "text": "r a joint liability of the Company.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.40205562273276907, "top_left_y": 0.23909324208725408, "lower_right_x": 0.6185006045949214, "lower_right_y": 0.25192472198460225, "height": 0.012831479897348175, "width": 0.21644498186215233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-5", "text": "          Upon a change-of-control, any amounts outstanding under the loan agreement immediately become due\nand payable. A change-of-control occurs if any person, other than the Selling Shareholder or the Company,\ndirectly or indirectly holds 50% or more of the share capital or voting rights in Dermapharm AG.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2523524379811805, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2994011976047904, "height": 0.04704875962360988, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-6", "text": "         The loan agreement with Baden-W\u00fcrttembergische Bank contains a number of covenants, including a\nnegative pledge and a maximum leverage covenant of Dermapharm. Baden-W\u00fcrttembergische Bank is entitled\nto terminate the loan agreement in case of an event of default, including if Dermapharm AG defaults under its\nother financial obligations (cross-default), unless such financial indebtedness does not amount to more than\n\u20ac5.0 million.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37254063301967494, "height": 0.06501283147989734, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-7", "text": "12.13.2.3   Loan Agreements of Mibe\n\n12.13.2.3.1 Loan Agreement with Bayerische Landesbank\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.43071000855431996, "height": 0.04106073567151414, "width": 0.39721886336154777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-8", "text": "          Pursuant to a loan agreement dated December 11, 2006, Bayerische Landesbank, acting as lender,\ngranted Mibe, acting as borrower, a loan in an aggregate amount of \u20ac10.0 million, which was paid out to Mibe\nin four tranches of \u20ac2.5 million each between June 6, 2007, and June 30, 2008. The loan amount was applied\ntowards expansion investments regarding Dermapharm\u2019s facilities in Brehna.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49957228400342174, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-9", "text": "        The loan amount must be repaid in two annual instalments of \u20ac0.5 million each beginning on\nDecember 30, 2008 and ending on June 29, 2018. As of the date of this Prospectus, an amount of \u20ac1.0 million\nremains outstanding under the loan with Bayerische Landesbank. The loan bears an interest rate which is the\naggregate of the EURIBOR on a one-month, two-month or three-month basis (depending on the interest period\nchosen by Mibe) and a margin of 150 BPs per annum.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5748502994011976, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-10", "text": "         Mibe has granted Bayerische Landesbank a land charge over its property in Brehna securing an amount\nof \u20ac12.9 million. In addition, Dermapharm AG issued a comfort letter for the benefit of Bayerische Landesbank.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6090675791274593, "height": 0.027801539777587703, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-11", "text": "         The loan with Bayerische Landesbank contains a number of covenants, including a negative pledge and\npari passu clause, a limitation on the disposal of assets, restrictions regarding the payment of dividends and\nfinancial covenants relating to the equity ratio and leverage of Dermapharm.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6569717707442259, "height": 0.04148845166809245, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-12", "text": "12.13.2.3.2 Loan Agreement with IKB Deutsche Industriebank\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.6702309666381523, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.6843455945252352, "height": 0.014114627887082953, "width": 0.4298669891172915}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-13", "text": "          On December 14, 2006, Mibe, acting as borrower, and IKB Deutsche Industriebank, acting as lender,\nentered into a loan agreement over an amount of \u20ac10.0 million, which provides for a joint liability of\nDermapharm AG with respect to all outstanding amounts thereunder. Apart from the joint liability, as to its\npurpose, term, interest rates, in rem transaction securities and covenants, the loan with IKB Deutsche\nIndustriebank is essentially similar to the stipulations provided by the loan with Bayerische Landesbank. With\nregards to the in rem transaction securities IKB Deutsche Industriebank and Bayerische Landesbank entered into\na collateral pooling agreement. As of the date of this Prospectus, an amount of \u20ac1.0 million is outstanding under\nthe loan agreement with IKB Deutsche Industriebank.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7010265183917879, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8088109495295124, "height": 0.10778443113772451, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-158-14", "text": "115\n", "page_number": 158, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-0", "text": "12.13.3 Purchase Agreements\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.21281741233373638}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-1", "text": "12.13.3.1   Asset Purchase Agreement for bite away\u00ae and Herpotherm\u00ae\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.11248930710008555, "lower_right_x": 0.6130592503022975, "lower_right_y": 0.12660393498716851, "height": 0.014114627887082967, "width": 0.4915356711003628}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-2", "text": "          On September 4, 2017, Dermapharm entered into an agreement for the acquisition of the assets\npertaining to the hyperthermic medical devices division of Riemser Pharma GmbH. The acquisition was\ncompleted on September 20, 2017. The acquired division has an innovative portfolio of medical devices,\nincluding bite away\u00ae, a device selectively targeting mosquito and insect stings, and Herpotherm \u00ae, which is used\nfor the treatment of herpes blisters. In addition, Dermapharm acquired a development project for the medical\ndevice Pruritherm\u00ae, which is used to treat dermatitis and its accompanying symptoms. The acquired assets\ninclude the intellectual property rights, the technical know-how of the division, the commercial know-how,\nrequired regulatory approvals as well as relevant inventories. Moreover, the employment relationships of some\nemployees of Riemser Pharma GmbH were transferred to Dermapharm at the closing date.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.26518391787852863, "height": 0.1218990590248075, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-3", "text": "12.13.3.2   Share Purchase Agreement for Bio-Di\u00e4t-Berlin Gesellschaft mit beschr\u00e4nkter Haftung\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.788391777509069, "lower_right_y": 0.29298545765611633, "height": 0.012831479897348175, "width": 0.6680773881499396}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-4", "text": "        On September 21, 2017, Dermapharm entered into an agreement for the acquisition of all shares in\nBio-Di\u00e4t-Berlin. The acquisition was completed on October 1, 2017. The acquired companies are manufacturing\nand marketing phytopharmaceuticals (herbal medicines) as well as homoeopathics and natural cosmetics.\nKr\u00e4uter K\u00fchne GmbH operates 16 sales outlets, an online shop and related services.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3618477331052181, "height": 0.054319931565440516, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-5", "text": "12.13.3.3   Share Purchase Agreement for Trommsdorff\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.3896492728828058, "height": 0.013686911890504694, "width": 0.38754534461910517}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-6", "text": "          On December 12, 2017, Dermapharm entered into a sale and purchase agreement for the acquisition of\nall shares in Trommsdorff. The acquisition was completed on January 23, 2018. Trommsdorff manufactures and\nmarkets 23 different prescription pharmaceuticals and OTC products, in particular Keltican\u00ae forte, a dietary\nproduct for the treatment of back pain, and Tromcardin \u00ae complex, which combines certain minerals and\nvitamins for the treatment of cardiac arrhythmia. Trommsdorff also serves its former parent group as a toll\nmanufacturer. In the fiscal year ended December 31, 2016, Trommsdorff generated aggregate revenues of\n\u20ac52.0 million and EBITDA of \u20ac10.6 million (based on Trommsdorff\u2019s financial statements prepared in\naccordance with HGB).\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5128314798973481, "height": 0.1094952951240376, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-7", "text": "12.13.3.4   Share Purchase Agreement for Strathmann\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5265183917878529, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.5406330196749358, "height": 0.014114627887082953, "width": 0.37726723095526}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-8", "text": "         On December 20, 2017, Dermapharm entered into a purchase agreement for the acquisition and transfer\nof all shares in Strathmann, which distributes a broad product offering primarily comprising OTC products,\nwhich complement Dermapharm\u2019s existing product portfolio, in particular with respect to the dermatologicals,\nwomen\u2019s healthcare and vitamins/minerals/enzymes product areas. In addition, Strathmann recently obtained a\nmarketing authorization for a prescription pharmaceutical for the treatment of muscle spasms and muscle aches\nand Dermapharm believes that this new product offers significant market potential. In the fiscal year ended\nDecember 31, 2016, Strathmann generated aggregate revenues of \u20ac27.9 million and EBITDA of \u20ac3.7 million\n(based on Strathmann\u2019s financial statements prepared in accordance with HGB).\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6638152266894782, "height": 0.10992301112061598, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-9", "text": "12.13.4 Rebate Agreements with SHI Providers\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6804961505560307, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.6916167664670658, "height": 0.011120615911035081, "width": 0.3343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-10", "text": "         Pursuant to Section 130a para. 8 Social Code V, SHI providers may enter into rebate agreements with\npharmaceuticals manufacturers in relation to a specific pharmaceutical, a group of pharmaceuticals containing\nthe same APIs or specific dosage forms of APIs. Before entering into such rebate agreements, SHI providers\nwill generally initiate a tender process in order to identify and select the manufacturer who is willing to grant the\nhighest rebate on its pharmaceuticals. Therefore, SHI providers may be able to offer their insured persons a\npharmaceutical well below the official selling price. Tender processes may also be initiated by several\nSHI providers acting jointly through a common representative.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7078699743370402, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8028229255774166, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-11", "text": "          Rebate agreements may offer the relevant pharmaceutical manufacturer(s) different degrees of\nexclusivity. Often, the agreement is not awarded to a single manufacturer, but to the three offering the most\nattractive rebates (semi-exclusive agreements). Rebate agreements may also provide for comprehensive\nexclusivity (i.e., the relevant SHI provider may not enter into any other rebate agreements with respect to the\nsame pharmaceutical during the term of the agreement). Furthermore, a rebate agreement may expressly state\nthat the SHI provider is free to enter into an unlimited number of additional rebate agreements or open-house\nagreements).\n", "page_number": 159, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8105218135158255, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9054747647562019, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-159-12", "text": "116\n", "page_number": 159, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-160-0", "text": "         As of the date of this Prospectus, Dermapharm has entered into 1,120 rebate agreements with\n113 different SHI providers, covering 37 different pharmaceuticals (753 exclusive rebate agreements,\n204 semi-exclusive agreements and 163 open-house agreements).\n", "page_number": 160, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-160-1", "text": "         The relevant SHI provider will usually prepare a quarterly invoice based on the volume of the relevant\npharmaceutical dispensed in order to obtain the agreed rebate. Rebate agreements generally provide for\ncomprehensive adjustment clauses (e.g., in the event of an increase or reduction of the ex-factory price for the\nrelevant pharmaceutical). Such clauses may also provide termination rights for the benefit of the relevant\npharmaceutical manufacturer if such rebate adjustments make the agreement economically unviable.\nFurthermore, rebate agreements often also provide for an automatic termination or a termination right for the\nbenefit of the relevant SHI provider if the ex-factory price exceeds the reference price and the pharmaceutical\nmanufacturer refuses to provide an additional rebate.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1330196749358426, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-160-2", "text": "         Rebate agreements generally have a term of two years, notwithstanding terminations without notice for\ncause. The pharmaceutical manufacturer is required to guarantee that it can supply wholesalers and pharmacies\nwith the relevant pharmaceuticals during the duration of the agreement. In case of a breach of this guarantee,\nmany rebate agreements provide for contractual penalties (Vertragsstrafen) to be borne by the pharmaceutical\nmanufacturer. Such penalties are usually calculated on a daily or weekly basis, taking into account the volume\nof pharmaceuticals dispensed during the relevant period.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24935842600513258, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3319076133447391, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-160-3", "text": "117", "page_number": 160, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-0", "text": "13.   REGULATORY AND LEGAL ENVIRONMENT\n", "page_number": 161, "bounding_box": {"top_left_x": 0.28960096735187424, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7110036275695284, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-1", "text": "        Dermapharm\u2019s business is subject to numerous laws and regulations including provisions on the\ndevelopment, manufacturing, approval process, labelling, distribution, pricing and/or marketing of\nDermapharm\u2019s pharmaceuticals and other healthcare products.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.11248930710008555, "lower_right_x": 0.880894800483676, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-2", "text": "          While the relevant laws and regulations are typically of a national scope, within the European Union,\na considerable degree of regulatory harmonization exists in a number of areas relevant to Dermapharm\u2019s\nbusiness, such as in the approval process of pharmaceuticals. The European Union has created a common\nregulatory framework that applies not only on Dermapharm\u2019s most important market Germany but in all\nmember states of the European Union and comprises directives and regulations. Directives only become\neffective once they are enacted in a member state of the European Union and the implementation of directives\nmay vary between member states. Regulations, however, do not require implementation into national law and\napply directly and uniformly in all member states of the European Union. In addition, EEA Member States\n(e.g., Switzerland) have enacted national regulatory frameworks that are somewhat similar to the framework\napplicable in the European Union.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29769033361847735, "height": 0.13729683490162534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-3", "text": "13.1   Pharmaceuticals\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3143712574850299, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.3246364414029085, "height": 0.010265183917878562, "width": 0.1789600967351874}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-4", "text": "         Dermapharm\u2019s activities as a manufacturer and importer of pharmaceuticals (Arzneimittel) in the\nGerman pharmaceuticals market are subject to laws and regulations on the level of the European level as well as\non a national level in Germany. These laws and regulations generally apply to prescription pharmaceuticals and\nOTC products and contain, inter alia, provisions on the testing, safety, efficacy, approval, manufacturing,\nlabeling (including warnings), promotion, marketing and post-marketing surveillance of pharmaceuticals.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34174508126603936, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4093242087254063, "height": 0.06757912745936695, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-5", "text": "13.1.1   Definition of Pharmaceuticals\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.4375534644995723, "height": 0.013686911890504694, "width": 0.2714631197097944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-6", "text": "          According to the harmonized European definition of pharmaceuticals set forth in Article 1 of the\nMedicinal Products Directive, which is also reflected in Section 2 para. 1 AMG, pharmaceuticals for human use\nare substances or preparations made from substances which (i) are intended for use on or in the human body,\nand as remedies with properties for curing, alleviating or preventing human diseases or disease symptoms, or\n(ii) can be used in or on the human body or can be administered to a human being either to restore, correct or\ninfluence the physiological functions through a pharmacological, immunological or metabolic effect, or to make\na medical diagnosis. Products categorized as foodstuffs, food supplements or cosmetics are never\npharmaceuticals and subject to specific laws (see \u201c13.3 Healthcare Products\u201d). The oftentimes difficult\ndistinction is based on an extensive body of case law.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5744225834046194, "height": 0.12318220701454241, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-7", "text": "13.1.2   Market Introduction of Pharmaceuticals\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.588109495295124, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.602224123182207, "height": 0.014114627887082953, "width": 0.3440145102781137}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-8", "text": "          As a manufacturer of patent-free pharmaceuticals, Dermapharm does not conduct any basic medical\nresearch (Grundlagenforschung) and its pharmaceuticals are based on existing APIs. However, pursuant to\nSection 21 para. 1 AMG, pharmaceuticals may generally only be marketed in Germany for a specific medical\nindication after receipt of a marketing authorization from the competent governmental authority. Therefore,\nDermapharm is required to obtain such marketing authorizations before introducing additional pharmaceuticals\nto its product portfolio.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.69803250641574, "height": 0.08254918733960659, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-9", "text": "13.1.2.1   Application Process for Patent-free Pharmaceuticals with Sufficient Data on the Originator\n           Pharmaceutical\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.739093242087254, "height": 0.02780153977758759, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-10", "text": "          The approval process for patent-free pharmaceuticals typically does not require pre-clinical and clinical\nstudies, instead relying on the previously conducted clinical studies which established the safety and efficacy of\nthe originator pharmaceutical and allowing Dermapharm to reference this pharmaceutical in its application\ndocumentation. The marketing authorization may be obtained in a centralized procedure through the EMA and\nthe European Commission, if the reference pharmaceutical has obtained its marketing authorization through a\ncentralized European procedure, or in a national procedure through the competent regulatory authority of the\nrelevant member state (see \u201c13.1.2.3 Marketing Authorizations for Pharmaceuticals\u201d).\n", "page_number": 161, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7557741659538066, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8502994011976048, "height": 0.09452523524379819, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-161-11", "text": "118", "page_number": 161, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-0", "text": "         Pursuant to Section 24b para. 1 AMG, Dermapharm is free to refer to the clinical and non-clinical part\nof the documentation submitted in a previous application relating to an originator pharmaceutical regardless of\nthe previous applicant\u2019s approval, provided that the marketing authorization for the originator pharmaceutical\nhas been issued for at least eight years in Germany or another member state of the European Union. Therefore,\nDermapharm is only required to prove the bioequivalence of its patent-free pharmaceutical to the originator\npharmaceutical that serves as a reference pharmaceutical in Dermapharm\u2019s application.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-1", "text": "          Dermapharm must submit data to the relevant governmental authorities and prove with bioavailability\nstudies that its patent-free pharmaceutical is bioequivalent to the originator pharmaceutical. Such studies\ncompare the bioavailability between pharmaceuticals and, when established, indicate whether the rate and extent\nof absorption of a patent-free pharmaceutical in the body are substantially equivalent to the originator\npharmaceutical. Two pharmaceuticals are therapeutically equivalent if they are pharmaceutically equivalent\n(patent-free pharmaceuticals must contain the same APIs as the originator pharmaceuticals) and if after\nadministration in the same molar dose, their effects with respect to both efficacy and safety are essentially the\nsame as those derived from applicable studies (e.g., bioequivalence, pharmacodynamics, clinical or in vitro\nstudies). Patent-free pharmaceuticals are considered essentially similar to the originator pharmaceutical in terms\nof dosage, strength, route of administration, safety, efficacy and intended use.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.13729683490162534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-2", "text": "          The most common process to assess bioequivalence is an analysis of the plasma concentration\ntime-profile data from a bioequivalence study typically involving 12 to 40 volunteers. However, this analysis is\nnot suitable for certain complex pharmaceuticals and other bioequivalence studies must be performed. In some\ncases, pharmacodynamics studies can establish equivalence. In other instances, this type of study cannot be\nperformed due to a lack of meaningful measurable pharmacodynamics parameters, and a comparative clinical\nstudy is required in order to demonstrate equivalence between two formulations. Clinical studies which are\nundertaken to prove equivalence are subject to the same statistical principles applying to other clinical studies\n(see \u201c13.1.2.2 Application Process for Patent-free Pharmaceuticals without Sufficient Data on the Originator\nPharmaceutical\u201d). The number of patients to be included in an equivalence study will depend on the variability\nof the target parameters and the acceptance range, and is usually much higher than the number of patients in the\nother studies.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46535500427716, "height": 0.14756201881950387, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-3", "text": "13.1.2.2   Application Process for Patent-free Pharmaceuticals without Sufficient Data on the Originator\n           Pharmaceutical\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.48246364414029086, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5085543199315654, "height": 0.026090675791274553, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-4", "text": "          If Dermapharm is unable to refer to sufficient data from a previous application when applying for a\nmarketing authorization, it must conduct original clinical studies to obtain the required data. Such clinical\nstudies are subject to strict requirements of good clinical practice, promulgated by the International Conference\non Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (\u201cICH\u201d), and\nadopted into European and national law through Regulation (EU) no. 536/2014 of the European Parliament and\nof the Council of April 16, 2014 on clinical studies on medicinal products for human use and the complementary\nnational laws in individual member states of the European Union (e.g., the AMG in Germany).\n", "page_number": 162, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.621043627031651, "height": 0.09452523524379808, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-5", "text": "          In Germany, clinical studies may only commence if a competent ethics committee has issued a\nfavorable opinion and the clinical study has been authorized by the competent federal authority, which in most\ncases is the Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und\nMedizinprodukte). The specific requirements to be met in order to receive the authorization are set forth in\nSections 40 through 42 AMG. Reasons for denying or repealing the authorization include (i) the incompleteness\nof the submitted documents, (ii) the non-compliance of the submitted documents (e.g., the protocol, the\ninvestigator\u2019s brochure, and the modalities for selecting subjects) with the current state of scientific knowledge\nor a lack of proof of safety or efficacy of the pharmaceutical, and (iii) findings which indicate that the testing\nfacility is not suitable to conduct the clinical study. The results of confirmatory clinical studies must be\nsubmitted to the competent regulatory authority for entry into a database-supported information system within\nsix months after the pharmaceutical received its marketing authorization. Data from the information system is to\nbe transmitted to relevant national authorities and the EMA. If a clinical study is conducted without reference to\nan existing pharmaceutical, Dermapharm has to make the results of its study available within one year of\ncompletion thereof.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8177929854576561, "height": 0.18862275449101795, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-162-6", "text": "119\n", "page_number": 162, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-163-0", "text": "         Clinical studies are generally conducted sequentially in four phases, although there may be overlap or\nomissions (in particular, Dermapharm generally only conducts Phase I and Phase III studies, see\n(\u201c12.4.1.3 Development\u201d)):\n", "page_number": 163, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-163-1", "text": "           \uf0b7   In Phase I, clinical studies are initially conducted in a limited clinical study population to evaluate\n               the safety profile of a pharmaceutical candidate and the range of doses that can be administered,\n               including the maximum tolerated dose that can be administered. The APIs are usually tested on\n               healthy volunteers to determine tolerability and to study the effects of APIs at their tissue sites of\n               action (i.e., pharmacodynamic effects) as well as the absorption, distribution, metabolism and\n               excretion of APIs in the body (i.e., pharmacokinetic effects). Bioequivalence studies are also\n               considered Phase I clinical studies.\n           \uf0b7   In Phase II, testing takes place on between 50 and 500 voluntary patients. The results in this phase\n               allow the evaluation of the efficacy of the pharmaceutical candidate for specific indications, the\n               determination of the candidate\u2019s optimal dosage and further collection of data to describe the\n               candidate\u2019s safety profile. This phase also aims to determine pharmacokinetic differences between\n               healthy and ill persons.\n           \uf0b7   Phase III is the most important phase to the development of new pharmaceuticals. The\n               pharmaceutical candidate is tested in randomized studies comparing it to an approved form of\n               therapy in an expanded and well-defined patient population, usually recruited from a large number\n               of hospitals and medical practices. When no alternative comparison is available, pharmaceutical\n               candidates may be tested against a placebo. Stringent criteria of statistical significance apply to\n               Phase III studies, which are sometimes referred to as registration or pivotal studies and are usually\n               undertaken once Phase II clinical studies suggest that the pharmaceutical candidate is effective and\n               has an acceptable safety profile, and an effective dosage has been identified. The goal of Phase III\n               studies is to demonstrate evidence of a clinical benefit, usually expressed as a positive benefit-risk\n               assessment for the pharmaceutical candidate in the relevant patient population.\n           \uf0b7   Phase IV studies close the study sequence after the marketing authorization has been granted and\n               consist of post-marketing surveillance. They aim to ensure safety for patients based on ongoing\n               and long-term monitoring (e.g., to identify rare side effects or side effects attributable to previously\n               unknown outside influences). Phase IV studies may be required by competent regulatory\n               authorities. In addition, Dermapharm may decide to initiate such studies voluntarily (e.g., to\n               identify a new market for its pharmaceuticals).\n\n13.1.2.3       Marketing Authorizations for Pharmaceuticals\n\n           If Dermapharm is able to meet the documentation requirements for the approval process, the competent\n", "page_number": 163, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1364414029084688, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5966638152266894, "height": 0.46022241231822064, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-163-2", "text": "regulatory authority will grant the desired marketing authorization. The authorization process usually takes more\nthan a year and may even last several years, depending on the nature and proposed use of the pharmaceutical\nunder review, the quality of the submitted data collected during the development process, and the efficiency of\nthe relevant competent regulatory authority. In the European Union, approval and manufacturing is\ncomprehensively regulated at both the European level and the national level in each member state. The\nEuropean legal framework for approval and manufacturing has been developed and amended on numerous\noccasions in recent decades, with an increasing tendency to shift decision-making and proceedings from the\nnational to the European level.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5970915312232677, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7065868263473054, "height": 0.10949529512403766, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-163-3", "text": "There are four registration procedures with different regional coverages available to Dermapharm:\n", "page_number": 163, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.7147134302822925, "lower_right_x": 0.841596130592503, "lower_right_y": 0.7275449101796407, "height": 0.01283147989734823, "width": 0.6632406287787183}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-163-4", "text": "\uf0b7   The European centralized procedure is set forth in Regulation (EC) 726/2004 of the European\n    Parliament and of the Council of March 31, 2004 laying down community procedures for the\n    authorization and supervision of medicinal products for human and veterinary use and establishing\n    a European Medicines Agency (the \u201cEMA Regulation\u201d). When the required documentation is\n    submitted to the EMA, the Committee for Medicinal Products for Human Use (\u201cCHMP\u201d) carries\n    out a scientific evaluation. The CHMP opinion is then transmitted to the European Commission for\n    its separate opinion, which, if also favorable, results in a marketing authorization which is valid in\n    all member states of the European Union. The centralized procedure is mandatory for certain\n    pharmaceuticals listed in the EMA Regulation. For all other pharmaceuticals, Dermapharm may\n    choose to submit a voluntary application for a centralized marketing authorization if the reference\n    pharmaceutical has obtained a centralized marketing authorization or certain other requirements\n    are met. However, Dermapharm has so far never used this centralized European procedure.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.7352437981180496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8999144568006844, "height": 0.16467065868263475, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-163-5", "text": "120", "page_number": 163, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-164-0", "text": "\uf0b7   Dermapharm may also use the mutual recognition procedure, if it intends to sell a pharmaceutical\n    in more than one member state, but not necessarily throughout the entire European Union. This\n    procedure is set forth in the Medicinal Products Directive and implemented into German law\n    through the AMG. If a marketing authorization for a pharmaceutical has already been granted in\n    one member state, other member states will normally grant additional marketing authorizations in\n    a facilitated procedure based on the European principle of mutual recognition. Such authorizations\n    are granted on the basis of an assessment report transmitted by the relevant member state in which\n    the original marketing authorization was granted, unless there is reason to believe that the relevant\n    pharmaceutical would represent a serious risk to public health. Dermapharm may use the\n    aforementioned procedure in order to introduce its existing products to new markets in the\n    European Union.\n\uf0b7   If no marketing authorization has been granted in any member state of the European Union yet,\n    Dermapharm must submit the application documentation to all competent authorities in the\n    respective member states where Dermapharm seeks approval and select a reference member state.\n    Dermapharm usually selects Germany or Austria for this purpose. The chosen member state must\n    then produce an assessment report, a summary of the characteristics of the relevant\n    pharmaceutical, the labelling and leaflet, and transmit these documents to the authorities in the\n    other member states where Dermapharm is seeking approval. These other member states will then\n    mutually recognize the decision of the regulatory authority of the chosen member state. This\n    procedure is also set forth in the Medicinal Products Directive and implemented into German law\n    through the AMG. The aforementioned procedure is the preferred procedure for Dermapharm\u2019s\n    product introductions with respect to both new and existing products.\n\uf0b7   Finally, Dermapharm can obtain a national marketing authorization under German law, which\n    mostly reflects the requirements of the Medicinal Products Directive. The Federal Institute for\n    Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte) is the\n    competent regulatory authority to grant such marketing authorization. The required documentation\n    is set forth in Sections 22 through 24b AMG. Pursuant to Sections 25 and 30 AMG, the application\n    may be rejected for various reasons (e.g., incompleteness of the submitted documentation,\n    insufficient testing, non-compliance of the manufacture process with recognized pharmaceutical\n    rules or appropriate quality standards, lack of therapeutic efficacy, or an unfavorable benefit/risk\n    profile). The marketing authorization expires after five years, unless renewed, or if the\n    pharmaceutical has not been placed on the market within three years after the marketing\n    authorization was granted, or is removed from the market for at least three successive years. If a\n    marketing authorization was received for a patent-free pharmaceutical through reference to the\n    authorization documentation of the existing pharmaceutical, such patent-free pharmaceutical may\n    only be placed on the market after ten years have elapsed since the first marketing authorization\n    was granted for the reference pharmaceutical. Under certain circumstances, this period is extended\n    to 11 years. Dermapharm will only rarely seek an isolated national marketing authorization.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6223267750213858, "height": 0.5337895637296834, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-164-1", "text": "13.1.3   Manufacturing\n", "page_number": 164, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.6501283147989735, "height": 0.014114627887082953, "width": 0.16989117291414754}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-164-2", "text": "          According to Section 13 AMG, commercial pharmaceuticals manufacturers based in Germany\ngenerally require a manufacturing authorization granted by the competent governmental authority of the relevant\nfederal state. The AMG defines manufacturing as producing, preparing, formulating, treating or processing,\nfilling as well as decanting, packaging, labelling and releasing pharmaceuticals. To obtain the relevant\nauthorization, a manufacturer must have at least one person that has expert knowledge and is able to ensure that\neach batch of a pharmaceutical is manufactured and tested in accordance with the applicable regulations. Such\nexpert knowledge is proven either through a license to practice as a pharmacist or a diploma in pharmacy,\nchemistry, biology or human medicine attained upon completion of university studies. In addition, a period of at\nleast two years of practical experience in the field of the qualitative and quantitative analysis and other quality\ntesting of pharmaceuticals is required. Special knowledge is, inter alia, required for the manufacturing and\ntesting of blood preparations, human plasma, allergens, test plasma and test antigens.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6638152266894782, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.1505560307955517, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-164-3", "text": "121", "page_number": 164, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-0", "text": "          The Ordinance on the Application of Good Manufacturing Practice in the Manufacture of\nPharmaceuticals and Active Pharmaceutical Ingredients and on the Good Professional Practice in the\nManufacture of Products of Human Origin (Verordnung \u00fcber die Anwendung der guten Herstellungspraxis bei\nder Herstellung von Arzneimitteln und Wirkstoffen und \u00fcber die Anwendung der guten fachlichen Praxis bei der\nHerstellung von Produkten menschlicher Herkunft) provides specific requirements as to the overall quality\nmanagement systems personnel, premises and facilities, hygiene, documentation, labelling, and storage in\nrelation to the manufacturing systems. This ordinance largely reflects and refers to the requirement of GMP as\nset forth in the European Guidelines on Good Manufacturing Practice for Medicinal Products for Human and\nVeterinary Use, which are published pursuant to Article 47 para. 2 of the Medicinal Products Directive and\nspecify GMP as prescribed by Commission Directive 2003/94/EC of October 8, 2003 laying down the principles\nand guidelines of good manufacturing practice in respect of medicinal products for human use and\ninvestigational medicinal products for human use.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-1", "text": "13.1.4   Labelling\n", "page_number": 165, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2630453378956373, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.2771599657827203, "height": 0.014114627887083009, "width": 0.13119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-2", "text": "          In Germany, the labelling of pharmaceuticals is governed by Sections 10 and 11 AMG, largely\nreflecting the requirements set forth in Title V of the Medicinal Products Directive. These provisions determine\nthe information that has to be displayed on the container and, if used, on the outer packaging of pharmaceuticals\nas well as the information to be contained in the leaflet.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.344311377245509, "height": 0.05047048759623607, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-3", "text": "         The information on the container and, if used, on the outer packaging of finished pharmaceuticals must\nbe displayed in the German-language and easily comprehensible and, inter alia, include the name and address of\nthe pharmaceutical manufacturer, the name of the pharmaceutical, information stating whether the\npharmaceutical is intended for administration to babies, children or adults, the marketing authorization number,\nthe batch number, the strength, dosage form and method of administration, the APIs, the content by weight,\nvolume or number of items, the expiry date and, if applicable, a note that the relevant pharmaceutical requires a\nprescription and can only be obtained through a pharmacy.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4499572284003422, "height": 0.09452523524379813, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-4", "text": "         Pharmaceuticals may only be marketed with a package leaflet bearing the heading instructions for use\n(Gebrauchsinformation) and containing, in the prescribed order, information such as the name of the\npharmaceutical, the APIs or indication group or the mode of administration, the therapeutic indications,\ninformation to be read before using the pharmaceutical (e.g., contra-indications), precautions and interactions\nwith other pharmaceuticals, instructions for normal use, information on potential adverse effects and a directions\non where to inspect the expiry date. Such information must be easily legible and comprehensible and is to be\nprovided in the German language.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5521813515825492, "height": 0.09409751924721987, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-5", "text": "          From February 9, 2019 on, Commission Delegated Regulation (EU) 2016/161 of October 2, 2015\nsupplementing the Directive 2001/83/EC will apply to the packaging of most pharmaceuticals and require\ncertain information to be contained in a unique identifier in the form of a two-dimensional barcode that must be\nplaced on the packaging of the relevant pharmaceutical. The unique identifier must consist of the following data\nelements: a code allowing for the identification of at least the name, the common name, the pharmaceutical\nform, the strength, the package size and the package type of the pharmaceutical, a serial number consisting of a\nnumeric or alphanumeric sequence of no more than 20 characters, generated by a deterministic or a\nnon-deterministic randomization algorithm, a national reimbursement number or other national number\nidentifying the pharmaceutical, if required by the member state where the pharmaceutical is intended to be\nplaced on the market, the batch number and the expiration date. In addition, an anti-tampering device must be\nadded to the packaging, allowing the verification of whether the packaging of the relevant pharmaceutical has\nbeen tampered with. While OTC and other healthcare products are generally exempt from these requirements,\nsome OTC products are specifically included in the scope of this regulation.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7382378100940975, "height": 0.17750213857998287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-165-6", "text": "122", "page_number": 165, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-0", "text": "13.1.5   Promotion and Improper Benefits\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4159613059250302, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2956469165659008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-1", "text": "           The promotion of pharmaceuticals in Germany is regulated by the German Drug Advertisement Act\n(Heilmittelwerbegesetz (\u201cHWG\u201d)). Prescription pharmaceuticals may only be advertised among expert circles\n(i.e., healthcare professionals, healthcare facilities and other persons authorized to trade pharmaceuticals). Such\nadvertisements may not be misleading, must disclose specific information and may not refer to certain sources\n(e.g., recommendations of scientists, patient histories and thank-you letters, letters of appreciation and letters of\nrecommendation by third parties).\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-2", "text": "           Providing benefits for the promotion of pharmaceuticals is generally prohibited. Violations of the\nHWG may constitute criminal or administrative offenses (Straftaten oder Ordnungswidrigkeiten). Pursuant to\nSection 299b of the German Criminal Code (Strafgesetzbuch), any person offering promising or providing\nbenefits to a healthcare professional to entice such professional to favor that person when prescribing, sourcing\nor administering pharmaceutical or medical devices (Medizinprodukte), faces a prison term of up to three years\nor a fine.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2831479897348161, "height": 0.08169375534644996, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-3", "text": "13.1.6     Distribution\n\n13.1.6.1      Distribution to Patients\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.33875106928999144, "height": 0.03806672369546621, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-4", "text": "          In Germany, the AMG provides that pharmaceuticals may generally only be sold to end consumers in\npharmacies. There are statutory exemptions for, inter alia, natural curative waters as well as their salts,\ntherapeutic clays, moor muds for baths and other peloids, soaps for external use, plants and parts of plants,\ndistillates made from plants, juices pressed from fresh plants if they are prepared without the use of solvents\nother than water, plasters and disinfectants intended exclusively or mainly for external use as well as\ndisinfectants for the mouth and throat area. In addition, the German Ordinance on Pharmacy-Only and Free\nMarket Pharmaceuticals (Verordnung \u00fcber apothekenpflichtige und freiverk\u00e4ufliche Arzneimittel) provides the\nsame exemption for certain pharmaceuticals containing specific substances. However, the ordinance also\nrequires that certain pharmaceuticals exempt under the AMG may nevertheless only be sold in pharmacies.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47818648417450815, "height": 0.1227544910179641, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-5", "text": "         German law further distinguishes between prescription pharmaceuticals (i.e., pharmaceuticals which\nmay only be provided to patients based on a prescription issued by a doctor) and non-prescription\npharmaceuticals that may be sold to patients at pharmacies without a prescription (OTC products). The\nOrdinance on the Mandatory Prescription of Pharmaceuticals (Verordnung \u00fcber die Verschreibungspflicht von\nArzneimitteln (the \u201cPrescription Ordinance\u201d)) lists specific substances and any pharmaceuticals containing\nthese substances are prescription pharmaceuticals, while all other pharmaceuticals are OTC products.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.567579127459367, "height": 0.08212147134302827, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-6", "text": "          Pharmaceuticals may also be distributed to patients via mail order. However, a distributor residing in\nGermany requires specific licenses according to the German Act on Pharmacies (Gesetz \u00fcber das\nApothekenwesen (\u201cApoG\u201d)). In addition, distributors require a specific authorization for the distribution of\npharmaceuticals via mail order pursuant to Sections 43 para. 1 AMG and Section 11a ApoG. In general,\ndistribution via mail order may include prescription pharmaceuticals as well as OTC products. According to the\nOrdinance on the German Operation of Pharmacies (Apothekenbetriebsordnung), however, distribution via mail\norder is not permitted if the safe application of the pharmaceutical requires a personal consultation, or if the\npharmaceutical contains certain substances. According to Section 73 para. 1 no. 1a AMG, the distribution of\npharmaceuticals to patients in Germany via mail order by pharmacies residing in another member state of the\nEEA (\u201cEEA Member State\u201d) is permitted if a marketing authorization for the relevant pharmaceutical has been\ngranted in Germany and the EEA Member State in which the pharmacy resides provides comparable safety\nstandards in relation to the operation of pharmacies. The German Federal Ministry of Health\n(Bundesministerium f\u00fcr Gesundheit) compiles a list of countries of EEA Member States that have established\ncomparable safety standards, which is published in, and periodically updated, in the German Federal Gazette\n(Bundesanzeiger).\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5744225834046194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7801539777587682, "height": 0.20573139435414878, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-7", "text": "13.1.6.2   Distribution to Pharmaceutical Wholesalers, Pharmacies, Doctors and Hospitals\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.75453446191052, "lower_right_y": 0.8075278015397775, "height": 0.014114627887082953, "width": 0.6342200725513906}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-8", "text": "        The distribution of pharmaceuticals to pharmaceutical wholesalers and pharmacies is unrestricted,\nalthough they require a specific license to operate their businesses. By comparison, the distribution of\npharmaceuticals to doctors, hospitals and certain other facilities is highly restricted and only certain\npharmaceuticals listed in Section 47 AMG may be distributed to these costumer groups.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.820786997433704, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8759623609923011, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-166-9", "text": "123", "page_number": 166, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-0", "text": "13.1.7   Monitoring and Supervision\n", "page_number": 167, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.37726723095526, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.25695284159613063}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-1", "text": "          Even after obtaining a marketing authorization, a pharmaceutical and its manufacturer remain subject\nto monitoring. The competent regulatory authority may have granted the relevant marketing authorization under\nthe condition that additional analytical and pharmaceutical-toxicological tests or clinical studies are carried out.\nSuch additional studies may also be conducted on a voluntary basis. Pursuant to Commission Regulation (EC)\nno. 1234/2008 of November 24, 2008 concerning the examination of variations to the terms of marketing\nauthorizations for medicinal products for human use and veterinary medicinal products, as amended, the\ncompetent regulatory authority must be notified of certain changes after the marketing authorization has been\ngranted (e.g., changes to the summary of the pharmaceutical\u2019s characteristics and any conditions, obligations, or\nrestrictions affecting the marketing authorization, or changes to the labelling or the packaging leaflet connected\nwith changes to the summary of the pharmaceutical\u2019s characteristics). Changes to the marketing authorization\nmay even require approval by the competent governmental authority or obtaining a new marketing\nauthorization.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2754491017964072, "height": 0.16295979469632166, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-2", "text": "          In addition, the holder of a marketing authorization has to comply with the comprehensive framework\non pharmacovigilance laid down in the Medicinal Products Directive, Directive 2010/84/EU of the European\nParliament and of the Council of December 15, 2010 and Regulation (EU) 1235/2010 of the European\nParliament and of the Council of December 15, 2010 (the \u201cPharmacovigilance Regulation\u201d), as well as\nnational legislation implementing the Pharmacovigilance Regulation (e.g., Sections 62 through 63j AMG in\nGermany). The Pharmacovigilance Regulation, inter alia, requires the holder of a marketing authorization to\nhave a qualified person responsible for pharmacovigilance, maintain and make available a pharmacovigilance\nsystem master file, operate a risk management system for each pharmaceutical and record all suspected adverse\nreactions which are brought to his attention and make these reports accessible. In addition, such holder must\nsubmit periodic safety update reports to the EMA. However, holders of marketing authorizations are generally\nexempt from the requirement to provide such safety update reports, unless the relevant pharmaceutical contains\nAPIs for which the EMA requires such safety update reports. The Pharmacovigilance Regulation provides for\nspecific labelling requirements with respect to certain pharmaceuticals which are on a list of medicinal products\nsubject to additional monitoring. Such pharmaceuticals must bear on their packaging and the leaflet the\ndisclaimer \u201cThis medicinal product is subject to additional monitoring\u201d, together with a black triangle.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4893071000855432, "height": 0.20573139435414883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-3", "text": "        Facilities where pharmaceuticals are manufactured, tested, stored, packaged or placed on the market, or\nin which any other form of trade with pharmaceuticals takes place, are subject to supervision by the competent\ngovernmental authority, which will, inter alia, monitor compliance with the rules on the trade in\npharmaceuticals, on active substances and other substances intended for use in the manufacture of\npharmaceuticals, and on advertising of pharmaceuticals. The competent governmental authorities may conduct\nunannounced inspections where necessary and stipulate effective follow-up measures (e.g., testing of\npharmaceutical samples, marketing restrictions and recalls).\n", "page_number": 167, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4957228400342173, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-4", "text": "13.1.8   Pricing and Reimbursements\n", "page_number": 167, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.6197604790419161, "height": 0.01112061591103497, "width": 0.2611850060459492}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-5", "text": "          Regulations with respect to pricing of, and reimbursement for, pharmaceuticals are not harmonized in\nthe European Union and are therefore subject to the exclusive jurisdiction of the member states. Consequently,\nreimbursement mechanisms by SHI providers and private health insurance providers vary from country to\ncountry. While the margins of pharmacies and wholesalers in relation to prescription pharmaceuticals are\nregulated in Germany by the German Drug Price Ordinance (Arzneimittelpreisverordnung) in order to provide\nfor a uniform price level for such prescription pharmaceuticals, pharmaceutical manufacturers are generally free\nto set their own prices (i.e., set an ex-factory price (Herstellerabgabepreis)). However, given that in 2017, 88%\nof the population in Germany benefited from reimbursements by SHI providers with respect to prescription\npharmaceuticals (source: OECD Germany 2017), pricing decisions are often influenced by the legal framework\nfor the public healthcare system, which depends on the overall economic situation in Germany\n(see \u201c1.1.1 Dermapharm could be adversely affected by developments in the German pharmaceuticals and\nhealthcare markets.\u201d) and consequently is subject to changes (see \u201c1.1.9 Healthcare reforms and related\nchanges to the framework applicable to the pharmaceuticals industry may adversely affect Dermapharm\u2019s\nbusiness.\u201d).\n", "page_number": 167, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8276304533789564, "height": 0.19161676646706582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-167-6", "text": "124", "page_number": 167, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-0", "text": "         The provisions of the Social Code V as well as the Guidelines of the Federal Joint Committee\n(gemeinsamer Bundesausschuss) (the \u201cGuidelines\u201d) indicate whether patients receive reimbursement from\nSHI providers for a certain pharmaceutical. Certain pharmaceuticals are statutorily excluded from\nreimbursements and, therefore, must be paid for by patients. This generally includes OTC products, unless such\nOTC products are deemed to be the therapeutic standard in case of a serious medical condition and a\nprescription is issued for such products. The exclusion of OTC products is not applicable to minors up to\n12 years of age with an SHI plan or minors up to 18 years of age suffering from a developmental disability.\nCosts for prescription contraceptives are only reimbursed if the insured person is less than 21 years of age.\nCertain other pharmaceuticals listed in Section 34 Social Code V are excluded from reimbursements for insured\npersons older than 18 years of age (e.g., pharmaceuticals for use against cold symptoms and flu infections,\npurgatives, and mouth and throat therapeutics except in case of fungal infections). Furthermore, pharmaceuticals\nare excluded from reimbursements if their primary focus is to increase the quality of life or if they are\nconsidered uneconomic (i.e., if such pharmaceuticals (i) contain APIs which are not required for the therapeutic\nobjective or for the reduction of risks, (ii) their effect cannot be determined with a sufficient degree of certainty\nbecause of the multiplicity of APIs, or (iii) their therapeutic benefit has not been proven).\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.20573139435414883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-1", "text": "Reference Prices and Reimbursements\n", "page_number": 168, "bounding_box": {"top_left_x": 0.2037484885126965, "top_left_y": 0.3041060735671514, "lower_right_x": 0.46372430471584036, "lower_right_y": 0.31822070145423437, "height": 0.014114627887082953, "width": 0.25997581620314386}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-2", "text": "13.1.8.1\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3041060735671514, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.3165098374679213, "height": 0.01240376390076986, "width": 0.05259975816203144}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-3", "text": "         The maximum price for prescription pharmaceuticals covered by a SHI providers is either determined\nby a fixed reference price set by the German Federal Central Association of the Statutory Health Insurance\nFunds (Spitzenverband Bund der Krankenkassen (the \u201cFederal Association\u201d)) or by direct negotiations between\nthe pharmaceuticals manufacturer and the Federal Association.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3866552609067579, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-4", "text": "         Pursuant to Section 35 paras. 1 and 3 Social Code V, the Guidelines set forth groups of\npharmaceuticals for which a reference price may be set by the Federal Association. The reference price is the\nmaximum price that is reimbursed by SHI providers. Any amounts exceeding the reference price must be borne\nby the relevant patient. The groups of pharmaceuticals subject to reference prices consist of pharmaceuticals\nwith the same APIs, or with comparable pharmacological-therapeutic APIs, or with a comparable therapeutic\neffect. Pharmaceuticals containing patent-protected APIs, the mode of action of which is considered to be new\nor which are regarded as a therapeutic improvement, may not be included in groups based on comparable\npharmacological-therapeutic APIs or a comparable therapeutic effect.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5029940119760479, "height": 0.10650128314798968, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-5", "text": "          In relation to pharmaceuticals with new APIs, a reimbursement price (Erstattungsbetrag) (i.e., the\nmaximum price reimbursed by SHI providers and private health insurance providers) is negotiated between the\nmanufacturer and the Federal Association as well as private health insurance providers pursuant to Section 130b\nSocial Code V. Key parameters to be considered in the course of such decision are (i) the effects of new APIs,\n(ii) the costs of a comparative therapy and (iii) the price for the relevant pharmaceutical in other member states\nof the European Union. The parties have discretion to determine whether pricing restrictions apply to the\nreimbursement price, except with respect to the mandatory rebate for patent-free pharmaceuticals pursuant to\nSection 130a para. 3b Social Code V and the price moratorium pursuant to Section 130a para. 3a Social Code V,\nwhich are not up for negotiation. The reimbursement price comes into effect from the thirteenth month after the\nrelevant pharmaceutical has been placed on the market and is binding for all subsequent pharmaceuticals\ncontaining the same APIs.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5128314798973481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.660393498716852, "height": 0.14756201881950393, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-6", "text": "13.1.8.2   Mandatory Rebates\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.6899059024807528, "height": 0.01283147989734812, "width": 0.21825876662636032}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-7", "text": "        Section 130a para. 3b Social Code V imposes a mandatory rebate of 10% of the ex-factory price, less\nvalue added tax (\u201cVAT\u201d), on all patent-free pharmaceuticals. This rebate is effectively borne by\npharmaceuticals manufacturers, since pharmacies and pharmaceutical wholesalers are entitled to claim\nreimbursement of the price difference resulting from such rebate from the respective manufacturer. However,\nsubsequent price reductions can be deducted from this rebate. Thus, a price reduction of 10% would release the\npharmaceutical manufacturer from the mandatory rebate requirement for patent-free pharmaceuticals.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.704448246364414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.786142001710864, "height": 0.08169375534644996, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-8", "text": "         A second statutory rebate applies to prescription pharmaceuticals and OTC products reimbursed by\nSHI providers for which no reference price has been set. Section 130a para. 1 Social Code V imposes a rebate of\n7% of the selling price, less VAT, for originator pharmaceuticals and 6% of the selling price, less VAT, for\npatent-free pharmaceuticals. This rebate is also effectively borne by pharmaceuticals manufacturers.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7934131736526946, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8477331052181352, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-168-9", "text": "125", "page_number": 168, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-0", "text": "13.1.8.3   Price Moratorium\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2079806529625151}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-1", "text": "          Section 130a para. 3a Social Code V contains the so-called price moratorium (Preismoratorium) in\ncase of price increases for prescription pharmaceuticals and OTC products reimbursed by SHI providers,\nirrespective of VAT. SHI providers reimbursing patients for the relevant pharmaceuticals receive a rebate, borne\nby the pharmaceutical manufacturer, on the new ex-factory price, which is equal to the difference between the\nnew price and the ex-factory price in pharmacies on August 1, 2009. This rule also applies to pharmaceuticals\nintroduced after such date, with the rebate being calculated based on the ex-factory price at market launch.\nBeginning on July 1, 2018, rising inflation will be taken into account and the original ex-factory price providing\nthe basis for calculating rebates under the price moratorium will be increased on July 1 each year in line with\ngeneral price increases as stated in the German consumer price index (Verbraucherpreisindex).\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1236099230111206, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-2", "text": "         While the price moratorium is not applicable to pharmaceuticals with an established reference price,\npharmaceuticals may be subject to both the price moratorium and mandatory rebates. The price moratorium was\nrecently extended until 2022.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2840034217279726, "height": 0.04148845166809237, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-3", "text": "13.1.8.4   Rebate Agreements with SHI Providers\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.3118049615055603, "height": 0.011120615911035081, "width": 0.3536880290205562}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-4", "text": "         Pursuant to Section 130a para. 8 Social Code V, SHI providers may enter into rebate agreements with\npharmaceuticals manufacturers in relation to a certain pharmaceutical, a group of pharmaceuticals containing\nthe same APIs or specific dosage forms of APIs. Before entering into such rebate agreements, SHI providers\nwill generally initiate a tender process in order to identify and typically select the manufacturer who is willing to\ngrant the highest rebate on its pharmaceuticals. Therefore, SHI providers may be able to offer their insured\npersons a pharmaceutical well below the official selling price. As of September 30, 2017, German SHI providers\nhad entered into a total of 27,187 rebate agreements (source: Pro Generika \u2013 Q3 2017).\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42301112061591106, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-5", "text": "13.1.8.5   Aut-idem-rule\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4375534644995723, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.4482463644140291, "height": 0.010692899914456822, "width": 0.17835550181378473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-6", "text": "         Section 129 Social Code V contains provisions on which prescription pharmaceuticals are distributed\nto patients in pharmacies. In general, this is determined by the relevant prescription. If the doctor has prescribed\na specific pharmaceutical and excluded the aut-idem-rule on the prescription (i.e., the general rule that the\npharmacy may exchange the prescribed pharmaceutical for comparable pharmaceuticals with the same strength,\npackage size and dosage form), the pharmacy is required to dispense the prescribed pharmaceutical.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5333618477331052, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-7", "text": "         If, however, the doctor has not excluded the aut-idem-rule, the pharmacy is required to dispense one of\nthe three cheapest comparable pharmaceuticals or an equivalent imported pharmaceutical which fulfills the\nrequirements for parallel imports (see \u201c13.1.9 Parallel Imports\u201d) pursuant to Section 129 para. 1 no. 1 Social\nCode V in conjunction with the Framework Agreement. If the prescribed pharmaceutical is amongst the three\ncheapest pharmaceuticals, the price for the pharmaceutical actually dispensed by the pharmaceutical may not\nexceed the price of the prescribed pharmaceutical. If the doctor has merely prescribed certain APIs, the\npharmacy is required to dispense one of the three cheapest pharmaceuticals containing the relevant APIs\npursuant to Section 129 para. 1 no. 1 Social Code V in conjunction with the Framework Agreement.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6501283147989735, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-8", "text": "         The aforementioned rules do, however, not apply if the patient\u2019s SHI provider has entered into a rebate\nagreement with respect to the relevant pharmaceutical. To the extent the aut-idem-rule is not excluded,\npharmacies are then required to dispense to the patient the equivalent pharmaceutical from the manufacturer\nwho has entered into a rebate agreement with the patient\u2019s SHI provider. Notwithstanding any rebate\nagreements, patients are free to request a pharmaceutical from a different manufacturer so long as the substitute\npharmaceutical is equivalent to the prescribed pharmaceutical. However, in such a case, the patient is required to\npay the entire purchase price and will only be reimbursed by his SHI provider after the relevant purchase and the\nreimbursement will exclude any additional costs of the selected pharmaceutical over the price agreed in the\nrebate agreement.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7801539777587682, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-9", "text": "13.1.8.6   Co-payments\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7934131736526946, "lower_right_x": 0.29443772672309554, "lower_right_y": 0.8075278015397775, "height": 0.014114627887082953, "width": 0.1735187424425635}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-10", "text": "         Despite coverage by SHI providers, consumers are generally required to make statutory co-payments.\nPursuant to Section 61 Social Code V, such co-payments amount to 10% of the selling price, with a minimum\nco-payment of \u20ac5.00 and a maximum co-payment of \u20ac10.00. Furthermore, the Federal Association may exclude\ncertain pharmaceuticals from co-payment requirements if such pharmaceuticals are offered at least 30% below\nthe relevant reference price.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.820786997433704, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8896492728828058, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-169-11", "text": "126", "page_number": 169, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-0", "text": "13.1.9     Parallel Imports\n\n13.1.9.1      Parallel Import Quota\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.23760580411124546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-1", "text": "          In order to reduce healthcare costs, the German legislator has decided to enact a regulatory framework\nthat facilitates parallel imports of prescription pharmaceuticals from other EEA Member States where prices for\nsuch pharmaceuticals may be significantly lower compared to prices in the German market. Pursuant to the\nFramework Agreement, at least 5% of all prescription pharmaceuticals sold within the statutory healthcare\nsystem in Germany must be brought into the market through parallel imports. According to Section 129 para. 1\nno. 2 Social Code V, only parallel imports with prices that are at least \u20ac15.00 or 15% lower than the price of the\nGerman original pharmaceutical, taking into account any mandatory rebates, count towards the 5% import\nquota. This quota is reduced for individual pharmacies in several steps if only a low percentage of such\npharmacy\u2019s quarterly revenues generated with a particular SHI provider is attributable to prescription\npharmaceuticals suitable for parallel imports.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2788708297690334, "height": 0.13558597091531224, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-2", "text": "13.1.9.2   Corresponding Authorizations\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2938408896492729, "lower_right_x": 0.4111245465538089, "lower_right_y": 0.306672369546621, "height": 0.01283147989734812, "width": 0.2908101571946795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-3", "text": "          In Germany, pharmaceuticals may generally only be imported by a pharmaceutical entrepreneur,\nwholesaler, pharmacist or hospital operator. If a centralized European marketing authorization was granted for\nany particular pharmaceutical, Dermapharm does not require any additional approvals for marketing the relevant\npharmaceutical in Germany. Dermapharm is, however, required to notify the EMA and the competent\ngovernmental authorities in all member states to which it intends to import such pharmaceuticals. In this\nnotification, Dermapharm is required to inform the relevant authorities of its intent to source, repackage and\ndistribute the relevant pharmaceutical from one or more member states to one or more other member states, and\nsubmit all relevant forms and documentation (e.g., intended packaging). The EMA will review whether the\nnotification complies with the relevant centralized European marketing authorization and the Medicinal\nProducts Directive. If compliance is confirmed, the EMA will issue a parallel distribution notice allowing the\nintended parallel import. Even after obtaining a parallel distribution notice, Dermapharm is required to notify\nthe EMA of changes (e.g., the introduction of additional sourcing states).\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48502994011976047, "height": 0.16381522668947818, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-4", "text": "          If no centralized European marketing authorization for the relevant pharmaceutical was granted,\nDermapharm is required to obtain a corresponding authorization (Bezugszulassung) in order to market such\npharmaceutical in Germany, which is, however, easier to obtain than a marketing authorization. Dermapharm\nonly has to prove that the imported pharmaceutical is pharmaceutically identical to the corresponding\npharmaceutical (i.e., equal with respect to APIs, dosage, and therapeutic effects, while auxiliary APIs may\ndiffer) for which a German market authorization was granted already. No clinical studies are required to provide\nthat a product is pharmaceutically identical. However, a corresponding authorization is required even where the\nimported pharmaceutical is identical to the corresponding pharmaceutical in Germany.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6013686911890505, "height": 0.10906757912745935, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-5", "text": "13.1.9.3   Repackaging and Monitoring\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.405683192261185, "lower_right_y": 0.6295979469632165, "height": 0.014114627887083064, "width": 0.2853688029020556}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-6", "text": "         The distribution of imported pharmaceuticals in Germany requires compliance with German labelling\nprovisions. Therefore, Dermapharm is required to relabel the relevant pharmaceuticals and will often have to\nobserve specific repackaging requirements tailored to the German destination market. Both the relabeling and\nthe repackaging require Dermapharm to hold a valid pharmaceutical manufacturing authorization in accordance\nwith the AMG. Importers of pharmaceuticals are considered pharmaceutical manufacturers and subject to\nsupervision by the relevant regulatory authorities.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7254063301967494, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-7", "text": "         As holder of a corresponding authorization, Dermapharm is subject to the various requirements with\nrespect to pharmacovigilance (see \u201c13.1.7 Monitoring and Supervision\u201d).\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7322497861420018, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7596236099230111, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-8", "text": "13.1.9.4\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7737382378100941, "lower_right_x": 0.17654171704957677, "lower_right_y": 0.7857142857142857, "height": 0.0119760479041916, "width": 0.055622732769044725}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-9", "text": "Trademark Protection\n", "page_number": 170, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.7737382378100941, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.7857142857142857, "height": 0.0119760479041916, "width": 0.15538089480048367}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-10", "text": "         While originator pharmaceuticals oftentimes enjoy trademark protection (see \u201c13.4 Trademarks\u201d), this\ndoes not prohibit the parallel import of such pharmaceuticals. The European Court of Justice has ruled that the\nowner of a trademark must tolerate the repackaging of branded goods and even the replacement of its trademark\nwith a trademark used in the destination state if the following conditions are met: (i) the repackaging does not\nadversely affect the original condition of the product, (ii) the new packaging identifies both the manufacturer\nand the entity that repackaged the product, (iii) the presentation of the repackaged product is not likely to\ndamage the reputation of the trademark or its owner, and (iv) the proprietor of the trademark receives prior\nnotice before the repackaged product is offered.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.800256629597947, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9101796407185628, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-170-11", "text": "127", "page_number": 170, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-0", "text": "13.1.10 Product Liability\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.1789600967351874}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-1", "text": "          The AMG provides specific product liability rules for persons who market pharmaceuticals in Germany\nset forth in Sections 84 through 94a AMG. Such persons are subject to liability irrespective of fault\n(Gef\u00e4hrdungshaftung), if, as a result of distributing pharmaceuticals to consumers a person is killed or a\nperson\u2019s health is substantially impaired, provided that (i) the relevant pharmaceutical is harmful when\nadministered and such harm exceed the limits considered tolerable in the light of current scientific knowledge,\nor (ii) the damage has occurred as a result of labelling, expert information or instructions for use which do not\ncomply with current scientific knowledge. However, the AMG also provides for the following liability limits:\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-2", "text": "\uf0b7   maximum damages of \u20ac600,000.00 or a maximum annual pension of \u20ac36,000.00 for each\n    individual case; and\n\uf0b7   maximum damages of \u20ac120 million or a maximum annual pension of \u20ac7.2 million in case several\n    persons are killed or substantially injured.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.218562874251497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2805816937553465, "height": 0.062018819503849465, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-3", "text": "         In addition to these specific provisions on product liability, the general rules of German tort law may\napply in case of a distribution of defective pharmaceuticals.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.28699743370402053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31479897348160824, "height": 0.027801539777587703, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-4", "text": "Medical Devices\n", "page_number": 171, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.32805816937553467, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.34046193327630453, "height": 0.01240376390076986, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-5", "text": "13.2\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.32934131736526945, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.3408896492728828, "height": 0.01154833190761334, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-6", "text": "         Dermapharm\u2019s product portfolio also includes medical devices, in particular bite away\u00ae for the external\ntreatment of bites and stings from insects and Herpotherm\u00ae for the treatment of herpes symptoms. Regulation\n(EU) 2017/745 of the European Parliament and of the Council of April 5, 2017 on medical devices sets forth the\ngeneral regulatory framework for the handling of medical devices. On the German level, medical devices are\nregulated by the German Act on Medical Devices (Gesetz \u00fcber Medizinprodukte (\u201cMPG\u201d)) and several related\nordinances. Where a product is a combination of a medical device and a pharmaceutical, the regulatory\nframework for pharmaceuticals applies to the pharmaceutical component (see \u201c13.1 Pharmaceuticals\u201d).\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4516680923866553, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-7", "text": "         Medical devices may only be marketed if they meet certain essential requirements, in particular with\nrespect to product safety and reliability. In addition, comprehensive provisions regarding the labelling of, and\nconsumer information with respect to, medical devices must be complied with. The manufacturer of the medical\ndevice is responsible for the marketing of such devices and his name and address must be included on the label\nor in the instructions for use and the manufacturer is usually the addressee of any measures ordered by the\ncompetent regulatory authorities. Clinical studies that may be necessary before marketing medical devices are\nregulated by Sections 19 through 24 MPG. Such studies require the issuance of a favorable opinion by a\ncompetent ethics commission and the authorization by the competent regulatory authority designated in the\nMPG. However, the marketing of medical devices in the European Union does not require a marketing\nauthorization.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5953806672369547, "height": 0.13729683490162536, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-8", "text": "          Every facility where medical devices are manufactured, tested, marketed or applied is subject to\nsupervision by the competent regulatory authorities. In case of non-compliance or suspicion of non-compliance,\nsuch authorities are entitled to order appropriate sanctions (e.g., prohibiting the marketing and ordering recalls).\nFurthermore, non-compliance with applicable regulations may result in criminal or administrative offenses\n(Straftaten oder Ordnungswidrigkeiten) and civil lawsuits.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6706586826347305, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-9", "text": "        In Germany, the distribution of medical devices to consumers is regulated by the German Ordinance on\nthe Dispensing of Medical Devices (Verordnung zur Regelung der Abgabe von Medizinprodukten), pursuant to\nwhich certain medical devices may only be distributed to consumers in pharmacies and require prescriptions.\nThe same holds true for medical devices containing APIs which qualify for prescription and/or pharmacy-only\nsubstances pursuant to the German Ordinance on Pharmacy-Only and Free Market Pharmaceuticals\n(Verordnung \u00fcber apothekenpflichtige und freiverk\u00e4ufliche Arzneimittel).\n", "page_number": 171, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7596236099230111, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-171-10", "text": "128", "page_number": 171, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-0", "text": "13.3   Healthcare Products\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2079806529625151}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-1", "text": "        Dermapharm also offers a wide range of other healthcare products, which are sold as foodstuffs, food\nsupplements or cosmetics. These products are subject to the comprehensive food and cosmetics regulations set\nby European and German law. Non-compliance with such regulations generally constitutes either a criminal or\nan administrative offense (Straftat oder Ordnungswidrigkeit) and may result in civil lawsuits. Unlike\npharmaceuticals and medical devices, other healthcare products are generally not subject to pricing restrictions.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-2", "text": "13.3.1   Foodstuffs\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.21086398631308811, "height": 0.012831479897348175, "width": 0.13603385731559856}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-3", "text": "         On a national level, the German Code on Foodstuffs, Consumer Goods and Fodder (Lebensmittel-,\nBedarfsgegenst\u00e4nde- und Futtermittelgesetzbuch (\u201cLFGB\u201d)), which is complemented by various ordinances,\nestablishes the regulatory framework for foodstuffs (Lebensmittel). However, such foodstuffs are also highly\nregulated on the European level. The European legislation places a strong focus on the safety of foodstuffs and\nconsumer information as evidenced by various regulations that apply directly in all member states of the\nEuropean Union.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.306672369546621, "height": 0.08126603934987167, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-4", "text": "         Regulation (EC) 178/2002 of the European Parliament and of the Council of January 28, 2002 laying\ndown the general principles and requirements of food law, establishing the European Food Safety Authority and\nlaying down procedures in matters of food safety (the \u201cFood Regulation\u201d) defines foodstuffs as any substance\nor product, whether processed, partially processed or unprocessed, intended or reasonably expected to be\ningested by humans. The LFGB has adopted the same definition.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3143712574850299, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3819503849443969, "height": 0.067579127459367, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-5", "text": "          The marketing of foodstuffs in Germany does not require an authorization from, or a notification to,\nany governmental authority. However, Article 6 of Regulation (EC) No 852/2004 of the European Parliament\nand of the Council of April 29, 2004 on the hygiene of foodstuffs (the \u201cHygiene Regulation\u201d), in conjunction\nwith the German General Administrative Regulations on the Administrative Performance of Checks to Verify\nthe Compliance with Hygiene Provisions and on the Procedure of Reviewing Guidelines on Good Practice\n(Allgemeine Verwaltungsvorschrift \u00fcber die Durchf\u00fchrung der amtlichen \u00dcberwachung der Einhaltung von\nHygienevorschriften f\u00fcr Lebensmittel und zum Verfahren zur Pr\u00fcfung von Leitlinien f\u00fcr eine gute\nVerfahrenspraxis), require every operator for a food business within the scope of the Food Regulation\n(i.e., anyone that controls any activity related to any stage of production, processing and distribution of food) to\nmaintain all of his establishments within the terms of the Hygiene Regulation (i.e., any unit of a food business)\nregistered with and approved by the competent German authorities. The Food Regulation and the LFGB prohibit\nthe production and marketing of unsafe foodstuffs (i.e., foodstuffs harmful to humans or unfit for human\nconsumption). These general rules are complemented by multiple regulations on the European and German\nlevel, in particular with respect to authorized additives, hygiene, as well as contamination and exposure to\nradiation.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5919589392643285, "height": 0.2023096663815227, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-6", "text": "         In addition to so-called vertical regulations (i.e., regulations which are applicable to foodstuffs in\ngeneral), there are so-called horizontal regimes which are only applicable to certain groups of foodstuffs. Of\nparticular relevance for Dermapharm are the regulations concerning food supplements and dietary products.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6432848588537211, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-7", "text": "13.3.1.1   Authorized Food Additives\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.6689478186484175, "height": 0.012403763900769915, "width": 0.2666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-8", "text": "         Regulation (EC) 1333/2008 and of the Council of December 16, 2008 as well as a number of related\nregulations set forth provisions on food additives food colors, sweeteners, or preservatives and their conditions\nof use, special labelling requirements with respect to foodstuffs containing certain food colors as well as rules\nregarding food enzymes and their conditions of use. The use of flavorings and substances permitted for such\nflavorings is governed by Regulation (EC) 1334/2008 of the European Parliament and of the Council of\nDecember 16, 2008 on flavorings and certain food ingredients with flavoring properties for use in and on foods.\nThe     European       regulations   are    complemented       by    the     German      Additives     Ordinance\n(Zusatzstoffzulassungs-Verordnung) and the German Flavoring Ordinance (Aromenverordnung).\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6839178785286569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7938408896492729, "height": 0.10992301112061598, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-172-9", "text": "129", "page_number": 172, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-0", "text": "13.3.1.2   Hygiene\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.14510278113663844}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-1", "text": "         Food business operators must comply with various provisions of the Hygiene Regulation, including\nrequirements relating to the condition of premises, facilities, containers and equipment used at any stage of their\nfood business. Pursuant to Article 5 of the Hygiene Regulation, food business operator are required to establish\na permanent procedure based on HACCP standards. They must perform testing when validating or verifying the\ncorrect functioning of their procedures based on HACCP principles and the guidelines on good hygiene practice\nestablished in the respective member state of the European Union in accordance with the Hygiene Regulation. If\nsuch tests are unsatisfactory, the respective product or batch of foodstuffs must be recalled. In addition,\nCommission Regulation (EC) no. 2073/2005 of November 15, 2005 on microbiological criteria for foodstuffs\nrequires food business operators to ensure that their foodstuffs comply with certain microbiological criteria. The\nGerman Food Hygiene Ordinance (Lebensmittelhygiene-Verordnung (\u201cLMHV\u201d)) sets forth hygiene\nrequirements on the German level and establishes a general obligation for food business operators to produce,\nprocess and distribute foodstuffs in a way that prevents them from being exposed to any adverse effects. In\naddition, the LMHV provides for specific provisions with respect to traditional foodstuffs and perishable food.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.17835757057313945, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-2", "text": "Contamination and Radiation\n", "page_number": 173, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.3075278015397776, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.3177929854576561, "height": 0.010265183917878506, "width": 0.2037484885126965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-3", "text": "13.3.1.3\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.31736526946107785, "height": 0.009837467921300247, "width": 0.053808948004836765}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-4", "text": "          The European and German legislators have enacted various rules and regulation with respect to the\ncontamination and radiation of foodstuffs which, inter alia, provide for limits with respect to certain substances\nin foodstuffs, the treatment of certain foodstuffs with specific radiation, a ban on offering foodstuffs which do\nnot comply with these provisions, special labelling requirements and criminal and administrative offenses\n(Straftaten oder Ordnungswidrigkeiten) in cases of non-compliance.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.334901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.402480752780154, "height": 0.067579127459367, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-5", "text": "13.3.1.4   Monitoring and Supervision\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4170230966638152, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.43028229255774164, "height": 0.013259195893926434, "width": 0.27569528415961303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-6", "text": "         The monitoring of foodstuffs and food businesses and the supervision of their compliance with\nEuropean and national food safety laws is conducted by the competent governmental authorities. Pursuant to\nRegulation (EC) No 882/2004 of the European Parliament and of the Council of April 29, 2004 on official\ncontrols performed to ensure the verification of compliance with feed and food law, animal health and animal\nwelfare rules and the LFGB, the competent governmental authorities may conduct official controls of food\nbusinesses. In case of non-compliance or suspicion of non-compliance, they authorities may take appropriate\nmeasures (e.g., ordering recalls and informing the public of the respective product and the responsible food\nbusiness operator).\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5543199315654406, "height": 0.10992301112061592, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-7", "text": "13.3.1.5   Labelling\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.5812660393498716, "height": 0.013686911890504638, "width": 0.1505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-8", "text": "         Regulation (EU) 1169/2011 of the European Parliament and of the Council of October 25, 2011 on the\nprovision of food information to consumers sets forth in detail the information to be displayed on the packaging\nof foodstuffs for consumers (e.g., the relevant foodstuff, the list of ingredients, the minimum durability and a\nnutrition declaration). This regulation is complemented by Regulation (EC) 1924/2006 of the European\nParliament and of the Council of December 20, 2006 on nutrition health claims made on foods, which governs\nclaims made on the labelling of foodstuffs with respect to certain beneficiary effects of such foodstuffs. On a\nnational level, the German Lot Identification Ordinance (Los-Kennzeichnungs-Verordnung) generally requires\nfood packages to be labelled with a certain combination of letters or numbers to enable identification of the\nrelevant foodstuffs.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7151411462788708, "height": 0.12018819503849443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-9", "text": "13.3.2   Food Supplements\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7322497861420018, "lower_right_x": 0.309552599758162, "lower_right_y": 0.7459366980325064, "height": 0.013686911890504638, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-10", "text": "          Directive 2002/46/EC of the European Parliament and of the Council of June 10, 2002 on the\napproximation of the laws of the member states relating to food supplements (the \u201cSupplements Directive\u201d)\nand the German Ordinance on Food Supplements (Verordnung \u00fcber Nahrungserg\u00e4nzungsmittel), which is based\non the LFGB and implements the Supplements Directive, provide the specific regulatory framework applicable\nto food supplements. These regulations define food supplements as concentrated foodstuffs with the specific\npurpose of supplementing the normal diet and are marketed in dose form or other similar forms. Only nutrients\nlisted in Annex I of the Supplements Directive may be used for the production of food supplements. Food\nsupplements may only be marketed as prepackaged products labelled as food supplements\n(Nahrungserg\u00e4nzungsmittel). In addition, the regulatory framework on foodstuffs also applies to food\nsupplements (see \u201c13.3.1 Foodstuffs\u201d).\n", "page_number": 173, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7591958939264328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8964927288280582, "height": 0.13729683490162536, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-173-11", "text": "130", "page_number": 173, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-0", "text": "13.3.3   Dietary Foodstuffs\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.31197097944377267, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.19165659008464328}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-1", "text": "          Regulation (EU) no. 609/2013 of the European Parliament and of the Council of June 12, 2013 on food\nintended for infants and young children, food for special medical purposes, and total diet replacement for weight\ncontrol establishes a specific regulatory framework applicable to, inter alia, the total diet replacement for weight\ncontrol (i.e., food especially formulated for use in energy restricted diets for weight reduction which, when used\nas instructed by the food business operator, replaces the whole daily diet). In particular, such dietary foodstuffs\nmust be appropriate for satisfying the nutritional requirements of, and suitable for, the persons for whom they\nare intended, in accordance with generally accepted scientific data, and may not contain any substance in such\nquantity as to endanger the health of these persons. In addition, the regulatory framework on foodstuffs also\napplies to dietary foodstuffs (see \u201c13.3.1 Foodstuffs\u201d).\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1236099230111206, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-2", "text": "13.3.4   Cosmetics\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.262617621899059, "height": 0.009837467921300247, "width": 0.13119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-3", "text": "         Regulation (EC) 1223/2009 of the European Parliament and of the Council of November 30, 2009 on\ncosmetic products (the \u201cCosmetics Regulation\u201d) establishes the regulatory framework for cosmetics on the\nEuropean level, which is complemented by the LFGB and the German Ordinance on Cosmetics (Verordnung\n\u00fcber kosmetische Mittel) on the German level. The Cosmetics Regulation and the LFGB define as cosmetics any\nsubstance or mixture intended for external use, or for use on the teeth and the mucous membranes of the oral\ncavity, for the primary or exclusive purpose of cleaning, perfuming, changing appearance, protecting,\npreserving, or deodorizing.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37510692899914455, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-4", "text": "         Pursuant to the Cosmetics Regulation, cosmetics may only be placed on the market if they are not\nharmful to humans when used under normal or reasonably foreseeable conditions. A legal or natural person\nresiding within the European Union must be designated as a responsible person for such cosmetics, taking\nresponsibility for monitoring and ensuring the manufacturer\u2019s compliance with the Cosmetics Regulation, while\nthe manufacturer is responsible for complying with GMP standards adopted by the Cosmetics Regulation. Prior\nto marketing cosmetics, the responsible person must ensure that such cosmetics have undergone a safety\nassessment in accordance with Annex I of the Cosmetics Regulation. The Cosmetic Regulation contains a list of\nprohibited substances which may not be contained in cosmetics as well as a list of restricted substances which\nmay only be used in the manufacturing process if certain conditions are met. Additional provisions of the\nCosmetics Regulation and applicable German laws deal with the use of nanomaterials, animal testing, and\nlabelling requirements as well as obligations for distributors.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.37553464499572287, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5325064157399487, "height": 0.15697177074422586, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-5", "text": "          To monitor compliance with the Cosmetics Regulation, competent authorities may perform appropriate\nchecks of cosmetics and the relevant business operators (e.g., manufacturers or retailers). In addition, these\nAuthorities may take appropriate measures to ensure compliance with the Cosmetics Regulation\n(e.g., prohibiting the marketing of cosmetics or ordering recalls and obligating the responsible person to take\ncorrective measures).\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6073567151411463, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-6", "text": "13.3.5   Import and export\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6223267750213858, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.6360136869118905, "height": 0.01368691189050475, "width": 0.18863361547763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-7", "text": "         Article 12 of the Food Regulation and Sections 53 through 57 LFGB govern the import and export of\nfoodstuffs and cosmetics into and out of Germany. Foodstuffs and cosmetics that were lawfully manufactured or\nplaced on the market in any EEA Member State may be imported into Germany without restrictions. Foodstuffs\nand cosmetics from countries outside the EEA may only be imported if they comply with the laws applicable to\nsuch products in Europe and Germany (i.e., directives are not taken into account). Any foodstuffs and cosmetics\nfrom Germany may be exported to another member state of the European Union if the respective product\ncomplies with the German rules on such products or the European regulations that apply directly in all member\nstates. Foodstuffs intended for export to states outside the European Union must comply with the laws of the\nrespective destination state, unless otherwise provided for in the laws of such state or in bilateral agreements.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6497005988023952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7733105218135158, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-174-8", "text": "131", "page_number": 174, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-175-0", "text": "13.4   Trademarks\n", "page_number": 175, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.14933494558645705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-175-1", "text": "          The registration and protection of trademarks is regulated by international, European and national\nlegislation:\n", "page_number": 175, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7587666263603386}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-175-2", "text": "\uf0b7   On an international level, trademark registration and protection are, inter alia, governed by the\n    Madrid Agreement Concerning the International Registration of Marks of June 27, 1989, as last\n    amended on September 28, 1979 (the \u201cMMA\u201d), the Protocol Relating to the Madrid Agreement\n    Concerning the International Registration of Marks of June 27, 1989, as last amended on\n    November 12, 2007 (the \u201cPMMA\u201d), and the Paris Convention for the Protection of Industrial\n    Property of March 20, 1883, as last amended on September 28, 1979.\n\uf0b7   On the European level, trademarks are governed by Directive 2008/95/EC of the European\n    Parliament and of the Council of October 22, 2008 on the approximation of the laws of the\n    member states relating to trademarks and, with respect to the creation of a union-wide trademark\n    registration and protection regime, by Council Regulation (EC) 207/2009 of February 26, 2009 on\n    the on the community trademark. In March 23, 2016, Regulation (EC) 207/2009 was amended by\n    Regulation (EU) 2015/2424 of the European Parliament and of the Council of December 16, 2015,\n    which provides for different trademark fees, technical changes as well as institutional changes to\n    the European Union Intellectual Property Office (the \u201cEUIPO\u201d). As part of a legislative package\n    to reform the European trademark regime, the Directive 2008/95/EC will be replaced by Directive\n    (EU) 2015/2436 of the European Parliament and of the Council of December 16, 2015 to\n    approximate the laws of the member states relating to trademarks, which will become effective on\n    January 15, 2019.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.15012831479897348, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4195893926432849, "height": 0.2694610778443114, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-175-3", "text": "         \uf0b7   In Germany, trademarks are governed by the German Federal Trademark Act (Markengesetz).\n          Trademarks may be registered with the respective national trademark authority (e.g., the German Patent\nand Trade Mark Office (Deutsches Patent- und Markenamt)), as well as with EUIPO for union-wide\nregistration, and, following either national or union-wide registration, via the World Intellectual Property\nOrganization in countries which are parties to the MMA or PMMA for 10-year periods. Such registrations may\nbe renewed repeatedly. Upon receiving an application, the EUIPO will examine whether there are grounds for\nrefusal of granting the trademark registration (e.g., due to earlier, identical or similar trademarks registered in a\nmember state of the European Union or a lack of distinctive character of the relevant trademark). Furthermore,\nproprietors of earlier trademarks may oppose the application for registration within three months of the\npublication of the application (e.g., if the new trademark and the products or services sold thereunder are\nidentical or similar to their trademark and the products or services sold thereunder). Upon registration of a\nEuropean trademark, the proprietor is entitled to prohibit any third party from using such trademark\ncommercially without his prior consent. In addition, national trademark laws of the member states of the\nEuropean Union stipulate that the proprietor of a European trademark is entitled to, inter alia, receive\ncompensation for damages arising from the illegal use his trademark.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42001710863986313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6227544910179641, "height": 0.20273738237810096, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-175-4", "text": "132", "page_number": 175, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-0", "text": "INFORMATION ON THE SELLING SHAREHOLDER\n", "page_number": 176, "bounding_box": {"top_left_x": 0.32406287787182586, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7351874244256348, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.4111245465538089}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-1", "text": "14.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.26541717049576785, "top_left_y": 0.08597091531223268, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-2", "text": "         The Company\u2019s sole shareholder is Themis Beteiligungs-Aktiengesellschaft, with its registered office\nat Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany, and registered in the commercial register of the local court\n(Amtsgericht) of Munich, Germany, under docket number HRB 212223.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-3", "text": "         The following table sets forth the shareholding of the Selling Shareholder immediately prior to the\nOffering, and its expected shareholding, together with the expected shareholding of the public float, upon\ncompletion of the Offering:\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2018819503849444, "height": 0.04148845166809237, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-4", "text": "                                                                                                Actual (direct) Ownership\n                                                                                                    Upon completion        Upon completion\n                                                                                                     of the Offering        of the Offering\n                                                                                                      (assuming no          (assuming full\n                                                                                                     exercise of the        exercise of the\n                                                                                                   Greenshoe Option       Greenshoe Option\n                                                                            Immediately prior      and issuance of all    and issuance of all\n                                                                             to the Offering          New Shares)            New Shares)\n                                                                                                          (in %)\nThemis Beteiligungs-Aktiengesellschaft ..........................                      100.0                     78.3                    75.0\nPublic float........................................................................     0.0                     21.7                    25.0\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.20829769033361847, "lower_right_x": 0.879081015719468, "lower_right_y": 0.334901625320787, "height": 0.12660393498716851, "width": 0.7539298669891172}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-5", "text": "        The following table sets forth the shareholders of the Selling Shareholder as of the Date of this\nProspectus:\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3900769888793841, "height": 0.027801539777587647, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-6", "text": "                                                                                            Actual (direct) Ownership\n                                                                                                      (in %)\n Mr. Wilhelm Beier ............................................................                                          80.00\n Ms. Elisabeth Beier...........................................................                                          19.26\n Mr. Michael Beier.............................................................                                           0.74\nTotal ...................................................................................                               100.00\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3964927288280582, "lower_right_x": 0.875453446191052, "lower_right_y": 0.47775876817792984, "height": 0.08126603934987164, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-7", "text": "         The Company is directly controlled by the Selling Shareholder due to its ownership of all voting rights\nin the Company and, as a result, its power to govern the financial and operating policies of the Company. The\nSelling Shareholder, in turn, is directly controlled by Mr. Wilhelm Beier due to his ownership of the majority of\nthe voting rights in the Selling Shareholder and, as a result, his power to govern the financial and operating\npolicies of the Selling Shareholder.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5748502994011976, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-176-8", "text": "133", "page_number": 176, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-0", "text": "15.   GENERAL INFORMATION ON THE COMPANY AND DERMAPHARM\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1977025392986699, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.6051995163240629}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-1", "text": "Formation, Incorporation, Commercial Name and Registered Office\n", "page_number": 177, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.11591103507271172, "lower_right_x": 0.6723095525997581, "lower_right_y": 0.1283147989734816, "height": 0.012403763900769887, "width": 0.4939540507859733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-2", "text": "15.1\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11633875106929, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.12617621899059026, "height": 0.00983746792130026, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-3", "text": "         The Company was formed as a as a European company (Societas Europaea (SE)) under European and\nGerman law by articles of association dated July 4, 2017. Its legal name was \u201cBlitz 17-663 SE\u201d with its\nregistered office in Munich, Germany, and registered in the commercial register of the local court (Amtsgericht)\nof Munich, Germany, under docket number HRB 234575. The Company\u2019s founder was Blitzstart\nGruendungs Ltd., London, United Kingdom. The Company commenced its business on July 12, 2017, the day\nthe remaining share capital at the time was fully paid in.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22412318220701455, "height": 0.08083832335329341, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-4", "text": "          On August 11, 2017, the Selling Shareholder acquired all shares in the Company through a share\npurchase and assignment agreement. On that same day, the Company\u2019s shareholders\u2019 meeting resolved to\nchange the Company\u2019s legal name to Dermapharm Holding SE and to transfer its registered office to Gr\u00fcnwald,\nGermany. The change in legal name and the transfer of the registered office were registered in the commercial\nregister of the local court (Amtsgericht) of Munich, Germany, on September 6, 2017.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2322497861420017, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2985457656116339, "height": 0.06629597946963217, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-5", "text": "         The Company is organized under European law as a European company (Societas Europaea (SE)) and\ntherefore subject to European legislations on such companies, especially to the SE Regulation. As a company\nregistered in Germany, the Company is also subject to German law. If any matter is not covered or only partially\ncovered by the SE Regulation, the provisions of German law that apply to a German stock corporation\n(Aktiengesellschaft) are also applicable to the Company. Therefore, the Company is generally governed by\nGerman law, subject to the provisions of the SE Regulation. Thus, the AktG as well as other laws applicable to\nGerman stock corporations (in particular the German Transformation Act (Umwandlungsgesetz (\u201cUmwG\u201d)), the\nHGB, the WpHG and the German Securities and Acquisition and Takeover Act (Wertpapiererwerbs- und\n\u00dcbernahmegesetz (\u201cWp\u00dcG\u201d)) may apply to the Company. In particular, German law (in particular the AktG)\napplies to capital measures of the Company (e.g., capital increases and reductions), the Company\u2018s\nshareholders\u2019 meetings and the Company\u2019s accounting.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2998289136013687, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4568006843455945, "height": 0.1569717707442258, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-6", "text": "          The Company\u2019s legal name is Dermapharm Holding SE. The Company is the holding company of\nDermapharm and primarily operates under the commercial name \u201cDermapharm\u201d. Dermapharm also operates\nunder additional commercial names, in particular \u201cmibe\u201d, \u201cH\u00fcbner\u201d and \u201caxicorp\u201d, as well as individual brands\nfor its specific pharmaceuticals and other healthcare products.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.518819503849444, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-7", "text": "         The Company has its registered office at Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany\n(telephone: +49 (0) 89 6 41 86 0) and is registered in the commercial register of the local court (Amtsgericht) of\nMunich, Germany, under docket number HRB 234575.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5667236954662105, "height": 0.04020530367835762, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-8", "text": "15.2   Fiscal Year and Duration\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5812660393498716, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.5919589392643285, "height": 0.010692899914456877, "width": 0.24667472793228534}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-9", "text": "The Company\u2019s fiscal year is the calendar year. The Company has been established for an unlimited\n", "page_number": 177, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6227544910179641, "height": 0.014114627887082953, "width": 0.7019347037484885}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-10", "text": "period.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6227544910179641, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.6360136869118905, "height": 0.013259195893926434, "width": 0.0483675937122128}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-11", "text": "15.3\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6505560307955518, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.6625320786997434, "height": 0.0119760479041916, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-12", "text": "History of Dermapharm\n", "page_number": 177, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6505560307955518, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.6638152266894782, "height": 0.013259195893926434, "width": 0.1795646916565901}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-13", "text": "         Dermapharm\u2019s business, which was established in 1991, initially focused on prescription\npharmaceuticals for the dermatology market, and Dermapharm continues to benefit from its long-standing\nexperience in this product area. Over the years, Dermapharm expanded its business through various\nacquisitions: Dermapharm\u2019s first expansions focussed on the dermatology market, including the acquisition of\nkey dermatology products from Bristol-Myers Squibb in 2002. Beginning in 2003, Dermapharm broadened its\nproduct range to encompass additional product areas, including through the acquisition of Jenapharm GmbH &\nCo. KG\u2019s therapeutic drugs division, which owned the marketing authorization for Dermapharm\u2019s current\nflagship product Dekristol\u00ae 20,000 I.E. Since 2009, Dermapharm has increasingly focused on other healthcare\nproducts, in particular acquiring several entities operating under the \u201cH\u00fcbner\u201d brand in 2010, which produce\nsupplements, dietary products and organic pharmaceuticals. In 2012, Dermapharm entered the parallel import\nbusiness to complement its other business areas by acquiring axicorp GmbH. In September 2017, Dermapharm\nfurther expanded its product offering by acquiring the right to market medical devices bite away\u00ae for the\nexternal treatment of bites and stings from insects and Herpotherm\u00ae for the treatment of herpes symptoms as\nwell as Bio-Di\u00e4t-Berlin, which develops, produces and markets OTC and other healthcare products, in particular\nfood supplements for the treatment of respiratory diseases and muscle aches. In December 2017 and January\n2018, respectively, Dermapharm furthermore acquired all shares in Strathmann and Trommsdorff.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8964927288280582, "height": 0.21941830624465353, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-177-14", "text": "134", "page_number": 177, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-0", "text": "15.4   Corporate Purpose\n", "page_number": 178, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.19770253929866988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-1", "text": "Section 2 of the Articles of Association defines the Company\u2019s corporate purpose as follows:\n1.   The Company\u2019s corporate purpose is the development, production and distribution of\n     pharmaceuticals, food supplements, cosmetics and related products, the licensing of the production\n     and/or the distribution of the aforementioned products as well as the consultation of other\n     enterprises in the aforementioned and related areas. Furthermore, the Company\u2019s corporate\n     purpose is the holding and administrating of shareholdings.\n2.   The Company may engage in any dealings and take any action connected to the aforementioned\n     areas of business or otherwise suited to directly or indirectly serve the corporate purpose.\n3.   The Company may set up branch offices and permanent establishments in and outside Germany as\n     well as establish, acquire, invest in or manage other entities in and outside Germany. The corporate\n     purpose of such subsidiaries or associated companies may include businesses outside the scope set\n     forth in no. 1 above.\n4.   The Company may limit its activities to one or several of the businesses set forth in no. 1 above.\n     The Company may also fully or partially conduct its business through subsidiaries, associated\n     companies or joint ventures. In particular, the Company may fully or partially leave its business to\n     controlled enterprises and/or outsource such business to controlled enterprises. The Company may\n     also limit its activities to functioning as a holding company and/or to administrating its own assets.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.11377245508982035, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3763900769888794, "height": 0.262617621899059, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-2", "text": "15.5   Group Structure\n", "page_number": 178, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3896492728828058, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.4033361847733105, "height": 0.013686911890504694, "width": 0.18379685610640872}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-3", "text": "          The Company is the holding company of Dermapharm. Dermapharm\u2019s business is conducted by\nDermapharm AG and its various subsidiaries. The group of consolidated companies comprising Dermapharm\nincludes all companies whose financial and business policy can be controlled by the Company, either directly or\nindirectly, and the equity interests of Dermapharm whose financial and business policy can be influenced by the\nCompany to a significant extent. As of the date of this Prospectus, Dermapharm comprises 26 companies, of\nwhich twelve are based in Germany.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4991445680068435, "height": 0.08212147134302827, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-4", "text": "15.6   Significant Subsidiaries\n", "page_number": 178, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5128314798973481, "lower_right_x": 0.34945586457073763, "lower_right_y": 0.5269461077844312, "height": 0.014114627887083064, "width": 0.22914147521160824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-5", "text": "The following table presents an overview of the Company\u2019s significant direct and indirect subsidiaries:\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1807738814993954, "top_left_y": 0.5402053036783576, "lower_right_x": 0.875453446191052, "lower_right_y": 0.5543199315654406, "height": 0.014114627887082953, "width": 0.6946795646916566}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-6", "text": "        As of the date of this Prospectus                            As of and for the fiscal year ended December 31, 2016\n                                                                                                                              Receivables\n                                    Company\u2019s                                                                Payables to         from\nLegal name and country of            share of                         Capital                 Net           Dermapharm       Dermapharm\n      incorporation                   capital       Issued capital    reserves            income/loss           AG                AG\n                                       (in %)                                            (in \u20ac million)\n acis Arzneimittel\n    GmbH, Germany .....                     100.0             0.0             0.0                  0.0                 0.0            0.2\n Anton H\u00fcbner GmbH\n    & Co. KG,\n    Germany..................          100.0(2)               7.2             9.9                  1.5                 0.0            2.0\n axicorp GmbH,\n    Germany(1)...............               100.0             0.2             7.2                    \uf02d                 0.0            0.0\n axicorp Pharma B.V.,\n    Netherlands(1) ..........               100.0             0.0             0.2                    \uf02d                 0.0            0.0\n AxiCorp Pharma\n    GmbH,\n    Germany(1)...............               100.0             0.0             0.0                    \uf02d                 0.0            0.0\n Dermapharm AG,\n    Germany                                 100.0             0.3             0.3                  3.8                   \uf02d             \uf02d\n Dermapharm AG,\n    Switzerland .............               100.0             0.1             0.0                  2.3                 0.0          14.7\n Dermapharm GmbH,\n    Austria .....................           100.0             0.0             0.5                  2.3                 0.1            3.1\n H\u00fcbner\n    Naturarzneimittel\n    GmbH, Germany .....                     100.0             0.1             0.8                  0.7                 5.7            0.0\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8999144568006844, "height": 0.33917878528656975, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-178-7", "text": "135", "page_number": 178, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-0", "text": "       As of the date of this Prospectus                            As of and for the fiscal year ended December 31, 2016\n                                                                                                                             Receivables\n                                 Company\u2019s                                                                  Payables to         from\nLegal name and country of         share of                           Capital                 Net           Dermapharm       Dermapharm\n      incorporation                capital         Issued capital    reserves            income/loss           AG                AG\n                                    (in %)                                              (in \u20ac million)\n Mibe GmbH\n   Arzneimittel,\n   Germany..................               100.0             2.5             0.0                  5.6               75.7             3.8\n", "page_number": 179, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8772672309552599, "lower_right_y": 0.18434559452523525, "height": 0.09923011120615911, "width": 0.7593712212817412}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-1", "text": "(1) These entities did not prepare individual financial statements for the fiscal year ended December 31, 2016, but were\n    included in the subgroup accounts of axicorp prepared in accordance with IFRS. For the fiscal year ended December 31,\n    2016, the consolidated net income of axicorp amounted to \u20ac3.2 million.\n(2) Dermapharm holds all limited partner\u2019s shares in Anton H\u00fcbner GmbH & Co. KG as well as all shares in Anton H\u00fcbner\n    Verwaltungsgesellschaft mbH, the sole general partner of Anton H\u00fcbner GmbH & Co. KG.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19846022241231823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.262617621899059, "height": 0.06415739948674079, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-2", "text": "15.7\n", "page_number": 179, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.276732249786142, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.2874251497005988, "height": 0.010692899914456766, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-3", "text": "Auditor\n", "page_number": 179, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.276732249786142, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.2874251497005988, "height": 0.010692899914456766, "width": 0.06287787182587667}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-4", "text": "         Warth & Klein Grant Thornton was appointed as auditor for the audited consolidated financial\nstatements of Dermapharm AG for the fiscal years ended December 31, 2016, 2015 and 2014 prepared in\naccordance with IFRS, as well as the Company\u2019s audited individual financial statements as of September 30,\n2017 and for the period from July 12, 2017 to September 30, 2017 prepared in accordance with IFRS, and\nissued in each case an unqualified audit opinion (uneingeschr\u00e4nkter Best\u00e4tigungsvermerk).\n", "page_number": 179, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3041060735671514, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37254063301967494, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"external_auditor": ["Warth & Klein Grant Thornton"], "accounting_standards": ["IFRS"]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-5", "text": "        Warth & Klein Grant Thornton is a member of the German Chamber of Public Accountants\n(Wirtschaftspr\u00fcferkammer), Rauchstra\u00dfe 26, 10787 Berlin, Germany.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3793840889649273, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.40718562874251496, "height": 0.027801539777587647, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-6", "text": "Announcements and Paying Agent\n", "page_number": 179, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.4204448246364414, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.4345594525235244, "height": 0.014114627887083009, "width": 0.25151148730350664}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-7", "text": "15.8", "page_number": 179, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42087254063301965, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.4311377245508982, "height": 0.010265183917878562, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-8", "text": "        Pursuant to the Articles of Association, the Company\u2019s announcements are published in the German\nFederal Gazette (Bundesanzeiger), unless provided otherwise by mandatory law.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.44781864841745084, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4756201881950385, "height": 0.027801539777587647, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-9", "text": "         Pursuant to Section 14 para. 2 WpPG, this Prospectus, as well as any supplements thereto, will be\npublished on the Company\u2019s website www.dermapharm.de under the section \u201cInvestor Relations\u201d. Printed\ncopies of this Prospectus are available from the Company free of charge during normal business hours at the\nfollowing address: Dermapharm Holding SE, Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4820359281437126, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5372112917023096, "height": 0.055175363558597035, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-10", "text": "The paying agent is Bankhaus Neelmeyer Aktiengesellschaft, Bremen, Germany.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.5436270316509837, "lower_right_x": 0.7255139056831923, "lower_right_y": 0.5577416595380668, "height": 0.014114627887083064, "width": 0.5453446191051996}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-179-11", "text": "136", "page_number": 179, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-0", "text": "16.   DESCRIPTION OF THE COMPANY\u2019S SHARE CAPITAL AND APPLICABLE\n                            REGULATIONS\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17533252720677148, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.111633875106929, "height": 0.02651839178785287, "width": 0.6469165659008463}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-1", "text": "16.1\n", "page_number": 180, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.12959794696321641, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.13986313088109495, "height": 0.010265183917878534, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-2", "text": "Current Share Capital; Shares\n", "page_number": 180, "bounding_box": {"top_left_x": 0.18137847642079807, "top_left_y": 0.12959794696321641, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.1424294268605646, "height": 0.012831479897348175, "width": 0.2200725513905683}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-3", "text": "         As of the date of this Prospectus, the share capital of the Company amounts to \u20ac50,000,000.00 and is\ndivided into 50,000,000 bearer shares with no par value (St\u00fcckaktien), each such share representing a notional\nvalue of \u20ac1.00. The share capital has been fully paid up. The Company\u2019s shares were created pursuant to the\nlaws of Germany.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15697177074422583, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21043627031650983, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-4", "text": "All existing shares of the Company are held by the Selling Shareholder.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.218562874251497, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.23182207014542344, "height": 0.013259195893926434, "width": 0.48428053204353083}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-5", "text": "Development of the Share Capital\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.24593669803250642, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.25962360992301114, "height": 0.013686911890504722, "width": 0.24667472793228534}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-6", "text": "16.2\n", "page_number": 180, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.24593669803250642, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.2557741659538067, "height": 0.009837467921300275, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-7", "text": "The Company\u2019s share capital has developed as follows:\n\uf0b7   On July 4, 2017, the Company, which was incorporated as a European company (Societas\n    Europaea (SE)) on that date, had a share capital of \u20ac120,000.00.\n\uf0b7   On December 6, 2017, the Company\u2019s shareholders\u2019 meeting resolved to increase the Company\u2019s\n    share capital from \u20ac120,000.00 by \u20ac49,880,000.00 to \u20ac50,000,000.00 against contributions in kind\n    in the form of 104,960 shares in Dermapharm AG by the Selling Shareholder (corresponding to\n    20.0% of the share capital of Dermapharm AG) as part of the Contribution Capital Increase (for\n    further information, see \u201c18.1.3 Contribution of all Shares in Dermapharm AG\u201d). The contribution\n    and transfer of all shares in Dermapharm AG were completed with effect from the end of\n    December 31, 2017 and the consummation of the Contribution Capital Increase was registered in\n    the commercial register of the local court (Amtsgericht) of Munich, Germany, on January 4, 2018.\n\uf0b7   Upon registration of the IPO Capital Increase, the Company\u2019s share capital will be increased from\n    \u20ac50,000,000.00 by up to \u20ac3,840,000.00 to up to \u20ac53,840,000.00. The consummation of the\n    IPO Capital Increase is expected to be registered in the commercial register of the local court\n    (Amtsgericht) of Munich, Germany, on or about February 8, 2018.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.27331052181351584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5029940119760479, "height": 0.22968349016253203, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-8", "text": "Authorized Capital\n", "page_number": 180, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.5162532078699743, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.5303678357570573, "height": 0.014114627887082953, "width": 0.14026602176541716}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-9", "text": "16.3\n", "page_number": 180, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5162532078699743, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.5265183917878529, "height": 0.010265183917878562, "width": 0.028415961305925025}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-10", "text": "         Pursuant to Section 4 para. 3 of the Articles of Association, the Management Board is authorized, with\nthe consent of the Supervisory Board, to increase the share capital of the Company prior to or on January 1,\n2023 by up to \u20ac16,100,000.00, by issuing, through a single offering or several offerings, up to 16,100,000 new\nbearer shares with no par value (St\u00fcckaktien) against contributions in cash and/or in kind. The Company expects\nthat the amount of the authorized capital will equal approximately 30% of the Company\u2019s share capital\nfollowing the consummation of the IPO Capital Increase.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5436270316509837, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6261762189905903, "height": 0.08254918733960659, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-11", "text": "         The Company\u2019s shareholders are to be granted subscription rights. However, the Management Board is\nauthorized, with the consent of the Supervisory Board, to exclude the subscription rights of the shareholders for\none or more capital increases from the authorized capital in the event of any of the following conditions:\n", "page_number": 180, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6325919589392643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6740804106073567, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-12", "text": "to exclude fractional amounts from subscription rights of the shareholders;\n", "page_number": 180, "bounding_box": {"top_left_x": 0.2079806529625151, "top_left_y": 0.6839178785286569, "lower_right_x": 0.7110036275695284, "lower_right_y": 0.6967493584260052, "height": 0.01283147989734823, "width": 0.5030229746070133}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-13", "text": "", "page_number": 180, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.6847733105218136, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.6911890504704876, "height": 0.00641573994867406, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-14", "text": "to grant subscription rights to holders or creditors, respectively, of conversion or option rights\nattached to convertible and/or option bonds that are or were issued by the Company or a national\nor foreign subsidiary in which the Company, either directly or indirectly, holds a majority of the\nvoting rights and capital, or, in case of an own conversion right of the Company, to holders or\ncreditors, respectively, being obligated thereby, preemptive rights to the extent they would be\nentitled to after exercising the conversion or option rights or after fulfilling a conversion or option\nobligation, respectively;\n", "page_number": 180, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.6971770744225834, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7998289136013687, "height": 0.10265183917878529, "width": 0.6729141475211609}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-15", "text": "", "page_number": 180, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.7082976903336184, "lower_right_x": 0.18863361547763, "lower_right_y": 0.713857998289136, "height": 0.0055603079555175405, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-180-16", "text": "137", "page_number": 180, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-181-0", "text": "\uf0b7   to increase the share capital against cash contributions pursuant to Section 186 para. 3 sentence 4\n    AktG, if the issue price of the new shares is not significantly lower than the market price of the\n    shares already listed on a stock exchange and the portion of the share capital attributable to the\n    new shares issued with an exclusion of subscription rights does not exceed a pro rata amount of\n    10% of the share capital, both at the time when the authorization takes effect and at the time when\n    the authorized share capital is utilized, provided that this 10% limit shall also include the pro rata\n    amount of the share capital attributable to: (i) new and existing shares sold or issued during the\n    term of the authorized capital on the basis of another authorization while excluding subscription\n    rights pursuant to, or in analogous application of, Section 186 para. 3 sentence 4 AktG; or\n    (ii) shares issued or issuable to satisfy convertible bonds or option bonds or bonds with a\n    conversion or option obligation, to the extent that these bonds were issued during the term of the\n    authorized capital on the basis of another authorization while excluding subscription rights of the\n    shareholders in analogous application of Section 186 para. 3 sentence 4 AktG;\n\uf0b7   to increase the share capital against contributions in kind for the issuance of shares especially for,\n    but not limited to, the purpose of acquiring enterprises, parts of enterprises, participations in\n    enterprises, and/or other assets in connection with a planned acquisition (including rights and\n    receivables); or\n\uf0b7   to issue shares as part of a participation program and/or as stock based compensation to persons,\n    who are employed by the Company (or dependent companies or companies in which the Company,\n    directly or indirectly, holds a majority interest) to the members of the Management Board and/or\n    members of the management of dependent companies or companies in which the Company,\n    directly or indirectly, holds a majority interest (or a third party who transfer the economic\n    ownership of their shares or the benefits therefrom to such persons), provided that portion of the\n    share capital attributable to the new shares issued with an exclusion of subscription rights does not\n    exceed a pro rata amount of 5% of the share capital, both at the time when the authorization takes\n    effect and at the time when the authorized share capital is utilized; the new shares may also be\n    issued to a credit institution or a company acting in the areas described in Section 53 para. 1\n    sentence 1 of the German Banking Act (Kreditwesengesetz) or Section 53b paras. 1 or 7 of the\n    German Banking Act (Kreditwesengesetz), if they assume the shares under an obligation of\n    offering them to the aforementioned persons.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5128314798973481, "height": 0.4242942686056458, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-181-1", "text": "16.4   Conditional Capital\n", "page_number": 181, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.5406330196749358, "height": 0.014114627887082953, "width": 0.20314389359129384}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-181-2", "text": "         The Company intends to create a conditional capital in an amount of \u20ac10,700,000.00 and expects that\nsuch amount will equal approximately 20% of the Company\u2019s share capital following the consummation of the\nIPO Capital Increase. The required resolutions are expected to be adopted by an extraordinary shareholders\u2019\nmeeting expected to be held on or about January 26, 2018 in connection with the IPO Capital Increase. The\nconditional capital will become effective upon registration in the commercial register. The Company expects\nthat the conditional capital will be registered in the commercial register of the local court (Amtsgericht) of\nMunich, Germany, on, or prior to, February 8, 2018.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6501283147989735, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-181-3", "text": "         Under the conditional capital, the share capital of the Company is expected to be conditionally\nincreased by up to \u20ac10,700,000.00 through the issuance of up to 10,700,000 new bearer shares with no par value\n(St\u00fcckaktien). The conditional capital increase will only be effected insofar as the holders or creditors, as the\ncase may be, of convertible bonds or option bonds or bonds with a conversion obligation, or a combination\nthereof, which have been issued by the Company or a company, in which the Company directly or indirectly\nholds a majority of the voting rights and capital, on the basis of the authorization by the Company\u2019s\nextraordinary shareholders\u2019 meeting to be held on or about January 26, 2018, exercise their conversion rights or\noptions or fulfill their conversion obligations and to the extent no other forms of fulfillment are used.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.10992301112061598, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-181-4", "text": "        The Management Board is expected to be authorized, with the consent of the Supervisory Board, to\nissue convertible bonds, or bonds with warrants or profit-sharing rights or bonds with conversion rights or\nwarrants up to a total nominal value of \u20ac450.0 million and with conversion rights or warrants for up to\n10,700,000 shares of the Company.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8280581693755347, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-181-5", "text": "138", "page_number": 181, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-0", "text": "16.5   Authorization to Purchase and Sell Treasury Shares\n", "page_number": 182, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4353083434099153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-1", "text": "         As of the date of this Prospectus, the Company does not hold any of its own shares, nor does a third\nparty hold any shares of the Company on behalf or for the account of the Company.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-2", "text": "         The Company\u2019s extraordinary shareholders\u2019 meeting expected to be held on or about January 26, 2018\nwill authorize the Management Board to purchase shares of the Company up to a total of 10% of the Company\u2019s\nshare capital (including share capital already held or attributable pursuant to law) prior to, or on, January 25,\n2023, provided the Management Board complies with the legal requirement of equal treatment. The\nManagement Board may utilize this authorization immediately following the commencement of trading of the\nCompany\u2019s shares on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange (Frankfurter\nWertpapierb\u00f6rse) with simultaneous admission to the sub-segment of the regulated market with additional post\nadmission obligations (Prime Standard) of the Frankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse).\n", "page_number": 182, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2566295979469632, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-3", "text": "The shares may be purchased:\n", "page_number": 182, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.26646706586826346, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.2788708297690334, "height": 0.012403763900769915, "width": 0.20253929866989118}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-4", "text": "\uf0b7   on the stock exchange;\n\uf0b7   by a public offer to all shareholders of the Company;\n\uf0b7   by a public invitation to the shareholders of the Company to submit offers for sale;\n\uf0b7   through derivatives; or\n\uf0b7   through a combination of the aforementioned options.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.28699743370402053, "lower_right_x": 0.7684401451027811, "lower_right_y": 0.3866552609067579, "height": 0.09965782720273736, "width": 0.5900846432889963}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-5", "text": "         The authorization may be used of for all legally permissible purposes, in particular, for one or several\nof the purposes listed below. However, an acquisition of shares by the Company for trading on the market is not\npermitted. The Management Board is authorized, with the consent of the Supervisory Board, to:\n", "page_number": 182, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.393071000855432, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4345594525235244, "height": 0.041488451668092396, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-6", "text": "\uf0b7   sell the purchased shares by any means other than through an offer to all shareholders or on the\n    stock exchange, provided that (i) the shares are sold for a cash consideration which does not\n    significantly fall short of the market price at the time of the sale and (ii) such shares do not exceed\n    10% of the share capital of the Company, both on the effective date and at the time of the\n    execution of this authorization (this limit includes (i) other shares sold or issued during the term of\n    this authorization on the basis of another authorization while excluding subscription rights\n    pursuant to, or in analogous application of, Section 186 para. 3 sentence 4 AktG; and (ii) shares\n    issued or to be issued to satisfy convertible bonds or option bonds or bonds with a conversion\n    obligation and/or convertible profit-sharing rights, to the extent such bonds and profit-sharing\n    rights, respectively, were issued during the term of this authorization on the basis of another\n    authorization while excluding subscription rights of shareholders in analogous application of\n    Section 186 para. 3 sentence 4 AktG);\n\uf0b7   transfer the purchased shares by any means other than through an offer to all shareholders or on the\n    stock exchange as consideration in kind, especially for the purpose of acquiring enterprises, parts\n    of enterprises, participations in enterprises, and/or other assets in connection with a planned\n    acquisition, including rights and receivables;\n\uf0b7   use the purchased shares to satisfy convertible bonds or option bonds or bonds with a conversion\n    or option obligation and/or convertible profit-sharing rights issued by the Company, or by\n    dependent companies or companies in which the Company holds a majority interest;\n\uf0b7   transfer the purchased shares to holders and creditors respectively, of convertible bonds or option\n    bonds or bonds with a conversion or option obligation and/or convertible profit-sharing rights\n    issued by the Company, or by dependent companies or companies in which the Company holds a\n    majority interest, to the extent they would be entitled to after exercising their conversion or option\n    rights or after fulfilling a conversion or option obligation; and\n\uf0b7   offer, transfer and/or agree to such transfer of the purchased shares as part of a participation\n    program to persons who are employed by the Company, or dependent companies or companies in\n    which the Company holds a majority interest, to the members of the Management Board and/or\n    members of the management of dependent companies or companies in which the Company holds a\n    majority interest, or a third party who transfers the economic ownership of their shares or the\n    benefits therefrom to such persons; this includes an authorization to transfer the shares free of\n    charge or at preferential price.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.44439692044482465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8986313088109495, "height": 0.4542343883661249, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-182-7", "text": "139", "page_number": 182, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-0", "text": "        To the extent the purchased shares are used for one or several purposes listed above with the consent of\nthe Supervisory Board, the subscription rights of the shareholders are excluded, if not otherwise determined by\nthe Management Board and the Supervisory Board.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-1", "text": "16.6   General Provisions Governing a Liquidation of the Company\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.13986313088109495, "lower_right_x": 0.619105199516324, "lower_right_y": 0.15397775876817793, "height": 0.014114627887082981, "width": 0.4987908101571946}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-2", "text": "           Apart from liquidation as a result of insolvency proceedings, the Company may only be liquidated with\na vote of 75% or more of the share capital represented at the vote. Furthermore, the commencement of\ninsolvency proceedings regarding the assets of the Company, the rejection of insolvency proceedings for\ninsufficient assets to cover the costs of the proceedings, a cancellation of the Company for lack of funds or the\nimposition of a final decision of the registry court about a material defect in the Articles of Association could\nlead to a cancellation of the Company. In the event of the Company\u2019s liquidation, Article 63 of the\nSE Regulation in conjunction with the AktG provide that any assets remaining once all of the Company\u2019s\nliabilities have been settled shall be distributed amongst the Company\u2019s shareholders in proportion to their\nshareholdings. The AktG provides certain protections for creditors in the event of a liquidation of the Company.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.17065868263473055, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2925577416595381, "height": 0.12189905902480752, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-3", "text": "General Provisions Governing a Change in the Share Capital\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.3075278015397776, "lower_right_x": 0.619105199516324, "lower_right_y": 0.32078699743370404, "height": 0.013259195893926434, "width": 0.439540507859734}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-4", "text": "16.7\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.31822070145423437, "height": 0.010692899914456766, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-5", "text": "         Pursuant to Articles 5, 57 and 59 of the SE Regulation in conjunction with the AktG, a resolution of the\nshareholders\u2019 meeting passed by a majority of at least 75% of the share capital represented at the vote is\nrequired to increase the share capital of a European company (Societas Europaea (SE)) and change the articles\nof association accordingly. However, the articles of association may provide that, instead of the 75% majority, a\nsimple majority of the share capital represented at the vote suffices to increase the Company\u2019s share capital,\nprovided that at least 50% of the Company\u2019s share capital is represented at the vote. Section 20 para. 3 of the\nArticles of Association has made use of this option, and consequently capital increases may be resolved by the\nCompany\u2019s shareholders\u2019 meeting with a simple majority of the share capital represented at the vote, if at least\n50% of the Company\u2019s share capital is represented at the vote.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.334901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4576561163387511, "height": 0.1227544910179641, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-6", "text": "         The shareholders\u2019 meeting may also create authorized capital. This requires a resolution passed by a\nmajority of at least 75% of the share capital represented at the vote, authorizing the Management Board to issue\na specific number of shares within a period of no more than five years. The aggregate nominal amount of the\nnew shares may not exceed 50% of the share capital existing at the time the authorization is granted (i.e., at the\ntime the authorized capital is registered in the commercial register).\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5329341317365269, "height": 0.06800684345594521, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-7", "text": "          In addition, the shareholders\u2019 meeting can create conditional capital through a resolution passed with a\nmajority of at least 75% of the share capital represented at the vote, for the purposes of (i) granting exchange or\nsubscription rights to holders of convertible bonds or other securities granting a right to subscribe for shares;\n(ii) preparing for a merger with other companies; or (iii) granting subscription rights to managers and employees\nof the Company or an affiliated company by way of an approval resolution or authorization resolution. The\nnominal amount of conditional capital may not exceed 10% of the share capital at the time the resolution is\npassed in cases where it is created to grant subscription rights to managers and employees, and may not exceed\n50% in all other cases.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6467065868263473, "height": 0.10650128314798968, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-8", "text": "          Resolutions to reduce the Company\u2019s share capital require a majority of at least 75% of the share\ncapital represented at the vote.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6843455945252352, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-9", "text": "General Provisions Governing Subscription Rights\n", "page_number": 183, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.6976047904191617, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.7117194183062446, "height": 0.014114627887082953, "width": 0.3663845223700121}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-10", "text": "16.8\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.69803250641574, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.7082976903336184, "height": 0.010265183917878451, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-11", "text": "          Article 5 of the SE Regulation in conjunction with Section 186 AktG generally grants all shareholders\nthe right to subscribe for new shares of the Company issued in case of a capital increase. The same applies to\nconvertible bonds, bonds with warrants, profit participation rights and participating bonds. Subscription rights\nare freely transferable and may be traded on German stock exchanges for a prescribed period before the deadline\nfor subscription expires. However, shareholders do not have the right to demand admission to trading for\nsubscription rights. The Company\u2019s shareholders\u2019 meeting may resolve to exclude shareholders\u2019 subscription\nrights with a vote of 75% or more of the share capital represented at the vote. Exclusion of shareholders\u2019\nsubscription rights, wholly or in part, also requires a report from the Management Board that justifies the\nexclusion to the shareholders\u2019 meeting and demonstrates that the Company\u2019s interest in excluding subscription\nrights outweighs the interests of the shareholders to be granted subscription rights. An exclusion of\nshareholders\u2019 subscription rights is, in particular, permissible if:\n", "page_number": 183, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8738237810094097, "height": 0.14884516680923865, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-12", "text": "lders\u2019 subscription rights is, in particular, permissible if:\n \uf0b7    the Company increases its share capital against cash contributions;\n", "page_number": 183, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.8738237810094097, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.8964927288280582, "height": 0.022668947818648477, "width": 0.47944377267230953}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-183-13", "text": "140", "page_number": 183, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-0", "text": "\uf0b7   the amount of the capital increase of the issued shares with no subscription rights does not exceed\n    10% of the share capital at issue, both at the time when the authorization takes effect and at the\n    time when it is authorized; and\n\uf0b7   the price at which the new shares are being issued is not materially lower than the stock exchange\n", "page_number": 184, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15739948674080412, "height": 0.06886227544910181, "width": 0.7007255139056833}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-1", "text": "             price of the Company\u2019s shares.\n\n16.9     Exclusion of Minority Shareholders\n\n16.9.1   Squeeze-Out under Stock Corporation Law\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15782720273738238, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.21899059024807527, "height": 0.06116338751069289, "width": 0.3585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-2", "text": "         Under Articles 5, 57 and 59 of the SE Regulation in conjunction with Sections 327a et seq. AktG,\nwhich govern the so-called \u201csqueeze-out under stock corporation law\u201d, upon request of a shareholder holding\n95% or more of the Company\u2019s share capital, the Company\u2019s shareholders\u2019 meeting may resolve to transfer the\nshares of minority shareholders to such majority shareholder against payment of an adequate compensation in\ncash. The amount of the cash payment offered to minority shareholders must to reflect \u201cthe circumstances of the\nCompany\u201d at the time the shareholders\u2019 meeting passes the resolution. The amount of the cash payment is based\non the full value of the Company, which is generally determined using the capitalized earnings method.\nMinority shareholders are entitled to file for a valuation proceeding (Spruchverfahren), wherein the court will\nreview the fairness (Angemessenheit) of the cash payment.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2322497861420017, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3558597091531223, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-3", "text": "2   Squeeze-Out and Tender Rights under Takeover Law\n", "page_number": 184, "bounding_box": {"top_left_x": 0.16142684401451027, "top_left_y": 0.36911890504704875, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.38323353293413176, "height": 0.014114627887083009, "width": 0.38996372430471593}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-4", "text": "16.9.2\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.1608222490931076, "lower_right_y": 0.38280581693755344, "height": 0.013686911890504694, "width": 0.04050785973397822}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-5", "text": "          Under Sections 39a and 39b Wp\u00dcG, in case of a so-called \u201csqueeze-out under takeover law\u201d, an\nofferor holding at least 95% of the voting share capital of a target company (as defined in the Wp\u00dcG) following\na takeover bid or mandatory offer, may, within three months of the expiration of the deadline for acceptance of\nthe offer, petition the regional court (Landgericht) of Frankfurt am Main, Germany, to order the transfer of the\nremaining voting shares to such offeror against payment of an adequate compensation. Such transfer does not\nrequire a resolution of the shareholders\u2019 meeting. The consideration paid in connection with the takeover or\nmandatory bid is considered adequate if the offeror has obtained at least 90% of the share capital that was\nsubject to the offer. The nature of the compensation must be the same as the consideration paid under the\ntakeover bid or mandatory offer, while at all times a cash compensation must also be offered.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.39692044482463645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.520530367835757, "height": 0.12360992301112056, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-6", "text": "         In addition, following a takeover bid or mandatory offer, the shareholders in a target company who\nhave not accepted the offer may do so up to three months after the acceptance period has expired\n(Section 39c Wp\u00dcG), provided the offeror is entitled to petition for the transfer of the outstanding voting shares\nin accordance with Section 39a Wp\u00dcG.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5299401197604791, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.583404619332763, "height": 0.05346449957228394, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-7", "text": "          The provisions for a squeeze-out under stock corporation law cease to apply once an offeror has\npetitioned for a squeeze-out under takeover law, and only apply again when these proceedings have been\ndefinitively completed.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5915312232677502, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6313088109495295, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-8", "text": "16.9.3   Squeeze-Out under Reorganization Law\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.646278870829769, "lower_right_x": 0.4588875453446191, "lower_right_y": 0.6595380667236954, "height": 0.013259195893926434, "width": 0.33857315598548976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-9", "text": "         Pursuant to Section 62 para. 5 sentence 1 UmwG, a majority shareholder holding at least 90% of the\nCompany\u2019s share capital may require the Company\u2019s shareholders\u2019 meeting to resolve to transfer the shares of\nthe minority shareholders to such majority shareholder against payment of an adequate compensation in cash,\nprovided that (i) the majority shareholder is a stock corporation (Aktiengesellschaft (AG)), a partnership limited\nby shares (Kommanditgesellschaft auf Aktien (KGaA)), or a European company (Societas Europaea (SE))\nhaving its seat in Germany; and (ii) the squeeze-out is performed to facilitate a merger under the UmwG\nbetween the majority shareholder and the Company. The shareholders\u2019 meeting held to approve the squeeze-out\nmust take place within three months of the conclusion of the merger agreement.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6736526946107785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.783147989734816, "height": 0.10949529512403755, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-10", "text": "        The procedure for a squeeze-out under the UmwG is essentially identical to the \u201csqueeze-out under\nstock corporation law\u201d described above, including the minority shareholders\u2019 right to judicial review of the\nappropriateness of the cash compensation.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7899914456800684, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8310521813515825, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-184-11", "text": "141", "page_number": 184, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-0", "text": "16.9.4   Integration\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.14087061668681986}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-1", "text": "         Under Article 9 para. 1 lit. c) (ii) of the SE Regulation in conjunction with Section 319 et seq. AktG,\nthe Company\u2019s shareholders\u2019 meeting may vote for an integration (Eingliederung) into another stock\ncorporation that has its registered office in Germany, provided the prospective parent company holds at least\n95% of the shares of the Company. The former shareholders of the Company are entitled to adequate\ncompensation, which generally must be provided in the form of shares in the parent company. In such case,\npursuant to Section 305 para. 3 sentence 1 AktG, shares must be issued based on the appropriate valuation in\ncase a merger had taken place between the two companies. Fractional amounts may be paid out in cash.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-2", "text": "16.10   Shareholder Notification Requirements; Mandatory Takeover Bids; Directors\u2019 Dealings\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8125755743651754, "lower_right_y": 0.23823781009409753, "height": 0.012831479897348175, "width": 0.6922611850060459}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-3", "text": "          Once the Company\u2019s shares are admitted to trading on the regulated market (regulierter Markt) of the\nFrankfurt Stock Exchange (Frankfurter Wertpapierb\u00f6rse) with simultaneous admission to the sub-segment of\nthe regulated market with additional post admission obligations (Prime Standard) of the Frankfurt Stock\nExchange (Frankfurter Wertpapierb\u00f6rse), the Company will be subject to WpHG provisions governing, inter\nalia, disclosure requirements for significant shareholdings, the Wp\u00dcG provisions governing takeover bids and\nmandatory offers, as well as the MAR provisions governing, inter alia, directors\u2019 obligations to disclose\ntransactions in the Company\u2019s shares, debt instruments, related derivatives or other related financial\ninstruments.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35885372112917024, "height": 0.10607356715141147, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-4", "text": "16.10.1 Notification Requirements of Shareholders\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.3896492728828058, "height": 0.013686911890504694, "width": 0.3585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-5", "text": "16.10.1.1\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.41402908468776733, "height": 0.010692899914456822, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-6", "text": "Notification Thresholds and Attribution Rules\n", "page_number": 185, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.4033361847733105, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.41659538066723695, "height": 0.013259195893926434, "width": 0.314993954050786}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-7", "text": "          Pursuant to Section 33 para. 1 WpHG, anyone who acquires or whose shareholding in any other way\nreaches or exceeds 3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the total number of voting rights in the\nCompany, is required to concurrently notify both the Company and BaFin of such occurrence. Subsequent\nnotifications are required if such person sells or in any other way falls below the aforementioned thresholds.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.43071000855431996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-8", "text": "          All such Notifications must be submitted without undue delay, and no later than within four trading\ndays. The four-day notification period starts at the time the person or entity subject to the notification\nrequirement has knowledge of or, in consideration of the circumstances should have had knowledge of, his\nproportion of voting rights reaching, exceeding or falling below the aforementioned thresholds. The WpHG\ncontains a conclusive presumption that the person or entity subject to the notification requirement has\nknowledge at the latest two trading days after such an event occurs. Moreover, a person or entity is deemed to\nalready hold shares as of the point in time such person or entity has an unconditional and due claim of transfer\nrelated to such shares. If a threshold has been reached or crossed due to a change in the total number of voting\nrights, the notification period starts at the time the person or entity subject to the notification requirement has\nknowledge about such change, or upon the publication of the revised total number of voting rights by the\nCompany, at the latest.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6432848588537211, "height": 0.15098374679213, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-9", "text": "          In connection with these requirements, Section 34 WpHG contains various attribution rules. For\nexample, voting rights attached to shares held by a subsidiary are attributed to its parent company. Similarly,\nvoting rights attached to shares held by a third party for the account of a person or entity are attributed to such\nperson or entity. Voting rights which a person or entity is able to exercise as a proxy according to such person\u2019s\nor entity\u2019s discretion are also attributed to such person or entity. Furthermore, any coordination by a person or\nentity with a third party on the basis of an agreement or in any other way generally results in an attribution of\nthe full amount of voting rights held by, or attributed to, the third party as well as to such person or entity. Such\nacting-in-concert generally requires a consultation on the exercise of voting rights or other efforts designed to\neffect a permanent and material change in the business strategy of the Company (e.g., fundamental changes to\nDermapharm\u2019s business model or a sale of a substantial part of Dermapharm\u2019s assets). Accordingly, the exercise\nof voting rights does not necessarily have to be the subject of acting-in-concert. Coordination in individual\ncases, however, is not considered as acting in concert.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6497005988023952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.16467065868263475, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-185-10", "text": "142", "page_number": 185, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-0", "text": "           Except for the 3%-threshold, similar notification requirements towards the Company and BaFin exist,\nif the aforementioned thresholds are reached, exceeded or undercut, because the shareholder holds financial\ninstruments that (i) confer to him (a) the unconditional right to acquire already issued shares of the Company to\nwhich voting rights are attached when due or (b) discretion to exercise his right to acquire such shares, or\n(ii) relate to such shares and have a similar economic effect as the aforementioned instruments, whether or not\nconferring a right to a physical settlement. Thus, the latter mentioned notification requirements also apply, for\nexample, to share swaps against cash consideration and contracts for difference. In addition, a person or entity is\nsubject to a notification requirement towards the Company and BaFin if the sum of the voting rights from shares\nand (financial) instruments held or attributed to such person or entity reaches, exceeds or falls below the\naforementioned thresholds, again excepting the 3% threshold.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-1", "text": "16.10.1.2   Exceptions to Notification Requirements\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.2356715141146279, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.24978614200171087, "height": 0.014114627887082981, "width": 0.35792019347037485}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-2", "text": "          There are certain exceptions to the notification requirements. For example, a company is exempt from\nnotification obligations if its parent company has filed a group notification pursuant to Section 37 para. 1\nWpHG. If the Company\u2019s parent company is itself a subsidiary, then the relevant company is exempt from\nnotification obligations if its parent\u2019s parent company has filed such group notification. Moreover, shares or\ninstruments held by a credit institution or a credit securities services company with a registered seat in the\nEuropean Union or in an EEA Member State are not taken into account for determining the notification\nobligation or proportion of voting rights held, provided (i) the shares or instruments are held in such credit\ninstitution\u2019s or credit securities services company\u2019s trading book, (ii) they amount to no more than 5% of the\nCompany\u2019s voting rights, do not grant the right to acquire more than 5% of the voting rights, or do not have a\nsimilar economic effect and (iii) it is ensured that the voting rights pertaining to such shares or instruments are\nnot exercised or otherwise utilized.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4127459366980325, "height": 0.14627887082976904, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-3", "text": "16.10.1.3   Fulfilment of Notification Requirements\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.43071000855431996, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.4431137724550898, "height": 0.01240376390076986, "width": 0.3536880290205562}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-4", "text": "          If any notification obligation is triggered, the notifying person or entity is required to fully complete the\nnotification form set forth as an annex to the German Securities Trading and Insider List Regulation\n(Wertpapierhandelsanzeige- und Insiderverzeichnisverordnung). The notice may be submitted either in German\nor English, in writing or via fax. Irrespective of the event triggering the notification, the notice must include\n(i) the number and proportion of voting rights, (ii) the number and proportion of instruments and (iii) the\naggregate number and proportion of voting rights and instruments held by, or attributed to, the notifying person\nor entity. In addition, the notice must include certain attribution details (e.g., the first name, surname and date of\nbirth of the notifying individual or the legal name, seat and state of a notifying entity, the event triggering the\nnotification, the date on which the threshold was reached or crossed and whether voting rights or instruments are\nattributed).\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.592814371257485, "height": 0.1347305389221557, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-5", "text": "         As a domestic issuer, the Company is required to publish such notices without undue delay, but no later\nthan three trading days after receipt, via media outlets or outlets where it can be assumed that the notice will be\ndisseminated in the entire European Union and in all EEA Member States. Such publications shall only be made\nin the English-language. The Company is also required to transmit these publications to BaFin, specifying the\ntime of publication and the media used and to the German Company Register (Unternehmensregister) for\nstorage.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6830624465355004, "height": 0.08126603934987164, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-6", "text": "Consequences of Violations of Notification Requirements\n", "page_number": 186, "bounding_box": {"top_left_x": 0.20253929866989118, "top_left_y": 0.6976047904191617, "lower_right_x": 0.594316807738815, "lower_right_y": 0.7112917023096664, "height": 0.01368691189050475, "width": 0.39177750906892383}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-7", "text": "16.10.1.4\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6976047904191617, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.7082976903336184, "height": 0.010692899914456766, "width": 0.06348246674727931}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-8", "text": "          Rights of shares held by shareholders, or from which voting rights are attributed to shareholders, do not\nexist for as long as the notification requirements are not fulfilled or not fulfilled appropriately. This temporary\nnullification of rights applies, in particular, to dividend, voting and subscription rights. However, it does not\napply to entitlements to dividend and liquidation gains if the notifications were not omitted willfully and have\nsince been submitted. If the shareholder willfully or grossly negligently fails to disclose the correct proportion of\nvoting rights held, then the rights attached to shares held by or attributed to such shareholder cease to exist for a\nperiod of six months after such shareholder has correctly filed the necessary notification, except if the variation\nwas less than 10% of the actual voting right proportion and no notification with respect to reaching, exceeding\nor falling below the aforementioned thresholds, including the 3% threshold, was omitted. In addition, a fine may\nbe imposed for failure to comply with notification obligations.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8618477331052181, "height": 0.13686911890504705, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-186-9", "text": "143", "page_number": 186, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-0", "text": "16.10.1.5   Special Notification Requirements for more than 10% of the Voting Rights\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-1", "text": "         Pursuant to Section 43 WpHG, a shareholder who reaches or exceeds the threshold of 10% of the\nvoting rights of the Company, or a higher threshold, is required to notify the Company within 20 trading days\nregarding the objective being pursued through the acquisition of such voting rights, as well as regarding the\nsource of funds used for the purchase. Changes in those objectives must also be reported within 20 trading days.\nThe Articles of Association have not made use of the option to release shareholders from this disclosure\nobligation. In calculating whether the 10%-threshold has been reached, the aforementioned attribution rules\napply.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-2", "text": "16.10.2 Mandatory Offers\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.23823781009409753, "height": 0.012831479897348175, "width": 0.18440145102781139}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-3", "text": "          Pursuant to the Wp\u00dcG, every person whose share of voting rights reaches or exceeds 30% of the voting\nrights of the Company is required to publish this fact, including the percentage of its voting rights, within seven\ncalendar days of crossing this threshold. Such publication must be furnished on the Internet and by means of an\nelectronically operated system for disseminating financial information. The Wp\u00dcG contains a series of\nprovisions intended to ensure the attribution of shareholdings to the person who actually controls the voting\nrights attached to such shares.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24935842600513258, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.33404619332763047, "height": 0.08468776732249789, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-4", "text": "          Once the share of voting rights exceeds 30% of the voting rights of the Company, such shareholder is\nrequired to make a mandatory tender offer to all shareholders of the Company. Under certain conditions, BaFin\nmay grant an exemption from this rule. If the relevant shareholder fails to give notice of reaching or exceeding\nthe 30%-threshold or fails to submit the mandatory tender offer, such shareholder is barred from exercising the\nrights associated with these shares (including voting rights and, in case of willful failure to send the notice and\nfailure to subsequently send the notice in a timely manner, the right to dividends) for the duration of the\ndelinquency. A fine may also be imposed in such cases.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34174508126603936, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43669803250641576, "height": 0.0949529512403764, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-5", "text": "16.10.3 Managers\u2019 Transactions\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.3524788391777509, "lower_right_y": 0.4649272882805817, "height": 0.01368691189050475, "width": 0.23216444981862153}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-6", "text": "           A person discharging managerial responsibilities within the meaning of Article 3 para. 1 no. 25 MAR\n(i.e., the members of the Management Board and the Supervisory Board), must notify the Company and BaFin\nof transactions undertaken for their own account relating to the Company\u2019s shares or to financial instruments\nbased on the Company\u2019s shares (subject to a \u20ac5,000.00 de-minimis exception per calendar year for all such\ntransactions). This also applies to persons closely associated with a person discharging managerial\nresponsibilities within the meaning of Article 3 para. 1 no. 26 MAR. Such notifications shall be made promptly\nand no later than three Business Days after the date of the relevant transaction. The Company shall ensure that\nsuch notifications are made public promptly and no later than three Business Days after the relevant transaction.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.588109495295124, "height": 0.1094952951240376, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-7", "text": "Short Selling Regulation (Ban on Naked Short-Selling)\n", "page_number": 187, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6017964071856288, "lower_right_x": 0.5719467956469165, "lower_right_y": 0.6159110350727117, "height": 0.014114627887082953, "width": 0.39359129383313174}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-8", "text": "16.11\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.6124893071000855, "height": 0.010692899914456766, "width": 0.03929866989117292}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-9", "text": "          Pursuant to Regulation (EU) no. 236/2012 of the European Parliament and of the Council of March 14,\n2012 on short selling and certain aspects of credit default swaps (the \u201cShort Selling Regulation\u201d), the European\nCommission\u2019s delegated regulation for the purposes of detailing the Short Selling Regulation, and the German\nEU Short Selling Implementation Act (EU-Leerverkaufs-Ausf\u00fchrungsgesetz) of November 15, 2012, the\nshort-selling of the Company\u2019s shares is only permitted under certain conditions. Additionally, under the\nprovisions of the Short Selling Regulation, significant net-short selling positions in the Company\u2019s shares must\nbe reported to BaFin and published if they exceed a specific percentage. The reporting and publication process\nis detailed in the German Regulation on Net-Short Positions (Netto-Leerverkaufspositionsverordnung) of\nDecember 17, 2012. The net short-selling positions are calculated by offsetting the short positions of a natural\nperson or legal entity in the Company\u2019s shares with its long positions in such shares. The details are regulated in\nthe Short Selling Regulation and the other regulations the European Commission enacted on short-selling. In\ncertain situations described in the Short Selling Regulation, BaFin may restrict short-selling and comparable\ntransactions.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.804961505560308, "height": 0.17579127459366983, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-187-10", "text": "144", "page_number": 187, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-0", "text": "17.   DESCRIPTION OF THE GOVERNING BODIES OF THE COMPANY\n", "page_number": 188, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5858524788391777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-1", "text": "17.1   Overview\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11591103507271172, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.12660393498716851, "height": 0.010692899914456794, "width": 0.13119709794437726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-2", "text": "        The Company\u2019s governing bodies are the Management Board, the Supervisory Board and the\nshareholders\u2019 meeting. The Company is a (Societas Europaea (SE)) and has a two-tier management and control\nsystem, consisting of the Management Board and the Supervisory Board. The responsibilities and powers of\nthese governing bodies are determined by the SE Regulation, the German Act on the SE-Implementation\n(SE-Ausf\u00fchrungsgesetz (\u201cSEAG\u201d)), the AktG, the Articles of Association and the rules of procedure of both the\nSupervisory Board and the Management Board.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22412318220701455, "height": 0.08083832335329341, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-3", "text": "          The members of the Management Board are appointed by the Supervisory Board and the Supervisory\nBoard is entitled to remove any member of the Management Board under certain circumstances. Simultaneous\nmembership in the Supervisory Board and the Management Board is not permitted under the SE Regulation, as\nthe Supervisory Board\u2019s is tasked with supervising the management of the Company by the Management Board.\nHowever, in exceptional cases and for an interim period, a member of the Supervisory Board may take a vacant\nseat on the Management Board. During this period, such individual may not perform any duties pertaining to his\nposition on the Supervisory Board. Additionally, the duration of such stand-in arrangements may not exceed one\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2245508982035928, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32763045337895635, "height": 0.10307955517536355, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-4", "text": "year.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3289136013686912, "lower_right_x": 0.154776299879081, "lower_right_y": 0.33875106928999144, "height": 0.009837467921300247, "width": 0.03385731559854896}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-5", "text": "         The Management Board is responsible for managing the Company in accordance with applicable\nEuropean and German law, the Articles of Association and its rules of procedure, including the schedule of\nresponsibilities. The Management Board represents the Company in dealings with third parties. As set out in\nArticle 40 of the SE Regulation in conjunction with the AktG, the Supervisory Board advises and oversees the\nManagement Board\u2019s administration of the Company, but is not itself authorized to manage the Company. The\nSupervisory Board may amend the Articles of Association if such amendments are purely semantic.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4294268605645851, "height": 0.08083832335329344, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-6", "text": "         The Articles of Association may designate types of transactions that may only be conducted with the\nprior approval of the Supervisory Board. In addition, the Supervisory Board may itself determine that certain\ntypes of transactions are subject to its prior approval. Matters subject to the prior approval of the Supervisory\nBoard or of a committee of the Supervisory Board pursuant to the Articles of Association or the rules of\nprocedure of the Management Board currently include:\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5051325919589392, "height": 0.06757912745936695, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-7", "text": "\uf0b7   acquisitions and disposals of enterprises, participations in enterprises and parts of enterprises, if the\n    consideration exceeds certain value thresholds determined by the Supervisory Board (except for\n    acquisitions and disposals within the group); and\n\uf0b7   the consummation of enterprise agreements on behalf of the company.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5128314798973481, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5748502994011976, "height": 0.062018819503849465, "width": 0.7007255139056832}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-8", "text": "          The Management Board is also required to obtain the prior approval of the Supervisory Board to\ncertain transactions concluded by subsidiaries of the Company if such transactions require approval of the\nSupervisory Board had they been undertaken by the Company.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6227544910179641, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-9", "text": "         In addition to the aforementioned transactions and measures, the Supervisory Board may make other\ntypes of transactions and measures subject to its prior approval by amending the rules of procedure of the\nManagement Board or the Supervisory Board or through a resolution of the Supervisory Board. The Supervisory\nBoard may also grant revocable consent in advance to a certain group of transactions in general or to individual\ntransactions that meet certain requirements.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.69803250641574, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-10", "text": "         Each member of the Management Board and Supervisory Board owes a duty of loyalty, duty of legality\nand duty of care to the Company. In discharging these duties, each member of these bodies must consider a\nbroad spectrum of interests, particularly those of the Company and its shareholders, employees and creditors. In\naddition, the Management Board must also take into consideration the shareholders\u2019 rights to equal treatment\nand equal access to information. If members of the Management Board or Supervisory Board breach their\nduties, they may be jointly and severally liable with the other members of the Management Board or the\nSupervisory Board to the Company for any damages the Company has incurred.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.704448246364414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8006843455945253, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-188-11", "text": "145", "page_number": 188, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-0", "text": "         Under German law, shareholders generally have no right to directly assert claims against members of\nthe Management Board or Supervisory Board if they believe that such members have violated their duties to the\nCompany (i.e., only the Company has the right to enforce such claims against the members of the Management\nBoard or Supervisory Board). With respect to claims against members of the Management Board, the Company\nis represented by the Supervisory Board, and with respect to claims against members of the Supervisory Board,\nthe Company is represented by the Management Board. The German Federal Supreme Court\n(Bundesgerichtshof) has ruled that the Supervisory Board is generally required to assert claims against members\nof the Management Board if it is likely that such claims can be pursued and enforced successfully, unless\nsignificant interests of the Company conflict with the pursuit of such claims and outweigh the interests of the\nCompany asserting such claims against members of the Management Board.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-1", "text": "         If either the Supervisory Board or the Management Board decides not to pursue claims of the Company\nagainst members of the respective other governing body for violations of their duties, such claims must\nnevertheless be asserted if the shareholders\u2019 meeting adopts a resolution to this effect with a simple majority of\nthe votes validly cast. The shareholders\u2019 meeting may also appoint a special representative (besonderer\nVertreter) to assert such claims. Shareholders whose aggregate shareholdings amount to 10% of the Company\u2019s\nshare capital or a pro rata share of \u20ac1 million in the Company\u2019s share capital may also motion for the competent\ncourt to appoint such a special representative. If there are facts that justify the suspicion that the Company was\nharmed by dishonesty or a gross violation of laws or the Articles of Association, shareholders whose aggregate\nshareholdings amount to 1% of the Company\u2019s share capital or a pro rata share of \u20ac100,000.00 of the\nCompany\u2019s share capital may under certain conditions assert claims of the Company against members of the\nManagement Board or Supervisory Board in their own names. However, such claims become inadmissible once\nthe Company itself files a suit to assert such claims.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.393071000855432, "height": 0.16424294268605646, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-2", "text": "         In addition, the Company\u2019s shareholders\u2019 meeting may appoint special auditors (Sonderpr\u00fcfer) to audit\ntransactions, particularly management transactions, with a simple majority of the votes validly cast. If the\nshareholders\u2019 meeting rejects a motion to appoint special auditors, the competent court shall appoint such\nspecial auditors upon a motion by shareholders whose aggregate shareholdings amount to 1% of the Company\u2019s\nshare capital or a pro rata share of \u20ac100,000.00 of the Company\u2019s share capital, if there are facts that justify the\nsuspicion that the relevant occurrence involved acts of dishonesty or gross violations of the law or the Articles\nof Association. If the shareholders\u2019 meeting has resolved to appoint special auditors, the competent court shall\nappoint different special auditors upon a motion by shareholders whose aggregate shareholdings amount to 1%\nof the Company\u2019s share capital or a pro rata share of \u20ac100,000.00 of the Company\u2019s share capital, if such\nappointment appears necessary due to reasons concerning the original special auditors.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3999144568006843, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5372112917023096, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-3", "text": "         Shareholders and shareholder associations may solicit via the shareholders\u2019 forum of the German\nFederal Gazette (Bundesanzeiger), which is also accessible via the website of the German Company Register\n(Unternehmensregister), other shareholders to file a motion, jointly or by proxy, for the appointment of special\nauditors, for the appointment of a special representative, the convention of a shareholders\u2019 meeting, or the\nexercise of voting rights in a shareholders\u2019 meeting.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5436270316509837, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6124893071000855, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-4", "text": "          The Company may only waive or settle claims for damages against members of the Management Board\nor Supervisory Board if at least three years have elapsed since such claims arose and if the shareholders\u2019\nmeeting has consented to such waiver or settlement by a simple majority vote, provided that a minority of the\nshareholders whose aggregate shareholdings amount to at least 10% of the Company\u2019s share capital does not\nobject to such resolution in the minutes of the shareholders\u2019 meeting.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6189050470487596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6877673224978614, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-5", "text": "         Under German law, neither individual shareholders nor other persons may use their influence on the\nCompany to cause a member of the Management Board or the Supervisory Board to act in a manner that would\nbe detrimental to the Company. Any person who uses his or her influence on the Company to cause a member of\nthe Management Board or the Supervisory Board, an authorized representative (Prokurist) or an authorized\nagent (Handlungsbevollm\u00e4chtigter) to act to the detriment of the Company or its shareholders may be liable to\ncompensate the Company and the affected shareholders for the resulting losses. Moreover, in this context, the\nmembers of the Management Board and Supervisory Board are jointly and severally liable in addition to the\nperson using his influence if such members acted in breach of their duty of care towards the Company.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6941830624465355, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8041060735671514, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-189-6", "text": "146", "page_number": 189, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-0", "text": "17.2   Management Board\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.2031438935912938}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-1", "text": "        Under the Articles of Association, the Management Board consists of one or more members. The\nSupervisory Board determines the exact number of the members of the Management Board. The Supervisory\nBoard may appoint members of the Management Board for a maximum term of up to five years.\nReappointments or extensions, each for a maximum term of up to five years, are permissible.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.055175363558597076, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-2", "text": "         The Supervisory Board may revoke for good cause (e.g., a gross breach of fiduciary duties, inability to\nproperly manage the Company or if the Company\u2019 shareholders\u2019 meeting has passed a vote of no-confidence\nwith respect to such member, unless the vote of no-confidence was clearly passed for arbitrary reasons) the\nappointment of a member of the Management Board prior to the expiration of the relevant member\u2019s term.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2292557741659538, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-3", "text": "         The Supervisory Board is also responsible for entering into, amending and terminating service\nagreements with members of the Management Board and, in general, for representing the Company in and out\nof court vis-\u00e0-vis the members of the Management Board.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23909324208725408, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27758768177929855, "height": 0.03849443969204447, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-4", "text": "        Pursuant to Article 9 para. 1 lit. c) (ii) of the SE Regulation in conjunction with Section 84 para. 2\nAktG, the Supervisory Board may appoint any member of the Management Board as chairperson of the\nManagement Board and any other member as deputy chairperson.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28699743370402053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32677502138579984, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-5", "text": "         If the Management Board consists of only two members, it has a quorum if both members participate in\nthe vote. If the Management Board consists of three or more members, it has a quorum if at least half of its\nmembers take part in the vote. Members of the Management Board who abstain from voting are also counted for\npurposes of calculating the quorum. Resolutions of the Management Board may also be adopted outside of\nmeetings through votes cast in writing, orally, by telefax, by email or any other customary (including electronic)\nmeans of communication or in a combination of the aforementioned forms, including by way of circular\nresolutions, as well as by combining a meeting with adopting resolutions outside of meetings. Resolutions are\npassed with a simple majority of the votes cast by the participating members of the Management Board, unless\nother majorities are required by compulsory law, the Articles of Association or the rules of procedure of the\nManagement Board. The chairperson of the Management Board does not have a deciding vote.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3272027373823781, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4704875962360992, "height": 0.1432848588537211, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-6", "text": "         The Company is represented vis-\u00e0-vis third parties and in court proceedings by two members of the\nManagement Board or a member of the Management Board jointly with any authorized representative\n(Prokurist), if the Management Board consists of several members. If only a single member of the Management\nBoard is appointed or if the Supervisory Board has authorized a single member of the Management Board to\nrepresent the Company alone, such member may solely represent the Company vis-\u00e0-vis third parties.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4786142001710864, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5461933276304534, "height": 0.06757912745936695, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-7", "text": "         The rules of procedure of the Management Board require that the delegation of responsibilities to\nindividual members of the Management Board is established on the basis of the business allocation plan\n(Gesch\u00e4ftsverteilungsplan). The business allocation plan is an annex to the rules of procedure of the\nManagement Board and may only be amended by resolution of the Supervisory Board.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6077844311377245, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-8", "text": "         Additional provisions regarding, inter alia, the composition of the Management Board, the duties of its\nmembers, the overall responsibility of the Management Board, the allocation of responsibilities for particular\nfunctions and the Management Board\u2019s internal organization are set forth in the rules of procedure of the\nManagement Board, which were adopted by the Supervisory Board on January 10, 2018.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6154833190761334, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6706586826347305, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-9", "text": "17.2.1   Members of the Management Board\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6839178785286569, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.6976047904191617, "height": 0.01368691189050475, "width": 0.314993954050786}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-10", "text": "          The following table sets forth the current members of the Management Board, their respective age and\nposition, and the duration of their respective current term:\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.739093242087254, "height": 0.02780153977758759, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-11", "text": "                                                                      Member    Appointed\nName                                                            Age    since      until                   Position\n Dr. Hans-Georg Feldmeier ..........................            55    2017(1)     2020      Chief Executive Officer\n Stefan H\u00fcmer ...............................................   53     2017       2020      Chief Financial Officer\n Stefan Grieving ............................................   52    2017(2)     2020      Chief Marketing Officer\n Karin Samusch.............................................     52    2017(3)     2020      Chief Business Development Officer\n", "page_number": 190, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7455089820359282, "lower_right_x": 0.8730350665054414, "lower_right_y": 0.8246364414029085, "height": 0.07912745936698029, "width": 0.752720677146312}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-12", "text": "(1) Dr. Feldmeier was appointed as a member of the management board of Dermapharm AG, the former parent company of\n    Dermapharm, in April 2009.\n(2) Mr. Grieving was appointed as a member of the management board of Dermapharm AG, the former parent company of\n    Dermapharm, in February 2011.\n(3) Ms. Samusch was appointed as a member of the management board of Dermapharm AG, the former parent company of\n    Dermapharm, in September 2013.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.834901625320787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9101796407185628, "height": 0.07527801539777579, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-190-13", "text": "147", "page_number": 190, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-0", "text": "Dr. Hans-Georg Feldmeier was born in Rostock, Germany, on May 7, 1962.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7055622732769045, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5272067714631197}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-1", "text": "         In 1987, Dr. Feldmeier graduated from the University of Greifswald in Pharmaceutical Sciences,\nGermany, and obtained a degree as a pharmacist (Diplom-Pharmazeut). In 1990, he also obtained his doctoral\ndegree at the Humboldt University in Berlin. Dr. Feldmeier initially joined VEB Berlin-Chemie in the former\nGerman Democratic Republic as a junior scientist. Following political changes in eastern Germany, he became\nManager of Production & Technical Services. Dr. Feldmeier\u2019s main challenge was to reorganize and refurbish\nthe manufacturing facilities in order to meet West European market standards and legal requirements, which\ntook until 2001 to complete. Following a short stint as Head of Supply Center with Schering Aktiengesellschaft,\nBerlin, in 2002, Dr. Feldmeier joined Dermapharm on January 1, 2003, as the project leader overseeing the\nconstruction of Dermapharm\u2019s Brehna facilities. Since 2009, he has been Head of Operations of Dermapharm.\nIn August 2017, Dr. Feldmeier was appointed Chief Executive Officer of Dermapharm.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.13729683490162534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-2", "text": "         Alongside his office as a member of the Management Board, Dr. Feldmeier is a member of the\nadministrative, management or supervisory bodies of and/or a partner in the following companies and\npartnerships outside Dermapharm:\n", "page_number": 191, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.24935842600513258, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.290846877673225, "height": 0.041488451668092396, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-3", "text": "\uf0b7   L.B. Bohle Maschinen und Verfahren Gesellschaft mit beschr\u00e4nkter Haftung (member of the\n    advisory board); and\n\uf0b7   O.E.M. GmbH Schneid- und Verschlei\u00dftechnik (managing director).\n", "page_number": 191, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3006843455945252, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3485885372112917, "height": 0.047904191616766456, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-4", "text": "         Other than listed above, Dr. Feldmeier has not been a member of any administrative, management or\nsupervisory body of any other company or partnership outside Dermapharm within the last five years.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38323353293413176, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-5", "text": "Stefan H\u00fcmer was born in Munich, Germany, on February 29, 1964.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3896492728828058, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.4037639007698888, "height": 0.014114627887082953, "width": 0.46977025392986693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-6", "text": "         Mr. H\u00fcmer started his career with CYANAMID GmbH and its subsidiary Durachemie GmbH & Co. as\nhead of sales processing and salesforce controlling in 1989. In 2001, he completed his professional training with\na diploma from the Munich Chamber of Industry and Commerce (Industrie- und Handelskammer) in business\nadministration and operations. Upon completion of such diploma, Mr. H\u00fcmer joined Hexal Aktiengesellschaft\nas a participation controller (Beteiligungscontroller). Following the merger between Hexal Aktiengesellschaft\nand Sandoz Group in October 2005, Mr. H\u00fcmer joined Sandoz Group, where he became International Head of\nControlling in the research and development department. In June 2006, Mr. H\u00fcmer joined Dermapharm as Head\nof Controlling and Finance. Since August 2017, Mr. H\u00fcmer has been CFO and a member of the Management\nBoard.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5303678357570573, "height": 0.12018819503849437, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-7", "text": "         Alongside his office as a member of the Management Board, Mr. H\u00fcmer is a member of the\nmanagement board of Channel 21 Holding AG. Other than that, Mr. H\u00fcmer has not been a member of any\nadministrative, management or supervisory body of any other company or partnership outside Dermapharm\nwithin the last five years.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5940975192472199, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-8", "text": "Stefan Grieving was born in Krefeld, Germany, on March 4, 1965.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6017964071856288, "lower_right_x": 0.6366384522370012, "lower_right_y": 0.6159110350727117, "height": 0.014114627887082953, "width": 0.45828295042321643}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-9", "text": "         In 1991, Mr. Grieving graduated from the University of Applied Sciences Niederrhein in\nM\u00f6nchengladbach, Germany. He holds a degree in Business Administration (Diplom als Betriebswirt).\nFollowing his graduation, Mr. Grieving joined Pharmacia as a medical representative. In 1995, he joined\npharmaceutical company Krewel-Meuselbach GmbH near Cologne as a Product Manager in the area of\nprescription branded generics. From 1998 until 2004, Mr. Grieving held the position of Head of Marketing &\nSales and later General Manager OTC and Generics Germany for STADA Arzneimittel Aktiengesellschaft in\nBad Vilbel, Germany. Before joining Dermapharm, Mr. Grieving spent six years at TAD Pharma\n(KRKA group) as Head of Marketing & Sales and later General Manager. In September 2010, Mr. Grieving\njoined Dermapharm as Head of Marketing & Sales Germany (now Chief Marketing Officer). In addition,\nMr. Grieving also heads Dermapharm\u2019s operations in Austria and Switzerland.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7596236099230111, "height": 0.13729683490162536, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-10", "text": "         Alongside his office as a member of the Management Board, Mr. Grieving has not been a member of\nany administrative, management or supervisory body of any other company or partnership outside Dermapharm\nwithin the last five years.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8075278015397775, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-191-11", "text": "148", "page_number": 191, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-0", "text": "Karin Samusch was born in Wolfratshausen, Germany, on October 1, 1965.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5181378476420798}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-1", "text": "         In 1989, Ms. Samusch began her career with seal producer Feodor Burgmann GmbH & Co. KG in\nWolfratshausen, where she was ultimately responsible for the export of mechanical seals. In that same year,\nMs. Samusch joined pharmaceutical company Dorsch GmbH, where she worked in business development,\nhuman resources and trademarks. Ms. Samusch then joined Dermapharm in 1991, where she assumed\nresponsibility for business development, international affairs as well as regulatory affairs and\npharmacovigilance. In 2000, Ms. Samusch completed her professional training with a diploma from the Munich\nChamber of Commerce (Industrie- and Handelskammer M\u00fcnchen) in marketing management. In addition,\nMs. Samusch attended the University of St. Gallen, Switzerland, to study chance and innovation management\nand obtained a certificate of advanced studies in September 2017. In 2013, Ms. Samusch was appointed\nDermapharm\u2019s Chief Business Development Officer.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.13729683490162534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-2", "text": "         Alongside her office as a member of the Management Board, Ms. Samusch has not been a member of\nany administrative, management or supervisory body of any other company or partnership outside Dermapharm\nwithin the last five years.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24935842600513258, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-3", "text": "        The members of the Management Board may be reached at the Company\u2019s office at\nLil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany (telephone: +49 (0) 89 6 41 86 0).\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.29726261762189904, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32506415739948674, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-4", "text": "17.2.2   Management Service Agreements\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34174508126603936, "lower_right_x": 0.4153567110036276, "lower_right_y": 0.35457656116338754, "height": 0.012831479897348175, "width": 0.2950423216444982}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-5", "text": "         In January 2018, the members of the Management Board entered into management service agreements\nwith the Company. These service agreements provide for employment until July 31, 2020.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.36911890504704875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39692044482463645, "height": 0.027801539777587703, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-6", "text": "17.2.3   Remuneration and Other Benefits of the Members of the Management Board\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.7152357920193471, "lower_right_y": 0.4238665526090676, "height": 0.013686911890504694, "width": 0.5949214026602176}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-7", "text": "         The compensation of the members of the Management Board under the new management service\nagreements was approved by the Supervisory Board, taking into account general market practice, legal\nrequirements in accordance with Section 87 AktG and additional recommendations of the Code. On\nDecember 6, 2017, the Company\u2019s shareholders\u2019 meeting resolved that the individual compensation of members\nof the Management Board will not be disclosed in accordance with Sections 285 no. 9 letter a) sentences 5\nthrough 8, 314 para. 1 no. 6 letter a) sentences 5 through 8 and 315e para. 1 HGB, as amended.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5201026518391788, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-8", "text": "         The compensation of the members of the Management Board consists of a fixed component and a\nvariable component.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5543199315654406, "height": 0.027801539777587703, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-9", "text": "        Under the management service agreements, the members of the Management Board are entitled to\nfixed cash compensation in an aggregate amount of approximately \u20ac1.0 million annually. Such fixed\ncompensation is payable in twelve monthly installments over the course of the respective fiscal year.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.602224123182207, "height": 0.04148845166809234, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-10", "text": "         In addition, the management service agreements provide for variable remuneration in an aggregate\namount of up to \u20ac3.6 million annually (the \u201cVariable Remuneration\u201d). At the beginning of a given fiscal year,\nthe Supervisory Board determines a target EBITDA of Dermapharm for each of the upcoming three fiscal years,\nwhich will be derived from Dermapharm\u2019s then current mid-term planning as approved by the Supervisory\nBoard. The Variable Remuneration, if any, is payable in three tranches following the adoption of the Company\u2019s\nconsolidated financial statements for the respective fiscal year, depending on the extent to which Dermapharm\u2019s\nactual EBITDA corresponds to the target EBITDA for the respective fiscal year.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7048759623609923, "height": 0.09623609923011112, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-11", "text": "         Furthermore, members of the Management Board are reimbursed for their out-of-pocket expenses\nincurred in connection with the performance of their duties. Furthermore, the members of the Management\nBoard are covered by Dermapharm\u2019s D&O insurance, the terms of which Dermapharm believes are in line with\nmarket practice and which provides for a deductible in line with the AktG (see \u201c12.11 Insurance\u201d).\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-12", "text": "       For information on the historical compensation of the members of the management board\nDermapharm AG, see \u201c18.2.1 Remuneration of the Members of the Management Board\u201d.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7728828058169376, "lower_right_x": 0.8536880290205562, "lower_right_y": 0.8006843455945253, "height": 0.027801539777587703, "width": 0.7333736396614268}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-13", "text": "of\n", "page_number": 192, "bounding_box": {"top_left_x": 0.8651753325272068, "top_left_y": 0.7737382378100941, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7857142857142857, "height": 0.0119760479041916, "width": 0.015114873035066534}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-192-14", "text": "149\n", "page_number": 192, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-0", "text": "17.3   Supervisory Board\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.19830713422007257}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-1", "text": "         In accordance with Article 9 para. 1 lit. c) (i) and 40 para. 3 of the SE Regulation in conjunction with\nSections 95 and 96 AktG and Section 10 para. 1 of the Articles of Association, the Supervisory Board consists\nof three members. All of the members are appointed by the Company\u2019s shareholders\u2019 meeting and represent the\nshareholders. Pursuant to Article 9 para 1 lit. c) (ii) of the SE Regulation in conjunction with Section 100 para. 5\nAktG, the members of the Supervisory Board as a whole shall be familiar with the industry in which the\nCompany conducts its business.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-2", "text": "          According to the Articles of Association, members of the Supervisory Board may be elected for a\nmaximum term lasting until the end of the shareholders\u2019 meeting which resolves on the discharge (Entlastung)\nof the relevant members of the Supervisory Board for the fourth fiscal year after the commencement of the term\nof office. The fiscal year in which the term of office commenced is not counted towards the aforementioned\nnumber of four years. For members of the Supervisory Board who leave office before the end of their term, a\nsuccessor shall be elected for the remaining term of the leaving member, unless the Company\u2019s shareholders\u2019\nmeeting specifies a different term for such successor. The same applies if a reelection becomes necessary due to\na challenge of a previous election. Reelection of members of the Supervisory Board is permissible.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.10992301112061592, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-3", "text": "           When electing members of the Supervisory Board, the shareholders\u2019 meeting may also appoint\nsubstitute members who shall replace any members of the Supervisory Board leaving their office before the end\nof their term or whose election has been successfully contested. The term of office of such substitute members\nshall terminate at the end of the Company\u2019s shareholders\u2019 meeting in which a successor is elected and, at the\nlatest, at the end of the term of office of the leaving member of the Supervisory Board. If the relevant substitute\nmember whose term of office was terminated due to the election of a successor was appointed as substitute\nmember for several members of the Supervisory Board, its position as substitute member shall revive.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41402908468776733, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-4", "text": "         The Supervisory Board shall elect a chairperson and a deputy chairperson from among its members to\nserve for the duration of those members\u2019 terms, unless a shorter period is determined at the time of their\nrespective election. If the chairperson or his deputy leaves office before the end of his term, the Supervisory\nBoard shall hold a new election without undue delay.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4773310521813516, "height": 0.053464499572284, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-5", "text": "         Each member of the Supervisory Board and each substitute member may resign from office with or\nwithout good cause, giving written notice one month in advance to the Management Board and the Management\nBoard shall inform the chairperson of the Supervisory Board or, in case of a resignation by the chairperson, to\nhis deputy. The chairperson of the Supervisory Board, or \uf02d in case of a resignation by the chairperson \uf02d his\ndeputy, may consent to shorten or waive such one month notice periods.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.553464499572284, "height": 0.06800684345594532, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-6", "text": "          The Supervisory Board shall hold at least two meetings in each calendar half-year. Meetings of the\nSupervisory Board are usually called at least ten calendar days in advance by the chairperson of the Supervisory\nBoard, not including the day on which the invitation is sent and the day of the meeting itself. Notice of meetings\nmay be given in writing, by telefax, by email or any other customary means of communication (including\nelectronic communication). In urgent cases, the chairperson may shorten this period and may call the meeting\norally or by telephone.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6424294268605646, "height": 0.08169375534644996, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-7", "text": "         The Articles of Association and the rules of procedure of the Supervisory Board provide that\nresolutions of the Supervisory Board shall generally be passed in meetings. At the order of the chairperson or\nwith the consent of all members of the Supervisory Board, the meetings of the Supervisory Board may also be\nheld in the form of a telephone conference or by other electronic means of communication (e.g., by video\nconference). Individual members of the Supervisory Board may be connected to the meetings via telephone or\nby other electronic means of communication (e.g., by video conference). In such cases, resolutions may also be\npassed by way of telephone conference or by other electronic means of communication (e.g., by video\nconference).\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6497005988023952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7587681779298546, "height": 0.10906757912745946, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-8", "text": "          Absent members of the Supervisory Board, or members who do not participate in, or are not connected\nto, the telephone or video conference, may also participate in the voting by submitting their votes in writing\nthrough another Supervisory Board member. In addition, such absent members may also cast their vote in oral\nform, by telephone, by telefax, by email or any other customary means of communication (including electronic\nmeans of communication) prior to or during the meeting or following the meeting within a reasonable period as\ndetermined by the chairperson of the Supervisory Board.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8481608212147135, "height": 0.08212147134302827, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-193-9", "text": "150", "page_number": 193, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-0", "text": "         Resolutions may also be adopted outside of meetings in writing, orally, by telephone, by telefax or by\nemail or any other comparable means of communication, whereas the aforementioned forms may also be\ncombined, including by way of a circular resolution, or in combination with adopting resolutions in a meeting at\nthe order of the chairperson of the Supervisory Board, if preceded by reasonable notice or if all members of the\nSupervisory Board participate in the vote. Objections to the form of voting determined by the chairperson are\nnot permitted.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16723695466210436, "height": 0.08212147134302823, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-1", "text": "          The Articles of Association and the rules of procedure for the Supervisory Board provide that the\nSupervisory Board has a quorum if at least half of its members participate in the vote. Absent members of the\nSupervisory Board who cast their vote in writing or in any other way permitted by the Articles of Association or\nthe rules of procedure of the Supervisory Board as well as any members who abstain from voting are considered\npresent for purposes of calculating the quorum. If one or more seats on the Supervisory Board remain\nunoccupied for more than two months, the Supervisory Board, no quorum is required for a vote of the\nSupervisory Board until all empty seats on the Supervisory Board have been filled.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.0962360992301112, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-2", "text": "         Unless otherwise provided for by mandatory law, resolutions of the Supervisory Board are passed with\na simple majority of the votes cast. If a vote by the Supervisory Board results in a tie, the chairperson shall have\na deciding vote.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.276732249786142, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.04148845166809234, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-3", "text": "         The Supervisory Board may adopt rules of procedure and form committees in accordance with the law\nand the Articles of Association. The Supervisory Board shall determine the composition, competences and\nprocedures of such committees, if any. To the extent permitted by law and by the Articles of Association, the\nSupervisory Board may delegate any of its duties, decision-making powers and rights to the chairperson, to any\nof the Supervisory Board member(s) or to any committee(s) established from amongst its members. The current\nversion of the Supervisory Board\u2019s rules of procedure was adopted by resolution of the Supervisory Board on\nJanuary 10, 2018.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3246364414029085, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42087254063301965, "height": 0.09623609923011117, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-4", "text": "17.3.1   Members of the Supervisory Board\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.42503022974607013, "lower_right_y": 0.4499572284003422, "height": 0.012403763900769915, "width": 0.3047158403869408}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-5", "text": "          The following table sets forth the current members of the Supervisory Board, their respective age and\nposition, and the duration of their respective current term:\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4914456800684346, "height": 0.02651839178785287, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-6", "text": "                                                                    Member   Appointed\nName                                                         Age     since     until                   Position\n Wilhelm Beier ............................................. 61     2017      2022(1)    Chairman of the Supervisory Board\n                                                                                         Deputy Chairman of the Supervisory\n Dr. Erwin Kern ............................................ 57     2017      2022(1)    Board\n Lothar Lanz ................................................. 69   2018      2022(1)    Member of the Supervisory Board\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4991445680068435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5748502994011976, "height": 0.0757057313943541, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-7", "text": "(1) The current term of the members of the Supervisory Board expires by the end of the Company\u2019s annual shareholders\u2019\n    meeting to be held in the fiscal year ending December 31, 2022.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.588109495295124, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6150556030795552, "height": 0.026946107784431184, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-8", "text": "Wilhelm Beier was born in Eicherscheid (Bad M\u00fcnstereifel), Germany, on April 21, 1956.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.6291702309666382, "lower_right_x": 0.7920193470374849, "lower_right_y": 0.6428571428571429, "height": 0.01368691189050475, "width": 0.6136638452237001}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-9", "text": "         Mr. Beier studied business administration. Starting his career in 1981, he held various positions in the\npharmaceuticals industry, including as a managing director of the German subsidiaries of an international\npharmaceuticals manufacturer. After founding Dermapharm in 1991, Mr. Beier served as Chief Executive\nOfficer of Dermapharm AG. In 2017, he was appointed as head of the Supervisory Board.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6497005988023952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7040205303678357, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-10", "text": "         Alongside his office as a member of the Supervisory Board, Mr. Beier is currently a member of the\nadministrative, management or supervisory bodies of and/or a partner in the following companies or\npartnerships outside Dermapharm:\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7112917023096664, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7519247219846023, "height": 0.04063301967493582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-11", "text": "\uf0b7   Themis Beteiligungs-Aktiengesellschaft (member of the management board);\n\uf0b7   Wilhelm Beier 1. Beteiligungsgesellschaft mbH (managing director); and\n\uf0b7   WB Medienbeteiligungsgesellschaft mbH (managing director).\n", "page_number": 194, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.7596236099230111, "lower_right_x": 0.7339782345828295, "lower_right_y": 0.8177929854576561, "height": 0.05816937553464496, "width": 0.5556227327690447}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-12", "text": "         Other than listed above, Mr. Beier has not been a member of any administrative, management or\nsupervisory body of any other company or partnership outside Dermapharm within the last five years.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8242087254063302, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8515825491873396, "height": 0.027373823781009388, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-194-13", "text": "151", "page_number": 194, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-0", "text": "Dr. Erwin Kern was born in Karlsruhe, Germany, on July 6, 1960.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.46009673518742444}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-1", "text": "         In 1986, Dr. Kern graduated from the Ludwig-Maximilian-University of Munich, obtaining a degree in\nbusiness administrations. He also obtained a doctoral degree in economics from the University of Paderborn in\n1989. Dr. Kern started his professional career as a manager of the HBK-Handel und Beteiligungen Kern GmbH\n& Co. KG in 1986. From 1991 onward, he was a member of the management board of Kies und Beton\nBaden-Baden GmbH & Co. Holding KG and Kies und Beton Aktiengesellschaft Baden-Baden. In 2007,\nDr. Kern became chairman of the management boards of these companies, offices he held until 2016. Alongside\nhis operative management activities, Dr. Kern has been engaged in various associations, predominantly in the\nconcrete industry. He currently serves as a member of the executive committee of the board of the European\nReady-Mixed Concrete Organization (ERMCO) and he was the chairman (from 2008 until 2011) and senior\nvice-chairman (from 2011 until 2013) of the Council of European Producers of Materials for Construction\n(CEPMC) (Vereinigung europ\u00e4ischer Baustoffhersteller). In 2017, Dr. Kern was appointed as a member of\nDermapharm\u2019s Supervisory Board and has been a member of the Supervisory Board since then.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.10564585115483319, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.16467065868263472, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-2", "text": "         Alongside his office as a member of the Supervisory Board, Dr. Kern is, or was within the last five\nyears, a member of the administrative, management or supervisory bodies of and/or a partner in the following\ncompanies or partnerships outside Dermapharm:\n", "page_number": 195, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.276732249786142, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31822070145423437, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-3", "text": "panies or partners\n    Currently:\n", "page_number": 195, "bounding_box": {"top_left_x": 0.16203143893591293, "top_left_y": 0.31822070145423437, "lower_right_x": 0.26481257557436516, "lower_right_y": 0.33875106928999144, "height": 0.02053036783575707, "width": 0.10278113663845223}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-4", "text": "Baden-W\u00fcrttembergische Bank (member of the advisory board);\nBeton & Graviere Service EURL (member of the management board);\nBeton- und Kies-Logistik Verwaltungs GmbH (member of the management board);\nBKG Transportbeton Verwaltungs-GmbH (member of the management board);\nBundesverband Baustoffe \u2013 Steine und Erden e.V. (vice-president of the board);\nBundesverband der Deutschen Transportbetonindustrie e.V. (president);\nDeupo Kies und Beton Vertriebs GmbH Verwaltungsgesellschaft (member of the management\nboard);\nForschungsgemeinschaft Transportbeton e.V. (FTB) (president);\nGewerbepark Iffezheim-Nordwest GmbH, Verwaltungsgesellschaft (member of the management\nboard);\nHeinz Mitteldorf Verwaltungs GmbH (member of the management board);\nIKE Iffezheimer Kies- und Edelsplittwerk Verwaltungs GmbH (member of the management\nboard);\nIndustrieverband Steine und Erden Baden-W\u00fcrttemberg e.V. (ISTE) (chairman of the advisory\nboard Transportbeton);\nin puncto Transportbeton GmbH (managing director);\nInstitut der deutschen Wirtschaft K\u00f6ln e.V. (member of the board);\nKern Verwaltungsgesellschaft mbH (member of the management board);\nKern Gesellschaft f\u00fcr Beteiligungen in der Bauzuliefererindustrie mbH, Verwaltungsgesellschaft\n(member of the management board);\nKies und Beton Aktiengesellschaft Baden-Baden (chairman of the management board);\nKieswerk Greffern Verwaltungs-GmbH (member of the management board);\nKieswerk Leiberstung Verwaltungs-GmbH (member of the management board);\nKieswerk St\u00fcrmlinger Verwaltungs-GmbH (member of the management board);\nMAK Mineralabbau Kelsterbach Verwaltungs GmbH (member of the management board);\nMRG Heinz Mitteldorf Recycling u. Baustoff-Verwertung, Verwaltungs-GmbH (member of the\n", "page_number": 195, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8857998289136013, "height": 0.5372112917023096, "width": 0.6729141475211609}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-5", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.18198307134220074, "top_left_y": 0.35201026518391787, "lower_right_x": 0.18863361547763, "lower_right_y": 0.35799828913601367, "height": 0.0059880239520958, "width": 0.006650544135429259}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-6", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.37254063301967494, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.3798118049615056, "height": 0.007271171941830634, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-7", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.39349871685201027, "lower_right_x": 0.18863361547763, "lower_right_y": 0.40034217279726264, "height": 0.006843455945252375, "width": 0.009673518742442572}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-8", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.18198307134220074, "top_left_y": 0.4170230966638152, "lower_right_x": 0.18863361547763, "lower_right_y": 0.42301112061591106, "height": 0.005988023952095856, "width": 0.006650544135429259}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-9", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.4375534644995723, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.4448246364414029, "height": 0.007271171941830634, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-10", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.45808383233532934, "lower_right_x": 0.18863361547763, "lower_right_y": 0.4649272882805817, "height": 0.006843455945252375, "width": 0.008464328899637247}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-11", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.18198307134220074, "top_left_y": 0.4820359281437126, "lower_right_x": 0.18863361547763, "lower_right_y": 0.4880239520958084, "height": 0.0059880239520958, "width": 0.006650544135429259}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-12", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5162532078699743, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.523524379811805, "height": 0.00727117194183069, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-13", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.5367835757057314, "lower_right_x": 0.18863361547763, "lower_right_y": 0.5436270316509837, "height": 0.006843455945252264, "width": 0.008464328899637247}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-14", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.18198307134220074, "top_left_y": 0.5744225834046194, "lower_right_x": 0.18863361547763, "lower_right_y": 0.5804106073567151, "height": 0.0059880239520957446, "width": 0.006650544135429259}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-15", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5949529512403764, "lower_right_x": 0.18863361547763, "lower_right_y": 0.6017964071856288, "height": 0.006843455945252375, "width": 0.009673518742442572}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-16", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.6291702309666382, "lower_right_x": 0.18863361547763, "lower_right_y": 0.6360136869118905, "height": 0.006843455945252375, "width": 0.008464328899637247}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-17", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.6642429426860564, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.6706586826347305, "height": 0.00641573994867406, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-18", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.6873396065012831, "lower_right_x": 0.18863361547763, "lower_right_y": 0.6941830624465355, "height": 0.006843455945252375, "width": 0.009673518742442572}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-19", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.7078699743370402, "lower_right_x": 0.18863361547763, "lower_right_y": 0.7147134302822925, "height": 0.006843455945252264, "width": 0.008464328899637247}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-20", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.7292557741659538, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.7356715141146278, "height": 0.00641573994867406, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-21", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.7660393498716852, "lower_right_x": 0.18863361547763, "lower_right_y": 0.7728828058169376, "height": 0.006843455945252375, "width": 0.009673518742442572}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-22", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.7865697177074422, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.7938408896492729, "height": 0.00727117194183069, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-23", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.8079555175363559, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.00641573994867406, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-24", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.8314798973481609, "lower_right_x": 0.18863361547763, "lower_right_y": 0.8370402053036784, "height": 0.0055603079555175405, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-25", "text": "\uf0b7\n", "page_number": 195, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.8515825491873396, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.8588537211291702, "height": 0.00727117194183069, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-26", "text": "", "page_number": 195, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.8729683490162532, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.8793840889649273, "height": 0.00641573994867406, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-27", "text": "management board);\n", "page_number": 195, "bounding_box": {"top_left_x": 0.2079806529625151, "top_left_y": 0.8857998289136013, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.897775876817793, "height": 0.011976047904191711, "width": 0.14510278113663844}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-195-28", "text": "152", "page_number": 195, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-0", "text": "\uf0b7   Quarzwerke Lauter Verwaltungs GmbH (member of the management board);\n\uf0b7   Riedbeton GmbH (member of the management board);\n\uf0b7   Schuler Service GmbH & Co. KG (member of the advisory board);\n\uf0b7   SPORT-ZENTRUM-MEHLISKOPF GmbH (member of the management board); and\n\uf0b7   Soci\u00e9t\u00e9 des Gravi\u00e8res de Lauterbourg S.A.S. (member of the management board).\nPreviously:\n\uf0b7   Ebert HERA Esser Holding GmbH (member of the supervisory board);\n\uf0b7   M\u00fcnchner Kies Union GmbH & Co. Sand- und Kieswerke KG (chairman of the advisory board);\n    and\n\uf0b7   Volksbank Baden-Baden Rastatt eG (member of the supervisory board).\n", "page_number": 196, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2865697177074423, "height": 0.19803250641573997, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-1", "text": "         Other than listed above, Dr. Kern has not been a member of any administrative, management or\nsupervisory body of any other company or partnership outside Dermapharm within the last five years.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.2938408896492729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3212147134302823, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-2", "text": "Lothar Lanz, was born in Bihlafingen, Germany, on October 1, 1948.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.32805816937553467, "lower_right_x": 0.6535671100362757, "lower_right_y": 0.3421727972626176, "height": 0.014114627887082953, "width": 0.47521160822249087}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-3", "text": "         From 1969 to 1974, Mr. Lanz studied at the universities in Stuttgart and Berlin, and holds a degree in\nBusiness Administration (Diplom Betriebswirt). Mr. Lanz started his professional career as an audit assistant to\nan auditor and tax advisor in Berlin. In 1977, Mr. Lanz joined Bayerische Hypotheken- und Wechselbank\nAktiengesellschaft, where he worked as a branch manager from 1983 until 1990. In 1991, Mr. Lanz became a\nmember of the managing board of H S B. HYPO Service-Bank Aktiengesellschaft, Munich. In 1996, he\ntransferred to Nassauische Sparkasse, Wiesbaden, where he also became a member of the management board. In\nthe same year, Mr. Lanz joined former ProSieben Media Aktiengesellschaft (now ProSiebenSat.1 Media AG) as\nChief Financial Officer, an office he held until 2008. From 2009 until 2014, Mr. Lanz was a member of the\nmanaging board of Axel Springer Aktiengesellschaft (now Axel Springer SE), serving as Chief Financial and\nOperating Officer.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.13729683490162536, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-4", "text": "       Alongside his office as member of the Supervisory Board, Mr. Lanz is a member of the administrative,\nmanagement or supervisory bodies of and/or a partner in the following companies or partnerships outside\nDermapharm:\n", "page_number": 196, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5333618477331052, "height": 0.04106073567151414, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-5", "text": "\uf0b7   Axel Springer SE (member of the supervisory board);\n\uf0b7   BAUWERT Aktiengesellschaft (member of the supervisory board);\n\uf0b7   Home24 AG (chairman of the supervisory board);\n\uf0b7   Kinnevik AB (member of the board of directors);\n\uf0b7   TAG Immobilien AG (deputy chairman of the supervisory board); and\n\uf0b7   Zalando SE (chairman of the supervisory board).\n", "page_number": 196, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.5414884516680923, "lower_right_x": 0.686819830713422, "lower_right_y": 0.6638152266894782, "height": 0.12232677502138589, "width": 0.5084643288996372}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-6", "text": "         Other than listed above, Mr. Lanz has not been a member of any administrative, management or\nsupervisory body of any other company or partnership outside Dermapharm within the last five years.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6702309666381523, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.69803250641574, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-7", "text": "        The members of the Supervisory Board may be reached at the Company\u2019s office at\nLil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany (telephone: +49 (0) 89 6 41 86 0).\n", "page_number": 196, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.704448246364414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7322497861420018, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-196-8", "text": "153", "page_number": 196, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-0", "text": "17.3.2   Remuneration and Other Benefits of the Members of the Supervisory Board\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7085852478839177, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.5882708585247883}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-1", "text": "         Section 15 of the Articles of Association governs the remuneration of the members of the Supervisory\nBoard. Each member receives a fixed remuneration of \u20ac70,000.00 for every full fiscal year where such person is\na member of the Supervisory Board. Persons who are members of the Supervisory Board for part of a fiscal year\nreceive a pro rata share of this fixed remuneration. The fixed remuneration is payable in four annual\ninstallments following the end of each quarter and will be paid for the first time with respect to the fiscal year\nending December 31, 2018.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-2", "text": "         In addition, members of the Supervisory Board are reimbursed for their out-of-pocket expenses\nincurred in connection with the performance of their duties. The Company also reimburses the members of the\nSupervisory Board for any VAT due on their remuneration and reimbursement for out-of-pocket expenses.\nFurthermore, the members of the Supervisory Board are covered by Dermapharm\u2019s D&O insurance, the terms\nof which Dermapharm believes are in line with market practice (see \u201c12.11 Insurance\u201d).\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2703165098374679, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-3", "text": "       For information on the historical compensation of the members of the supervisory board\nDermapharm AG, see \u201c18.2.2 Remuneration of the Members of the Supervisory Board\u201d.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8561064087061668, "lower_right_y": 0.30624465355004277, "height": 0.02609067579127461, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-4", "text": "of\n", "page_number": 197, "bounding_box": {"top_left_x": 0.8645707376058042, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2904191616766467, "height": 0.010265183917878562, "width": 0.01571946795646917}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-5", "text": "Shareholdings of the Members of the Management Board and the Supervisory Board\n", "page_number": 197, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3212147134302823, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.33447390932420873, "height": 0.013259195893926434, "width": 0.6148730350665054}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-6", "text": "17.4\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3220701454234388, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.3319076133447391, "height": 0.009837467921300302, "width": 0.029020556227327687}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-7", "text": "        As of the date of this Prospectus, neither the members of the Management Board nor the members of\nthe Supervisory Board hold any shares of the Company. However, Mr. Beier, the chairman of the Supervisory\nBoard, holds the majority of the shares of the Selling Shareholder, who in turn is the sole shareholder of the\nCompany as of the date of this Prospectus (see \u201c14. Information on the Selling Shareholder\u201d).\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3485885372112917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40290846877673225, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-8", "text": "17.5   Certain Information Regarding the Members of the Management Board and the Supervisory\n       Board\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4414029084687767, "height": 0.024379811804961515, "width": 0.7587666263603385}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-9", "text": "In the last five years, no member of the Management Board or the Supervisory Board has been:\n", "page_number": 197, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.45808383233532934, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.4721984602224123, "height": 0.014114627887082953, "width": 0.6438935912938331}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-10", "text": "\uf0b7   convicted of fraudulent offences; or\n\uf0b7   associated with any bankruptcy, receivership or liquidation acting in its capacity as a member of\n    any administrative, management or supervisory body.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4798973481608212, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5303678357570573, "height": 0.05047048759623607, "width": 0.7013301088270858}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-11", "text": "        In the last five years, no official public incriminations and/or sanctions have been pending or imposed\nby statutory or legal authorities (including designated professional bodies) against the members of the\nManagement Board or Supervisory Board.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5367835757057314, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5774165953806673, "height": 0.04063301967493582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-12", "text": "         No court has ever disqualified any of the members of the Management Board or the Supervisory Board\nfrom acting as a member of the administrative, management, or supervisory body of an issuer.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5846877673224978, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6120615911035072, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-13", "text": "         No court has ever disqualified any of the members of the Management Board or the Supervisory Board\nfrom acting in the management or conduct of the affairs of any issuer for at least the previous five years.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6189050470487596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.646278870829769, "height": 0.027373823781009388, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-14", "text": "          There are no conflicts of interest or potential conflicts of interest between the members of the\nManagement Board and Supervisory Board with respect to their duties to the Company on the one hand and\ntheir private interests, membership in governing bodies of companies, or other obligations on the other hand.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6946107784431138, "height": 0.04148845166809245, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-15", "text": "       None of the members of the Management Board or the Supervisory Board has entered into a service\nagreement with a company of Dermapharm that provides for benefits upon termination of employment or office.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.7010265183917879, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7288280581693756, "height": 0.027801539777587703, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-16", "text": "         There are no family relationships between the members of the Management Board and the Supervisory\nBoard, either among themselves or in relation to the members of the respective other body.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7352437981180496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7630453378956373, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-197-17", "text": "154", "page_number": 197, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-0", "text": "17.6     Shareholders\u2019 Meeting\n\n17.6.1   Convening of Shareholders\u2019 Meetings\n", "page_number": 198, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.1300256629597947, "height": 0.04491017964071857, "width": 0.3246674727932285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-1", "text": "         Pursuant to Article 54 para. 1 of the SE Regulation, the annual shareholders\u2019 meeting of the Company\nis held within the first six months of each fiscal year. At the choice of the body convening the shareholders\u2019\nmeeting, the meeting is held either at the registered seat of the Company or in a German city within a radius of\n50 kilometers of the Company\u2019s seat or in a German city with a stock exchange. The Company\u2019s shareholders\u2019\nmeeting is generally convened by the Management Board. Notice must be issued in the German Federal Gazette\n(Bundesanzeiger) at least 30 days before the day of the shareholders\u2019 meeting. The day of the meeting and the\nday of the receipt of the notice are disregarded when calculating this 30-day period. This period is extended for\nthe period for registration by the shareholders (see \u201c17.6.2 Shareholders\u2019 Right to participate in Shareholders\u2019\nMeetings\u201d).\n", "page_number": 198, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.26518391787852863, "height": 0.1218990590248075, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-2", "text": "          A shareholders\u2019 meeting may also be convened by the Supervisory Board. In addition, shareholders\nwhose aggregate shareholdings amount to 5% of the Company\u2019s share capital may request that a shareholders\u2019\nmeeting be held. Shareholders or shareholder associations may solicit other shareholders to submit such request,\njointly or by proxy, in the shareholders\u2019 forum of the German Federal Gazette (Bundesanzeiger), which is also\naccessible via the website of the German Company Register (Unternehmensregister). If, following a request\nsubmitted by shareholders whose aggregate shareholdings amount to 5% of the Company\u2019s share capital, a\nshareholders\u2019 meeting of the Company is not held in a timely manner, the competent local court (Amtsgericht)\nmay authorize the shareholders who have requested such meeting or their representatives to convene a\nshareholders\u2019 meeting of the Company.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.27331052181351584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39520958083832336, "height": 0.12189905902480752, "width": 0.7605804111245467}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-3", "text": "17.6.2   Shareholders\u2019 Right to participate in Shareholders\u2019 Meetings\n", "page_number": 198, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.6045949214026602, "lower_right_y": 0.4234388366124893, "height": 0.013259195893926434, "width": 0.48428053204353083}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-4", "text": "          Pursuant to the Articles of Association, all shareholders of the Company who have duly submitted\nnotification of attendance as well as evidence of their shareholdings are entitled to participate in the\nshareholders\u2019 meeting and to exercise their voting rights. The registration for participation must be received by\nthe Company by the end of the sixth day prior to the date on which the shareholders\u2019 meeting is held, unless a\nshorter period of time was set forth in the convocation for the shareholders\u2019 meeting. When calculating this\nperiod, the day of the meeting and the day of the receipt of the notice are disregarded.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5192472198460223, "height": 0.08169375534645001, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-5", "text": "         The shareholder\u2019s registration shall be submitted in the German- or English-language in writing\n(Textform) or by way of other electronic means as specified by the Company in greater detail. The evidence of\nshareholdings shall be submitted in the form of an account record by a depository institution in the German- or\nEnglish-language and in writing (Textform). Such evidence shall refer to the start of the 21 st day prior to the\nshareholders\u2019 meeting (record date) and be received by the Company at least six days prior to the meeting,\nunless a shorter period of time was set forth in the convocation notice for the shareholders\u2019 meeting. When\ncalculating such period, the day of the meeting and the day of the receipt of the notice shall be disregarded.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6218990590248076, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-6", "text": "          Voting rights may be exercised by proxy. The granting of the proxy, its revocation and the evidence of\npower of representation to be provided to the Company shall be submitted in writing (Textform), unless the\nconvening notice for the shareholders\u2019 meeting provides for a less restrictive form. The Management Board is\nauthorized to allow audio-visual transmissions of the shareholders\u2019 meeting and to allow shareholders to cast\ntheir votes in writing or by means of electronic communication without attending the shareholders\u2019 meeting\n(absentee vote). The Management Board is further authorized to allow shareholders to participate in the\nshareholders\u2019 meeting without being present in person or represented at the shareholders\u2019 meeting by exercising\nall or specific shareholder rights in total or in part by electronic communication (online participation).\n", "page_number": 198, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6291702309666382, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7386655260906758, "height": 0.10949529512403766, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-198-7", "text": "155", "page_number": 198, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-0", "text": "17.6.3   Conduct of Shareholders\u2019 Meetings\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.3101571946795647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-1", "text": "         The shareholders\u2019 meeting is chaired by the chairperson of the Supervisory Board. The shareholders\u2019\nmeeting may also be chaired by any other member of the Supervisory Board or a third party who has been\ndesignated in advance by the chairperson of the Supervisory Board. If the chairperson of the Supervisory Board\ndoes not take the chair and neither another Supervisory Board member nor a third party has been designated to\nchair the shareholders\u2019 meeting or such designee is unable to attend, the chairperson of the meeting shall be\nelected by the members of the Supervisory Board present at such shareholders\u2019 meeting. If no member of the\nSupervisory Board is present at the shareholders\u2019 meeting and neither another Supervisory Board member nor a\nthird party has been designated to chair the shareholders\u2019 meeting or such designee is unable to attend, the\nshareholders\u2019 meeting itself shall elect the chairperson of the shareholders\u2019 meeting, which vote shall be chaired\nby the shareholder, or his representative, with the highest number of shares present at the meeting.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24978614200171087, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-2", "text": "         The chairperson of the shareholders\u2019 meeting chairs the proceedings of the meeting and directs the\ncourse of the proceedings. In particular, the chairperson may exercise rules of order and make use of assistants.\nThe chairperson shall determine the sequence of speakers and the consideration of the items on the agenda as\nwell as the form, procedure and further details of voting. The chairperson may also, to the extent permitted by\nlaw, decide on the bundling of factually related items into a single resolution. The chairperson is further\nauthorized to impose a reasonable time limit on the right to ask questions and to speak. In particular, the\nchairperson may establish a limit on the time allowed to speak or ask questions or on the combined time to\nspeak and ask questions at any time during the shareholders\u2019 meeting. The chairperson may also determine an\nappropriate time frame for the course of the entire shareholders\u2019 meeting, for individual items on the agenda or\nindividual speakers. If necessary, the chairperson may order the end of the debate in the shareholders\u2019 meeting.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25620188195038496, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39349871685201027, "height": 0.1372968349016253, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-3", "text": "17.6.4   Resolutions of the Shareholders\u2019 Meeting\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.42258340461933275, "height": 0.01240376390076986, "width": 0.348851269649335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-4", "text": "         Pursuant to Section 20 para. 2 of the Articles of Association, resolutions of the shareholders\u2019 meeting\nmay generally be passed with a simple majority of the votes validly cast. If a majority of the share capital is\nrequired by law, a simple majority of the registered share capital represented at the vote shall be sufficient,\nunless mandatory law or the Articles of Association stipulate a higher majority. Amendments of the Articles of\nAssociation may be passed with a simple majority of the votes, provided that at least half of the Company\u2019s\nshare capital is represented and unless provided otherwise by mandatory law or the Articles of Association.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.518819503849444, "height": 0.0812660393498717, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-5", "text": "         According to Articles 5, 57 and 59 of the SE Regulation, and Section 51 of the SEAG in conjunction\nwith the AktG, resolutions of fundamental importance (grundlegende Bedeutung) require a majority of at least\n75% of the share capital represented at the vote. Resolutions of fundamental importance include:\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5265183917878529, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5667236954662105, "height": 0.04020530367835762, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-6", "text": "the approval to conclude, amend or terminate affiliation agreements (Unternehmensvertr\u00e4ge);\n", "page_number": 199, "bounding_box": {"top_left_x": 0.21039903264812576, "top_left_y": 0.5744225834046194, "lower_right_x": 0.841596130592503, "lower_right_y": 0.5885372112917023, "height": 0.014114627887082953, "width": 0.6311970979443773}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-7", "text": "\uf0b7\n", "page_number": 199, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5778443113772455, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.5851154833190761, "height": 0.00727117194183069, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-8", "text": "\uf0b7   the creation of conditional or authorized capital;\n\uf0b7   the issuance of, or authorization to issue, convertible and profit-sharing certificates and other\n    profit-sharing rights;\n\uf0b7   an exclusion of subscription rights as part of a capital increase by the shareholders\u2019 meeting;\n\uf0b7   an authorization on the use of treasury shares;\n\uf0b7   capital reductions;\n\uf0b7   a liquidation of the Company or a subsequent continuation of the liquidated Company;\n\uf0b7   the approval of contracts within the meaning of Section 179a AktG (transfer of the entire assets of\n    the Company) and management actions of special significance that require the approval of the\n    shareholders\u2019 meeting in compliance with legal precedents;\n\uf0b7   an integration of the Company into another corporation or a squeeze-out of the Company\u2019s\n    minority shareholders; and\n\uf0b7   any actions within the meaning of the UmwG.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.5949529512403764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8378956372968349, "height": 0.24294268605645852, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-9", "text": "        Neither German law nor the Articles of Association limit the right of foreign shareholders or\nshareholders not domiciled in Germany to hold shares or exercise the voting rights associated therewith.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8447390932420873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8725406330196749, "height": 0.02780153977758759, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-199-10", "text": "156", "page_number": 199, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-0", "text": "17.7   Corporate Governance\n", "page_number": 200, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-1", "text": "         The German Corporate Governance Code, as amended on February 7, 2017 (the \u201cCode\u201d), contains\nrecommendations and suggestions for the management and supervision of German companies listed on a stock\nexchange. The Code incorporates nationally and internationally recognized standards of good and responsible\ncorporate governance. The purpose of the Code is to increase the transparency of the German system of\ncorporate governance and supervision for investors. The Code includes recommendations and suggestions for\nmanagement and supervision with regards to shareholders and shareholders\u2019 meetings, management and\nsupervisory boards, transparency, accounting and auditing.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-2", "text": "         There is no obligation to comply with the recommendations or suggestions of the Code. However,\npursuant to Section 161 para. 1 AktG, the Management Board and the Supervisory Board are required to declare\nthat Dermapharm has either complied or will comply with the recommendations of the Code, or which\nrecommendations have not or will not be complied with, and explain why the Management Board and the\nSupervisory Board do not or will not comply with certain recommendations. This declaration must be submitted\nannually and must be made permanently accessible to the shareholders. There is no requirement to disclose any\ndeviations from the suggestions of the Code.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-3", "text": "         As of the date of this Prospectus, the Company complies with all recommendations of the Code, apart\nfrom the following:\n", "page_number": 200, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3177929854576561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3455945252352438, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-4", "text": "No. 3.8 of the Code: According to the Code\u2019s recommendations, the Company\u2019s D&O insurance\n", "page_number": 200, "bounding_box": {"top_left_x": 0.20858524788391777, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.36911890504704875, "height": 0.013686911890504694, "width": 0.6711003627569528}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-5", "text": "\uf0b7\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.3592814371257485, "lower_right_x": 0.18863361547763, "lower_right_y": 0.36484174508126604, "height": 0.0055603079555175405, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-6", "text": "    should include a deductible of at least 10% of the relevant losses, up to at least an amount of\n    1.5 times the fixed annual compensation of members of the Supervisory Board. The Company\u2019s\n    D&O insurance does not provide for a deductible with respect to coverage for members of the\n    Supervisory Board, given that the Company does not believe that such deductible would increase\n    the motivation and responsibility of the members of the Supervisory Board.\n\uf0b7   No. 4.2.5 of the Code: According to the Code\u2019s recommendations, the individual compensation of\n    the members of the Management Board should be disclosed, using the model tables provided for in\n    the Code. On December 6, 2017, the Company\u2019s shareholders\u2019 meeting resolved that the\n    individual compensation of members of the Management Board will not be disclosed in\n    accordance with Sections 285 no. 9 letter a) sentences 5 through 8, 314 para. 1 no. 6 letter a)\n    sentences 5 through 8 and 315e para. 1 HGB, as amended. Therefore, the Company will not\n    disclose such individual compensation and will not use the model tables provided for by the Code.\n\uf0b7   No. 5.3 of the Code: According to the Code\u2019s recommendations, the Supervisory Board shall form\n    committees of members with relevant expertise. In particular, the Supervisory Board shall form an\n    audit committee that addresses the monitoring of the accounting, the accounting process, the\n    effectiveness of the internal control system, the risk management system, the internal audit system,\n    the audit and compliance. The chair of such audit committee shall have specific knowledge and\n    experience in applying accounting principles and internal control procedures. In addition, the\n    Supervisory Board shall form a nomination committee composed exclusively of shareholder\n    representatives, which proposes suitable candidates to the Supervisory Board for its\n    recommendations to the General Meeting. The Supervisory Board has not formed any committees,\n    given that the Supervisory Board is comprised of just three members and can therefore efficiently\n    fulfil its functions without the help of any committees.\n\uf0b7   No. 5.4.6 of the Code: According to the Code\u2019s recommendations, the compensation of individual\n    members of the Supervisory Board should take into account their status as chairman or deputy\n    chairman of the Supervisory Board, if applicable, as well as any membership in committees of the\n    Supervisory Board. Given that the Supervisory Board comprises just three members, the Company\n    believes that there is no need to provide for additional remuneration for the chairman or deputy\n    chairman of the Supervisory Board. In addition, due to the fact that the Supervisory Board has not\n    formed any committees, there is no need to provide for additional remuneration for membership in\n    any committees.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.369546621043627, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.4448246364414029, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-200-7", "text": "157", "page_number": 200, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-201-0", "text": "\uf0b7   No. 7.1.2 of the Code: According to the Code\u2019s recommendations, the Company\u2019s consolidated\n    financial statements and the respective management report for a given fiscal year should be\n    published within 90 days from the end of such fiscal year, and its consolidated interim financial\n    statements and the respective management report should be published within 45 days from the end\n    of the respective reporting period. The Company will publish its consolidated financial statements\n    and the respective management reports in accordance with applicable regulations and may\n    therefore not comply with the shorter periods provided for by the Code. The Company does not\n    believe that an accelerated publication of its consolidated financial statements would serve the\n    interests of investors, creditors, employees or the general public.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.12018819503849446, "width": 0.7001209189842805}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-201-1", "text": "158", "page_number": 201, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-0", "text": "18.   CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS\n", "page_number": 202, "bounding_box": {"top_left_x": 0.19649334945586458, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.6064087061668681}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-1", "text": "         In accordance with IAS 24, transactions with persons or companies that are, inter alia, members of the\nsame group as the Company or that are in control of or controlled by the Company must be disclosed unless\nthey are already included as consolidated companies in the Company\u2019s audited consolidated financial\nstatements. Control exists if a shareholder owns more than one half of the voting rights in the Company or, by\nvirtue of an agreement, has the power to control the financial and operating policies of the Company\u2019s\nmanagement. The disclosure requirements under IAS 24 also extend to transactions with associated companies\n(including joint ventures) as well as transactions with persons who have significant influence on the Company\u2019s\nfinancial and operating policies, including close family members and intermediate entities. This includes the\nmembers of the Management Board and Supervisory Board and close members of their families, as well as\nthose entities over which the members of the Management Board and Supervisory Board or their close family\nmembers are able to exercise a significant influence or in which they hold a significant share of the voting\nrights.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2771599657827203, "height": 0.16467065868263475, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-2", "text": "         Set forth below in is a summary of such transactions with related parties for the fiscal years ended\nDecember 31, 2014, 2015 and 2016, the nine-month period ended September 30, 2017 and up to and including\nthe date of this Prospectus. Further information, including quantitative amounts, of related-party transactions\nare contained in the notes to Dermapharm AG\u2019s audited consolidated financial statements as of and for the\nfiscal years ended December 31, 2016, 2015 and 2014, and the unaudited interim condensed consolidated\nfinancial statements as of and for the nine-month period ended September 30, 2017, which are all included in\nthe Section \u201c22. Financial Information\u201d on pages F-16 et seq. and F-84 et seq. of this Prospectus. Business\nrelationships between companies of Dermapharm are not included.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28357570573139435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39349871685201027, "height": 0.10992301112061592, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-3", "text": "18.1     Relationships and Transactions with Related Parties\n\n18.1.1   Profit Transfer Agreement\n", "page_number": 202, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.4516680923866553, "height": 0.041488451668092396, "width": 0.43591293833131795}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-4", "text": "         On April 13, 2016, Dermapharm AG and the Selling Shareholder entered into the Profit Transfer\nAgreement to create fiscal units for tax purposes with retroactive effect from January 1, 2016. The Profit\nTransfer Agreement replaced an existing profit transfer agreement dated December 13, 2015, which was\nterminated by Dermapharm and the Selling Shareholder with effect from December 31, 2015. Under the Profit\nTransfer Agreement, Dermapharm AG was required to transfer its entire profits, if any, to the Selling\nShareholder, who in turn was required to assume Dermapharm AG\u2019s losses in any given fiscal year, if any (in\neach case, as determined by Dermapharm AG\u2019s individual annual financial statements prepared in accordance\nwith HGB).\n", "page_number": 202, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5731394354148845, "height": 0.10821214713430283, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-5", "text": "         The Profit Transfer Agreement was terminated with effect from the end of December 31, 2017.\nDermapharm AG is required to transfer its profits for the fiscal year ended December 31, 2017, if any, to the\nSelling Shareholder. However, Dermapharm AG has provided the Selling Shareholder with certain shareholder\nloans. Consequently, the claims of the Selling Shareholder under the Profit Transfer Agreement with respect to\nthe fiscal year ended December 31, 2017 will be offset against Dermapharm AG\u2019s claims under these\nshareholder loans and Dermapharm AG expects that its claims will exceed those of the Selling Shareholder by\nmore than \u20ac50 million.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6740804106073567, "height": 0.09281437125748504, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-6", "text": "18.1.2   Indemnification Agreement with respect to UniCredit Litigation\n", "page_number": 202, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6907613344739093, "lower_right_x": 0.6221281741233373, "lower_right_y": 0.7048759623609923, "height": 0.014114627887082953, "width": 0.5018137847642079}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-7", "text": "         Dermapharm is currently involved in litigation with UniCredit, whereby Dermapharm demands the\nrescission of certain currency related swap transactions entered into with UniCredit between 2006 and 2010 as\nwell as compensation for all damages incurred in connection with these swaps (see \u201c12.12 Litigation\u201d). On\nDecember 21, 2015, Dermapharm AG and the Selling Shareholder entered into an indemnification agreement\n(the \u201cIndemnification Agreement\u201d), pursuant to which Dermapharm assigned its claims against UniCredit to\nthe Selling Shareholder. In turn, the Selling Shareholder has agreed to assume any payments required from\nDermapharm to UniCredit under the currency related swap transactions as well as attorneys\u2019 fees in connection\nwith the proceedings at the regional court (Landgericht) of Munich, unless Dermapharm AG has set up a\nprovision for such costs in its consolidated statement of financial position as of December 31, 2015. As a result\nof the Indemnification Agreement, the Selling Shareholder has effectively assumed the majority of the\noutstanding risks and payment obligations associated with the currency related swap transactions with\n", "page_number": 202, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.878956372968349, "height": 0.16082121471343036, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-202-8", "text": "159", "page_number": 202, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-0", "text": "18.1.3   Contribution of all Shares in Dermapharm AG\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.38754534461910517}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-1", "text": "         On December 6, 2017, the Company\u2019s shareholders\u2019 meeting resolved to increase the Company\u2019s share\ncapital from \u20ac120,000.00 by \u20ac49,880,000.00 to \u20ac50,000,000.00 by issuing 49,880,000 new shares in the\nCompany against contributions in kind in the form of 104,960 shares in Dermapharm AG (the \u201cContribution\nCapital Increase\u201d) by the Selling Shareholder (corresponding to 20.0% of the share capital of\nDermapharm AG). In addition, the Selling Shareholder contributed the remaining 419,840 shares in\nDermapharm AG (corresponding to 80.0% of the share capital of Dermapharm AG) to the Company\u2019s free\nreserves (freie R\u00fccklagen) without consideration.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-2", "text": "         The contribution and transfer of all shares in Dermapharm AG were completed with effect from the end\nof December 31, 2017 and the consummation of the Contribution Capital Increase was registered in the\ncommercial register of the local court (Amtsgericht) of Munich, Germany, on January 4, 2018. Warth & Klein\nGrant Thornton acted as auditor with respect to the Contribution Capital Increase pursuant to\nSection 183 para. 3 AktG.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2840034217279726, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-3", "text": "18.1.4   Cost Sharing and Indemnity Agreement\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.3135158254918734, "height": 0.012831479897348175, "width": 0.3391777509068924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-4", "text": "         On January 25, 2017, the Selling Shareholder and the Company entered into an agreement regarding\ntheir cooperation relating to the preparation of the Offering. As required by law, the Selling Shareholder has\nagreed that it will reimburse the Company for all external costs incurred in connection with the preparation and\nthe execution of the Offering (except for costs relating to certain corporate measures such as the IPO Capital\nIncrease) on a pro rata basis calculated in accordance with the ratio of (i) the gross proceeds from the Existing\nShares placed in the Offering to (ii) the sum of the gross proceeds from the Existing Shares and the New Shares\nplaced in the Offering. The costs for which the Selling Shareholder will reimburse the Company include legal,\nauditor and other advisors\u2019 fees as well as expenses, for which the Company has agreed to reimburse the Sole\nBookrunner. With respect to commissions to be paid to the Sole Bookrunner in connection with the Offering,\nsee \u201c19.3 Commission\u201d.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4619332763045338, "height": 0.13387510692899912, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-5", "text": "         The obligations of the Selling Shareholder to reimburse the Company remain unaffected if the Offering\nis postponed or terminated. As required by law, the Selling Shareholder has also agreed to indemnify the\nCompany from any potential liability in connection with the Offering on a pro rata basis in accordance with the\naforementioned ratio, including for the pro rata share of any reasonable legal costs and expenses. Furthermore,\nthe Company has agreed that upon indemnification by the Selling Shareholder and to the extent legally\npermissible, it will assign certain claims the Company may have against members of the Management Board or\nthe Supervisory Board or third parties to the Selling Shareholder.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.47177074422583404, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.567579127459367, "height": 0.09580838323353297, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-6", "text": "18.1.5   Sale of Centuere Beteiligungs-Aktiengesellschaft i.L.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.5459492140266021, "lower_right_y": 0.5953806672369547, "height": 0.014114627887083064, "width": 0.4256348246674727}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-7", "text": "         On December 31, 2015, Dermapharm sold and transferred a 75.1%-stake in Centuere to the Selling\nShareholder for a consideration of \u20ac6.5 million. The sale of Centuere helped end marginal activities not relating\nto Dermapharm\u2019s pharma business and thereby focus on the core business. A negative result in an amount of\n\u20ac0.7 million was recognized in other operating expenses in the consolidated statement of comprehensive income\nof Dermapharm AG in connection with the sale of Centuere.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6770744225834047, "height": 0.06843455945252352, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-8", "text": "18.1.6   Sale of SLG Service Logistik G\u00fcnthersdorf GmbH\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6907613344739093, "lower_right_x": 0.528415961305925, "lower_right_y": 0.7048759623609923, "height": 0.014114627887082953, "width": 0.40810157194679564}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-9", "text": "         On December 31, 2015, Dermapharm sold and transferred its shares in SLG to the Selling Shareholder\nfor a consideration of \u20ac25,000.00. The sale of SLG helped end marginal activities not relating to Dermapharm\u2019s\npharma business and thereby focus on the core business. A positive result in an amount of \u20ac0.6 million was\nrecognized in other operating income in the consolidated statement of comprehensive income of\nDermapharm AG in connection with the sale of SLG Service Logistik G\u00fcnthersdorf GmbH.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7869974337040205, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-203-10", "text": "160", "page_number": 203, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-0", "text": "18.1.7   Other Relations with the Selling Shareholder\n\n         The following table shows the payments made by Dermapharm to the Selling Shareholder for the\nperiods indicated:\n", "page_number": 204, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.055175363558597104, "width": 0.7599758162031439}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-1", "text": "                                                                                                                                        For the\n                                                                                                                                      nine-month\n                                                                                          For the fiscal year                       period ended\n                                                                                         ended December 31,                         September 30,\n                                                                             2014                 2015                2016               2017\n                                                                                  (audited, unless otherwise specified)               (unaudited)\n                                                                                              (in \u20ac million)                         (in \u20ac million)\n Profit transfer agreement .........................................................11.2              25.9                   24.4             66.9\n Financial instruments ...............................................................0.6              1.6                   15.3                \uf02d\n Purchase of goods ....................................................................  \uf02d               \uf02d                      \uf02d              0.3\n Indirect taxes from tax group ...................................................    4.2                \uf02d                    3.8              9.3\n Interest .....................................................................................\n                                                                                      1.2                \uf02d                    1.6                \uf02d\n Consultancy services ............................................................... 0.2              0.4                    0.6              0.7\n Other services ..........................................................................\n                                                                                      0.6                \uf02d                    0.9              0.4\n Loans .......................................................................................\n                                                                                    23.9               2.2                      \uf02d                \uf02d\n Sale of companies ....................................................................  \uf02d             7.2                      \uf02d                \uf02d\n                                                                                    41.9\nTotal (unaudited) .....................................................................               37.3                   46.6             77.6\n", "page_number": 204, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.14713430282292558, "lower_right_x": 0.875453446191052, "lower_right_y": 0.3759623609923011, "height": 0.22882805816937554, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-2", "text": "          The following table shows the payments received by Dermapharm from the Selling Shareholder and its\naffiliates for the periods indicated:\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.42899914456800686, "height": 0.02566295979469635, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-3", "text": "                                                                                                                                  For the\n                                                                                                                                nine-month\n                                                                                     For the fiscal year                      period ended\n                                                                                    ended December 31,                        September 30,\n                                                                        2014                 2015                2016              2017\n                                                                             (audited, unless otherwise specified)              (unaudited)\n                                                                                         (in \u20ac million)                        (in \u20ac million)\n Consultancy services ...............................................................\n                                                                                1.3                1.2                  1.3               0.8\n Compensation from Dermapharm AG,\n   Switzerland ..........................................................................\n                                                                                0.1                0.1                  0.1               0.1\n                                                                                1.4\nTotal (unaudited) .....................................................................            1.3                  1.4               0.9\n", "page_number": 204, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.43669803250641576, "lower_right_x": 0.875453446191052, "lower_right_y": 0.5761334473909324, "height": 0.13943541488451666, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-4", "text": "18.2     Relationships with Members of the Management Board and Supervisory Board\n\n18.2.1   Remuneration of the Members of the Management Board\n", "page_number": 204, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.6467065868263473, "height": 0.04491017964071853, "width": 0.6293833131801693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-5", "text": "       The following table shows the remuneration paid to members of the management board of\nDermapharm AG for the periods indicated:\n", "page_number": 204, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6599657827202737, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6873396065012831, "height": 0.027373823781009388, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-6", "text": "                                                                                                                              For the\n                                                                                                                            nine-month\n                                                                                 For the fiscal year                      period ended\n                                                                                ended December 31,                        September 30,\n                                                                    2014                 2015                2016              2017\n                                                                         (audited, unless otherwise specified)              (unaudited)\n                                                                                     (in \u20ac million)                        (in \u20ac million)\n Short-term employee benefits ..................................................\n                                                                           1.5                 1.7                  2.2               0.8\n Long-term employee benefits ..................................................\n                                                                           0.0                 0.0                  0.0               0.0\n                                                                           1.6\nTotal remuneration..................................................................           1.8                  2.2               0.9\n", "page_number": 204, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6920444824636441, "lower_right_x": 0.875453446191052, "lower_right_y": 0.8173652694610778, "height": 0.12532078699743365, "width": 0.7551390568319226}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-204-7", "text": "161", "page_number": 204, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-205-0", "text": "18.2.2   Remuneration of the Members of the Supervisory Board\n", "page_number": 205, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.45042321644498184}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-205-1", "text": "        In the fiscal years ended December 31, 2014, 2015, 2016 and 2017, the members of the supervisory\nboard of Dermapharm AG received an aggregate compensation of \u20ac45,000.00, \u20ac51,000.00, \u20ac60,000.00 and\n\u20ac60,000.00, respectively, from Dermapharm AG. In the nine-month period ended September 30, 2017, the\nmembers of the supervisory board of Dermapharm AG did not receive any remuneration, given that such\nremuneration is paid at the end of a given fiscal year in full.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.0688622754491018, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-205-2", "text": "18.2.3   Pensions\n", "page_number": 205, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.24244256348246676, "lower_right_y": 0.20829769033361847, "height": 0.010265183917878534, "width": 0.12212817412333737}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-205-3", "text": "       As of September 30, 2017, Dermapharm had not made any pension commitments to members of the\nManagement Board or the Supervisory Board.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.25192472198460225, "height": 0.026518391787852896, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-205-4", "text": "162", "page_number": 205, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-0", "text": "19.   UNDERWRITING\n", "page_number": 206, "bounding_box": {"top_left_x": 0.40084643288996374, "top_left_y": 0.08511548331907613, "lower_right_x": 0.599758162031439, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.1989117291414752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-1", "text": "19.1\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11591103507271172, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.12617621899059026, "height": 0.010265183917878534, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-2", "text": "General\n", "page_number": 206, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.11591103507271172, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.12660393498716851, "height": 0.010692899914456794, "width": 0.06287787182587667}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-3", "text": "       On January 26, 2018, the Company, the Selling Shareholder and the Offering Banks entered into the\nUnderwriting Agreement relating to the offer and sale of the Offer Shares in connection with the Offering.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16937553464499572, "height": 0.02609067579127458, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-4", "text": "         Under the terms of the Underwriting Agreement and subject to certain conditions, including the\nexecution of the pricing agreement, the Sole Bookrunner Joh. Berenberg, Gossler & Co. KG, Neuer\nJungfernstieg 20, 20354 Hamburg, Germany, is required to acquire such number of Offer Shares at the Offer\nPrice as will be specified in the pricing agreement.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1775021385799829, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23139435414884515, "height": 0.053892215568862256, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-5", "text": "         In connection with the Offering, the Sole Bookrunner and any of its affiliates, acting as an investor for\nits own account, may subscribe for Offer Shares in the Offering and in that capacity may retain, purchase or sell\nsuch Offer Shares or related investments for its own account and may offer or sell such Offer Shares or other\ninvestments outside the Offering. Accordingly, references in this Prospectus to Offer Shares being offered or\nplaced should be construed as including any offering or placement of Offer Shares to the Sole Bookrunner or\nany of its affiliates acting in such capacity. The Sole Bookrunner does not intend to disclose the extent of any\nsuch investments or transactions other than in accordance with any legal or regulatory obligation to do so. In\naddition, the Sole Bookrunner or its affiliates may enter into financing arrangements, including swaps with\ninvestors, due to which the Sole Bookrunner or its affiliates may, from time to time, acquire, hold or dispose of\nOffer Shares.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23182207014542344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37254063301967494, "height": 0.1407185628742515, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-6", "text": "Underwriting Agreement\n", "page_number": 206, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3896492728828058, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.4033361847733105, "height": 0.013686911890504694, "width": 0.18379685610640872}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-7", "text": "19.2\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3896492728828058, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.3999144568006843, "height": 0.010265183917878506, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-8", "text": "         In the Underwriting Agreement, the Sole Bookrunner, subject to certain conditions, including the\nexecution of a pricing agreement to determine the Offer Price, agreed to underwrite and purchase the Offer\nShares with a view to offering them to investors in this Offering. The Sole Bookrunner agreed to remit to the\nCompany the Offer Price from the sale of the New Shares (less agreed commissions and expenses), at the time\nthe Company\u2019s shares are delivered to investors, which is expected to be three banking days after admission to\ntrading of the Company\u2019s shares on the regulated market (regulierter Markt) of the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse) and simultaneous admission to the sub-segment of the regulated market with\nadditional post admission obligations (Prime Standard) of the Frankfurt Stock Exchange (Frankfurter\nWertpapierb\u00f6rse).\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5402053036783576, "height": 0.12318220701454241, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-9", "text": "          In the Underwriting Agreement, the Sole Bookrunner, subject to certain conditions, including the\nexecution of a pricing agreement to determine the Offer Price, further agreed to acquire the Existing Shares\nfrom the holdings of the Selling Shareholder and to sell such Existing Shares as part of the Offering. The Sole\nBookrunner agreed to remit the purchase price from the sale of the Existing Shares (less agreed upon\ncommissions and expenses) to the Selling Shareholder at the time the Existing Shares are delivered to investors,\nwhich is expected to occur on February 13, 2018. For the purpose of a potential Over-Allotment, the Sole\nBookrunner will be provided with 1,755,000 Over-Allotment Shares from the holdings of the Selling\nShareholder in the form of a securities loan. The total number of Over-Allotment Shares will not exceed 15% of\nthe final number of Base Shares placed with investors. The Selling Shareholder granted the Sole Bookrunner an\noption to acquire a number of the Company\u2019s shares equal to the number of Over-Allotment Shares at the Offer\nPrice, less agreed commissions.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6976047904191617, "height": 0.1505560307955518, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-10", "text": "         The obligations of the Offering Banks under the Underwriting Agreement are subject to various\nconditions, including (i) the agreement of the Sole Bookrunner, the Company and the Selling Shareholder on the\nOffer Price and the final number of Base Shares to be purchased by the Sole Bookrunner, (ii) the absence of a\nmaterial event (e.g., a reasonably likely material adverse change in or affecting the condition, business,\nprospects, management, consolidated financial position, shareholders\u2019 equity, or results of operations of\nDermapharm, or a suspension or material limitation in trading in securities in general on the Frankfurt Stock\nExchange (Frankfurter Wertpapierb\u00f6rse)), (iii) receipt of customary officers\u2019 certificates, legal opinions and\ncomfort letters, and (iv) the admission of the Company\u2019s shares to trading on the Frankfurt Stock Exchange\n(Frankfurter Wertpapierb\u00f6rse).\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.704448246364414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8276304533789564, "height": 0.1231822070145423, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-11", "text": "         The Offering Banks have provided, and may in the future provide, services to Dermapharm in the\nordinary course of business and may extend credit to, and have regular business dealings with Dermapharm in\ntheir capacity as financial institutions. For a more detailed description of the interests of the Offering Banks in\nthe Offering, see \u201c3.12 Interests of Parties Participating in the Offering\u201d.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8344739093242087, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8892215568862275, "height": 0.054747647562018775, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-206-12", "text": "163", "page_number": 206, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-0", "text": "19.3   Commissions\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.15477629987908104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-1", "text": "         The Offering Banks will offer the Offer Shares at the Offer Price. In return, the Sole Bookrunner will\nreceive a fixed underwriting commission calculated as a percentage of the gross proceeds from the Offering. In\naddition, the Company and the Selling Shareholder, respectively, may in their sole discretion decide to pay the\nSole Bookrunner a discretionary fee, which is also calculated as a percentage of the gross proceeds from the\nOffering.\n         The Company will bear any fees in connection with the sale of the New Shares, while the Selling\nShareholder will bear any fees in connection with the sale of the Existing Shares and the Over-Allotment\nShares. Assuming a placement of all Base Shares, full exercise of the Greenshoe Option and payment of the\ndiscretionary fee in full, the Company estimates that at the mid-point of the Price Range, the Sole Bookrunner\nwould receive commissions in an amount of approximately \u20ac10.2 million in connection with the Offering.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2566295979469632, "height": 0.14414029084687768, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {"underwriting_fees": ["\u20ac10.2 million"]}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-2", "text": "         The Sole Bookrunner will withhold the respective base fees and the fixed fee of the Co-Lead Manager\nfrom the proceeds from the sale of the New Shares, the Existing Shares and the Over-Allotment Shares,\nrespectively. The Company and the Selling Shareholder, respectively, will decide whether to grant the\nrespective discretionary fees, if any, within five banking days after the expiration of the Stabilization Period.\nThe Company has also agreed to reimburse the Sole Bookrunner for certain expenses incurred in connection\nwith the Offering.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3455945252352438, "height": 0.07912745936698035, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-3", "text": "         In addition to the commissions payable to the Sole Bookrunner, the Co-Lead Manager will receive a\nfixed fee for its role as a Co-Lead Manager in connection with the Offering.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38023952095808383, "height": 0.024807527801539775, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-4", "text": "Greenshoe Option and Securities Loan\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1795646916565901, "top_left_y": 0.3964927288280582, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.40975192472198463, "height": 0.013259195893926434, "width": 0.27992744860943164}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-5", "text": "19.4\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3964927288280582, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.40718562874251496, "height": 0.010692899914456766, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-6", "text": "         To cover potential Over-Allotments, the Selling Shareholder has provided the Sole Bookrunner with\n1,755,000 Over-Allotment Shares free of charge in the form of a securities loan. The Sole Bookrunner is entitled\nto exercise the Greenshoe Option to the extent Over-Allotments were initially made. The number of shares of\nthe Company that can be acquired under the Greenshoe Option is reduced by the number of shares held by the\nSole Bookrunner on the date when the Greenshoe Option is exercised and that were acquired by the Sole\nBookrunner in the context of stabilization measures, if any. The Greenshoe Option will terminate 30 calendar\ndays after commencement of stock exchange trading of the Company\u2019s shares (i.e., March 11, 2018).\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5192472198460223, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-7", "text": "19.5   Termination; Indemnification\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5333618477331052, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.5470487596236099, "height": 0.013686911890504638, "width": 0.27569528415961303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-8", "text": "         The Sole Bookrunner, on behalf of the Offering Banks, may, under certain circumstances, terminate the\nUnderwriting Agreement, including after the Offer Shares have been allocated and admitted to trading, up to\nclosing of the Offering, in particular, if any of the following has occurred:\n", "page_number": 207, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5607356715141146, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.602224123182207, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-9", "text": "\uf0b7   Dermapharm has sustained a loss or interference with respect to its business from fire, explosion,\n    flood or other calamity (whether or not covered by insurance), or from any labor dispute or court\n    or governmental;\n\uf0b7   any material change or development reasonably likely to result in a material change to the share\n    capital of the Company;\n\uf0b7   any material change or development reasonably likely to result in a material change in the\n    long-term debt of the Company or Dermapharm;\n\uf0b7   any material adverse change, or any development involving a reasonably likely prospective\n    material adverse change, in or affecting the condition, business, prospects, management,\n    consolidated financial position, shareholders\u2019 equity or results of operations of the Company or\n    Dermapharm;\n\uf0b7   any material adverse change that would prevent the Company from performing any of its\n    obligations under the Underwriting Agreement;\n\uf0b7   the Company or Dermapharm has incurred any liability or obligation, direct or contingent, or\n    entered into any material transaction not in the ordinary course of business; or\n\uf0b7   a suspension in trading on the stock exchanges in Frankfurt am Main, Germany, London, United\n    Kingdom, or New York, United States;\n", "page_number": 207, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8896492728828058, "height": 0.2810094097519247, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-207-10", "text": "164", "page_number": 207, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-0", "text": "\uf0b7   a general moratorium on banking activities is imposed in Frankfurt am Main, London, or\n    New York by the relevant authorities;\n\uf0b7   a material adverse change in national or international financial, political, or economic conditions or\n    currency exchange rates or currency controls which could have a material adverse impact on the\n    financial markets in the Federal Republic of Germany, the United Kingdom or the United States;\n\uf0b7   an outbreak or escalation of hostilities or the declaration of a national emergency or war which\n    have a material adverse impact on the financial markets in Germany, the United Kingdom or the\n    United States; or\n\uf0b7   any acts of terrorism or any other calamity or crisis or any change in financial, political or\n    economic conditions or currency exchange rates or currency control which have a material adverse\n    impact on the financial markets in Germany, the United Kingdom or the United States.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.0885372112917023, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2600513259195894, "height": 0.1715141146278871, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-1", "text": "          If the Underwriting Agreement is terminated, the Offering will not take place, in which case any\nallocations already made to investors will be invalidated and investors will have no claim for delivery of Offer\nShares. Claims with respect to purchase fees already paid and costs incurred by an investor in connection with\nthe purchase will be governed solely by the legal relationship between the investor and the financial\nintermediary to which the investor submitted its purchase order. Investors who engage in short-selling bear the\nrisk of being unable to satisfy their delivery obligations.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26988879384088965, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34901625320787, "height": 0.07912745936698035, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-2", "text": "         In the Underwriting Agreement, the Company and the Selling Shareholder have agreed to indemnify\nthe Offering Banks against certain liabilities that may arise in connection with the Offering, including liabilities\nunder applicable securities laws.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35885372112917024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39863130881094955, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-3", "text": "19.6   Selling Restrictions\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4136013686911891, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.4268605645851155, "height": 0.013259195893926434, "width": 0.19830713422007254}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-4", "text": "          The distribution of this Prospectus and the sale of the Offer Shares may be restricted by law in certain\njurisdictions. No action has been or will be taken by the Company, the Selling Shareholder or the Offering\nBanks to permit a public offering of the Offer Shares anywhere other than in Germany and Luxembourg or the\ntransmission or distribution of this Prospectus into any other jurisdiction, where action for that purpose may be\nrequired.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.44097519247219846, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5089820359281437, "height": 0.06800684345594527, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-5", "text": "          Accordingly, neither this Prospectus nor any advertisement or any other offering material may be\ndistributed or published in any jurisdiction other than in Germany and Luxembourg, except under circumstances\nthat will result in compliance with any applicable laws and regulations. Persons into whose possession this\nProspectus comes are required to inform themselves about and observe any such restrictions, including those set\nout in the following paragraphs. Any failure to comply with these restrictions may constitute a violation of the\nsecurities laws of any such jurisdiction.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5162532078699743, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5983746792130026, "height": 0.08212147134302827, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-6", "text": "         The Company does not intend to register either the Offering or any portion of the Offering in the\nUnited States, or to conduct a public offering of shares in the United States. The Offer Shares are not and will\nnot be registered pursuant to the provisions of the Securities Act or with securities regulators of individual states\nof the United States. The Offer Shares may not be offered, sold or delivered, directly or indirectly, in or into the\nUnited States, except pursuant to an exemption from the registration and reporting requirements of the United\nStates securities laws and in compliance with all other applicable United States legal requirements. The Offer\nShares may only be sold in or into the United States to persons who are QIBs as defined in, and in reliance on,\nRule 144A, or pursuant to another available exemption from, or transactions not subject to, the registration\nrequirements of the Securities Act, and outside the United States in accordance with Rule 903 of Regulation S\nand in compliance with other United States legal requirements, and no (i) \u201cdirect selling efforts\u201d as defined in\nRegulation S or (ii) \u201cgeneral advertising\u201d or \u201cgeneral solicitation\u201d, each as defined in Regulation D under the\nSecurities Act in relation to the Offer Shares may take place. Any offer or sale of Offer Shares in reliance on\nRule 144A will be made by broker dealers who are registered as such under the Securities Act. Terms used\nabove shall have the meanings ascribed to them by Regulation S and Rule 144A under the Securities Act.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.605218135158255, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7964071856287425, "height": 0.1911890504704875, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-7", "text": "         In addition, until 40 days after the commencement of the Offering, an offer or sale of Offer Shares\nwithin the United States by any dealer (whether or not participating in the Offering) may violate the registration\nrequirements of the Securities Act, if such offer or sale is does not comply with Rule 144A or another\nexemption from registration under the Securities Act.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8036783575705732, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8584260051325919, "height": 0.054747647562018775, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-208-8", "text": "165\n", "page_number": 208, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-0", "text": "         In the United Kingdom, this Prospectus is only addressed and directed to Qualified Investors (i) who\nhave professional experience in matters relating to investments falling within Article 19 para. 5 of the Financial\nServices and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \u201cOrder\u201d), and/or (ii) who\nare high net worth entities falling within Article 49 para. 2 lit. a) through d) of the Order, and (iii) other persons\nto whom it may otherwise lawfully be communicated (all such persons together being referred to as \u201cRelevant\nPersons\u201d). In the United Kingdom, the Offer Shares are only available to, and any invitation, offer or agreement\nto subscribe, purchase or otherwise acquire Offer Shares in the United Kingdom will only be engaged in with,\nRelevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this\nProspectus or any of its contents.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.12360992301112063, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-1", "text": "         No offer to the public of any Offer Shares which are the subject of this Offering has been and will be\nmade in any EEA Member State, other than the offers contemplated in this Prospectus in Germany and\nLuxembourg (once the Prospectus has been approved by BaFin, notified to the CSSF and published in\naccordance with Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003 on\nthe prospectus to be published when securities are offered to the public or admitted to trading, as last amended\non July 20, 2017 (the \u201cProspectus Directive\u201d), except that offers to the public of Offer Shares in any\nEEA Member State are permitted in accordance with the following exceptions under the Prospectus Directive:\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31137724550898205, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-2", "text": "\uf0b7   to legal entities which are qualified investors as defined in Article 2 para. 1 lit. e) of the Prospectus\n    Directive;\n\uf0b7   to fewer than 150 natural or legal persons per EEA Member State (other than qualified investors as\n    defined in Article 2 para. 1 lit. e) of the Prospectus Directive), subject to obtaining the prior\n    consent of the Sole Bookrunner for any such offer; or\n\uf0b7   in any other circumstances falling within Article 3 para. 2 of the Prospectus Directive.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3212147134302823, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4174508126603935, "height": 0.09623609923011123, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-3", "text": "         For the purposes of this Prospectus, the expression \u201coffer to the public\u201d in relation to any Offer Shares\nin any EEA Member State means a communication to persons in any form and by any means, presenting\nsufficient information on the terms of the Offering and the Offer Shares, so as to enable an investor to decide to\npurchase or subscribe to Offer Shares, including any placing of Offer Shares through financial intermediaries.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47904191616766467, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-4", "text": "19.7   Other Interests of the Sole Bookrunner in the Offering\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.5064157399486741, "height": 0.014114627887082953, "width": 0.45525997581620314}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-5", "text": "        In connection with the Offering and the admission to trading of the Company\u2019s shares, the Offering\nBanks have formed a contractual relationship with the Company and the Selling Shareholder.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5230966638152267, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5491873396065012, "height": 0.026090675791274553, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-6", "text": "         Berenberg is acting for the Company and the Selling Shareholder on the Offering and on coordinating\nthe structuring and execution of the Offering. Upon successful completion of the Offering, Berenberg will\nreceive a commission and the size of this commission depends on the results of the Offering. As a result,\nBerenberg has a financial interest in the success of the Offering at the best possible terms.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5573139435414884, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6107784431137725, "height": 0.05346449957228405, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-7", "text": "         ODDO BHF is acting as Co-Lead Manager and will receive a fixed fee for its services in connection\nwith the Offering. As a result, ODDO BHF has a financial interest in the success of the Offering.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.6189050470487596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6454234388366125, "height": 0.02651839178785287, "width": 0.7587666263603386}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-8", "text": "         The Offering Banks or their respective affiliates have, and may from time to time in the future continue\nto have, business relations with Dermapharm and the Selling Shareholder, including lending activities, or may\nperform services for Dermapharm or the Selling Shareholder in the ordinary course of business.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6531223267750214, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.693327630453379, "height": 0.04020530367835762, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-209-9", "text": "166", "page_number": 209, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-0", "text": "20.   TAXATION IN THE FEDERAL REPUBLIC OF GERMANY\n", "page_number": 210, "bounding_box": {"top_left_x": 0.24123337363966144, "top_left_y": 0.08511548331907613, "lower_right_x": 0.75453446191052, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.5133010882708585}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-1", "text": "          The following section outlines certain key German tax principles that may be relevant with respect to\nthe acquisition, holding or transfer of shares in the Company. It is important to note that the legal situation may\nchange, possibly with retroactive effect. This summary is not and does not purport to be a comprehensive or\nexhaustive description of all German tax considerations that may be relevant to shareholders of the Company.\nIn particular, this summary does not cover tax considerations that may be relevant to a shareholder that is a tax\nresident of a jurisdiction other than Germany. This presentation is based upon domestic German tax laws in\neffect as of the date of this Prospectus and the provisions of double taxation treaties currently in force between\nGermany and other countries.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22241231822070145, "height": 0.10992301112061591, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-2", "text": "         This section does not replace the need for individual shareholders of the Company to seek personal tax\nadvice. It is therefore recommended that shareholders consult their own tax advisors regarding the tax\nimplications of acquiring, holding or transferring shares of the Company and what procedures are necessary to\nsecure the repayment of German withholding tax (Kapitalertragsteuer), if possible. Only qualified tax advisors\nare in a position to adequately consider the particular tax situation of individual shareholders.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22882805816937554, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29769033361847735, "height": 0.06886227544910181, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-3", "text": "20.1   Taxation of the Company\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3143712574850299, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.3272027373823781, "height": 0.012831479897348175, "width": 0.247279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-4", "text": "          The Company\u2019s taxable income, whether distributed or retained, is generally subject to German\ncorporate income tax at a uniform rate of 15% plus the solidarity surcharge of 5.5% thereon, resulting in a total\ntax rate of 15.825%.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.34174508126603936, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3798118049615056, "height": 0.03806672369546621, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-5", "text": "         Dividends and other shares in profits which the Company receives from domestic and foreign\ncorporations are generally not subject to corporate income tax; however, 5% of this type of income are deemed\nto be a non-deductible business expense and are thus taxable. The same generally applies to profits earned by\nthe Company from the sale of shares in another domestic or foreign corporation. Losses incurred from the sale\nof such shares are not deductible for tax purposes, regardless of the percentage of shares held. Different rules\napply to free-floating dividends (i.e., dividends earned on direct shareholdings in a distributing corporation\nequal to less than 10% of its share capital at the start of the respective calendar year (\u201cPortfolio Dividends\u201d)).\nPortfolio Dividends are fully taxed at the corporate income tax rate (plus solidarity surcharge thereon). The\nacquisition of a shareholding of at least 10% is deemed to have occurred at the beginning of the calendar year.\nCapital gains arising from the disposal of shares held by the Company are effectively 95% tax exempt.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5269461077844312, "height": 0.13729683490162536, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-6", "text": "          Participations in the share capital of other corporations which the Company holds through partnerships,\nincluding co-entrepreneurships (Mitunternehmerschaften), are attributable to the Company only on a pro rata\nbasis at the ratio of the interest share of the Company in the assets of relevant partnership.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5333618477331052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5739948674080411, "height": 0.04063301967493582, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-7", "text": "        In addition, the Company is subject to trade tax with respect to its taxable trade profits from its\npermanent establishments in Germany. The trade tax rate depends on the local municipality/municipalities in\nwhich the Company maintains its permanent establishment(s). For the Company, the trade tax burden currently\namounts to 8.4% of the taxable trade profit.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6355859709153122, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-8", "text": "          For trade tax purposes, dividends received from domestic and foreign corporations and capital gains\nfrom the sale of shares in other corporations are treated in principle in the same manner as for corporate income\ntax purposes. However, shares in profits received from domestic and foreign corporations are effectively 95%\nexempt from trade tax only if, inter alia, the company that is receiving the dividends has held or holds a stake of\nat least 15% in the share capital of the company making the distribution at the beginning or \u2013 in the case of\nforeign corporations \u2013 since the beginning of the assessment period. In the case of distributing companies\ndomiciled in another member state of the European Union, a stake of 10% at the beginning of the assessment\nperiod is sufficient. Additional limitations apply with respect to shares in profits received from foreign\ncorporations domiciled outside the European Union.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7664670658682635, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-210-9", "text": "167", "page_number": 210, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-211-0", "text": "           The provisions of the interest barrier (Zinsschranke) restrict the extent to which interest expenses are\ntax deductible. Under these rules, net interest expenses (interest expenses minus interest income in any given\nfiscal year) are generally only deductible up to 30% of the taxable EBITDA (taxable earnings adjusted for, in\nparticular, interest expenses, interest income, and certain depreciation and amortization), although there are\ncertain exceptions to this rule. The interest barrier rules do not apply in any given fiscal year (i) if the annual net\ninterest expense is less than \u20ac3.0 million, (ii) if the respective entity is not or only partially part of a consolidated\ngroup, or (iii) if the respective entity is part of a consolidated group but its equity ratio is no more than two\npercentage points below the equity ratio of the consolidated group. For the eligibility of exemption (ii), the\nentity must prove that it did not pay more than 10% of the net interest expense to shareholders with a (direct or\nindirect) shareholding in the entity of more than 25% or to an associated person. For the eligibility of exemption\n(iii), the entity must prove that the entity itself and any other company of the consolidated group did not pay\nmore than 10% of the net interest expense to shareholders with a (direct or indirect) shareholding in a group\ncompany of more than 25% or to an associated person. Interest expense that is not deductible in any given fiscal\nyear may be carried forward to subsequent fiscal years of the Company (interest carryforward) and will increase\nthe interest expense in those subsequent years. Under certain conditions, non-offsettable EBITDA may also be\ncarried forward to subsequent fiscal years (EBITDA carryforward). For the purpose of trade tax, however, the\ndeductibility of interest expenses is further restricted to the extent that the sum of certain trade taxable add back\nitems exceeds \u20ac100,000.00. In such cases 25% of the interest expenses, to the extent they were deducted for\ncorporate income tax purposes, are added back for purposes of the trade tax base; consequently, in these cases\nthe deductibility is limited to 75% of the interest expenses.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3567151411462789, "height": 0.27159965782720275, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-211-1", "text": "expenses.", "page_number": 211, "bounding_box": {"top_left_x": 0.45102781136638453, "top_left_y": 0.3502994011976048, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.358426005132592, "height": 0.008126603934987209, "width": 0.06287787182587662}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-211-2", "text": "the deductibility is limited to 75% of the interest expenses.\n         Losses of the Company can be carried forward to subsequent fiscal years and used to fully offset\ntaxable income for corporate income tax and trade tax purposes only up to an amount of \u20ac1.0 million. If the\ntaxable income for the year or taxable profit subject to trade taxation exceeds this threshold, only up to 60% of\nthe amount exceeding the threshold may be offset by tax loss carryforwards. The remaining 40% are subject to\ntaxation (minimum taxation). The rules also provide for a tax loss carryback in an amount of up to \u20ac1.0 million\nto the previous year with regards to corporate income tax. Unused tax loss carryforwards may generally be\ncarried forward for an unlimited period of time.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.35714285714285715, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4619332763045338, "height": 0.10479041916167664, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-211-3", "text": "         If more than 50% of the subscribed capital or voting rights of the Company are directly or indirectly\ntransferred to an acquirer (including parties related to the acquirer) within five years or comparable\ncircumstances occur, all tax loss carryforwards and interest carryforwards are forfeited. A group of acquirers\nwith aligned interests is also considered to be an acquirer for these purposes. In addition, any current annual\nlosses incurred prior to the acquisition will not be deductible. If more than 25% up to and including 50% of the\nsubscribed capital or voting rights of the Company are transferred to an acquirer (including parties related to the\nacquirer) or comparable circumstances occur, a proportional amount of tax loss carryforwards, unused current\nlosses and interest carryforwards are forfeited. While the Federal Constitutional Court\n(Bundesverfassungsgericht) on March 29, 2017 ruled that the relevant provision of the German Corporate Tax\nAct (K\u00f6rperschaftsteuergesetz) on this pro-rata forfeiture is unconstitutional, such decision only covers the time\nperiod up to and including December 31, 2015. Therefore, the Federal Constitutional Court\n(Bundesverfassungsgericht) ruled that a retroactive implementation of a new provision substituting the\nunconstitutional legislation will only be required for the period from January 1, 2008 up to and including\nDecember 31, 2015.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46834901625320785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6599657827202737, "height": 0.19161676646706588, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-211-4", "text": "          The rules on the forfeiture of tax loss carryforwards, unused current losses and interest carryforwards\ndo not apply to share transfers where (i) the acquirer directly or indirectly holds a participation of 100% in the\ntransferring entity, (ii) the vendor directly or indirectly holds a participation of 100% in the receiving entity, or\n(iii) the same natural or legal person or commercial partnership directly or indirectly holds a participation of\n100% in the transferring and the receiving entity. Furthermore, tax loss carryforwards, unused current losses and\ninterest carryforwards taxable in Germany will not expire to the extent that they are covered by built in gains\ntaxable in Germany at the time of such acquisition.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6668092386655261, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7630453378956373, "height": 0.09623609923011123, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-211-5", "text": "168", "page_number": 211, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-0", "text": "          In accordance with legislation enacted on December 23, 2016, a new rule was introduced to the\nGerman Corporate Tax Act (K\u00f6rperschaftsteuergesetz) with retroactive effect from January 1, 2016. Based upon\nthis legislation and assuming that the required application has been filed, any share transfer that would otherwise\nbe subject to the aforementioned rules does not result in a forfeiture of tax loss carryforwards resulting from\ncurrent business operations (Gesch\u00e4ftsbetrieb) of the Company, if, in addition to other requirements, the current\nbusiness operations of the Company remained the same (i) from the time of its establishment; or (ii) during the\nlast three business years prior to the share transfer and such business operations are maintained after the transfer.\nThe determination of whether the business operations have been maintained is assessed on the basis of\nqualitative factors (e.g., produced goods and services, target markets, client and supplier bases). However, the\nrelevant retained tax loss carryforwards will be subject to a special regime, providing, inter alia, that they will\nbe forfeited in any event if, after the share transfer, the business operations of the Company become dormant or\nare amended, the Company becomes a partner in an operating partnership (Mitunternehmerschaft), the Company\nbecomes a fiscal unity parent, or assets are transferred from the Company and recognized at a value lower than\nthe fair market value. Whether any of the aforementioned detrimental circumstances occur is monitored until the\nretained tax loss carryforwards have been fully utilized.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.290846877673225, "height": 0.20573139435414883, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-1", "text": "Taxation of Shareholders\n", "page_number": 212, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.3041060735671514, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.31736526946107785, "height": 0.013259195893926434, "width": 0.18379685610640872}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-2", "text": "20.2\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.30538922155688625, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.31736526946107785, "height": 0.0119760479041916, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-3", "text": "           Shareholders are taxed in particular in connection with the holding of shares (taxation of dividend\nincome), upon the sale of shares (taxation of capital gains) and the gratuitous transfer of shares (inheritance and\ngift tax).\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3314798973481608, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3729683490162532, "height": 0.041488451668092396, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-4", "text": "20.2.1\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3896492728828058, "lower_right_x": 0.16384522370012092, "lower_right_y": 0.40034217279726264, "height": 0.010692899914456822, "width": 0.04836759371221282}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-5", "text": "Taxation of Dividend Income\n", "page_number": 212, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.3896492728828058, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.40290846877673225, "height": 0.013259195893926434, "width": 0.20858524788391777}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-6", "text": "          In the future, the Company may pay dividends out of a tax recognized contribution account\n(steuerliches Einlagekonto). To the extent that the Company pays dividends from the tax-recognized\ncontribution account (steuerliches Einlagekonto), the dividends are not subject to withholding tax, personal\nincome tax (including the solidarity surcharge and church tax, if any) or corporate income tax, as the case may\nbe. However, dividends paid out of a tax-recognized contribution account lower the acquisition costs of the\nshares, which may result in a higher amount of taxable capital gains upon the shareholder\u2019s sale of the shares.\nSpecial rules apply to the extent that dividends from the tax-recognized contribution account exceed the then\nlowered acquisition costs of the shares (the details are outlined below).\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4170230966638152, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5256629597946963, "height": 0.10863986313088114, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-7", "text": "20.2.2   Withholding Tax\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5402053036783576, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.5538922155688623, "height": 0.013686911890504638, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-8", "text": "          Dividends distributed by the Company that are not paid out of the tax-recognized contribution account\n(steuerliches Einlagekonto) are subject to a deduction at source (withholding tax) at a 25% rate plus a solidarity\nsurcharge of 5.5% on the amount of withholding tax (amounting in total to a rate of 26.375%) and church tax\n(Kirchensteuer), if applicable. The basis for determining the dividend withholding tax is the dividend approved\nfor distribution by the Company\u2019s shareholders\u2019 meeting.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.567579127459367, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6364414029084687, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-9", "text": "        In general, dividend withholding tax is withheld regardless of whether and, if so, to what extent the\nshareholder must report the dividend for tax purposes and regardless of whether the shareholder is a resident of\nGermany or of a foreign country.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6428571428571429, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6843455945252352, "height": 0.04148845166809234, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-10", "text": "          As the Company\u2019s shares are admitted to be held in collective safe custody (Sammelverwahrung) with\na central securities depository (Wertpapiersammelbank) pursuant to Section 5 of the German Act on Securities\nAccounts (Depotgesetz) and are entrusted to such central securities depository for collective safe custody in\nGermany, the Company is not responsible for withholding the withholding tax. Instead, one of the following\nentities in Germany is responsible and authorized to collect withholding tax and to remit it to the relevant tax\nauthority for the account of the relevant shareholder: (i) a domestic bank or financial service institute, a\ndomestic securities trading company or a domestic securities trading bank (including the domestic branches of\nforeign banks or financial service institutes) that holds the shares in custody or that manages such shares and\nthat pays out or credits the shareholder\u2019s investment income or that pays the investment income to a foreign\nentity, or (ii) the central securities depository (Wertpapiersammelbank) holding the collective deposit shares in\ncustody if it pays the investment income to a foreign entity, or (iii) the Company itself if and to the extent shares\nheld in collective safe custody (girosammelverwahrt) by the central securities depository\n(Wertpapiersammelbank) are treated as stock being held separately (abgesetzte Best\u00e4nde).\n", "page_number": 212, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6907613344739093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8691189050470488, "height": 0.1783575705731395, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-212-11", "text": "169\n", "page_number": 212, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.009837467921300247, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-0", "text": "          The Company assumes responsibility for the withholding of taxes on distributions at source, in\naccordance with statutory provisions. This means that the Company is released from liability for the violation of\nits legal obligation to withhold and transfer the taxes at source if it provides evidence that it has not breached its\nduties intentionally or grossly negligently.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13986313088109495, "height": 0.05474764756201882, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-1", "text": "          Where dividends are distributed to a company resident in another member state of the European Union\nwithin the meaning of Article 2 of the Council Directive 2011/96/EU of November 30, 2011 on the common\nsystem of taxation applicable in the case of parent companies and subsidiaries of different member states, as\namended (the \u201cParent-Subsidiary Directive\u201d), withholding of the dividend withholding tax may not be\nrequired, upon application, provided that additional requirements are met (withholding tax exemption). This also\napplies to dividends distributed to a permanent establishment located in another member state of the European\nUnion of such parent company or of a parent company that is tax resident in Germany, if the interest in the\ndividend-paying subsidiary is part of the respective permanent establishment\u2019s business assets. An important\nprerequisite for the exemption from withholding at the source under the Parent-Subsidiary Directive is that the\nshareholder has directly held at least 10% of the Company\u2019s registered share capital continuously for one year\nand that the German Federal Central Office of Taxation (Bundeszentralamt f\u00fcr Steuern), with its registered\noffice in An der K\u00fcppe 1, 53225 Bonn, Germany, has certified to the creditor of the dividends, based upon an\napplication filed by such creditor on the officially prescribed form, that the prerequisites for exemption have\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32934131736526945, "height": 0.18263473053892215, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-2", "text": "been met.\n          The dividend withholding tax rate for dividends paid to shareholders without a tax residence in\nGermany will be reduced in accordance with any applicable double taxation treaty between Germany and the\nrelevant shareholder\u2019s country of residence, provided that the shares are neither held as part of the business\nassets of a permanent establishment or a fixed base in Germany nor as part of the business assets for which a\npermanent representative in Germany has been appointed. The reduction in the dividend withholding tax is\ngenerally obtained by applying to the Federal Central Office of Taxation (Bundeszentralamt f\u00fcr Steuern), with\nits registered office in An der K\u00fcppe 1, 53225 Bonn, Germany, for a refund of the difference between the\ndividend withholding tax withheld, including the solidarity surcharge, and the amount of withholding tax\nactually owed under the applicable double taxation treaty, which usually amounts to between 5% and 15%.\nDepending on the applicable double taxation treaty, a reduced withholding tax rate may be applicable, if the\nshareholder has applied for an exemption from the Federal Central Office of Taxation (Bundeszentralamt f\u00fcr\nSteuern). The applicable double taxation treaty may also provide for a full exemption from the German dividend\nwithholding tax, if the relevant shareholder has directly held at least 10% of the Company\u2019s registered share\ncapital and if further prerequisites are met. Forms for the refund and exemption procedure may be obtained from\nthe Federal Central Office of Taxation (Bundeszentralamt f\u00fcr Steuern), as well as German embassies and\nconsulates.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3297690333618477, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.561163387510693, "height": 0.23139435414884524, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-3", "text": "        Corporations that are not tax residents in Germany will upon application receive a refund of two fifths\nof the dividend withholding tax that was withheld and remitted to the tax authorities subject to certain\nrequirements. This applies regardless of any further reduction or exemption provided for under the\nParent-Subsidiary Directive or a double taxation treaty.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5710008554319932, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6261762189905903, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-4", "text": "          Foreign corporations will generally have to meet certain stringent substance criteria defined by statute\nin order to receive an exemption from, or (partial) refund of, German dividend withholding tax.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6325919589392643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.660393498716852, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-5", "text": "          Pursuant to a special rule on the restriction of withholding tax credit, the aforementioned relief in\naccordance with applicable double taxation treaties as well as the credit of withholding tax described for shares\nheld as private and as business assets (see \u201c20.3 Taxation of Dividends of Shareholders with a Tax Residence in\nGermany\u201d) is subject to the following three cumulative prerequisites: (i) the relevant shareholder must qualify as\nbeneficial owner of the shares in the Company for a minimum holding period of 45 consecutive days occurring\nwithin a period of 45 days prior and 45 days after the due date of the dividends, (ii) the shareholder has to bear\nat least 70% of the change in value risk related to the shares in the Company during the minimum holding\nperiod without being directly or indirectly hedged, and (iii) the shareholder is not required to fully or largely,\ndirectly or indirectly, transfer the dividends to third parties.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6668092386655261, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7904191616766467, "height": 0.12360992301112061, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-213-6", "text": "170\n", "page_number": 213, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.009837467921300247, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-0", "text": "Should any of the three prerequisites not be met, the following applies:\n", "page_number": 214, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.6571946795646917, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.4788391777509069}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-1", "text": "\uf0b7   As regards the taxation of dividends of shareholders with a tax residence in Germany, three fifths\n    of the withholding tax imposed on the dividends may not be credited against the shareholder\u2019s\n    (corporate) income tax liability, but may, upon application, be deducted from the shareholder\u2019s tax\n    base for the relevant assessment period. A shareholder that has received gross dividends without\n    any deduction of withholding tax due to a tax exemption without qualifying for a full tax credit has\n    to notify the competent local tax office accordingly and has to make a payment in the amount of\n    the withholding tax deduction which was omitted. The special rule on the restriction of\n    withholding tax credit does not apply to a shareholder whose overall dividend earnings within an\n    assessment period do not exceed \u20ac20,000.00 or who has been the beneficial owner of the shares in\n    the Company for at least one uninterrupted year upon receipt of the dividends.\n\uf0b7   As regards the taxation of dividends of shareholders without a tax residence in Germany who have\n    applied for a full or partial refund of the withholding tax pursuant to a double taxation treaty, no\n    refund is available. This restriction does not apply to a shareholder (i) that directly holds at least\n    10% of the shares in the Company and that is subject to (corporate) income tax in the country of its\n    tax residence without any exemptions, or (ii) that has been the beneficial owner of the shares in the\n    Company for at least one uninterrupted year upon receipt of the dividends, or (iii) if the applicable\n    tax rate pursuant to the applicable double taxation treaty is at least 15%.\n\uf0b7   In addition to the aforementioned statutory provisions, the German Federal Ministry of Finance\n    (Bundesministerium der Finanzen) recently published a decree, which outlines the treatment of\n    transactions where the credit of withholding tax will be denied even when the statutory minimum\n    tests as described above are met, in order to prevent abuse. Shareholders of the Company should\n    seek their own professional tax advice on the possibility of obtaining a tax credit or refund of\n    withholding tax on dividends.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.10906757912745936, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43798118049615054, "height": 0.3289136013686912, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-2", "text": "20.3     Taxation of Dividends of Shareholders with a Tax Residence in Germany\n\n20.3.1   Individuals who hold the Shares as Private Assets\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45124037639007697, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.49272882805816937, "height": 0.041488451668092396, "width": 0.590689238210399}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-3", "text": "          For individuals who are tax resident in Germany (generally, individuals whose domicile or usual\nresidence is located in Germany) and who hold their shares in the Company as private assets, the withholding\ntax of 25% plus solidarity surcharge of 5.5% thereon, resulting in a total tax rate of 26.375% (plus church tax, if\nany) will generally serve as a final tax (i.e., once such tax has been deducted, the shareholder\u2019s income tax\nliability on the dividends will be settled, and he or she will no longer have to declare them on his or her annual\ntax return (the \u201cFlat Tax\u201d)).\n", "page_number": 214, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5094097519247219, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5898203592814372, "height": 0.08041060735671524, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-4", "text": "          The purpose of the Flat Tax is to provide for separate and final taxation of capital investment income\nearned (i.e., taxation that is irrespective of the individual\u2019s personal income tax rate). Shareholders may apply to\nhave their capital investment income assessed in accordance with the general rules and with an individual\u2019s\npersonal income tax rate if this would result in a lower tax burden. In this case, the base for taxation would be\nthe gross dividend income less the savers\u2019 allowance of \u20ac801.00 (\u20ac1,602.00 for jointly filing individuals). Any\ntax and solidarity surcharge already withheld would be credited against the income tax and solidarity surcharge\nso determined, and any overpayment refunded. Income-related expenses cannot be deducted from capital gains\nin either case. The only possible deduction is the savers\u2019 allowance of \u20ac801.00 (\u20ac1,602.00 for jointly filing\nindividuals) on all private capital income. Furthermore, dividend income can only be offset by losses from\ncapital income, except for losses generated by the disposal of shares.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5983746792130026, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7339606501283148, "height": 0.13558597091531222, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-5", "text": "         If the individual owns (i) at least 1% of the shares in the Company and is able to exercise a significant\nentrepreneurial influence on the business activity of the Company by virtue of his professional activity\n(berufliche T\u00e4tigkeit) for the Company, or (ii) at least 25% of the shares in the Company, the tax authorities may\nupon application allow for the dividends to be taxed under the partial-income method (see \u201c20.3.2.2 Sole\nProprietors (Individuals)\u201d).\n", "page_number": 214, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.742087254063302, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8092386655260907, "height": 0.06715141146278869, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-214-6", "text": "171", "page_number": 214, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-0", "text": "          Entities required to collect withholding taxes on capital investment income are required to likewise\nwithhold the church tax on payments to shareholders who are subject to church tax, unless the shareholder\nobjects in writing to the Federal Central Office of Taxation (Bundeszentralamt f\u00fcr Steuern) against the sharing\nof his or her private information regarding his affiliation with a religious denomination (Sperrvermerk). If\nchurch tax is withheld and remitted to the tax authority as part of the withholding tax deduction, the church tax\non the dividends is also deemed to be discharged when it is deducted. The withheld church tax cannot be\ndeducted in the tax assessment as a special expense. However, 26.375% of the church tax withheld on the\ndividends is deducted from the withholding tax (including the solidarity surcharge) withheld. If no church taxes\nare withheld along with the withholding of the withholding tax, the shareholder who owes church tax is required\nto report his dividends in his income tax return. The church tax on the dividends will then be imposed during the\nassessment.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23267750213858, "height": 0.14756201881950387, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-1", "text": "          Contrary to the above, dividend payments that are funded from the Company\u2019s tax-recognized\ncontribution account (steuerliches Einlagekonto) and are paid to shareholders who are tax resident in Germany\nwhose shares are held as private assets, do not form part of the shareholder\u2019s taxable income. If the dividend\npayment funded from the Company\u2019s tax-recognized contribution account (steuerliches Einlagekonto) exceeds\nthe shareholder\u2019s acquisition costs, the German tax authorities take the view that negative acquisition costs will\narise, which may result in a higher capital gain in case of a disposal of the shares. This will not apply if (i) the\nshareholder or, in the event of a gratuitous transfer, its legal predecessor, or, if the shares have been gratuitously\ntransferred several times in succession, one of his legal predecessors at any point during the five years preceding\nthe disposal directly or indirectly held at least 1% of the share capital of the Company (a \u201cQualified\nParticipation\u201d) and (ii) the dividend payment funded from the Company\u2019s tax-recognized contribution account\n(steuerliches Einlagekonto) exceeds the acquisition costs of the shares. In case of a Qualified Participation, a\ndividend payment funded from the Company\u2019s tax-recognized contribution account (steuerliches Einlagekonto)\nis considered a sale of the shares and is taxable as a capital gain if and to the extent the dividend payment\nfunded from the Company\u2019s tax-recognized contribution account (steuerliches Einlagekonto) exceeds the\nacquisition costs of the shares. In this case the taxation corresponds to the taxation of capital gains of\nshareholders maintaining a Qualified Participation (see \u201c20.5 Taxation of Capital Gains\u201d).\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4619332763045338, "height": 0.21941830624465355, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-2", "text": "20.3.2   Shares Held as Business Assets\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4751924721984602, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.48845166809238666, "height": 0.013259195893926434, "width": 0.28597339782345826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-3", "text": "         The Flat Tax does not apply to dividends from shares of the Company held as business assets of\nshareholders who are tax resident in Germany. In this case, the taxation is based on whether the shareholder is a\ncorporation, an individual or a partnership. The withholding tax withheld and paid to the tax authorities,\nincluding the solidarity surcharge, is credited against the income or corporate income tax and the solidarity\nsurcharge of the shareholder, and any overpayment will be refunded.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5025662959794697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5714285714285714, "height": 0.06886227544910173, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-4", "text": "          Dividend payments that are funded from the Company\u2019s tax-recognized contribution account\n(steuerliches Einlagekonto) and paid to shareholders who are tax resident in Germany and whose shares are held\nas business assets are generally fully tax-exempt in the hands of such shareholders. At the same time, such\ndividend payments lead to a corresponding reduction of the acquisition costs/book value for the relevant shares.\nTo the extent the dividend payments funded from the Company\u2019s tax-recognized contribution account\n(steuerliches Einlagekonto) exceed the acquisition costs/book value of the shares, a taxable capital gain should\noccur. The taxation of such gain corresponds to the taxation of shareholders whose shares are held as business\nassets (see \u201c20.5 Taxation of Capital Gains\u201d). However, as regards the application of the 95% exemption in case\nof a corporation, this is not undisputed.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5812660393498716, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7014542343883661, "height": 0.12018819503849443, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-5", "text": "20.3.2.1   Corporations\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7181351582549187, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.7309666381522669, "height": 0.01283147989734823, "width": 0.1789600967351874}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-6", "text": "          Dividends received by corporations that are tax resident in Germany are generally exempt from\ncorporate income tax and solidarity surcharge. However, 5% of the dividends are treated as a non-deductible\nbusiness expenses and, as such, are subject to corporate income tax (plus the solidarity surcharge) with a total\ntax rate of 15.825%.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7455089820359282, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7972626176218991, "height": 0.0517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-7", "text": "         Portfolio Dividends are fully taxed at the corporate income tax rate (plus solidarity surcharge thereon).\nThe acquisition of a shareholding of at least 10% during a calendar year is deemed to have occurred at the\nbeginning of the respective calendar year. Participations which a shareholder holds through a commercial\npartnership are only attributable to such shareholder on a pro rata basis at the ratio of the interest share of the\nshareholder in the assets of the relevant partnership.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8071000855431993, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8751069289991446, "height": 0.06800684345594521, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-8", "text": "         Business expenses actually incurred and with a direct business relationship to the dividends may be\nfully deducted.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.8823781009409752, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9097519247219846, "height": 0.027373823781009388, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-215-9", "text": "172", "page_number": 215, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-0", "text": "         Any dividends (after deducting business expenses related to the dividends) are fully subject to trade\ntax, unless the corporation held at least 15% of the Company\u2019s registered share capital at the beginning of the\nrelevant tax assessment period, entitling it to an intercorporate privilege for trade tax purposes. In such case, the\naforementioned exemption of 95% of the dividend income applies analogously for trade tax purposes.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.055175363558597104, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-1", "text": "20.3.2.2   Sole Proprietors (Individuals)\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15355004277159967, "lower_right_x": 0.40870616686819833, "lower_right_y": 0.16766467065868262, "height": 0.014114627887082953, "width": 0.28839177750906897}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-2", "text": "         If the shares in the Company are held as part of the business assets of a sole proprietor (individual) with\nhis or her tax residence in Germany, 40% of any dividend is tax exempt (so-called partial income method). Only\n60% of the expenses economically related to the dividends are tax deductible. The partial income method also\napplies when individuals hold the shares indirectly through a partnership (with the exception of individual\ninvestors who hold their shares through partnerships that are neither commercial partnerships nor deemed to be\ncommercial partnerships). However, the partial-income method does not apply with respect to church tax (if\napplicable). If the shares are held as business assets of a domestic commercial permanent establishment, the full\namount of the dividend income (after deducting business expenses that are economically related to the\ndividends) is also subject to trade tax, unless the taxpayer held at least 15% of the Company\u2019s registered share\ncapital at the beginning of the relevant tax assessment period. In the latter case, the net dividends (after\ndeducting directly related expenses) are exempt from trade tax. However, trade tax is generally credited, in full\nor in part, as a lump sum against the relevant shareholder\u2019s personal income tax liability, depending on the tax\nrate imposed by the local municipality and certain individual tax-relevant circumstances of such shareholder.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18434559452523525, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3592814371257485, "height": 0.17493584260051326, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-3", "text": "20.3.2.3   Partnerships\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3759623609923011, "lower_right_x": 0.29443772672309554, "lower_right_y": 0.3887938408896493, "height": 0.012831479897348175, "width": 0.17412333736396615}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-4", "text": "         If a shareholder is a partnership, the personal income tax or corporate income tax, as the case may be,\nand the solidarity surcharge are levied at the level of each partner rather than at the level of the partnership. The\ntaxation of each partner depends upon whether the partner is a corporation or an individual. If the partner is a\ncorporation, dividends are generally 95% tax exempt. However, dividends from an indirect shareholding\nrepresenting less than 10% of the share capital for the relevant partner are fully subject to taxation\n(see \u201c20.3.2.1 Corporations\u201d). If the partner is an individual and the shares are held as business assets of the\npartnership, only 60% of the dividend income is subject to income tax. In this case, the partial-income method\ndoes not apply with respect to church tax, if applicable (see \u201c20.3.2.2 Sole Proprietors (Individuals)\u201d).\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5119760479041916, "height": 0.10863986313088109, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-5", "text": "          Additionally, if the shares are held as business assets of a domestic permanent establishment of an\nactual or presumed commercial partnership, the full amount of dividend income is generally also subject to trade\ntax at the level of the partnership. In the case of partners who are individuals, the trade tax that the partnership\npays on the relevant partner\u2019s portion of the partnership\u2019s income is generally credited as a lump sum \u2013 fully or\nin part \u2013 against the individual\u2019s personal income tax liability, depending on the tax rate imposed by the local\nmunicipality and certain individual tax-relevant circumstances of such shareholder. If the partnership held at\nleast 15% of the Company\u2019s registered share capital at the beginning of the relevant tax assessment period, the\ndividends (after deduction of business expenses economically related thereto) should generally not be subject to\ntrade tax. In this case, trade tax should, however, be levied on 5% of the dividends to the extent they are\nattributable to the profit share of such corporate partners to whom at least 10% of the shares in the Company are\nattributable on a look-through basis, since this portion of the dividends should be deemed to be non-deductible\nbusiness expenses. The remaining portion of the dividend income attributable to partners other than such\nspecific corporate partners (which includes individual partners and should, according to a literal reading of the\nlaw, also include corporate partners to whom, on a look-through basis, only portfolio participations are\nattributable) should not be subject to trade tax.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7249786142001711, "height": 0.20530367835757057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-6", "text": "20.3.2.4   Financial and Insurance Sector\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7386655260906758, "lower_right_x": 0.42019347037484883, "lower_right_y": 0.7502138579982891, "height": 0.011548331907613285, "width": 0.2998790810157195}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-7", "text": "         Special rules apply to companies operating in the financial and insurance sector, as well as pension\nfunds (see \u201c20.6 Special Treatment of Companies in the Financial and Insurance Sectors and Pension Funds\u201d).\n", "page_number": 216, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7660393498716852, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7938408896492729, "height": 0.027801539777587703, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-216-8", "text": "173", "page_number": 216, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-0", "text": "20.4   Taxation of Dividends of Shareholders without a Tax Residence in Germany\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7297460701330108, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.6094316807738814}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-1", "text": "         Dividends paid to shareholders of the Company (individuals and corporations) without a tax residence\nin Germany are taxed in Germany, provided that the shares are held as part of the business assets of a permanent\nestablishment or a fixed base in Germany or as part of the business assets for which a permanent representative\nin Germany has been appointed. The withholding tax (including solidarity surcharge) withheld and remitted to\nthe German tax authorities is credited against the respective shareholder\u2019s personal income tax or corporate\nincome tax liability, and any overpayment will be refunded. The same applies to the solidarity surcharge. These\nshareholders are essentially subject to the same rules applicable to tax resident shareholders, as discussed above.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20872540633019676, "height": 0.09623609923011121, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-2", "text": "        In all other cases, the withholding of the dividend withholding tax discharges any tax liability of the\nshareholder in Germany. A refund or exemption is granted only as discussed with respect to dividend\nwithholding tax (see \u201c20.2.2 Withholding Tax\u201d).\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.21514114627887082, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2566295979469632, "height": 0.041488451668092396, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-3", "text": "          Dividend payments that are funded from the Company\u2019s tax-recognized contribution account\n(steuerliches Einlagekonto) are generally not taxable in Germany.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.26646706586826346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2925577416595381, "height": 0.02609067579127461, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-4", "text": "20.5       Taxation of Capital Gains\n\n20.5.1     Taxation of Capital Gains of Shareholders with a Tax Residence in Germany\n\n20.5.1.1      Shares Held as Private Assets\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3075278015397776, "lower_right_x": 0.7152357920193471, "lower_right_y": 0.3763900769888794, "height": 0.06886227544910178, "width": 0.599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-5", "text": "          Gains on the sale of shares of the Company that are held as private assets by shareholders with a tax\nresidence in Germany and which were acquired after December 31, 2008, are generally taxable regardless of the\nlength of time held. The tax rate is generally a uniform 25% plus the 5.5% solidarity surcharge thereon\n(resulting in an aggregate tax rate of 26.375%) as well as any church tax, if applicable.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4448246364414029, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-6", "text": "         The taxable capital gains are the difference between (i) the proceeds from the disposal of the shares\nafter deducting the direct sales costs and (ii) the acquisition costs of the shares. Under certain conditions, prior\npayments from the tax-recognized contribution account (steuerliches Einlagekonto) may lead to reduced\nacquisition costs of the shares held as private assets and, as a consequence, increase the taxable sales gain.\nLosses on the sale of shares can only be used to offset gains made on the sale of shares during the same year or\nin subsequent years.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5329341317365269, "height": 0.08169375534644996, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-7", "text": "          If the shares are held in custody or administered by a domestic bank or financial service institute, a\ndomestic securities trading company or a domestic securities trading bank (including the domestic branches of\nforeign banks and financial service institutes), or if such entity or branch sells the shares and pays out or credits\nthe capital gains (each a \u201cDomestic Paying Agent\u201d), such Domestic Paying Agent withholds a withholding tax\nof 25% plus 5.5% solidarity surcharge thereon and any church tax, if applicable, and remits such taxes to the tax\nauthority. In such a case, the tax on the capital gain will generally be discharged. If the shares were only held in\ncustody or administered by the respective Domestic Paying Agent continuously after acquisition, the amount of\ntaxes withheld is generally based on the difference between the proceeds from the sale, after deducting expenses\ndirectly related to the sale, and the amount paid to acquire such shares. However, the withholding tax rate of\n25% plus the 5.5% solidarity surcharge thereon and any church tax, if applicable, will be applied to 30% of the\ngross sales proceeds, if the shares were not administered by the same custodian bank since acquisition and the\noriginal cost of the shares cannot be verified or such verification is not admissible. In this case, the shareholder\nis entitled to, and in case the actual gain is higher than 30% of the gross proceeds required to, verify the original\ncosts of the shares in his annual tax return.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5402053036783576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7288280581693756, "height": 0.18862275449101795, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-8", "text": "         Entities required to collect withholding taxes on capital investment income are also required to\nwithhold the church tax for shareholders who are subject to church tax, unless the shareholder objects in writing\nto the Federal Central Office of Taxation (Bundeszentralamt f\u00fcr Steuern) against the sharing of his private\ninformation regarding his affiliation with a denomination (Sperrvermerk). If church tax is withheld and remitted\nto the tax authority as part of the withholding tax deduction, then the church tax on the capital gain is also\ndeemed to be discharged when it is deducted. The withheld church tax cannot be deducted in the tax assessment\nas a special expense. However, 26.375% of the church tax withheld on the capital gain is deducted from the\nwithholding tax (including the solidarity surcharge) withheld.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7386655260906758, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8485885372112917, "height": 0.10992301112061587, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-217-9", "text": "174", "page_number": 217, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-0", "text": "         A shareholder may request that all of his items of capital investment income, along with his other\ntaxable income, are subject to the progressive income tax rate instead of the uniform tax rate for private capital\ninvestment income if this lowers his tax burden. In such case, the base for taxation would be the gross income\nless the savers\u2019 allowance of \u20ac801.00 (\u20ac1,602.00 for jointly filing individuals). The prohibition on deducting\nincome-related costs and the restrictions on offsetting losses also apply to tax assessments based on the\nprogressive income tax rate. Any tax already withheld would be credited against the income tax so determined,\nand any overpayment refunded.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18135158254918735, "height": 0.09623609923011121, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-1", "text": "         One exception to this rule is that a shareholder\u2019s capital gains are subject to the partial income method\nand not the Flat Tax. Consequently, 60% of the proceeds from the sale of shares are subject to the individual\nincome tax rate, if the shareholder, or his legal predecessor in case of acquisition without consideration, has\ndirectly or indirectly held shares equal to at least 1% of the Company\u2019s share capital at any time during the\nprevious five years. 60% of the expenses economically related to the proceeds from the sale of shares are\ntax-deductible.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.18776732249786143, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2686056458511548, "height": 0.08083832335329338, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-2", "text": "         In the case of a Qualified Participation, withholding tax (including the solidarity surcharge) is also\nwithheld by the Domestic Paying Agent. The tax withheld, however, is not treated as a final tax. Hence, the\nshareholder is required to declare the gains from the sale in his income tax return. The withholding tax\n(including solidarity surcharge) withheld and remitted to the German tax authorities is credited against the\nrespective shareholder\u2019s personal income tax liability, and any overpayment will be refunded.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.276732249786142, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3455945252352438, "height": 0.06886227544910178, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-3", "text": "20.5.1.2   Shares Held as Business Assets\n", "page_number": 218, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35885372112917024, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.3721129170230967, "height": 0.013259195893926434, "width": 0.3004836759371221}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-4", "text": "         The Flat Tax does not apply to proceeds from the sale of shares held as business assets by shareholders\ntax resident in Germany. If the shares form part of a shareholder\u2019s business assets, taxation of the capital gains\nrealized will then depend upon whether the shareholder is a corporation, sole proprietor or partnership. Dividend\npayments that are funded from the Company\u2019s tax-recognized contribution account (steuerliches Einlagekonto)\nreduce the original acquisition costs/book value. This may give rise to a higher taxable capital gain in case of a\nsale of shares. If the dividend payments exceed the shares\u2019 book value for tax purposes, a taxable capital gain\n", "page_number": 218, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4751924721984602, "height": 0.0855431993156544, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-5", "text": "may arise.\n        1.   Corporations: In general, capital gains earned from the sale of shares by corporations domiciled\n             in Germany are exempt from corporate income tax (including the solidarity surcharge) and trade\n             tax, irrespective of the stake represented by the shares and the length of time the shares are held.\n             However, 5% of the capital gains are treated as a non-deductible business expenses and, as such,\n             are subject to corporate income tax (plus the solidarity surcharge thereon) and to trade tax.\n        2.   Sole proprietors (individuals): If the shares of the Company were acquired after December 31,\n             2008 and form part of the business assets of a sole proprietor (individual) who is tax resident in\n             Germany, 60% of the capital gains on their sale are subject to the individual\u2019s personal tax rate\n             plus the solidarity surcharge thereon (partial income method). Correspondingly, only 60% of\n             losses from such sales and 60% of expenses economically related to such sales are deductible. For\n             church tax, if applicable, the partial income method does not apply. If the shares are held as\n             business assets of a commercial permanent establishment located in Germany, 60% of the capital\n             gains are also subject to trade tax. The trade tax is fully or partially credited as a lump sum against\n             the shareholder\u2019s personal income tax liability, depending on the tax rate imposed by the local\n             municipality and certain individual tax-relevant circumstances of such shareholder.\n        3.   Commercial partnerships: If the shareholder is a partnership, personal income tax or corporate\n             income tax, as the case may be, is assessed at the level of each partner rather than at the level of\n             the partnership. The taxation of each partner depends upon whether the respective partner is a\n             corporation or an individual. If the partner is a corporation, the tax principles applying to capital\n             gains which are outlined in subsection 1 apply. If the partner is an individual, the tax principles\n             applying to capital gains that are outlined in subsection 2 apply. Upon application and provided\n             that additional prerequisites are met, an individual who is a partner may obtain a reduction of his\n             personal income tax rate for profits not withdrawn from the partnership. In addition, capital gains\n             from the sale of shares attributable to a permanent establishment maintained in Germany by an\n             actual or presumed commercial partnership are subject to trade tax at the level of the partnership.\n             In such case, generally only 60% of the gains are subject to trade tax to the extent the partners in\n             the partnership are individuals, while 5% are subject to trade tax to the extent the partners are\n             corporations and shares are sold. Under the principles discussed above, losses on sales and other\n             reductions in profit related to the shares sold are generally not deductible or only partially\n", "page_number": 218, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4756201881950385, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9033361847733106, "height": 0.4277159965782721, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-218-6", "text": "175\n", "page_number": 218, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010265183917878562, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-0", "text": "deductible, if the partner is a corporation. If the partner is an individual, the trade tax the\npartnership pays on his share of the partnership\u2019s income is generally credited as a lump sum \u2013\nfully or in part \u2013 against his personal income tax liability, depending on the tax rate imposed by the\nlocal municipality and certain individual tax-relevant circumstances of the taxpayer.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.055175363558597104, "width": 0.6729141475211609}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-1", "text": "         Special rules apply to capital gains realized by companies operating in the financial and insurance\nsectors, as well as pension funds (see \u201c20.6 Special Treatment of Companies in the Financial and Insurance\nSectors and Pension Funds\u201d).\n", "page_number": 219, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881950384944397, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-2", "text": "          If a Domestic Paying Agent is involved, the proceeds from the sale of shares of the Company held as\nbusiness assets are generally subject to the same withholding tax rate as those of shareholders whose shares are\nheld as private assets (see \u201c20.5.1.1 Shares Held as Private Assets\u201d). However, the Domestic Paying Agent may\nrefrain from withholding the withholding tax if (i) the shareholder is a corporation, association or estate with its\ntax residence in Germany, or (ii) the shares form part of the shareholder\u2019s domestic business assets, and the\nshareholder informs the Domestic Paying Agent of this on the officially prescribed form and meets certain\nadditional prerequisites. If the Domestic Paying Agent nevertheless withholds taxes, the withholding tax\nwithheld and remitted (including the solidarity surcharge and church tax, if applicable) will be credited against\nthe relevant shareholder\u2019s income tax or corporate income tax liability (including the solidarity surcharge and\nchurch tax, if applicable) and any excess amount will be refunded.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19461077844311378, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3319076133447391, "height": 0.13729683490162534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-3", "text": "20.5.2   Taxation of Capital Gains of Shareholders without a Tax Residence in Germany\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34602224123182207, "lower_right_x": 0.7394195888754534, "lower_right_y": 0.36142001710863986, "height": 0.015397775876817787, "width": 0.6239419588875453}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-4", "text": "         Capital gains realized by a shareholder without a tax residence in Germany are only subject to German\nincome tax if the selling shareholder holds a Qualified Participation or if the shares form part of the business\nassets of a permanent establishment in Germany or of business assets for which a permanent representative is\nappointed.\n          Most double taxation treaties provide for an exemption from German taxes and assign the right of\ntaxation to the shareholder\u2019s country of tax residence in the former case.\n\n20.6    Special Treatment of Companies in the Financial and Insurance Sectors and Pension Funds\n", "page_number": 219, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3618477331052181, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4923011120615911, "height": 0.130453378956373, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-5", "text": "          As an exception to the aforementioned rules, dividends paid to, and capital gains realized by, certain\ncompanies in the financial and insurance sector are fully taxable. This applies to dividends received on, as well\nas gains from the disposal of, shares in a trading portfolio within the meaning of Section 340e para. 3 HGB of\ncredit institutions and financial services institutions, and shares that are, upon acquisition of the shares, allocable\nto the current assets of a financial enterprise within the meaning of the German Banking Act\n(Kreditwesengesetz) that is directly or indirectly held by a credit institution or financial services institution to\nmore than 50%. The same applies to shares of the Company held as investments by life insurance providers,\nhealth insurance providers and pension funds. If the shareholding at the beginning of the relevant assessment\nperiod is 15% or higher, the dividends may, subject to certain conditions, be fully exempted from trade tax.\nHowever, an exemption to the foregoing (i.e., a 95% effective tax exemption) applies to dividends obtained by\nthe aforementioned companies, if such companies fall within the scope of the Parent-Subsidiary Directive.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6565440547476475, "height": 0.1505560307955517, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-6", "text": "20.7   Inheritance and Gift Tax\n", "page_number": 219, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6702309666381523, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.6834901625320787, "height": 0.013259195893926434, "width": 0.24244256348246676}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-7", "text": "         The transfer of shares to another person by inheritance or gift is generally only subject to German\ninheritance or gift tax if:\n", "page_number": 219, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6976047904191617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7254063301967494, "height": 0.027801539777587703, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-8", "text": "1.   the decedent, donor, heir, beneficiary or other transferee maintained his domicile or habitual abode\n     in Germany, or had its place of management or registered office in Germany at the time of the\n     transfer, or is a German citizen who has spent no more than five consecutive years (this term is\n     extended to ten years for German expatriates with residence in the United States) prior to the\n     transfer outside Germany without maintaining a residence in Germany (special rules apply to\n     certain former German citizens who neither maintain their domicile nor have their habitual abode\n     in Germany); or\n2.   the shares were held by the decedent or donor as part of business assets for which a permanent\n     establishment was maintained in Germany or for which a permanent representative in Germany\n     had been appointed; or\n", "page_number": 219, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.7318220701454234, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8759623609923011, "height": 0.14414029084687763, "width": 0.7013301088270859}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-219-9", "text": "176", "page_number": 219, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-0", "text": "3.   the decedent or donor, either individually or collectively with related parties, held, directly or\n     indirectly, at least 10% of the Company\u2019s registered share capital at the time of the inheritance or\n     gift.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-1", "text": "         The few German double taxation treaties relating to inheritance tax and gift tax currently in force\nusually provide that the German inheritance tax or gift tax can only be levied in the cases of (1.) above, and also\nwith certain restrictions in case of (2.) above. Special provisions apply to certain German nationals living\noutside Germany and former German nationals.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1330196749358426, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881950384944397, "height": 0.05517536355859709, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-2", "text": "        The fair value of the shares represents the tax assessment base, which generally corresponds to the\nstock exchange price of the Company\u2019s shares. Depending on the degree of relationship between decedent or\ndonor and recipient, different tax-free allowances and tax rates apply.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19461077844311378, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.04148845166809237, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-3", "text": "20.8   The Proposed Financial Transactions Tax\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.26518391787852863, "height": 0.01240376390076986, "width": 0.3633615477629988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-4", "text": "         On February 14, 2013, the European Commission published a proposal (the \u201cCommission\u2019s\nProposal\u201d) for a Directive for a common financial transaction tax in Belgium, Germany, Estonia, Greece,\nSpain, France, Italy, Austria, Portugal, Slovenia and Slovakia (the \u201cParticipating Member States\u201d). However,\nEstonia has since stated that it will not participate. The Commission\u2019s Proposal is currently under review and it\nis unclear if and to what extent it will be implemented, if ever.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34773310521813516, "height": 0.067579127459367, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-5", "text": "         The Commission\u2019s Proposal has very broad scope and could, if introduced, apply to certain dealings in\nthe Company\u2019s shares (including secondary market transactions) in certain circumstances. The issuance and\nsubscription of shares should, however, be exempt.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.35543199315654406, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3956372968349016, "height": 0.04020530367835756, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-6", "text": "         Under the Commission\u2019s Proposal the financial transaction tax could apply in certain circumstances to\npersons both within and outside of the Participating Member States. Generally, it would apply to certain\ndealings in the Company\u2019s shares where at least one party is a financial institution, and at least one party is\nestablished in a Participating Member State. A financial institution may be, or be deemed to be, established in a\nParticipating Member State in a broad range of circumstances (e.g., by transacting with a person established in a\nParticipating Member State or where the financial instrument which is subject to the dealings is issued in a\nParticipating Member State).\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49871685201026517, "height": 0.09538066723695465, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-7", "text": "         However, the Commission\u2019s Proposal remains subject to negotiations between Participating Member\nStates. It may, therefore, be altered prior to any implementation, the timing of which remains unclear.\nAdditional member states of the European Union may decide to participate.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5059880239520959, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5466210436270317, "height": 0.04063301967493582, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-8", "text": "        Prospective holders are advised to seek their own professional advice in relation to the Commission\u2019s\nProposal to introduce a financial transaction tax.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5538922155688623, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5812660393498716, "height": 0.027373823781009388, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-9", "text": "20.9   Other Taxes\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5949529512403764, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.6060735671514115, "height": 0.011120615911035081, "width": 0.1505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-10", "text": "         No German transfer tax, value-added tax, stamp duty or similar taxes are assessed on the purchase, sale\nor other transfer of shares of the Company. Provided that certain requirements are met, an entrepreneur may,\nhowever, opt for the payment of value-added tax on transactions that are otherwise tax-exempt. Net wealth tax is\ncurrently not imposed in Germany.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6223267750213858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6775021385799829, "height": 0.05517536355859709, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-220-11", "text": "ET", "page_number": 220, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-0", "text": "TAXATION IN THE GRAND DUCHY OF LUXEMBOURG\n", "page_number": 221, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.08511548331907613, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.44014510278113667}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-1", "text": "21.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.2460701330108827, "top_left_y": 0.08597091531223268, "lower_right_x": 0.26964933494558646, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.023579201934703753}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-2", "text": "          The following information is of a general nature only and is based on the laws in force in Luxembourg\nas of the date of this Prospectus and is subject to any change in law that may take effect after such date. It does\nnot purport to be a comprehensive description of all tax considerations that might be relevant to an investment\ndecision. It is not intended to be, nor should it be construed to be, legal or tax advice. It is a description of the\nessential material Luxembourg tax consequences with respect to the listing and may not include tax\nconsiderations that arise from rules of general application or that are generally assumed to be known to\nshareholders. Prospective shareholders should consult their professional advisors with respect to particular\ncircumstances, the effects of state, local or foreign laws to which they may be subject, and as to their tax\nposition.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23609923011120615, "height": 0.1236099230111206, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-3", "text": "          Please be aware that the residence concept used under the respective headings applies for Luxembourg\nincome tax assessment purposes only. Any reference in this section to a tax, duty, levy impost or other charge or\nwithholding of a similar nature refers to Luxembourg tax law and/or concepts only. In addition, please note that\na reference to Luxembourg income tax generally encompasses corporate income tax (imp\u00f4t sur le revenu des\ncollectivit\u00e9s), municipal business tax (imp\u00f4t commercial communal), a solidarity surcharge (contribution au\nfonds pour l\u2019emploi) as well as personal income tax (imp\u00f4t sur le revenu). Corporate Shareholders may further\nbe subject to net wealth tax (imp\u00f4t sur la fortune) as well as other duties, levies or taxes. Corporate income tax,\nmunicipal business tax, the solidarity surcharge and the net wealth tax invariably apply to most corporate\ntaxpayers resident in Luxembourg for tax purposes. Individual taxpayers are generally subject to personal\nincome tax and the solidarity surcharge. Under certain circumstances, where an individual taxpayer acts in the\ncourse of the management of a professional or business undertaking, municipal business tax may apply as well.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24251497005988024, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39349871685201027, "height": 0.15098374679213003, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-4", "text": "21.1   Withholding Taxes\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4101796407185629, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.42172797262617623, "height": 0.01154833190761334, "width": 0.19891172914147523}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-5", "text": "          Dividend payments made to shareholders by a non-resident company, such as the Company, as well as\nliquidation proceeds and capital gains derived therefrom, are not subject to a withholding tax in Luxembourg.\nTherefore, the Company does not assume liability for withholding Luxembourg taxes at the source.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4375534644995723, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47904191616766467, "height": 0.041488451668092396, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-6", "text": "21.2   Taxation of Dividend Income\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4923011120615911, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.5029940119760479, "height": 0.010692899914456766, "width": 0.2714631197097944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-7", "text": "        Under certain conditions, a corresponding tax credit may be granted to the shareholders of the\nCompany for foreign withholding taxes against Luxembourg income tax due on these dividends, without\nexceeding in any case Luxembourg tax on such income.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5196749358426005, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.561163387510693, "height": 0.04148845166809245, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-8", "text": "21.2.1   Luxembourg Resident Shareholders\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5744225834046194, "lower_right_x": 0.42986698911729143, "lower_right_y": 0.5885372112917023, "height": 0.014114627887082953, "width": 0.313180169286578}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-9", "text": "         Dividends and other payments derived from the shares of the Company held by resident individual\nshareholders, who act in the course of the management of either their private wealth or their\nprofessional/business activity, are subject to income tax at the ordinary progressive rates with a current top\neffective marginal tax rate of 42% (45.78% including the maximum 9% solidarity surcharge), depending on the\nannual level of income of the shareholders.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6017964071856288, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6706586826347305, "height": 0.06886227544910173, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-10", "text": "          Furthermore, actual income related expenses (e.g., bank fees) are deducted, provided that they are\nsupported by documents or a lump-sum deduction of \u20ac25.00 applies (doubled for individual taxpayers who are\njointly taxable).\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6770744225834047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718562874251497, "height": 0.04148845166809234, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-11", "text": "         Under current Luxembourg tax laws, 50% of the gross amount of dividends received by resident\nindividuals from the Company may however be exempt from income tax, since the Company is a company\nbased in the European Union and covered by Article 2 of the Parent-Subsidiary Directive. In addition, a total\nlump-sum exemption of \u20ac1,500 (doubled for individual taxpayers who are jointly taxable) applies to the total\ninvestment income (dividends and interest) received during the tax year.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7249786142001711, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7938408896492729, "height": 0.06886227544910184, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-12", "text": "         Dividends derived from the shares of the Company by fully taxable Luxembourg resident companies\nare subject to income taxes, unless the conditions of the participation exemption regime are satisfied.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.800256629597947, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8280581693755347, "height": 0.027801539777587703, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-221-13", "text": "178", "page_number": 221, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-0", "text": "         Subject to the anti-abuse provisions of Article 166 of the Luxembourg Income Tax Law, the\nparticipation exemption regime provides that dividends derived from the shares of the Company may be exempt\nfrom income tax at the level of the shareholder if cumulatively:\n", "page_number": 222, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-1", "text": "\uf0b7   the Shareholder receiving the dividends is either (i) a fully taxable Luxembourg resident company,\n    or (ii) a domestic permanent establishment of a company resident in the European Union falling\n    under Article 2 of the Parent-Subsidiary Directive, or (iii) a domestic permanent establishment of a\n    joint-stock company limited by shares (soci\u00e9t\u00e9 de capitaux) that is resident in a state with which\n    Luxembourg has concluded a double taxation treaty, or (iv) a domestic permanent establishment of\n    a joint-stock company limited by shares (soci\u00e9t\u00e9 de capitaux) or of a cooperative company which\n    is a resident of an EEA Member State (other than a member state of the European Union) (each an\n    \u201cEligible Parent\u201d);\n\uf0b7   the Company is (i) a Luxembourg resident fully-taxable joint-stock company limited by shares\n    (soci\u00e9t\u00e9 de capitaux), or (ii) a company covered by Article 2 of the Parent-Subsidiary Directive, or\n    (iii) a non-resident joint-stock company limited by shares (soci\u00e9t\u00e9 de capitaux) liable to a tax\n    corresponding to Luxembourg corporate income tax at a rate of a minimum of 9.5% (and 9.0%\n    from January 1, 2018) (\u201cQualified Subsidiary\u201d); and\n\uf0b7   at the date on which the relevant income is made available, the shareholder of the Company\n    directly holds or commits to hold for an uninterrupted period of at least twelve months a\n    shareholding representing a direct participation of at least 10% in the share capital of the Qualified\n    Subsidiary or a direct participation in the Qualified Subsidiary of an acquisition price of at least\n    \u20ac1.2 million, or an equivalent amount in another currency (\u201cQualified Shareholding\u201d).\n", "page_number": 222, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.1364414029084688, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39692044482463645, "height": 0.26047904191616766, "width": 0.7019347037484885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-2", "text": "         Liquidation proceeds are assimilated to a dividend received and may be exempt under the same\nconditions. Shares held through a tax transparent entity are considered as being a direct participation\nproportionally to the percentage held in the net assets of the transparent entity. To the extent that business\nexpenses incurred during the year of receipt of the dividend are in an economic relation with the participation in\nthe Company, these expenses will not be deductible up to the amount of exempt dividends and/or liquidation\nproceeds derived from the shareholding in the Company (during the year of receipt of the dividend).\n", "page_number": 222, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48588537211291705, "height": 0.08254918733960653, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-3", "text": "         If the participation exemption does not apply, dividends may benefit from the 50% exemption under\nthe relevant conditions set out above.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5175363558597091, "height": 0.025235243798118034, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-4", "text": "          Any shareholder of the Company which is a Luxembourg resident entity governed by the Luxembourg\nLaw of December 17, 2010 on undertakings for collective investment, as amended, by the Luxembourg Law of\nFebruary 13, 2007 on specialized investment funds, as amended, by the Luxembourg Law of May 11, 2007 on\nthe family wealth management company, as amended, or by the Luxembourg Law of July 23, 2016 on reserved\nalternative investment funds (without having opted for the application of the venture capital regime), is exempt\nfrom Luxembourg income taxes, and profits derived from the shares in the Company are therefore not subject to\nLuxembourg income taxes.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5273738237810094, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6227544910179641, "height": 0.09538066723695471, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-5", "text": "21.2.2   Non-Resident Shareholders\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.636869118905047, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.6501283147989735, "height": 0.013259195893926434, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-6", "text": "          Shareholders of the Company who are non-residents of Luxembourg and who have neither a permanent\nestablishment nor a fixed place of business or a permanent representative in Luxembourg to which the shares are\nattributable are not liable to any Luxembourg income tax on dividends received from the Company.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6668092386655261, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7065868263473054, "height": 0.0397775876817793, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-7", "text": "         Subject to the provisions of double taxation treaties, dividends on the shares received by non-resident\nshareholders holding the shares through a Luxembourg permanent establishment or through a Luxembourg\npermanent representative to which or whom the shares are attributable are subject to income tax at ordinary rates\nunless the conditions of the participation exemption as described above apply. If the conditions of the\nparticipation exemption are not fulfilled, 50% of the gross dividends of the Company received by a Luxembourg\npermanent establishment or permanent representative may, however, be exempt from Luxembourg income\ntaxes, given that the Company is a company based in the European Union and covered by Article 2 of the\nParent-Subsidiary Directive.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7147134302822925, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8229255774165953, "height": 0.10821214713430283, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-222-8", "text": "179\n", "page_number": 222, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9443969204448246, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.009837467921300247, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-0", "text": "21.3     Taxation of Capital Gains\n\n21.3.1   Luxembourg Resident Shareholders\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08511548331907613, "lower_right_x": 0.42986698911729143, "lower_right_y": 0.1270316509837468, "height": 0.04191616766467067, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-1", "text": "         Capital gains realized on the disposal of shares of the Company by individual shareholders resident in\nLuxembourg, who act in the course of the management of their private wealth, are not subject to income tax,\nunless said capital gains qualify either as speculative gains or as gains on a substantial participation\n(\u201cSubstantial Participation\u201d). Capital gains are deemed to be speculative and are subject to income tax at\nordinary rates if the shares are disposed of within six months after their acquisition or if their disposal precedes\ntheir acquisition. A disposal may include a sale, an exchange, a contribution or any other kind of alienation of\nthe shares.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.14328485885372114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2352437981180496, "height": 0.09195893926432847, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-2", "text": "          A participation is deemed to be substantial where a resident individual shareholder holds, either alone\nor together with his spouse or partner and/or minor children, directly or indirectly at any time within the five\nyears preceding the disposal, more than 10% of the share capital of the Company. A shareholder is also deemed\nto transfer a Substantial Participation if within the five years preceding the transfer he acquired free of charge a\nparticipation that constituted a Substantial Participation in the hands of the transferor (or the transferors in case\nof successive transfers free of charge within the same five-year period). Capital gains realized on a Substantial\nParticipation more than six months after the acquisition thereof are subject to Luxembourg income tax according\nto the half-global rate method (i.e., the average rate applicable to the total income is calculated according to\nprogressive income tax rates and half of the average rate is applied to the capital gains realized on a Substantial\nParticipation) and may benefit from an allowance of up to \u20ac50,000.00 granted for a ten-year period (doubled for\nindividual taxpayers who are jointly taxable).\n", "page_number": 223, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.24593669803250642, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39520958083832336, "height": 0.14927288280581694, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-3", "text": "       Capital gains realized on the disposal of shares of the Company by individual shareholders resident in\nLuxembourg, who act in the course of their professional/business activity, are subject to income tax at ordinary\nrates.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4405474764756202, "height": 0.03721129170230969, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-4", "text": "          Capital gains realized on the shares of the Company by (i) a fully taxable Luxembourg resident\ncompany or (ii) the Luxembourg permanent establishment or permanent representative of a non-resident foreign\ncompany to which the shares are attributable, are subject to Luxembourg income tax at the maximum global rate\nof 26.01% (in Luxembourg-City in 2018), unless the conditions of the participation exemption regime, as\ndescribed below, are satisfied, provided that the acquisition price must amount to at least \u20ac6.0 million for capital\ngain exemption purposes. Shares held through a tax transparent entity are considered as a direct participation\nholding proportionally to the percentage held in the assets of the transparent entity. To the extent that expenses\nrelated to the (exempt) shareholding or write-downs deducted in relation to the participation have reduced the\nrelevant shareholder\u2019s taxable profits (during the year of the sale or in prior years), the exempt amount of the\ncapital gain will be reduced by the sum of the excess expenses and capital write-downs which are in direct\neconomic connection with the participation and were deducted over current and previous years.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.45124037639007697, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6000855431993156, "height": 0.14884516680923865, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-5", "text": "        Taxable gains are determined as being the difference between the price for which the shares have been\ndisposed of and the lower of their cost or book value. Any expenses in excess of the capital gains remain fully\ntax deductible.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6086398631308811, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6467065868263473, "height": 0.038066723695466154, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-6", "text": "          Any shareholder of the Company which is a Luxembourg resident entity governed by the Luxembourg\nLaw of December 17, 2010 on undertakings for collective investment, as amended, by the Luxembourg Law of\nFebruary 13, 2007 on specialized investment funds, as amended, by the Luxembourg Law of May 11, 2007 on\nthe family estate management company, as amended, or by the Luxembourg Law of July 23, 2016 on reserved\nalternative investment funds (without having opted for the application of the venture capital regime), is not\nsubject to any Luxembourg income taxes in respect of capital gains realized upon disposal of its shares.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6565440547476475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.739093242087254, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-223-7", "text": "180", "page_number": 223, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-0", "text": "21.3.2   Non-Resident Shareholders\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08511548331907613, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.25634824667472794}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-1", "text": "         Non-resident shareholders who have neither a permanent establishment nor a permanent representative\nin Luxembourg to which the shares in the Company are attributable, are not liable for any Luxembourg income\ntax on capital gains upon disposal of shares in the Company, except with respect to capital gains realized on a\nSubstantial Participation prior to the acquisition or within the first six months of the acquisition thereof, in\nwhich case capital gains are subject to income tax in Luxembourg at ordinary rates (subject to the provisions of\na relevant double taxation treaty).\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19503849443969204, "height": 0.08254918733960649, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-2", "text": "          Under Luxembourg tax laws and subject to the provisions of double taxation treaties, capital gains\nrealized on the disposal of shares in the Company by a non-resident shareholder holding the shares through a\nLuxembourg permanent establishment or through a Luxembourg permanent representative to which or whom\nthe shares are attributable are subject to income tax at ordinary rates unless the conditions of the participation\nexemption as described above are satisfied. Taxable gains are determined as being the difference between the\nprice for which the shares have been disposed of and the lower of their cost or book value.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2840034217279726, "height": 0.08254918733960648, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-3", "text": "21.4   Net Wealth Tax\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.3109495295124038, "height": 0.010265183917878562, "width": 0.1747279322853688}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-4", "text": "          Luxembourg resident shareholders of the Company, as well as non-resident shareholders who have a\npermanent establishment or a permanent representative in Luxembourg to which or whom the shares are\nattributable, are subject to Luxembourg net wealth tax on its net assets as determined for net wealth tax purposes\non the net wealth tax assessment date (January 1 of each year), except if the relevant shareholder is (i) a resident\nor non-resident individual, (ii) governed by the Luxembourg Law of May 11, 2007 on family estate\nmanagement companies, as amended, (iii) governed by the Luxembourg Law of December 17, 2010 on\nundertakings for collective investment, as amended, (iv) governed by the Luxembourg Law of February 13,\n2007 on specialized investment funds, as amended, (v) a securitization company governed by the Luxembourg\nLaw of March 22, 2004 on securitization, as amended, (vi) a venture capital company governed by the\nLuxembourg Law of June 15, 2004 on venture capital vehicles, as amended, (vii) a professional pension\ninstitution governed by the Luxembourg Law of July 13, 2005, as amended, or (viii) a reserved alternative\ninvestment fund vehicle governed by the Luxembourg Law of July 23, 2016.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4914456800684346, "height": 0.16338751069289992, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-5", "text": "          Please note, however, that securitization companies governed by the Luxembourg Law of March, 22,\n2004 on securitization, as amended, venture capital companies governed by the Luxembourg Law of June 15,\n2004 on venture capital vehicles, as amended, professional pension institutions governed by the Luxembourg\nLaw of July 13, 2005, as amended, or reserved alternative investment funds (opting to be treated as a venture\ncapital vehicle for Luxembourg tax purposes) governed by the Luxembourg Law of July 23, 2016 on reserved\nalternative investment funds may, under certain conditions, remain subject to minimum net wealth tax.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4991445680068435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5804106073567151, "height": 0.08126603934987164, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-6", "text": "          Furthermore, shares in the Company held by any shareholder who is an Eligible Parent may be exempt\nfrom net wealth tax for any given year, if at the net wealth tax assessment date, the shares represent a\nparticipation of at least 10% in the share capital of the Company or a participation of an acquisition price of at\nleast \u20ac1.2 million. However, if the relevant shareholder is a vehicle not listed under the exceptions (i) to\n(v) listed above or is not a reserved alternative investment fund vehicle governed by the Luxembourg Law of\nJuly 23, 2016 on reserved alternative investment funds (without having opted for the application of the venture\ncapital regime), as from January 1, 2017, it might be subject to a minimum net wealth tax of \u20ac4,815.00 if it\nholds assets (e.g., fixed financial assets, receivables owed to affiliated companies, transferable securities, postal\nchecking accounts, checks and cash) in a proportion that exceeds 90% of its total balance sheet value and if the\ntotal balance sheet value exceeds \u20ac350,000.00, or to a minimum net wealth tax between \u20ac535.00 and \u20ac32,100.00\nbased on the total amount of its assets.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.588109495295124, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7356715141146278, "height": 0.14756201881950382, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-7", "text": "21.5   Value Added Tax\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7523524379811805, "lower_right_x": 0.309552599758162, "lower_right_y": 0.7630453378956373, "height": 0.010692899914456877, "width": 0.18923821039903263}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-8", "text": "       There is no Luxembourg VAT payable in respect of payments in consideration for the subscription of\nthe Company\u2019s shares or in respect of the payment of dividends or the transfer of the shares.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.77972626176219, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8075278015397775, "height": 0.02780153977758759, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-224-9", "text": "181", "page_number": 224, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-225-0", "text": "21.6   Other Taxes\n", "page_number": 225, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.09923011120615911, "height": 0.014114627887082981, "width": 0.1505441354292624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-225-1", "text": "         Under current Luxembourg tax laws, no registration tax or similar tax is in principle payable by\nshareholders upon the acquisition, holding or disposal of shares in the Company. However, a fixed registration\nduty of \u20ac12.00 may be due upon registration of the shares in Luxembourg on a voluntary basis.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15397775876817793, "height": 0.04148845166809238, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-225-2", "text": "          A fixed registration duty of \u20ac75.00 is due upon incorporation of and any subsequent increase in the\ncapital of a Luxembourg company.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16039349871685202, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881950384944397, "height": 0.027801539777587675, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-225-3", "text": "         Under current Luxembourg tax law, where an individual shareholder of the Company is a resident of\nLuxembourg for inheritance tax purposes at the time of his death, the shares are included in his taxable basis for\ninheritance tax purposes.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.19803250641573994, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23438836612489308, "height": 0.03635585970915314, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-225-4", "text": "inheritance tax purposes.\n         Gift tax may be due on a gift or donation of the shares if the gift is recorded in a Luxembourg notarial\ndeed or otherwise registered in Luxembourg.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23481608212147134, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27074422583404617, "height": 0.03592814371257483, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-225-5", "text": "182", "page_number": 225, "bounding_box": {"top_left_x": 0.48851269649334944, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.02357920193470381}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-0", "text": "22. FINANCIAL INFORMATION\n", "page_number": 226, "bounding_box": {"top_left_x": 0.37182587666263606, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6287787182587666, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-1", "text": "Unaudited condensed consolidated interim financial statements of Dermapharm AG as of and for\n the nine-month period ended September 30, 2017 prepared in accordance with IFRS\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8216444981862152, "lower_right_y": 0.11970927746900385, "height": 0.02778965369816161, "width": 0.7055622732769045}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-2", "text": "Condensed Consolidated Interim Statement of Financial Position . . . . . . . . . . . . . . . . . . . . .                      F-3\nCondensed Consolidated Interim Statement of Comprehensive Income . . . . . . . . . . . . . . . . . .                          F-4\nCondensed Consolidated Interim Statement of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . .                      F-5\nCondensed Consolidated Interim Statement of Changes in Equity . . . . . . . . . . . . . . . . . . . . .                       F-6\nNotes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   F-8\n", "page_number": 226, "bounding_box": {"top_left_x": 0.13482466747279323, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.22445489525438223, "height": 0.09833262077811031, "width": 0.749093107617896}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-3", "text": "Audited consolidated financial statements of Dermapharm AG as of and for the fiscal years\n  ended December 31, 2016, 2015 and 2014 prepared in accordance with IFRS\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.7835550181378477, "lower_right_y": 0.26934587430525864, "height": 0.026934587430525847, "width": 0.6680773881499396}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-4", "text": "Consolidated Statement of Financial Position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .              F-20\nConsolidated Statement of Comprehensive Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                    F-21\nConsolidated Statement of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .              F-22\nConsolidated Statement of Changes in Equity                . ..... .... ..... .... .... ..... .... .                          F-23\nNotes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   F-26\nAudit Opinion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     F-90\n", "page_number": 226, "bounding_box": {"top_left_x": 0.13301088270858524, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.39675074818298417, "height": 0.12697734074390765, "width": 0.7521160822249093}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-5", "text": "Audited individual financial statements of Dermapharm Holding SE as of September 30, 2017\n  and for the period from July 12, 2017 to September 30, 2017 prepared in accordance\n  with IFRS\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.41000427533133815, "lower_right_x": 0.7980652962515115, "lower_right_y": 0.4514749893116717, "height": 0.04147071398033353, "width": 0.6819830713422007}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-6", "text": "Statement of Financial Position as of September 30, 2017 . . . . . . . . . . . . . . . . . . . . . . . . .                     F-93\nStatement of Comprehensive Income for the Period from July 12, 2017 to September 30, 2017 .                                    F-94\nStatement of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .          F-95\nStatement of Changes in Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             F-96\nNotes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    F-98\nAudit Opinion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     F-103\n", "page_number": 226, "bounding_box": {"top_left_x": 0.12998790810157196, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5814450619923044, "height": 0.12013681060282172, "width": 0.7551390568319225}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-226-7", "text": "F-1", "page_number": 226, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5084643288996372, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.020556227327690413}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-227-0", "text": "        Unaudited condensed consolidated interim financial statements of Dermapharm AG\nas of and for the nine-month period ended September 30, 2017 prepared in accordance with IFRS\n", "page_number": 227, "bounding_box": {"top_left_x": 0.12998790810157196, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.4754168448054724, "height": 0.02778965369816161, "width": 0.7357920193470375}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-227-1", "text": "F-2", "page_number": 227, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-228-0", "text": "Condensed consolidated statement of financial position at 30 September 2017 and 31 December 2016\n", "page_number": 228, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.0645575032064985, "lower_right_x": 0.875453446191052, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.7496977025392987}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-228-1", "text": "Assets                                                                                                                                                                   30 September    31 December\nin kEUR                                                                                                                                                                      2017            2016\nNON-CURRENT ASSETS\nIntangible assets . . . . . . . . . . .                          .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        129,682          70,025\nGoodwill . . . . . . . . . . . . . . . .                         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         17,033          17,033\nProperty, plant and equipment . .                                .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         52,920          53,357\nInvestments measured at equity .                                 .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          4,441           3,197\nInvestments . . . . . . . . . . . . . .                          .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            166             262\nOther non-current financial assets                               .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         22,426          10,648\nDeferred tax assets . . . . . . . . .                            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          1,659             218\nTotal non-current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                        228,327        154,740\nCURRENT ASSETS\nInventories . . . . . . . . . . . . . .                      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         81,938          84,779\nTrade accounts receivable . . . .                            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         34,675          26,302\nOther current financial assets . .                           .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         68,658          39,976\nOther current assets . . . . . . . .                         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          2,042           1,692\nIncome tax receivables\u2014current                               .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            429             394\nCash and cash equivalents . . . .                            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         12,578           3,816\nTotal current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                      200,320        156,959\nTOTAL ASSETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                          428,647         311,699\n\nEquity and liabilities                                                                                                                                                   30 September    31 December\nin kEUR                                                                                                                                                                      2017            2016\nEQUITY\nIssued capital . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          1,342           1,342\nCapital reserves . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            250             250\nRetained earnings        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         70,037          56,274\nOther reserves . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         (2,141)           (951)\nEquity attributable to owners of the company . . . . . . . . . . . . . . . .                                                                                                   69,488          56,915\nNon-controlling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                          \u2014            3,891\nTotal equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                   69,488          60,806\nNON-CURRENT LIABILITIES\nDefined benefit obligations and other accrued employee benefits                                                                                  .   .   .   .   .   .         13,251          13,250\nFinancial liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                .   .   .   .   .   .        235,397          96,896\nOther non-current financial liabilities . . . . . . . . . . . . . . . . . .                                                                      .   .   .   .   .   .          8,093          10,464\nOther non-current liabilities . . . . . . . . . . . . . . . . . . . . . . . .                                                                    .   .   .   .   .   .         10,381          11,495\nDeferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                   .   .   .   .   .   .          5,806           3,365\nTotal non-current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                       272,928        135,470\nCURRENT LIABILITIES\nOther provisions . . . . . . . . . .                         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          6,002           6,951\nFinancial liabilities . . . . . . . . .                      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         43,422          65,883\nTrade accounts payable . . . . . .                           .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         19,273          24,526\nOther current financial liabilities                          .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          2,120           4,303\nOther current liabilities . . . . . .                        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         11,485          10,983\nIncome tax liabilities . . . . . . .                         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          3,929           2,777\nTotal current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                      86,231         115,423\nTOTAL EQUITY AND LIABILITIES . . . . . . . . . . . . . . . . . . . . . .                                                                                                      428,647         311,699\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8225737494655836, "height": 0.7340743907652844, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-228-2", "text": "F-3", "page_number": 228, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-229-0", "text": "Condensed consolidated statement of comprehensive income\n", "page_number": 229, "bounding_box": {"top_left_x": 0.2750906892382104, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7249093107617895, "lower_right_y": 0.0778110303548525, "height": 0.013253527148353997, "width": 0.44981862152357915}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-229-1", "text": "                     for the nine month ended 30 September 2017 and 30 September 2016\n\n                                                                                                                              9 months ended\n                                                                                                                      30 September      30 September\nin kEUR                                                                                                                   2017              2016\nRevenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .        349,690           319,221\nIncrease/decrease in finished goods and work-in-process               .   .   .   .   .   .   .   .   .   .   .   .            418             4,087\nOwn work capitalised . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .          7,999             5,436\nOther operating income . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .          4,141             5,226\nCost of material . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .       (195,968)         (181,540)\nPersonnel expenses . . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .        (46,535)          (42,024)\nDepreciation and amortisation . . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .        (11,175)          (10,287)\nOther operating expenses . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .        (38,127)          (35,063)\nOperating income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                    70,443            65,056\nResult from investments measured at equity . . . . . . . . . . . . . . . . . . .                                              1,245             1,092\nFinancial income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                    3,277             4,094\nFinancial expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                   (7,812)           (8,414)\nFinancial result . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                   (3,290)           (3,228)\nEarnings before taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                     67,153            61,828\nIncome taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                   (4,300)           (5,968)\nProfit or (loss) for the period . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                     62,853            55,860\nProfit transfers due to profit transfer agreements . . . . . . . . . . . . . . . . .                                       (46,422)          (44,792)\nProfit or (loss) for the period after profit distribution . . . . . . . . . . .                                             16,431            11,068\nOther comprehensive income/(loss) that will not be reclassified to profit\n  or loss in subsequent periods:\nActuarial gains/losses from remeasurement of defined benefit pension\n  plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                       .              \u2014                \u2014\nDeferred taxes effect relating to items that will not be reclassified . . . .                                     .              \u2014                 6\nOther comprehensive income/(loss) that may be reclassified to profit or\n  loss in subsequent periods:\nExchange differences on translation of foreign operations . . . . . . . . . .                                     .          (1,190)            (309)\nDeferred taxes effect relating to items that may be reclassified . . . . . .                                      .              \u2014                \u2014\nOther comprehensive income/(loss) for the period, net of tax . . . . . .                                                     (1,190)            (303)\nTotal comprehensive income for the period, net of tax . . . . . . . . . . .                                                 15,241            10,765\nProfit attributable to:\nOwners of the company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                       16,431            10,800\nNon-controlling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                       \u2014                268\n                                                                                                                            16,431            11,068\nTotal comprehensive income attributable to:\nOwners of the company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                       15,241            10,497\nNon-controlling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                       \u2014                268\n                                                                                                                            15,241            10,765\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.07823856348867037, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.7554510474561779, "height": 0.6772124839675076, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-229-2", "text": "F-4", "page_number": 229, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-230-0", "text": "           Condensed consolidated statement of cash flows\nfor the nine month ended 30 September 2017 and 30 September 2016\n", "page_number": 230, "bounding_box": {"top_left_x": 0.23639661426844014, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.09191962377084224, "height": 0.027362120564343742, "width": 0.5229746070133011}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-230-1", "text": "                                                                                                                                  9 months ended\n                                                                                                                          30 September      30 September\nin kEUR                                                                                                                       2017              2016\nProfit or loss for the period . . . . . . . . . . . . . . . . . . . . . . . . . . . .                             .   .         62,853            55,860\nAmortisation of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . .                               .   .          7,166             6,718\nDepreciation of property, plant and equipment . . . . . . . . . . . . . . . .                                     .   .          3,709             3,569\nIncrease /(decrease) in other accrued employee benefits . . . . . . . . . .                                       .   .              1                33\nIncrease /(decrease) in other current provisions . . . . . . . . . . . . . . . .                                  .   .           (950)             (741)\nOther non-cash items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                              .   .             70            (5,293)\n(Increase) /decrease in inventories . . . . . . . . . . . . . . . . . . . . . . . .                               .   .          2,830           (10,669)\n(Increase) /decrease in trade receivables . . . . . . . . . . . . . . . . . . . .                                 .   .         (8,353)          (11,840)\n(Increase) /decrease in other assets . . . . . . . . . . . . . . . . . . . . . . .                                .   .          1,267             1,816\nIncrease /(decrease) in trade payables . . . . . . . . . . . . . . . . . . . . . .                                .   .         (5,209)            4,743\nIncrease /(decrease) in other liabilities . . . . . . . . . . . . . . . . . . . . .                               .   .         (5,292)           (2,685)\nShare of profit of equity-accounted investees, net of tax . . . . . . . . . .                                     .   .         (1,245)           (1,092)\nNet (gain) /loss on disposal of intangible assets . . . . . . . . . . . . . . .                                   .   .            341               142\nNet (gain) /loss on disposal of property, plant and equipment . . . . . .                                         .   .             15               (10)\nInterest expenses /(income) . . . . . . . . . . . . . . . . . . . . . . . . . . . .                               .   .          3,240             2,902\nIncrease /(decrease) in income tax payables and deferred tax liabilities                                          .   .          3,338             4,960\nIncome tax (paid) /received . . . . . . . . . . . . . . . . . . . . . . . . . . . .                               .   .         (1,201)             (838)\nNet cash flows from operating activities . . . . . . . . . . . . . . . . . . . . .                                              62,580            47,575\nProceeds from sale of intangible assets . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .            194              2,438\nProceeds from sale of property, plant and equipment               .   .   .   .   .   .   .   .   .   .   .   .   .   .            157                127\nAcquisition of subsidiary, net of cash acquired . . . .           .   .   .   .   .   .   .   .   .   .   .   .   .   .             \u2014              (1,420)\n(Purchase) of intangible assets . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .        (67,358)            (8,705)\n(Purchase) of property, plant and equipment . . . . .             .   .   .   .   .   .   .   .   .   .   .   .   .   .         (3,378)            (4,187)\nPayments for investment in financial assets . . . . . .           .   .   .   .   .   .   .   .   .   .   .   .   .   .        (14,510)               (50)\nDividends from equity-accounted investees . . . . . .             .   .   .   .   .   .   .   .   .   .   .   .   .   .             \u2014                  \u2014\nInterest received . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .              7                 96\nNet cash flows used in investing activities . . . . . . . . . . . . . . . . . . .                                              (84,888)          (11,701)\nPayment of profit transfers due to profit transfer            agreements              .   .   .   .   .   .   .   .   .        (66,854)          (39,480)\nAcquisition of non-controlling interests . . . . . .          ... .... .              .   .   .   .   .   .   .   .   .         (6,559)           (1,850)\nPayments for financial receivables . . . . . . . . .          ... .... .              .   .   .   .   .   .   .   .   .         (8,180)               \u2014\nProceeds from financial liabilities . . . . . . . . .         ... .... .              .   .   .   .   .   .   .   .   .        151,824             2,819\n(Repayment) of financial liabilities . . . . . . . .          ... .... .              .   .   .   .   .   .   .   .   .        (52,756)           (6,202)\nPayment of finance lease liabilities . . . . . . . .          ... .... .              .   .   .   .   .   .   .   .   .           (107)             (151)\nInterest (paid) . . . . . . . . . . . . . . . . . . . . . .   ... .... .              .   .   .   .   .   .   .   .   .         (3,247)           (2,998)\nNet cash flows from / used in financing activities . . . . . . . . . . . . . .                                                  14,121           (47,862)\nNet increase in cash, cash equivalents and bank overdrafts . . . . . . .                                                         (8,187)         (11,988)\nCash, cash equivalents and bank overdrafts at the beginning of the period                                                        (1,051)          (9,644)\nChange in cash, cash equivalents and bank overdrafts due to foreign\n  exchange differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                            (84)                   9\nCash, cash equivalents and bank overdrafts at the end of the period .                                                            (9,322)         (21,623)\nBank overdrafts at the beginning the period . . . . . . . . . . . . . . . . . . .                                               (4,867)          (12,435)\nBank overdrafts at the end of the period . . . . . . . . . . . . . . . . . . . . . .                                           (21,900)          (25,828)\nCash and cash equivalents at the end of the period . . . . . . . . . . . . .                                                    12,578             4,205\n", "page_number": 230, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10303548525010689, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8029072253099615, "height": 0.6998717400598546, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-230-2", "text": "F-5", "page_number": 230, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-231-0", "text": "Condensed consolidated statement of changes in equity at 30 September 2017 and 31 December 2016\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.0645575032064985, "lower_right_x": 0.875453446191052, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.7539298669891173}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-231-1", "text": "                                                                  Attributable to owners of the company                  Non-\n                                                    Issued           Capital     Retained      Other                  controlling     Total\nin kEUR                                             capital         reserves      earnings    reserves    Total        interests     Equity\nAs at 1 January 2016                                    1,342             250       39,457          53      41,102          3,340      44,442\nProfit for the period . . . . . . . . . . . .                 \u2014            \u2014        10,800          \u2014       10,800           268       11,068\nOther comprehensive income/(loss) for\n  the period . . . . . . . . . . . . . . . . .                \u2014            \u2014           \u2014          (303)       (303)            \u2014         (303)\nTotal comprehensive income for the\n  period . . . . . . . . . . . . . . . . . . . .              \u2014            \u2014        10,800        (303)     10,497           268       10,765\nIssue of share capital . . . . . . . . . . .    .             \u2014            \u2014           \u2014            \u2014             \u2014            \u2014              \u2014\nReduction of statutory reserves . . . . .       .             \u2014            \u2014           \u2014            \u2014             \u2014            \u2014              \u2014\nAcquisition of subsidiary with\n   non-controlling interests . . . . . . . .    .             \u2014            \u2014           \u2014            \u2014             \u2014          283          283\nAcquisition of non-controlling interests                      \u2014            \u2014           \u2014            \u2014             \u2014           29           29\nDividends . . . . . . . . . . . . . . . . . .   .             \u2014            \u2014           \u2014            \u2014             \u2014           \u2014            \u2014\nAs at 30 September 2016 . . . . . . . .                 1,342             250       50,257        (250)     51,599          3,920      55,519\nAs at 1 January 2017 . . . . . . . . . . .              1,342             250       56,274        (951)     56,915          3,891      60,806\nProfit for the period . . . . . . . . . . . .                 \u2014            \u2014        16,431          \u2014       16,431             \u2014       16,431\nOther comprehensive income/(loss) for\n  the period . . . . . . . . . . . . . . . . .                \u2014            \u2014           \u2014        (1,190)     (1,190)            \u2014       (1,190)\nTotal comprehensive income for the\n  period . . . . . . . . . . . . . . . . . . . .              \u2014            \u2014        16,431      (1,190)     15,241             \u2014       15,241\nIssue of share capital . . . . . . . . . . .    .             \u2014            \u2014           \u2014            \u2014             \u2014            \u2014              \u2014\nDivestiture of subsidiary . . . . . . . . .     .             \u2014            \u2014           \u2014            \u2014             \u2014            \u2014              \u2014\nAcquisition of subsidiary with\n   non-controlling interests . . . . . . . .    .             \u2014            \u2014           \u2014            \u2014             \u2014            \u2014              \u2014\nAcquisition of non-controlling interests\n   without change in control . . . . . .        .             \u2014            \u2014        (2,668)         \u2014       (2,668)        (3,891)     (6,559)\nDividends . . . . . . . . . . . . . . . . . .   .             \u2014            \u2014            \u2014           \u2014           \u2014              \u2014           \u2014\nAs at 30 September 2017 . . . . . . . .                 1,342             250       70,037      (2,141)     69,488             \u2014       69,488\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.49080803762291575, "height": 0.40230867892261646, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-231-2", "text": "", "page_number": 231, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-232-0", "text": "Table of contents\n", "page_number": 232, "bounding_box": {"top_left_x": 0.4347037484885127, "top_left_y": 0.0645575032064985, "lower_right_x": 0.5652962515114873, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.13059250302297465}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-232-1", "text": "1.   General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                              F-8\n     1.1   Corporate Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                      F-8\n2.   Accounting policies . . . . . . . . . . . . . . . . . . . . . . . .      . .... .... .               .   .   .   .   .   .   .   .   .   .   F-8\n     2.1   Changes in accounting policies . . . . . . . . . . . .             . .... .... .               .   .   .   .   .   .   .   .   .   .   F-8\n     2.2   Effects of new or amended financial standards and                  interpretations             .   .   .   .   .   .   .   .   .   .   F-8\n     2.3   Basis of consolidation . . . . . . . . . . . . . . . . . .         . .... .... .               .   .   .   .   .   .   .   .   .   .   F-9\n3.   Notes   to the condensed consolidated statement of financial position                    .   .   .   .   .   .   .   .   .   .   .   .   .   F-9\n     3.1      Intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-9\n     3.2      Other non-current financial assets . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-10\n     3.3      Other current financial assets . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-10\n     3.4      Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-10\n     3.5      Financial liabilities . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-10\n     3.6      Fair value measurement . . . . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-11\n     3.7      Other non-current financial liabilities . . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-12\n     3.8      Current and deferred income tax . . . . . . . . . . . . . . . . .           .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-12\n4.   Notes to the condensed consolidated statement of comprehensive income . . . . . . . . . .                                                    F-13\n     4.1    Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                 F-13\n5.   Other disclosures on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                       F-13\n6.   Other financial obligations and contingent liabilities . . . . . . . . . . . . . . . . . . . . . . . .                                       F-15\n7.   Related party disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                  F-16\n     7.1    Significant transactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                  F-16\n     7.2    Open balances of significant related parties . . . . . . . . . . . . . . . . . . . . . . . .                                          F-17\n8.   Disclosures on the Management Board and the Supervisory Board . . . . . . . . . . . . . .                                                    F-17\n9.   Events after the reporting period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                    F-18\n", "page_number": 232, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.4890979050876443, "height": 0.39717828131680205, "width": 0.7357920193470374}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-232-2", "text": "F-7\n", "page_number": 232, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9341598973920479, "height": 0.011115861479264577, "width": 0.024183796856106443}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-0", "text": "Notes to the condensed consolidated interim financial statements of Dermapharm AG\n", "page_number": 233, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8174123337363967, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.6390568319226119}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-1", "text": "1.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.09491235570756734, "height": 0.00983326207781103, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-2", "text": "General\n", "page_number": 233, "bounding_box": {"top_left_x": 0.15900846432889965, "top_left_y": 0.08507909362975631, "lower_right_x": 0.21523579201934703, "lower_right_y": 0.09576742197520308, "height": 0.010688328345446765, "width": 0.05622732769044739}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-3", "text": "1.1\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.10602821718683197, "lower_right_x": 0.13845223700120918, "lower_right_y": 0.11714407866609662, "height": 0.011115861479264647, "width": 0.02176541717049575}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-4", "text": "Corporate Information\n", "page_number": 233, "bounding_box": {"top_left_x": 0.15114873035066506, "top_left_y": 0.10602821718683197, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.11970927746900385, "height": 0.013681060282171878, "width": 0.17230955259975816}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-5", "text": "     Dermapharm AG (hereafter referred to as the \u201cCompany\u201d or \u201cDermapharm\u201d) as the parent company of the\nDermapharm Group (hereafter referred to as \u201cGroup\u201d) based at Lil-Dagover-Ring 7, Gr\u00fcnwald, Germany, is an\ninternational corporation mainly active in the healthcare and pharmaceuticals business in the GSA region,\nespecially in generics, high-quality dermatological and allergic medical products. The company is registered in\nthe commercial register of Munich local court under HRB 124373.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.19837537409149208, "height": 0.07225309961522017, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-6", "text": "     Dermapharm is a leading independent specialty pharmaceuticals company in the German market that\napplies formulation and development expertise to the development, manufacture and marketing of a broad\nassortment of patent free branded pharmaceuticals in niche markets, holding approximately 900 marketing\nauthorisations for more than 200 active ingredients. Dermapharm also offers a growing portfolio of other\nhealthcare products such as cosmetics, food supplements and dietary products. The company operates primarily\nin Germany, has subsidiaries in Austria and Switzerland and has presences in eastern Europe (Croatia, Poland\nand Ukraine).\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3039760581445062, "height": 0.09918768704574601, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-7", "text": "     The company and the domestic and international subsidiaries concentrate on the development, licensing,\nmanufacture and sale of products using off-patent pharmaceutical active ingredients in the healthcare and in\nparticular the pharmaceutical industry. The core products are generics, branded generics, non-prescription\nnatural remedies, OTC products and parallel-imported original medicines.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.3685335613510047, "height": 0.05771697306541257, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-8", "text": "     Dermapharm AG is a wholly owned subsidiary of Themis Beteiligungs-AG. Themis Beteiligungs-AG\npublishes exempting condensed consolidated interim financial statements in accordance with \u00a7 291 HGB.\nConsequently, these financial statements were voluntarily prepared in accordance with IFRS as adopted by\nthe EU.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.430525865754596, "height": 0.05472424112868751, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-9", "text": "     The condensed consolidated interim financial statements were authorised by the Management Board by\nresolution dated 13 December 2017.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.46515604959384355, "height": 0.02436938862761867, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-10", "text": "Accounting policies\n", "page_number": 233, "bounding_box": {"top_left_x": 0.15840386940749698, "top_left_y": 0.48182984181274047, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.49551090209491233, "height": 0.013681060282171864, "width": 0.1408706166868198}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-11", "text": "2.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48225737494655835, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.493373236425823, "height": 0.011115861479264633, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-12", "text": "     The condensed consolidated interim financial statements as of 30 September 2017 were prepared pursuant\nto IAS 34 \u2018Interim Financial Reporting\u2019. They do not contain all of the necessary disclosures pursuant to IFRSs\nfor the preparation of year-end consolidated financial statements and should be read in conjunction with the\nconsolidated financial statements for Dermapharm AG as of 31 December 2016.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5604959384352287, "height": 0.058144506199230395, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-13", "text": "     The condensed consolidated interim financial statements have been prepared in euros (EUR). All values\nare rounded to the nearest thousand euros (kEUR) unless otherwise stated. Differences can result from the use\nof rounded amounts and percentages.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6088071825566481, "height": 0.04147071398033342, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-14", "text": "     The preparation of condensed consolidated interim financial statements in compliance with IAS 34\nrequires the use of certain accounting estimates. There have been no material revisions to the nature and\namount of changes in estimates of amounts reported in the annual financial statements for the year ended\n31 December 2016.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6703719538264216, "height": 0.051731509191962344, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-15", "text": "2.1 Changes in accounting policies\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.37908101571946795, "lower_right_y": 0.7011543394613082, "height": 0.01410859341598969, "width": 0.26360338573155984}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-16", "text": "     In these condensed consolidated interim financial statements the same accounting policies and methods of\nvaluation are applied as in the consolidated financial statements for financial year 2016. With regard to the\nprinciples and methods used in the context of Group Accounting, we generally refer to the notes to the\nconsolidated financial statements of the Annual Report 2016.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7661393758016246, "height": 0.05515177426250528, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-17", "text": "2.2 Effects of new or amended financial standards and interpretations\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.6463119709794438, "lower_right_y": 0.7935014963659683, "height": 0.01410859341598969, "width": 0.5308343409915357}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-18", "text": "     Dermapharm Group observed and applied the amendments to IAS 7 and IAS 12 which were first\napplicable as of 1 January 2017. The changes had no or no significant effect on the presentation of the Group\u2019s\nbusiness, financial, or earnings situation or cash flows.\n", "page_number": 233, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.844377939290295, "height": 0.04104318084651559, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-233-19", "text": "F-8", "page_number": 233, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-0", "text": "     As compared to the previous financial statements, the following additions were made to the Standards\nissued but not yet in effect: The Group intends to adopt these standards, if applicable, when they take effect.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.09191962377084224, "height": 0.027362120564343742, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-1", "text": "Standard/                             Effective     Endorsement\nInterpretation    Issued by IASB        Date            EU                        Name\nIFRS 9 . . . . . . October 17      January 19     Pending         Amendments to IFRS 9: Prepayment\n                                                                  Features with Negative Compensation\nIAS 28 . . . . . . October 17      January 19     Pending         Amendments to IAS 28: Long-term\n                                                                  Interests in Associates and Joint\n                                                                  Ventures\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19794784095767423, "height": 0.09576742197520309, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-2", "text": "2.3 Basis of consolidation\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.21504916631038906, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.22573749465583584, "height": 0.01068832834544678, "width": 0.19830713422007257}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-3", "text": "     The condensed consolidated interim financial statements of the Dermapharm Group have been prepared\nfor Dermapharm AG as the parent company.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.26336041043180847, "height": 0.02778965369816161, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-4", "text": "Acquisitions of non-controlling interests:\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.28003420265070544, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.29243266353142366, "height": 0.01239846088071822, "width": 0.284764207980653}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-5", "text": "     On 1 January 2017, the Group acquired the remaining 15% stake in axicorp GmbH, Friedrichsdorf,\nGermany, from DU Verm\u00f6gensverwaltungs GmbH, Weiden, Germany for a cash consideration of kEUR 6,509\nin total. The consideration comprises an amount of kEUR 5,250 which was paid in January 2017 and another\npayment of kEUR 1,259 of profit attributable to the former shareholder which was made after the approval of\nthe 2016 annual financial statements of axicorp GmbH.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.36938862761864044, "height": 0.0688328345446772, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-6", "text": "     The acquisition increases the stake in axicorp GmbH from 85% to 100%. axicorp GmbH had already been\nfully consolidated in the prior year when Dermapharm held an 85% stake in the company. There is no change\nin the basis of consolidation or presentation in the IFRS consolidated financial statements. The carrying amount\nof axicorp GmbH\u2019s net assets in the Group\u2019s consolidated financial statements on the date of acquisition was\nkEUR 25,962. The Group recognised a decrease in non-controlling interest (NCI) of kEUR 3,851 and a\ndecrease in retained earnings of kEUR 2,658.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.46173578452330055, "height": 0.08251389482684907, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-7", "text": "     The Group company axicorp GmbH acquired the remaining 24.9% stake in Remedix GmbH,\nFriedrichsdorf, Germany, from a private stakeholder on 1 March 2017 for a cash consideration of kEUR 50.\nThe Group now owns 100% of the shares in Remedix GmbH. There is no change in the basis of consolidation\nor presentation in the IFRS consolidated financial statements. The carrying amount of Remedix GmbH\u2019s net\nassets in the Group\u2019s consolidated financial statements on the date of acquisition was kEUR 157. The Group\nrecognised a decrease in NCI of kEUR 39 and a decrease in retained earnings of kEUR 11.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5540829414279607, "height": 0.08251389482684907, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-8", "text": "Merger of Cancernova GmbH onkologische Arzneimittel:\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.5187424425634825, "lower_right_y": 0.5823001282599402, "height": 0.011543394613082514, "width": 0.40326481257557434}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-9", "text": "   With effect from 18 August 2017, Cancernova GmbH onkologische Arzneimittel was merged with mibe\nGmbH Arzneimittel.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5912783240701154, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6156477126977341, "height": 0.024369388627618727, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-10", "text": "3.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6331765711842667, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.6451474989311672, "height": 0.01197092774690045, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-11", "text": "Notes to the condensed consolidated statement of financial position\n", "page_number": 234, "bounding_box": {"top_left_x": 0.15840386940749698, "top_left_y": 0.6331765711842667, "lower_right_x": 0.652962515114873, "lower_right_y": 0.6464300983326208, "height": 0.013253527148354038, "width": 0.49455864570737607}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-12", "text": "Intangible assets\n", "page_number": 234, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6562633604104318, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.669089354424968, "height": 0.012825994014536213, "width": 0.126360338573156}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-13", "text": "3.1\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6566908935442497, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.6665241556220607, "height": 0.00983326207781099, "width": 0.024788391777509064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-14", "text": "    On 20 September 2017, the Group acquired the assets pertaining to the hyperthermic medical devices of\nRiemser Pharma GmbH, Greifswald-Insel Riems.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7045746045318512, "height": 0.027789653698161554, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-15", "text": "     The acquired group of assets has a highly innovative medical applications portfolio selectively targeting\nmosquito and insect stitches (bite away), herpes blisters (Herpotherm) as well as a development project\nfocusing on dermatitis and its accompanying symptoms. However, the latter is not yet being produced,\nmarketed or sold.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7661393758016246, "height": 0.05515177426250528, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-16", "text": "     The acquired assets include the intellectual property rights, the purchased regulatory approvals, as well as\nthe inventories. The acquisition does not qualify as a business combination as defined by IFRS 3. No material\nprocesses were acquired.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8174433518597691, "height": 0.04147071398033342, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-17", "text": "In connection with the acquisition, intangible assets amounting to kEUR 58,602 were acquired.\nThe assets are amortised on a straight-line basis over the expected useful life.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.8589140658401027, "height": 0.03505771697306548, "width": 0.6729141475211607}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-234-18", "text": "", "page_number": 234, "bounding_box": {"top_left_x": 0.4879081015719468, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-0", "text": "    The following table depicts the carrying amounts and remaining useful lives of these assets as at\n30 September 2017.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.09191962377084224, "height": 0.027362120564343742, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-1", "text": "                                                                      Carrying       Remaining\n30 September 2017                                                     Amount         useful life   Asset origin\nTrademark (bite away) . . . . . . . . . . . . . . . . . . . . . . . . . kEUR 2,590    8 years      Acquired\nTechnology (bite away) . . . . . . . . . . . . . . . . . . . . . . . . kEUR 51,209   21 years      Acquired\nTechnology (Herpotherm) . . . . . . . . . . . . . . . . . . . . . . . kEUR 4,803      7 years      Acquired\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.17101325352714836, "height": 0.06883283454467722, "width": 0.7593712212817412}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-2", "text": "3.2 Other non-current financial assets\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.19794784095767423, "height": 0.010260795211628926, "width": 0.29081015719467956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-3", "text": "    The increase in other non-current financial assets relates to one prepayment on investments.\n     Under the purchase agreement dated 21 September 2017, the Group acquired all of the shares and voting\ninterests in Bio-Di\u00e4t-Berlin GmbH, Berlin, along with its wholly owned distribution subsidiary Kr\u00e4uter K\u00fchne\nGmbH, Berlin, from the former shareholder.\n    The transaction closed on 1 October 2017. Therefore, Bio-Di\u00e4t-Berlin was not consolidated as at\n30 September 2017.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3065412569474134, "height": 0.09833262077811028, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-4", "text": "3.3 Other current financial assets\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.37182587666263606, "lower_right_y": 0.3317657118426678, "height": 0.010688328345446751, "width": 0.25634824667472794}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-5", "text": "     The increase in other current financial assets by kEUR 28,682 is due to an increase in receivables from the\nparent company Themis Beteiligungs AG. For further information on the receivables from related parties,\nplease refer to 7.2.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.38392475416844807, "height": 0.042325780247969236, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-6", "text": "3.4 Cash and cash equivalents\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.3464328899637243, "lower_right_y": 0.41299700726806327, "height": 0.013253527148353983, "width": 0.23095525997581617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-7", "text": "     The cash and cash equivalents changed as follows:\n                                                                                             30 September   31 December\nkEUR                                                                                             2017           2016\nCash at banks and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . .               12,561          3,806\nCash on hand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             17             10\nCash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .              12,578          3,816\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5203078238563489, "height": 0.1000427533133818, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-8", "text": "     Additional information for the increase as at 30 September 2017 is depicted in the condensed consolidated\nstatement of cash flows.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5643437366395896, "height": 0.024369388627618616, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-9", "text": "3.5 Financial liabilities\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5810175288584866, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.5951261222744763, "height": 0.01410859341598969, "width": 0.17412333736396618}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-10", "text": "      In order to finance the expansion of the Group, Dermapharm took out new bank loans with nominal values\ntotalling kEUR 150,000 from four different banks in September 2017.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6327490380504489, "height": 0.027789653698161554, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-11", "text": "All four bank loans are due in September 2022 and bear interest at variable rates.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.639162035057717, "lower_right_x": 0.7303506650544136, "lower_right_y": 0.6532706284737068, "height": 0.0141085934159898, "width": 0.5810157194679565}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-12", "text": "     In connection with the new bank loans, Dermapharm raised new derivative financial instruments related to\nthe interest rate risk. These derivatives are described under 3.7.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6874732791791364, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-13", "text": "In the first nine month of financial year 2017, the following material repayments were made:\n\u2022   Participation right issued in 2010 with amount of kEUR 4,496 was repaid in January 2017.\n\u2022   Promissory note loan issued in 2012 with amount of kEUR 40,000 was repaid In September 2017.\nAs at 30 September 2017, the financial liabilities of the Group were as follows:\n", "page_number": 235, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6973065412569475, "lower_right_x": 0.879081015719468, "lower_right_y": 0.7729799059427106, "height": 0.07567336468576313, "width": 0.7297460701330108}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-14", "text": "                                                                                                                                                           30 September   31 December\nkEUR                                                                                                                                                           2017           2016\nBank loans . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        147,493          2,713\nPromissory note loans . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         87,747         87,680\nLeasing liabilities . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            157            143\nParticipation rights . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .             \u2014           6,360\nNon-current financial liabilities                  ... .... ..... .... .... ..... .                                                                             235,397         96,896\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8858486532706284, "height": 0.09961522017956392, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-235-15", "text": "F-10", "page_number": 235, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-0", "text": "                                                                                                                                                                30 September   31 December\nkEUR                                                                                                                                                                2017           2016\nBank loans . . . . . .     ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         12,927         14,660\nPromissory note loans       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          1,546         40,413\nLeasing liabilities . .    ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            101            112\nParticipation rights . .   ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          6,948          5,831\nBank overdrafts . . . .    ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         21,900          4,867\nCurrent financial liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                               43,422         65,883\n", "page_number": 236, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.17528858486532706, "height": 0.11415134672937152, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-1", "text": "3.6 Fair value measurement\n", "page_number": 236, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.20863616930312098, "height": 0.010688328345446751, "width": 0.21765417170495766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-2", "text": "     The fair value hierarchy level to which the financial asset or financial liability is classified is determined\non the basis of the lowest level input that is significant to the fair value measurement. Financial assets and\nfinancial liabilities are classified in their entirety into only one of the three levels.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.21846943138093203, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2573749465583583, "height": 0.03890551517742627, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-3", "text": "financial liabilities are classified in their entirety into only one of the three levels.\n     The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, as\nwell as the significant unobservable inputs used.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.2578024796921761, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.294570329200513, "height": 0.03676784950833689, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-4", "text": "l as the significant unobservable inputs used.\n Financial instruments measured at fair value:\n", "page_number": 236, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.2949978623343309, "lower_right_x": 0.46372430471584036, "lower_right_y": 0.314664386489953, "height": 0.01966652415562209, "width": 0.3137847642079806}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-5", "text": "                                                                                                    Interrelationship between\n                                                                                      Significant    significant unobservable\n                                                                                     unobservable      inputs and fair value\nType                                     Valuation technique                            inputs             measurement\nAvailable for sale\n  Investments (n/a) . Due to a lack of information and immateriality of n/a                         n/a\n                      available for sale investments, the fair value of\n                      those investments is assumed to be equal to the\n                      carrying amount. The Group does not intend to\n                      dispose of these financial instruments.\nInterest rate swaps\n   (Level 2) . . . . . . Swap Models:                                          n/a                  n/a\n                         Fair value is calculated as the present value of the\n                         estimated future cash flows. Estimates of future\n                         floating-rate cash flows are based on quoted swap\n                         rates, futures prices and interbank borrowing rates.\n                         Estimated cash flows are discounted using a yield\n                         curve constructed from similar sources and which\n                         reflects the relevant benchmark interbank rate used\n                         by market participants for this purpose when\n                         pricing interest rate swaps. The fair value\n                         measurement is subject to a credit/debit valuation\n                         adjustment that reflects the credit risk of the Group\n                         and the counterparty, which is calculated based on\n                         credit spreads.\nFloors (Level 3) . . . Floor Pricing:                                         Volatility            A decrease in volatility\n                       Fair value is calculated as the present value of the   30 September          would result in a\n                       estimated future cash flows based on an adjusted       2017: 25%             decrease of the\n                       Black 76 model for interest rate derivatives. In       31 December           (negative) Fair Values\n                       order to take the negative interest rate environment   2016: n/a             of the Floors. An\n                       into consideration, the standard Black 76 model is                           increase in volatility\n                       enhanced by a shifting parameter for the floor and                           would result in\n                       forward rates. Input data include the relevant                               increased negative Fair\n                       observable reference rate curves and the observable                          Values of the Floors.\n                       forward rates as well as the unobservable\n                       parameter, namely the expected volatility which is\n                       based on an expert estimate.\n                       The fair value measurement is subject to a credit/\n                       debit valuation adjustment that reflects the credit\n                       risk of the Group which is calculated based on\n                       credit spreads.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.831124412141941, "height": 0.503206498503634, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-236-6", "text": "F-11", "page_number": 236, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5163240628778718, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.0332527206771463}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-0", "text": "                                                                                                Interrelationship between\n                                                                                  Significant    significant unobservable\n                                                                                 unobservable      inputs and fair value\nType                                   Valuation technique                          inputs             measurement\n\nCurrency-related\n  swaps (Level 2) . . Option Pricing:                                      n/a                  n/a\n                      Fair value is calculated as the present value of the\n                      estimated future cash flows based on a Black\n                      76 model for foreign exchange derivatives.\n                      The fair values are determined using an option\n                      pricing model using only observable input data\n                      including the relevant reference rate curve, the\n                      forward rates as well as quoted foreign exchange\n                      spot and forward rates. The fair value measurement\n                      is subject to a credit/debit valuation adjustment\n                      that reflects the credit risk of the Group and the\n                      counterparty, which is calculated based on credit\n                      spreads.\nForeign Exchange\n  Forwards (Level 2) Forward pricing:                                    n/a                    n/a\n                     The fair values are determined using quoted\n                     forward exchange rates at the reporting date and\n                     present value calculations based on high credit\n                     quality yield curves in the respective currencies.\n                     The fair value measurement is subject to a credit/\n                     debit valuation adjustment that reflects the credit\n                     risk of the Group and the counterparty, which is\n                     calculated based on credit spreads.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4035912783240701, "height": 0.34245404018811454, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-1", "text": "     As at 30 September 2017 (31 December 2016: n/a), a volatility of 25% is assumed. A decrease in\nvolatility of 10 percentage points or an increase in volatility of 5 percentage points would not have a material\nimpact on the fair values of the financial instruments measured at fair value level 3.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4600256519880291, "height": 0.039760581445062004, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-2", "text": "The fair values of the level 3 financial liabilities changed as follows:", "page_number": 237, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.4681487815305686, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.47798204360837965, "height": 0.009833262077811045, "width": 0.4885126964933495}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-3", "text": "     The fair values of the level 3 financial liabilities changed as follows:\n                                                                                                                                                                                                         Financial\n                                                                                                                                                                                                         liabilities\n                                                                                                                                                                                                        measured at\n                                                                                                                                                                                                        Fair Value\nBalance at 1 January 2017 . .           .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014\nReclassification from level 2 . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014\nAdditions . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           632\nTransfer out of level 3 . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014\nResult realised in Profit or Loss       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014\nBalance at 30 September 2017            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           632\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6088071825566481, "height": 0.1303976058144506, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-4", "text": "3.7 Other non-current financial liabilities\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.6361693031209918, "height": 0.010688328345446751, "width": 0.31499395405078595}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-5", "text": "     In connection with the new bank loans taken out by the Group in September 2017, Dermapharm has\nentered into a new interest rate swap in order to hedge the interest rate risk associated with a variable interest\nloan. Moreover, several floors were embedded in the recently signed loan agreements. These derivatives were\nseparated from the host contract and measured at their fair values.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7011543394613082, "height": 0.05515177426250528, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-6", "text": "     In this context, the negative fair value of an embedded derivative was set off with the positive fair value of\na separately concluded derivative. The fair value of the financial asset and the financial liability amounted to\nkEUR 82.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7490380504489098, "height": 0.03805044890979048, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-7", "text": "3.8 Current and deferred income tax\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.7772552372808893, "height": 0.011543394613082514, "width": 0.28536880290205563}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-8", "text": "     Themis Beteiligungs-AG and Dermapharm AG plan to rescind their profit-and-loss transfer agreement in\nthe near future. Due to this fact the existing tax group between Themis Beteiligungs-AG and the Dermapharm\nGroup will expire. The deferred taxes presented in the Dermapharm Group\u2019s financial statements as at\n30 September 2017 were reported under the assumption that the profit and loss transfer agreement had already\nbeen rescinded. The Company is operating under the assumption that no material deferred taxes will be\nrecognised between 30 September 2017 and the date on which the profit and loss transfer agreement is\nrescinded.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8845660538691749, "height": 0.09833262077811034, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-9", "text": "The Dermapharm Group estimated year-end tax rate for 2017 is 22.36% (2016: 22.95%).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.8956819153484396, "lower_right_x": 0.7762998790810157, "lower_right_y": 0.9080803762291577, "height": 0.012398460880718165, "width": 0.626360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-237-10", "text": "F-12", "page_number": 237, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-0", "text": "Notes to the condensed consolidated statement of comprehensive income\n", "page_number": 238, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.0778110303548525, "height": 0.013253527148353997, "width": 0.5423216444981862}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-1", "text": "4.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.06541256947413425, "lower_right_x": 0.12998790810157196, "lower_right_y": 0.07524583155194528, "height": 0.00983326207781103, "width": 0.014510278113663858}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-2", "text": "4.1 Revenue\n    Revenue at Dermapharm Group resulted solely from the sale of products.\n      In the nine months ended on 30 September 2017, consolidated revenue of kEUR 323,784 was recognised\nin Germany (30 September 2016: kEUR 295,683). The revenue realised in Germany made up for 92.6% of\ntotal revenue (30 September 2016: 92.6%).\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.07823856348867037, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.17101325352714836, "height": 0.09277469003847799, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-3", "text": "   The Austrian and Swiss subsidiaries (central Europe region) realised third party revenues amounting to\nkEUR 16,970 in the first nine months of financial year 2017 (30 September 2016: kEUR 15,196).\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.20521590423257802, "height": 0.02778965369816161, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-4", "text": "    The Dermapharm Group companies that are operating in eastern Europe contributed kEUR 8,937 to\nconsolidated revenue in the nine-month period ended 30 September 2017 (30 September 2016: kEUR 8,342).\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2394185549380077, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-5", "text": "Other disclosures on financial instruments\n", "page_number": 238, "bounding_box": {"top_left_x": 0.15900846432889965, "top_left_y": 0.25609234715690465, "lower_right_x": 0.4727932285368803, "lower_right_y": 0.2667806755023514, "height": 0.010688328345446751, "width": 0.3137847642079806}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-6", "text": "5.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2573749465583583, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.2667806755023514, "height": 0.009405728943993108, "width": 0.013301088270858533}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-7", "text": "     The following tables show the carrying amounts of all financial instruments reported in the condensed\nconsolidated statements of financial position and how the assets and liabilities or parts of the totals of each\ncategory are classified into the categories in accordance with IAS 39.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.3180846515604959, "height": 0.04147071398033347, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-8", "text": "     Moreover, the table presents the fair values of the financial instruments and the fair value hierarchy level\napplied to obtain the value.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.354424967935015, "height": 0.02650705429670802, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-238-9", "text": "F-13", "page_number": 238, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-239-0", "text": "30 September 2017\n", "page_number": 239, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.2599758162031439, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.1444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-239-1", "text": "                                                                      Measurement acc. to IAS 39\n                                  Category acc.    Book value                  Fair value    Measurement    Fair value\n                                       to         30 September                  (through       acc. to     30 September   Fair value\nkEUR                                 IAS 39           2017       At cost          p&l)         IAS 17          2017          level\n\nAssets\nOther non-current\n  financial assets . . . . .      LaR / HfT            22,426      15,034           7,392            \u2014          22,426                 2\nInvestments . . . . . . . . .        AfS                  166         166              \u2014             \u2014             166\nTrade receivables . . . . .         LaR                34,675      34,675              \u2014             \u2014          34,675\nOther current financial\n  assets . . . . . . . . . . .    LaR / HfT            68,658      68,646               12           \u2014          68,658                 2\nCash and cash\n  equivalents . . . . . . .           LaR              12,578      12,578               \u2014            \u2014          12,578\nLiabilities\nFinancial\n  liabilities\u2014non-current\n  of which bank loans .             FLAC             147,493      147,493               \u2014            \u2014        148,092                  2\n  of which promissory\n     note loans . . . . . .         FLAC               87,747      87,747               \u2014            \u2014          90,698                 2\n  of which participation\n     rights . . . . . . . . .       FLAC                   \u2014               \u2014            \u2014            \u2014              \u2014                  2\n  of which leasing\n     liabilities . . . . . . .        n.a.                157              \u2014            \u2014           157            157\nOther non-current\n  financial liabilities . . .         HfT               8,093              \u2014        8,093            \u2014           8,093            2/3\nFinancial\n  liabilities\u2014current\n  of which bank loans .             FLAC               12,927      12,927               \u2014            \u2014          15,488                 2\n  of which promissory\n     note loans . . . . . .         FLAC                1,546        1,546              \u2014            \u2014           1,640                 2\n  of which participation\n     rights . . . . . . . . .       FLAC                6,948        6,948              \u2014            \u2014           6,611                 2\n  of which bank\n     overdrafts . . . . . . .       FLAC               21,900      21,900               \u2014            \u2014          21,900\n  of which leasing\n     liabilities . . . . . . .       n.a.                 101          \u2014                \u2014           101            101\nTrade payables . . . . . .          FLAC               19,273      19,273               \u2014            \u2014          19,273\nOther current financial\n  liabilities . . . . . . . . .   FLAC / HfT            2,120        2,093              27           \u2014           2,120                 2\nTotals per category acc.\n  to IAS 39\nAvailable for sale (AfS) .            AfS                 166          166              \u2014            \u2014             166\nFinancial Asset Held for\n  Trading (HfT) . . . . .             HfT               7,404              \u2014        7,404            \u2014           7,404\nFinancial Liabilities Held\n  for Trading (HfT) . . .             HfT               8,120              \u2014        8,120            \u2014           8,120\nLoans and\n  receivables (LaR) . . .             LaR            130,933      130,933               \u2014            \u2014        130,933\nFinancial liabilities\n  measured at amortised\n  cost (FLAC) . . . . . .           FLAC             299,927      299,927               \u2014            \u2014        305,795\n", "page_number": 239, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7443351859769132, "height": 0.6558358272766139, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-239-2", "text": "F-14", "page_number": 239, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-0", "text": "31 December 2016\n", "page_number": 240, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-1", "text": "                                                                        Measurement acc. to IAS 39\n                                      Category acc.    Book value                 Fair value   Measurement    Fair value\n                                           to         31 December                  (through      acc. to     31 December   Fair value\nkEUR                                     IAS 39           2016      At cost          p&l)        IAS 17          2016         level\n\nAssets\nOther non-current financial\n  assets . . . . . . . . . . . . .    LaR / HfT           10,648         523         10,125            \u2014         10,648                 2\nInvestments . . . . . . . . . . .        AfS                 262         262             \u2014             \u2014            262\nTrade receivables . . . . . . .         LaR               26,302      26,302             \u2014             \u2014         26,302\nOther current financial\n  assets . . . . . . . . . . . . .    LaR / HfT           39,976      39,969              7            \u2014         39,976                 2\nCash and cash equivalents .             LaR                3,816       3,816              \u2014            \u2014          3,816\nLiabilities\nFinancial\n  liabilities\u2014non-current\n  of which bank loans . . .             FLAC               2,713       2,713              \u2014            \u2014          1,586                 2\n  of which promissory note\n     loans . . . . . . . . . . . .      FLAC              87,680      87,680              \u2014            \u2014         91,450                 2\n  of which participation\n     rights . . . . . . . . . . . .     FLAC               6,360       6,360              \u2014            \u2014          6,415                 2\n  of which leasing\n     liabilities . . . . . . . . .        n.a.               143              \u2014           \u2014           143           143\nOther non-current financial\n  liabilities . . . . . . . . . . .       HfT             10,464              \u2014      10,464            \u2014         10,464                 2\nFinancial liabilities\u2014current\n  of which bank loans . . .             FLAC              14,660      14,660              \u2014            \u2014         13,693                 2\n  of which promissory note\n     loans . . . . . . . . . . . .      FLAC              40,413      40,413              \u2014            \u2014         42,532                 2\n  of which participation\n     rights . . . . . . . . . . . .     FLAC               5,831       5,831              \u2014            \u2014          5,344                 2\n  of which bank overdrafts              FLAC               4,867       4,867              \u2014            \u2014          4,867\n  of which leasing\n     liabilities . . . . . . . . .       n.a.                112          \u2014               \u2014           112           112\nTrade payables . . . . . . . . .        FLAC              24,526      24,526              \u2014            \u2014         24,526\nOther current financial\n  liabilities . . . . . . . . . . .   FLAC / HfT           4,303       4,285              18           \u2014          4,303                 2\nTotals per category acc. to\n  IAS 39\nAvailable for sale (AfS) . . .            AfS                262         262              \u2014            \u2014            262\nFinancial Asset Held for\n  Trading (HfT) . . . . . . . .           HfT             10,132          \u2014          10,132            \u2014         10,132\nLoans and receivables (LaR)               LaR             70,610      70,610             \u2014             \u2014         70,610\nFinancial Liabilities Held\n  for Trading (HfT) . . . . .             HfT             10,482              \u2014      10,482            \u2014         10,482\nFinancial liabilities\n  measured at amortised\n  cost (FLAC) . . . . . . . .           FLAC             191,335    191,335               \u2014            \u2014        194,698\n", "page_number": 240, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6908935442496793, "height": 0.6023941855493801, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-2", "text": "     Other non-current financial liabilities comprise the negative fair values of derivatives measured at fair\nvalue through profit or loss amounting to kEUR 632 as at 30 September 2017.\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.735356990166738, "height": 0.027789653698161665, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-3", "text": "6.   Other financial obligations and contingent liabilities\n", "page_number": 240, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.7627191107310817, "height": 0.0141085934159898, "width": 0.42623941958887546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-4", "text": "      With regards to other financial obligations, please refer to the notes to the financial statement for the\nperiod ended 31 December 2016. There were no changes regarding litigations, guarantees or contingent\nliabilities.\n", "page_number": 240, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8106028217186833, "height": 0.03805044890979059, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-5", "text": "Purchase commitments:\n", "page_number": 240, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.827704147071398, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.8396750748182984, "height": 0.01197092774690034, "width": 0.16989117291414751}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-6", "text": "    At 30 September 2017, the Group has purchase commitments relating to inventories of kEUR 40,645\n(31 December 2016: kEUR 72,985).\n", "page_number": 240, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8760153911928175, "height": 0.02821718683197949, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-240-7", "text": "F-15", "page_number": 240, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-0", "text": "Related party disclosures\n", "page_number": 241, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.343409915356711, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.18863361547763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-1", "text": "7.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.06498503634031637, "lower_right_x": 0.12998790810157196, "lower_right_y": 0.07524583155194528, "height": 0.010260795211628912, "width": 0.013301088270858533}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-2", "text": "     Related parties as defined in IAS 24 Related Party Disclosures are those legal entities and natural persons\nthat are able to exert influence on Dermapharm and its subsidiaries or over which the company or its\nsubsidiaries exercise control or joint control or have a significant influence. Key Management Personnel\nincludes members of the Management Board and the Supervisory Board. Significant Shareholders are those\nwho own or are the beneficial owners of more than ten percent of the Dermapharm\u2019s voting shares.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.155622060709705, "height": 0.07054296707994868, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-3", "text": "     Transactions with related parties for the condensed consolidated financial statements at 30 September 2017\nand 31 December 2016 between the Dermapharm Group and significant shareholders and other related parties\nare summarised below.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.20179563916203505, "height": 0.03805044890979051, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-4", "text": "7.1 Significant transactions\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21846943138093203, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.23257802479692177, "height": 0.014108593415989745, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-5", "text": "Significant shareholder transactions:\n\nkEUR                                                                                            2017         2016\nConsultancy services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .               835          837\nCompensation from Dermapharm CH . . . . . . . . . . . . . . . . . . . . . . . .                         85           85\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .          920          922\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.32834544677212485, "height": 0.08593415989739206, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-6", "text": "     The consultancy services consist of marketing and advertising costs and related activities rendered by\nsignificant shareholders.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3792218896964515, "height": 0.027362120564343728, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-7", "text": "Significant related party transactions:\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3864899529713553, "lower_right_x": 0.37726723095526, "lower_right_y": 0.40017101325352716, "height": 0.013681060282171864, "width": 0.2617896009673519}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-8", "text": "kEUR                                                                                                    2017       2016\n   Parent company (Themis Beteiligungs-AG)                 of   Dermapharm AG       .   .   .   .   .     66,854     44,842\nProfit and loss transfer agreement . . . . . . .           ..   ... .... .... .     .   .   .   .   .     66,854     44,842\n   Non-consolidated subsidiaries . . . . . . . .           ..   ... .... .... .     .   .   .   .   .        331        158\nPurchase of goods . . . . . . . . . . . . . . . . .        ..   ... .... .... .     .   .   .   .   .        331        158\n   Parent company (Themis Beteiligungs-AG)                 of   Dermapharm AG       .   .   .   .   .      9,333      3,486\nIndirect taxes from tax group . . . . . . . . . .          ..   ... .... .... .     .   .   .   .   .      9,333      3,486\n   Parent company (Themis Beteiligungs-AG)                 of   Dermapharm AG       .   .   .   .   .        315        293\n   Non-consolidated subsidiaries . . . . . . . .           ..   ... .... .... .     .   .   .   .   .        382        422\nConsultancy services . . . . . . . . . . . . . . .         ..   ... .... .... .     .   .   .   .   .        697        715\n   Non-consolidated subsidiaries . . . . . . . .           ..   ... .... .... .     .   .   .   .   .         \u2014          99\nLoans . . . . . . . . . . . . . . . . . . . . . . . . .    ..   ... .... .... .     .   .   .   .   .         \u2014          99\n   Non-consolidated subsidiaries . . . . . . . .           ..   ... .... .... .     .   .   .   .   .         \u2014          93\nInterest . . . . . . . . . . . . . . . . . . . . . . . .   ..   ... .... .... .     .   .   .   .   .         \u2014          93\n   Parent company (Themis Beteiligungs-AG)                 of   Dermapharm AG       .   .   .   .   .      1,746      1,611\nFinancial instruments . . . . . . . . . . . . . . .        ..   ... .... .... .     .   .   .   .   .      1,746      1,611\n   Parent company (Themis Beteiligungs-AG)                 of   Dermapharm AG       .   .   .   .   .        354      1,020\n   Non-consolidated subsidiaries . . . . . . . .           ..   ... .... .... .     .   .   .   .   .         52         45\nOther services . . . . . . . . . . . . . . . . . . . .     ..   ... .... .... .     .   .   .   .   .        406      1,065\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             79,367     52,069\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7075673364685763, "height": 0.29414279606669513, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-9", "text": "     Related party transactions arise primarily from the profit and loss transfer agreement with Themis\nBeteiligungs-AG; other material transactions arise from the tax group with Themis Beteiligungs-AG.\n", "page_number": 241, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7524583155194527, "height": 0.027789653698161554, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-241-10", "text": "F-16", "page_number": 241, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-0", "text": "7.2 Open balances of significant related parties\n", "page_number": 242, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.0645575032064985, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.35731559854897216}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-1", "text": "                                                                                                        30 September   31 December\nkEUR                                                                                                        2017           2016\n  Parent company (Themis Beteiligungs-AG) of Dermapharm AG                          .   .   .   .   .         42,601         24,423\nReceivables from profit and loss transfer agreement . . . . . . . . .               .   .   .   .   .         42,601         24,423\n  Parent company (Themis Beteiligungs-AG) of Dermapharm AG                          .   .   .   .   .          9,333             \u2014\nReceivables from Indirect taxes from tax group . . . . . . . . . . . .              .   .   .   .   .          9,333             \u2014\n  Parent company (Themis Beteiligungs-AG) of Dermapharm AG                          .   .   .   .   .             11             \u2014\nReceivables from purchase of goods . . . . . . . . . . . . . . . . . . .            .   .   .   .   .             11             \u2014\n  Parent company (Themis Beteiligungs-AG) of Dermapharm AG                          .   .   .   .   .          2,480             \u2014\n  Associated companies . . . . . . . . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .             \u2014              90\n  Non-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . .         .   .   .   .   .             \u2014               6\nReceivables from loans . . . . . . . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .          2,480             96\n  Parent company (Themis Beteiligungs-AG) of Dermapharm AG                          .   .   .   .   .         20,556         15,270\nReceivables from financial instruments . . . . . . . . . . . . . . . . . .          .   .   .   .   .         20,556         15,270\n  Parent company (Themis Beteiligungs-AG) of Dermapharm AG                          .   .   .   .   .          1,022             \u2014\n  Non-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . .         .   .   .   .   .              5             20\nReceivables from other services . . . . . . . . . . . . . . . . . . . . . .         .   .   .   .   .          1,027             20\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 76,008         39,809\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0778110303548525, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.34587430525865753, "height": 0.26806327490380505, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-2", "text": "     Receivables from indirect taxes from the tax group relate to the acquisition of Riemser Pharma GmbH,\nGreifswald-Insel Riems.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39333048311244123, "height": 0.02436938862761867, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-3", "text": "                                                                                                        30 September   31 December\nkEUR                                                                                                        2017           2016\n  Parent company (Themis Beteiligungs-AG)                of   Dermapharm AG         .   .   .   .   .          1,842          3,848\nPayables from Indirect taxes from tax group              ..   ... .... .... .       .   .   .   .   .          1,842          3,848\n  Parent company (Themis Beteiligungs-AG)                of   Dermapharm AG         .   .   .   .   .             \u2014             420\nPayables from consultancy services . . . . . .           ..   ... .... .... .       .   .   .   .   .             \u2014             420\n  Parent company (Themis Beteiligungs-AG)                of   Dermapharm AG         .   .   .   .   .             \u2014              10\nPayables from loans . . . . . . . . . . . . . . . .      ..   ... .... .... .       .   .   .   .   .             \u2014              10\n  Parent company (Themis Beteiligungs-AG)                of   Dermapharm AG         .   .   .   .   .            302             \u2014\n  Non-consolidated subsidiaries . . . . . . . .          ..   ... .... .... .       .   .   .   .   .             \u2014              \u2014\nPayables from other services . . . . . . . . . .         ..   ... .... .... .       .   .   .   .   .            302             \u2014\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                  2,144          4,278\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5823001282599402, "height": 0.17571611799914494, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-4", "text": "8.\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.6122274476271911, "height": 0.010688328345446751, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-5", "text": "Disclosures on the Management Board and the Supervisory Board\n", "page_number": 242, "bounding_box": {"top_left_x": 0.15538089480048367, "top_left_y": 0.6015391192817443, "lower_right_x": 0.6517533252720678, "lower_right_y": 0.6152201795639162, "height": 0.013681060282171864, "width": 0.4963724304715841}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-6", "text": "The Company\u2019s corporate boards are composed as follows:\n", "page_number": 242, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6220607097050022, "lower_right_x": 0.5640870616686819, "lower_right_y": 0.6361693031209918, "height": 0.01410859341598969, "width": 0.41475211608222484}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-7", "text": "Members of the Management Board of Dermapharm AG:\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6502778965369816, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.6635314236853356, "height": 0.013253527148353927, "width": 0.40689238210399037}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-8", "text": "                                                                                    Appointed\nName                                                                                  until                Position            Occupation\nWilhelm Beier . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .     2020         Chief Executive Officer      Merchant\nDr. Hans-Georg Feldmeier        .   .   .   .   .   .   .   .   .   .   .   .   .     2019         Chief Operating Officer     Pharmacist\nStefan H\u00fcmer . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .     2020         Chief Financial Officer      Merchant\nStefan Grieving . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .     2019       Head of Marketing & Sales      Merchant\nKarin Samusch . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .     2019      Head of Business Development    Merchant\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7712697734074391, "height": 0.09448482257374946, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-9", "text": "Members of the Supervisory Board of Dermapharm AG:\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.8003420265070543, "height": 0.0141085934159898, "width": 0.40205562273276907}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-10", "text": "                                                  Appointed\nName                                                until                   Position                Occupation\nElisabeth Beier . . . . . . . . . . . . . . . .     2018      Chairwoman of the Supervisory Board   Merchant\nDr. Erwin Kern . . . . . . . . . . . . . . . .      2018       Member of the Supervisory Board      Merchant\nMichael Beier . . . . . . . . . . . . . . . . .     2018       Member of the Supervisory Board      Merchant\n", "page_number": 242, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.880718255664814, "height": 0.06712270200940573, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-242-11", "text": "F-17", "page_number": 242, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9333048311244121, "height": 0.010260795211628815, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-0", "text": "    At the beginning of the third quarter of 2017, changes were made to the Management Board. Dermapharm\nGroup appointed Mr. Stefan H\u00fcmer as a member of the Management Board as Chief Financial Officer.\n", "page_number": 243, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.09234715690466011, "height": 0.02778965369816161, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-1", "text": "9.   Events after the reporting period\n", "page_number": 243, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.11970927746900385, "height": 0.014108593415989745, "width": 0.29081015719467956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-2", "text": "    On 21 September 2017, the Group acquired all of the shares and voting interests in Bio-Di\u00e4t-Berlin\nGmbH, Berlin, along with its wholly owned distribution subsidiary Kr\u00e4uter K\u00fchne GmbH, Berlin, from the\nformer shareholder. The transaction closed on 1 October 2017.\n", "page_number": 243, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.1675929884566054, "height": 0.04147071398033347, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-3", "text": "     The acquired companies are successfully producing and marketing phytopharmaceuticals (herbal\nmedicines) as well as homoeopathics and natural cosmetics. Kr\u00e4uter K\u00fchne GmbH, Berlin, operates 16 sales\noutlets, an online shop and related services. With the acquisition, the Group intends to extend its product\npipeline. For information on the purchase price, please refer to the condensed consolidated statement of cash\nflows.\n", "page_number": 243, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.24540401881145787, "height": 0.06797776827704147, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-4", "text": "     Due to the timing of the transaction, it was not yet possible to provide any information about the fair value\nof the acquired assets and liabilities because the purchase price allocation is not yet finalised.\n", "page_number": 243, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.25609234715690465, "lower_right_x": 0.880894800483676, "lower_right_y": 0.2834544677212484, "height": 0.027362120564343728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-5", "text": "Gr\u00fcnwald, 13 December 2017, the Management Board\n", "page_number": 243, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.31124412141941, "height": 0.014108593415989745, "width": 0.38754534461910517}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-6", "text": "Stefan H\u00fcmer              Karin Samusch\nChief Financial Officer   Head of Business Development\n", "page_number": 243, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.5598548972188634, "lower_right_y": 0.354424967935015, "height": 0.02650705429670802, "width": 0.4443772672309553}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-243-7", "text": "F-18", "page_number": 243, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-244-0", "text": "                      Audited consolidated financial statements of Dermapharm AG\nas of and for the fiscal years ended December 31, 2016, 2015 and 2014 prepared in accordance with IFRS\n", "page_number": 244, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4754168448054724, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-244-1", "text": "F-19", "page_number": 244, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-245-0", "text": "Consolidated statement of financial position at 31 December 2016, 31 December 2015,\n                      31 December 2014 and 1 January 2014\n", "page_number": 245, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8180169286577993, "lower_right_y": 0.09234715690466011, "height": 0.02778965369816161, "width": 0.6396614268440145}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-245-1", "text": "Assets                                                                           31 December   31 December   31 December   1 January\nin kEUR                                                                  Notes       2016          2015          2014         2014\nNON-CURRENT ASSETS\nIntangible assets . . . . . . . . . . .                          .   .    4.1        70,025        67,966        71,713       70,315\nGoodwill . . . . . . . . . . . . . . . .                         .   .    4.1        17,033        16,444        21,553       26,743\nProperty, plant and equipment . .                                .   .    4.2        53,357        53,406        56,547       57,352\nInvestments measured at equity .                                 .   .    4.3         3,197         2,659         1,628        2,755\nInvestments . . . . . . . . . . . . . .                          .   .    4.4           262           218           461          797\nOther non-current financial assets                               .   .    4.5        10,648        13,841         9,205        9,641\nDeferred tax assets . . . . . . . . .                            .   .   4.17           218            28           952          472\nTotal non-current assets . . . . . . .                                              154,740       154,562       162,059      168,075\nCURRENT ASSETS\nInventories . . . . . . . . . . . . .                    .   .   .   .    4.6        84,779        76,957        71,516       68,242\nTrade accounts receivable . . .                          .   .   .   .    4.7        26,302        17,423        22,791       22,388\nOther current financial assets .                         .   .   .   .    4.8        39,976        42,499        58,810       83,309\nOther current assets . . . . . . .                       .   .   .   .    4.8         1,692         1,445         3,043        2,932\nIncome tax receivables\u2013current                           .   .   .   .   4.17           394           989           733          366\nCash and cash equivalents . . .                          .   .   .   .    4.9         3,816         2,791        11,645        4,665\nTotal current assets . . . . . . . . . .                                            156,959       142,104       168,538      181,902\nTOTAL ASSETS . . . . . . . . . . . .                                                311,699       296,666       330,597      349,977\n\nEquity and liabilities                                                           31 December   31 December   31 December   1 January\nin kEUR                                                                  Notes       2016          2015          2014         2014\nEQUITY\nIssued capital . . .     .   .   .   .   .   .   .   .   .   .   .   .   4.10         1,342         1,342         1,342        1,342\nCapital reserves . .     .   .   .   .   .   .   .   .   .   .   .   .   4.10           250           250           250          250\nRetained earnings        .   .   .   .   .   .   .   .   .   .   .   .   4.10        56,274        39,457        28,616       33,911\nOther reserves . .       .   .   .   .   .   .   .   .   .   .   .   .   4.10          (951)           53        (1,932)          \u2014\nEquity attributable to owners of\n  the company . . . . . . . . . . . . .                                              56,915        41,102        28,276       35,503\nNon-controlling interests . . . . . . . .                                             3,891         3,340         5,734        5,858\nTotal equity . . . . . . . . . . . . . . . .                                         60,806        44,442        34,010       41,361\nNON-CURRENT LIABILITIES\nDefined benefit obligations and other\n  accrued employee benefits . . . . .                                    4.11        13,250        12,080        12,445        9,744\nOther provisions . . . . . . . . . . . . .                               4.12            \u2014             \u2014             78           64\nFinancial liabilities . . . . . . . . . . . .                            4.13        96,896       151,073       161,530      100,831\nOther non-current financial liabilities                                  4.15        10,464        14,050         9,946       10,491\nOther non-current liabilities . . . . . .                                4.15        11,495        13,257        15,551       18,826\nDeferred tax liabilities . . . . . . . . .                               4.17         3,365           191            \u2014            \u2014\nTotal non-current liabilities . . . . .                                             135,470       190,651       199,550      139,956\nCURRENT LIABILITIES\nOther provisions . . . . . . . . . .                         .   .   .   4.12         6,951         6,405         6,118        5,569\nFinancial liabilities . . . . . . . . .                      .   .   .   4.13        65,883        24,906        20,382       52,118\nTrade accounts payable . . . . . .                           .   .   .   4.14        24,526        18,139        27,449       25,378\nOther current financial liabilities                          .   .   .   4.16         4,303         2,389        30,605       77,596\nOther current liabilities . . . . . .                        .   .   .   4.16        10,983         8,221        11,443        7,525\nIncome tax liabilities . . . . . . .                         .   .   .   4.17         2,777         1,513         1,040          474\nTotal current liabilities . . . . . . . .                                           115,423        61,573        97,037      168,660\nTOTAL EQUITY AND\n LIABILITIES . . . . . . . . . . . . .                                              311,699       296,666       330,597      349,977\n", "page_number": 245, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8824283882000855, "height": 0.7802479692176144, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-245-2", "text": "F-20", "page_number": 245, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-246-0", "text": "Consolidated statement of comprehensive income for the years ended 2016, 2015 and 2014\n", "page_number": 246, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8343409915356711, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.6704957678355502}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-246-1", "text": "in kEUR                                                                          Notes     2016          2015          2014\nRevenue . . . . . . . . . . . . . . . . . . .   .. ..... .                        5.1      444,478       384,843       391,340\nIncrease/decrease in finished goods and\n  work-in-process . . . . . . . . . . . . .     .   .   .   .   .   .   .   .     4.6         1,007         2,887         8,300\nOwn work capitalised . . . . . . . . . . .      .   .   .   .   .   .   .   .     4.1         8,301         7,983         8,465\nOther operating income . . . . . . . . . .      .   .   .   .   .   .   .   .     5.2         9,916         9,944         6,221\nCost of material . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .     4.6      (252,756)     (215,912)     (237,077)\nPersonnel expenses . . . . . . . . . . . . .    .   .   .   .   .   .   .   .     5.3       (58,749)      (55,739)      (57,676)\nDepreciation and amortisation . . . . . .       .   .   .   .   .   .   .   .   4.1, 4.2    (14,448)      (22,921)      (28,289)\nOther operating expenses . . . . . . . . .      .   .   .   .   .   .   .   .     5.4       (50,955)      (50,322)      (48,029)\nOperating income . . . . . . . . . . . . . . . . . . . . .                                  86,794        60,763        43,255\nResult from investments measured at equity . . . . .                              4.3         1,464           985           863\nFinancial income . . . . . . . . . . . . . . . . . . . . . .                      5.5         7,297         9,365         3,325\nFinancial expenses . . . . . . . . . . . . . . . . . . . . .                      5.5       (12,689)      (15,814)      (11,956)\nFinancial result . . . . . . . . . . . . . . . . . . . . . .                                 (3,928)       (5,464)       (7,768)\nEarnings before taxes . . . . . . . . . . . . . . . . . .                                   82,866        55,299        35,487\nIncome taxes      . .... ..... .... .... ..... .                                 4.17        (5,871)       (2,920)       (2,244)\nProfit or (loss) for the period . . . . . . . . . . . . .                                   76,995        52,379        33,243\nProfit transfers due to profit transfer agreements . .                                      (59,931)      (39,480)      (33,006)\nProfit or (loss) for the period after profit\n  distribution . . . . . . . . . . . . . . . . . . . . . . . .                              17,064        12,899              237\nOther comprehensive income/(loss) that will not be\n  reclassified to profit or loss in subsequent\n  periods:\nActuarial gains/losses from remeasurement of\n  defined benefit pension plans . . . . . . . . . . . . .                        4.11        (1,058)            481      (2,527)\nDeferred taxes effect relating to items that will not\n  be reclassified . . . . . . . . . . . . . . . . . . . . . .                    4.17             104           (36)          283\nOther comprehensive income/(loss) that may be\n  reclassified to profit or loss in subsequent\n  periods:\nExchange differences on translation of foreign\n  operations . . . . . . . . . . . . . . . . . . . . . . . . .                    2.5             (51)      1,539             313\nDeferred taxes effect relating to items that may be\n  reclassified . . . . . . . . . . . . . . . . . . . . . . . .                                     \u2014             \u2014             \u2014\nOther comprehensive income/(loss) for the\n  period, net of tax . . . . . . . . . . . . . . . . . . .                                   (1,005)        1,984        (1,931)\nTotal comprehensive income for the period, net\n  of tax . . . . . . . . . . . . . . . . . . . . . . . . . . .                              16,059        14,883         (1,694)\nProfit attributable to:\nOwners of the company . . . . . . . . . . . . . . . . .                                     16,824        12,701              (61)\nNon-controlling interests . . . . . . . . . . . . . . . . .                                    240           198              298\n                                                                                            17,064        12,899              237\nTotal comprehensive income attributable to:\nOwners of the company . . . . . . . . . . . . . . . . .                                     15,819        14,685         (1,992)\nNon-controlling interests . . . . . . . . . . . . . . . . .                                    240           198            298\n                                                                                            16,059        14,883         (1,694)\n", "page_number": 246, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8281316802052159, "height": 0.7396323215049166, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-246-2", "text": "F-21", "page_number": 246, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-247-0", "text": "Consolidated statement of cash flows for the years ended 2016, 2015 and 2014\n", "page_number": 247, "bounding_box": {"top_left_x": 0.2079806529625151, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.0778110303548525, "height": 0.013253527148353997, "width": 0.585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-247-1", "text": "in kEUR                                                                                Notes      2016        2015        2014\nProfit or loss for the period . . . . . . . . . . . . . . . . . . .                                17,064       12,899         237\nAmortisation of intangible assets . . . . . . . . . . . . . . . .                      4.1          9,211        9,886      13,499\nAmortisation of intangible assets\u2013impairment charges . .                               4.1             \u2014         5,109       9,863\nDepreciation of property, plant and equipment . . . . . . .                            4.2          4,892        5,173       4,927\nIncrease /(decrease) in other accrued employee benefits .                              4.11           112          116         174\nIncrease /(decrease) in other non-current provisions . . . .                           4.12            \u2014           (78)         14\nIncrease /(decrease) in other current provisions . . . . . .                           4.12           544          284         551\nOther non-cash expenses /(income) items . . . . . . . . . .                                        39,501       33,735      40,357\n(Increase) /decrease in inventories . . . . . . . . . . . . . . .                       4.6        (6,078)      (5,354)     (3,291)\n(Increase) /decrease in trade receivables . . . . . . . . . . .                         4.7        (8,737)       5,423        (434)\n(Increase) /decrease in other assets . . . . . . . . . . . . . .                      4.5, 4.8      6,343      (19,003)     24,944\nIncrease /(decrease) in trade payables . . . . . . . . . . . . .                        4.14        5,510       (9,086)      2,079\nIncrease /(decrease) in other liabilities . . . . . . . . . . . .                    4.15, 4.16      (180)      (7,141)    (46,806)\nShare of profit of equity-accounted investees, net of tax                               4.3        (1,464)        (985)       (863)\nNet (gain) /loss on disposal of intangible assets . . . . . .                           4.1         1,563        2,574       2,369\nNet (gain) /loss on disposal of property, plant and\n   equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                  4.2           (23)         30         111\nNet (gain) /loss on sale of investments . . . . . . . . . . . .                         2.4            \u2014          100          \u2014\nInterest expenses /(income) . . . . . . . . . . . . . . . . . . .                       5.5         4,203       5,403       6,528\nIncrease /(decrease) in income tax payables and deferred\n   tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . .               4.17         4,320        3,132       2,440\nIncome tax (paid) /received . . . . . . . . . . . . . . . . . . .                      4.17            (3)      (1,840)     (2,443)\nNet cash flows from operating activities               .. . . . .. . .                             76,778      40,377      54,256\nProceeds from sale of intangible assets . . . . . . . . .                .   .   .      4.1          2,426       3,088         210\nProceeds from sale of property, plant and equipment                      .   .   .      4.2            258         394       1,992\nProceeds from sale of investments . . . . . . . . . . . .                .   .   .      2.4              9       6,837          \u2014\nAcquisition of subsidiary, net of cash acquired . . . .                  .   .   .      2.4         (1,420)         \u2014           \u2014\n(Purchase) of intangible assets . . . . . . . . . . . . . .              .   .   .      4.1        (12,708)    (11,740)    (22,157)\n(Purchase) of property, plant and equipment . . . . .                    .   .   .      4.2         (5,050)     (3,193)     (6,267)\nPayments for investment in financial assets . . . . . .                  .   .   .      2.4            (52)     (1,069)         \u2014\nDividends from equity-accounted investees . . . . . .                    .   .   .      4.3            926         963       1,990\nInterest received . . . . . . . . . . . . . . . . . . . . . . .          .   .   .      5.5          3,332       3,799       2,310\nNet cash flows used in investing activities . . . . . . . .                                        (12,279)      (921)     (21,922)\nPayment of profit transfers due to profit           transfer\n   agreements . . . . . . . . . . . . . . . . .     . . .. . .   .   .   .   .   .                 (39,480)    (33,006)    (39,859)\nAcquisition of non-controlling interests .          . . .. . .   .   .   .   .   .     2.4          (1,850)        (93)        (25)\nDividends (paid) . . . . . . . . . . . . . . .      . . .. . .   .   .   .   .   .     4.10             \u2014          (90)     (5,633)\nProceeds from financial liabilities . . . .         . . .. . .   .   .   .   .   .     4.13          6,082       9,787      74,328\n(Repayment) of financial liabilities . . .          . . .. . .   .   .   .   .   .     4.13        (12,544)    (22,591)    (16,696)\nPayment of finance lease liabilities . . .          . . .. . .   .   .   .   .   .     4.13           (601)       (418)       (273)\nInterest (paid) . . . . . . . . . . . . . . . . .   . . .. . .   .   .   .   .   .     5.5          (7,535)     (9,202)     (8,838)\nNet cash flows from / used in financing activities . . .                                           (55,928)    (55,613)     3,005\nNet increase in cash, cash equivalents and bank\n  overdrafts . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 4.9, 6.1c      8,571      (16,157)    35,339\nCash, cash equivalents and bank overdrafts at the\n  beginning of the period . . . . . . . . . . . . . . . . . . . .                       4.9         (9,644)     6,483      (28,859)\nChange in cash, cash equivalents and bank overdrafts\n  due to foreign exchange differences . . . . . . . . . . . .                                            22          30          3\nCash, cash equivalents and bank overdrafts at the\n  end of the period . . . . . . . . . . . . . . . . . . . . . . .                                   (1,051)     (9,644)     6,483\nBank overdrafts at the beginning the period . . . . . . . .                            4.13        (12,435)     (5,162)    (33,524)\nBank overdrafts at the end of the period . . . . . . . . . .                           4.13         (4,867)    (12,435)     (5,162)\nCash and cash equivalents at the end of the period . .                                              3,816       2,791      11,645\n", "page_number": 247, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.07823856348867037, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.837964942283027, "height": 0.7597263787943567, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-247-2", "text": "F-22", "page_number": 247, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-248-0", "text": "                 Consolidated statement of changes in equity\nat 31 December 2016, 31 December 2015, 31 December 2014 and 1 January 2014\n", "page_number": 248, "bounding_box": {"top_left_x": 0.19407496977025393, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.09234715690466011, "height": 0.02778965369816161, "width": 0.6088270858524788}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-248-1", "text": "                                           Attributable to owners of the company\n                                                                                                                  Non-\n                                            Issued        Capital     Retained      Other                      controlling     Total\nin kEUR                            Notes    capital       reserves    earnings     reserves     Total           interests     Equity\nAs at 1 January 2014 . .           4.10         1,342           250      33,911           \u2014       35,503             5,858      41,361\nProfit for the period . . . .                         \u2014          \u2014          (61)          \u2014             (61)          298          237\nOther comprehensive\n  income/(loss) for the\n  period . . . . . . . . . . .                        \u2014          \u2014           \u2014        (1,931)     (1,931)               \u2014       (1,931)\nTotal comprehensive\n  income for the period .                             \u2014          \u2014          (61)      (1,931)     (1,992)             298       (1,694)\nIssue of share capital . . .                          \u2014          \u2014           \u2014            \u2014             \u2014               \u2014              \u2014\nReduction of statutory\n   reserves . . . . . . . . . .                       \u2014          \u2014          (24)          \u2014             (24)            \u2014          (24)\nAcquisition of subsidiary\n   with non-controlling\n   interests . . . . . . . . . .                      \u2014          \u2014           \u2014            \u2014             \u2014               \u2014              \u2014\nAcquisition of\n   non-controlling interests                          \u2014          \u2014           \u2014            \u2014           \u2014                 \u2014           \u2014\nDividends . . . . . . . . . .      4.10               \u2014          \u2014       (5,210)          \u2014       (5,210)             (423)     (5,633)\nAs at 31 December 2014             4.10         1,342           250      28,616       (1,931)     28,277             5,733      34,010\nAs at 1 January 2015 . .           4.10         1,342           250      28,616       (1,931)     28,277             5,733      34,010\nProfit for the period . . . .                         \u2014          \u2014       12,701           \u2014       12,701              198       12,899\nOther comprehensive\n  income/(loss) for the\n  period . . . . . . . . . . .                        \u2014          \u2014           \u2014         1,984       1,984                \u2014        1,984\nTotal comprehensive\n  income for the period .                             \u2014          \u2014       12,701        1,984      14,685              198       14,883\nIssue of share capital . . .                          \u2014          \u2014           \u2014            \u2014             \u2014               \u2014           \u2014\nDivestiture of subsidiary .         2.4               \u2014          \u2014           \u2014            \u2014             \u2014           (2,409)     (2,409)\nAcquisition of subsidiary\n   with non-controlling\n   interests . . . . . . . . . .                      \u2014          \u2014           \u2014            \u2014             \u2014               \u2014              \u2014\nAcquisition of\n   non-controlling interests\n   without change in\n   control . . . . . . . . . . .   2.4                \u2014          \u2014       (1,770)          \u2014       (1,770)             (182)     (1,952)\nDividends . . . . . . . . . .      4.10               \u2014          \u2014          (90)          \u2014          (90)               \u2014          (90)\nAs at 31 December 2015             4.10         1,342           250      39,457           53      41,102             3,340      44,442\nAs at 1 January 2016 . .           4.10         1,342           250      39,457           53      41,102             3,340      44,442\nProfit for the period . . . .                         \u2014          \u2014       16,824           \u2014       16,824              240       17,064\nOther comprehensive\n  income/(loss) for the\n  period . . . . . . . . . . .                        \u2014          \u2014           \u2014        (1,005)     (1,005)               \u2014       (1,005)\nTotal comprehensive\n  income for the period .                             \u2014          \u2014       16,824       (1,005)     15,819              240       16,059\nIssue of share capital . . .                          \u2014          \u2014           \u2014            \u2014             \u2014               \u2014              \u2014\nReduction of statutory\n   reserves . . . . . . . . . .                       \u2014          \u2014           (7)          \u2014              (7)            \u2014              (7)\nAcquisition of subsidiary\n   with non-controlling\n   interests . . . . . . . . . .    2.4               \u2014          \u2014           \u2014            \u2014             \u2014             283          283\nAcquisition of\n   non-controlling interests\n   without change in\n   control . . . . . . . . . . .    2.4               \u2014          \u2014           \u2014            \u2014             \u2014               29             29\nDividends . . . . . . . . . .                         \u2014          \u2014           \u2014            \u2014             \u2014               \u2014              \u2014\nAs at 31 December 2016             4.10         1,342           250      56,274         (952)     56,914             3,892      60,806\n", "page_number": 248, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09876015391192818, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8683197947840958, "height": 0.7695596408721677, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-248-2", "text": "F-23", "page_number": 248, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-249-0", "text": "                                                      Table of contents\n\n1.   General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                    F-26\n     1.1   Corporate information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                            F-26\n     1.2   First Time Adoption of IFRS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                F-26\n2.   Significant accounting policies and changes . . . . . . . . .            . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-30\n     2.1     Basis of preparation of financial statements . . . .             . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-30\n     2.2     Effects of new or amended financial standards and                interpretations                   .   .   .   .   .   .   .   .   .   .   F-31\n     2.3     Changes in accounting policies . . . . . . . . . . . .           . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-33\n     2.4     Basis of consolidation . . . . . . . . . . . . . . . . . .       . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-33\n     2.5     Currency translation . . . . . . . . . . . . . . . . . . .       . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-37\n     2.6     Business combinations . . . . . . . . . . . . . . . . . .        . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-37\n     2.7     Intangible assets . . . . . . . . . . . . . . . . . . . . . .    . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-39\n     2.8     Property, plant and equipment . . . . . . . . . . . . .          . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-41\n     2.9     Financial assets . . . . . . . . . . . . . . . . . . . . . .     . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-41\n     2.10 Inventories . . . . . . . . . . . . . . . . . . . . . . . . .       . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-42\n     2.11 Cash and cash equivalents . . . . . . . . . . . . . . .             . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-42\n     2.12 Financial liabilities . . . . . . . . . . . . . . . . . . . .       . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-43\n     2.13 Government grants . . . . . . . . . . . . . . . . . . . .           . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-43\n     2.14 Provisions for pensions . . . . . . . . . . . . . . . . .           . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-44\n     2.15 Other Provisions . . . . . . . . . . . . . . . . . . . . . .        . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-44\n     2.16 Employee benefits . . . . . . . . . . . . . . . . . . . . .         . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-45\n     2.17 Current and deferred income tax . . . . . . . . . . .               . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-45\n     2.18 Recognition of income and expenses . . . . . . . . .                . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-46\n     2.19 Leases . . . . . . . . . . . . . . . . . . . . . . . . . . . .      . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-46\n     2.20 Derivatives . . . . . . . . . . . . . . . . . . . . . . . . .       . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-47\n     2.21 Fair value measurement . . . . . . . . . . . . . . . . .            . .... .... .                     .   .   .   .   .   .   .   .   .   .   F-47\n3.   Estimates and judgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                           F-48\n     3.1    Critical accounting estimates and assumptions . . . . . . . . . . . . . . . . . . . . . . .                                                 F-48\n4.   Notes   to the consolidated statement of financial position . . . . . . .                  ..      .   .   .   .   .   .   .   .   .   .   .   .   F-50\n     4.1      Intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . .         ..      .   .   .   .   .   .   .   .   .   .   .   .   F-50\n     4.2      Property, plant and equipment . . . . . . . . . . . . . . . . . . .               ..      .   .   .   .   .   .   .   .   .   .   .   .   F-54\n     4.3      Investments measured at equity . . . . . . . . . . . . . . . . . .                ..      .   .   .   .   .   .   .   .   .   .   .   .   F-56\n     4.4      Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         ..      .   .   .   .   .   .   .   .   .   .   .   .   F-57\n     4.5      Other non-current financial assets . . . . . . . . . . . . . . . . .              ..      .   .   .   .   .   .   .   .   .   .   .   .   F-57\n     4.6      Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         ..      .   .   .   .   .   .   .   .   .   .   .   .   F-58\n     4.7      Trade accounts receivable . . . . . . . . . . . . . . . . . . . . . .             ..      .   .   .   .   .   .   .   .   .   .   .   .   F-58\n     4.8      Other current assets and other current financial assets . . . .                   ..      .   .   .   .   .   .   .   .   .   .   .   .   F-60\n     4.9      Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . .               ..      .   .   .   .   .   .   .   .   .   .   .   .   F-60\n     4.10     Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .        ..      .   .   .   .   .   .   .   .   .   .   .   .   F-60\n     4.11     Provisions for pensions . . . . . . . . . . . . . . . . . . . . . . .             ..      .   .   .   .   .   .   .   .   .   .   .   .   F-61\n     4.12     Other provisions . . . . . . . . . . . . . . . . . . . . . . . . . . . .          ..      .   .   .   .   .   .   .   .   .   .   .   .   F-65\n     4.13     Financial liabilities . . . . . . . . . . . . . . . . . . . . . . . . . .         ..      .   .   .   .   .   .   .   .   .   .   .   .   F-66\n     4.14     Trade accounts payable . . . . . . . . . . . . . . . . . . . . . . .              ..      .   .   .   .   .   .   .   .   .   .   .   .   F-66\n     4.15     Other non-current liabilities . . . . . . . . . . . . . . . . . . . . .           ..      .   .   .   .   .   .   .   .   .   .   .   .   F-66\n     4.16     Other current liabilities and other current financial liabilities                  .      .   .   .   .   .   .   .   .   .   .   .   .   F-67\n     4.17     Income taxes and deferred taxes . . . . . . . . . . . . . . . . .                 ..      .   .   .   .   .   .   .   .   .   .   .   .   F-67\n5.   Notes   to the consolidated statement of comprehensive income                  .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-70\n     5.1      Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-70\n     5.2      Other operating income . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-70\n     5.3      Personnel expenses and numbers of employees . . . . .                 .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-70\n     5.4      Other operating expenses . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-71\n     5.5      Financial result . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-71\n", "page_number": 249, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.8413852073535699, "height": 0.7768277041470715, "width": 0.7357920193470374}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-249-1", "text": "F-24", "page_number": 249, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-250-0", "text": "6.    Financial risk management and financial instruments . . . . . . . . . . . . . . .                                           .. ...              .   .   .   F-72\n      6.1    Financial risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                 .. ...              .   .   .   F-72\n         a) Market risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                 .. ...              .   .   .   F-72\n         b) Credit risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                 .. ...              .   .   .   F-74\n         c) Liquidity risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                .. ...              .   .   .   F-75\n      6.2    Risk management, derivative financial instruments and disclosures on                                                 capital\n             management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                   .. ...              . ..        F-76\n      6.3    Additional disclosures on financial instruments . . . . . . . . . . . . . .                                          .. ...              . ..        F-76\n7.    Other   disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-81\n      7.1      Notes to the consolidated statement of cash flows .                    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-81\n      7.2      Other financial obligations and contingent liabilities                 .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-82\n         a)    Obligations from finance leases . . . . . . . . . . . . .              .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-82\n         b)    Obligations from operating leases . . . . . . . . . . . .              .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-82\n         c)    Other financial obligations . . . . . . . . . . . . . . . .            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-83\n      7.3      Collateral . . . . . . . . . . . . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-84\n8.    Related party disclosures . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-84\n        a) Significant transactions . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-84\n        b) Year-end balances of significant related parties               .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-86\n        c) Key Management personnel compensation . . .                    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   F-87\n9.    Disclosures on the Management Board and the Supervisory Board . . . . . . . . . . . . . .                                                                   F-88\n10.   Events after the reporting period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                   F-88\n", "page_number": 250, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.38991021804189824, "height": 0.32535271483539974, "width": 0.7357920193470374}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-250-1", "text": "F-25", "page_number": 250, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-0", "text": "Notes to the consolidated financial statements of Dermapharm AG\n", "page_number": 251, "bounding_box": {"top_left_x": 0.25151148730350664, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.49818621523579204}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-1", "text": "1.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.09491235570756734, "height": 0.00983326207781103, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-2", "text": "General\n", "page_number": 251, "bounding_box": {"top_left_x": 0.15900846432889965, "top_left_y": 0.08507909362975631, "lower_right_x": 0.21523579201934703, "lower_right_y": 0.09576742197520308, "height": 0.010688328345446765, "width": 0.05622732769044739}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-3", "text": "1.1\n", "page_number": 251, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.10602821718683197, "lower_right_x": 0.13845223700120918, "lower_right_y": 0.11714407866609662, "height": 0.011115861479264647, "width": 0.02176541717049575}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-4", "text": "Corporate information\n", "page_number": 251, "bounding_box": {"top_left_x": 0.15114873035066506, "top_left_y": 0.10602821718683197, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.11970927746900385, "height": 0.013681060282171878, "width": 0.16807738814993956}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-5", "text": "     Dermapharm AG (hereafter referred to as the \u201cCompany\u201d or \u201cDermapharm\u201d) as the parent company of the\nDermapharm Group (hereafter referred to as \u201cGroup\u201d) based at Lil-Dagover-Ring 7, Gr\u00fcnwald, Germany, is an\ninternational corporation mainly active in the healthcare and pharmaceuticals business in the GSA region,\nespecially in generics, high-quality dermatological and allergic medical products.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.18426678067550234, "height": 0.05814450619923042, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-6", "text": "     Dermapharm is a leading independent specialty pharmaceuticals company in the German market that\napplies formulation and development expertise to the development, manufacture and marketing of a broad\nassortment of patent-free branded pharmaceuticals in niche markets, holding approximately 900 marketing\nauthorisations for more than 200 active ingredients. Dermapharm also offers a growing portfolio of other\nhealthcare products such as cosmetics, food supplements and dietary products. The company operates primarily\nin Germany, has subsidiaries in Austria and Switzerland and has presences in eastern Europe (Croatia, Poland\nand Ukraine).\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1911073108165883, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2902949978623343, "height": 0.09918768704574601, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-7", "text": "     The company and the domestic and international subsidiaries concentrate on the development, licensing,\nmanufacture and sale of products using off-patent pharmaceutical active ingredients in the healthcare and in\nparticular the pharmaceutical industry. The core products are generics, branded generics, non-prescription\nnatural remedies, OTC products and parallel-imported original medicines.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.35271483539974346, "height": 0.05557930739632322, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-8", "text": "natural remedies, OTC products and parallel-imported original medicines.\n     Dermapharm AG is a wholly owned subsidiary of Themis Beteiligungs AG. Themis Beteiligungs AG\npublishes exempting consolidated financial statements in accordance with \u00a7 291 HGB. Consequently, these\nfinancial statements were voluntarily prepared in accordance with IFRS.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35314236853356135, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4035912783240701, "height": 0.050448909790508756, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-9", "text": "    The consolidated financial statements were authorised by the Management Board by resolution dated\n29 December 2017.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43779392902949976, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-10", "text": "1.2 First Time Adoption of IFRS\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.37122128174123337, "lower_right_y": 0.4681487815305686, "height": 0.013681060282171864, "width": 0.25574365175332525}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-11", "text": "      These financial statements for the year ended 31 December 2016 are the first the Group has prepared in\naccordance with IFRS. For periods up to and including the year ended 31 December 2016, the Group prepared\nits financial statements in accordance with the German Commercial Code (HGB).\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.516460025651988, "height": 0.04147071398033347, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-12", "text": "     Accordingly, the Group has prepared financial statements that comply with IFRS applicable as at\n31 December 2016, together with the comparative period data for the years ended 31 December 2015 and\n31 December 2014, as described in the summary of significant accounting policies. In preparing the financial\nstatements, the Group\u2019s opening statement of financial position was prepared as at 1 January 2014, the Group\u2019s\ndate of transition to IFRS. This note explains the principal adjustments made by the Group in restating its local\nGAAP financial statements, including the statement of financial position as at 1 January 2014 and the financial\nstatements for the years ended 31 December 2014, 2015 and 2016. IFRS 1 allows first-time adopters certain\nexemptions from the retrospective application of certain requirements under IFRS.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6383069687900812, "height": 0.11201368106028209, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-13", "text": "The Group has applied the following exemptions:\n", "page_number": 251, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.6669516887558786, "height": 0.0141085934159898, "width": 0.35368802902055624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-14", "text": "\u2022   IFRS 3 Business Combinations has not been applied to either acquisitions of subsidiaries that are\n    considered businesses under IFRS, or acquisitions of interests in associates and joint ventures that\n    occurred before 1 January 2014. Use of this exemption means that the local GAAP carrying amount\n    of assets and liabilities, that are required to be recognised under IFRS, is their deemed cost at the date\n    of the acquisition. After the date of the acquisition, measurement is in accordance with IFRS. The\n    Group did not recognise or exclude any previously recognised amounts as a result of IFRS\n    recognition requirements. IFRS 1 also requires that the local GAAP carrying amount of goodwill\n    must be reported in the opening IFRS statement of financial position (apart from adjustments for\n    goodwill impairment and recognition or derecognition of intangible assets). In accordance with\n    IFRS 1, the Group has tested goodwill for impairment at the date of transition to IFRS. No goodwill\n    impairment was deemed necessary at 1 January 2014.\n", "page_number": 251, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6737922188969645, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8302693458743052, "height": 0.15647712697734073, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-251-15", "text": "F-26", "page_number": 251, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-0", "text": "\u2022   The Group has not applied IAS 21, the Effects of Changes in Foreign Exchange Rates retrospectively\n    to fair value adjustments and goodwill from business combinations that occurred before the date of\n    transition to IFRS. Such fair value adjustments and goodwill are treated as assets and liabilities of the\n    parent rather than as assets and liabilities of the acquiree. Therefore, those assets and liabilities are\n    already expressed in the functional currency of the parent or are non-monetary foreign currency items\n    and no further translation differences occur. Cumulative currency translation differences for all\n    foreign operations are deemed to be zero as at 1 January 2014.\n\u2022   The Group has applied the transitional provisions in IAS 23 Borrowing Costs and capitalises\n    borrowing costs relating to all qualifying assets after the date of transition. Similarly, the Group has\n    not restated borrowing costs capitalised under local GAAP for qualifying assets prior to the date of\n    transition to IFRS.\n", "page_number": 252, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22573749465583584, "height": 0.16117999144933734, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-1", "text": "Estimates\n", "page_number": 252, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2424112868747328, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.2526720820863617, "height": 0.010260795211628926, "width": 0.06771463119709793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-2", "text": "     The estimates at 1 January 2014 and at 31 December 2014, 2015 and 2016 are consistent with those made\nfor the same dates in accordance with local GAAP (after adjustments to reflect any differences in accounting\npolicies) apart from the following item:\n", "page_number": 252, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.30440359127832406, "height": 0.04147071398033347, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-3", "text": "Pensions and other post-employment benefits\n", "page_number": 252, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.31209918768704575, "lower_right_x": 0.46856106408706166, "lower_right_y": 0.32492518170158186, "height": 0.012825994014536102, "width": 0.3186215235792019}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-4", "text": "     The estimates used by the Group to present these amounts in accordance with IFRS reflect conditions as at\n1 January 2014, the date of transition to IFRS, and as at 31 December 2014, 2015 and 2016.\n", "page_number": 252, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.334330910645575, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.36169303120991875, "height": 0.027362120564343728, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-5", "text": "    The following reconciliation depicts the effect of the transition to IFRS on total equity as at 1 January\n2014 and 31 December 2016.\n", "page_number": 252, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3946130825138948, "height": 0.02565198802907226, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-6", "text": "                                                                                                                                                               as at         as at\n                                                                                                                                                            1 January    31 December\nkEUR                                                                                                                                                           2014          2016\nTotal equity according to German GAAP (HGB) . . . . . . . . . . . . . . . . . .                                                                                45,933        79,873\nGoodwill . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014          3,725\nOther intangible assets . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014         (3,771)\nAcquisition of subsidiary . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014            215\nInvestments measured at equity . . . . .            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       1,845         1,278\nChange in group structure . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       2,741            \u2014\nInventories . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       4,902            \u2014\nTrade receivables . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          83            17\nParticipation rights . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     (10,981)      (10,856)\nDefined benefit obligations . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      (2,393)       (4,394)\nAcquisition of non-controlling interests            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014         (1,751)\nFinancial liabilities and derivatives . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      (1,230)         (448)\nFinance Leases . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         (10)           26\nDeferred taxes . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         472        (3,114)\nOther . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          (1)            6\nTotal equity according to IFRS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                     41,361        60,806\n", "page_number": 252, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.6797776827704147, "height": 0.2697734074390766, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-252-7", "text": "F-27", "page_number": 252, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-0", "text": "    The following reconciliation depicts the effect of the transition to IFRS on profit for the period ended at\n31 December 2016.\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.08892689183411714, "height": 0.024369388627618643, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-1", "text": "                                                                                                                                                                                                      Period ended\n                                                                                                                                                                                                           at\n                                                                                                                                                                                                      31 December\nkEUR                                                                                                                                                                                                      2016\nProfit for the period according to German GAAP (HGB)                                                              .. .... .... ..... .... ..                                                               21,167\nGoodwill . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         3,215\nOther intangible assets . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        (1,460)\nAcquisition of subsidiary . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          (197)\nInvestments measured at equity . .            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           538\nDefined benefit obligations . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          (206)\nFinancial liabilities and derivatives         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           440\nFinance Leases . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .             9\nTrade receivables . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           (53)\nDeferred taxes . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        (6,419)\nOther . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            30\nProfit for the period according to IFRS                           ..... .... ..... .... .... ..... .... ..                                                                                                 17,064\nActuarial gains/losses from remeasurement of defined benefit pension plans . . . . . . . . . . . .                                                                                                         (1,058)\nDeferred taxes effect relating to items that will not be reclassified . . . . . . . . . . . . . . . . . .                                                                                                     104\nExchange differences on translation of foreign operations . . . . . . . . . . . . . . . . . . . . . . . .                                                                                                     (51)\nTotal comprehensive income for the period according to IFRS . . . . . . . . . . . . . . . . . .                                                                                                            16,059\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10303548525010689, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.3963232150491663, "height": 0.29328772979905937, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-2", "text": "Goodwill Impairment\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.4300983326207781, "height": 0.013253527148353983, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-3", "text": "     Goodwill was amortised on a straight-line basis under local GAAP. In line with the IFRS\n\u201cimpairment-only-approach\u201d, scheduled amortisation of goodwill is suspended as at 1 January 2014. Instead,\ngoodwill is tested for impairment at each reporting date and whenever there are triggering events for\nimpairment testing. The suspension of goodwill amortisation does not have an impact on retained earnings as at\n1 January 2014. The effect on income for the years ended 31 December 2014, 2015 and 2016 is recognised in\nprofit for the year under IFRS. For further information on goodwill impairment testing, please refer to 4.1.\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5224454895254382, "height": 0.0850790936297563, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-4", "text": "Change in Group Structure\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.309552599758162, "lower_right_y": 0.5506626763574177, "height": 0.0141085934159898, "width": 0.1940749697702539}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-5", "text": "    The 75.1% interest in Centuere Beteiligungs AG i.L., Hanover, which was measured at cost under local\nGAAP meets the criteria for inclusion in the consolidated financial statements under IFRS 10. The inclusion of\nCentuere Beteiligungs AG i.L. results in an increase in equity as at the date of transition to IFRS. The company\nwas sold in financial year 2015. For further information, please refer to 2.4.\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6147926464300983, "height": 0.05771697306541257, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-6", "text": "Other intangible assets\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.6430098332620778, "height": 0.0141085934159898, "width": 0.15961305925030228}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-7", "text": "     The 2014 acquisition of Naturwohl Vertriebs GmbH by H\u00fcbner Naturarzneimittel GmbH classifies as a\nbusiness combination under local GAAP. In the absence of \u201cprocesses\u201d, however, Naturwohl Vertriebs GmbH\ndoes not qualify as a \u201cbusiness\u201d under IFRS 3. Accordingly, the acquisition cannot be classified as a business\ncombination under IFRS. In the course of the transaction, H\u00fcbner Naturarzneimittel GmbH acquired the brand\nname \u201cLactoStop\u201d. As a consequence, no goodwill is recognised under IFRS. Instead, an intangible asset\n(brand) is capitalised and depreciated over its useful life. Moreover, a customer relationship identified in the\ncourse of the purchase price allocation of Remedix GmbH was capitalised. This results in a decrease in equity\nas at 31 December 2016 of kEUR (3,771) in total.\n", "page_number": 253, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7627191107310817, "height": 0.11329628046173579, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-253-8", "text": "F-28", "page_number": 253, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-0", "text": "Acquisition of subsidiary\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.29383313180169285, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.17835550181378473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-1", "text": "     In 2016, Axicorp GmbH obtained control over Remedix GmbH. IFRS 3 Business Combinations has been\napplied to the acquisition. The purchase price allocation conducted in accordance with IFRS differs from the\napproach chosen under local GAAP. The total effect on equity as at 31 December 2016 amounts to an increase\nof kEUR 215.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.14023086789226166, "height": 0.05515177426250535, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-2", "text": "Investments measured at equity\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.16973065412569474, "height": 0.01282599401453613, "width": 0.2230955259975816}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-3", "text": "     Dermapharm holds 25.1% of shares in Gynial GmbH in Austria and 30% in Hasan Pharma Ltd, Saigon,\nVietnam. These interests are classified as investments under local GAAP and measured at cost. Under IFRS,\nGynial and Hasan qualify as associate companies of Dermapharm and thus have to be accounted for as\nat-equity investments. The change in accounting for these interests results in an increase in equity of\nkEUR 1,278 in 2016.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.24625908507909364, "height": 0.06883283454467723, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-4", "text": "Inventories\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.2740487387772552, "height": 0.011115861479264633, "width": 0.0773881499395405}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-5", "text": "     In the light of the transition to IFRS, the measurement of inventories as at 1 January 2014 increased by\nkEUR 4,902 in order to account for the overhead not taken into account as at the opening balance. The\nadjustment does not have an impact on the total change in equity as at 31 December 2016.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.32492518170158186, "height": 0.04147071398033347, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-6", "text": "Trade receivables\n", "page_number": 254, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.34159897392047883, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.3522873022659256, "height": 0.010688328345446751, "width": 0.12575574365175335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-7", "text": "     Provisions for impairment of receivables under local GAAP consist of both a specific allowance for\nimpairments and a lump-sum allowance for expected future losses. IFRS does not permit recognition of\nimpairment for expected future losses and this amount has been eliminated against retained earnings at\n1 January 2014. The effect on earnings for the years ended 31 December 2014, 2015 and 2016 is also\nrecognised in profit for the year under IFRS.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.43266353142368535, "height": 0.07054296707994873, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-8", "text": "Participation Rights\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.46130825138948267, "height": 0.013681060282171864, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-9", "text": "     Participation rights issued by Dermapharm are recognised as equity under local GAAP. The issued\nparticipation rights, however, do not meet the criteria for being classified as equity instruments under IFRS but\nare classified as financial liabilities. The reclassification of participation rights does not have an effect on profit\nfor the period ended 31 December 2016.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5245831551945276, "height": 0.05643437366395898, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-10", "text": "Defined benefit obligation\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.5532278751603249, "height": 0.013253527148353927, "width": 0.18379685610640867}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-11", "text": "    The assumptions used for measuring defined benefit obligations under local GAAP differ from the\nassumptions used under IFRS.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5878580589995724, "height": 0.027362120564343728, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-12", "text": "Non-Controlling Interest\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.6156477126977341, "height": 0.0141085934159898, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-13", "text": "   The acquisition of shares after the transfer of control resulted in the recognition of goodwill under local\nGAAP.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6498503634031637, "height": 0.024369388627618616, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-14", "text": "     Under IFRS, when there is a change in a parent\u2019s ownership interest in a subsidiary, but the parent does\nnot cease to have control, this is accounted for as an equity transaction and no further goodwill is recognised.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6874732791791364, "height": 0.027789653698161554, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-15", "text": "    The derecognition of goodwill from the acquisition of non-controlling interests in Farmal (financial years\n2013 and 2014) and Melasan (financial year 2015) results in a reduction of equity of kEUR (1,751) as at\n31 December 2016.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.735356990166738, "height": 0.04147071398033353, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-16", "text": "Financial liabilities and derivatives\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.7652843095339888, "height": 0.013253527148353927, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-17", "text": "    The fair value of forward foreign exchange contracts is recognised under IFRS, and was not recognised\nunder local GAAP. The contracts, which were designated as hedging instruments under local GAAP, have not\nbeen designated as hedging instruments as at the date of transition to IFRS.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8157332193244976, "height": 0.04318084651560494, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-18", "text": "     The fair values of interest rate swaps and one currency-related swap are recognised under IFRS, and were\nnot recognised under local GAAP. The effect on earnings at 1 January 2014 has been recognised in retained\nearnings. For the years ended 31 December 2014, 2015 and 2016, the effect is recognised in profit for the\nrespective year under IFRS.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8161607524583155, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8790081231295426, "height": 0.06284737067122703, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-254-19", "text": "F-29", "page_number": 254, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-0", "text": "     Moreover, effects on equity arise from the recognition of loans at amortised cost using the effective\ninterest method to account for transaction costs for financial liabilities measured at amortised cost.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.08892689183411714, "height": 0.024369388627618643, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-1", "text": "Deferred tax\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.11842667806755024, "height": 0.01282599401453613, "width": 0.09250302297460701}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-2", "text": "     The transitional adjustments lead to temporary differences in case they are recorded at the separate\nfinancial statement level of an entity which is not part of the Themis Beteiligungs AG tax group. According to\nthe accounting policies in 2.18, the Group has to account for such differences. Deferred tax adjustments are\nrecognised in connection with the underlying transaction either in retained earnings or the other comprehensive\nincome.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.19495510902094912, "height": 0.0688328345446772, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-3", "text": "Finance Leases\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.21205643437366395, "lower_right_x": 0.2267230955259976, "lower_right_y": 0.22402736212056434, "height": 0.011970927746900395, "width": 0.11003627569528417}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-4", "text": "     Several lease contracts which were classified as operating leases under local GAAP, need to be classified\nas finance leases under IFRS. The respective lease assets and liabilities have been capitalised in accordance\nwith IAS 17. The effect on earnings at the date of transition has been recognised in retained earnings. The\neffect on earnings for the years ended 31 December 2014, 2015 and 2016 is also recognised in profit for the\nyear under IFRS.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.30440359127832406, "height": 0.0688328345446772, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-5", "text": "Statement of cash flows\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.3309106455750321, "height": 0.013253527148354038, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-6", "text": "     The transition from local GAAP to IFRS has no material impact on the statement of cash flows.\n\n2.   Significant accounting policies and changes\n2.1 Basis of preparation of financial statements\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8313180169286578, "lower_right_y": 0.4027362120564344, "height": 0.06113723813595556, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-7", "text": "    The consolidated financial statements of the Group have been prepared in accordance with International\nFinancial Reporting Standards (IFRS) and the interpretations of the IFRS Interpretations Committee (IFRIC) as\nadopted in the European Union (EU).\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.45404018811457886, "height": 0.044035912783240705, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-8", "text": "    The consolidated financial statements have been prepared on a historical cost basis, except for plan assets\ndue to post-employment benefits, which are measured at fair value in accordance with the requirements of\nIAS 19 Employee Benefits. Derivatives are measured at fair value at the balance sheet date.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5027789653698161, "height": 0.04147071398033347, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-9", "text": "     To improve the clarity of presentation, various items in the consolidated statement of financial position\nand consolidated statement of comprehensive income have been summarised. These items are shown separately\nand explained in the notes to the consolidated financial statements.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5519452757588713, "height": 0.03933304831124407, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-10", "text": "The consolidated statement of comprehensive income is prepared based on the nature of expense method.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.7303506650544135}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-11", "text": "      As a rule, Dermapharm classifies assets as current if they are expected to be recovered within twelve\nmonths from the reporting date. Liabilities are classified as non-current if the Company has the right to defer\nsettlement beyond one year. Deferred tax assets and liabilities are classified as non-current assets or liabilities\nin accordance with IAS 1.56.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6361693031209918, "height": 0.05515177426250528, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-12", "text": "    The financial statements are presented in EUR (\u20ac). Amounts are shown in thousands of euros\n(kEUR) unless otherwise stated. As such, insignificant rounding differences could occur in period-over-period\nchanges and percentages reported throughout.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6874732791791364, "height": 0.04147071398033342, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-13", "text": "     The financial year corresponds to the calendar year. The separate financial statements of the companies\nincluded in the scope of consolidation are prepared as of the same reporting date as the consolidated financial\nstatements.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.735356990166738, "height": 0.04147071398033353, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-14", "text": "     The preparation of financial statements in conformity with IFRS requires the use of certain critical\naccounting estimates. It also requires Management to exercise its judgment in the process of applying the\nGroup\u2019s accounting policies. Areas involving a higher degree of judgment or complexity, or areas where\nassumptions and estimates are significant to the consolidated financial statements are disclosed in section 3.1 of\nthe Notes.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8131680205215904, "height": 0.0679777682770415, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-15", "text": "The management prepared the consolidated financial statements on a going concern basis.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.8238563488670372, "lower_right_x": 0.7835550181378477, "lower_right_y": 0.8371098760153912, "height": 0.013253527148354038, "width": 0.6318016928657799}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-255-16", "text": "F-30", "page_number": 255, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-256-0", "text": "2.2 Effects of new or amended financial standards and interpretations\n", "page_number": 256, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.5326481257557436}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-256-1", "text": "     The    Group applied all standards and interpretations (including amendments) as adopted by the EU in its\nfinancial   statements, which are mandatory for financial years starting on or after 1 January 2016. For the\nfinancial   year, the Group applied the following new and amended standards and interpretations that were\nendorsed    by the EU:\n", "page_number": 256, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.14023086789226166, "height": 0.05515177426250535, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-256-2", "text": "Standard/                             Effective     Endorsement\nInterpretation    Issued by IASB        Date            EU                        Name\nIAS 1 . . . . . . . 14 May         16 January     15 December     Amendments to IAS 1: Disclosure\n                                                                  Initiative\nIAS 16 . . . . . . 14 May          16 January     15 December     Amendments to IAS 16 and\nIAS 38                                                            IAS 38: Clarification of Acceptable\n                                                                  Methods of Depreciation and\n                                                                  Amortisation\nIAS 16 . . . . . . 14 June         16 January     15 November     Amendments to IAS 16 and\nIAS 41                                                            IAS 41: Agriculture: Bearer Plants\nIAS 27 . . . . . . 14 August       16 January     15 December     Amendments to IAS 27: Equity Method\n                                                                  in Separate Financial Statements\nIFRS 10 . . . . . 14 December 16 January          16 September    Amendments to IFRS 10, IFRS 12 and\nIFRS 12                                                           IAS 28: Investment Entities: Applying\nIAS 28                                                            the Consolidation Exception\nIAS 19 . . . . . . 13 November 15 February        14 December     Amendments to IAS 19: Defined Benefit\n                                                                  Plans: Employee Contributions\nIFRS 11 . . . . . 14 May           16 January     15 November     Amendments to IFRS 11: Accounting\n                                                                  Acquisitions of Interests in Joint\n                                                                  Operations\nDIV . . . . . . . . 13 December    15 February    14 December     Annual Improvements to\n                                                                  IFRS\u20142010\u20132012 cycle\nDIV . . . . . . . . 14 September 16 January       15 December     Annual Improvements to\n                                                                  IFRS\u20142012\u20132014 cycle\n", "page_number": 256, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4916631038905515, "height": 0.33817870884993584, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-256-3", "text": "     The amendments and improvements do not have a material impact on the Group\u2019s consolidated financial\nstatements.\n", "page_number": 256, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5301410859341599, "height": 0.024369388627618616, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-256-4", "text": "F-31", "page_number": 256, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-257-0", "text": "Standards and interpretations issued but not yet applied by the group:\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.07652843095339888, "height": 0.011970927746900381, "width": 0.4933494558645708}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-257-1", "text": "     The Group intends to adopt these standards, if applicable, when they take effect. Only those standards and\ninterpretations which may be relevant for the Group are discussed below:\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11286874732791792, "height": 0.02778965369816161, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-257-2", "text": "Standard/                              Effective     Endorsement\nInterpretation     Issued by IASB        Date            EU                          Name\nIAS 7 . . . . . . . 16 January      17 January     17 November     Amendments to IAS 7: Disclosure\n                                                                   Initiative\nIAS 12 . . . . . . 16 January       17 January     17 November     Amendments to IAS 12: Recognition of\n                                                                   Deferred Tax Assets for Unrealised\n                                                                   Losses\nIAS 28 . . . . . . 17 December      19 January     Pending         Amendments to IAS 28: Long-term\n                                                                   Interests in Associates and Joint\n                                                                   Ventures\nIAS 40 . . . . . . 16 December      18 January     Pending         Amendments to IAS 40: Transfers of\n                                                                   Investment Property\nIFRS 2 . . . . . . 16 June          18 January     Pending         Amendments to IFRS 2: Classification\n                                                                   and Measurement of Share-based\n                                                                   Payment Transactions\nIFRS 4 . . . . . . 16 September 18 January         17 November     Amendments to IFRS 4: Applying\nIFRS 9                                                             IFRS 9 Financial Instruments with\n                                                                   IFRS 4 Insurance Contracts\nIFRS 9 . . . . . . 14 July          18 January     16 November     Financial Instruments\nIFRS 9 . . . . . . 17 December      19 January     Pending         Amendments to IFRS 9: Prepayment\n                                                                   Features with Negative Compensation\nIFRS 10 . . . . . 14 September Postponed           Pending         Sale or contribution of assets between an\nIAS 28                         indefinitely                        investor and its associate or joint venture\nIFRS 15 . . . . . 14 May       18 January          16 September    Revenue from Contracts with Customers\nIFRS 15 . . . . . 16 June      18 January          17 October      Clarifications to IFRS 15: Revenue from\n                                                                   Contracts with Customers\nIFRS 16 . . . . . 16 January        19 January     17 October      Leases\nIFRS 17 . . . . . 17 May            21 January     Pending         Insurance contracts\u2014IFRS 17 will\n                                                                   replace IFRS 4\nIFRIC 22 . . . . . 16 December      18 January     Pending         IFRIC Interpretation 22: Foreign\n                                                                   Currency Transactions and Advance\n                                                                   Consideration\nIFRIC 23 . . . . . 17 June          19 January     Pending         IFRIC Interpretation 23: Uncertainty\n                                                                   over Income tax treatments\nDIV . . . . . . . . 16 December     18 January     Pending         Annual Improvements to\n                                                                   IFRS\u20142014\u20132016 cycle\nDIV . . . . . . . . 17 December     19 January     Pending         Annual Improvements to\n                                                                   IFRS\u20142015\u20132017 cycle\n", "page_number": 257, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.875453446191052, "lower_right_y": 0.619067977768277, "height": 0.49294570329200516, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-257-3", "text": "IFRS 9 Financial Instruments addresses the classification, measurement and recognition of financial\nassets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces\nthe guidance in IAS 39 that relates to the classification and measurement of financial instruments.\nIFRS 9 retains but simplifies the mixed measurement model and establishes three primary\nmeasurement categories for financial assets: amortised cost, fair value through other comprehensive\nincome (OCI) and fair value through profit and loss. The basis of classification depends on the\nentity\u2019s business model and the contractual cash flow characteristics of the financial asset.\nInvestments in equity instruments are required to be measured at fair value through profit or loss with\nthe irrevocable option at inception to present changes in fair value in other comprehensive income\n(OCI) without recycling. There is now a new expected credit loss model that replaces the incurred\nloss impairment model used in IAS 39. For financial liabilities there were no changes to classification\nand measurement except for the recognition of changes in own credit risk in other comprehensive\nincome for liabilities designated at fair value through profit or loss. IFRS 9 relaxes the requirements\nfor hedge effectiveness by replacing the bright line hedge effectiveness tests. It requires an economic\nrelationship between the hedged item and hedging instrument and for the \u201chedged ratio\u201d to be the\nsame as the one Management actually uses for risk management purposes. Contemporaneous\ndocumentation is still required but is different from that currently prepared under IAS 39. The\nstandard is effective for accounting periods beginning on or after 1 January 2018. Early adoption is\npermitted. The Group has yet to assess the full impact of IFRS 9.\n", "page_number": 257, "bounding_box": {"top_left_x": 0.18319226118500603, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8956819153484396, "height": 0.27020094057289445, "width": 0.7019347037484884}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-257-4", "text": "F-32", "page_number": 257, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-0", "text": "\u2022   IFRS 15 Revenue from Contracts with Customers deals with revenue recognition and establishes\n    principles for reporting useful information to users of financial statements about the nature, amount,\n    timing and uncertainty of revenue and cash flows arising from an entity\u2019s contracts with customers.\n    Revenue is recognised when a customer obtains control of a good or service and thus has the ability\n    to direct the use and obtain the benefits from the good or service. The standard replaces IAS 18\n    Revenue and IAS 11 Construction Contracts and related interpretations. The standard is effective for\n    annual periods beginning on or after 1 January 2018 and earlier application is permitted. The Group\n    is assessing the impact of IFRS 15.\n\u2022   IFRS 16 Leases was released on 13 January 2016. In accordance with this new standard, the lessee\n    must recognise the leased asset and the lease liability for most types of leases. The new standard on\n    leases applies to all reporting periods beginning on or after 1 January 2019 and replaces IAS 17. The\n    Group is assessing the impact of IFRS 16.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2394185549380077, "height": 0.1748610517315092, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-1", "text": "     There are no other IFRSs or IFRIC interpretations that are not yet effective that would be expected to have\na material impact on the Group financial statements. Early adoption of the above-mentioned publications is\ncurrently not planned.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2907225309961522, "height": 0.04147071398033347, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-2", "text": "2.3 Changes in accounting policies\n", "page_number": 258, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.3180846515604959, "height": 0.014108593415989745, "width": 0.2660217654171705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-3", "text": "    There were no changes to accounting policies with significant consequences for the presentation of the\nGroup\u2019s net assets, financial position and results of operations or cash flows in financial year 2016.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.354424967935015, "height": 0.02650705429670802, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-4", "text": "2.4 Basis of consolidation\n", "page_number": 258, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.37964942283026937, "height": 0.010688328345446807, "width": 0.1989117291414752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-5", "text": "     Dermapharm is the holding company of the Group. Group business is conducted by Dermapharm AG and\nits various subsidiaries. The consolidated financial statements include all material companies whose financial\nand business policy can be controlled by the Company, either directly or indirectly, and the material equity\ninterests of Dermapharm whose financial and business policy can be influenced by the Company to a\nsignificant extent.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.38948268490808036, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4608807182556648, "height": 0.07139803334758443, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-258-6", "text": "F-33", "page_number": 258, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-0", "text": "As of 2016, Dermapharm directly or indirectly holds shares in the following companies:\n", "page_number": 259, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7738814993954051, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.624546553808948}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-1", "text": "                                                                    Proportion of shares        Proportion of shares\nCompany name and registered office                                 directly held by parent   directly held by the Group\n\nconsolidated subsidiary\nMibe GmbH Arzneimittel, Brehna . . . . . . . . . . . . . . .                         100%\nMibe Vertrieb GmbH, Gr\u00fcnwald . . . . . . . . . . . . . . . .                         100%\nCancernova GmbH, Gr\u00fcnwald . . . . . . . . . . . . . . . . .                          100%\naxicorp GmbH, Friedrichsdorf . . . . . . . . . . . . . . . . .                        85%\nAnton H\u00fcbner GmbH & Co. KG, Ehrenkirchen . . . . . .                                 100%\nH\u00fcbner Naturarzneimittel GmbH, Ehrenkirchen . . . . . .                              100%\nDermapharm GmbH, Vienna, Austria . . . . . . . . . . . . .                           100%\nDermapharm AG, H\u00fcnenberg, Switzerland . . . . . . . . .                              100%\nSun-Farm Sp. z o.o, Warsaw, Poland . . . . . . . . . . . . .                         100%\nFarmal d.d, Ludbreg, Croatia . . . . . . . . . . . . . . . . . .                     100%\nMibe Pharmaceuticals d.o.o Ludbreg, Croatia . . . . . . . .                          100%\nacis Arzneimittel GmbH, Gr\u00fcnwald . . . . . . . . . . . . . .                                                    100%\naxicorp Pharma GmbH, Friedrichsdorf . . . . . . . . . . . .                                                     100%\nPodolux GmbH, Friedrichsdorf . . . . . . . . . . . . . . . . .                                                  100%\naxicorp Pharma B.V, The Hague, Netherlands . . . . . . .                                                        100%\naxicorp ApS, Hellerup, Denmark . . . . . . . . . . . . . . .                                                    100%\nremedix GmbH, Koblenz . . . . . . . . . . . . . . . . . . . .                                                    75%\nMelasan GmbH, Salzburg, Austria . . . . . . . . . . . . . . .                                                   100%\nFarmal BH d.o.o, Sarajevo, Bosnia-Herzegovina . . . . . .                                                       100%\nAktival d.o.o, Ludbreg, Croatia . . . . . . . . . . . . . . . .                                                 100%\nsubsidiary not consolidated\nAnton H\u00fcbner Verwaltungs GmbH, Ehrenkirchen . . . . .                                100%\nTiroler Nuss\u00f6l Sonnenkosmetik GmbH, Kitzb\u00fchel, Austria                               100%\nEast Pharma AG, Gr\u00fcnwald . . . . . . . . . . . . . . . . . . .                       100%\nMibe Ukraine LLC, Kiev, Ukraine . . . . . . . . . . . . . .                                                     100%\nPragopharm Research, Prague, Czech Republic . . . . . .                                                         100%\nPragopharm Production, Prague, Czech Republic . . . . .                                                         100%\nassociated companies\nHasan Pharma Ltd, Saigon, Vietnam . . . . . . . . . . . . .                           30%\nGynial GmbH, Vienna, Austria . . . . . . . . . . . . . . . . .                                                    25%\nGynial AG, H\u00fcnenberg, Switzerland . . . . . . . . . . . . .                                                       40%\nother investments\nHasan Dermapharm Joint Venture Ltd, Saigon, Vietnam .                                   5%\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6378794356562634, "height": 0.5493800769559641, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-2", "text": "Changes in the scope of consolidation:\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6528430953398888, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.6660966224882429, "height": 0.013253527148354038, "width": 0.2750906892382104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-3", "text": "    Changes in the scope of consolidation in the reporting period from 1 January 2014 to 31 December 2016\nstem from a number of acquisitions, sales of companies and one merger. On 21 December 2015, Axicorp\nGmbH, in which Dermapharm holds an interest of 85%, entered into a contract to acquire a 75.1% interest in\nRemedix GmbH (please refer to 2.7 for more information on the acquisition of Remedix GmbH).\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7302265925609235, "height": 0.05686190679777681, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-4", "text": "Merger of Naturwohl Vertriebs GmbH:\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.7592988456605387, "height": 0.0141085934159898, "width": 0.2762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-5", "text": "     Naturwohl Vertriebs GmbH, Gr\u00e4felfing, was merged with Huebner Naturarzneimittel GmbH, Gr\u00fcnwald, in\nfinancial year 2015. For further information, please refer to 4.1.\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7935014963659683, "height": 0.027789653698161554, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-6", "text": "Investment in Gynial GmbH, Vienna, Austria:\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.44014510278113667, "lower_right_y": 0.8135955536554083, "height": 0.013681060282171864, "width": 0.32466747279322855}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-7", "text": "     Dermapharm GmbH, Vienna, acquired a 25.1% interest of the Gynial GmbH, Vienna, in 2015. The\ninvestment is accounted for using the equity method; please refer to section 4.3 for further details.\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8507909362975631, "height": 0.026934587430525903, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-259-8", "text": "F-34", "page_number": 259, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-0", "text": "Acquisitions of non-controlling interests:\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.28536880290205563}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-1", "text": "     In 2015, Dermapharm GmbH, Vienna, Austria, increased its stake in Melasan GmbH, Salzburg, Austria,\nby 25% to 100% for a cash consideration of kEUR 1,850, which was paid in financial year 2016. Melasan\nGmbH had already been fully consolidated in the prior year when Dermapharm held a 75% stake in the\ncompany. There is no change in the basis of consolidation or presentation in the IFRS consolidated financial\nstatements. The carrying amount of Melasan GmbH\u2019s net assets in the Group\u2019s consolidated financial\nstatements on the date of acquisition was kEUR 1,930. The Group recognised a decrease in NCI of kEUR 483\nand a decrease in retained earnings of kEUR 1,367.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.18426678067550234, "height": 0.09918768704574603, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-2", "text": "     The Group also acquired an additional stake of 2.9% in Farmal d.d., Ludberg, Croatia, in 2015 and\nincreased its stake to 100% for a cash consideration of kEUR 93. Farmal d.d. had already been fully\nconsolidated in the prior year when the Group held a 97.1% stake in the company. There is no change in the\nbasis of consolidation or presentation in the IFRS consolidated financial statements. The carrying amount of\nFarmal d.d.\u2019s net assets in the Group\u2019s consolidated financial statements on the date of acquisition was\nkEUR-10,369. The Group recognised an increase in NCI of kEUR 301 and a decrease in retained earnings of\nkEUR 403.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1911073108165883, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.28730226592560926, "height": 0.09619495510902096, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-3", "text": "Divestments:\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3039760581445062, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.3172295852928602, "height": 0.013253527148354038, "width": 0.09068923821039902}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-4", "text": "     In 2015, the Group sold the Dermapharm Verwaltungs GmbH, Gr\u00fcnwald (100%), Dermapharm\nBeteiligungsgesellschaft mbH & Co. KG, Gr\u00fcnwald (100%), SLG Service Logistik G\u00fcntherdorf GmbH,\nLeuna (100%), the 26.3% stake in HMO AG, Oberhaching, and its 75.1% stake in the Centuere\nBeteiligungs AG i.L., Hanover.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.3826421547669944, "height": 0.054724241128687456, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-5", "text": "     At the end of 2014 a decision was made to close down the subsidiary Farmal d.o.o., Belgrade. The\nliquidation process was finalised in December 2016.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.38948268490808036, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.41727233860624197, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-6", "text": "    SLG Service Logistik G\u00fcnthersdorf GmbH, Leuna, as well as Centuere Beteiligungs AG i.L., Hanover,\nhave been deconsolidated.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4514749893116717, "height": 0.02436938862761867, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-7", "text": "     The sale of Centuere Beteiligungs AG i.L., Hanover, to Themis Beteiligungs AG for kEUR 6,534 was\ncompleted on 17 December 2015. The sale was concluded in order to adjust the portfolio with respect to\nmarginal activities not relating to the pharma business. The decision to sell the subsidiary was made at short\nnotice in 2015 and Centuere was therefore not classified as a held-for-sale investment in accordance with\nIFRS 5 as at 31 December 2014. The negative result from the divestiture of kEUR 731 has been recognised in\nother operating expenses.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5459598118854211, "height": 0.08465156049593842, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-8", "text": "Result from the deconsolidation of Centuere Beteiligungs AG i.L.:\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.585247883917775, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.46977025392986693}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-9", "text": "Deconsolidation of Centuere Beteiligungs AG\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5810175288584866, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.5951261222744763, "height": 0.01410859341598969, "width": 0.33857315598548976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-10", "text": "                                                                                                                       31 December\nkEUR                                                                                                                       2015\nConsideration (total received in cash) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             6,534\nDivested Assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         (7,581)\nDivested Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .           316\nResult from divestiture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .            (731)\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.6977340743907653, "height": 0.089354424967935, "width": 0.7738814993954051}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-11", "text": "     With effect from 31 December 2015, the sale of SLG Service Logistik, Leuna, to Themis Beteiligungs AG\nfor kEUR 25 was completed. The sale was concluded in order to adjust the portfolio with respect to marginal\nactivities not relating to the pharma business. The decision to sell the subsidiary was made at short notice in\n2015 and SLG was therefore not classified as a held-for-sale investment in accordance with IFRS 5 as at\n31 December 2014. The positive result from the divestiture of kEUR 612 has been recognised in other\noperating income.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8003420265070543, "height": 0.08593415989739206, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-260-12", "text": "F-35", "page_number": 260, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-0", "text": "Result from the deconsolidation of SLG Service Logistik:\nDeconsolidation of SLG Service Logistik\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.09876015391192818, "height": 0.034202650705429674, "width": 0.41172914147521156}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-1", "text": "                                                                                                                       31 December\nkEUR                                                                                                                       2015\nConsideration (total received in cash) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .               25\nDivested Assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       (31,549)\nDivested Liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       32,136\nResult from divestiture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             612\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10902094912355707, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.195382642154767, "height": 0.08636169303120993, "width": 0.7714631197097944}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-2", "text": "Consolidation principles:\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21846943138093203, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.23257802479692177, "height": 0.014108593415989745, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-3", "text": "     All material subsidiaries are included in the consolidated financial statements. Subsidiaries are all entities\nDermapharm has direct or indirect control of. Control exists if Dermapharm or its subsidiaries have rights to\nvariable returns from their involvement with the entity and have the ability to affect those returns through their\npower over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to\nDermapharm or the respective subsidiary. They are deconsolidated from the date that control ceases.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23899102180418982, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3108165882855921, "height": 0.07182556648140229, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-4", "text": "     Associates are companies over which Dermapharm is able to exercise significant influence, generally\nthrough an ownership interest between 20% and 50%, and which are not subsidiaries or joint ventures. They\nare included in the consolidated financial statements using the equity method.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3591278324070115, "height": 0.04147071398033347, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-5", "text": "     Intercompany expenses and income as well as balances between the Group companies are eliminated. The\nelimination of unrealised gains on transactions, however, is deemed to be immaterial for giving a true and fair\nview of the profit or loss of the Group. When necessary, amounts reported by subsidiaries have been adjusted\nto conform to the Group accounting policy. Effects of consolidation on income taxes are accounted for by\nrecognising deferred taxes.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.43779392902949976, "height": 0.0688328345446772, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-6", "text": "      When the Group ceases to have control, any retained interest in the entity is remeasured to its fair value at\nthe date when control is lost, with the change in carrying amount recognised in profit or loss. The fair value is\nthe initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate,\njoint venture or financial asset. In addition, any amounts previously recognised in other comprehensive income\nin respect of that entity are accounted for as if the Group had directly disposed of the related assets or\nliabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified\nto profit or loss.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.44420692603676787, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5438221462163317, "height": 0.09961522017956387, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-7", "text": "     Subsidiaries, whose influence, both individually and as a whole, on the net assets, financial position and\nresults of operations of the Group is immaterial, are not consolidated or accounted for using the equity method.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5805899957246686, "height": 0.02693458743052579, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-8", "text": "The financial statements of subsidiaries are prepared using uniform accounting policies.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.1505441354292624, "top_left_y": 0.5878580589995724, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.6015391192817443, "height": 0.013681060282171864, "width": 0.6136638452237001}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-261-9", "text": "F-36", "page_number": 261, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-0", "text": "2.5 Currency translation\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.3041112454655381, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.18863361547762997}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-1", "text": "     The Group\u2019s consolidated financial statements are presented in EUR. In the financial statements of\ncompanies included in the Group financial statements, foreign currency transactions are translated in the\nfunctional currency at the respective exchange rate. A company\u2019s functional currency is that of the economic\nenvironment in which it primarily generates and expends cash.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.14023086789226166, "height": 0.05515177426250535, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-2", "text": "     Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the\ndate of the transaction. Non-monetary items that are measured in terms of historical cost in a foreign currency\nare not retranslated. Monetary items (cash and cash equivalents, receivables and liabilities) denominated in\nforeign currencies are translated into the functional currency at closing rates. The resulting exchange rate gains\nand losses are recognised through profit and loss under net foreign exchange gains and losses. They are\nreported separately if they are material.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.23257802479692177, "height": 0.0825138948268491, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-3", "text": "     The financial statements of the consolidated foreign companies whose functional currency is not EUR are\ntranslated into Dermapharm\u2019s reporting currency, EUR. In accordance with IAS 21, assets, including goodwill,\nand liabilities are translated at closing rates, and statement of comprehensive income items are translated at the\naverage exchange rates for the reporting period. Differences from currency translation of statements of\ncomprehensive income at average rates and statements of financial position at closing rates are reported outside\nprofit or loss in other comprehensive income. The currency difference resulting from the translation of equity at\nhistorical rates is likewise posted to other comprehensive income. Currency differences recognised in other\ncomprehensive income are recycled to profit and loss if the corresponding Group Company is sold.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.354424967935015, "height": 0.1120136810602822, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-4", "text": "     The exchange rates for significant currencies taken as the basis for the currency translation developed as\nfollows (equivalent value for EUR 1):\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.38991021804189824, "height": 0.02778965369816161, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-5", "text": "                 Currency                        Average rate                                                Closing rate\n                            31 December    31 December    31 December    1 January     31 December    31 December    31 December     1 January\nCountry          1 EUR =        2016           2015           2014          2014           2016           2015           2014           2014\nSwitzerland           CHF         1.0902         1.0679         1.2146        1.2311         1.0739         1.0835          1.2024        1.2276\nDenmark . .           DKK         7.4452         7.4587         7.4548        7.4579         7.4344         7.4626          7.4453        7.4593\nCroatia . . .         HRK         7.5333         7.6137         7.6344        7.5786         7.5597          7.638           7.658        7.6265\nPoland . . . .        PLN         4.3632         4.1841         4.1843        4.1975         4.4103         4.2639          4.2732        4.1543\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4685763146643865, "height": 0.0688328345446772, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-6", "text": "2.6 Business combinations\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48525010688328346, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.4959384352287302, "height": 0.010688328345446751, "width": 0.2031438935912938}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-7", "text": "     The Group accounts for business combinations using the acquisition method when control is transferred.\nAssets, liabilities and contingent liabilities from the business combination are recognised in full for Remedix\nGmbH, regardless of the amount of the investment with the respective fair value at the acquisition date.\nGoodwill that arises is tested for impairment annually. Any gain on a bargain purchase is recognised in profit\nor loss immediately, transaction costs are expensed as incurred.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5775972637879435, "height": 0.07182556648140226, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-8", "text": "Acquisition of Remedix GmbH, Koblenz, Germany:\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5912783240701154, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.6053869174861052, "height": 0.0141085934159898, "width": 0.3681983071342201}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-9", "text": "     At 21 December 2015, Axicorp GmbH, in which Dermapharm holds an 85% interest, entered into a\ncontract to acquire 75.1% of Remedix GmbH, an importer and distributor of narcotic drugs and psychotropics\nin the EU. With the acquisition, the Group intends to extend its product pipeline and access the re-import\nbusiness.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6669516887558786, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-10", "text": "    The last condition precedent to the purchase agreement was met on 29 February 2016, when cash payment\nwas transferred to the former shareholder. With the transfer of 75.1% of the voting rights, Axicorp GmbH\nacquired initial control over the legal entity.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.718255664814023, "height": 0.04147071398033342, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-262-11", "text": "F-37\n", "page_number": 262, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9345874305258658, "height": 0.011543394613082514, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-0", "text": "    The preliminary fair values of the identifiable assets and liabilities of Remedix GmbH (in accordance with\nIFRS 3.47) as of the date of acquisition were as follows:\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.09191962377084224, "height": 0.027362120564343742, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-1", "text": "                                                                                                                                                                       Fair value as of\nkEUR                                                                                                                                                                  29 February 2016\nPurchase Price\nCash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                               1,442\nTotal consideration transferred . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                        1,442\nFair values of acquired assets and liabilities\nIntangible assets . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .              2,533\nthereof identified during purchase price allocation               .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .              2,287\nFixed assets . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                 37\nInventories . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .              1,755\nTrade receivables . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                172\nOther current assets . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                663\nCash and cash equivalents . . . . . . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                 22\nAccruals . . . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                 61\nLiabilities to banks . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .             (1,409)\nLiabilities to related parties . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .               (890)\nOther non-interest bearing provisions . . . . . . . . .           .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .               (116)\nDeferred tax liabilities . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .               (629)\nTrade payables . . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .               (878)\nOther short-term liabilities . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .               (184)\nFair value of acquired net assets for 100% . . .                  .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .              1,136\nFair value of acquired net assets for 75.1% . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                853\nGoodwill arising on acquisition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                          589\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.4480547242411287, "height": 0.34587430525865753, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-2", "text": "     Acquired gross contractual amounts receivable amount to kEUR 172, of which none were estimated to be\nuncollectible as of the acquisition date. The gross amount corresponds to the fair value as the remaining term of\nthe receivables is less than one year.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5061992304403591, "height": 0.04147071398033342, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-3", "text": "     The right to acquire the minority shares was granted within the share purchase agreement. The option was\nassessed to be immaterial. The consideration transferred for the transferred 75.1% of the shares amounted to\nkEUR 1,442.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5566481402308678, "height": 0.040615647712697656, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-4", "text": "      Comparing the consideration transferred for 75.1% of the shares to the identified fair values of assets and\nliabilities for 75.1% of the shares (kEUR 853) results in goodwill of kEUR 589. Factors underlying this\ngoodwill arise from expected synergies from the combined business activities and other intangible assets that\ncannot be reported separately, such as the combined workforce.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6212056434373664, "height": 0.05728943993159474, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-5", "text": "    Customer relationships in the amount of kEUR 2,287 were identified as an intangible asset during the\npurchase price allocation. The key assumptions of the valuation of the customer relationship are as follows:\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6566908935442497, "height": 0.027789653698161665, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-6", "text": "Customer relationship\n", "page_number": 263, "bounding_box": {"top_left_x": 0.7158403869407497, "top_left_y": 0.6669516887558786, "lower_right_x": 0.8458282950423216, "lower_right_y": 0.6797776827704147, "height": 0.012825994014536102, "width": 0.1299879081015719}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-7", "text": "Valuation method used . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         Multi-period excess earnings\nUseful life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                        7 years\nCost of capital (indefinite maturity) . . . . . . . . . . . . . . . . . . . . . . . . . . .                                5.6%\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.728516460025652, "height": 0.048311244121419405, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-8", "text": "    The former shareholders of Remedix GmbH were propharmed GmbH (70%) and Mrs Nicole\nBroockmann (30%).\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7695596408721675, "height": 0.027789653698161554, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-9", "text": "    No transaction costs had to be recognised as an administrative expense in connection with the acquisition\nof Remedix GmbH.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8029072253099615, "height": 0.02693458743052579, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-10", "text": "     Remedix GmbH contributed total revenue of kEUR 5,735 to consolidated revenue for the period from\n29 February 2016 to 31 December 2016 and decreased the profit for the period by a total of kEUR \u20131,397 over\nthe same period. If the combination had taken place at the beginning of the year, Remedix GmbH would have\ncontributed kEUR 6,549 to consolidated revenue and kEUR \u20131,734 to profit for the period, net of tax.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8687473279179136, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-263-11", "text": "F-38", "page_number": 263, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-0", "text": "2.7 Intangible assets\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.15961305925030228}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-1", "text": "Software, licenses, patents and similar rights\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0778110303548525, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.09876015391192818, "height": 0.020949123557075677, "width": 0.31499395405078595}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-2", "text": "     In line with the business model of the Dermapharm Group, the Group companies do not conduct any\nfundamental pharmaceutical research. Instead, the focus is on the development of preparations using\npharmaceutical ingredients which as a rule are no longer patent-protected. Dermapharm Group\u2019s intangible\nassets primarily comprise drug approvals.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1628901239846088, "height": 0.0572894399315947, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-3", "text": "      The drug approvals are partly acquired from third parties and partly developed by Dermapharm Group\nitself.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17058572039333048, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.19495510902094912, "height": 0.024369388627618643, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-4", "text": "     In accordance with IAS 38.72, the Group can choose between the cost method and the revaluation method\nfor each group of intangible assets.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.23257802479692177, "height": 0.02778965369816161, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-5", "text": "     Under the acquisition cost method (IAS 38.74), intangible assets are recognised at its acquisition or\nproduction cost after initial recognition, less any amortisation and impairment losses. The revaluation method\ncan only be applied if the fair value can be derived from an active market. There is no active market for drug\napprovals. Therefore, the revaluation method is not applied. Dermapharm Group applies the acquisition cost\nmethod.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.30867892261650276, "height": 0.06626763574176997, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-6", "text": "    Software, licenses, patents and similar rights have a finite useful life and are carried at cost less\naccumulated amortisation and impairment.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34587430525865753, "height": 0.02821718683197949, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-7", "text": "Capitalised development costs\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.3758016246259085, "height": 0.013681060282171864, "width": 0.21342200725513905}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-8", "text": "     Development costs that are capitalised relate to the costs incurred to maintain and expand our technical\nposition by continually enhancing our embedded products. The capitalised development costs have mainly been\nrecognised for development projects that create new pharmaceutical products. Development costs of a single\nproject are only capitalised as an intangible asset if the following criteria pursuant to IAS 38 have been met:\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4395040615647713, "height": 0.05686190679777686, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-9", "text": "roject are only capitalised as an intangible asset if the foll\n   \u2022    Newly developed products are identifiable assets.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.13482466747279323, "top_left_y": 0.4395040615647713, "lower_right_x": 0.5278113663845224, "lower_right_y": 0.4608807182556648, "height": 0.021376656690893503, "width": 0.3929866989117292}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-10", "text": "\u2022   Newly developed products are identifiable assets.\n\u2022   Completing the intangible asset is technically feasible so that it will be available for use.\n\u2022   Management intends to complete and use the product.\n\u2022   It is probable that the product will generate future economic benefits.\n\u2022   Adequate technical, financial, and other resources are available so that the development can be\n    completed and the product can be used.\n\u2022   The expenditure during development can be reliably measured.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5814450619923044, "height": 0.12013681060282172, "width": 0.7351874244256348}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-11", "text": "     The previously mentioned criteria are assessed and analysed on a project by project basis as well as\nreviewed and approved by Management. Once the project is approved in accordance with the criteria in\nIAS 38, costs are capitalised. Those costs directly attributable to the development project\u2014including personnel\ncosts for members of staff involved in the development process, an appropriate part of the corresponding\ndirectly attributable overhead costs and costs for external resources\u2014are used.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5882855921333904, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6596836254809748, "height": 0.07139803334758443, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-12", "text": "    Other development expenditures that do not meet these criteria are recognised as an expense as incurred.\nDevelopment costs previously recognised as an expense are not recognised as an asset in a subsequent period.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6943138093202224, "height": 0.027789653698161665, "width": 0.7623941958887545}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-13", "text": "     Since the Dermapharm Group does not conduct any fundamental pharmaceutical research no research\ncosts are incurred.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.728516460025652, "height": 0.024369388627618616, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-14", "text": "Intangible assets acquired in business combinations or separately\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.5749697702539298, "lower_right_y": 0.7520307823856349, "height": 0.013681060282171864, "width": 0.4594921402660217}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-15", "text": "    The cost of intangible assets acquired in a business combination is their fair value at the date of\nacquisition.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7866609662248825, "height": 0.027789653698161665, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-16", "text": "     The Group has capitalised a customer relationship which was identified in the context of the purchase\nprice allocation of Remedix GmbH (please refer to 2.7 for more information on the acquisition of Remedix\nGmbH).\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8371098760153912, "height": 0.04061564771269777, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-17", "text": "     In the course of the acquisition of the trademark \u201cLactoStop\u201d in financial year 2014, Dermapharm\ncapitalised a trademark. For further information, please refer to 2.4.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8721675929884566, "height": 0.027789653698161554, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-264-18", "text": "F-39", "page_number": 264, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-0", "text": "Goodwill\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.07695596408721676, "height": 0.012398460880718262, "width": 0.06771463119709793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-1", "text": "     Goodwill represents the excess of the consideration transferred over the Group\u2019s interest in the net fair\nvalue of the identifiable assets, liabilities and contingent liabilities of an acquiree. If the consideration is less\n(negative goodwill), it is recognised in profit or loss. Capitalised goodwill is not subject to amortisation. It is\nassessed annually for impairment and can be assessed more frequently, if there is any indication for impairment\nduring the year (impairment-only approach).\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.155622060709705, "height": 0.07054296707994868, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-2", "text": "Amortisation and impairment of intangible assets\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17058572039333048, "lower_right_x": 0.46372430471584036, "lower_right_y": 0.18426678067550234, "height": 0.013681060282171864, "width": 0.34824667472793225}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-3", "text": "     Amortisation and impairment write-offs of revenue generating assets are recorded in the consolidated\nstatement of comprehensive income as amortisation and are shown as amortisation of intangible assets in the\nconsolidated statement of cash flows. The carrying amounts, economic useful lives and amortisation methods\nare verified at each balance sheet date and prospectively adjusted where appropriate. If the recoverable amount\nof an asset is less than its carrying amount, the carrying amount is reduced to the recoverable amount in\naccordance with IAS 36. If there is an indication that a previously recorded impairment loss may no longer\nexist, the carrying amount of the asset is increased. Impairment write-offs related to capitalised development\ncosts, which are not revenue generating, are charged to \u201cother operating expenses\u201d in the consolidated\nstatement of comprehensive income and are reported under \u201cAmortisation of intangible assets\u2014impairment\ncharges\u201d in the consolidated statement of cash flows. The reversal shall not exceed the carrying amount that\nwould have been determined had no impairment loss been recognised.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1911073108165883, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.34544677212483965, "height": 0.15433946130825135, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-4", "text": "uld have been determined had no impairment loss been recognis\n Amortisation is primarily based on the following useful lives:\n", "page_number": 265, "bounding_box": {"top_left_x": 0.14328899637243048, "top_left_y": 0.34544677212483965, "lower_right_x": 0.5882708585247884, "lower_right_y": 0.36896109448482256, "height": 0.02351432235998291, "width": 0.44498186215235797}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-5", "text": "Intangible assets                                                    Years                  Note\nSoftware, licenses, patents and similar rights . . . . . .           3\u201315    Approvals, trademarks and software\nGoodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    n/a\nAdvance payments . . . . . . . . . . . . . . . . . . . . . . .        n/a\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36938862761864044, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.43779392902949976, "height": 0.06840530141085932, "width": 0.7666263603385731}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-6", "text": "     In accordance with IAS 38.88, a distinction between intangible assets with definite and indefinite useful\nlives has to be made. The assessment of the management of the Group is that the approvals generate profit for\nthe company only for a limited period of time. The market for medicinal products subject to authorisation is\nsubject to frequent changes. Therefore, the Group assumes a life cycle of drug approvals and licenses of\n15 years. Amortisation is calculated using the straight-line method to allocate the cost of licenses, patents and\nsimilar rights over their estimated useful lives.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5369816160752459, "height": 0.08251389482684912, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-7", "text": "     Capitalised development costs for development projects are also amortised on a straight-line basis over the\nperiod of expected future benefit (generally 15 years). Amortisation of capitalised development costs that are\nrevenue generating begins when development is complete and the asset is available for use, which is normally\nthe release of the developed product to mass production.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6019666524155622, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-8", "text": "     Recognised development costs are also tested for impairment in accordance with IAS 36 (IAS 38.111). At\neach balance sheet date, the approvals are tested for impairment in accordance with IAS 36. There was no need\nfor impairment as at the presented balance sheet dates.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6519880290722531, "height": 0.04360837964942277, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-9", "text": "   The customer relationship, which was identified in the context of the purchase price allocation of Remedix\nGmbH, is amortised on a straight-line basis over the expected useful life of seven years.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6874732791791364, "height": 0.027789653698161554, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-10", "text": "     The trademark \u201cLactoStop\u201d, which was acquired in financial year 2014, is amortised on a straight-line\nbasis over the expected useful life of nine years. The following table depicts the remaining useful lives of these\nassets as at 31 December 2016.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.73492945703292, "height": 0.04104318084651559, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-11", "text": "                                                                                                      Remaining\n31 December 2016                                                                                      useful life   Asset origin\nCustomer relationship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       6.2 years     Acquired\nTrademark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   6.4 years     Acquired\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.8037622915775973, "height": 0.05515177426250539, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-12", "text": "     For a detailed description of the acquired customer relationship and the recognised carrying amount,\nplease refer to 2.7. For more detailed information on the acquired trademark and the respective carrying amount\nas at the balance sheet date, please refer to in 4.1.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8584865327062847, "height": 0.04147071398033342, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-265-13", "text": "F-40", "page_number": 265, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-0", "text": "2.8 Property, plant and equipment\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.2666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-1", "text": "    All items of property, plant and equipment are measured at cost less accumulated depreciation and\naccumulated impairment losses.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11286874732791792, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-2", "text": "     Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of\nself-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to\nbringing the assets to a working condition for their intended use and the costs of dismantling and removing the\nitems.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.17443351859769132, "height": 0.05515177426250535, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-3", "text": "     Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the\nproceeds from disposal with the carrying amount of property, plant and equipment and are recognised on a net\nbasis within other operating income or other operating expenses in profit or loss.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.22573749465583584, "height": 0.0414707139803335, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-4", "text": "    The cost of replacing part of an item of property, plant and equipment is recognised in the carrying\namount of the item, if it is probable that the future economic benefits embodied within the part will flow to the\nGroup and its cost can be measured reliably. The carrying amount of the replaced part is derecognised.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.27618640444634457, "height": 0.04061564771269771, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-5", "text": "     Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful lives of each\npart of an item of property, plant and equipment. Land is not depreciated. Depreciation methods, useful lives\nand residual values are reviewed at each reporting date.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.32492518170158186, "height": 0.04147071398033347, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-6", "text": "The estimated useful lives for the current and comparative periods are as follows:\n", "page_number": 266, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.3347584437793929, "lower_right_x": 0.727932285368803, "lower_right_y": 0.3471569046601112, "height": 0.012398460880718276, "width": 0.5779927448609432}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-7", "text": "", "page_number": 266, "bounding_box": {"top_left_x": 0.11024123591516154, "top_left_y": 0.34737315305077454, "lower_right_x": 0.3116270958152042, "lower_right_y": 0.363919531027442, "height": 0.01654637797666747, "width": 0.20138585990004265}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-8", "text": "Property, plant and equipment                            Years   Note\nLand and Buildings including buildings on\n  third party land . . . . . . . . . . . . . . . . . .   10\u201360   Building plots, buildings, outdoor installations\nTechnical equipment and machinery . . . . . .             5\u201320   Tools / Aids / Machinery production and\n                                                                 filling, air conditioning, ventilation\nOther fixed assets and office equipment . . . .          3\u201323    IT, (office / production) equipment and\n                                                                 business equipment, video surveillance,\n                                                                 telephone system, small value assets\nAdvance payments . . . . . . . . . . . . . . . . .        n/a\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4890979050876443, "height": 0.1303976058144506, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-9", "text": "2.9 Financial assets\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.516460025651988, "height": 0.01410859341598969, "width": 0.15054413542926237}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-10", "text": "IAS 39 requires financial assets to be classified in one of the following categories:\n\u2022   Financial assets at fair value through profit or loss\n\u2022   Available-for-sale financial assets\n\u2022   Loans and receivables\n\u2022   Held-to-maturity investments\n", "page_number": 266, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5228730226592561, "lower_right_x": 0.7351874244256348, "lower_right_y": 0.62248824283882, "height": 0.09961522017956392, "width": 0.5858524788391777}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-11", "text": "     Those categories are used to determine how a particular financial asset is recognised and measured in the\nfinancial statements.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6566908935442497, "height": 0.024369388627618616, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-12", "text": "Initial recognition and measurement\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.6802052159042326, "height": 0.013681060282171864, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-13", "text": "     Financial assets are classified into categories as defined in IAS 39, with their classification depending on\nthe purpose for which the financial assets have been acquired. In line with that classification, the Group\u2019s\nfinancial assets consist of loans, receivables and positive fair values of derivatives.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7297990594271055, "height": 0.042753313381787006, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-14", "text": "     Loans and receivables are non-derivative financial assets with fixed or determinable payments which are\nnot listed in an active market. They are classified as current assets provided that their maturities do not exceed\ntwelve months following the balance sheet date. The latter are presented as non-current assets. Loans and\nreceivables of the Group are classified in the statement of financial position as \u201ctrade receivables\u201d and \u201cother\ncurrent financial assets\u201d. Trade receivables include receivables falling due resulting from the sale of goods in\nthe course of normal business activities. Loans and receivables are measured at amortised cost in accordance\nwith IAS 39.46(a).\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8366823428815733, "height": 0.09833262077811022, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-15", "text": "     Financial assets are measured initially at fair value adjusted for transaction costs, except for those carried\nat fair value through profit and loss.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-266-16", "text": "F-41", "page_number": 266, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-0", "text": "    In accordance with IAS 39.9, a derivative is classified as \u201cat fair value through profit or loss\u201d. Derivatives\nare measured at their fair value (excluding transaction costs) upon initial recognition in accordance with\nIAS 39.43.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.10260795211628901, "height": 0.03805044890979051, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-1", "text": "     Available-for-sale financial assets are non-derivative financial assets that are either designated to this\ncategory or do not qualify for inclusion in any of the other categories of financial assets. Equity investments are\nmeasured at cost less any impairment charges, as its fair value cannot currently be estimated reliably. All other\navailable-for-sale financial assets are measured at fair value.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1671654553227875, "height": 0.05472424112868747, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-2", "text": "Subsequent measurement\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.19837537409149208, "height": 0.014108593415989745, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-3", "text": "     Loans and receivables, after initial measurement, are subsequently measured at amortised cost using the\neffective interest rate (EIR) method, less impairment, if any. Amortised cost is calculated by taking into account\nany discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR\namortisation is included in financial income in the statement of comprehensive income. The losses arising from\nimpairment are recognised in profit or loss.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.27618640444634457, "height": 0.0713980333475844, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-4", "text": "     The amortised cost of trade receivables, due to their short term maturity, in general matches their fair\nvalues, taking into account any impairment losses.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.31124412141941, "height": 0.02778965369816161, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-5", "text": "     In accordance with IAS 39.55, gains or losses from derivatives measured at fair value through profit or\nloss are recognised in profit or loss in the income statement.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.34587430525865753, "height": 0.02821718683197949, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-6", "text": "     Fair value changes for available-for-sale financial assets are recognised directly in equity, through the\nstatement of changes in equity, except for interest on these assets (which is recognised in income on an\neffective yield basis), impairment losses and foreign exchange gains or losses. The cumulative gain or loss that\nwas recognised in equity is recognised in profit or loss when an available-for-sale financial asset is\nderecognised.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4241128687473279, "height": 0.0688328345446772, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-7", "text": "Derecognition of financial assets\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.45404018811457886, "height": 0.013253527148353983, "width": 0.2327690447400242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-8", "text": "     Financial assets are derecognised when the contractual rights to the cash flows from the financial asset\nexpire or the financial asset is transferred to a third party.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4890979050876443, "height": 0.02778965369816161, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-9", "text": "     Receivables, including associated impairment losses, are derecognised if they are classified as\nuncollectable. If a derecognised receivable is later reclassified as collectable on the basis of an event that\nhas occurred after it was derecognised, then the corresponding amount is recorded directly in other operating\nincome.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5506626763574177, "height": 0.05515177426250539, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-10", "text": "Derivatives are derecognised at the end of the contractual obligation.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.5604959384352287, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.4866989117291415}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-11", "text": "2.10 Inventories\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.6019666524155622, "height": 0.0141085934159898, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-12", "text": "Inventories include raw materials and supplies, semi-finished goods and finished goods.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.6117999144933732, "lower_right_x": 0.7684401451027811, "lower_right_y": 0.6241983753740915, "height": 0.012398460880718276, "width": 0.6166868198307134}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-13", "text": "     Inventories are measured at the lower of cost or net realisable value. The cost of inventories includes\nexpenditure incurred in acquiring the inventories, production costs and other costs incurred in bringing them to\ntheir existing location and condition. In the case of manufactured inventories and work in progress, cost of\ninventories includes direct material and production costs and an appropriate share of production overheads\nbased on normal operating capacity. The cost of raw materials is assigned individually or based on the FIFO\nmethod.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7148353997434801, "height": 0.08251389482684901, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-14", "text": "    Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of\ncompletion and selling expenses.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7524583155194527, "height": 0.027789653698161554, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-15", "text": "2.11 Cash and cash equivalents\n", "page_number": 267, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.3464328899637243, "lower_right_y": 0.7798204360837965, "height": 0.01410859341598969, "width": 0.23095525997581617}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-16", "text": "     Cash and cash equivalents include cash deposits. Cash and cash equivalents are reported in accordance\nwith their definition as financial resources in IAS 7.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8140230867892262, "height": 0.027789653698161665, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-267-17", "text": "F-42", "page_number": 267, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-0", "text": "2.12 Financial liabilities\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.28960096735187424, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.17412333736396612}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-1", "text": "Recognition and measurement\n     Financial liabilities regularly lead to a contractual obligation to deliver cash or another financial asset and\nare classified pursuant to IAS 39.\n      The Group\u2019s financial liabilities consist of financial liabilities measured at amortised cost and derivatives\nmeasured at fair value through profit or loss.\n      Financial liabilities measured at amortised cost include trade payables, financial liabilities and other\nfinancial liabilities not held for trading purposes. Trade payables are payment obligations for goods and\nservices acquired in the course of normal business activities. Financial liabilities are recognised as current\nliabilities if the payment obligation is due within one year. Otherwise they will be classified as non-current\nliabilities. The Group\u2019s financial liabilities measured at amortised cost are recognised as \u201ctrade payables\u201d and\n\u201cother financial liabilities\u201d.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2496793501496366, "height": 0.1646002565198803, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-2", "text": "Management defines the classification of financial liabilities at initial recognition.\nAll financial liabilities are measured at fair value upon initial recognition.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.25609234715690465, "lower_right_x": 0.7255139056831923, "lower_right_y": 0.2868747327917914, "height": 0.030782385634886722, "width": 0.5761789600967352}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-3", "text": "Subsequent measurement\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.29443772672309554, "lower_right_y": 0.314664386489953, "height": 0.014108593415989745, "width": 0.17896009673518742}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-4", "text": "      In order to simplify subsequent measurement, current trade payables as well as other current financial\nliabilities are measured using their settlement amount. Non-current financial liabilities as well as bank liabilities\nare carried at amortised cost in accordance with the effective interest method. Gains and losses are recognised\nin profit or loss when the liabilities are derecognised as well as through the effective interest rate\n(EIR) amortisation process. Amortised cost is calculated by taking into account any discount or premium on\nacquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as financial\nexpenses in the statement of comprehensive income.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.41727233860624197, "height": 0.09961522017956392, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-5", "text": "     Gains or losses from derivatives measured at fair value through profit or loss are recognised in profit or\nloss in the income statement.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4480547242411287, "height": 0.024369388627618616, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-6", "text": "Derecognition\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.21704957678355502, "lower_right_y": 0.4788371098760154, "height": 0.014108593415989745, "width": 0.10157194679564692}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-7", "text": "     A financial liability is derecognised if the corresponding obligation is settled, revoked or expired. The\ndifference between the carrying amount of the financial obligation derecognised and the consideration obtained\nor to be obtained is recognised in profit or loss.\n      When an existing financial liability is replaced through the same lender by another financial liability with\nsubstantially different contractual terms, or the terms of an existing liability are materially modified, such an\nexchange or modification is treated as a derecognition of the original liability and the recognition of a new\nliability.\nOffsetting financial instruments\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6053869174861052, "height": 0.12355707567336471, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-8", "text": "     Financial assets and financial liabilities are offset and the net amount is reported in the consolidated\nstatement of financial position if there is a currently enforceable legal right to offset the recognised amounts\nand there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6528430953398888, "height": 0.04104318084651559, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-9", "text": "Financial guarantees\n", "page_number": 268, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6665241556220607, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.6802052159042326, "height": 0.013681060282171864, "width": 0.1451027811366385}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-10", "text": "     Financial guarantees are those contracts that require a payment to be made to reimburse the holder for a\nloss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a\ndebt instrument. Obligations from financial guarantees are determined upon acquisition at their fair value and,\nif not measured at fair value through profit or loss, are valued subsequently at the higher amount resulting from\nthe value calculated pursuant to IAS 37 Provisions, Contingent Liabilities and Contingent Assets for the\ncontractual obligation and resulting from the originally calculated amount less the cumulated amortisation.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7695596408721675, "height": 0.08593415989739206, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-11", "text": "2.13 Government grants\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.7969217614365113, "height": 0.01410859341598969, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-12", "text": "     Mibe GmbH Arzneimittel received government grants for the construction and extension of the plant in\nBrehna, Germany. Government grants are accounted for as deferred income in accordance with IAS 20.24. The\ngrants are systematically recognised as income over the period necessary to match them with the related costs\nthey are intended to compensate. Government grants are reported under other non-current liabilities. The parts\nof the grants which will be reversed within the next twelve months are reported under current liabilities.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8760153911928175, "height": 0.07268063274903802, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-13", "text": "     As at the balance sheet date, there were no unfulfilled conditions and contingencies attached to\nrecognised grants.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8760153911928175, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9046601111586148, "height": 0.028644719965797316, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-14", "text": "the\n", "page_number": 268, "bounding_box": {"top_left_x": 0.8609431680773881, "top_left_y": 0.8764429243266353, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8884138520735357, "height": 0.01197092774690045, "width": 0.023579201934703753}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-268-15", "text": "F-43", "page_number": 268, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-0", "text": "2.14 Provisions for pensions\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-1", "text": "     Provisions for pensions are recognised for obligations relating to vested benefits and current benefit\npayments to eligible active and former employees of the Group companies and their surviving dependants.\nProvisions for pensions are only recognised for companies from Germany and are generally based on the\nemployees\u2019 remuneration and years of service. Pension plans are generally either defined contribution plans or\ndefined benefit plans.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.155622060709705, "height": 0.07054296707994868, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-2", "text": "      In the case of defined contribution plans, the company contributes to publicly or privately administered\npension plans on a mandatory or contractual basis. Once the contributions have been paid, the company has no\nfurther payment obligations. Contributions are recognised as personnel expenses in the year in which they are\npaid.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.21633176571184268, "height": 0.052586575459598134, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-3", "text": "paid.\n     In the case of defined benefit plans, the company agrees to render the benefits promised to active and\nformer employees, whereby a distinction is made between systems that are financed by provisions and those\nfinanced through pension funds.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21675929884566053, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.26934587430525864, "height": 0.052586575459598106, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-4", "text": "      The present value of provisions of defined benefit plans and the resulting expense are calculated in\naccordance with IAS 19 using the projected unit credit (PUC) method. In addition to vested pensions and\nentitlements, the calculation also includes future salary and pension increases. Provisions for pensions are\ncalculated based on the biometric accounting principles of the Heubeck 2005 G mortality tables. The discount\nrates used are calculated from the yields of high-quality corporate bond portfolios in specific currencies with\ncash flows approximately equivalent to the expected disbursements from the pension plans. The uniform\ndiscount rate derived from this interest-rate structure is thus based on the yields, at the closing date, of a\nportfolio of high-quality corporate bond.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.38991021804189824, "height": 0.12013681060282172, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-5", "text": "     For provisions financed through pension funds, the fair value of plan assets is deducted from the present\nvalue of the defined benefit obligation for pensions and other post-employment benefits to determine the net\ndefined benefit liability. The obligations and plan assets are valued at regular intervals. Comprehensive\nactuarial valuations for all plans are performed annually as of 31 December. Plan assets in excess of the benefit\nobligation are reported under other receivables, subject to the asset ceiling specified in IAS 19.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3963232150491663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4681487815305686, "height": 0.07182556648140231, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-6", "text": "     IAS 19 only permits actuarial gains and losses to be recognised with no effect on income. It differentiates\nbetween gains and losses due to changes in demographic assumptions, changes in financial assumptions and\nexperience-based adjustments. They are recognised directly in equity with no effect on income in the period in\nwhich they occur (other comprehensive income). The relevant amounts are reported separately in the\nconsolidated statement of comprehensive income. In accordance with IAS 19, the discount rate underlying the\nobligation is used to calculate the interest income on plan assets recognised through profit or loss. The\nremainder of the actual income from plan assets must be recognised directly in other comprehensive income\nwith no effect on profit or loss. The current service cost is recognised as personnel expenses. All past service\ncost that arises in the financial year shall be recognised immediately through profit or loss.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6019666524155622, "height": 0.1269773407439077, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-7", "text": "2.15 Other Provisions\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.629328772979906, "height": 0.010688328345446751, "width": 0.16021765417170497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-8", "text": "    Provisions are recognised pursuant to IAS 37, provided the following conditions have been\ncumulatively met:\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6665241556220607, "height": 0.027362120564343728, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-9", "text": "\u2022   The Group has a present legal or constructive obligation.\n\u2022   This obligation is the result of a past event.\n\u2022   It is more likely than not that the settling of this obligation will lead to an outflow of resources.\n\u2022   The provision amount can be reliably measured.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6737922188969645, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.7520307823856349, "height": 0.07823856348867042, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-10", "text": "      Where there are a number of similar obligations, the probability that an outflow will be required in\nsettlement is determined by considering the class of obligations as a whole. A provision is recognised even if\nthe probability of an outflow with respect to any one item included in the same class of obligations may be\nsmall.\n     The amount recognised as a provision shall be the best estimate of the expenditure required to settle the\npresent obligation at the end of the reporting period.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8512184694313809, "height": 0.09234715690466011, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-269-11", "text": "F-44", "page_number": 269, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9234715690466011, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010260795211628926, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-0", "text": "2.16 Employee benefits\nBonus schemes\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.09705002137665669, "height": 0.03249251817015819, "width": 0.16989117291414751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-1", "text": "     For bonus payments after the end of the respective financial year for the preceding financial year, an\nobligation is recognised and the corresponding expenses are recognised as personnel expenses. The amount of\nthe obligation is measured individually for each employee for whom either a contractual bonus obligation or a\nconstructive obligation due to past practice exists.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1628901239846088, "height": 0.0572894399315947, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-2", "text": "2.17 Current and deferred income tax\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.1881145788798632, "height": 0.01068832834544678, "width": 0.28597339782345826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-3", "text": "     The tax expense for the period comprises current and deferred tax. Tax is recognised in the consolidated\nstatement of comprehensive income, except to the extent that it relates to items recognised in other\ncomprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive\nincome or directly in equity, respectively. The Company\u2019s taxable income, whether distributed or retained, is\ngenerally subject to German corporate income tax at a uniform rate of 15% plus the solidarity surcharge of\n5.5% thereon, resulting in a total tax rate of 15.825%.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2834544677212484, "height": 0.08550662676357415, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-4", "text": "Current taxes\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.29713552800342025, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.30910645575032064, "height": 0.011970927746900395, "width": 0.09673518742442562}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-5", "text": "     Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid\nto the taxation authorities. The current income tax charge is calculated on the basis of the tax laws enacted or\nsubstantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate\nand generate taxable income. Management periodically evaluates positions taken in tax returns with respect to\nsituations in which applicable tax regulation is subject to interpretation. It establishes provisions where\nappropriate on the basis of amounts expected to be paid to the tax authorities.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4035912783240701, "height": 0.08593415989739206, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-6", "text": "Deferred taxes\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41043180846515603, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.4236853356135101, "height": 0.013253527148354038, "width": 0.10701330108827085}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-7", "text": "      Deferred tax liabilities are created for temporary differences between the tax base of the assets or\nliabilities and their valuation rate in the IFRS financial statements as well as for tax loss carryforwards in the\nconsolidated financial statements.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4719965797349295, "height": 0.038050448909790535, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-8", "text": "Deferred tax liabilities are recognised for all taxable temporary differences, except:\n", "page_number": 270, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.48182984181274047, "lower_right_x": 0.7351874244256348, "lower_right_y": 0.4959384352287302, "height": 0.014108593415989745, "width": 0.5858524788391777}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-9", "text": "\u2022   Where the deferred tax liability arises from the initial recognition of goodwill or of an asset or\n    liability in a transaction that is not a business combination and, at the time of the transaction, affects\n    neither the accounting profit nor taxable profit or loss; and\n\u2022   In respect of taxable temporary differences associated with investments in subsidiaries, associates and\n    interests in joint ventures, where the timing of the reversal of the temporary differences can be\n    controlled and it is probable that the temporary differences will not reverse in the foreseeable future.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5951261222744763, "height": 0.09277469003847794, "width": 0.7351874244256348}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-10", "text": "      Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively\nenacted by the balance sheet date and are expected to apply when the related deferred income tax asset is\nrealised or the deferred income tax liability is settled.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.645575032064985, "height": 0.044035912783240705, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-11", "text": "     Deferred tax assets are recognised to the extent that it is probable that a taxable profit will result against\nwhich the temporary difference can be utilised. Deferred tax liabilities are recognised for temporary differences\ntaxable in the future.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6943138093202224, "height": 0.04147071398033353, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-12", "text": "     Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset\ncurrent tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to\nincome taxes levied by the same taxation authority on either the same taxable entity or different taxable entities\nwhere there is an intention to settle the balances on a net basis.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7558785805899957, "height": 0.051731509191962344, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-13", "text": "Deferred taxes are considered non-current.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.7657118426678068, "lower_right_x": 0.44619105199516323, "lower_right_y": 0.7781103035485251, "height": 0.012398460880718276, "width": 0.2968561064087062}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-270-14", "text": "F-45", "page_number": 270, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-0", "text": "2.18 Recognition of income and expenses\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.42019347037484883, "lower_right_y": 0.07866609662248825, "height": 0.014108593415989745, "width": 0.3047158403869407}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-1", "text": "Revenue\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.09619495510902094, "height": 0.011115861479264633, "width": 0.06348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-2", "text": "     Revenue is measured at the fair value of the consideration received or receivable, and represents amounts\nreceivable for goods supplied or services rendered, stated net of discounts, returns and value added taxes. An\nexchange for goods or services of a similar nature and value is not regarded as a transaction that generates\nrevenue. However, exchanges for dissimilar items are regarded as generating revenue. The Group recognises\nrevenue when the amount of revenue can be reliably measured, when it is probable that future economic\nbenefits will flow to the entity, and when specific criteria have been met for each of the Group\u2019s activities, as\ndescribed below.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.20179563916203505, "height": 0.09619495510902094, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-3", "text": "Sale of goods\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21846943138093203, "lower_right_x": 0.21704957678355502, "lower_right_y": 0.23257802479692177, "height": 0.014108593415989745, "width": 0.10157194679564692}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-4", "text": "     Dermapharm sells a broad assortment of patent-free branded pharmaceuticals, healthcare products such as\ncosmetics, food supplements, dietary products and imported pharmaceuticals from other EEA Member states\nfor resale in the German market in order to profit from pricing differences between the different markets.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.2834544677212484, "height": 0.04104318084651559, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-5", "text": "     Revenue from the sale of goods is recognised when significant risks and rewards of ownership (the\ntransfer of title per incoterms agreed with the buyer) of the goods have passed to the buyer. This is generally\nthe case upon delivery of the goods and merchandise. Revenue is presented net of discounts, rebates and\nreturns.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.34459170585720394, "height": 0.05429670799486963, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-6", "text": "     The German pharmaceuticals market is highly regulated, requiring manufacturers to obtain marketing\nauthorisations before introducing a new product for sale. Extensive regulation also affects prices for\nprescription pharmaceuticals (i.e., pharmaceuticals that require a doctor\u2019s prescription for distribution) in\nGermany. Certain prescription pharmaceuticals, in particular those with high volumes, are subject to a reference\nprice, which is the maximum price for which patients are reimbursed by statutory health insurance (\u201cSHI\u201d)\nproviders. All other prescription pharmaceuticals (i.e., those without a reference price) are subject to a\nmandatory manufacturer rebate of 6% as well as a price moratorium, which was recently extended until 2022.\nUnder this moratorium, pharmaceuticals manufacturers are required to compensate SHI providers and private\nhealth insurance companies for any price increases, making such increases economically unattractive. In\naddition, generics manufacturers such as Dermapharm are generally required to offer a mandatory generics\nrebate of 10% on the ex-factory price of their prescription pharmaceuticals. Rebates are accounted for as\ndeductions from revenue in the consolidated statement of comprehensive income.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5237280889268918, "height": 0.16844805472424113, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-7", "text": "Rendering of services:\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.27388149939540507, "lower_right_y": 0.5532278751603249, "height": 0.013253527148353927, "width": 0.15840386940749696}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-8", "text": "The Group does not provide or render any services.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5604959384352287, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.5746045318512185, "height": 0.0141085934159898, "width": 0.3651753325272068}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-9", "text": "Other operating income/expenses:\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.3524788391777509, "lower_right_y": 0.6019666524155622, "height": 0.0141085934159898, "width": 0.2370012091898428}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-10", "text": "     Other operating expenses are recognised at the point at which the service is rendered, the delivery is\nreceived or at the date they are incurred. Other operating income is recognised when the economic benefits\nflow to the entity.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6113723813595554, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6528430953398888, "height": 0.04147071398033342, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-11", "text": "Interest income:\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.6802052159042326, "height": 0.013681060282171864, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-12", "text": "     Interest income is recognised using the effective interest method. When a loan and receivable is impaired,\nthe Group reduces the carrying amount to its recoverable amount, which is the estimated future cash flow\ndiscounted at the original effective interest rate of the instrument, and continues unwinding the discount as\ninterest income. Interest income on impaired loan and receivables is recognised using the original effective\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7558785805899957, "height": 0.06883283454467715, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-13", "text": "2.19 Leases\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.7849508336896109, "height": 0.012398460880718276, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-14", "text": "     A lease is an agreement whereby the lessor conveys to the lessee in return for payment the right to use an\nasset for an agreed period of time. The Group companies do not act as lessors.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8230012825994014, "height": 0.026507054296707966, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-15", "text": "     Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are\nclassified as operating leases. Payments made under operating leases (net of any incentives received from the\nlessor) are charged to the statement of comprehensive income on a straight-line basis over the term of the lease.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8721675929884566, "height": 0.04147071398033342, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-271-16", "text": "F-46", "page_number": 271, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-0", "text": "     A lease that transfers substantially all the risks and rewards incidental to ownership to the Group is\nclassified as a finance lease. Finance leases are capitalised at the lease\u2019s commencement at the lower of the fair\nvalue of the leased property and the present value of the minimum lease payments.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.10602821718683197, "height": 0.04147071398033347, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-1", "text": "      Each lease payment is allocated between the liability and finance charges. The corresponding lease\nobligations, net of finance charges, are reported under either current or non-current financial liabilities. The\ninterest element of the finance cost is charged to the statement of comprehensive income over the lease period\nso as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.\nThe property, plant and equipment acquired under finance leases is depreciated over the shorter of the useful\nlife of the asset and the lease term.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.19495510902094912, "height": 0.08251389482684908, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-2", "text": "    Rental and lease payments made by the Group under operating leases are recognised in other operating\nexpenses as they incur. All relevant details are reported in 7.2.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.23257802479692177, "height": 0.02778965369816161, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-3", "text": "2.20 Derivatives\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.2599401453612655, "height": 0.010688328345446751, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-4", "text": "     The Group uses derivatives to mitigate the risk of changes in exchange rates or interest rates. The\ninstruments used include forward exchange contracts and interest-rate swaps. Derivatives are recognised at the\ntrade date.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.30782385634886705, "height": 0.038050448909790535, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-5", "text": "trade date.\n    Depending on whether the market value of the derivatives is positive or negative, they are recognised\nunder the \u201cOther financial assets\u201d or \u201cOther financial liabilities\u201d. The Group does not apply hedge accounting.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.30910645575032064, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3471569046601112, "height": 0.038050448909790535, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-6", "text": "2.21 Fair value measurement\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.37280889268918344, "height": 0.010688328345446807, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-7", "text": "     The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, as\nwell as the significant unobservable inputs used.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.41043180846515603, "height": 0.02778965369816161, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-8", "text": "Financial instruments measured at fair value:\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.43736639589568194, "height": 0.010260795211628926, "width": 0.31983071342200725}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-9", "text": "Financial instruments measured at fair value:\n                                                                                                        Interrelationship between\n                                                                                          Significant    significant unobservable\n                                                                                         unobservable      inputs and fair value\nType                                           Valuation technique                          inputs             measurement\nAvailable for sale\n   Investments (n/a) . . . . Due to a lack of information and immateriality of                    n/a                         n/a\n                               available for sale investments, the fair value of those\n                               investments is assumed to be equal to the carrying\n                               amount.\nInterest rate swaps\n   (Level 2) . . . . . . . . . Swap Models:                                                       n/a                         n/a\n                               Fair value is calculated as the present value of the\n                               estimated future cash flows. Estimates of future\n                               floating-rate cash flows are based on quoted swap\n                               rates, futures prices and interbank borrowing rates.\n                               Estimated cash flows are discounted using a yield\n                               curve constructed from similar sources and which\n                               reflects the relevant benchmark interbank rate used\n                               by market participants for this purpose when pricing\n                               interest rate swaps. The fair value measurement is\n                               subject to a credit/debit valuation adjustment that\n                               reflects the credit risk of the Group and the\n                               counterparty, which is calculated based on credit\n                               spreads.\nCurrency-related swaps\n   (Level 2) . . . . . . . . . Option Pricing:                                                    n/a                         n/a\n                               Fair value is calculated as the present value of the\n                               estimated future cash flows based on a Black 76\n", "page_number": 272, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43779392902949976, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7832407011543394, "height": 0.34544677212483965, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-10", "text": "estimated future cash flows based on a Black 76\nmodel for foreign exchange derivatives.\nThe fair values are determined using an option\npricing model using only observable input data\nincluding the relevant reference rate curve, the\nforward rates as well as quoted foreign exchange spot\nand forward rates. The fair value measurement is\nsubject to a credit/debit valuation adjustment that\nreflects the credit risk of the Group and the\ncounterparty, which is calculated based on credit\nspreads.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.7862334330910645, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.9093629756306114, "height": 0.12312954253954689, "width": 0.3391777509068924}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-272-11", "text": "F-47", "page_number": 272, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-0", "text": "                                                                                                 Interrelationship between\n                                                                                   Significant    significant unobservable\n                                                                                  unobservable      inputs and fair value\nType                                       Valuation technique                       inputs             measurement\n\nForeign Exchange\n  Forwards (Level 2) . . Forward pricing:                                                  n/a                         n/a\n                         The fair values are determined using quoted forward\n                         exchange rates at the reporting date and present value\n                         calculations based on high credit quality yield curves\n                         in the respective currencies. The fair value\n                         measurement is subject to a credit/debit valuation\n                         adjustment that reflects the credit risk of the Group\n                         and the counterparty, which is calculated based on\n                         credit spreads.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22573749465583584, "height": 0.1646002565198803, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-1", "text": "Financial instruments not measured at fair value:\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.46009673518742444, "lower_right_y": 0.25309961522017954, "height": 0.010688328345446751, "width": 0.34461910519951633}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-2", "text": "                                                                                             Interrelationship between\n                                                                               Significant    significant unobservable\n                                                                              unobservable      inputs and fair value\nType                                     Valuation technique                     inputs             measurement\nBank loans and leasing\n  liabilities (Level 2) . Discounted cash flows: The valuation model                   n/a                         n/a\n                          considers the present value of future cash flows,\n                          discounted using a risk-adjusted discount rate.\n                          The discount rate is determined using a\n                          benchmark-yield curve that is consistent with\n                          the timing and the estimated riskiness of the\n                          bank loan at the closing date of the contract.\n                          The discount rate used for the balance sheet\n                          date corresponds to the value of the benchmark-\n                          yield curve on that date. Discount rates for\n                          future due dates correspond to the values of the\n                          term-equivalent benchmark- yield curve.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2663531423685336, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4959384352287302, "height": 0.22958529286019663, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-3", "text": "3.   Estimates and judgements\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.5250106883283454, "height": 0.012398460880718165, "width": 0.23760580411124543}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-4", "text": "     Estimates and judgments are continually evaluated and are based on historical experience and other\nfactors, including expectations of future events that are believed to be reasonable under the circumstances.\nEstimates and assumptions are reviewed on an on-going basis. Revisions to estimates are recognised\nprospectively.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5882855921333904, "height": 0.05515177426250539, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-5", "text": "3.1 Critical accounting estimates and assumptions\n", "page_number": 273, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6019666524155622, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.6156477126977341, "height": 0.013681060282171864, "width": 0.37726723095526}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-6", "text": "     The company makes estimates and assumptions concerning the future. The resulting accounting estimates\nwill, by definition, seldom equal the related actual results. The estimates and assumptions that have a\nsignificant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next\nfinancial year are addressed below.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6806327490380505, "height": 0.05515177426250539, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-7", "text": "     Significant judgement was necessary to decide whether the criteria pursuant to IAS 38 for capitalising\ndevelopment costs have been met. Other judgements relate to the decision of whether a lease contract is to be\nclassified as a finance or an operating lease and whether triggering events for impairment testing existed.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.731936725096195, "height": 0.04489097905087647, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-8", "text": "Business Combinations\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.7592988456605387, "height": 0.0141085934159898, "width": 0.16505441354292621}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-9", "text": "     Various valuation methods are used in the context of purchase price allocations in business combinations\nthat are primarily based on estimates and assumptions. The employed methods and carrying amounts identified\nin the acquisition of Remedix GmbH are presented in 2.7.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8088926891834117, "height": 0.04318084651560494, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-10", "text": "Goodwill Impairment Test\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8238563488670372, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.8371098760153912, "height": 0.013253527148354038, "width": 0.18923821039903266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-11", "text": "     Dermapharm AG tests any capitalised goodwill for impairment at least once a year. The necessary\nassumptions and estimates are presented in detail in 4.1. For the carrying amounts of goodwill as at the balance\nsheet date, please refer to 4.1.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8858486532706284, "height": 0.04147071398033342, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-273-12", "text": "F-48", "page_number": 273, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-0", "text": "Impairment of other assets\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.18923821039903266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-1", "text": "     For items of property, plant and equipment and intangible assets, the expected useful lives and associated\namortisation or depreciation expenses are determined on the basis of the Management\u2019s expectations and\nassessments. The Group assesses whether there are any indications of impairment for all non-financial assets at\neach reporting date. Especially in the context of impairment tests for yet unused approvals, the growth rates\napplied for the test as well as the price and cost development of active pharmaceutical ingredients are based on\nbest possible estimates. The carrying amounts of the items of property, plant and equipment and intangible\nassets as well as the respective amortisation, depreciation and impairment expenses are shown in the tables in\n4.1 and 4.2.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.19495510902094912, "height": 0.10987601539119281, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-2", "text": "Development Costs\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.21889696451474988, "height": 0.014108593415989718, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-3", "text": "     Development costs are capitalised based on the assessment of whether the capitalisation requirements of\nIAS 38 are met. Planning calculations are necessary to determine the future economic benefit, which are by\ntheir nature subject to estimates and may therefore deviate from actual circumstances in the future. For the\ncarrying amounts of capitalised development costs as at the balance sheet date, please refer to 4.1.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2834544677212484, "height": 0.05814450619923042, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-4", "text": "Taxation\n", "page_number": 274, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.29713552800342025, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.30910645575032064, "height": 0.011970927746900395, "width": 0.06287787182587666}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-5", "text": "     Dermapharm Group operates in various countries and is obliged to pay respective income taxes in each tax\njurisdiction. In order to calculate the income tax provisions and the deferred tax liabilities in the Group, the\nexpected income tax as well as the temporary differences resulting from the different treatment of certain\nbalance sheet items pursuant to IFRS and their accounting in accordance with tax law are each to be\ndetermined on the basis of assumptions. If the final taxation imposed deviates from the assumed values, this\nhas a corresponding effect on current and deferred taxes and thus on the net assets, financial position and\nresults of operations of the Group in the respective period. For more detailed information on the income taxes\nand deferred taxes, please refer to 4.17.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4313809320222317, "height": 0.11372381359555367, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-6", "text": "Fair value of financial assets and liabilities\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.45874305258657544, "height": 0.011115861479264633, "width": 0.3053204353083434}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-7", "text": "     When determining the fair values of derivatives and other financial instruments, for which no market price\nin an active market is available, valuation models based on input parameters observable in the market are\napplied. The cash flows, which are already fixed or calculated by means of the current yield curve using\nso-called \u201cforward rates\u201d, are discounted to the measurement date with the discount factors determined by\nmeans of the yield curve valid on the reporting date. All carrying amounts are shown in 6.3.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5391192817443352, "height": 0.07097050021376661, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-8", "text": "     Trade and other receivables, cash and cash equivalents, trade and other payables, current liabilities to\nbanks, current leasing liabilities and other current financial liabilities generally have a short maturity. The\ncarrying amounts less allowances, where applicable, approximate the fair values.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5882855921333904, "height": 0.04147071398033353, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-9", "text": "Pension and other post-employment benefits\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.42986698911729143, "lower_right_y": 0.6156477126977341, "height": 0.0141085934159898, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-10", "text": "     The carrying amounts of defined benefit pension plans and other post-employment benefits are based on\nactuarial valuations. The actuarial valuations involved making assumptions about discount rates, expected rates\nof return on plan assets, future salary increases, mortality rates and future pension increases. Due to the\nlong-term nature of these plans, such estimates are subject to significant uncertainty. Further details are given\nin 4.17.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6934587430525866, "height": 0.0679777682770415, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-11", "text": "Other provisions\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.7148353997434801, "height": 0.010688328345446751, "width": 0.12091898428053204}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-12", "text": "     Such provisions are recognised when it is considered probable that economical, legal, ecological and\ndecommissioning obligations will result in future outflows of economic benefits, when the costs can be\nestimated reliably and the measures in question are not expected to result in future inflows of economic\nbenefits. The estimate of future costs is subject to many uncertainties, including legal uncertainties based on the\napplicable laws and regulations and with uncertainties regarding to the actual conditions in the different\ncountries and operating locations. In particular, estimates of costs are based on previous experiences in similar\ncases, the conclusions of expert opinions commissioned by the Group, current costs and new developments that\nhave a bearing on the costs. Any changes to these estimates could have an impact on the future results of the\nGroup. The carrying amounts as at the balance sheet dates are shown in 4.12.\n", "page_number": 274, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8512184694313809, "height": 0.12654980761008972, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-274-13", "text": "F-49", "page_number": 274, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-275-0", "text": "4.   Notes to the consolidated statement of financial position\n4.1 Intangible assets\n     Intangible assets changed as follows:\n", "page_number": 275, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.11970927746900385, "height": 0.05515177426250535, "width": 0.46009673518742444}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-275-1", "text": "                                                                                                                  Software,\n                                                                                                                   licenses,      Capitalised\nkEUR                                                                                                             patents and     development\nCost                                                                                                Goodwill    similar rights      costs       Total\nAt 1 January 2016 . . . . . . . . . . . . . . . . . . . .                                              37,659       133,216           19,867    190,742\nExchange    differences . . .       .. .... ...                         .   .   .   .   .   .   .          \u2014              58              \u2014          58\nAdditions   through business        combinations                        .   .   .   .   .   .   .         589          2,533              \u2014       3,122\nAdditions    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014           4,389           8,319     12,708\nDisposals    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014          (6,001)         (1,119)    (7,120)\nTransfers    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014              \u2014               \u2014          \u2014\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                38,248       134,195           27,067    199,510\nAmortisation and impairment\nAt 1 January 2016 . . . . . . . . . . . . . . . . . . . .                                              21,215        80,442            4,675    106,332\nExchange    differences .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014              40              \u2014          40\nAdditions    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014           9,187              24      9,211\nAdditions   (impairment)    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014              \u2014               \u2014          \u2014\nDisposals    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014          (3,131)             \u2014      (3,131)\nTransfers    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014              \u2014               \u2014          \u2014\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                21,215        86,538            4,699    112,452\nCarrying amount\nAt 31 December 2015 . . . . . . . . . . . . . . . . . . .                                              16,444        52,774           15,192     84,410\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                17,033        47,657           22,368     87,058\n\n                                                                                                                  Software,\n                                                                                                                   licenses,      Capitalised\nkEUR                                                                                                             patents and     development\nCost                                                                                                Goodwill    similar rights      costs       Total\nAt 1 January 2015 . . . . . . . . . . . . . . . . . . . .                                              37,659       149,057           12,499    199,215\nExchange    differences . . .       .. .... ...                         .   .   .   .   .   .   .          \u2014            289               \u2014         289\nAdditions   through business        combinations                        .   .   .   .   .   .   .          \u2014             \u2014                \u2014          \u2014\nAdditions    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014          3,659            8,081     11,740\nDisposals    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014        (19,789)            (713)   (20,502)\nTransfers    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014             \u2014                \u2014          \u2014\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                37,659       133,216           19,867    190,742\nAmortisation and impairment\nAt 1 January 2015 . . . . . . . . . . . . . . . . . . . .                                              16,106        85,170            4,673    105,949\nExchange    differences .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014            228               \u2014         228\nAdditions    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014          9,884                2      9,886\nAdditions   (impairment)    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       5,109            \u2014                \u2014       5,109\nDisposals    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014        (14,840)              \u2014     (14,840)\nTransfers    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014             \u2014                \u2014          \u2014\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                21,215        80,442            4,675    106,332\nCarrying amount\nAt 31 December 2014 . . . . . . . . . . . . . . . . . . .                                              21,553        63,887            7,826     93,266\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                16,444        52,774           15,192     84,410\n", "page_number": 275, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8221462163317658, "height": 0.6891834117144079, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-275-2", "text": "F-50", "page_number": 275, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-0", "text": "                                                                                                                  Software,\n                                                                                                                   licenses,      Capitalised\nkEUR                                                                                                             patents and     development\nCost                                                                                                Goodwill    similar rights      costs       Total\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . .                                              37,659       134,184            8,452    180,295\nExchange    differences . . .       .. .... ...                         .   .   .   .   .   .   .          \u2014             36               \u2014          36\nAdditions   through business        combinations                        .   .   .   .   .   .   .          \u2014             \u2014                \u2014          \u2014\nAdditions    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014         14,812            7,345     22,157\nDisposals    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014           (911)          (2,362)    (3,273)\nTransfers    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          \u2014            936             (936)        \u2014\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                37,659       149,057           12,499    199,215\nAmortisation and impairment\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . .                                              10,916        72,321               \u2014      83,237\nExchange    differences .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014             44               \u2014          44\nAdditions    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014         13,499               \u2014      13,499\nAdditions   (impairment)    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       5,190            \u2014             4,673      9,863\nDisposals    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014           (694)              \u2014        (694)\nTransfers    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          \u2014             \u2014                \u2014          \u2014\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                16,106        85,170            4,673    105,949\nCarrying amount . . . . . . . . . . . . . . . . . . . . .                                                                                               \u2014\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . . .                                            26,743        61,863            8,452     97,058\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                21,553        63,887            7,826     93,266\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.3997434801197093, "height": 0.3386062419837538, "width": 0.7732769044740024}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-1", "text": "     In financial year 2016, the Group acquired a 75% stake in Remedix GmbH; for further details please refer\nto section 2.7. This transaction resulted in an increase in the accumulated cost of software, licenses, patents and\nrights of kEUR 2,533 and goodwill in the amount of kEUR 589.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4566053869174861, "height": 0.04318084651560494, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-2", "text": "     Intangible assets include goodwill, customer relationships, trademarks and capitalised development costs\nfor development projects. Goodwill, customer relationships and trademarks represent acquired intangible assets\nwhile development costs stem from internal developments. The recognised goodwill and customer relationships\nwere reported under acquisitions through business combinations. The trademarks relate to the \u201cLactoStop\u201d\nbrand which was acquired in 2014.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5335613510047028, "height": 0.06883283454467715, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-3", "text": "    Amortisation of intangible assets, excluding impairment charges, with a total value of kEUR 9,211\n(2015: kEUR 9,886; 2014: kEUR 13,499) were recorded in 2016.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5699016673792219, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-4", "text": "     During the period ended 31 December 2016, no impairment charges on capitalised development costs were\nrecorded in profit or loss (31 December 2015: kEUR 0; 31 December 2014: kEUR 4,673). The value in use of\nthe impaired capitalised development costs in 2014 was nil.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.619067977768277, "height": 0.04147071398033353, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-5", "text": "    In the financial year 2016, kEUR 8,319 of development costs were capitalised (31 December\n2015: kEUR 8,081; 31 December 2014: kEUR 7,345).\n", "page_number": 276, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.628901239846088, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6554082941427961, "height": 0.026507054296708077, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-6", "text": "     At 31 December 2016, intangible assets (mainly medical licences) with a carrying amount of kEUR 2,242\n(31 December 2015: kEUR 2,462; 31 December 2014: kEUR 2,363; 1 January 2014: kEUR 2,575) were\npledged to different banks in order to provide security for bank loans.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7045746045318512, "height": 0.04147071398033342, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-7", "text": "    In financial year 2016, no changes were made to the useful lives of internally generated intangible assets\n(31 December 2015: 0 assets; 31 December 2014: 0 assets).\n", "page_number": 276, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7413424540401881, "height": 0.03035485250106873, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-8", "text": "     The impairments relate to specific projects where the revised business expectations indicated that the\ncapitalised amounts were no longer recoverable. The recoverable amount of internally generated intangible\nassets is determined based on a value-in-use calculation using cash flow projections. Please refer to the section\n\u201cImpairment testing: capitalised development projects\u201d in this chapter for a detailed overview of the\nperformance of capitalised development cost impairment test.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8174433518597691, "height": 0.06883283454467726, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-9", "text": "     In the financial year 2014, H\u00fcbner Arzneimittel GmbH, a wholly owned subsidiary of Dermapharm,\nacquired the trademark \u201cLactoStop\u201d, which was valued with kEUR 13,138. The trademark has a useful life of\nnine years resulting in an annual amortisation of kEUR 1,460 (partial amortisation in 2014: kEUR 852). At\n31 December 2016, the carrying amount is kEUR 9,366 (31 December 2015: kEUR 10,826; 31 December\n2014: kEUR 12,286).\n", "page_number": 276, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8961094484822574, "height": 0.06883283454467726, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-276-10", "text": "F-51", "page_number": 276, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-0", "text": "      In the financial year 2016, the acquisition of Remedix GmbH resulted in an identified customer\nrelationship of kEUR 2,533 which is amortised over its useful life of seven years (partial amortisation in\nDecember 2016: kEUR 273). At 31 December 2016, the carrying amount is kEUR 2,015.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.10602821718683197, "height": 0.04147071398033347, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-1", "text": "     Impairment of goodwill in the amount of kEUR 5,190 as of 31 December 2014 relates to goodwill that\nwas allocated to Cancernova GmbH. After declining revenues in financial year 2014, caused by general market\nuncertainty as a consequence of re-import forgery, goodwill impairment tests led to a partial impairment of\nallocated goodwill.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.16973065412569474, "height": 0.0572894399315947, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-2", "text": "     As of 31 December 2015, the company realised an impairment loss of kEUR 5,109. This represents a\nwrite-off of the goodwill allocated to Farmal d.d. due to provisions for an indictment filed against the company.\nAs a result of the purchase price allocation conducted for the acquisition of Remedix GmbH through Axicorp\nGmbH, in which Dermapharm AG holds an 85% interest, Dermapharm recognised additional goodwill of\nkEUR 589 in 2016 (please refer to 2.7 for more information on the acquisition of Remedix GmbH).\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2479692176143651, "height": 0.0705429670799487, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-3", "text": "Notes on the annual impairment tests\n", "page_number": 277, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2629328772979906, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.27618640444634457, "height": 0.013253527148353983, "width": 0.2660217654171705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-4", "text": "Goodwill and capitalised development cost were tested for impairment by the Group on an annual basis.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2975630611372381, "height": 0.020949123557075677, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-5", "text": "Impairment testing: capitalised development projects\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31209918768704575, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.32492518170158186, "height": 0.012825994014536102, "width": 0.3681983071342201}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-6", "text": "      Capitalised development costs which are not yet complete are not amortised but is subject to impairment\ntesting as described below.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.36169303120991875, "height": 0.026934587430525847, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-7", "text": "     The recoverable amount of the individual projects was determined by calculating the value in use, which is\nbased on the projected cash flows of the individual development projects. The cash flow projections underlying\nthe value in use calculation were derived based on management inputs of key parameters for each project\nwhich comprised the total market size, the target market share, the expected go-to-market year, the duration of\nthe ramp-up period, the total lifetime, expected EBIT-margins as well as the percentage of completion as per\nvaluation date. As a result, each development project was valued based on a distinct business plan with cash\nflow projections and a specific lifetime.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4681487815305686, "height": 0.09918768704574604, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-8", "text": "     The respective applied discount rate matches the discount rate of Mibe Arzneimittel GmbH and amounts\nto 7.47% as per 31 December 2014, 6.87% as per 31 December 2015 and 6.38% as per 31 December 2016.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5027789653698161, "height": 0.02778965369816161, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-9", "text": "Sensitivity analyses\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5194527575887131, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.5318512184694314, "height": 0.012398460880718276, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-10", "text": "     The results of the test are based mainly on the management assumptions presented. To validate these\nresults, the assumptions made were subjected to sensitivity analyses where the impact of a change in\nparameters on the values was calculated. Modified assumptions involved pre-tax interest rates and EBIT\nmargins applied in the terminal value.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5951261222744763, "height": 0.05515177426250528, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-11", "text": " A 1% increase in the pre-tax interest rates as part of the sensitivity analysis did not result in the need for\nimpairment charges for the development projects.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1505441354292624, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6318939717828131, "height": 0.03035485250106884, "width": 0.7321644498186215}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-12", "text": "any i\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6203505771697306, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.6318939717828131, "height": 0.011543394613082514, "width": 0.034461910519951636}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-13", "text": "    Likewise, the sensitivity analysis of the expected EBIT margin showed that the projects do not require an\nimpairment charge in the case of a 2% reduction.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6669516887558786, "height": 0.027789653698161665, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-14", "text": "Goodwill impairment tests\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.6874732791791364, "height": 0.01410859341598969, "width": 0.18923821039903266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-15", "text": "     The Management Board monitors and manages Group performance based on the different legal entities.\nThe Group defines all legal entities as CGUs which are tested for impairment. As a result, nine CGUs were\ntested as per 1 January 2014. Of the nine CGUs, two have only negligible goodwill as at the date of transition\nto IFRS. In the following, detailed information is only presented for the CGUs which have material goodwill as\nat the reported balance sheet dates.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7661393758016246, "height": 0.0722530996152202, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-16", "text": "     The recoverable amount of the individual CGUs was determined by calculating the value in use, which is\nbased on the projected cash flows of the individual entities. The cash flow projections underlying the value in\nuse calculation stem from the financial plans for a period of four years as of the respective valuation date as\napproved by the Management Board and the Supervisory Board.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8302693458743052, "height": 0.05771697306541257, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-277-17", "text": "F-52", "page_number": 277, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-0", "text": "     As the management plans show that the CGUs have not yet reached their steady state as of the end of the\nperiod, the reconciliation to the steady state was planned using a three-year transition period. The first year of\nthe transition period is characterised by decreasing growth rates while EBITDA margins were kept constant, in\norder to transfer the business plans to a steady state status. The remaining two transition periods were already\nplanned with terminal value assumptions, i.e. a growth rate of 1% and constant EBITDA margins. Due\ndiscounting effects, recognising the two additional transition periods does not significantly impact the\nvaluations. This state was extrapolated using a perpetual growth rate of 1%.\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1628901239846088, "height": 0.09833262077811031, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-1", "text": "     The respective carrying amounts and goodwill as well as the key assumptions for the calculation of values\nin use for each CGU were as follows. The budgeted EBITDA margins and budgeted EBITDA growth rates\npresented reflect average values over the four planning years:\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17058572039333048, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-2", "text": "                                                 Mibe           Acis\n                                              Arzneimittel   Arzneimittel   Cancernova    axicorp      Melasan      Sun-Farm\n1 January 2014                                  GmbH           GmbH           GmbH        GmbH         GmbH          sp Z.o.o.    Farmal d.d.\nBudgeted EBITDA margin            .   .   .         37.90%         33.37%         8.71%        4.13%       22.59%        22.82%         26.50%\nBudgeted EBITDA growth            .   .   .          5.00%         20.33%        20.41%       17.69%       14.63%        37.78%         72.67%\nDiscount rate . . . . . . . . .   .   .   .          9.62%          9.26%         9.35%        9.74%        9.26%        11.01%         14.55%\nGoodwill in kEUR . . . . .        .   .   .         1,700             47         5,190       12,177          673         1,848          5,109\nValue in Use in kEUR . .          .   .   .       425,609         82,880        15,369      116,538       13,134        18,330         23,994\nCarrying amount in kEUR           .   .   .       102,900             (2)        8,110       39,666        2,440         4,778         14,386\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.32834544677212485, "height": 0.10303548525010689, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-3", "text": "                                                 Mibe           Acis\n                                              Arzneimittel   Arzneimittel   Cancernova    axicorp     Melasan      Sun-Farm\n31 December 2014                                GmbH           GmbH           GmbH        GmbH        GmbH          sp Z.o.o.    Farmal d.d.\nBudgeted EBITDA margin            .   .   .         17.65%         84.05%         3.50%       3.91%       26.99%        20.18%         23.60%\nBudgeted EBITDA growth            .   .   .          6.47%          8.87%        25.81%      17.27%       18.98%        43.33%         41.97%\nDiscount rate . . . . . . . . .   .   .   .         10.55%          9.98%         n/a1       10.52%       10.03%        11.84%         15.01%\nGoodwill in kEUR . . . . .        .   .   .         1,700             47         5,190      12,177          673         1,848          5,109\nValue in Use in kEUR . .          .   .   .       352,263         66,027         4,862     121,951       25,087        15,901         18,767\nCarrying amount in kEUR           .   .   .        91,520           (513)        7,633      34,456        2,737         4,803         14,430\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.4480547242411287, "height": 0.10645575032064986, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-4", "text": "                                                                                       Mibe           Acis\n                                                                                    Arzneimittel   Arzneimittel   axicorp     Melasan      Sun-Farm\n31 December 2015                                                                      GmbH           GmbH         GmbH        GmbH          sp Z.o.o.    Farmal d.d.\nBudgeted EBITDA margin          .   .   .   .   .   .   .   .   .   .   .   .   .         29.08%         81.36%       3.76%       25.53%        33.11%          5.99%\nBudgeted EBITDA growth          .   .   .   .   .   .   .   .   .   .   .   .   .          9.39%          9.06%      24.66%       12.28%        67.30%         65.40%\nDiscount rate . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .          9.99%          9.45%       9.92%        9.54%        11.02%            n/a(1)\nGoodwill in kEUR . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .         1,700             47      12,177          673         1,848          5,109\nValue in Use in kEUR . .        .   .   .   .   .   .   .   .   .   .   .   .   .       640,886         63,379     134,398       22,321        46,562           (645)\nCarrying amount in kEUR         .   .   .   .   .   .   .   .   .   .   .   .   .        97,123             (6)     37,334        2,765         4,998         11,874\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.5643437366395896, "height": 0.10303548525010692, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-5", "text": "                                                                                                                             Mibe           Acis\n                                                                                                                          Arzneimittel   Arzneimittel   axicorp      Melasan      Sun-Farm\n31 December 2016                                                                                                            GmbH           GmbH         GmbH         GmbH          sp Z.o.o.\nBudgeted EBITDA margin            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         30.87%         24.96%        3.84%       23.51%        27.86%\nBudgeted EBITDA growth            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          5.08%          2.93%        3.35%       11.50%        52.31%\nDiscount rate . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          8.48%          8.08%        8.53%        8.91%         9.63%\nGoodwill in kEUR . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         1,700             47       12,766          673         1,848\nValue in Use in kEUR . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       980,608         39,060      116,198       21,997        48,015\nCarrying amount in kEUR           .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       107,078           (615)      47,697        3,242         5,317\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.6827704147071398, "height": 0.10517315091919632, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-6", "text": "(1) Since the goodwill for both CGUs is fully impaired due to a negative value in use in the respective year no pre-tax discount rate\n    is available.\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7114151346729372, "height": 0.020949123557075677, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-7", "text": "Sensitivity analyses\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.7421975203078238, "height": 0.01410859341598969, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-8", "text": "     The results of the test are based mainly on the management assumptions presented. To validate these\nresults, the assumptions made were subjected to sensitivity analyses where the impact of a change in\nparameters on the values was calculated. Modified assumptions involved pre-tax interest rates and EBITDA\nmargins applied at the terminal value.\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.751603249251817, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8071825566481402, "height": 0.05557930739632322, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-9", "text": "    A 1% increase in the pre-tax interest rates in the sensitivity analysis did not result in the need for any\nimpairment charges for the CGUs.\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8413852073535699, "height": 0.027789653698161665, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-10", "text": "    Likewise, the sensitivity analysis of the expected EBITDA margin showed that the CGUs do not require\nan impairment charge in the case of a 3% reduction.\n", "page_number": 278, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8503634031637451, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8781530568619068, "height": 0.027789653698161665, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-278-11", "text": "F-53", "page_number": 278, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-279-0", "text": "4.2 Property, plant and equipment\n    Property, plant and equipment changed as follows:\n", "page_number": 279, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.507255139056832, "lower_right_y": 0.09918768704574604, "height": 0.03463018383924754, "width": 0.39177750906892383}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-279-1", "text": "                                                                                                     Land and\n                                                                                                     Buildings\n                                                                                                     including      Technical    Other fixed\n                                                                                                    buildings on   equipment     assets and\n                                                                                                    third party       and          office\nkEUR                                                                                                    land       machinery     equipment     Total\nCost\nAt 1 January 2016 . . . . . . . . . . . . . . . . . . . .                                                48,523        29,857        16,541     94,921\nExchange    differences . . .       .. .... ...                         .   .   .   .   .   .   .            21            (8)           (4)         9\nAdditions   through business        combinations                        .   .   .   .   .   .   .            \u2014             \u2014             37         37\nAdditions    .... .... ...          .. .... ...                         .   .   .   .   .   .   .            90         3,428         1,532      5,050\nDisposals    .... .... ...          .. .... ...                         .   .   .   .   .   .   .            (4)         (330)       (1,274)    (1,608)\nTransfers    .... .... ...          .. .... ...                         .   .   .   .   .   .   .           604          (578)          (26)        \u2014\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                  49,234        32,369        16,806     98,409\nDepreciation and impairment\nAt 1 January 2016 . . . . . . . . . . . . . . . . . . . .                                                12,359        18,710        10,446     41,515\nExchange    differences .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            19            (4)            3         18\nAdditions    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         1,537         1,730         1,625      4,892\nAdditions   (impairment)    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nDisposals    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            (3)         (203)       (1,167)    (1,373)\nTransfers    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                  13,912        20,233        10,907     45,052\nCarrying amount\nAt 31 December 2015 . . . . . . . . . . . . . . . . . . .                                                36,164        11,147         6,095     53,406\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                  35,322        12,136         5,899     53,357\n\n                                                                                                     Land and\n                                                                                                     Buildings\n                                                                                                     including      Technical    Other fixed\n                                                                                                    buildings on   equipment     assets and\n                                                                                                    third party       and          office\nkEUR                                                                                                    land       machinery     equipment     Total\nCost\nAt 1 January 2015 . . . . . . . . . . . . . . . . . . . .                                                48,460        32,181        16,132     96,773\nExchange    differences . . .       .. .... ...                         .   .   .   .   .   .   .           117             2            39        158\nAdditions   through business        combinations                        .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nAdditions    .... .... ...          .. .... ...                         .   .   .   .   .   .   .            18         2,275           900      3,193\nDisposals    .... .... ...          .. .... ...                         .   .   .   .   .   .   .          (537)       (1,276)       (3,390)    (5,203)\nTransfers    .... .... ...          .. .... ...                         .   .   .   .   .   .   .           465        (3,325)        2,860         \u2014\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                  48,523        29,857        16,541     94,921\nDepreciation and impairment\nAt 1 January 2015 . . . . . . . . . . . . . . . . . . . .                                                11,560        18,946         9,720     40,226\nExchange    differences .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           107             2            33        142\nAdditions    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         1,462         2,040         1,671      5,173\nAdditions   (impairment)    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nDisposals    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          (258)       (1,061)       (2,707)    (4,026)\nTransfers    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          (512)       (1,217)        1,729         \u2014\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                  12,359        18,710        10,446     41,515\nCarrying amount\nAt 31 December 2014 . . . . . . . . . . . . . . . . . . .                                                36,900        13,235         6,412     56,547\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                  36,164        11,147         6,095     53,406\n", "page_number": 279, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11073108165882856, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8721675929884566, "height": 0.761436511329628, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-279-2", "text": "F-54", "page_number": 279, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-0", "text": "                                                                                                     Land and\n                                                                                                     Buildings\n                                                                                                     including      Technical    Other fixed\n                                                                                                    buildings on   equipment     assets and\n                                                                                                    third party       and          office\nkEUR                                                                                                    land       machinery     equipment     Total\nCost\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . .                                                48,674        31,961        15,921     96,556\nExchange    differences . . .       .. .... ...                         .   .   .   .   .   .   .            \u2014            (29)           \u2014         (29)\nAdditions   through business        combinations                        .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nAdditions    .... .... ...          .. .... ...                         .   .   .   .   .   .   .         1,054         3,832         1,381      6,267\nDisposals    .... .... ...          .. .... ...                         .   .   .   .   .   .   .        (1,798)       (2,787)       (1,436)    (6,021)\nTransfers    .... .... ...          .. .... ...                         .   .   .   .   .   .   .           530          (796)          266         \u2014\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                  48,460        32,181        16,132     96,773\nDepreciation and impairment\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . .                                                10,950        18,473         9,781     39,204\nExchange    differences .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            27           (11)           (3)        13\nAdditions    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         1,541         2,063         1,323      4,927\nAdditions   (impairment)    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nDisposals    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          (958)       (1,579)       (1,381)    (3,918)\nTransfers    .... .... .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            \u2014             \u2014             \u2014          \u2014\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                  11,560        18,946         9,720     40,226\nCarrying amount . . . . . . . . . . . . . . . . . . . . .                                                                                           \u2014\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . . .                                              37,724        13,488         6,140     57,352\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                  36,900        13,235         6,412     56,547\n", "page_number": 280, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.42838820008550665, "height": 0.3672509619495511, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-1", "text": "     In financial year 2016, the Group acquired a 75% stake in Remedix GmbH; for further details please refer\nto 2.7. This transaction resulted in an increase in the accumulated cost of other fixed assets and office\nequipment of kEUR 37.\n     Property, plant and equipment comprises land and buildings, technical equipment and machinery and other\nfixed assets and office equipment.\n", "page_number": 280, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5433946130825139, "height": 0.09234715690466011, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-2", "text": "    Indications of impairment pursuant to IAS 36 were not present at the date of these financial statements.\n     During the period ended 31 December 2016, depreciation in the amount of kEUR 4,892 was recorded in\nprofit or loss (31 December 2015: kEUR 5,173; 31 December 2014: kEUR 4,927).\n", "page_number": 280, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5438221462163317, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5848653270628473, "height": 0.04104318084651559, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-3", "text": "Finance lease assets changed as follows:\n", "page_number": 280, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.5912783240701154, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.6053869174861052, "height": 0.0141085934159898, "width": 0.28355501813784767}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-4", "text": "                                                        31 December   31 December   31 December   1 January\nkEUR                                                        2016          2015          2014         2014\nTechnical equipment and machinery . . . . . . . . . .           \u2014            143           250          356\nOther equipment, factory and office equipment . . .            279           246           237          109\nNet carrying amount of leased assets . . . . . . . .           279           389           487          465\n", "page_number": 280, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6943138093202224, "height": 0.07567336468576313, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-5", "text": "For further details regarding obligations from finance leases, please refer to section 7.2a).\n", "page_number": 280, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.7109876015391193, "lower_right_x": 0.7817412333736397, "lower_right_y": 0.725096194955109, "height": 0.01410859341598969, "width": 0.6299879081015719}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-280-6", "text": "F-55", "page_number": 280, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-0", "text": "4.3 Investments measured at equity\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.2714631197097944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-1", "text": "     Two associates (31 December 2015: 2; 31 December 2014: 1; 1 January 2014: 1) were accounted for in\nthe consolidated financial statements using the equity method.\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.11286874732791792, "height": 0.02778965369816161, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-2", "text": "Company Name                                                   Place of Business        Share in capital (%)\n31 December 2016\nHasan Dermapharm Co.Ltd.        ... .... ..... .... .   Binh Duong Province, Vietnam                   30.0\nGynial GmbH . . . . . . . . .   ... .... ..... .... .                 Vienna, Austria                  25.1\n31 December 2015\nHasan Dermapharm Co.Ltd.        ... .... ..... .... .   Binh Duong Province, Vietnam                   30.0\nGynial GmbH . . . . . . . . .   ... .... ..... .... .                 Vienna, Austria                  25.1\n31 December 2014\nHasan Dermapharm Co.Ltd.        ... .... ..... .... .   Binh Duong Province, Vietnam                   30.0\n1 January 2014\nHasan Dermapharm Co.Ltd.        ... .... ..... .... .   Binh Duong Province, Vietnam                   30.0\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2830269345874305, "height": 0.15690466011115858, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-3", "text": "Gynial GmbH, Vienna, Austria:\n", "page_number": 281, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.29713552800342025, "lower_right_x": 0.34280532043530837, "lower_right_y": 0.31124412141941, "height": 0.014108593415989745, "width": 0.2255139056831923}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-4", "text": "     Dermapharm GmbH, Vienna, acquired 25.1% of Gynial GmbH, Vienna, in 2015. Gynial focuses on the\nphysical health and the well-being of women with an emphasis on prophylactic measures. Due to its\nlong-standing activities for Shering AG, Gynial\u2019s management team has extensive expertise in this sector.\nGynial is purely a sales company and has no production facility. Its strategic objective is to shift existing job\norder productions with third party suppliers gradually to mibe GmbH, which already has a manufacturing area\nfor contraceptives, thus expanding value creation to production. Furthermore, Gynial GmbH can benefit from\nfuture developments of the Group within the women\u2019s health sector.\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.41727233860624197, "height": 0.09961522017956392, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-5", "text": "     The following table summarises Gynial GmbH\u2019s financial information as presented in its own financial\nstatements:\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4510474561778538, "height": 0.027362120564343728, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-6", "text": "                                                                                                                                                                              31 December   31 December\nkEUR                                                                                                                                                                              2016          2015\nPercentage ownership interest (%)                         .. ..... .... ..... .... ..... ....                                                                                        25.1          25.1\nNon-current assets . .     .. .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          319           286\nCurrent assets . . . .     .. .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        1,016           951\nNon-current liabilities     . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            0           100\nCurrent liabilities . .    .. .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          738           809\nNet assets (100%) . .      .. .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          597           328\nCarrying amount of interest in associate . . . . . . . . . . . . . . . . . . . . . . . .                                                                                           1,163         1,095\nRevenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                4,231         3,693\nProfit / Loss after Tax (100%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                                       269           345\nGroup\u2019s share of total comprehensive income                                                   .. ..... .... ..... ....                                                                67            86\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6498503634031637, "height": 0.18512184694313805, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-7", "text": "Hasan Dermapharm Co. Ltd, Saigon, Vietnam:\n", "page_number": 281, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6665241556220607, "lower_right_x": 0.4443772672309553, "lower_right_y": 0.6806327490380505, "height": 0.0141085934159898, "width": 0.3270858524788392}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-8", "text": "     In 2007, Dermapharm invested in Hasan Dermapharm Co. Ltd. Currently, Dermapharm holds 30% of the\ncompany. Vietnam is characterised by an open market with the highest growth rate in southeast Asia. Hasan\nPharma operates a WHO-GMP certified production plant capable of producing nearly all drugs sold on the\nVietnamese market. The cooperation with Hasan Pharma should serve as a platform for entering the Asian\nmarket. Initially, the focus will be on Vietnam itself, but subsequently the focus would be expanded to\ncountries like Singapore, Malaysia and Cambodia. Dermapharm\u2019s contribution is the delivery of dossiers, which\nwill be adjusted to Vietnamese standards and submitted to the local regulatory authority. Following approval,\nlocal production will start; however, preparations that have been produced under license are distributed at\nhigher prices than products produced only locally.\n", "page_number": 281, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8165882855921334, "height": 0.1261222744762719, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-281-9", "text": "F-56", "page_number": 281, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-0", "text": "    The following table summarises Hasan Dermapharm Co. Ltd.\u2019s financial information as presented in its\nown financial statements:\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.08892689183411714, "height": 0.024369388627618643, "width": 0.7666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-1", "text": "                                                                                                        31 December   31 December   31 December   1 January\nkEUR                                                                                                        2016          2015          2014         2014\nPercentage ownership interest (%) . . . . . . . . . . .                                                         30            30            30            30\nNon-current assets . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        4,307         4,707         4,956        3,979\nCurrent assets . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        6,181         5,286         5,826        6,657\nNon-current liabilities     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            0             0             0            0\nCurrent liabilities . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          504           641           566        1,453\nNet assets (100%) . . . . . . . . . . . . . . . . . . . . .                                                  9,984         9,352        10,217        9,183\nCarrying amount of interest in associate . . . . .                                                           2,034         1,563         1,628        2,755\nRevenue . . . . . . . . . . . . . . . . . . . . . . . . . . .                                               13,698        12,476        12,724       10,915\nProfit / Loss after Tax (100%) . . . . . . . . . . . . .                                                     3,977         2,794         3,294        3,421\nGroup\u2019s share of total comprehensive income . .                                                              1,193           838           988        1,026\nExchange rate . . . . . . . . . . . . . . . . . . . . . . . .                                               29,340        26,354        24,844       29,340\n", "page_number": 282, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3099615220179564, "height": 0.20778110303548525, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-2", "text": "4.4 Investments\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.32791791363830697, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.3394613082513895, "height": 0.011543394613082514, "width": 0.12515114873035066}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-3", "text": "     Investments comprise interests in non-consolidated subsidiaries and associates, which are not accounted\nfor using the equity method.\n", "page_number": 282, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37665669089354425, "height": 0.02821718683197949, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-4", "text": "     As at 31 December 2016, the Group held 100% of the shares in Tiroler Nuss\u00f6l Sonnenkosmetik GmbH,\nKitzb\u00fchel, Austria, 40% of shares in Gynial AG, H\u00fcnenberg, Switzerland, and 100% of shares in East\nPharma AG, Gr\u00fcnwald. The interests are deemed immaterial and thus their not being consolidated results in a\ntrue and fair view of the assets, liabilities, financial position and profit or loss of the Group. As at 31 December\n2016, interests in non-consolidated subsidiaries and associates, which are not accounted for using the equity\nmethod, have a carrying amount of kEUR 262 (31 December 2015: kEUR 218; 31 December 2014: kEUR 461;\n1 January 2014: kEUR 797). The investments qualify as available-for-sale financial assets under IAS 39. They\nthus have to be measured at fair value in the statement of financial position. However, since the fair value of\nthese investments could not be measured reliably, they are measured at cost less impairment charges.\nDermapharm has no intention to dispose these investments.\n", "page_number": 282, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5267208208636169, "height": 0.14065840102607952, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-5", "text": "4.5 Other non-current financial assets\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5433946130825139, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.5536554082941428, "height": 0.010260795211628926, "width": 0.29020556227327693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-6", "text": "     Other non-current financial assets includes positive fair values of derivatives and capitalised life insurance\ncontracts by Anton H\u00fcbner GmbH & Co. KG. The positive fair values of derivatives recognised mainly result\nfrom a claim that Dermapharm AG has against Themis Beteiligungs AG to compensate for all future payments\npertaining to two currency-related swaps which Dermapharm AG concluded with Unicredit Bank in 2010. The\nswaps will expire in 2018 and 2020, respectively.\n", "page_number": 282, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6327490380504489, "height": 0.06883283454467726, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-7", "text": "     The positive fair values of held-for-trading derivatives recognised amounted to kEUR 10,125 as of\n31 December 2016 (31 December 2015: kEUR 13,314; 31 December 2014: kEUR 8,779; 1 January\n2014: kEUR 9,242). The corresponding negative fair value of the derivative is recognised in other non-current\nfinancial liabilities. In connection with the currency-related swaps, Dermapharm AG has filed a lawsuit against\nUnicredit Bank. For further information, please refer to 7.2c).\n", "page_number": 282, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7114151346729372, "height": 0.06883283454467726, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-282-8", "text": "F-57\n", "page_number": 282, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9345874305258658, "height": 0.011543394613082514, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-0", "text": "     Anton H\u00fcbner GmbH & Co. KG capitalised life insurance policies, which do not qualify as plan assets in\naccordance with IAS 19 and cannot be netted with future pension obligations. The carrying amount of\nkEUR 523 as at 31 December 2016 (31 December 2015: kEUR: 527; 31 December 2014: kEUR 426;\n1 January 2014: kEUR 399) is taken from an expert opinion.\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.11970927746900385, "height": 0.05515177426250535, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-1", "text": "    Furthermore, other non-current financial assets comprise deposits amounting to kEUR 10,648 as at\n31 December 2016 (31 December 2015: kEUR 13,841; 31 December 2014: kEUR 9,205; 1 January\n2014: kEUR 9,641).\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.16973065412569474, "height": 0.043608379649422824, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-2", "text": "4.6 Inventories\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.19495510902094912, "height": 0.01068832834544678, "width": 0.11608222490931076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-3", "text": "Inventories consist of the following:\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.21889696451474988, "height": 0.014108593415989718, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-4", "text": "                                                                                31 December   31 December   31 December   1 January\nkEUR                                                                                2016          2015          2014         2014\nRaw materials . .    ... ..... ...       . ..   .   .   .   .   .   .   .   .       30,775        24,519        22,394       27,591\nWork in progress     ... ..... ...       . ..   .   .   .   .   .   .   .   .        6,807         5,650         3,087        3,100\nFinished products    and merchandise       ..   .   .   .   .   .   .   .   .       47,000        46,743        45,665       36,825\nPrepayments . . .    ... ..... ...       . ..   .   .   .   .   .   .   .   .          197            45           370          726\nInventories . . . . . . . . . . . . . . . . . . . . . . . . .                       84,779        76,957        71,516       68,242\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2321504916631039, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.3317657118426678, "height": 0.0996152201795639, "width": 0.7666263603385731}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-5", "text": "     Inventories are measured at the lower of cost and net realisable value. Net realisable value is the estimated\nsales price less all estimated costs to complete and selling and marketing costs.\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3548525010688328, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.3817870884993587, "height": 0.026934587430525903, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-6", "text": "     The costs recognised as an expense for raw materials and consumables, labour costs and other costs\ntogether with the amount of the net change in inventories changed as follows:\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.38948268490808036, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.41727233860624197, "height": 0.02778965369816161, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-7", "text": "kEUR                                                                               2016        2015        2014\nCost of material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   (252,755)   (215,911)   (237,076)\nNet Increase in finished goods and work in progress . . . . . . . .                   1,008       2,888       8,301\nExpenses of the period . . . . . . . . . . . . . . . . . . . . . . . . . . .       (251,747)   (213,023)   (228,775)\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.4916631038905515, "height": 0.0645575032064985, "width": 0.7726723095525997}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-8", "text": "     In the financial years 2016, 2015 and 2014, write-downs of inventories had be to recognised for the\ndestruction of expired finished goods, destruction due to quality shortcomings in raw materials and other\ndefects.\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5532278751603249, "height": 0.040615647712697656, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-9", "text": "kEUR                                                                              2016      2015      2014\nRaw Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       732       447       767\nFinished Products and merchandise and work in progress . . . . .                    2,233     4,782     1,506\nWrite-downs of the period . . . . . . . . . . . . . . . . . . . . . . . .           2,965     5,229     2,273\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6310389055151774, "height": 0.06370243693886268, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-10", "text": "    The write-downs of inventories are recognised as decrease in finished goods and work in progress.\n    No inventories were pledged as securities for liabilities at the end of financial years 2016, 2015 and 2014.\n\n4.7 Trade accounts receivable\n", "page_number": 283, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7122702009405729, "height": 0.059427105600684094, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-11", "text": "     All trade receivables are due within one year and do not bear interest. The accounts receivable are in\ngeneral due within a payment period of between 30 and 120 days. There are no limitations of any kind on\nrights of disposal.\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.764856776400171, "height": 0.04360837964942288, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-12", "text": "                                                                31 December   31 December   31 December   1 January\nkEUR                                                                2016          2015          2014         2014\nTrade receivables . . . . . . . . . . . . . . . . . . . . . .       26,541        17,665        23,032       22,666\nLess: provision for impairment of trade receivables                   (239)         (242)         (241)        (278)\nTrade receivables net . . . . . . . . . . . . . . . . . .           26,302        17,423        22,791       22,388\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8520735356990167, "height": 0.07610089781958096, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-13", "text": "    As of 31 December 2016, trade receivables of kEUR 22,913 (31 December 2015: kEUR 14,480;\n31 December 2014: kEUR 18,708; 1 January 2014: kEUR 18,893) were fully performing.\n", "page_number": 283, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8717400598546388, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8986746472851646, "height": 0.02693458743052579, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-283-14", "text": "F-58", "page_number": 283, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-0", "text": "    As of 31 December 2016, trade receivables of kEUR 3,378 (31 December 2015: kEUR 2,929;\n31 December 2014: kEUR 4,069; 1 January 2014: kEUR 3,454) were past due but not impaired. These relate to\na number of independent customers for whom there is no recent history of default.\n", "page_number": 284, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.10602821718683197, "height": 0.04147071398033347, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-1", "text": "The maturity analysis of these trade receivables is as follows:\n", "page_number": 284, "bounding_box": {"top_left_x": 0.15114873035066506, "top_left_y": 0.11244121419410004, "lower_right_x": 0.5840386940749698, "lower_right_y": 0.12654980761008977, "height": 0.014108593415989731, "width": 0.4328899637243047}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-2", "text": "                                                                  31 December   31 December   31 December   1 January\nkEUR                                                                  2016          2015          2014         2014\nUp to 1 month . . . . . . . . . . . . . . . . . . . . . . .            1,780         1,290         1,683        2,048\n1 to 2 months . . . . . . . . . . . . . . . . . . . . . . . .            331           272           492          306\n2 to 3 months . . . . . . . . . . . . . . . . . . . . . . . .            247           (30)        1,001          209\nOver 3 months . . . . . . . . . . . . . . . . . . . . . . .            1,020         1,397           893          891\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . .        3,378         2,929         4,069        3,454\n", "page_number": 284, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.2394185549380077, "height": 0.09961522017956392, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-3", "text": "    The Group companies in Germany have a solvent customer base with high credit ratings, and defaults\namong them are extremely rare. For all of the overdue receivables, instalments have been agreed upon, which\nwere/will all be paid.\n", "page_number": 284, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2625053441641727, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.30354852501068835, "height": 0.04104318084651565, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-4", "text": "     As of the balance sheet date, there were some debtors which were not able to meet their payment\nobligations.\n", "page_number": 284, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3386062419837537, "height": 0.02778965369816161, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-5", "text": "Past due and impaired trade receivables consisted of the following:\n", "page_number": 284, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.3450192389910218, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.3591278324070115, "height": 0.01410859341598969, "width": 0.4740024183796856}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-6", "text": "                                                                                                              31 December   31 December   31 December   1 January\nkEUR                                                                                                              2016          2015          2014         2014\nUp to 1 month     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014             \u2014             \u2014            \u2014\n1 to 2 months .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014             \u2014             \u2014            \u2014\n2 to 3 months .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014             \u2014             \u2014            \u2014\nOver 3 months     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          250           256           255          319\nTotal   . ..... .... ..... .... .... ..... .                                                                         250           256           255          319\n", "page_number": 284, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4715690466011116, "height": 0.09918768704574604, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-7", "text": "     Only those receivables are impaired where the customer is already insolvent or where the customer has\nfiled for insolvency.\n", "page_number": 284, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5224454895254382, "height": 0.026934587430525903, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-8", "text": "The carrying amounts of the Group\u2019s trade receivables were denominated in the following currencies:\n", "page_number": 284, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.529713552800342, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.5438221462163317, "height": 0.01410859341598969, "width": 0.7164449818621523}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-9", "text": "                                                                                                                               31 December   31 December   31 December   1 January\nkEUR                                                                                                                               2016          2015          2014         2014\nEUR    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       22,915        15,038        18,558       17,352\nCHF    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          188           309           360          456\nHRK    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        2,112         1,209         3,191        4,096\nPLN    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        1,326         1,109           923          762\n", "page_number": 284, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6361693031209918, "height": 0.08251389482684901, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-10", "text": "The Group\u2019s provision for impairment of trade receivables changed as follows:\n", "page_number": 284, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.6528430953398888, "lower_right_x": 0.7037484885126964, "lower_right_y": 0.6660966224882429, "height": 0.013253527148354038, "width": 0.5519951632406287}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-11", "text": "kEUR                                                                                       2016       2015       2014\nAt 1 January . . . . . . . . . . . . . . . . . . . . . . . . . . .   ...   .   .   .   .      (242)      (241)      (278)\nProvision for receivables impairment . . . . . . . . . . . .         ...   .   .   .   .        \u2014          (1)        \u2014\nReceivables written off during the year as uncollectible              ..   .   .   .   .         3         \u2014          37\nUnused amounts reversed . . . . . . . . . . . . . . . . . . .        ...   .   .   .   .        \u2014          \u2014          \u2014\nAt 31 December . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                  (239)      (242)      (241)\n", "page_number": 284, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.7687045746045319, "height": 0.10218041898247121, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-284-12", "text": "F-59", "page_number": 284, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-0", "text": "4.8 Other current assets and other current financial assets\n    The other current assets consisted of the following:\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.5610640870616687, "lower_right_y": 0.09876015391192818, "height": 0.034202650705429674, "width": 0.44558645707376054}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-1", "text": "                                                                                          31 December   31 December   31 December   1 January\nkEUR                                                                                          2016          2015          2014         2014\nReceivables from related parties          .   .   .   .   .   .   .   .   .   .   .   .       39,809        42,400        58,638       82,589\nSuppliers with debit balances . .         .   .   .   .   .   .   .   .   .   .   .   .          130            66            \u2014           418\nDeposits . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .           30            29           120          120\nDerivatives . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .            7             4            52          182\nOther current financial assets . . . . . . . . . . . . .                                      39,976        42,499        58,810       83,309\nPrepaid expenses . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .        1,022           638           698          772\nVAT receivables . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .          139           485           770          889\nRefund Claims . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .          138           168           323          632\nReceivables from personnel . . .          .   .   .   .   .   .   .   .   .   .   .   .           46            63            52           63\nReceivables from social security          .   .   .   .   .   .   .   .   .   .   .   .           22            22            15           25\nGovernment grants . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .           \u2014             \u2014            228          251\nOther . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .          325            69           957          300\nOther current assets . . . . . . . . . . . . . . . . . . .                                     1,692         1,445         3,043        2,932\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10902094912355707, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.33561351004702866, "height": 0.22659256092347158, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-2", "text": "    Prepaid expenses consist of payments made for services not rendered until after the balance sheet date.\n     Other current financial assets comprise the fair values of foreign exchange forwards and options entered\ninto by Axicorp GmbH, which will be settled within one year.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.048311244121419405, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-3", "text": "     As at 31 December 2015, receivables from related parties amounting to kEUR 42,400 were recognised,\nwhereof receivables from the sale of companies amounting to kEUR 6,534 were past due but not impaired. The\nreceivable results from the sale of shares between Centuere AG and Channel 21 Holding. All other receivables\nfrom related parties were fully performing. For detailed information regarding the receivables from related\nparties, please refer to 8.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.48525010688328346, "height": 0.07182556648140231, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-4", "text": "    The receivables from government grants recognised in other current assets as at 31 December 2014\n(kEUR 228) and 31 December 2013 (kEUR 251) relate to an assured but not yet received grant.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4920906370243694, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.519880290722531, "height": 0.027789653698161554, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-5", "text": "4.9 Cash and cash equivalents\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.529713552800342, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.5421120136810603, "height": 0.012398460880718276, "width": 0.23216444981862155}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-6", "text": "                                                               31 December   31 December   31 December   1 January\nkEUR                                                               2016          2015          2014         2014\nCash at banks and cash equivalents . . . . . . . . . .              3,806         2,774        11,627        4,125\nCash on hand . . . . . . . . . . . . . . . . . . . . . . . .           10            17            18          540\nCash and cash equivalents . . . . . . . . . . . . . . .             3,816         2,791        11,645        4,665\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.629328772979906, "height": 0.07567336468576313, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-7", "text": "     The Group maintains credit facilities with various German and international banks. For information about\nthe utilisation of these credit facilities at the respective balance sheet date, please refer to 6.1c).\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.675502351432236, "height": 0.02949978623343308, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-8", "text": "4.10 Equity\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6904660111158615, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.7041470713980333, "height": 0.013681060282171864, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-9", "text": "     The issued capital of the parent company consists of 524,800 registered shares with restricted\ntransferability and a par value of EUR 2.56, with one share representing one voting right. Preference shares or\ndifferent classes of shares do not exist. The issued capital is fully paid in.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7524583155194527, "height": 0.04147071398033342, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-10", "text": "The capital reserve includes the premium from the issuing of shares.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1505441354292624, "top_left_y": 0.7622915775972637, "lower_right_x": 0.6330108827085853, "lower_right_y": 0.7751175716118, "height": 0.012825994014536213, "width": 0.4824667472793229}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-11", "text": "     Retained earnings are the result of profits and losses carried forward from the previous reporting periods\nand the profit for the 2016 period. Effects from the first time adoption of IFRS were also included in retained\nearnings.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8242838820008551, "height": 0.04147071398033353, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-285-12", "text": "F-60", "page_number": 285, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-0", "text": "     Other reserves contain kEUR 1,801 in currency translation differences as at 31 December 2016\n(31 December 2015: kEUR 1,852; 31 December 2014: kEUR 313; 1 January 2014: kEUR 0) and kEUR \u20133,104\nin cumulated actuarial gains/losses from the remeasurement of defined benefit pension plans (31 December\n2015: kEUR \u20132,046; 31 December 2014: kEUR \u20132,527; 1 January 2014: kEUR 0). Moreover, as at\n31 December 2016, deferred taxes of kEUR 352 were recognised in other comprehensive income in the amount\nof kEUR 351 for actuarial gains/losses from the remeasurement of defined benefit pension plans (31 December\n2015: kEUR 247; 31 December 2014: kEUR 283; 1 January 2014: kEUR 0).\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1628901239846088, "height": 0.09833262077811031, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-1", "text": "     In 2015, Dermapharm GmbH, Vienna, Austria, increased its stake in Melasan GmbH, Salzburg, Austria,\nby 25% to 100% for kEUR 1,850 in cash, which was paid in financial year 2016. Melasan GmbH had already\nbeen fully consolidated in the prior year when Dermapharm held a 75% stake in the company. There is no\nchange in the basis of consolidation or presentation in the IFRS consolidated financial statements. The carrying\namount of Melasan GmbH\u2019s net assets in the Group\u2019s consolidated financial statements on the date of\nacquisition was kEUR 1,930. The Group recognised a decrease in NCI of kEUR 483 and a decrease in retained\nearnings of kEUR 1,367.\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17058572039333048, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.26934587430525864, "height": 0.09876015391192816, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-2", "text": "     The Group also acquired an additional stake of 2.9% in Farmal d.d., Ludberg, Croatia, in 2015 and\nincreased its stake to 100% for kEUR 93 in cash. Farmal d.d. had already been fully consolidated in the prior\nyear when the Group held a 97.1% stake in the company. There is no change in the basis of consolidation or\npresentation in the IFRS consolidated financial statements. The carrying amount of Farmal d.d.\u2019s net assets in\nthe Group\u2019s consolidated financial statements on the date of acquisition was kEUR \u201310,369. The Group\nrecognised an increase in NCI of kEUR 301 and a decrease in retained earnings of kEUR 403.\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.36169303120991875, "height": 0.0850790936297563, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-3", "text": "     In February 2016, the Group acquired 75.1% of Remedix GmbH. As a result of this transaction, the Group\nrecognised an increase in NCI of kEUR 283. Please also refer to section 2.7 for further details.\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.39675074818298417, "height": 0.02778965369816161, "width": 0.7672309552599759}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-4", "text": "For information on the change in equity, please refer to the consolidated statement of changes in equity.\n", "page_number": 286, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.4031637451902522, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41727233860624197, "height": 0.014108593415989745, "width": 0.7285368802902056}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-5", "text": "4.11 Provisions for pensions\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.427105600684053, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.4395040615647713, "height": 0.012398460880718276, "width": 0.2079806529625151}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-6", "text": "4.11 Provisions for pensions\n    The amount of the provisions for pensions recognised as of the reporting date for the company with plan\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43993159469858917, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4719965797349295, "height": 0.03206498503634031, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-7", "text": "Net defined benefit liability with plan assets:\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4886703719538264, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.5027789653698161, "height": 0.014108593415989745, "width": 0.31741233373639666}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-8", "text": "                                                              31 December   31 December   31 December   1 January\nkEUR                                                              2016          2015          2014         2014\nDefined benefit obligation . . . . . . . . . . . . . . . .           799           713           751          556\nFair Value of plan assets . . . . . . . . . . . . . . . . .          495           556           575          544\nLimit on a defined benefit asset . . . . . . . . . . . .              \u2014             \u2014             \u2014            \u2014\nTotal   . ..... .... ..... .... .... ..... .                         304           157           176            12\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6023941855493801, "height": 0.08636169303120989, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-9", "text": "     The amount of the provisions for pensions recognised as of the reporting date for the companies without\nplan assets is as follows:\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6152201795639162, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6430098332620778, "height": 0.027789653698161665, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-10", "text": "Net defined benefit liability without plan assets:\n                                                                 31 December   31 December   31 December   1 January\nkEUR                                                                 2016          2015          2014         2014\nDefined benefit obligation . . . . . . . . . . . . . . . .           12,946        11,924        12,269        9,732\nTotal    . ..... .... ..... .... .... ..... .                        12,946        11,924        12,269        9,732\n\n\nExpenses for defined benefit plans were as follows:\n                                                                 31 December   31 December   31 December   1 January\nkEUR                                                                 2016          2015          2014         2014\nCurrent service cost . . . . . . . . . . . . . . . . . . . .            159           170           133            \u2014\nPast service cost . . . . . . . . . . . . . . . . . . . . . .            \u2014             \u2014             \u2014             \u2014\nNet interest . . . . . . . . . . . . . . . . . . . . . . . . .          283           267           345            \u2014\n", "page_number": 286, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8687473279179136, "height": 0.20906370243693884, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-286-11", "text": "F-61", "page_number": 286, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-287-0", "text": "     The following table shows the reconciliation from the opening balances to the closing balances for the net\ndefined benefit liability and its components:\n", "page_number": 287, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.09191962377084224, "height": 0.027362120564343742, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-287-1", "text": "                                                                                                   Defined                      Net defined\n                                                                                                   Benefit      Fair Value of     benefit\nkEUR                                                                                              Obligation     plan assets     liability\nAs of 1 January 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . .                            10,289            544          9,744\nProfit or Loss\nCurrent service cost . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .          133              \u2014            133\nPast service cost . . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .           \u2014               \u2014             \u2014\nGains (\u2013) / losses from settlements . . . . . . . . . . . . .         .   .   .   .   .   .   .           \u2014               \u2014             \u2014\nInterest expense . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .          364              \u2014            364\nInterest income . . . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .           \u2014               19           (19)\nRemeasurement\nActuarial Gain (\u2013) / Loss (+)\n   thereof due to changes in financial assumptions . . .              .... .              ..           2,626              \u2014          2,626\n   thereof due to changes in demographic assumptions                  .... .              ..              \u2014               \u2014             \u2014\n   thereof due to experience adjustments . . . . . . . . .            .... .              ..             (97)             \u2014            (97)\nReturn on plan assets excluding amounts recognised as                 interest\n   income . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .... .              ..              \u2014                2             (2)\nRemeasurement of asset ceiling . . . . . . . . . . . . . . .          .... .              ..              \u2014               \u2014              \u2014\nOthers\nTransfers . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nAcquisitions / Divestments (\u2013) . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nEmployer contributions . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               13            (13)\nEmployee contributions . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               15            (15)\nPlan assets administration cost . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nTaxes and duties . . . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nSettlement service . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nRetirement benefits . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .         (294)            (19)          (275)\nAs of 31 December 2014 . . . . . . . . . . . . . . . . . . . . . . . . .                              13,020            575         12,445\n", "page_number": 287, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.5019238991021804, "height": 0.3997434801197092, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-287-2", "text": "F-62", "page_number": 287, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-288-0", "text": "                                                                                                   Defined                      Net defined\n                                                                                                   Benefit      Fair Value of     benefit\nkEUR                                                                                              Obligation     plan assets     liability\nAs of 1 January 2015 . . . . . . . . . . . . . . . . . . . . . . . . . . .                            13,020            575         12,445\nProfit or Loss\nCurrent service cost . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .          170              \u2014            170\nPast service cost . . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .           \u2014               \u2014             \u2014\nGains (\u2013) / losses from settlements . . . . . . . . . . . . .         .   .   .   .   .   .   .           \u2014               \u2014             \u2014\nInterest expense . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .          279              \u2014            279\nInterest income . . . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .           \u2014               12           (12)\nRemeasurement\nActuarial Gain (\u2013) / Loss (+)\n   thereof due to changes in financial assumptions . . .              .... .              ..            (423)             \u2014            (423)\n   thereof due to changes in demographic assumptions                  .... .              ..              \u2014               \u2014              \u2014\n   thereof due to experience adjustments . . . . . . . . .            .... .              ..             (33)             \u2014             (33)\nReturn on plan assets excluding amounts recognised as                 interest\n   income . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .... .              ..              \u2014               23            (23)\nRemeasurement of asset ceiling . . . . . . . . . . . . . . .          .... .              ..              \u2014               \u2014              \u2014\nOthers\nTransfers . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nAcquisitions / Divestments (\u2013) . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nEmployer contributions . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               12            (12)\nEmployee contributions . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               15            (15)\nPlan assets administration cost . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nTaxes and duties . . . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nSettlement service . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nRetirement benefits . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .         (376)            (82)          (294)\nAs of 31 December 2015 . . . . . . . . . . . . . . . . . . . . . . . . .                              12,636            556         12,080\n\n                                                                                                   Defined                      Net defined\n                                                                                                   Benefit      Fair Value of     benefit\nkEUR                                                                                              Obligation     plan assets     liability\nAs of 1 January 2016 . . . . . . . . . . . . . . . . . . . . . . . . . . .                            12,636            556         12,080\nProfit or Loss\nCurrent service cost . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .          159              \u2014            159\nPast service cost . . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .           \u2014               \u2014             \u2014\nGains (\u2013) / losses from settlements . . . . . . . . . . . . .         .   .   .   .   .   .   .           \u2014               \u2014             \u2014\nInterest expense . . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .          296              \u2014            296\nInterest income . . . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .           \u2014               13           (13)\nRemeasurement\nActuarial Gain (\u2013) / Loss (+)\n   thereof due to changes in financial assumptions . . .              .... .              ..           1,185              \u2014          1,185\n   thereof due to changes in demographic assumptions                  .... .              ..              \u2014               \u2014             \u2014\n   thereof due to experience adjustments . . . . . . . . .            .... .              ..            (194)             \u2014           (194)\nReturn on plan assets excluding amounts recognised as                 interest\n   income . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .... .              ..              \u2014              (66)            66\nRemeasurement of asset ceiling . . . . . . . . . . . . . . .          .... .              ..              \u2014               \u2014              \u2014\nOthers\nTransfers . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nAcquisitions / Divestments (\u2013) . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nEmployer contributions . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014                9             (9)\nEmployee contributions . . . . . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .           \u2014               10            (10)\nPlan assets administration cost . . . . . . . . . . . . . . . .       .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nTaxes and duties . . . . . . . . . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nSettlement service . . . . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .           \u2014               \u2014              \u2014\nRetirement benefits . . . . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .         (338)            (28)          (310)\nAs of 31 December 2016 . . . . . . . . . . . . . . . . . . . . . . . . .                              13,745            495         13,250\n", "page_number": 288, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8824283882000855, "height": 0.82129115006413, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-288-1", "text": "F-63", "page_number": 288, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-0", "text": "      There were no exchange differences because all provisions for pensions were realised within German\nentities.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.08892689183411714, "height": 0.024369388627618643, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-1", "text": "Composition of plan assets:\n                                                                 31 December   31 December   31 December   1 January\nkEUR                                                                 2016          2015          2014         2014\nSecurity funds . . . . . . . . . . . . . . . . . . . . . . . .          495           556           575          544\nTotal    . ..... .... ..... .... .... ..... .                           495           556           575          544\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10602821718683197, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1911073108165883, "height": 0.08507909362975632, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-2", "text": "All security funds have quoted prices in active markets.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.20478837109876016, "lower_right_x": 0.5423216444981862, "lower_right_y": 0.21889696451474988, "height": 0.014108593415989718, "width": 0.3929866989117291}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-3", "text": "Risk resulting from pension obligations:\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2321504916631039, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.24625908507909364, "height": 0.014108593415989745, "width": 0.28597339782345826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-4", "text": "     The risks from defined benefit plans arise partly from the defined benefit obligations and partly from the\ninvestment in plan assets. The risks result from the possibility that higher direct pension payments will have to\nbe made to the beneficiaries.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2526720820863617, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2941427960666952, "height": 0.04147071398033347, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-5", "text": "Demographic/biometric risks:\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.32492518170158186, "height": 0.014108593415989745, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-6", "text": "     Since a large proportion of the defined benefit obligations comprises lifelong pension payments to retirees\nor surviving dependents, pensions, longer claim periods or earlier claims may result in higher benefit\nobligations, higher benefit expense and/or higher pension payments than previously anticipated.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.3745190252244549, "height": 0.04318084651560494, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-7", "text": "Investment risks:\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.39333048311244123, "height": 0.010688328345446807, "width": 0.1215235792019347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-8", "text": "     If the actual return on plan assets were below the return anticipated on the basis of the discount rate, the\nnet defined benefit liability would increase, assuming there were no changes in other parameters. This could\nhappen as a result of a drop in share prices, increases in market rates of interest, default of individual debtors or\nthe purchase of low-risk but low-interest bonds, for example.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4031637451902522, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4583155194527576, "height": 0.05515177426250539, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-9", "text": "Interest-rate risks:\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.48567764001710134, "height": 0.010688328345446807, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-10", "text": "     A decline in capital market interest rates, especially for high-quality corporate bonds, would increase the\ndefined benefit obligation. This effect would be at least partially offset by the ensuing increase in the market\nvalues of the debt instruments held.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5352714835399743, "height": 0.039760581445062004, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-11", "text": "     The following were the principal actuarial assumptions at the reporting date (expressed as weighted\naverages):\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5733219324497648, "height": 0.026507054296707966, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-12", "text": "                                                                 31 December   31 December   31 December   1 January\nin %                                                                 2016          2015          2014         2014\nDiscount rate . . . . . . . . . . . . . . . . . . . . . . . .            1.7           2.2           2.0          3.4\nSalary trend . . . . . . . . . . . . . . . . . . . . . . . . .           0.7           0.7           0.7          0.7\nPension trend . . . . . . . . . . . . . . . . . . . . . . . .            2.3           2.3           2.3          2.3\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5737494655835828, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6498503634031637, "height": 0.07610089781958096, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-13", "text": "The sensitivity of the total pension commitments to changes in the average assumptions is as follows:\n", "page_number": 289, "bounding_box": {"top_left_x": 0.15114873035066506, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.6737922188969645, "height": 0.01410859341598969, "width": 0.7194679564691657}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-14", "text": "Defined\nBenefit                  Changes in           Impact             Impact             Impact            Impact\nObligation                Actuarial      31 December 2016   31 December 2015   31 December 2014   1 January 2014\nkEUR                     assumptions      DBO     Change     DBO     Change     DBO     Change    DBO     Change\nDiscount rate   . ..   1,00% increase    11,702   (2,043)   10,806   (1,830)   11,056   (1,964)    8,400   (1,332)\n                       1,00% decrease    16,378    2,633    14,985    2,348    15,560    2,540    11,423    1,691\nSalary trend . . . .   0,50% increase    13,632       38    12,514       36    12,890       41     9,592       30\n                       0,50% decrease    13,558      (36)   12,444      (34)   12,809      (39)    9,535      (28)\nPension trend . . .    0,50% increase    14,440      846    13,226      748    13,632      783    10,087    5,239\n                       0,50% decrease    12,820     (774)   11,792     (686)   12,130     (718)    9,080     (483)\nLife expectancy . .    1 year increase   13,852      107    12,729       93    13,119       98     9,786       53\n                       1 year decrease   12,866      (80)   11,853      (71)   12,195      (75)    9,678      (54)\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.837964942283027, "height": 0.15091919623770844, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-15", "text": "    As of 31 December 2016, the weighted duration of the pension obligations amounts to 14 years\n(31 December 2015: 14 years; 31 December 2014: 14 years).\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.847798204360838, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8743052586575459, "height": 0.026507054296707966, "width": 0.7672309552599759}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-289-16", "text": "F-64", "page_number": 289, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-0", "text": "     The above sensitivity analysis is based on the change in one assumption, with all other factors remaining\nconstant. Changes in several assumptions can be correlated. The same method was used to calculate the\nsensitivity of defined benefit obligations to actuarial assumptions as was used to calculate the provisions for\npensions in the statement of financial position.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.11970927746900385, "height": 0.05515177426250535, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-1", "text": "4.12 Other provisions\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13638306968790082, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.14920906370243694, "height": 0.01282599401453613, "width": 0.15961305925030234}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-2", "text": "                                                                                                                  Current              Non-current\n                                                                                                        discounts\n                                                                                                        to health                       Onerous\nkEUR                                                                                                    insurance       Litigations     Contracts     Total\nAt 1 January 2014 . . . . . . . . . . . . . . . . . . . .                                                    4,875              694             64      5,633\nAdditions . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        5,482              640             78      6,200\nRelease . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014                \u2014              \u2014           0\nUtilisation . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       (4,875)            (693)           (64)    (5,632)\nExchange differences        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014                (5)            \u2014          (5)\nAt 31 December 2014 . . . . . . . . . . . . . . . . . .                                                      5,482              636             78      6,196\nAt 1 January 2015 . . . . . . . . . . . . . . . . . . . .                                                    5,482              636             78      6,196\nAdditions . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        5,950              456             \u2014       6,406\nRelease . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014                \u2014              \u2014           0\nUtilisation . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       (5,482)            (642)           (78)    (6,202)\nExchange differences        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014                 5             \u2014           5\nAt 31 December 2015 . . . . . . . . . . . . . . . . . .                                                      5,950              455             \u2014       6,405\nAt 1 January 2016 . . . . . . . . . . . . . . . . . . . .                                                    5,950              455             \u2014       6,405\nAdditions . . . . . . . . . . . . . . . . . . . . . . . . . . .                                              6,418              534             \u2014       6,952\nRelease . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                 \u2014                \u2014              \u2014           0\nUtilisation . . . . . . . . . . . . . . . . . . . . . . . . . .                                             (5,950)            (458)            \u2014      (6,408)\nExchange differences . . . . . . . . . . . . . . . . . . .                                                      \u2014                 2             \u2014           2\nAt 31 December 2016 . . . . . . . . . . . . . . . . . .                                                      6,418              533             \u2014       6,951\n", "page_number": 290, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1496365968362548, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.51004702864472, "height": 0.36041043180846516, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-3", "text": "     Other provisions include provisions for discounts to health insurances, provisions for litigations and\nprovisions for onerous contracts.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.533133817870885, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5604959384352287, "height": 0.027362120564343728, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-4", "text": "    As a consequence of regulatory state interventions on the pharmaceutical market in Germany, the Group\ncompanies are obliged to negotiate discount agreements with health insurance organisations.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5951261222744763, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-5", "text": "     Expenses from the creation of these provisions are considered in sales and charged against income. For\nthis purpose, expenses are estimated based on the relevant underlying two-year discount agreement and\ninformation gathered from a database, which tracks the historical volumes of drugs reimbursed by each\ninsurance company. Actual expenses for these discounts may differ from the estimate and sales would\naccordingly be higher or lower. Billing of the discounts and thus utilisation of provisions for discounts to health\ninsurance is generally expected within the next twelve months.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6874732791791364, "height": 0.08593415989739206, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-6", "text": "     Provisions for litigations mainly refer to the estimated financial outcome due to an indictment filed by the\nCroatian governmental agency \u201cUSKOK\u201d against Farmal d.d. regarding criminal activities involving bribery in\n2012. In 2015, Farmal d.d. was ordered to pay a fine which resulted in the full utilisation of the provision in\nthe following years. Furthermore, another provision for litigation is recognised for a compensation claim of a\nformer employee of Farmal d.d.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7661393758016246, "height": 0.0722530996152202, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-7", "text": "    Provisions for onerous contracts were recognised for vacancy costs for a building rented by Axicorp ApS\nin Denmark.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8003420265070543, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-290-8", "text": "F-65", "page_number": 290, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-0", "text": "4.13 Financial liabilities\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.28960096735187424, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.17412333736396612}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-1", "text": "    The principle sources of liquidity were cash inflows from on-going business operations as well as short-,\nmedium- and long-term loans.\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11286874732791792, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-2", "text": "Non-current financial liabilities:\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.11928174433518597, "lower_right_x": 0.3422007255139057, "lower_right_y": 0.13168020521590423, "height": 0.012398460880718262, "width": 0.2249093107617896}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-3", "text": "Non-current financial liabilities:\n                                                                                                        31 December   31 December   31 December   1 January\nkEUR                                                                                                        2016          2015          2014         2014\nBank loans . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        2,713        12,466        22,228       38,531\nPromissory note loans       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       87,680       127,514       127,984       50,995\nLeasing liabilities . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          143           137           337          324\nParticipation rights . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        6,360        10,956        10,981       10,981\nNon-current financial liabilities . . . . . . . . . . . .                                                   96,896       151,073       161,530      100,831\n\n\nCurrent financial liabilities:\n                                                                                                        31 December   31 December   31 December   1 January\nkEUR                                                                                                        2016          2015          2014         2014\nBank loans . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       14,660         9,997        13,113       16,525\nPromissory note loans       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       40,413           916           600          600\nLeasing liabilities . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .          112           235           189          151\nParticipation rights . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        5,831         1,323         1,318        1,318\nBank overdrafts . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        4,867        12,435         5,162       33,524\nCurrent financial liabilities . . . . . . . . . . . . . . .                                                 65,883        24,906        20,382       52,118\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13210773834972211, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4082941427960667, "height": 0.27618640444634457, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-4", "text": "     For the long-term financing of the Group, Dermapharm took out a promissory note loan in 2012 and\nanother one in 2014, for nominal values amounting to kEUR 50,000 and kEUR 78,000, respectively. The notes\nmature in 2017, 2019 and 2021. This enables the Group to secure the current extremely low interest rates for\nthe coming years as well.\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.430525865754596, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.48567764001710134, "height": 0.05515177426250534, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-5", "text": "     Dermapharm has also issued participation rights, which mature in 2017 and 2018. Throughout their term,\nparticipation certificate holders receive constant guaranteed remuneration as well as a potential profit share of\n2% of the nominal amount, while also participating in any losses up to the nominal amount.\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5365540829414279, "height": 0.04104318084651559, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-6", "text": "4.14 Trade accounts payable\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5502351432235998, "lower_right_x": 0.3282950423216445, "lower_right_y": 0.5643437366395896, "height": 0.0141085934159898, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-7", "text": "     Trade accounts payables become due within one year and do not bear interest. The item also includes all\ntrade payables not invoiced as of the balance sheet date. They generally become due for payment within 0 to\n60 days.\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6156477126977341, "height": 0.04489097905087647, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-8", "text": "4.15 Other non-current liabilities", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.6395895681915349, "height": 0.010688328345446862, "width": 0.24667472793228534}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-9", "text": "     Other non-current financial liabilities mainly comprise the fair values of held-for-trading derivatives. As\nmentioned in 4.4, Dermapharm AG recognises the negative fair value of two currency-related swaps within\nother non-current financial liabilities. Moreover, other non-current financial liabilities include the negative fair\nvalues of interest rate swaps. The negative fair value of derivatives amounted to kEUR 10,464 as at\n31 December 2016 (31 December 2015: kEUR 14,050; 31 December 2014: kEUR 9,946; 1 January\n2014: kEUR 10,491).\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.735356990166738, "height": 0.08593415989739206, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-10", "text": "     Other non-current liabilities mainly comprise government grants. The government grants relating to assets\nare presented as deferred income in accordance with IAS 20.24 and had a carrying amount of kEUR 11,495 as\nof 31 December 2016 (31 December 2015: kEUR 13,232; 31 December 2014: kEUR 15,469; 1 January\n2014: kEUR 18,826).\n", "page_number": 291, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7994869602394186, "height": 0.05771697306541257, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-291-11", "text": "F-66", "page_number": 291, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-0", "text": "4.16 Other current liabilities and other current financial liabilities\n    The other current financial liabilities and the other current liabilities were composed as follows:\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8264812575574365, "lower_right_y": 0.09833262077811031, "height": 0.03377511757161181, "width": 0.7110036275695284}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-1", "text": "                                                                                                31 December   31 December   31 December   1 January\nkEUR                                                                                                2016          2015          2014         2014\nLiabilities to related parties      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        4,278           470        28,448       77,555\nDerivatives . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           18            67           157           41\nPurchase price liability . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014          1,850            \u2014            \u2014\nEarn out liabilities . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           \u2014             \u2014          2,000           \u2014\nOther . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .            7             2            \u2014            \u2014\nOther current financial liabilities                     .... ..... .                                 4,303         2,389        30,605       77,596\nVAT payables . . . . . . . . . . . .            .   .   .   .   .   .   .   .   .   .   .   .        5,073         2,295         4,394        1,057\nOther personnel-related liabilities             .   .   .   .   .   .   .   .   .   .   .   .        3,128         2,487         2,385        2,107\nGovernment grants . . . . . . . . .             .   .   .   .   .   .   .   .   .   .   .   .        1,737         2,238         3,357        2,323\nPrepayments received . . . . . . .              .   .   .   .   .   .   .   .   .   .   .   .          340           332            46           91\nPrepaid income . . . . . . . . . . .            .   .   .   .   .   .   .   .   .   .   .   .           86           164           208          110\nOther . . . . . . . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .          619           705         1,053        1,837\nOther current liabilities . . . . . . . . . . . . . . . . .                                         10,983         8,221        11,443        7,525\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10902094912355707, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.33561351004702866, "height": 0.22659256092347158, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-2", "text": "    Other current liabilities have a maturity of up to one year and do not bear interest. For further information\nconcerning the liabilities to related parties, please refer to 8.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.38563488670371954, "height": 0.026934587430525847, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-3", "text": "    Derivatives comprise the negative fair values of foreign exchange forwards and options entered into by\nAxicorp GmbH to hedge the risk from exchange rate fluctuations. The earn-out liability of kEUR 2,000 as at\n31 December 2014 was recognised in the course of the acquisition of Naturwohl Vertriebs GmbH (LactoStop).\nThe prerequisites for the payment were fulfilled in financial year 2015 and the payment was made to the\nformer shareholder in the same year.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4638734501923899, "height": 0.07097050021376655, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-4", "text": "     Current government grants comprise the portion of government grants which will be reversed in the course\nof the next 12 months.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4959384352287302, "height": 0.024369388627618616, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-5", "text": "Prepaid income relates to payments that have been received, but were not delivered.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.506626763574177, "lower_right_x": 0.7448609431680774, "lower_right_y": 0.519880290722531, "height": 0.013253527148353927, "width": 0.5931076178960096}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-6", "text": "    Personnel-related liabilities comprise holiday accruals, income and church taxes due, liabilities for bonuses\nand company pensions and other submissions related to personnel.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5292860196665241, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.55622060709705, "height": 0.026934587430525903, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-7", "text": "4.17 Income taxes and deferred taxes\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5707567336468576, "lower_right_x": 0.39117291414752114, "lower_right_y": 0.5814450619923044, "height": 0.010688328345446751, "width": 0.2750906892382104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-8", "text": "     Income taxes include taxes on income and earnings paid or owed in the individual countries as well as\ndeferred tax assets or liabilities.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.619067977768277, "height": 0.027789653698161665, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-9", "text": "The significant components of income tax expenses for the financial years 2016, 2015 and 2014 were\n", "page_number": 292, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.628901239846088, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6417272338606242, "height": 0.012825994014536213, "width": 0.7327690447400241}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-10", "text": "composed as follows:\nkEUR                                                                  2016      2015      2014\nCurrent income taxes\nCurrent income taxes . . . . .         .. ..... .... ..... .... ...     3,409     1,878     2,395\nSubtotal . . . . . . . . . . . . . .   .. ..... .... ..... .... ...     3,409     1,878     2,395\nDeferred taxes\nFrom temporary differences .           .. ..... .... ..... .... ...     2,043     1,042      (151)\nFrom tax loss carried forward          .. ..... .... ..... .... ...       419        \u2014         \u2014\nSubtotal . . . . . . . . . . . . . .   .. ..... .... ..... .... ...     2,462     1,042      (151)\nTotal income taxes        .... .... ..... .... ..... .... ...           5,871     2,920     2,244\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6421547669944421, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8033347584437794, "height": 0.16117999144933737, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-11", "text": "     For the calculation of the current taxes as well as deferred tax assets and liabilities for the foreign\nsubsidiaries, tax rates of between 12% and 29% were applied. In calculating deferred tax assets and liabilities,\nthe tax rates valid at the time of realising the asset or repaying the liability were applied. The Group\u2019s deferred\ntax assets and liabilities were measured on the basis of Dermapharm AG\u2019s total tax rate of 24.23% for all\nfinancial years presented.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8926891834117144, "height": 0.06883283454467726, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-292-12", "text": "F-67\n", "page_number": 292, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9345874305258658, "height": 0.011543394613082514, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-0", "text": "     The following overview explains how the effective income tax expense reported in the income statement\nwas derived from the expected income tax expense. The expected income tax expense is calculated by applying\nthe nominal tax rate of a corporation headquartered in Gr\u00fcnwald to earnings before taxes.\n", "page_number": 293, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.10602821718683197, "height": 0.04147071398033347, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-1", "text": "Deferred income taxes in the financial years 2016, 2015 and 2014 were as follows:\n", "page_number": 293, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.11244121419410004, "lower_right_x": 0.7400241837968561, "lower_right_y": 0.12654980761008977, "height": 0.014108593415989731, "width": 0.590689238210399}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-2", "text": "kEUR                                                                                                             2016       2015       2014\nEarnings before taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                     82,866     55,299     35,487\nExpected income tax expense . . . . . . . . . . . . . . . . . . . . . .                                           19,018     12,481      8,190\nUtilisation of tax loss carried forward . . . .          .   .   .   .   .   .   .   .   .   .   .   .   .   .    (1,283)       (42)       (25)\nNon-deductible operating expenses . . . . . .            .   .   .   .   .   .   .   .   .   .   .   .   .   .       211        343        174\nTax-exempt income . . . . . . . . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .      (276)       (65)      (387)\nTaxes for previous years . . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .        \u2014          29         \u2014\nConsideration of tax group . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   (12,599)   (11,701)    (5,756)\nDifference to Group tax rate . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .     1,994      2,099      1,326\nOther deviations . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .        67       (342)      (172)\nAdjustment of annual profit \u00a760 (2) EStDV                .   .   .   .   .   .   .   .   .   .   .   .   .   .    (1,256)      (830)    (1,804)\nNon-utilisation of tax loss carried forwards             .   .   .   .   .   .   .   .   .   .   .   .   .   .        \u2014          \u2014         624\nInterest barrier . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        (6)        (9)        75\nNon-utilisation of deferred taxes . . . . . . .          .   .   .   .   .   .   .   .   .   .   .   .   .   .        \u2014         959         \u2014\nAccounting deferred taxes HGB . . . . . . . .            .   .   .   .   .   .   .   .   .   .   .   .   .   .        \u2014          \u2014          \u2014\nEffective income tax expense . . . . . . . . . . . . . . . . . . . . . . .                                         5,871      2,920      2,244\nExpected income tax rate (in %) . . . . . . . . . . . . . . . . . . . . .                                          22.95      22.57      23.08\nEffective income tax rate (in %) . . . . . . . . . . . . . . . . . . . . .                                          7.08       5.28       6.32\n", "page_number": 293, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.41299700726806327, "height": 0.27319367250961946, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-3", "text": "     The expected income tax expense is the tax calculated at domestic tax rates applicable to profits in the\nrespective countries. The expected Group tax rate for a given year is determined by averaging out the\nindividual tax rates to which all the companies included in the consolidated financial statements are subjected.\nThe tax rate was 22.95% in 31 December 2016 (31 December 2015: 22.57%; 31 December 2014: 23.08%).\n", "page_number": 293, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4839675074818298, "height": 0.05686190679777681, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-4", "text": "     The low effective income tax rates result from the tax group with Themis Beteiligungs AG, where Themis\nBeteiligungs AG is the taxpaying entity.\n", "page_number": 293, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4920906370243694, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5194527575887131, "height": 0.027362120564343728, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-5", "text": "Deferred income tax at the balance sheet dates was as follows:\n", "page_number": 293, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5262932877297991, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.5386917486105173, "height": 0.012398460880718165, "width": 0.44558645707376054}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-6", "text": "                                                                31 December    31 December    31 December   1 January\nkEUR                                                                2016           2015           2014         2014\nDeferred tax assets\nDeferred tax assets to be recovered after more than\n  12 months . . . . . . . . . . . . . . . . . . . . . . . . .        1,508          2,049            957          514\nDeferred tax asset to be recovered within\n  12 months . . . . . . . . . . . . . . . . . . . . . . . . .          218             28            124            \u2014\nTotal deferred tax assets . . . . . . . . . . . . . . . .            1,725          2,077          1,081          514\nDeferred tax liabilities\nDeferred tax liability to be    recovered after more\n  than 12 months . . . . .      .. .... .... ..... .                 (4,872)        (2,240)         (129)          (42)\nDeferred tax liability to be    recovered within\n  12 months . . . . . . . . .   .. .... .... ..... .                    \u2014              \u2014              \u2014             \u2014\nTotal deferred tax assets . . . . . . . . . . . . . . . .            (4,872)        (2,240)         (129)          (42)\nthereof recognised as deferred tax assets . . . . .                    218             28            952          472\nthereof recognised as deferred tax liabilities . . .                 (3,365)         (191)            \u2014             \u2014\n", "page_number": 293, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.8037622915775973, "height": 0.25010688328345443, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-293-7", "text": "F-68", "page_number": 293, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-294-0", "text": "Reconciliation of tax expense and the accounting loss for the periods ended 31 December 2016, 2015 and\n", "page_number": 294, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.0778110303548525, "height": 0.013253527148353997, "width": 0.7309552599758162}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-294-1", "text": "2014:\n", "page_number": 294, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.07823856348867037, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.08892689183411714, "height": 0.01068832834544678, "width": 0.04413542926239421}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-294-2", "text": "                                        1 January                               31 December    Def. tax         Def. tax\nkEUR                                       2014       P&L          OCI              2014        assets         liabilities\nIntangible assets . . . . . . . . .             \u2014           (87)          \u2014             (87)              \u2014             (87)\nFinance Lease . . . . . . . . . .               (3)          \u2014            \u2014              (3)                             (3)\nOther current financial assets                 (39)          66           \u2014              27               69            (42)\nDefined benefit obligations\n   and other accrued\n   employee benefits . . . . . .              514            94          283           891           888                  3\nOther provisions . . . . . . . .               \u2014              6           \u2014              6             6                 \u2014\nInterim result . . . . . . . . . .             \u2014            118           \u2014            118           118                 \u2014\nTax assets/liabilities . . . . . .            472           198          283           952         1,081              (129)\n\n                                        1 January                               31 December    Def. tax         Def. tax\nkEUR                                       2015       P&L          OCI              2015        assets         liabilities\nIntangible assets . . . . . . . . .            (87)    (1,782)            \u2014          (1,869)         296           (2,165)\nFinance Lease . . . . . . . . . .               (3)        \u2014              \u2014              (3)          \u2014                (3)\nInvestments . . . . . . . . . . . .             \u2014         675             \u2014             675          675               \u2014\nInvestments measured at\n   equity . . . . . . . . . . . . . .           \u2014           (22)          \u2014             (22)              \u2014             (22)\nOther current financial assets                  27          (50)          \u2014             (23)              29            (53)\nDefined benefit obligations\n   and other accrued\n   employee benefits . . . . . .              891        198             (38)        1,051         1,048                  3\nOther provisions . . . . . . . .                6         12              \u2014             18            18                 \u2014\nInterim result . . . . . . . . . .            118       (108)             \u2014             10            10\nTax assets/liabilities . . . . . .            952      (1,077)           (39)         (163)        2,077           (2,240)\n\n                                        1 January                               31 December    Def. tax         Def. tax\nkEUR                                       2016       P&L          OCI              2016        assets         liabilities\nIntangible assets . . . . . . . . .         (1,869)    (2,908)            \u2014          (4,776)               4       (4,781)\nFinance Lease . . . . . . . . . .               (3)        \u2014              \u2014              (3)              \u2014            (3)\nInvestments . . . . . . . . . . . .            675       (675)            \u2014              \u2014                \u2014            \u2014\nInvestments measured at\n   equity . . . . . . . . . . . . . .          (22)         (17)          \u2014             (38)              \u2014             (38)\nOther current financial assets                 (23)         (12)          \u2014             (35)              18            (53)\nDefined benefit obligations\n   and other accrued\n   employee benefits . . . . . .            1,051           (25)         105         1,131         1,128                  3\nOther provisions . . . . . . . .               18            10           \u2014             28            28                 \u2014\nInterim result . . . . . . . . . .             10           118           \u2014            129           129                 \u2014\nDeferred taxes on tax loss\n   carried forward . . . . . . . .              \u2014           419           \u2014            419           419                 \u2014\nTax assets/liabilities . . . . . .           (163)     (3,089)           105         (3,147)       1,725           (4,872)\n", "page_number": 294, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10218041898247114, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.7268063274903805, "height": 0.6246259085079094, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-294-3", "text": "     The deferred taxes mainly arise from capitalised development costs. This effect of kEUR 4,203 in 2016\n(2015: kEUR 2.167; 2014 kEUR 87) can be traced back to mibe GmbH. The subsidiary is in a tax group with\nDermapharm, but the respective tax effect cannot be transferred to Themis Beteiligungs AG through\nDermapharm since German tax law prohibits the distribution of effects resulting from capitalised development\ncosts.\n", "page_number": 294, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8170158187259513, "height": 0.06840530141085943, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-294-4", "text": "     As of 31 December 2016, the Group carried forward tax losses in Germany of kEUR 419. These tax\nlosses arose from Remedix GmbH in 2016 after acquisition of this entity.\n", "page_number": 294, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8550662676357418, "height": 0.027789653698161665, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-294-5", "text": "F-69", "page_number": 294, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-0", "text": "     In financial years 2014 and 2016, Dermapharm is the parent company of a tax group with a variety of\nGerman subsidiaries. Simultaneously, Dermapharm has a profit-and-loss transfer agreement and a tax group\nwith its parent company Themis Beteiligungs AG. In the respective financial years 2014 and 2016, the\nsubstantial portion of tax expenses is transferred to Themis Beteiligungs AG.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.11970927746900385, "height": 0.05515177426250535, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-1", "text": "     In financial year 2015, the profit-and-loss transfer agreement between Dermapharm and the parent\ncompany, Themis Beteiligungs AG, was terminated. Due to this fact, the tax group with Themis dissolved for\n2015 and deferred taxes had to be recognised. As of 1 January 2016, a new profit-and-loss transfer agreement\nwith the same subsidiaries as in the previous agreement was concluded. The tax group was reinstated. As a\nresult, deferred taxes amounting to kEUR 1,055 were recognised in 2015 and were reversed in 2016.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.195382642154767, "height": 0.06926036767849508, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-2", "text": "result, deferred taxes amounting to kEUR 1,055 were recognised in 2015 and were reversed in 2016.\n     No deferred tax liabilities were recognised on temporary differences in connection with interests in\nsubsidiaries. A deferred tax asset on the tax loss carryforwards of Remedix GmbH, which was acquired in\n2016, was recognised.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19581017528858485, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.2466866182129115, "height": 0.05087644292432664, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-3", "text": "     For the subsidiary Farmal d.d. no deferred taxes on tax loss carryforwards were recognised since it is\nunlikely that these differences will be reversed in the near future. For 2016, the total tax loss carried forward\namounts to kEUR 12,317(2015: kEUR 10,933; 2014 kEUR 7,606).\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2975630611372381, "height": 0.04147071398033347, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-4", "text": "5.   Notes to the consolidated statement of comprehensive income\n5.1 Revenue\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.34459170585720394, "height": 0.033775117571611835, "width": 0.498186215235792}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-5", "text": "Revenue at Dermapharm Group resulted solely from the supply of products.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.3552800342026507, "lower_right_x": 0.685006045949214, "lower_right_y": 0.3685335613510047, "height": 0.013253527148353983, "width": 0.5356711003627569}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-6", "text": "      In the period ended 31 December 2016, consolidated revenue of kEUR 413,099 was recognised in\nGermany (2015: kEUR 360,895; 2014: kEUR 370,775). The revenues realised in Germany made up for 93% of\ntotal revenue.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4155622060709705, "height": 0.039760581445062004, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-7", "text": "   The Austrian and Swiss subsidiaries (central Europe region) realised third party revenues amounting to\nkEUR 20,083 in 2016 (2015: kEUR 18,817; 2014: kEUR 13,929).\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.427105600684053, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.45404018811457886, "height": 0.026934587430525847, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-8", "text": "    The Dermapharm Group companies that are operating in eastern Europe contributed kEUR 11,295 in 2016\n(2015: kEUR 5,134; 2014: kEUR 6,635) to consolidated revenue.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4890979050876443, "height": 0.02778965369816161, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-9", "text": "5.2 Other operating income\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.516460025651988, "height": 0.01410859341598969, "width": 0.21342200725513905}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-10", "text": "kEUR                                                                                  2016      2015      2014\nGovernment grants . . . . . . . . . . . . . . . . . . . . . . . . . . . .     ..        2,238     3,357     2,399\nInsurance refunds and damage compensation . . . . . . . . . . .               ..        1,661       113       148\nReversal of provisions, including provisions on impairment of\n  trade receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .       741       706       293\nIncome from disposals . . . . . . . . . . . . . . . . . . . . . . . . . .     .   .       417       621       217\nForeign exchange gains . . . . . . . . . . . . . . . . . . . . . . . . .      .   .       197       494       797\nMiscellaneous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .   .     4,662     4,653     2,367\nTotal other operating income . . . . . . . . . . . . . . . . . . . . . .                9,916     9,944     6,221\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6665241556220607, "height": 0.13681060282171864, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-11", "text": "    The increase in insurance refunds and damage compensation in 2016 can mainly be traced back to\ndamage compensation awarded by court to Mibe GmbH amounting to kEUR 1,003.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.7139803334758443, "height": 0.03035485250106884, "width": 0.7503022974607013}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-12", "text": "a\n", "page_number": 295, "bounding_box": {"top_left_x": 0.871825876662636, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6964514749893117, "height": 0.009405728943993164, "width": 0.01209189842805325}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-13", "text": "5.3\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7280889268918341, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.7387772552372809, "height": 0.010688328345446751, "width": 0.0241837968561064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-14", "text": "Personnel expenses and numbers of employees\n", "page_number": 295, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.7280889268918341, "lower_right_x": 0.49758162031438935, "lower_right_y": 0.741769987174006, "height": 0.013681060282171864, "width": 0.34824667472793225}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-15", "text": "     Personnel expenses comprise of the following:\n\nkEUR                                                                             2016      2015      2014\nWages and salaries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    49,766    46,722    48,505\nSocial security expenses . . . . . . . . . . . . . . . . . . . . . . . . . . .     8,794     8,981     9,087\nTermination benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       189        36        84\nPersonnel expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . .      58,749    55,739    57,676\n", "page_number": 295, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8512184694313809, "height": 0.10260795211628904, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-295-16", "text": "F-70\n", "page_number": 295, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-0", "text": "    In financial year 2016, expenses for pension schemes in the amount of kEUR 404 (2015: kEUR 335;\n2014: kEUR 586) were recorded in personnel expenses and included in social security expenses in the table\nabove.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.10218041898247114, "height": 0.03762291577597264, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-1", "text": "     In 2016, a total of kEUR 185 (2015: kEUR 231; 2014: kEUR 252) was spent on employer contributions to\ndefined contribution plans.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14023086789226166, "height": 0.027789653698161623, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-2", "text": "5.4 Other operating expenses\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.1633176571184267, "height": 0.01325352714835401, "width": 0.2230955259975816}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-3", "text": "kEUR                                                                                                          2016      2015      2014\nMarketing and advertising . . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .     7,347     7,258     7,102\nResearch and development . . . . . . . . . . . .          .   .   .   .   .   .   .   .   .   .   .   .   .     4,821     4,621     7,340\nContributions, fees and charges . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .     4,654     3,798     3,897\nWarehousing and freight . . . . . . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .     4,604     3,778     5,548\nRent, building, land and fixtures maintenance             .   .   .   .   .   .   .   .   .   .   .   .   .     4,590     3,992     3,840\nMaintenance expenses . . . . . . . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .     3,318     3,221     2,906\nLegal, consulting and audit fees . . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .     3,246     3,464     3,041\nSelling costs . . . . . . . . . . . . . . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .     2,879     2,659     2,301\nThird party services . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .     1,221       799       548\nLosses from disposals . . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .       838     3,556       351\nBank charges . . . . . . . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .       334       269       139\nForeign exchange losses . . . . . . . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .       238     1,826       832\nExpenses from write-downs . . . . . . . . . . .           .   .   .   .   .   .   .   .   .   .   .   .   .       168     2,455       806\nMiscellaneous . . . . . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .    12,697     8,626     9,378\nTotal operating expenses . . . . . . . . . . . . . . . . . . . . . . . . .                                     50,955    50,322    48,029\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.40914920906370245, "height": 0.2454040188114579, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-4", "text": "     Selling costs include expenses for sales fairs, samples and third party sales service providers. The increase\nin selling costs is attributable to an increase in sales volume.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.430525865754596, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.45746045318512185, "height": 0.026934587430525847, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-5", "text": "      The increase in losses from disposals in the period ended 31 December 2015 mainly results from the\nrealised loss in the course of the deconsolidation of Centuere and realised losses from the disposal of drug\nlicenses. Expenses from write-downs include bad debt losses.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5061992304403591, "height": 0.04147071398033342, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-6", "text": "5.5 Financial result\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5228730226592561, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.5327062847370672, "height": 0.0098332620778111, "width": 0.15054413542926237}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-7", "text": "kEUR                                                                                                                   2016       2015       2014\nIncome from fair value measurement             .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     3,659      5,128        913\nInterest and other income . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .     3,332      3,799      2,310\nForeign Exchange Gains . . . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       236        110         51\nIncome from divestiture . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        15        285         \u2014\nMiscellaneous . . . . . . . . . . . . . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        55         43         51\nFinancial income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                           7,297      9,365      3,325\nInterest and other expenses . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    (9,316)   (11,067)   (10,389)\nExpenses from fair value measurement               .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    (3,211)    (4,654)    (1,077)\nForeign Exchange Losses . . . . . . . . .          .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      (114)       (40)      (274)\nFinance leases . . . . . . . . . . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       (14)       (22)       (32)\nImpairment of financial assets . . . . . .         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        (5)        (4)      (151)\nMiscellaneous . . . . . . . . . . . . . . . .      .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       (29)       (27)       (33)\nFinancial expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                         (12,689)   (15,814)   (11,956)\nFinancial result . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                        (5,392)    (6,449)    (8,631)\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.7862334330910645, "height": 0.23941855493800768, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-8", "text": "    The increase in expenses from fair value measurement in financial year 2015 compared to financial year\n2014 results from the increased negative fair value of the currency-related swap entered into by Dermapharm in\n2010 as a result of the euro\u2019s depreciation against the Swiss franc.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8482257374946558, "height": 0.04147071398033342, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-9", "text": "    Since Dermapharm has a claim against Themis Beteiligungs AG to compensate for all expenses resulting\nfrom the currency-related swap, the income from fair value measurement increases in the same amount.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8824283882000855, "height": 0.027789653698161665, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-296-10", "text": "F-71\n", "page_number": 296, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-0", "text": "6.   Financial risk management and financial instruments\n6.1 Financial risk factors\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.09576742197520308, "height": 0.031209918768704575, "width": 0.44074969770253924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-1", "text": "     Dermapharm Group\u2019s management sees on-going risks to future development due to the difficult,\ngovernment-regulated competitive environment, volatile raw material prices and stagnating price levels\nresulting from the government-initiated price freeze.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14878153056861906, "height": 0.043180846515604956, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-2", "text": "     However, given its financial stability, the Group is well prepared to overcome future risks. At present, no\nrisks that could jeopardise the Company\u2019s ability to operate as a going concern have been identified.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.18469431380932022, "height": 0.02778965369816161, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-3", "text": "Financial risk factors\n", "page_number": 297, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19794784095767423, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.2099187687045746, "height": 0.011970927746900367, "width": 0.14993954050785974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-4", "text": "     Due to its business activities, the Group is exposed to various financial risks (market risk resulting from\ncurrency, interest, credit and liquidity risks).\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21846943138093203, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.2479692176143651, "height": 0.02949978623343308, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-5", "text": "     The Group\u2019s risk management is focused on the unpredictability of financial markets and aims to minimise\npotentially negative effects on the financial position of the Group.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.248396750748183, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2834544677212484, "height": 0.035057716973065395, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-6", "text": "     The central finance department carries out risk management in accordance with the Management\u2019s\nguidelines. The risk management system covers all subsidiaries. The Group\u2019s finance department identifies and\nassesses financial risks in close co-operation with the Group\u2019s operating units. Management provides both the\nprinciples for cross-divisional risk management and guidelines for specific risks, such as exposure to foreign\ncurrency, interest and credit risks, the use of derivative and non-derivative financial instruments and\ninvestments of liquidity surpluses.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3758016246259085, "height": 0.08550662676357418, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-7", "text": "     The significant financial liabilities incorporate interest-bearing financial liabilities, trade accounts payable\nand other liabilities. The primary purpose of these financial liabilities is to finance the Group\u2019s business\nactivities and to ensure that these activities are retained. The Group has access to trade accounts receivable and\nother receivables, as well as cash and cash equivalents, which result directly from its business activities.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4395040615647713, "height": 0.05686190679777686, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-8", "text": "The Group uses derivative financial instruments to hedge certain risks.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.15175332527206772, "top_left_y": 0.4476271911073108, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.4608807182556648, "height": 0.013253527148353983, "width": 0.49637243047158397}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-9", "text": "      The following statements discuss the Group\u2019s exposure to identified risks. Furthermore, the goals,\nstrategies and processes for risk management as well as the methods used to measure the risks are indicated.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-10", "text": "Market risk\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.5228730226592561, "height": 0.010260795211628815, "width": 0.08282950423216444}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-11", "text": "     Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and\nequity prices, will affect the Group\u2019s income or the value of its holdings of financial instruments. The objective\nof market risk management is to manage and control market risk exposures within acceptable parameters, while\noptimising the return.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5882855921333904, "height": 0.05515177426250539, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-12", "text": "Currency risk\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6019666524155622, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.6156477126977341, "height": 0.013681060282171864, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-13", "text": "     Currency risk arises from future commercial transactions, recognised assets and liabilities and net\ninvestments in foreign operations. The foreign exchange risk can be split into two types: translation risk and\ntransaction risk.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6631038905515177, "height": 0.037622915775972654, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-14", "text": "     The translation risk describes the risk from changes to the statement of financial position and statement of\ncomprehensive income items of a subsidiary due to changes to the exchange rates when converting local\nindividual financial statements into the Group\u2019s presentation currency. The changes caused by currency\nfluctuations when translating statement of financial position items were recognised in equity. The Group is\ncurrently exposed to such a risk with six subsidiaries, though this risk is minimal due to the size of these\ncompanies.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7588713125267208, "height": 0.08550662676357412, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-15", "text": "     Transaction risk is the risk that the value of future foreign currency payments may change due to exchange\nrate fluctuations. The Group operates internationally and is exposed to foreign exchange risks arising from\nvarious currency exposures, primarily with respect to euros.\n", "page_number": 297, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.8088926891834117, "height": 0.04318084651560494, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-297-16", "text": "F-72\n", "page_number": 297, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-298-0", "text": "     The Group does not account for any fixed-rate financial assets or liabilities at fair value through profit or\nloss, and the Group does not designate derivatives (interest swap rates) as hedging instruments under a fair\nvalue hedge accounting model. Therefore, a change in interest rates at the reporting date would not affect profit\nor loss.\n", "page_number": 298, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.11714407866609662, "height": 0.05258657545959812, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-298-1", "text": "Sensitivity analysis:\n\nkEUR                                                                                      31 December 2016\nAssumed change in currency                                                EUR appreciates by 10% EUR depreciates by 10%\nFair Value Changes\nFX FWD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                    (174)                    123\nTotal Changes in Fair Value . . . . . . . . . . . . . . . . . . .                         (174)                    123\nProfit- and Loss Effects\nProfit (+) / Loss (\u2013) . . . . . . . . . . . . . . . . . . . . . . . . .                   (163)                    134\n\nkEUR                                                                                      31 December 2015\nAssumed change in currency                                                EUR appreciates by 10% EUR depreciates by 10%\nFair Value Changes\nFX FWD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                     252                   (322)\nTotal Changes in Fair Value . . . . . . . . . . . . . . . . . . .                          252                   (322)\nProfit- and Loss Effects\nProfit (+) / Loss (\u2013) . . . . . . . . . . . . . . . . . . . . . . . . .                    316                   (259)\n\nkEUR                                                                                      31 December 2014\nAssumed change in currency                                                EUR appreciates by 10% EUR depreciates by 10%\nFair Value Changes\nFX FWD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                     433                   (597)\nTotal Changes in Fair Value . . . . . . . . . . . . . . . . . . .                          433                   (597)\nProfit- and Loss Effects\nProfit (+) / Loss (\u2013) . . . . . . . . . . . . . . . . . . . . . . . . .                    566                   (464)\n\nkEUR                                                                                       1 January 2014\nAssumed change in currency                                                EUR appreciates by 10% EUR depreciates by 10%\nFair Value Changes\nFX FWD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                   1,412                   (881)\nTotal Changes in Fair Value . . . . . . . . . . . . . . . . . . .                        1,412                   (881)\nProfit- and Loss Effects\nProfit (+) / Loss (\u2013) . . . . . . . . . . . . . . . . . . . . . . . . .                  1,262                  (1,031)\n", "page_number": 298, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6434373663958957, "height": 0.5070542967079948, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-298-2", "text": "     To reflect market risks, IFRS 7 requires sensitivity analyses that demonstrate the effects of hypothetical\nchanges of relevant risk variables on the profit for the period as well as equity. The following observation is\none-dimensional and does not take into account the effect of taxes. The table shows the positive and negative\neffects had the euro depreciated or appreciated by 5% (CHF, PLN) in comparison to the displayed currencies,\nprovided all other variables had remained constant. Here, currency gains and losses from foreign currency\ndenominated financial assets and financial liabilities equally impact the Group\u2019s profit and equity. Apart from\nthe Group\u2019s profit, there exist no other effects on equity resulting from changes in exchange rates.\n", "page_number": 298, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7627191107310817, "height": 0.09961522017956392, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-298-3", "text": "     A reasonable potential strengthening (weakening) of the euro against material currencies used by Group\ncompanies at 31 December of the respective year would have affected the measurement of financial position by\nthe amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain\nconstant and ignores any impact of forecast sales and purchases.\n", "page_number": 298, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8242838820008551, "height": 0.05515177426250539, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-298-4", "text": "                                                                  Balance in                      +5%              \u20135%\n                                                                    foreign     Balance in     Impact on        Impact on\n31 December 2016                                                   currency       kEUR        profit or loss   profit or loss\nCHF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       15,803        15,490            (713)             789\nPLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       (1,323)         (316)            (20)              22\n", "page_number": 298, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.837537409149209, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9025224454895254, "height": 0.06498503634031638, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-298-5", "text": "F-73\n", "page_number": 298, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-0", "text": "                                                                  Balance in                      +5%              \u20135%\n                                                                    foreign     Balance in     Impact on        Impact on\n31 December 2015                                                   currency       kEUR        profit or loss   profit or loss\nCHF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       13,587        13,200            (598)             661\nPLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       (1,886)         (466)             (27)              29\n\n                                                                  Balance in                      +5%              \u20135%\n                                                                    foreign     Balance in     Impact on        Impact on\n31 December 2014                                                   currency       kEUR        profit or loss   profit or loss\nCHF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       14,985        13,118            (603)             667\nPLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       (1,607)         (396)             (19)              22\n\n                                                                  Balance in                      +5%              \u20135%\n                                                                    foreign     Balance in     Impact on        Impact on\n1 January 2014                                                     currency       kEUR        profit or loss   profit or loss\nCHF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .           \u2014             \u2014                \u2014                \u2014\nPLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       (1,727)         (438)             (20)              22\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2954253954681488, "height": 0.23428815733219324, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-1", "text": "   The Group\u2019s risk from exchange rate fluctuations for all other currencies not presented here was\nimmaterial.\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3142368533561351, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3386062419837537, "height": 0.024369388627618616, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-2", "text": "Interest rate risk\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3557075673364686, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.36810602821718685, "height": 0.012398460880718276, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-3", "text": "     The interest rate risk includes the effect of positive and negative changes to interest rates on profit, equity,\nor cash flows in the current or a future reporting period. Interest rate risks from financial instruments can arise\nwithin the Group mainly in connection with financial liabilities.\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4202650705429671, "height": 0.04104318084651559, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-4", "text": "    The following table depicts the change in income or expenses from interest rate swaps, which would result\nfrom a decrease or increase of the EURIBOR by 50 basis points:\n", "page_number": 299, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.427105600684053, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4548952543822146, "height": 0.02778965369816161, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-5", "text": "                                                               31 December   31 December   31 December    1 January\nkEUR                                                               2016          2015          2014          2014\nAssumed change in interest rates\n\u201350 Basis Points . . . . . . . . . . . . . . . . . . . . . .         (390)         (888)        (1,448)       (1,682)\nCurrent Swap expense . . . . . . . . . . . . . . . . . . .           (340)         (735)        (1,167)       (1,249)\n+ 50 Basis Points . . . . . . . . . . . . . . . . . . . . .          (289)         (580)         (893)         (848)\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.5536554082941428, "height": 0.08550662676357423, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-6", "text": "    The following table shows the change in interest expenses for variable rate loans, which would result from\na decrease or increase of the EURIBOR by 50 basis points:\n", "page_number": 299, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6006840530141085, "height": 0.029927319367250904, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-7", "text": "                                                               31 December   31 December   31 December   1 January\nkEUR                                                               2016          2015          2014         2014\nAssumed change in interest rates\n\u201350 Basis Points . . . . . . . . . . . . . . . . . . . . . .          327           484           634          725\nCurrent interest expense . . . . . . . . . . . . . . . . .            477           691           864          946\n+ 50 Basis Points . . . . . . . . . . . . . . . . . . . . .           635           899         1,094        1,166\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6977340743907653, "height": 0.08593415989739206, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-8", "text": "Credit risk\n", "page_number": 299, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7178281316802052, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.7302265925609235, "height": 0.012398460880718276, "width": 0.07617896009673518}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-9", "text": "     Credit risk is the risk of financial loss arising from a counterparty\u2019s inability to repay or service debt in\naccordance with the contractual terms. Credit risk includes both the direct risk of default and the risk of a\ndeterioration of creditworthiness as well as concentration risk.\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7793929029499786, "height": 0.04104318084651559, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-10", "text": "     Credit risk is managed at Group level, except for credit risk relating to accounts receivable balances. Each\nlocal entity is responsible for managing and analysing the credit risk for each of their new clients before\nstandard payment and delivery terms and conditions are offered.\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8306968790081232, "height": 0.04104318084651559, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-11", "text": "     The extent of this credit risk for the Group corresponds to the sum of trade receivables, other financial\nassets and cash or cash equivalents. The maximum credit risk in case of a counterparty defaulting corresponds\nfor all classes of financial assets to the book value on the balance sheet date in each case. No significant\nconcentration risks for the Group exist at the balance sheet date or prior periods.\n", "page_number": 299, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.837537409149209, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8943993159469859, "height": 0.05686190679777681, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-299-12", "text": "F-74\n", "page_number": 299, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-0", "text": "     Risks of default arise mainly from trade receivables from customers. Credit risks from financial\ntransactions are managed centrally in the Finance department. To minimise risks, financial transactions are only\nconducted within short defined terms of payments and with banks and other partners that preferably have\ninvestment-grade ratings. In the past, no major impairments of trade receivables were necessary.\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.11970927746900385, "height": 0.05515177426250535, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-1", "text": "      In addition, there exists a risk of default for cash and cash equivalents to the effect that financial\ninstitutions can no longer fulfil their obligations. This risk of default is limited by investing only with various\nbanking institutions with good ratings.\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.16973065412569474, "height": 0.043608379649422824, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-2", "text": "Liquidity risk\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.19837537409149208, "height": 0.014108593415989745, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-3", "text": "      Liquidity risk includes the risk that the Group is not in the position to settle its assumed financial\nliabilities upon maturity. This is why a significant aim of the liquidity management is to ensure that payment is\npossible at all times. Management constantly monitors the risk of liquidity shortfalls by using the liquidity\nplanning capabilities of its ERP system. This takes account of payments in and out of the financial assets and\nfinancial liabilities as well as expected cash flows from business activities.\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.27618640444634457, "height": 0.0713980333475844, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-4", "text": "     The Group\u2019s aim is to maintain a balance between continuously covering the required financial resources\nand ensuring flexibility by using bank credit facilities. Any remaining short-term liquidity requirement peaks\nare balanced out by using those credit facilities.\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.32492518170158186, "height": 0.04147071398033347, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-5", "text": "are balanced out by using those credit facilities.\n    The Group had access to the following lines of credit:\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1293833131801693, "top_left_y": 0.32492518170158186, "lower_right_x": 0.5362756952841596, "lower_right_y": 0.3471569046601112, "height": 0.02223172295852932, "width": 0.40689238210399037}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-6", "text": "                                                               31 December   31 December   31 December   1 January\nkEUR                                                               2016          2015          2014         2014\nAggregate line of credit . . . . . . . . . . . . . . . . .         75,501        76,517        72,751       47,723\nAvailable line of credit . . . . . . . . . . . . . . . . . .       70,634        64,082        67,589       14,199\nNumber of banks . . . . . . . . . . . . . . . . . . . . . .            16            17            17           17\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4241128687473279, "height": 0.06541256947413421, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-7", "text": "     The following table shows the Group\u2019s financial liabilities according to class of maturity, based on the\nremaining maturity at the balance sheet dates in each case and related to the contractually agreed,\nnon-discounted cash flows. Financial liabilities payable at any time are allocated to the earliest possible time of\npayment. Variable interest payments from the financial instruments, where applicable, were calculated on the\nbasis of respective forward rates at the balance sheet date in each case.\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5121846943138093, "height": 0.07139803334758443, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-8", "text": "                                                                                                             Due between\nkEUR                                                                                            Due within      1 and      Due after\n1 January 2014                                                                                   one year      5 years      5 years\nExpected Cashflows from          Financial Liabilities\nInterest . . . . . . . . . . .   . .... ..... .... ....         .   .   .   .   .   .   .   .        5,716       11,142          338\nRepayment . . . . . . . . .      . .... ..... .... ....         .   .   .   .   .   .   .   .       52,649       86,014       10,126\nExpected Cashflows from          Trade Payables . . . . . . .   .   .   .   .   .   .   .   .       25,378           \u2014            \u2014\nExpected Cashflows from          Other Financial Liabilities    .   .   .   .   .   .   .   .       77,555           \u2014            \u2014\n31 December 2014\nExpected Cashflows from          Financial Liabilities\nInterest . . . . . . . . . . .   . .... ..... .... ....         .   .   .   .   .   .   .   .        5,311       12,687        1,264\nRepayment . . . . . . . . .      . .... ..... .... ....         .   .   .   .   .   .   .   .       22,051      131,444       30,095\nExpected Cashflows from          Trade Payables . . . . . . .   .   .   .   .   .   .   .   .       27,449           \u2014            \u2014\nExpected Cashflows from          Other Financial Liabilities    .   .   .   .   .   .   .   .       30,448           \u2014            \u2014\n31 December 2015\nExpected Cashflows from          Financial Liabilities\nInterest . . . . . . . . . . .   . .... ..... .... ....         .   .   .   .   .   .   .   .        5,077        8,732          598\nRepayment . . . . . . . . .      . .... ..... .... ....         .   .   .   .   .   .   .   .       24,034      121,612       30,084\nExpected Cashflows from          Trade Payables . . . . . . .   .   .   .   .   .   .   .   .       18,139           \u2014            \u2014\nExpected Cashflows from          Other Financial Liabilities    .   .   .   .   .   .   .   .        2,322           \u2014            \u2014\n31 December 2016\nExpected Cashflows from          Financial Liabilities\nInterest . . . . . . . . . . .   . .... ..... .... ....         .   .   .   .   .   .   .   .        8,088        5,409            \u2014\nRepayment . . . . . . . . .      . .... ..... .... ....         .   .   .   .   .   .   .   .       65,139       96,075            32\nExpected Cashflows from          Trade Payables . . . . . . .   .   .   .   .   .   .   .   .       24,526           \u2014             \u2014\nExpected Cashflows from          Other Financial Liabilities    .   .   .   .   .   .   .   .        4,285           \u2014             \u2014\n", "page_number": 300, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9063702436938863, "height": 0.39375801624625906, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-300-9", "text": "F-75\n", "page_number": 300, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-0", "text": "     Proceeds and payments from derivatives were expected as follows:\n\n                                                                                            Due between\n                                                                              Due within       1 and       Due after\nkEUR                                                                           one year       5 years       5 years\n1 January 2014\nExpected Cashflows from Derivatives\nDerivative contracts\u2014receipts . . . . . . . . . . . . . . . . . . . . . . .        1,469          6,551         2,216\nDerivative contracts\u2014payments . . . . . . . . . . . . . . . . . . . . . .         (1,964)        (7,186)       (2,216)\n31 December 2014\nExpected Cashflows from Derivatives\nDerivative contracts\u2014receipts . . . . . . . . . . . . . . . . . . . . . . .        1,643          6,670           754\nDerivative contracts\u2014payments . . . . . . . . . . . . . . . . . . . . . .         (2,287)        (7,310)         (754)\n31 December 2015\nExpected Cashflows from Derivatives\nDerivative contracts\u2014receipts . . . . . . . . . . . . . . . . . . . . . . .        3,207        10,407             \u2014\nDerivative contracts\u2014payments . . . . . . . . . . . . . . . . . . . . . .         (3,699)      (10,719)            \u2014\n31 December 2016\nExpected Cashflows from Derivatives\nDerivative contracts\u2014receipts . . . . . . . . . . . . . . . . . . . . . . .        3,338          6,949            \u2014\nDerivative contracts\u2014payments . . . . . . . . . . . . . . . . . . . . . .         (3,667)        (6,971)           \u2014\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.37280889268918344, "height": 0.30825138948268493, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-1", "text": "6.2 Risk management, derivative financial instruments and disclosures on capital management\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.8258766626360339, "lower_right_y": 0.40017101325352716, "height": 0.014108593415989745, "width": 0.7103990326481258}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-2", "text": "     The Group\u2019s capital management objectives are primarily to maintain and ensure an optimum capital\nstructure to continue financing the growth plan and to manage the company\u2019s value over the long term. Here,\nparticular focus is placed on the reduction of capital costs, the generation of liquid funds and the active\nmanagement of the net working assets.\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.46515604959384355, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-3", "text": "    The Group manages its capital structure on the basis of various figures, such as the equity ratio, and\nmakes adjustments where appropriate, taking into account changes to the general state of the economy.\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4993587002992732, "height": 0.02778965369816161, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-4", "text": "                                                                   31 December    31 December    31 December    1 January\nkEUR                                                                   2016           2015           2014          2014\nEquity . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       60,806         44,442         34,010        41,361\nTotal Equity and Liabilities . . . . . . . . . . . . . . .            311,699        296,666        330,597       349,977\nEquity ratio in % . . . . . . . . . . . . . . . . . . . . .               19.5%          15.0%          10.3%         11.8%\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5848653270628473, "height": 0.07225309961522008, "width": 0.7841596130592503}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-5", "text": "6.3 Additional disclosures on financial instruments\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.6147926464300983, "height": 0.013253527148354038, "width": 0.3827085852478839}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-6", "text": "     The following table shows the carrying amounts of all financial instruments recorded in the consolidated\nstatements of financial position and how the assets and liabilities or parts of the totals of each category are\nclassified into the categories in accordance with IAS 39.\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6669516887558786, "height": 0.04147071398033353, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-7", "text": "     Moreover, the table depicts the fair values of the financial instruments and the fair value hierarchy level\napplied to obtain the value.\n", "page_number": 301, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7011543394613082, "height": 0.027789653698161554, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-301-8", "text": "F-76\n", "page_number": 301, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-302-0", "text": "31 December 2016\n", "page_number": 302, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-302-1", "text": "                                                                            Measurement acc. to IAS 39\n                                                           Book value                 Fair value   Measurement    Fair value\n                                          Category acc.   31 December                  (through      acc. to     31 December   Fair value\nkEUR                                       to IAS 39          2016      At cost          p&l)        IAS 17          2016         level\n\nAssets\nOther non-current financial\n  assets . . . . . . . . . . . . .    .   LaR / HfT           10,648         523         10,125            \u2014         10,648                 2\nInvestments . . . . . . . . . . .     .         AfS              262         262             \u2014             \u2014            262\nTrade receivables . . . . . . .       .         LaR           26,302      26,302             \u2014             \u2014         26,302\nOther current financial assets            LaR / HfT           39,976      39,969              7            \u2014         39,976                 2\nCash and cash equivalents .           .         LaR            3,816       3,816             \u2014             \u2014          3,816\nLiabilities\nFinancial\n  liabilities\u2014non-current\nof which bank loans . . . . .         .        FLAC            2,713       2,713              \u2014            \u2014          1,586                 2\nof which promissory note\n  loans . . . . . . . . . . . . .     .        FLAC           87,680      87,680              \u2014            \u2014         91,450                 2\nof which participation rights         .        FLAC            6,360       6,360              \u2014            \u2014          6,415                 2\nof which leasing liabilities .        .          n.a.            143          \u2014               \u2014           143           143\nOther non-current financial\n  liabilities . . . . . . . . . . .   .           HfT         10,464              \u2014      10,464            \u2014         10,464                 2\nFinancial liabilities\u2014current\nof which bank loans . . . . .         .        FLAC           14,660      14,660              \u2014            \u2014         13,693                 2\nof which promissory note\n  loans . . . . . . . . . . . . .     .        FLAC           40,413      40,413              \u2014            \u2014         42,532                 2\nof which participation rights         .        FLAC            5,831       5,831              \u2014            \u2014          5,344                 2\nof which bank overdrafts . .          .        FLAC            4,867       4,867              \u2014            \u2014          4,867\nof which leasing liabilities .        .          n.a.            112          \u2014               \u2014           112           112\nTrade payables . . . . . . . . .      .        FLAC           24,526      24,526              \u2014            \u2014         24,526\nOther current financial                        FLAC\n  liabilities . . . . . . . . . . .   .        / HfT           4,303       4,285              18           \u2014          4,303                 2\nTotals per category acc. to\n  IAS 39\nAvailable for sale (AfS) . . .        .           AfS            262         262              \u2014            \u2014            262\nFinancial Asset Held for\n  Trading (HfT) . . . . . . . .       .           HfT         10,132          \u2014          10,132            \u2014         10,132\nLoans and receivables (LaR)           .           LaR         70,610      70,610             \u2014             \u2014         70,610\nFinancial Liabilities Held for\n  Trading (HfT) . . . . . . . .       .           HfT         10,482              \u2014      10,482            \u2014         10,482\nFinancial liabilities measured\n  at amortised cost (FLAC)            .        FLAC          191,335    191,335               \u2014            \u2014        194,698\n", "page_number": 302, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6143651132962804, "height": 0.5258657545959812, "width": 0.7654171704957679}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-302-2", "text": "F-77\n", "page_number": 302, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-303-0", "text": "31 December 2015\n", "page_number": 303, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-303-1", "text": "                                                                      Measurement acc. to IAS 39\n                                    Category acc.    Book value                 Fair value   Measurement    Fair value\n                                         to         31 December                  (through      acc. to     31 December   Fair value\nkEUR                                   IAS 39           2015      At cost          p&l)        IAS 17          2015         level\n\nAssets\nOther non-current financial                LaR\n  assets . . . . . . . . . . . .         / HfT         13,841         527         13,314             \u2014        13,841                  2\nInvestments . . . . . . . . . .            AfS            218         218             \u2014              \u2014           218\nTrade receivables . . . . . .              LaR         17,423      17,423             \u2014              \u2014        17,423\nOther current financial                    LaR\n  assets . . . . . . . . . . . .         / HfT         42,499      42,495               4            \u2014        42,499                  2\nCash and cash equivalents                  LaR          2,791       2,791               \u2014            \u2014         2,791\nLiabilities\nFinancial\n  liabilities\u2014non-current\nof which bank loans . . . .              FLAC          12,466      12,466               \u2014            \u2014        10,200                  2\nof which promissory note\n  loans . . . . . . . . . . . .          FLAC         127,514     127,514               \u2014            \u2014       132,181                  2\nof which participation\n  rights . . . . . . . . . . . .         FLAC          10,956      10,956               \u2014            \u2014        11,748                  2\nof which leasing liabilities               n.a.           137          \u2014                \u2014           137          137\nOther non-current financial\n  liabilities . . . . . . . . . .          HfT         14,050               \u2014     14,050             \u2014        14,050                  2\nFinancial\n  liabilities\u2014current\nof which bank loans . . . .              FLAC            9,997       9,997              \u2014            \u2014        12,270                  2\nof which promissory note\n  loans . . . . . . . . . . . .          FLAC              916         916              \u2014            \u2014          3,289                 2\nof which participation\n  rights . . . . . . . . . . . .         FLAC           1,323       1,323               \u2014            \u2014         1,325                  2\nof which bank overdrafts .               FLAC          12,435      12,435               \u2014            \u2014        12,435\nof which leasing liabilities               n.a.           235          \u2014                \u2014           235          235\nTrade payables . . . . . . . .           FLAC          18,139      18,139               \u2014            \u2014        18,139\nOther current financial                  FLAC\n  liabilities . . . . . . . . . .        / HfT           2,389       2,322              67           \u2014          2,389                 2\nTotals per category acc.\n  to IAS 39\nAvailable for sale (AfS) . .                AfS            218         218              \u2014            \u2014            218\nFinancial Asset Held for\n  Trading (HfT) . . . . . . .              HfT         13,318               \u2014     13,318             \u2014        13,318\nFinancial Liabilities Held\n  for Trading (HfT) . . . .                HfT              \u2014               \u2014      14,117            \u2014        14,117\nLoans and\n  receivables (LaR) . . . .                LaR         63,236      63,236               \u2014            \u2014        63,236\nFinancial liabilities\n  measured at amortised\n  cost (FLAC) . . . . . . . .            FLAC         196,068     196,068               \u2014            \u2014       203,909\n", "page_number": 303, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7421975203078238, "height": 0.6536981616075246, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-303-2", "text": "F-78\n", "page_number": 303, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-304-0", "text": "31 December 2014\n", "page_number": 304, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-304-1", "text": "                                                                            Measurement acc. to IAS 39\n                                          Category acc.    Book value                 Fair value   Measurement    Fair value\n                                               to         31 December                  (through      acc. to     31 December   Fair value\nkEUR                                         IAS 39           2014      At cost          p&l)        IAS 17          2014         level\n\nAssets\nOther non-current financial\n  assets . . . . . . . . . . . . .    .   LaR / HfT            9,205         426           8,779           \u2014          9,205                 2\nInvestments . . . . . . . . . . .     .         AfS              461         461              \u2014            \u2014            461\nTrade receivables . . . . . . .       .         LaR           22,791      22,791              \u2014            \u2014         22,791\nOther current financial assets            LaR / HfT           58,810      58,803               7           \u2014         58,810                 2\nCash and cash equivalents .           .         LaR           11,645      11,645              \u2014            \u2014         11,645\nLiabilities\nFinancial\n  liabilities\u2014non-current\nof which bank loans . . . . .         .        FLAC           22,228      22,228              \u2014            \u2014         18,822                 2\nof which promissory note\n  loans . . . . . . . . . . . . .     .        FLAC          127,984    127,984               \u2014            \u2014        133,958                 2\nof which participation rights         .        FLAC           10,981     10,981               \u2014            \u2014         13,034                 2\nof which leasing liabilities .        .          n.a.            337         \u2014                \u2014           337           337\nOther non-current financial\n  liabilities . . . . . . . . . . .   .           HfT          9,946              \u2014        9,946           \u2014          9,946                 2\nFinancial liabilities\u2014current\nof which bank loans . . . . .         .        FLAC           13,113      13,113              \u2014            \u2014         17,076                 2\nof which promissory note\n  loans . . . . . . . . . . . . .     .        FLAC              600         600              \u2014            \u2014          3,377                 2\nof which participation rights         .        FLAC            1,318       1,318              \u2014            \u2014          1,321                 2\nof which bank overdrafts . .          .        FLAC            5,162       5,162              \u2014            \u2014          5,162\nof which leasing liabilities .        .          n.a.            189          \u2014               \u2014           189           189\nTrade payables . . . . . . . . .      .        FLAC           27,449      27,449              \u2014            \u2014         27,449\nOther current financial                        FLAC\n  liabilities . . . . . . . . . . .   .        / HfT          30,605      30,448             157           \u2014         30,605                 2\nTotals per category acc. to\n  IAS 39\nAvailable for sale (AfS) . . .        .           AfS            461         461              \u2014            \u2014            461\nFinancial Asset Held for\n  Trading (HfT) . . . . . . . .       .           HfT          8,786              \u2014        8,786           \u2014          8,786\nFinancial Liabilities Held for\n  Trading (HfT) . . . . . . . .       .           HfT             \u2014           \u2014          10,103            \u2014         10,103\nLoans and receivables (LaR)           .           LaR         93,665      93,665             \u2014             \u2014         93,665\nFinancial liabilities measured\n  at amortised cost (FLAC)            .        FLAC          239,283    239,283               \u2014            \u2014        250,647\n", "page_number": 304, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6147926464300983, "height": 0.5262932877297991, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-304-2", "text": "F-79\n", "page_number": 304, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-305-0", "text": "1 January 2014\n", "page_number": 305, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-305-1", "text": "                                                                           Measurement acc. to IAS 39\n                                          Category acc.   Book value                 Fair value   Measurement   Fair value\n                                               to         1 January                   (through      acc. to     1 January    Fair value\nkEUR                                         IAS 39          2014      At cost          p&l)        IAS 17         2014         level\n\nAssets\nOther non-current financial\n  assets . . . . . . . . . . . . .    .   LaR / HfT           9,641         399           9,242           \u2014         9,641                 2\nInvestments . . . . . . . . . . .     .         AfS             797         797              \u2014            \u2014           797\nTrade receivables . . . . . . .       .         LaR          22,388      22,388              \u2014            \u2014        22,388\nOther current financial assets            LaR / HfT          83,309      83,127             182           \u2014        83,309                 2\nCash and cash equivalents .           .         LaR           4,665       4,665              \u2014            \u2014         4,665\nLiabilities\nFinancial\n  liabilities\u2014non-current\nof which bank loans . . . . .         .        FLAC          38,531      38,531              \u2014            \u2014        32,923                 2\nof which promissory note\n  loans . . . . . . . . . . . . .     .        FLAC          50,995      50,995              \u2014            \u2014        52,043                 2\nof which participation rights         .        FLAC          10,981      10,981              \u2014            \u2014            \u2014                  2\nof which leasing liabilities .        .          n.a.           324          \u2014               \u2014           324          324\nOther non-current financial\n  liabilities . . . . . . . . . . .   .           HfT        10,491              \u2014      10,491            \u2014        10,491                 2\nFinancial liabilities\u2014current\nof which bank loans . . . . .         .        FLAC          16,525      16,525              \u2014            \u2014        20,831                 2\nof which promissory note\n  loans . . . . . . . . . . . . .     .        FLAC             600         600              \u2014            \u2014         1,950                 2\nof which participation rights         .        FLAC           1,318       1,318              \u2014            \u2014         1,321                 2\nof which bank overdrafts . .          .        FLAC          33,524      33,524              \u2014            \u2014        33,524\nof which leasing liabilities .        .          n.a.           151          \u2014               \u2014           151          151\nTrade payables . . . . . . . . .      .        FLAC          25,378      25,378              \u2014            \u2014        25,378\nOther current financial                        FLAC\n  liabilities . . . . . . . . . . .   .        / HfT         77,596      77,554              42           \u2014        77,596                 2\nTotals per category acc. to\n  IAS 39\nAvailable for sale (AfS) . . .        .           AfS            797        797              \u2014            \u2014            797\nFinancial Asset Held for\n  Trading (HfT) . . . . . . . .       .           HfT          9,424             \u2014        9,424           \u2014          9,424\nFinancial Liabilities Held for\n  Trading (HfT) . . . . . . . .       .           HfT            \u2014          \u2014           10,533            \u2014        10,533\nLoans and receivables (LaR)           .           LaR       110,579    110,579              \u2014             \u2014       110,579\nFinancial liabilities measured\n  at amortised cost (FLAC)            .        FLAC         255,406    255,406               \u2014            \u2014       245,525\n", "page_number": 305, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08849935870029928, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6152201795639162, "height": 0.5267208208636169, "width": 0.7684401451027811}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-305-2", "text": "     All financial assets and liabilities classified as held for trading were recorded at their fair values in the\nfinancial statement.\n", "page_number": 305, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6554082941427961, "height": 0.026507054296708077, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-305-3", "text": "     Due to the short maturity of the cash and cash equivalents, trade receivables and payables as well as\ncurrent financial liabilities, other current financial assets and other current financial liabilities, it is assumed that\nthe carrying amounts of these items were reasonable approximations of their fair values.\n", "page_number": 305, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7071398033347585, "height": 0.044035912783240705, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-305-4", "text": "     The investments qualify as available-for-sale financial assets under IAS 39. They thus have to be\nmeasured at fair value in the statement of financial position. However, due to the immateriality of the\ninvestments and because the fair value could not be measured reliably, they are measured at cost less\nimpairment charges.\n", "page_number": 305, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7695596408721675, "height": 0.05515177426250528, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-305-5", "text": "F-80", "page_number": 305, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-0", "text": "    The following table depicts the net result from financial instruments for the periods ended 31 December\n2016, 31 December 2015 and 31 December 2014.\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.0910645575032065, "height": 0.026507054296707994, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-1", "text": "Net result from financial instruments\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.39600967351874244, "lower_right_y": 0.11714407866609662, "height": 0.011543394613082514, "width": 0.28053204353083433}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-2", "text": "kEUR                                                                                                                  2016       2015       2014\nInterest income on:\nLoans and Receivables . . . . . . . . . . . . . . . . . . . . . . . . . . .                                               677        196       (596)\nHeld-for-trading Derivatives . . . . . . . . . . . . . . . . . . . . . . . .                                            3,180      3,542      1,509\nFinance income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                          3,857      3,738           913\nInterest expense on:\nFinancial liabilities measured at amortised cost . . . . . . . . . . . .                                               (5,700)    (6,882)    (8,545)\nHeld-for-trading Derivatives . . . . . . . . . . . . . . . . . . . . . . . .                                           (3,616)    (4,185)    (1,844)\nFinance expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                          (9,316)   (11,067)   (10,389)\nWrite down of receivables (LaR) . . . . . . . . . . . . . . . . . .                                       .   .   .      (158)       (27)      (123)\nImpairment of financial assets (AfS) . . . . . . . . . . . . . . . .                                      .   .   .        (5)        (4)      (151)\nNet result from subsequent measurement (HfT) through P&L                                                  .   .   .       448        474       (164)\nIncome from subsequent measurement (HfT) through P&L .                                                    .   .   .     3,659      5,128        913\nExpenses from subsequent measurement (HfT) through P&L .                                                               (3,211)    (4,654)    (1,077)\nNet foreign exchange loss . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      (399)    (1,533)      (398)\nForeign Exchange Gains . . . . . . . .        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       433        602        847\nForeign Exchange Gains from LaR . .           .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .         5          2          6\nForeign Exchange Gains from FLAC              .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .       428        600        842\nForeign Exchange Losses . . . . . . . .       .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      (832)    (2,135)    (1,245)\nForeign Exchange Losses from LaR .            .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .        (3)        (3)        (2)\nForeign Exchange Losses from FLAC             .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      (496)      (705)    (1,103)\nNet result from financial instruments . . . . . . . . . . . . . . . . .                                                (5,573)    (8,419)   (10,312)\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.4843950406156477, "height": 0.3514322359982899, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-3", "text": "      The increase of the Group\u2019s net result from financial instruments in 2016 compared to financial year 2015\nis attributable to foreign exchange effects and the decline in interest expenses.\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5335613510047028, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-4", "text": "    The impairment of available-for-sale financial assets in 2014 relates to write downs of stakes in companies\nwhich are not included in the Group\u2019s consolidated financial statements.\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5677640017101325, "height": 0.027789653698161554, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-5", "text": "7.   Other disclosures\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5844377939290295, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.5951261222744763, "height": 0.010688328345446751, "width": 0.16928657799274482}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-6", "text": "7.1 Notes to the consolidated statement of cash flows", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.6156477126977341, "height": 0.010688328345446751, "width": 0.40205562273276907}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-7", "text": "     The consolidated statement of cash flows was prepared in accordance with IAS 7 Statement of Cash Flows\nand shows the changes in the Group\u2019s cash and cash equivalents during the course of the reporting period due\nto cash inflows and outflows.\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6660966224882429, "height": 0.04061564771269777, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-8", "text": "     Under IAS 7, cash flows are disclosed separately based on origin and use between the operating sector and\nthe cash flows from the investment and financing activities. The cash inflows and outflows from operating\nactivities are derived indirectly from the Group\u2019s profit or loss for the year. Cash inflows and outflows from\ninvesting and financing activities are derived directly. The funds in the consolidated statement of cash flows\ncorrespond to the value of cash and cash equivalents and bank overdrafts in the consolidated statement of\nfinancial position. Cash and cash equivalents include the freely available cash deposits and deposits with\nfinancial institutions.\n", "page_number": 306, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7729799059427106, "height": 0.09619495510902099, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-306-9", "text": "F-81", "page_number": 306, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-0", "text": "7.2 Other financial obligations and contingent liabilities\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.0645575032064985, "lower_right_x": 0.5362756952841596, "lower_right_y": 0.07866609662248825, "height": 0.014108593415989745, "width": 0.4195888754534462}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-1", "text": "Obligations from finance leases\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.2230955259975816}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-2", "text": "     The Group has entered into various lease agreements for various vehicles and technical equipment; the\nstructure of those lease agreements requires them to be recognised as finance leases. The agreements do not\ncontain escalation clauses.\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1466438648995297, "height": 0.041043180846515606, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-3", "text": "     Future minimum lease payments under finance leases and lease-purchase contracts together with the\npresent value of the net minimum lease payments are as follows:\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.18469431380932022, "height": 0.02778965369816161, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-4", "text": "                                  31 December 2016          31 December 2015          31 December 2014            1 January 2014\n                                Min. lease   PV min       Min. lease   PV min       Min. lease   PV min       Min. lease    PV min\nkEUR                             pymts.    lease pymts.    pymts.    lease pymts.    pymts.    lease pymts.    pymts.     lease pymts.\n\nWith a remaining term\n of up to one year . .                235          223          259          239          260          231          290           258\nWith a remaining term\n of between one and\n five years . . . . . . .             157          151          290          277          412          387          500           462\nWith a remaining term\n of more than five\n years . . . . . . . . . .              5            5           13           12           \u2014            \u2014            \u2014             \u2014\nTotal . . . . . . . . . . . .         397          379          562          528          672          618          790           720\nLess financing costs . .              (18)          \u2014           (33)          \u2014           (52)          \u2014            (70)          \u2014\nPresent value of\n  minimum lease\n  payments . . . . . . .              379          379          529          528          620          618          720           720\nOf which current\n  liabilities . . . . . . . .          \u2014           223           \u2014           239           \u2014           231           \u2014            258\nOf which non-current\n  liabilities . . . . . . . .          \u2014           156           \u2014           289           \u2014           387           \u2014            462\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.46515604959384355, "height": 0.2706284737067123, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-5", "text": "Obligations from operating leases\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.35308343409915355, "lower_right_y": 0.4959384352287302, "height": 0.014108593415989745, "width": 0.23760580411124543}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-6", "text": "     The Group has concluded lease agreements for office and warehouse spaces, various vehicles and office\nequipment. These leases have an average term of between one and five years. Some of the lease agreements\nrenew automatically if they are not terminated within a certain notice period. The Group is not subject to any\nlimitations by the leasing agreements.\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5604959384352287, "height": 0.058144506199230395, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-7", "text": "At 31 December the following future minimum leasing obligations from non-cancellable operating leases\n", "page_number": 307, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5814450619923044, "height": 0.01410859341598969, "width": 0.7309552599758162}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-8", "text": "existed:\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5818725951261223, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.5938435228730227, "height": 0.01197092774690034, "width": 0.05320435308343409}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-9", "text": "                                                               31 December   31 December   31 December   1 January\nkEUR                                                               2016          2015          2014         2014\nUp to 1 year . . . . . . . . . . . . . . . . . . . . . . . .        1,695         1,781         1,677        1,721\nAbove 1 year and up to 5 years . . . . . . . . . . . .              2,111         2,844         2,889        2,093\nAbove 5 years . . . . . . . . . . . . . . . . . . . . . . .         5,167         5,267         5,367        5,467\nTotal   . ..... .... ..... .... .... ..... .                        8,973         9,892         9,933        9,281\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.695168875587858, "height": 0.08678922616502771, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-10", "text": "    In the financial year 2016, expenses from operating leases amounted to kEUR 2,118 (2015: kEUR 1,952;\n2014: kEUR 1,988).\n", "page_number": 307, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7456177853783669, "height": 0.031209918768704603, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-307-11", "text": "F-82", "page_number": 307, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-0", "text": "Other financial obligations\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.0645575032064985, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.07866609662248825, "height": 0.014108593415989745, "width": 0.1874244256348247}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-1", "text": "Litigation\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.18863361547763, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.0731559854897219}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-2", "text": "     In the course of its business activities, Dermapharm is regularly exposed to numerous legal risks,\nparticularly in the areas of product liability, competition, intellectual property disputes and tax matters. The\nfollowing legal disputes are the only material proceedings that Dermapharm is currently involved in or was\ninvolved in during the past twelve months:\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.1633176571184267, "height": 0.05771697306541258, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-3", "text": "\u2022   In 2009, Israel-based SuperMedic (MediLight) Ltd. and various related parties (together\n    \u201cSuperMedic\u201d) asserted claims for damages and infringement of intellectual property in an\n    aggregate amount of approximately kEUR 9,700 against Anton H\u00fcbner GmbH & Co. KG relating to\n    the termination of a distribution agreement between the parties concerning certain products and an\n    alleged trademark infringement concerning the \u201cTannenblut\u201d trademark in Israel. At the time, Anton\n    H\u00fcbner GmbH & Co. KG was owned by Nordzucker AG and filed a counterclaim against\n    SuperMedic for infringement of this trademark, seeking to cancel SuperMedic\u2019s registration as owner\n    of the \u201cTannenblut\u201d trademark in Israel before the Israeli Trademark Office. In accordance with the\n    share purchase agreement between Dermapharm AG and Nordzucker AG dated 8 December 2010,\n    Nordzucker AG was required to bear all financial risks arising from SuperMedic\u2019s lawsuit. In May\n    2017, Anton H\u00fcbner GmbH & Co. KG and SuperMedic settled the dispute. SuperMedic agreed to\n    pay compensation in an amount of 100,000 Israeli shekels (approximately kEUR 24) and to recognise\n    the trademarks asserted by Anton H\u00fcbner GmbH & Co. KG, in particular the \u201cTannenblut\u201d\n    trademark.\n\u2022   In addition, Dermapharm filed a lawsuit against UniCredit Bank AG (\u201cUniCredit\u201d) before the\n    regional court of Munich in December 2011. Dermapharm demands the rescission of certain\n    currency-related swap transactions entered into with UniCredit between 2006 and 2010, as well as\n    payments in an aggregate amount of approximately kEUR 20,093. Dermapharm entered into these\n    transactions as part of its interest rate hedging and optimisation strategy and is of the opinion that\n    UniCredit breached its obligation to properly advise Dermapharm on the risks associated with these\n    transactions. Given that Dermapharm is acting as claimant, this lawsuit generally only provides\n    upside to Dermapharm. The lawsuit was dismissed in the first two instances. Dermapharm has filed\n    an appeal against denial of leave to appeal with the German Federal Supreme Court and expects that\n    a decision will be made shortly. Although the company has lost in the first two instances, there a\n    several precedents which gave justice to the claimants. Dermapharm did not recognise a provision for\n    this legal claim, since the parent company of the Dermapharm AG, Themis Beteiligungs AG, will\n    cover all losses and all legal costs. An agreement to this effect was signed on 20 December 2013.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5609234715690466, "height": 0.3971782813168021, "width": 0.7303506650544135}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-4", "text": "     In addition to the above-mentioned legal disputes, the Group is involved in other legal proceedings;\nhowever, none of these are material to the Group\u2019s financial position and are within the scope of normal\nbusiness.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6079521162890124, "height": 0.040615647712697656, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-5", "text": "     Apart from the proceedings described above, Dermapharm is not aware of any governmental, legal or\narbitration proceedings (whether pending or threatened) which may have, or have had, a significant effect on\nDermapharm\u2019s financial position or profitability.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6596836254809748, "height": 0.04104318084651559, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-6", "text": "Guarantees\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.685335613510047, "height": 0.01197092774690034, "width": 0.07799274486094317}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-7", "text": "    There were no material guarantees as at 31 December 2016 or as at the 31 December 2015, 31 December\n2014 or 1 January 2014 balance sheet dates.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7216759298845661, "height": 0.027789653698161665, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-8", "text": "Contingent liabilities\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.7520307823856349, "height": 0.013681060282171864, "width": 0.14993954050785974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-9", "text": "    There were no material contingent liabilities as at 31 December 2016 or as at the 31 December 2015,\n31 December 2014 or 1 January 2014 balance sheet dates.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7866609662248825, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-10", "text": "Purchase commitments\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.8067550235143224, "height": 0.010260795211628926, "width": 0.16505441354292621}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-11", "text": "    At 31 December 2016, the Group has purchase commitments relating to inventories of kEUR 72,985 (31\nDecember 2015: kEUR 88,969; 31 December 2014: kEUR 65,401; 1 January 2014: kEUR 65,174).\n", "page_number": 308, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.844377939290295, "height": 0.027362120564343728, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-308-12", "text": "F-83", "page_number": 308, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-0", "text": "7.3 Collateral\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.0645575032064985, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.11064087061668683}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-1", "text": "     At 31 December 2016, intangible assets (mainly medical licences) with a carrying amount of kEUR 2,242\n(31 December 2015: kEUR 2,462; 31 December 2014: kEUR 2,363; 1 January 2014: kEUR 2,575) were\npledged to different banks in order to provide collateral for bank loans.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.12654980761008977, "height": 0.04147071398033346, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-2", "text": "     In 2013, Dermapharm, as seller, entered into two sale purchase agreements relating to all of its shares in\nProfarma sha and Galaxy shpk. The parties agreed that shares reflecting 51% of the share capital of Profarma\nand Galaxy shall be retained by Dermapharm until the purchase price is fully paid to Dermapharm. The\noutstanding purchase price was paid in 2016.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13595553655408293, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.1911073108165883, "height": 0.055151774262505365, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-3", "text": "    The Group did not hold any further collateral as at 31 December 2016 or as at the 31 December 2015 and\n31 December 2014 balance sheet dates.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19794784095767423, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22402736212056434, "height": 0.026079521162890112, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-4", "text": "Related party disclosures\n", "page_number": 309, "bounding_box": {"top_left_x": 0.154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.343409915356711, "lower_right_y": 0.2552372808892689, "height": 0.012825994014536102, "width": 0.18863361547763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-5", "text": "8.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.12998790810157196, "lower_right_y": 0.25309961522017954, "height": 0.010688328345446751, "width": 0.014510278113663858}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-6", "text": "     Related parties as defined in IAS 24 Related Party Disclosures are those legal entities and natural persons\nthat are able to exert influence on Dermapharm and its subsidiaries or over which the company or its\nsubsidiaries exercise control or joint control or have a significant influence. In the scope of the ordinary course\nof business, Dermapharm and its subsidiaries or over which the company or its subsidiaries exercise control or\njoint control or have a significant influence have entered into related party transactions. In principle, all trades\nare settled with related companies and natural persons at market-rate conditions and all outstanding balances\nwith related parties are priced on an arm\u2019s length basis. Key Management Personnel includes members of the\nManagement Board and the Supervisory Board. Significant Shareholders are those who own or are the\nbeneficial owners of more than ten percent of the Dermapharm\u2019s voting shares.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2556648140230868, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.38991021804189824, "height": 0.13424540401881147, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-7", "text": "     Transactions with related parties for the financial years ended 31 December 2014, 2015 and 2016 between\nthe Group and Significant Shareholders and other related parties are summarised below.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3963232150491663, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4241128687473279, "height": 0.02778965369816161, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-8", "text": "Significant transactions\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4407866609662249, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.45404018811457886, "height": 0.013253527148353983, "width": 0.16444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-9", "text": "Significant related shareholder transactions:\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.47498931167165453, "height": 0.020521590423257796, "width": 0.3053204353083434}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-10", "text": "kEUR                                                                                  2016      2015      2014\nConsultancy services . . . . . . . . . . . . . . . . . . . . . . . . . . . . .          1,314     1,216     1,337\nCompensation from Dermapharm CH . . . . . . . . . . . . . . . . . .                       113       116       102\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     1,427     1,332     1,439\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.48525010688328346, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5523728088926891, "height": 0.06712270200940568, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-11", "text": "     The consultancy services consist of marketing and advertising costs and related activities rendered by\nsignificant shareholders.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5985463873450192, "height": 0.027789653698161554, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-12", "text": "Compensation from Dermapharm CH results from salary payments to Wilhelm Beier.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6083796494228303, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.6207781103035486, "height": 0.012398460880718276, "width": 0.6003627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-309-13", "text": "F-84", "page_number": 309, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-310-0", "text": "Significant related party transactions\n\nkEUR                                                                                  2016         2015         2014\nParent company (Themis Beteiligungsgesellschaft               AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . .         .... .... ...            24,423       25,853       11,191\nNon-consolidated subsidiaries . . . . . . . . . . . .         .... .... ...                \u2014           597           \u2014\nAssociated companies . . . . . . . . . . . . . . . . .        .... .... ...               926          963        1,990\nProfit and loss transfer agreement . . . . . . . . . . . . . . . . . . . .             25,350       27,414       13,182\nParent company (Themis Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .            15,270        1,561             572\nFinancial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .        15,270        1,561             572\nParent company (Themis Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             3,848              \u2014      4,242\nIndirect taxes from tax group . . . . . . . . . . . . . . . . . . . . . . .             3,848              \u2014      4,242\nParent company (Themis Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             1,611              \u2014      1,229\nNon-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . . .               103             229       654\nInterest    ... ..... .... .... ..... .... ..... .... ...                               1,714             229     1,883\nParent company (Themis Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                  591          420          210\nNon-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . . .                  577          558          840\nConsultancy services . . . . . . . . . . . . . . . . . . . . . . . . . . . . .          1,168             978     1,050\nParent company (Themis Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                  944           \u2014           554\nNon-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . . .                   68           48          213\nOther services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .        1,012              49          767\nNon-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . . .                   \u2014            \u2014      1,179\nAssociated companies . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 214           17        \u2014\nPurchase of goods . . . . . . . . . . . . . . . . . . .       .... ..     .. ...             214           17     1,179\nParent company (Themis Beteiligungsgesellschaft               AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . .         .... ..     .. ...              \u2014      2,223       23,878\nNon-consolidated subsidiaries . . . . . . . . . . . .         .... ..     .. ...              \u2014      4,971       35,971\nAssociated companies . . . . . . . . . . . . . . . . .        .... ..     .. ...             145        91           \u2014\nLoans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .            145     7,285       59,848\nParent company (Themis Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                   \u2014      7,152           \u2014\nNon-consolidated subsidiaries . . . . . . . . . . . . . . . . . . . . . . .                   \u2014         \u2014         8,932\nSale of companies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 \u2014      7,152        8,932\nTotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    48,720       44,685       91,655\n", "page_number": 310, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6908935442496793, "height": 0.6263360410431809, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-310-1", "text": "     Related party transactions arise primarily from the profit and loss transfer agreement with Themis\nBeteiligungs AG.\n    Related party transactions from financial instruments result from the currency-related swap with the\nUniCredit Bank AG. For further information please refer to 7.2c) Litigations.\n    Loans in 2014 mainly comprise loans from Themis Beteiligungs AG, Gr\u00fcnwald, and SLG Service\nLogistik, Leuna, to Channel 21, Gr\u00fcnwald.\n    For further information on the sale of companies please refer to section 2.4. Basis of consolidation.\n", "page_number": 310, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.827704147071398, "height": 0.12013681060282178, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-310-2", "text": "F-85", "page_number": 310, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-311-0", "text": "Year-end balances of significant related parties\n", "page_number": 311, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.3295042321644498}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-311-1", "text": "                                                                                31 December   31 December   31 December   1 January\nkEUR                                                                                2016          2015          2014         2014\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . .       ... ..... .                                 \u2014             \u2014             \u2014        73,393\nPayables from profit and loss transfer      agreement . .                               \u2014             \u2014             \u2014        73,393\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . .       ... ..... .                              3,848            \u2014          3,821        3,627\nPayables from Indirect taxes from tax       group . . . .                            3,848            \u2014          3,821        3,627\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . .       .   .   .   .   .   .   .   .   .          420           420           210          420\nPayables from consultancy services .        .   .   .   .   .   .   .   .   .          420           420           210          420\nNon-consolidated subsidiaries . . . . .     .   .   .   .   .   .   .   .   .           \u2014             \u2014             31           \u2014\nPayables from other services . . . . .      .   .   .   .   .   .   .   .   .           \u2014             \u2014             31           \u2014\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . .       ... ..... .                                 10            50        24,386          115\nPayables from loans . . . . . . . . . . .   ... ..... .                                 10            50        24,386          115\nTotal   . ..... .... ..... .... .... ..... .                                         4,278           470        28,448       77,555\n", "page_number": 311, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0778110303548525, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.38820008550662677, "height": 0.3103890551517743, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-311-2", "text": "F-86", "page_number": 311, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-0", "text": "                                                                31 December   31 December   31 December   1 January\nkEUR                                                                2016          2015          2014         2014\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .             24,423        25,853        11,191            \u2014\nNon-consolidated subsidiaries . . . . . . . . . . . . . .               \u2014            597            \u2014             \u2014\nReceivables from profit and loss transfer\n  agreement . . . . . . . . . . . . . . . . . . . . . . . . .       24,423        26,451        11,191            \u2014\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .             15,270         1,561           572            \u2014\nReceivables from financial instruments . . . . . . . .              15,270         1,561           572            \u2014\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .                 \u2014             \u2014            976          495\nReceivables from Indirect taxes from tax group . .                      \u2014             \u2014            976          495\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .                 \u2014             \u2014             \u2014            \u2014\nNon-consolidated subsidiaries . . . . . . . . . . . . . .               20             1            59          622\nReceivables from other services         .. .... ..... .                 20              1           59          622\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .                 \u2014             \u2014             \u2014             \u2014\nNon-consolidated subsidiaries . . . . . . . . . . . . . .               \u2014             \u2014            179            \u2014\nReceivables from purchase of goods . . . . . . . . . .                  \u2014             \u2014            179            \u2014\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .                 \u2014          2,223            \u2014            \u2014\nNon-consolidated subsidiaries . . . . . . . . . . . . . .                6         5,013        36,729       56,881\nAssociated companies . . . . . . . . . . . . . . . . . . .              90            \u2014             \u2014            \u2014\nReceivables from loans . . . . . . . . . . . . . . . . . .              96         7,236        36,729       56,881\nParent company (Themis\n  Beteiligungsgesellschaft AG) of\n  Dermapharm AG . . . . . . . . . . . . . . . . . . . .                 \u2014          7,152            \u2014            \u2014\nNon-consolidated subsidiaries . . . . . . . . . . . . . .               \u2014             \u2014          8,932       24,590\nReceivables from sale of companies . . . . . . . . . .                  \u2014          7,152         8,932       24,590\nTotal    . ..... .... ..... .... .... ..... .                       39,809        42,400        58,638       82,589\n", "page_number": 312, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.061137238135955535, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6601111586147926, "height": 0.5989739204788371, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-1", "text": "     Receivables from the sale of companies amounting to kEUR 6,534 were past due and not impaired. The\nreceivables result from the sale of shares between Centuere AG and Channel 21 Holding. All other receivables\nfrom related parties are fully performing. For further information on the sale of companies please refer to\nsection 2.4. Basis of consolidation.\n", "page_number": 312, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.731936725096195, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-2", "text": "Key Management personnel compensation\n", "page_number": 312, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.4153567110036276, "lower_right_y": 0.75502351432236, "height": 0.013253527148354038, "width": 0.2998790810157195}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-3", "text": "The members of the Key Management were remunerated as follows:\n", "page_number": 312, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.7622915775972637, "lower_right_x": 0.6330108827085853, "lower_right_y": 0.7764001710132535, "height": 0.0141085934159898, "width": 0.4836759371221282}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-4", "text": "kEUR                                                                           2016      2015      2014\nShort-term employee benefits . . . . . . . . . . . . . . . . . . . . . . .       2,177     1,720     1,510\nLong-term employee benefits . . . . . . . . . . . . . . . . . . . . . . .           43        44        44\nTotal remuneration . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     2,220     1,764     1,554\n", "page_number": 312, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8503634031637451, "height": 0.06412997007268062, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-5", "text": "     The members of Key Management are only compensated due to their function as a person in a key\nposition.\n", "page_number": 312, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8717400598546388, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8995297135528003, "height": 0.027789653698161554, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-312-6", "text": "F-87\n", "page_number": 312, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9345874305258658, "height": 0.011543394613082514, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-0", "text": "9.   Disclosures on the Management Board and the Supervisory Board\n     The Company\u2019s corporate boards are composed as follows:\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6523579201934704, "lower_right_y": 0.09918768704574604, "height": 0.03463018383924754, "width": 0.5368802902055623}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-1", "text": "Members of the Management Board of Dermapharm AG:\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11244121419410004, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.12654980761008977, "height": 0.014108593415989731, "width": 0.40689238210399037}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-2", "text": "Name                                                                                                                                                                   Position\nWilhelm Beier . . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      Chief Executive Officer\nDr. Hans-Georg Feldmeier        .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      Chief Operating Officer\nStefan Grieving . . . . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    Head of Marketing & Sales\nKarin Samusch . . . . . . .     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   Head of Business Development\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.21205643437366395, "height": 0.07225309961522017, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-3", "text": "Members of the Supervisory Board of Dermapharm AG:\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.2394185549380077, "height": 0.014108593415989745, "width": 0.40205562273276907}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-4", "text": "Name                                                                                                                                                                 Position\nElisabeth Beier . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   Chairman of the Supervisory Board\nDr. Erwin Kern . . .    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   Member of the Supervisory Board\nMichael Beier . . . .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   Member of the Supervisory Board\nEckhard Strohscheer     .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   Member of the Supervisory Board\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2526720820863617, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.32492518170158186, "height": 0.07225309961522014, "width": 0.7666263603385731}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-5", "text": "     In the financial years presented, there were no pension obligations due to members of Key Management or\nformer members of Key Management. However, the Supervisory Board members are covered by a Group D&O\ninsurance policy.\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.880894800483676, "lower_right_y": 0.3817870884993587, "height": 0.043608379649422824, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-6", "text": "10.   Events after the reporting period\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3963232150491663, "lower_right_x": 0.40447400241837966, "lower_right_y": 0.41000427533133815, "height": 0.013681060282171864, "width": 0.28899637243047155}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-7", "text": "     Events after the reporting date with a significant or possibly significant impact on the net assets, financial\npositions and results of operations of the Group:\n", "page_number": 313, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4446344591705857, "height": 0.027789653698161554, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-8", "text": "\u2022   On 1 January 2017, the Group acquired the remaining 15% stake in axicorp GmbH, Friedrichsdorf,\n    Germany, from DU Verm\u00f6gensverwaltungs GmbH, Weiden, Germany. The acquisition increases the\n    stake in axicorp GmbH from 85% to 100%.\n\u2022   The Group company axicorp GmbH acquired the remaining 24.9% stake in Remedix GmbH,\n    Friedrichsdorf, Germany, from a private stakeholder on 1 March 2017. The Group now owns all of\n    the shares in Remedix GmbH.\n\u2022   On 5 July 2017, mibe Logistik & Services GmbH & Co. KG, headquartered in Sandersdorf-Brehna,\n    Germany, was founded. The object of the company is the operation of logistic services and other\n    various services. mibe Logisitik & Services GmbH & Co. KG is a wholly owned subsidiary of mibe\n    GmbH.\n\u2022   With effect from 1 September 2017, Stefan H\u00fcmer took over as Chief Financial Officer of the Group.\n\u2022   With effect from 18 August 2017, Cancernova GmbH onkologische Arzneimittel was merged with\n    Mibe GmbH Arzneimittel.\n\u2022   On 20 September 2017 (Closing Date), the group acquired the assets pertaining to the hyperthermic\n    medical devises division of Riemser Pharma GmbH, Greifswald-Insel Riems. The acquired division\n    has a highly innovative medical applications portfolio selectively targeting mosquito and insect\n    stitches (bite away), herpes blisters (Herpotherm) as well as a development project focusing on\n    dermatitis and its accompanying symptoms. The acquisition provides further growth potential for the\n    Group. The acquired assets include the business intellectual property rights, the technical know-how\n    of the division, the commercial know-how, the purchased regulatory approvals, as well as the\n    inventories. Moreover, the employment relationships of some employees of the division were\n    transferred to Dermapharm at the closing date. At the time these financial statements were approved\n    for publication, the assessment of the applicable accounting requirements is ongoing.\n", "page_number": 313, "bounding_box": {"top_left_x": 0.15417170495767835, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8140230867892262, "height": 0.35955536554082945, "width": 0.7309552599758162}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-9", "text": "", "page_number": 313, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.4553227875160325, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.46130825138948267, "height": 0.00598546387345017, "width": 0.0042321644498186095}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-10", "text": "\u2022\n", "page_number": 313, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.5057716973065413, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.5117571611799915, "height": 0.005985463873450225, "width": 0.003627569528415947}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-11", "text": "", "page_number": 313, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.5545104745617785, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.5604959384352287, "height": 0.005985463873450225, "width": 0.0042321644498186095}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-12", "text": "", "page_number": 313, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.6186404446344592, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.6254809747755451, "height": 0.0068405301410858765, "width": 0.003627569528415947}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-13", "text": "", "page_number": 313, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6400171013253527, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.646002565198803, "height": 0.005985463873450225, "width": 0.0042321644498186095}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-14", "text": "", "page_number": 313, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.6772124839675074, "lower_right_x": 0.15356711003627568, "lower_right_y": 0.6802052159042326, "height": 0.0029927319367251126, "width": 0.003627569528415947}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-313-15", "text": "F-88", "page_number": 313, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-0", "text": "On 21 September 2017, the Group acquired all of the shares and voting interests in Bio-Di\u00e4t-Berlin\n", "page_number": 314, "bounding_box": {"top_left_x": 0.18319226118500603, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.0778110303548525, "height": 0.013253527148353997, "width": 0.6995163240628779}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-1", "text": "", "page_number": 314, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.06797776827704147, "lower_right_x": 0.15719467956469166, "lower_right_y": 0.07182556648140231, "height": 0.003847798204360847, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-2", "text": "    GmbH, Berlin, along with its wholly owned distribution subsidiary Kr\u00e4uter K\u00fchne GmbH, Berlin,\n    from the former shareholder. The transaction closed on 1 October 2017.\n\u2022   The acquired companies are successfully producing and marketing phytopharmaceuticals (herbal\n    medicines) as well as homoeopathics and natural cosmetics. Kr\u00e4uter K\u00fchne GmbH, Berlin, operates\n    16 sales outlets, an online shop and related services. With the acquisition, the Group intends to extend\n    its product pipeline. The purchase price amounts to kEUR 14,500.\n\u2022   Due to the timing of the transaction, it was not yet possible to provide any information about the fair\n    value of the acquired assets and liabilities because the purchase price allocation is not yet finalised.\n\u2022   On December 12, 2017, Dermapharm entered into a sale and purchase agreement for the acquisition\n    of all shares in Trommsdorff GmbH & Co. KG and Cl. Lageman Gesellschaft mit beschr\u00e4nkter\n    Haftung (together, \u201cTrommsdorff\u201d). Trommsdorff markets 23 different prescription pharmaceuticals\n    and OTC products, in particular Keltican\u00ae forte, a dietary product for the treatment of back pain, and\n    Tromcardin\u00ae complex, which combines certain minerals and vitamins for the treatment of cardiac\n    arrhythmia. Trommsdorff also serves its former parent group as a toll manufacturer. The acquisition\n    of Trommsdorff is subject to approval by the German Federal Cartel Office (Bundeskartellamt) and is\n    expected to close in the first quarter of the fiscal year ending December 31, 2018. The parties agreed\n    to keep the purchase price confidential. Due to the timing of the Transaction, it was not yet possible\n    to provide any information about the fair value of the transaction.\n\u2022   On December 20, 2017, Dermapharm acquired all shares in Strathmann GmbH & Co. KG,\n    Strathmann Service GmbH and Biokirch GmbH Pharmaproduktion und \u00c4rzteservice (together,\n    \u201cStrathmann\u201d). Strathmann manufactures a broad product offering primarily comprising OTC\n    products, which complement Dermapharm\u2019s existing product portfolio, in particular with respect to\n    the dermatologicals, women\u2019s healthcare and vitamins/minerals/enzymes product areas. The parties\n    agreed to keep the purchase price confidential. Due to the timing of the Transaction, it was not yet\n    possible to provide any information about the fair value of the transaction.\n\u2022   In order to finance the acquisition of \u201cTrommsdorff\u201d, Dermapharm entered in a new bank loan\n    agreement with Baden-W\u00fcrttembergische Bank. The payment of the loan will made after the approval\n", "page_number": 314, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.07823856348867037, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4959384352287302, "height": 0.41769987174005985, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-3", "text": "by the German Federal Cartel Office (Bundeskartellamt).\n", "page_number": 314, "bounding_box": {"top_left_x": 0.18319226118500603, "top_left_y": 0.4963659683625481, "lower_right_x": 0.5846432889963724, "lower_right_y": 0.5096194955109021, "height": 0.013253527148354038, "width": 0.4014510278113664}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-4", "text": "Gr\u00fcnwald, 29 December 2017, the Management Board\n", "page_number": 314, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.5391192817443352, "height": 0.012825994014536102, "width": 0.38754534461910517}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-5", "text": "Stefan H\u00fcmer              Karin Samusch\nChief Financial Officer   Head of Business Development\n", "page_number": 314, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.5610640870616687, "lower_right_y": 0.5810175288584866, "height": 0.027362120564343728, "width": 0.44558645707376054}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-314-6", "text": "F-89", "page_number": 314, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-0", "text": "AUDITOR\u2019S OPINION\n", "page_number": 315, "bounding_box": {"top_left_x": 0.4105199516324063, "top_left_y": 0.0645575032064985, "lower_right_x": 0.585247883917775, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.17472793228536876}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-1", "text": "Independent Auditor\u2019s Report\nTo Dermapharm AG\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.34280532043530837, "lower_right_y": 0.11970927746900385, "height": 0.03463018383924754, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-2", "text": "Opinion\n", "page_number": 315, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.13638306968790082, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.14878153056861906, "height": 0.012398460880718248, "width": 0.062273276904474}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-3", "text": "     We have audited the consolidated financial statements of Dermapharm AG, Gr\u00fcnwald, and its subsidiaries\n(the Group), which comprise the consolidated statements of financial position as at 31 December 2016, 31\nDecember 2015 and 31 December 2014, and the consolidated statements of comprehensive income,\nconsolidated statements of changes in equity and consolidated statements of cash flows for the years then\nended, and notes to the consolidated financial statements, including a summary of significant accounting\npolicies.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2394185549380077, "height": 0.0825138948268491, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-4", "text": "    In our opinion, the accompanying consolidated financial statements give a true and fair view of the\nconsolidated financial position of the Group as at 31 December 2016, 31 December 2015 and 31 December\n2014, and of its consolidated financial performance and its consolidated cash flows for the years then ended in\naccordance with International Financial Reporting Standards as adopted by the EU.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.30440359127832406, "height": 0.05515177426250534, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-5", "text": "Basis for Opinion\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3185121846943138, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.3317657118426678, "height": 0.013253527148353983, "width": 0.13603385731559853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-6", "text": "     We conducted our audit in accordance with International Standards on Auditing (ISAs). Our\nresponsibilities under those standards are further described in the \u201cAuditor\u2019s Responsibilities for the Audit\nof the Consolidated Financial Statements\u201d section of our report. We are independent of the Group in\naccordance with the ethical requirements that are relevant to our audit of the consolidated financial statements\nin Germany, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We\nbelieve that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4241128687473279, "height": 0.08251389482684907, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-7", "text": "Responsibilities of Management and Supervisory Board for the Consolidated Financial Statements\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.845223700120919, "lower_right_y": 0.45404018811457886, "height": 0.013253527148353983, "width": 0.7297460701330108}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-8", "text": "     Management is responsible for the preparation of the consolidated financial statements that give a true and\nfair view in accordance with International Financial Reporting Standards as adopted by the EU, and for such\ninternal control as management determines is necessary to enable the preparation of consolidated financial\nstatements that are free from material misstatement, whether due to fraud or error.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.516460025651988, "height": 0.05515177426250534, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-9", "text": "      In preparing the consolidated financial statements, management is responsible for assessing the Group\u2019s\nability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the\ngoing concern basis of accounting unless management either intends to liquidate the Group or to cease\noperations, or has no realistic alternative but to do so.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.5810175288584866, "height": 0.054724241128687456, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-10", "text": "The Supervisory Board is responsible for overseeing the Group\u2019s financial reporting process.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.15114873035066506, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8010882708585247, "lower_right_y": 0.6019666524155622, "height": 0.0141085934159898, "width": 0.6499395405078596}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-11", "text": "Auditor\u2019s Responsibilities for the Audit of the Consolidated Financial Statements\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.720677146311971, "lower_right_y": 0.6314664386489953, "height": 0.012825994014536102, "width": 0.6051995163240629}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-12", "text": "     Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a\nwhole are free from material misstatement, whether due to fraud or error, and to issue an auditor\u2019s report that\nincludes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit\nconducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements\ncan arise from fraud or error and are considered material if, individually or in the aggregate, they could\nreasonably be expected to influence the economic decisions of users taken on the basis of these consolidated\nfinancial statements.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.735356990166738, "height": 0.09619495510902099, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-13", "text": "     As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional\nskepticism throughout the audit. We also:\n", "page_number": 315, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7729799059427106, "height": 0.027789653698161665, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-14", "text": "\u2022   Identify and assess the risks of material misstatement of the consolidated financial statements,\n    whether due to fraud or error, design and perform audit procedures responsive to those risks, and\n    obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of\n    not detecting a material misstatement resulting from fraud is higher than for one resulting from error,\n    as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of\n    internal control.\n", "page_number": 315, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8627618640444634, "height": 0.08336896109448477, "width": 0.7351874244256348}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-315-15", "text": "F-90\n", "page_number": 315, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-316-0", "text": "\u2022   Obtain an understanding of internal control relevant to the audit in order to design audit procedures\n    that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the\n    effectiveness of the Group\u2019s internal control.\n\u2022   Evaluate the appropriateness of accounting policies used and the reasonableness of accounting\n    estimates and related disclosures made by management.\n\u2022   Conclude on the appropriateness of management\u2019s use of the going concern basis of accounting and,\n    based on the audit evidence obtained, whether a material uncertainty exists related to events or\n    conditions that may cast significant doubt on the Group\u2019s ability to continue as a going concern. If we\n    conclude that a material uncertainty exists, we are required to draw attention in our auditor\u2019s report to\n    the related disclosures in the consolidated financial statements or, if such disclosures are inadequate,\n    to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our\n    auditor\u2019s report. However, future events or conditions may cause the Group to cease to continue as a\n    going concern.\n\u2022   Evaluate the overall presentation, structure and content of the consolidated financial statements,\n    including the disclosures, and whether the consolidated financial statements represent the underlying\n    transactions and events in a manner that achieves fair presentation.\n\u2022   Obtain sufficient appropriate audit evidence regarding the financial information of the entities or\n    business activities within the Group to express an opinion on the consolidated financial statements.\n    We are responsible for the direction, supervision and performance of the group audit. We remain\n    solely responsible for our audit opinion.\n", "page_number": 316, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3758016246259085, "height": 0.31124412141941, "width": 0.7357920193470374}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-316-1", "text": "     We communicate with those charged with governance regarding, among other matters, the planned scope\nand timing of the audit and significant audit findings, including any significant deficiencies in internal control\nthat we identify during our audit.\n", "page_number": 316, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4241128687473279, "height": 0.04147071398033347, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-316-2", "text": "D\u00fcsseldorf, 15 January 2018\n", "page_number": 316, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.45404018811457886, "height": 0.013253527148353983, "width": 0.2037484885126965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-316-3", "text": "Warth & Klein Grant Thornton AG\nWirtschaftspr\u00fcfungsgesellschaft\n", "page_number": 316, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.5096194955109021, "height": 0.027789653698161665, "width": 0.2521160822249093}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-316-4", "text": "Dr. Thomas Senger         Andr\u00e9 Prengel\nWirtschaftspr\u00fcfer         Wirtschaftspr\u00fcfer\n(German Public Auditor)   (German Public Auditor)\n", "page_number": 316, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.5814450619923044, "height": 0.04147071398033342, "width": 0.3778718258766626}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-316-5", "text": "F-91\n", "page_number": 316, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-317-0", "text": "Audited individual financial statements of Dermapharm Holding SE as of September 30, 2017 and for\n      the period from July 12, 2017 to September 30, 2017 prepared in accordance with IFRS\n", "page_number": 317, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4754168448054724, "height": 0.02778965369816161, "width": 0.76360338573156}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-317-1", "text": "F-92\n", "page_number": 317, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-318-0", "text": "    Dermapharm Holding SE\n            Gr\u00fcnwald\n(former Blitz 17-663 SE, Munich)\n", "page_number": 318, "bounding_box": {"top_left_x": 0.3724304715840387, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.10560068405301411, "height": 0.041043180846515606, "width": 0.25151148730350664}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-318-1", "text": "    Statement of financial position\nat 30 September 2017 and 12 July 2017\n", "page_number": 318, "bounding_box": {"top_left_x": 0.3482466747279323, "top_left_y": 0.11928174433518597, "lower_right_x": 0.6475211608222491, "lower_right_y": 0.15391192817443353, "height": 0.034630183839247555, "width": 0.2992744860943168}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-318-2", "text": "Assets\n                                                                                            30 September\nin EUR                                                                             Notes        2017       12 July 2017\nCURRENT ASSETS\nCash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . .           4.1    119,973.93      30,750.00\nTotal current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .               119,973.93      30,750.00\nTOTAL ASSETS            . .... .... ..... .... ..... .... ...                                119,973.93      30,750.00\n\nEquity and liabilities\n\n                                                                                            30 September\nin EUR                                                                             Notes        2017       12 July 2017\nEQUITY\nIssued capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .      4.2    120,000.00         30.750\nRetained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       4.2        (26.07)            \u2014\nTOTAL EQUITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                     119,973.93      30,750.00\n", "page_number": 318, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16973065412569474, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.41641727233860626, "height": 0.24668661821291152, "width": 0.7696493349455864}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-318-3", "text": "F-93\n", "page_number": 318, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5139056831922612, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.029625151148730322}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-319-0", "text": "                                                 Dermapharm Holding SE\n                                                         Gr\u00fcnwald\n                                             (former Blitz 17-663 SE, Munich)\n\n                                         Statement of comprehensive income for\n                                           the period ended 30 September 2017\n\n                                                                                                                    12 July -\nin EUR                                                                                             Notes       30 September 2017\nOther operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 5              (26.07)\nNet loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                          (26.07)\n", "page_number": 319, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.22274476271911073, "height": 0.15818725951261223, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-319-1", "text": "F-94\n", "page_number": 319, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-320-0", "text": "      Dermapharm Holding SE\n              Gr\u00fcnwald\n  (former Blitz 17-663 SE, Munich)\n\nStatement of cash flows for the period\n      ended 30 September 2017\n", "page_number": 320, "bounding_box": {"top_left_x": 0.3573155985489722, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6432889963724304, "lower_right_y": 0.1496365968362548, "height": 0.0850790936297563, "width": 0.2859733978234582}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-320-1", "text": "                                                                                                                                                                    12 July -\nin EUR                                                                                                                                             Notes       30 September 2017\nNet loss for the period . . . . . . . .   ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .           5             (26.07)\nNet cash from operating activities         .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                         (26.07)\nContributions to the issued capital .     ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .      4.2             89,250.00\nNet cash from financing activities        ..   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .                      89,250.00\nNet increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . .                                                                                   89,223.93\nCash and cash equivalents at 12 July 2017 . . . . . . . . . . . . . . . . . . . . . .                                                                 4.1            (30,750.00)\nCash and cash equivalents at 30 September 2017 . . . . . . . . . . . . . . . . . .                                                                    4.1            119,973.93\nNet change in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . .                                                                                   89,223.93\n", "page_number": 320, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.30782385634886705, "height": 0.14749893116716548, "width": 0.7732769044740024}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-320-2", "text": "F-95\n", "page_number": 320, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-321-0", "text": "     Dermapharm Holding SE\n             Gr\u00fcnwald\n (former Blitz 17-663 SE, Munich)\n\n  Statement of changes in equity at\n30 September 2017 and 12 July 2017\n", "page_number": 321, "bounding_box": {"top_left_x": 0.3573155985489722, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.14878153056861906, "height": 0.08422402736212056, "width": 0.281136638452237}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-321-1", "text": "                                                                                Issued     Retained\nin EUR                                                               Notes      capital    Earnings       Total\nAs at 12 July 2017 . . . . . . . . . . . . . . . . . . . . . .          4.2    30,750.00          \u2014      30,750.00\nContributions to the issued capital . . . . . . . . . . . . .           4.2    89,250.00          \u2014      89,250.00\nNet loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       5.           \u2014       (26.07)       (26.07)\nAs at 30 September 2017 . . . . . . . . . . . . . . . . . .             4.2   120,000.00      (26.07)   119,973.93\n", "page_number": 321, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.2509619495510902, "height": 0.09063702436938861, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-321-2", "text": "F-96\n", "page_number": 321, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-322-0", "text": "                                                       Table of contents\n\n1.   General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    F-98\n     1.1 Corporate information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .          F-98\n     1.2 First Time Adoption of IFRS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .              F-98\n2.   Significant accounting policies and changes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .              F-98\n     2.1 Basis of preparation of financial statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .               F-98\n     2.2 Effects of new or amended financial standards and interpretations . . . . . . . . . . . . . . . .                      F-98\n     2.3 Changes in accounting policies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             F-99\n     2.4 Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .            F-99\n     2.5 Recognition of income and expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .               F-99\n3.   Estimates and judgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         F-99\n4.   Notes to the statement of financial position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             F-99\n     4.1 Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .            F-99\n     4.2 Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     F-99\n5.   Notes to the statement of comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 F-99\n6.   Risk management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .        F-99\n7.   Other disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     F-100\n     7.1 Notes to the statement of cash flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .              F-100\n     7.2 Other financial obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         F-100\n8.   Related party disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .       F-100\n9.   Disclosures on the Management Board and the Supervisory Board . . . . . . . . . . . . . . . . . . .                       F-100\n10. Events after the reporting period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .          F-101\n", "page_number": 322, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5327062847370672, "height": 0.46814878153056866, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-322-1", "text": "F-97\n", "page_number": 322, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.030229746070133068}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-0", "text": "    Dermapharm Holding SE\n(former Blitz 17-663 SE, Munich)\n\n              NOTES\nTo the interim financial statements\n     as of September 30, 2017\n", "page_number": 323, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.0645575032064985, "lower_right_x": 0.6287787182587666, "lower_right_y": 0.15006412997007268, "height": 0.08550662676357418, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-1", "text": "General\n", "page_number": 323, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.1569046601111586, "lower_right_x": 0.2097944377267231, "lower_right_y": 0.16802052159042324, "height": 0.011115861479264633, "width": 0.060459492140266025}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-2", "text": "1.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1573321932449765, "lower_right_x": 0.12998790810157196, "lower_right_y": 0.1675929884566054, "height": 0.010260795211628898, "width": 0.014510278113663858}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-3", "text": "1.1 Corporate information\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.19153484395040615, "height": 0.014108593415989745, "width": 0.2037484885126965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-4", "text": "The Company has its registered office at Lil-Dagover-Ring 7, 82031 Gr\u00fcnwald, Germany.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.19837537409149208, "lower_right_x": 0.7484885126964933, "lower_right_y": 0.21205643437366395, "height": 0.013681060282171864, "width": 0.6299879081015719}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-5", "text": "Dermapharm Holding SE was founded on 4 July 2017 with the intention of establishing the holding company\nof the Dermapharm Group. Dermapharm Holding SE does not yet engage in any commercial activity.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21846943138093203, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2479692176143651, "height": 0.02949978623343308, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-6", "text": "Dermapharm Holding SE is a wholly owned subsidiary of Themis Beteiligungs AG.\nThese financial statements were voluntarily prepared in accordance with IFRS as adopted by the EU.\nThese interim financial statements were authorised by the Management Board by resolution dated 25 January\n2018.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.880894800483676, "lower_right_y": 0.32492518170158186, "height": 0.0688328345446772, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-7", "text": "1.2 First Time Adoption of IFRS\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.3688029020556227, "lower_right_y": 0.354424967935015, "height": 0.012825994014536157, "width": 0.2533252720677146}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-8", "text": "These interim financial statements for the period ended 30 September 2017 are the first Dermapharm Holding\nSE has prepared in accordance with IFRS. The company did not present financial statements for previous\nperiods. Retrospective application of IFRS is therefore not necessary and consequently there are no effects of\nthe transition to IFRS on total equity or on the profit or loss for the period.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.41727233860624197, "height": 0.05515177426250534, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-9", "text": "2.   Significant accounting policies and changes\n2.1 Basis of preparation of financial statements\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.4740024183796856, "lower_right_y": 0.4681487815305686, "height": 0.03420265070542966, "width": 0.3585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-10", "text": "The interim financial statements of Dermapharm Holding SE have been prepared in accordance with\nInternational Financial Reporting Standards (IFRS) and the interpretations of the IFRS Interpretations\nCommittee (IFRIC) as adopted in the European Union (EU).\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.516460025651988, "height": 0.04147071398033347, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-11", "text": "The statement of comprehensive income is prepared based on the nature of expense method.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5262932877297991, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.5404018811457888, "height": 0.01410859341598969, "width": 0.652962515114873}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-12", "text": "As a rule, Dermapharm Holding SE classifies assets as current if they are expected to be recovered within\ntwelve months from the reporting date. Liabilities are classified as non-current if the Company has the right to\ndefer settlement beyond one year. Deferred tax assets and liabilities are classified as non-current assets or\nliabilities in accordance with IAS 1.56.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6002565198802907, "height": 0.05344164172723387, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-13", "text": "The interim financial statements are presented in EUR. Amounts are shown in euros (EUR) unless otherwise\nstated. As such, insignificant rounding differences could occur in period-over-period changes and percentages\nreported throughout.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.652415562206071, "height": 0.04061564771269777, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-14", "text": "The financial year corresponds to the calendar year.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6596836254809748, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.6737922188969645, "height": 0.01410859341598969, "width": 0.36759371221281745}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-15", "text": "The management prepared the interim financial statements on a going concern basis. Other than that, the\npreparation of these interim financial statements in conformity with IFRS did not require the use of any critical\naccounting estimates or judgement.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7233860624198375, "height": 0.04318084651560494, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-16", "text": "2.2 Effects of new or amended financial standards and interpretations\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.7520307823856349, "height": 0.013681060282171864, "width": 0.5326481257557436}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-17", "text": "Dermapharm Holding SE applied all standards and interpretations (including amendments) as adopted by the\nEU in its interim financial statements, which are mandatory for financial years starting on or after 1 January\n2017. For the period ending on 30 September 2017, there were no new or amended standards and\ninterpretations that were endorsed by the EU Dermapharm Holding SE had to apply.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8157332193244976, "height": 0.05686190679777681, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-18", "text": "There are no IFRSs or IFRIC interpretations that are issued but not yet effective that would be expected to have\na material impact on Dermapharm Holding SE financial statements as of 30 September 2017. Early adoption of\nany of the publications is not planned.\n", "page_number": 323, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8653270628473707, "height": 0.04147071398033353, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-323-19", "text": "F-98\n", "page_number": 323, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-0", "text": "2.3 Changes in accounting policies\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.07738349722103463, "height": 0.01282599401453613, "width": 0.2660217654171705}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-1", "text": "There were no changes to accounting policies with significant consequences for the presentation of\nDermapharm Holding SE\u2019s net assets, financial position and results of operations or cash flows in the period\nended 30 September 2017.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.12654980761008977, "height": 0.04147071398033346, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-2", "text": "2.4 Cash and cash equivalents\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.14322359982898675, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.155622060709705, "height": 0.012398460880718248, "width": 0.2327690447400242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-3", "text": "Cash and cash equivalents include cash deposits. Cash and cash equivalents are reported in accordance with\ntheir definition as financial resources in IAS 7.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.1881145788798632, "height": 0.024369388627618643, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-4", "text": "2.5 Recognition of income and expenses\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.42019347037484883, "lower_right_y": 0.21889696451474988, "height": 0.014108593415989718, "width": 0.3047158403869407}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-5", "text": "Other operating income/expenses:\n", "page_number": 324, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.21889696451474988, "lower_right_x": 0.36094316807738813, "lower_right_y": 0.2394185549380077, "height": 0.020521590423257824, "width": 0.24486094316807738}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-6", "text": "Other operating expenses are recognised at the point at which the service is rendered, the delivery is received\nor at the date they are incurred. Other operating income is recognised when the economic benefits flow to the\nentity.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.880894800483676, "lower_right_y": 0.2907225309961522, "height": 0.04147071398033347, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-7", "text": "3.   Estimates and judgements\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.3476420798065296, "lower_right_y": 0.3180846515604959, "height": 0.014108593415989745, "width": 0.2321644498186215}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-8", "text": "Estimates and judgments are continually evaluated and are based on historical experience and other factors,\nincluding expectations of future events that are believed to be reasonable under the circumstances. Estimates\nand assumptions are reviewed on an on-going basis. Revisions to estimates are recognised prospectively.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3274903805044891, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3685335613510047, "height": 0.04104318084651559, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-9", "text": "4.   Notes to the statement of financial position\n", "page_number": 324, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3826421547669944, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.39675074818298417, "height": 0.014108593415989745, "width": 0.3530834340991536}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-10", "text": "4.1\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4112868747327918, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.4232578024796922, "height": 0.011970927746900395, "width": 0.024788391777509064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-11", "text": "Cash and cash equivalents\n", "page_number": 324, "bounding_box": {"top_left_x": 0.14993954050785974, "top_left_y": 0.4112868747327918, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.4241128687473279, "height": 0.012825994014536102, "width": 0.19830713422007257}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-12", "text": "The cash amounting to EUR 119,974 as at the reporting date (12 July 2017: EUR 30,750) is the total of\nbalances on account with one German bank.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4583155194527576, "height": 0.02436938862761867, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-13", "text": "4.2 Equity\n", "page_number": 324, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.47498931167165453, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.4890979050876443, "height": 0.014108593415989745, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-14", "text": "The issued capital of EUR 120,000 consists of 120,000 bearer shares with no par value. Preference shares or\ndifferent classes of shares do not exist. As at the reporting date, the contributions to the issued capital were\npaid in full. As at 12 July 2017: EUR 89,250 of contributions were outstanding and not requested.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5391192817443352, "height": 0.04360837964942288, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-15", "text": "For information on the change in equity, please refer to the statement of changes in equity.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5468148781530568, "lower_right_x": 0.7587666263603385, "lower_right_y": 0.5609234715690466, "height": 0.0141085934159898, "width": 0.6426844014510278}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-16", "text": "5.   Notes to the statement of comprehensive income\nOther operating expenses relate to banking fees.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.6088071825566481, "height": 0.03463018383924754, "width": 0.39661426844014513}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-17", "text": "6.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.1293833131801693, "lower_right_y": 0.6361693031209918, "height": 0.010688328345446751, "width": 0.013905683192261195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-18", "text": "Risk management\n", "page_number": 324, "bounding_box": {"top_left_x": 0.14933494558645707, "top_left_y": 0.6254809747755451, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.6387345019238991, "height": 0.013253527148354038, "width": 0.13603385731559856}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-19", "text": "As at the reporting date, Dermapharm Holding SE is not exposed to any specific market, credit or liquidity risk.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6601111586147926, "height": 0.01410859341598969, "width": 0.7642079806529625}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-20", "text": "Dermapharm Holding SE\u2019s capital management objectives are primarily to maintain and ensure an optimum\ncapital structure to continue financing the growth plan and to manage the company\u2019s value over the long term.\nDermapharm Holding SE manages its capital structure on the basis of various figures, such as the equity ratio,\nand makes adjustments where appropriate, taking into account changes to the general state of the economy.\n", "page_number": 324, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.725096194955109, "height": 0.05857203933304833, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-324-21", "text": "F-99\n", "page_number": 324, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9350149636596836, "height": 0.01197092774690034, "width": 0.03325272067714635}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-0", "text": "7.   Other disclosures\n", "page_number": 325, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.0645575032064985, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.16324062877871826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-1", "text": "7.1 Notes to the statement of cash flows\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.4195888754534462, "lower_right_y": 0.09576742197520308, "height": 0.010688328345446765, "width": 0.3041112454655381}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-2", "text": "The statement of cash flows was prepared in accordance with IAS 7 Statement of Cash Flows and shows the\nchanges in Dermapharm Holding SE\u2019s cash and cash equivalents during the course of the reporting period due\nto cash inflows and outflows.\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.14621633176571183, "height": 0.040615647712697725, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-3", "text": "Under IAS 7, cash flows are disclosed separately based on origin and use between the operating sector and the\ncash flows from the investment and financing activities. The cash inflows and outflows from operating\nactivities are derived directly from Dermapharm Holding SE\u2019s profit or loss for the year. Cash inflows and\noutflows from investing and financing activities are derived directly. The funds in the statement of cash flows\ncorrespond to the value of cash and cash equivalents in the statement of financial position. Cash and cash\nequivalents include the freely available cash deposits and deposits with financial institutions.\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2394185549380077, "height": 0.0825138948268491, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-4", "text": "7.2 Other financial obligations\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.3476420798065296, "lower_right_y": 0.26934587430525864, "height": 0.013253527148353983, "width": 0.2321644498186215}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-5", "text": "Guarantees\n", "page_number": 325, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.27661393758016245, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.28858486532706284, "height": 0.011970927746900395, "width": 0.07557436517533252}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-6", "text": "Dermapharm Holding SE has assumed joint liability with respect to all claims and liabilities arising from a loan\nagreement entered into by Dermapharm AG with Commerzbank AG. On 14 September 2017,\nDermapharm AG, as borrower, and Commerzbank AG, as lender, entered into a EUR 50,000,000 loan\nagreement. The funds were utilized to finance two acquisitions of Dermapharm AG. The loan expires on\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.3557075673364686, "height": 0.05857203933304833, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-7", "text": "30 September 2022.\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3557075673364686, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.36810602821718685, "height": 0.012398460880718276, "width": 0.14026602176541714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-8", "text": "Dermapharm Holding SE has acceded to a loan agreement between Dermapharm AG and Raiffeisen\nLandesbank Ober\u00f6sterreich as a co-debtor. On 14 September 2017, Dermapharm AG, as borrower, and\nRaiffeisen Landesbank Ober\u00f6sterreich, as lender, entered into a EUR 20,000,000 loan agreement.\nDermapharm AG utilized the funds to refinance a portion of its promissory notes issued in 2011, which\nbecame due and payable on 19 September 2017. The loan expires on 30 September 2022.\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4467721248396751, "height": 0.07097050021376661, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-9", "text": "8.   Related party disclosures\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.47498931167165453, "height": 0.013681060282171864, "width": 0.2230955259975816}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-10", "text": "Related parties as defined in IAS 24 Related Party Disclosures are those legal entities and natural persons that\nare able to exert influence on Dermapharm Holding SE company exercises control or joint control or has a\nsignificant influence. Dermapharm Holding SE has not entered into any related party transactions in the\nreporting period.\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5391192817443352, "height": 0.05728943993159474, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-11", "text": "The members of the management board did not receive any compensation until 30 September 2017.\n", "page_number": 325, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8204353083434099, "lower_right_y": 0.5604959384352287, "height": 0.013681060282171864, "width": 0.7031438935912938}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-12", "text": "9.   Disclosures on the Management Board and the Supervisory Board\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.5878580589995724, "height": 0.013681060282171864, "width": 0.5326481257557436}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-13", "text": "The Company\u2019s corporate boards are composed as follows:\nMembers of the Management Board of Dermapharm Holding SE:\nName                            Member since   Appointed until          Position           Occupation\n\nNicole Lotz    .........         July 2017      August 2017      Chief Executive Officer   Merchant\nDr. Hans-Georg Feldmeier        August 2017         2020         Chief Executive Officer   Pharmacist\nStefan H\u00fcmer . . . . . . . .    August 2017         2020         Chief Financial Officer   Merchant\nStefan Grieving . . . . . . .   August 2017         2020         Chief Marketing Officer   Merchant\nKarin Samusch . . . . . . .     August 2017         2020            Chief Business         Merchant\n                                                                  Development Officer\n", "page_number": 325, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.595981188542112, "lower_right_x": 0.8700120918984281, "lower_right_y": 0.7614365113296281, "height": 0.16545532278751607, "width": 0.75453446191052}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-325-14", "text": "F-100", "page_number": 325, "bounding_box": {"top_left_x": 0.4782345828295042, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.04413542926239428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-0", "text": "Members of the Supervisory Board of Dermapharm Holding SE:\n\nName                            Member since   Appointed until          Position           Occupation\nGabriele Roskothen . . . . .     July 2017      August 2017         Chairman of the       Music teacher\n                                                                   Supervisory Board\nRandi Mette Selnes     ....      July 2017      August 2017      Deputy Chairman of the     Merchant\n                                                                   Supervisory Board\nKatja Gogalla . . . . . . . .    July 2017      August 2017         Member of the           Merchant\n                                                                   Supervisory Board\nWilhelm Beier . . . . . . . .   August 2017         2022            Chairman of the         Merchant\n                                                                   Supervisory Board\nDr. Erwin Kern . . . . . . .    August 2017         2022         Deputy Chairman of the     Merchant\n                                                                   Supervisory Board\nMichael Beier . . . . . . . .   August 2017    December 2017        Member of the           Merchant\n                                                                   Supervisory Board\nLothar Lanz . . . . . . . . .   January 2018        2022            Member of the           Merchant\n                                                                   Supervisory Board\n", "page_number": 326, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8585247883917775, "lower_right_y": 0.32407011543394615, "height": 0.25951261222744765, "width": 0.7430471584038694}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-1", "text": "10. Events after the reporting period\n", "page_number": 326, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.3984280532043531, "lower_right_y": 0.3539974348011971, "height": 0.012398460880718276, "width": 0.282950423216445}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-2", "text": "Events after the reporting date with a significant or possibly significant impact on the net assets, financial\npositions and results of operations of Dermapharm Holding SE:\n", "page_number": 326, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.38948268490808036, "height": 0.027362120564343728, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-3", "text": "On 6 December 2017, the Company\u2019s shareholders\u2019 meeting resolved to increase the Company\u2019s share capital\nfrom EUR 120,000.00 by EUR 49,880,000 to EUR 50,000,000 by issuing 49,880,000 new shares in the\nCompany against contributions kind in the form of 104,960 shares in Dermapharm AG by Themis\nBeteiligungs AG (corresponding to 20.0% of the share capital of Dermapharm AG).\n", "page_number": 326, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3963232150491663, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.45318512184694315, "height": 0.05686190679777686, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-4", "text": "In addition, Themis Beteiligungs AG contributed the remaining 419,840 shares in Dermapharm AG\n(corresponding to 80.0% of the share capital of Dermapharm AG) to the Company\u2019s free reserves without\nconsideration. The contribution and transfer of all shares in Dermapharm AG were completed with effect from\nthe end of 31 December 2017 and the consummation of the capital increase was registered in the commercial\nregister of the local court of Munich, Germany, on 4 January 2018\n", "page_number": 326, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5301410859341599, "height": 0.0688328345446772, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-5", "text": "In connection with the capital contribution, Dermapharm Holding SE has assumed joint liability with respect to\nall claims and liabilities arising from the following loans entered into by Dermapharm AG:\n", "page_number": 326, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5669089354424968, "height": 0.02693458743052579, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-6", "text": "\u25cf   Loan agreement with Bayerische Landesbank: On 8 September 2017, Dermapharm AG, as borrower,\n    and Bayerische Landesbank, as lender, entered into a EUR 60,000,000 loan agreement. The funds\n    were utilized to finance the acquisition of the assets pertaining to the hyperthermic medical devices\n    division of Riemser Pharma GmbH. The loan expires on 8 September 2022.\n\u25cf   Loan agreement with Deutsche Postbank AG: On 14 September 2017, Dermapharm AG, as borrower,\n    and Deutsche Postbank AG, as lender, entered into a EUR 20,000,000 loan agreement.\n    Dermapharm AG utilized the funds to refinance a portion of its promissory notes issued in 2011,\n    which became due and payable on 19 September 2017. The loan expires on 19 September 2022.\n\u25cf   2014 Promissory notes: The terms of the Promissory notes taken out by Dermapharm AG in 2014\n    were amended by an agreement dated 4 October 2017, entered into between Dermapharm AG as\n    borrower, Bayerische Landesbank as original lender and agent, the investors holding commitments\n    under the 2014 Promissory notes, Themis Beteiligungs AG as original guarantor and the Company as\n    new guarantor. All sums payable under the 2014 Promissory Notes are guaranteed by the Company.\n\u25cf   2012 Promissory notes: The terms of the Promissory notes taken out by Dermapharm AG in 2012\n    were amended by an agreement dated 4 October 2017, entered into between Dermapharm AG as\n    borrower, Bayerische Landesbank as original lender and agent, Oberbank Aktiengesellschaft as the\n    sole investor holding 2012 Promissory Notes, Themis Beteiligungs AG as original guarantor and the\n    Company as new guarantor. All sums payable under the 2012 Promissory Notes are guaranteed by the\n    Company.\n", "page_number": 326, "bounding_box": {"top_left_x": 0.13482466747279323, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8648995297135528, "height": 0.2907225309961522, "width": 0.7496977025392987}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-326-7", "text": "F-101", "page_number": 326, "bounding_box": {"top_left_x": 0.4782345828295042, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5169286577992744, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.03869407496977023}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-0", "text": "\u25cf   Loan agreement with Baden W\u00fcrttembergische Bank: On 4 December 2017, Dermapharm AG, as\n    borrower, and Baden W\u00fcrttembergische Bank, as lender, entered into a EUR 80,000,000 loan\n    agreement. Dermapharm AG will utilize the funds from the loan agreement as bridge financing to\n    partially finance its future capital expenditures.\n", "page_number": 327, "bounding_box": {"top_left_x": 0.13482466747279323, "top_left_y": 0.0645575032064985, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.11970927746900385, "height": 0.05515177426250535, "width": 0.749093107617896}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-1", "text": "On 6 December 2017, the profit transfer agreement between Themis Beteiligungs AG and Dermapharm AG\nwas terminated with effect from the end of 31 December 2017.\n", "page_number": 327, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.15348439504061565, "height": 0.027362120564343728, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-2", "text": "Dermapharm Holding SE seeks to list its shares on the regulated market (Prime Standard) of the Frankfurt\nStock Exchange. The proceeds from the issuance of new shares will be used to finance further growth of the\nDermapharm Group. The company announced the intention to float on 15 January 2018.\n", "page_number": 327, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.20478837109876016, "height": 0.04104318084651562, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-3", "text": "Gr\u00fcnwald, 25 January 2018, the Management Board\n", "page_number": 327, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.22573749465583584, "height": 0.020949123557075677, "width": 0.3730350665054413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-4", "text": "Karin Samusch\nChief Business Development Officer\n", "page_number": 327, "bounding_box": {"top_left_x": 0.49758162031438935, "top_left_y": 0.29713552800342025, "lower_right_x": 0.7557436517533253, "lower_right_y": 0.32492518170158186, "height": 0.02778965369816161, "width": 0.2581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-5", "text": "Stefan H\u00fcmer\nChief Financial Officer\n", "page_number": 327, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.32407011543394615, "height": 0.026934587430525903, "width": 0.16505441354292621}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-327-6", "text": "F-102", "page_number": 327, "bounding_box": {"top_left_x": 0.4782345828295042, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.04413542926239428}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-0", "text": "The following auditor\u2019s opinion is a translation of the German language auditor\u2019s opinion.\n", "page_number": 328, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7503022974607013, "lower_right_y": 0.07866609662248825, "height": 0.014108593415989745, "width": 0.6342200725513906}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-1", "text": "Auditor\u2019s Opinion\n", "page_number": 328, "bounding_box": {"top_left_x": 0.43047158403869407, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5652962515114873, "lower_right_y": 0.10474561778537837, "height": 0.01282599401453613, "width": 0.13482466747279326}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-2", "text": "To Dermapharm Holding SE:\n", "page_number": 328, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.11244121419410004, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.12654980761008977, "height": 0.014108593415989731, "width": 0.20737605804111248}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-3", "text": "We have audited the interim financial statements prepared on a voluntary basis\u2014comprising the statement of\nfinancial position, the statement of comprehensive income, the statement of cash flows, the statement of\nchanges in equity and the notes to the interim financial statements\u2014together with the bookkeeping system of\nDermapharm Holding SE, Gr\u00fcnwald, for the reporting period from 12 July 2017 to 30 September 2017. The\nmaintenance of the books and records and the preparation of the interim financial statements in accordance\nwith IFRS as adopted by the EU are the responsibility of the company\u2019s management. Our responsibility is to\nexpress an opinion on the interim financial statements, together with the accounting system, based on our audit.\n", "page_number": 328, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13638306968790082, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.23257802479692177, "height": 0.09619495510902096, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-4", "text": "We conducted our audit of the interim financial statements prepared on a voluntary basis in accordance with\nsection 317 HGB and German generally accepted standards for the audit of financial statements promulgated by\nthe Institut der Wirtschaftspr\u00fcfer [Institute of Public Auditors in Germany] (IDW). Those standards require that\nwe plan and perform the audit such that misstatements materially affecting the presentation of the net assets,\nfinancial position and results of operations in the interim financial statements prepared on a voluntary basis in\naccordance with IFRS as adopted by the EU are detected with reasonable assurance. Knowledge of the business\nactivities and the economic and legal environment of the company and expectations as to possible\nmisstatements are taken into account in the determination of audit procedures. The effectiveness of the\naccounting-related internal control system and the evidence supporting the disclosures in the books and records,\nthe interim financial statements prepared on a voluntary basis are examined primarily on a sample basis within\nthe framework of the audit. The audit includes assessing the accounting principles used and significant\nestimates made by management, as well as evaluating the overall presentation of the interim financial\nstatements. We believe that our audit provides a reasonable basis for our opinion.\n", "page_number": 328, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4241128687473279, "height": 0.1817015818725951, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {"gaas": ["German generally accepted standards for the audit of financial statements"]}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-5", "text": "Our audit has not led to any reservations.\n", "page_number": 328, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.43394613082513894, "lower_right_x": 0.40931076178960096, "lower_right_y": 0.4467721248396751, "height": 0.012825994014536157, "width": 0.2920193470374849}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-6", "text": "In our opinion, based on the findings of our audit, the interim financial statements of Dermapharm Holding SE\nfor the reporting period from 12 July 2017 to 30 September 2017 comply with IFRS as adopted by the EU and\ngive a true and fair view of the net assets, financial position and results of operations of the company in\naccordance with these requirements.\n", "page_number": 328, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5096194955109021, "height": 0.05515177426250539, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-7", "text": "D\u00fcsseldorf, 25. Januar 2018\n", "page_number": 328, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.5369816160752459, "height": 0.010688328345446751, "width": 0.1989117291414752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-8", "text": "Warth&Klein Grant Thornton AG\nWirtschaftspr\u00fcfungsgesellschaft\n", "page_number": 328, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.35489721886336156, "lower_right_y": 0.5951261222744763, "height": 0.027789653698161554, "width": 0.23941958887545345}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-9", "text": "Andr\u00e9 Prengel       Dr. Thomas Senger\nWirtschaftspr\u00fcfer   Wirtschaftspr\u00fcfer\n", "page_number": 328, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.652415562206071, "height": 0.026934587430525903, "width": 0.3391777509068924}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-328-10", "text": "F-103", "page_number": 328, "bounding_box": {"top_left_x": 0.4782345828295042, "top_left_y": 0.9230440359127833, "lower_right_x": 0.5217654171704957, "lower_right_y": 0.93373236425823, "height": 0.010688328345446751, "width": 0.04353083434099153}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-329-0", "text": "(This page has been left blank intentionally)\n", "page_number": 329, "bounding_box": {"top_left_x": 0.33313180169286577, "top_left_y": 0.43394613082513894, "lower_right_x": 0.6650544135429263, "lower_right_y": 0.4480547242411287, "height": 0.014108593415989745, "width": 0.3319226118500605}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-0", "text": "GLOSSARY\n", "page_number": 330, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.08511548331907613, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.0979469632164243, "height": 0.01283147989734816, "width": 0.09129383313180173}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-1", "text": "23.\n", "page_number": 330, "bounding_box": {"top_left_x": 0.42019347037484883, "top_left_y": 0.08597091531223268, "lower_right_x": 0.4437726723095526, "lower_right_y": 0.0979469632164243, "height": 0.011976047904191614, "width": 0.023579201934703753}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-2", "text": "\u20ac ..........................................................................\n                                                          The single European currency adopted by certain participating member\n                                                          states of the European Union, including Germany.\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.11248930710008555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14029084687767324, "height": 0.02780153977758769, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-3", "text": "  Promissory note agreements (Schuldscheindarlehen) entered into by\n....................\n  Dermapharm AG, as borrower, and Bayerische Landesbank, as lender and\n  arranger on September 19, 2012, of which an aggregate amount of\n  \u20ac10.0 million is still outstanding as of the date of this Prospectus.\n", "page_number": 330, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.1467065868263473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2018819503849444, "height": 0.05517536355859709, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-4", "text": "2012 Promissory Notes ..................\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15012831479897348, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.16082121471343028, "height": 0.010692899914456794, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-5", "text": "  Promissory note agreements (Schuldscheindarlehen), entered into between\n....................\n  Dermapharm AG, as borrower, and Bayerische Landesbank, as lender on\n  November 20, 2014, of which an aggregate amount of \u20ac71.5 million is still\n  outstanding as of the date of this Prospectus.\n", "page_number": 330, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.21171941830624466, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2617621899059025, "height": 0.05004277159965784, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-6", "text": "2014 Promissory Notes ..................\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21171941830624466, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.22540633019674935, "height": 0.013686911890504694, "width": 0.24183796856106407}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-7", "text": " outstanding as of the date of this Prospectus.\n  Pharmaceuticals and Cooperation in the Healthcare System Association\n....................\n  (Arzneimittel und Kooperation im Gesundheitswesen e.V.).\n", "page_number": 330, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.26218990590248076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29897348160821213, "height": 0.036783575705731375, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-8", "text": "AKG ................................................\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.27331052181351584, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.2840034217279726, "height": 0.010692899914456766, "width": 0.2412333736396614}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-9", "text": "                                                     The German Stock Corporation Act (Aktiengesetz).\nAktG ..................................................................\n                                                    The German Pharmaceuticals Act (Arzneimittelgesetz).\nAMG ..................................................................\n                                                      Active pharmaceutical ingredients.\nAPIs....................................................................\n                                                     The German Act on Pharmacies (Gesetz \u00fcber das Apothekenwesen).\nApoG ..................................................................\n                                            The Company\u2019s articles of association.\nArticles of Association ......................................\n                                                     axicorp GmbH, together with its direct and indirect subsidiaries.\naxicorp ...............................................................\n                                                     The German Federal Financial Supervisory Authority (Bundesanstalt f\u00fcr\nBaFin..................................................................\n                                                     Finanzdienstleistungsaufsicht).\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.879081015719468, "lower_right_y": 0.4585115483319076, "height": 0.15098374679213, "width": 0.7587666263603385}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-10", "text": "                                                 The New Shares and the Existing Shares.\nBase Shares........................................................\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4649272882805817, "lower_right_x": 0.6444981862152358, "lower_right_y": 0.47904191616766467, "height": 0.014114627887082953, "width": 0.5241837968561064}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-11", "text": "                                                  Joh. Berenberg, Gossler & Co. KG, Hamburg, Germany.\nBerenberg ..........................................................\n                                                Bio-Di\u00e4t-Berlin Gesellschaft mit beschr\u00e4nkter Haftung and Kr\u00e4uter\nBio-Di\u00e4t-Berlin ..................................................\n                                                K\u00fchne GmbH.\n                                                       Basis points.\nBPs .....................................................................\n                                                   Compound annual growth rate.\nCAGR ................................................................\n                                                   Centuere Beteiligungs-Aktiengesellschaft i.L.\nCentuere ............................................................\n                                                      Central European Time or Central European Summertime, as the case may\nCET ....................................................................\n                                                      be.\n                                                   The Committee for Medicinal Products for Human Use.\nCHMP ................................................................\n                                                 Clearstream Banking Aktiengesellschaft,\nClearstream .......................................................                                Mergenthalerallee   61,\n                                                 65760 Eschborn, Germany.\n                                           ODDO BHF.\nCo-Lead Manager .............................................\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.48545765611633873, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7082976903336184, "height": 0.22284003421727971, "width": 0.7599758162031439}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-12", "text": "Commission\u2019s Proposal ....................................\n                                        The proposal published by the European Commission on February 14,\n                                        2013.\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7147134302822925, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.739093242087254, "height": 0.024379811804961515, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-13", "text": "  Dermapharm Holding SE, with its registered office at Lil-Dagover-Ring 7,\n....................\n  82031 Gr\u00fcnwald, Germany (telephone: +49 (0) 89 6 41 86 0), and\n  registered with the commercial register (Handelsregister) of the local court\n  (Amtsgericht) of Munich, Germany, under docket number HRB 234575.\n", "page_number": 330, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.7489307100085543, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8036783575705732, "height": 0.054747647562018886, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-14", "text": "Company ......\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7489307100085543, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.7630453378956373, "height": 0.014114627887083064, "width": 0.09673518742442563}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-15", "text": "", "page_number": 330, "bounding_box": {"top_left_x": 0.32889963724304716, "top_left_y": 0.7557741659538066, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.7591958939264328, "height": 0.0034217279726261873, "width": 0.0332527206771463}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-16", "text": "  The capital increase resolved by the Company\u2019s shareholders\u2019 meeting on\n....................\n  December 6, 2017 for the increase of the Company\u2019s share capital from\n  \u20ac120,000.00 by \u20ac49,880,000.00 to \u20ac50,000,000.00 through the issuance of\n  49,880,000 new shares in the Company against contributions in kind in the\n  form of 104,960 shares in Dermapharm AG by the Selling Shareholder\n  (corresponding to 20.0% of the share capital of Dermapharm AG).\n", "page_number": 330, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.8105218135158255, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.893071000855432, "height": 0.08254918733960648, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-17", "text": "Contribution Capital Increase ......\n", "page_number": 330, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8105218135158255, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.8242087254063302, "height": 0.013686911890504638, "width": 0.24183796856106407}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-330-18", "text": "G-1", "page_number": 330, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.029020556227327687}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-0", "text": "                                          Regulation (EC) 1223/2009 of the European Parliament and of the Council\nCosmetics Regulation .......................................\n                                          of November 30, 2009 on cosmetic products.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.879081015719468, "lower_right_y": 0.11291702309666382, "height": 0.02780153977758769, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-1", "text": "                                                     The Luxembourg Commission for the Supervision of the Financial Sector\nCSSF ..................................................................\n                                                     (Commission de Surveillance du Secteur Financier).\n", "page_number": 331, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.1193327630453379, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.14713430282292558, "height": 0.02780153977758769, "width": 0.7581620314389359}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-2", "text": "                                                     Directors and officers.\nD&O ...................................................................\n                                              The Company, together with its direct and indirect consolidated\nDermapharm .....................................................\n                                              subsidiaries.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.15483319076133448, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20059880239520958, "height": 0.0457656116338751, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-3", "text": "                                          Dermapharm Aktiengesellschaft.\nDermapharm AG ..............................................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21171941830624466, "lower_right_x": 0.5888754534461911, "lower_right_y": 0.2249786142001711, "height": 0.013259195893926434, "width": 0.46856106408706166}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-4", "text": "                                        A domestic bank or financial service institute, a domestic securities trading\nDomestic Paying Agent ....................................\n                                        company or a domestic securities trading bank (including the domestic\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.22540633019674935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25748502994011974, "height": 0.03207869974337038, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-5", "text": "company or a domestic securities trading bank (includi\nbranches of foreign banks and financial service institutes).\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.25791274593669805, "lower_right_x": 0.7587666263603385, "lower_right_y": 0.27245508982035926, "height": 0.014542343883661213, "width": 0.3917775090689238}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-6", "text": "  Earnings before interest, taxes depreciation and amortization.\n....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.28015397775876816, "lower_right_x": 0.7835550181378477, "lower_right_y": 0.29298545765611633, "height": 0.012831479897348175, "width": 0.4165659008464329}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-7", "text": "EBITDA ...\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28015397775876816, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.290846877673225, "height": 0.010692899914456822, "width": 0.07255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-8", "text": "EEA ..\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3006843455945252, "lower_right_x": 0.16324062877871826, "lower_right_y": 0.31137724550898205, "height": 0.010692899914456822, "width": 0.04292623941958887}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-9", "text": "   European Economic Area\n.....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3603385731559855, "top_left_y": 0.3006843455945252, "lower_right_x": 0.5411124546553809, "lower_right_y": 0.3143712574850299, "height": 0.013686911890504694, "width": 0.18077388149939544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-10", "text": "EEA Member State ........................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3212147134302823, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.3319076133447391, "height": 0.010692899914456822, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-11", "text": "  A member state of the EEA.\n....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3675937122128174, "top_left_y": 0.3212147134302823, "lower_right_x": 0.5610640870616687, "lower_right_y": 0.3319076133447391, "height": 0.010692899914456822, "width": 0.19347037484885127}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-12", "text": " The European Medicines Agency.\n...................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3681983071342201, "top_left_y": 0.34174508126603936, "lower_right_x": 0.599758162031439, "lower_right_y": 0.35543199315654406, "height": 0.013686911890504694, "width": 0.23155985489721886}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-13", "text": "EMA ...\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.34174508126603936, "lower_right_x": 0.1717049576783555, "lower_right_y": 0.35201026518391787, "height": 0.010265183917878506, "width": 0.05078597339782345}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-14", "text": "......T\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3512696493349456, "top_left_y": 0.3485885372112917, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.35201026518391787, "height": 0.0034217279726261873, "width": 0.016324062877871803}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-15", "text": "  Regulation (EC) 726/2004 of the European Parliament and of the Council\n....................\n  of March 31, 2004 laying down community procedures for the\n  authorization and supervision of medicinal products for human and\n  veterinary use and establishing a European Medicines Agency.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4170230966638152, "height": 0.054747647562018775, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-16", "text": "EMA Regulation ..\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.36227544910179643, "lower_right_x": 0.25211608222490933, "lower_right_y": 0.3763900769888794, "height": 0.014114627887082953, "width": 0.13119709794437728}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-17", "text": "    The European Union Intellectual Property Office.\n......................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.4238665526090676, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.43798118049615054, "height": 0.014114627887082953, "width": 0.341596130592503}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-18", "text": "EUIPO ..\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.42429426860564584, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.43627031650983744, "height": 0.0119760479041916, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-19", "text": "EURIBOR ....\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4448246364414029, "lower_right_x": 0.2158403869407497, "lower_right_y": 0.4550898203592814, "height": 0.010265183917878506, "width": 0.09552599758162031}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-20", "text": "   Euro Interbank Offered Rate.\n.....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3603385731559855, "top_left_y": 0.4448246364414029, "lower_right_x": 0.56590084643289, "lower_right_y": 0.4550898203592814, "height": 0.010265183917878506, "width": 0.20556227327690446}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-21", "text": "    The single European currency adopted by certain participating member\n......................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.46535500427716, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.47904191616766467, "height": 0.013686911890504694, "width": 0.5205562273276905}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-22", "text": "Euro ...\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.46578272027373824, "lower_right_x": 0.17230955259975816, "lower_right_y": 0.47775876817792984, "height": 0.0119760479041916, "width": 0.05199516324062878}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-23", "text": "  The single European currency adopted by certa\n....................\n  states of the European Union, including Germany.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.47904191616766467, "lower_right_x": 0.7043530834340992, "lower_right_y": 0.49272882805816937, "height": 0.013686911890504694, "width": 0.33736396614268443}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-24", "text": "Euroclear ....\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.5119760479041916, "height": 0.0119760479041916, "width": 0.08766626360338572}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-25", "text": "   Euroclear Bank SA/NV, 1\n.....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36094316807738813, "top_left_y": 0.5, "lower_right_x": 0.5483675937122128, "lower_right_y": 0.5132591958939264, "height": 0.013259195893926434, "width": 0.18742442563482464}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-26", "text": "Boulevard du Roi Albert II,\n", "page_number": 331, "bounding_box": {"top_left_x": 0.5652962515114873, "top_left_y": 0.5, "lower_right_x": 0.7684401451027811, "lower_right_y": 0.5132591958939264, "height": 0.013259195893926434, "width": 0.2031438935912938}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-27", "text": ", 1210 Brussels,\n", "page_number": 331, "bounding_box": {"top_left_x": 0.7690447400241838, "top_left_y": 0.5, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5132591958939264, "height": 0.013259195893926434, "width": 0.11124546553808956}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-28", "text": "1\n", "page_number": 331, "bounding_box": {"top_left_x": 0.5483675937122128, "top_left_y": 0.5004277159965783, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.5119760479041916, "height": 0.011548331907613285, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-29", "text": "Belgium.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.5136869118905047, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.5265183917878529, "height": 0.01283147989734812, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-30", "text": "                                                7,860,000 existing bearer shares with no par value (St\u00fcckaktien) from the\nExisting Shares ..................................................\n                                                holdings of the Existing Shareholder.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5333618477331052, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.561163387510693, "height": 0.027801539777587703, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-31", "text": "Farmal ..\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5688622754491018, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.5808383233532934, "height": 0.0119760479041916, "width": 0.06348246674727931}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-32", "text": "   Farmal d.d.\n.....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36094316807738813, "top_left_y": 0.5688622754491018, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.5808383233532934, "height": 0.0119760479041916, "width": 0.08403869407496978}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-33", "text": "  The Federal Central Association of the Statutory Health Insurance Funds\n....................\n  (Spitzenverband Bund der Krankenkassen).\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.5889649272882805, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6159110350727117, "height": 0.026946107784431184, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-34", "text": "Federal Association........................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5915312232677502, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.602224123182207, "height": 0.010692899914456766, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-35", "text": "                                              Regulation (EC) 178/2002 of the European Parliament and of the Council\nFood Regulation ................................................\n                                              of January 28, 2002 laying down the general principles and requirements of\n                                              food law, establishing the European Food Safety Authority and laying\n                                              down procedures in matters of food safety.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.625748502994012, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6800684345594525, "height": 0.05431993156544057, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-36", "text": "  The Framework Agreement on Drug Provision according to Section 129 of\n....................\n  the Social Code, Book V (Rahmenvertrag \u00fcber die Arzneimittelversorgung\n  nach \u00a7 129 Abs. 2 Sozialgesetzbuch V).\n", "page_number": 331, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.6873396065012831, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7266894781864842, "height": 0.0393498716852011, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-37", "text": "Framework Agreement .................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6873396065012831, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.7001710863986313, "height": 0.01283147989734823, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-38", "text": "                                                  The Federal Republic of Germany.\nGermany ............................................................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7352437981180496, "lower_right_x": 0.6045949214026602, "lower_right_y": 0.7493584260051326, "height": 0.014114627887082953, "width": 0.48428053204353083}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-39", "text": " Good manufacturing practice.\n...................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3681983071342201, "top_left_y": 0.7557741659538066, "lower_right_x": 0.5701330108827086, "lower_right_y": 0.7686056458511549, "height": 0.01283147989734823, "width": 0.20193470374848854}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-40", "text": "GMP ..................................................G\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7557741659538066, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.7664670658682635, "height": 0.010692899914456877, "width": 0.247279322853688}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-41", "text": "                                            The option to acquire the Over-Allotment Shares at the Offer Price, less\nGreenshoe Option .............................................\n                                            agreed commissions, which the Selling Shareholder will grant the Sole\n                                            Bookrunner.\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7763045337895638, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8143712574850299, "height": 0.038066723695466154, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-42", "text": "Guidelines ....\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8242087254063302, "lower_right_x": 0.2140266021765417, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.09371221281741232}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-43", "text": "     The\n.............\n", "page_number": 331, "bounding_box": {"top_left_x": 0.35368802902055624, "top_left_y": 0.8242087254063302, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.04292623941958884}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-44", "text": "  Guidelines\n.........\n", "page_number": 331, "bounding_box": {"top_left_x": 0.4105199516324063, "top_left_y": 0.8242087254063302, "lower_right_x": 0.4879081015719468, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.07738814993954052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-45", "text": "the\n", "page_number": 331, "bounding_box": {"top_left_x": 0.5344619105199516, "top_left_y": 0.8242087254063302, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.021765417170495738}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-46", "text": "Federal\n", "page_number": 331, "bounding_box": {"top_left_x": 0.5707376058041113, "top_left_y": 0.8242087254063302, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.053204353083434075}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-47", "text": "Joint\n", "page_number": 331, "bounding_box": {"top_left_x": 0.6378476420798065, "top_left_y": 0.8242087254063302, "lower_right_x": 0.6765417170495768, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.03869407496977029}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-48", "text": "Committee\n", "page_number": 331, "bounding_box": {"top_left_x": 0.6910519951632407, "top_left_y": 0.8242087254063302, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.834901625320787, "height": 0.010692899914456877, "width": 0.0779927448609431}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-49", "text": "(gemeinsamer\n", "page_number": 331, "bounding_box": {"top_left_x": 0.782950423216445, "top_left_y": 0.8242087254063302, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8383233532934131, "height": 0.014114627887082953, "width": 0.09673518742442555}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-50", "text": "of\n", "page_number": 331, "bounding_box": {"top_left_x": 0.5030229746070133, "top_left_y": 0.8246364414029085, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.834901625320787, "height": 0.010265183917878562, "width": 0.0145102781136639}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-51", "text": "  The Guidelines\n....................\n  Bundesausschuss).\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3675937122128174, "top_left_y": 0.8378956372968349, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.8511548331907614, "height": 0.013259195893926434, "width": 0.13059250302297465}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-52", "text": "HACCP...", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8584260051325919, "lower_right_x": 0.19105199516324062, "lower_right_y": 0.8691189050470488, "height": 0.010692899914456877, "width": 0.07073760580411123}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 53, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-53", "text": "   Hazard analysis and critical control points.\n.....................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3615477629987908, "top_left_y": 0.8584260051325919, "lower_right_x": 0.656590084643289, "lower_right_y": 0.8725406330196749, "height": 0.014114627887082953, "width": 0.29504232164449823}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 54, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-54", "text": "HGB ...\n", "page_number": 331, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.878956372968349, "lower_right_x": 0.1717049576783555, "lower_right_y": 0.8896492728828058, "height": 0.010692899914456766, "width": 0.051390568319226115}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 55, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-55", "text": "    The German Commercial Code (Handelsgesetzbuch).\n......................\n", "page_number": 331, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.878956372968349, "lower_right_x": 0.7303506650544136, "lower_right_y": 0.893071000855432, "height": 0.014114627887082953, "width": 0.3712212817412334}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 56, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-331-56", "text": "G-2", "page_number": 331, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.029020556227327687}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-0", "text": "                                                    The German Drug Advertisement Act (Heilmittelwerbegesetz).\nHWG ..................................................................\n                                           Regulation (EC) No 852/2004 of the European Parliament and of the\nHygiene Regulation...........................................\n                                           Council of April 29, 2004 on the hygiene of foodstuffs.\n                                                      The International Conference on Harmonization of Technical Requirements\nICH ....................................................................\n                                                      for Registration of Pharmaceuticals for Human Use.\n                                                      International Financial Reporting Standards, as adopted by the European\nIFRS ...................................................................\n                                                      Union.\n                                     The indemnification agreement entered into between Dermapharm AG and\nIndemnification Agreement .............................\n                                     the Selling Shareholder on December 21, 2015.\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2369546621043627, "height": 0.15183917878528658, "width": 0.7599758162031439}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-1", "text": "                                           A capital increase against contributions in cash to be resolved by an\nIPO Capital Increase ........................................\n                                           extraordinary shareholders\u2019 meeting of the Company on or about\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.24593669803250642, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2711719418306245, "height": 0.025235243798118062, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-2", "text": "                                     January 26, 2018.\n                                                    The German Code on Foodstuffs, Consumer Goods and Fodder\nLFGB .................................................................\n                                                    (Lebensmittel-, Bedarfsgegenst\u00e4nde- und Futtermittelgesetzbuch).\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.27159965782720275, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3203592814371258, "height": 0.04875962360992303, "width": 0.7593712212817412}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-3", "text": "LMHV..................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.32805816937553467, "lower_right_x": 0.2478839177750907, "lower_right_y": 0.33875106928999144, "height": 0.010692899914456766, "width": 0.1275695284159613}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-4", "text": "    The German Food Hygiene Ordinance (Lebensmittelhygiene-Verordnung).\n......................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8700120918984281, "lower_right_y": 0.34174508126603936, "height": 0.013686911890504694, "width": 0.5108827085852479}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-5", "text": ".........\n", "page_number": 332, "bounding_box": {"top_left_x": 0.2889963724304716, "top_left_y": 0.3361847733105218, "lower_right_x": 0.3180169286577993, "lower_right_y": 0.33875106928999144, "height": 0.0025662959794696127, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-6", "text": "Luxembourg ........................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3485885372112917, "lower_right_x": 0.313180169286578, "lower_right_y": 0.3627031650983747, "height": 0.014114627887083009, "width": 0.19226118500604594}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-7", "text": "    The Grand Duchy of Luxembourg.\n......................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.3485885372112917, "lower_right_x": 0.6045949214026602, "lower_right_y": 0.36227544910179643, "height": 0.01368691189050475, "width": 0.24546553808948007}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-8", "text": "                                         The Company\u2019s management board (Vorstand).\nManagement Board ..........................................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.68863361547763, "lower_right_y": 0.38323353293413176, "height": 0.014114627887083009, "width": 0.5683192261185006}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-9", "text": "                                                    Regulation (EU) no.\nMAR ..................................................................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.3896492728828058, "lower_right_x": 0.5102781136638452, "lower_right_y": 0.402480752780154, "height": 0.012831479897348175, "width": 0.3893591293833132}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-10", "text": "o. 596/2014 of the European Parliament and of the\n", "page_number": 332, "bounding_box": {"top_left_x": 0.5108827085852479, "top_left_y": 0.3896492728828058, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4020530367835757, "height": 0.01240376390076986, "width": 0.3688029020556227}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-11", "text": "  Regulation (EU) no. 596/2014 of the European Parl\n....................\n  Council of April 16, 2014 on market abuse, as amended\n", "page_number": 332, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.40290846877673225, "lower_right_x": 0.7424425634824667, "lower_right_y": 0.4174508126603935, "height": 0.014542343883661268, "width": 0.375453446191052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-12", "text": "                                     Directive 2001/83/EC of the European Parliament and of the Council of\nMedicinal Products Directive ..........................\n                                     November 6, 2001 on the community code relating to medicinal products\n                                     for human use.\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4619332763045338, "height": 0.03806672369546621, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-13", "text": ". Mibe GmbH Arzneimittel.", "page_number": 332, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.47177074422583404, "lower_right_x": 0.5459492140266021, "lower_right_y": 0.48246364414029086, "height": 0.010692899914456822, "width": 0.18681983071342195}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-14", "text": "                                                   The Madrid Agreement Concerning the International Registration of Marks\nMMA..................................................................\n                                                   of June 27, 1989, as last amended on September 28, 1979.\n", "page_number": 332, "bounding_box": {"top_left_x": 0.13240628778718258, "top_left_y": 0.4923011120615911, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5201026518391788, "height": 0.027801539777587703, "width": 0.7478839177750908}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-15", "text": "MPG ...\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5273738237810094, "lower_right_x": 0.1717049576783555, "lower_right_y": 0.5397775876817793, "height": 0.012403763900769915, "width": 0.051390568319226115}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-16", "text": "    The German Act on Medical Devices (Gesetz \u00fcber Medizinprodukte).\n......................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.5273738237810094, "lower_right_x": 0.8367593712212817, "lower_right_y": 0.5406330196749358, "height": 0.013259195893926434, "width": 0.47762998790810157}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-17", "text": "  3,840,000 newly issued bearer shares with no par value (St\u00fcckaktien) from\n....................\n  a capital increase against contributions in cash from the IPO Capital\n  Increase.\n", "page_number": 332, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.5470487596236099, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.5885372112917023, "height": 0.04148845166809245, "width": 0.5114873035066505}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-18", "text": "New Shares ..................................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5470487596236099, "lower_right_x": 0.35006045949214026, "lower_right_y": 0.561163387510693, "height": 0.014114627887083064, "width": 0.22974607013301088}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-19", "text": ".....\n", "page_number": 332, "bounding_box": {"top_left_x": 0.3512696493349456, "top_left_y": 0.5551753635585971, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.5603079555175363, "height": 0.0051325919589392255, "width": 0.010882708585247869}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-20", "text": "                                              ODDO BHF Aktiengesellschaft, Frankfurt am Main, Germany.\nODDO BHF .......................................................\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5962360992301112, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.6090675791274593, "height": 0.01283147989734812, "width": 0.6729141475211607}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-21", "text": "                                                   Organization for Economic Co-operation and Development.\nOECD ................................................................\n                                               Berenberg and ODDO BHF.\nOffering Banks ..................................................\n                                                 The period during which investors may submit purchase orders for the\nOffer Period ......................................................\n                                                 Offer Shares, which is expected to commence on January 29, 2018, and to\n                                                 expire on February 8, 2018.\n                                                   The offer price for the Offering.\nOffer Price .........................................................\n                                                 The Base Shares and the Over-Allotment Shares.\nOffer Shares ......................................................\n                                                    The offering of 13,455,000 bearer shares of the Company with no par value\nOffering .............................................................\n                                                    (St\u00fcckaktien), each such share representing a notional value of \u20ac1.00.\n                                                     The Financial Services and Markets Act 2000 (Financial Promotion) Order\nOrder .................................................................\n                                                     2005, as amended.\n                                                     Non-prescription pharmaceuticals sold over the counter.\nOTC ...................................................................\n                                              The allocation of up to 1,755,000 Over-Allotment Shares as part of the\nOver-Allotment .................................................\n                                              allocation of the Offer Shares.\nOver-Allotment Shares .....................................\n                                         1,755,000 existing bearer shares with no par value (St\u00fcckaktien) from the\n                                         holdings of the Selling Shareholder.\n", "page_number": 332, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6167664670658682, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8999144568006844, "height": 0.28314798973481614, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-332-22", "text": "G-3", "page_number": 332, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.029020556227327687}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-0", "text": "                                      Council Directive 2011/96/EU of November 30, 2011 on the common\nParent-Subsidiary Directive ............................\n                                      system of taxation applicable in the case of parent companies and\n                                      subsidiaries of different member states, as amended.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.08511548331907613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12660393498716851, "height": 0.04148845166809238, "width": 0.7593712212817413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-1", "text": "                                     Belgium,\nParticipating Member States ........................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.13387510692899915, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.14713430282292558, "height": 0.013259195893926434, "width": 0.3101571946795647}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-2", "text": "...Germany,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.4371221281741233, "top_left_y": 0.13387510692899915, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.14713430282292558, "height": 0.013259195893926434, "width": 0.07557436517533256}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-3", "text": "Greece,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.5894800483675937, "top_left_y": 0.13387510692899915, "lower_right_x": 0.6432889963724304, "lower_right_y": 0.14713430282292558, "height": 0.013259195893926434, "width": 0.05380894800483671}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-4", "text": "Spain,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.6571946795646917, "top_left_y": 0.13387510692899915, "lower_right_x": 0.7013301088270859, "lower_right_y": 0.14713430282292558, "height": 0.013259195893926434, "width": 0.04413542926239422}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-5", "text": "Italy,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.7756952841596131, "top_left_y": 0.13387510692899915, "lower_right_x": 0.8125755743651754, "lower_right_y": 0.14713430282292558, "height": 0.013259195893926434, "width": 0.03688029020556227}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-6", "text": "Estonia,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.5181378476420798, "top_left_y": 0.1343028229255774, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.14713430282292558, "height": 0.012831479897348175, "width": 0.06227327690447404}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-7", "text": "France,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.7103990326481258, "top_left_y": 0.1343028229255774, "lower_right_x": 0.7642079806529625, "lower_right_y": 0.14713430282292558, "height": 0.012831479897348175, "width": 0.05380894800483671}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-8", "text": "Austria,\n", "page_number": 333, "bounding_box": {"top_left_x": 0.8216444981862152, "top_left_y": 0.1360136869118905, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14713430282292558, "height": 0.011120615911035081, "width": 0.05864570737605812}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-9", "text": "Portugal, Slovenia and Slovakia.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.3675937122128174, "top_left_y": 0.14756201881950384, "lower_right_x": 0.5894800483675937, "lower_right_y": 0.16082121471343028, "height": 0.013259195893926434, "width": 0.22188633615477632}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-10", "text": "  Regulation (EU) 1235/2010 of the European Parliament and of the Council\n....................\n  of December 15, 2010.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.16723695466210436, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.19503849443969204, "height": 0.027801539777587675, "width": 0.5126964933494558}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-11", "text": "Pharmacovigilance Regulation .....\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16852010265183917, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.18135158254918735, "height": 0.012831479897348175, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-12", "text": "     The Protocol Relating to the Madrid Agreement Concerning the\n.......................\n     International Registration of Marks of June 27, 1989, as last amended on\n     November 12, 2007.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.35368802902055624, "top_left_y": 0.20145423438836613, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24294268605645852, "height": 0.041488451668092396, "width": 0.526602176541717}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-13", "text": "PMMA .......\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20487596236099231, "lower_right_x": 0.2037484885126965, "lower_right_y": 0.21514114627887082, "height": 0.010265183917878506, "width": 0.08343409915356712}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-14", "text": "  Free-floating dividends (i.e., dividends earned on direct shareholdings in a\n....................\n  distributing corporation equal to less than 10% of its share capital at the\n  start of the respective calendar year).\n", "page_number": 333, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.25278015397775877, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2904191616766467, "height": 0.03763900769888795, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-15", "text": "Portfolio Dividends ........................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.25278015397775877, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.2630453378956373, "height": 0.010265183917878506, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-16", "text": "                                 start of the respective calendar year).\n                                         The Ordinance on the Mandatory Prescription of Pharmaceuticals\nPrescription Ordinance ....................................\n                                         (Verordnung \u00fcber die Verschreibungspflicht von Arzneimitteln).\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.290846877673225, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32677502138579984, "height": 0.035928143712574856, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-17", "text": "  The price range for the Offering within which purchase orders may be\n....................\n  placed is \u20ac26.00 to \u20ac30.00 per Offer Share.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.3272027373823781, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36142001710863986, "height": 0.03421727972626176, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-18", "text": "Price Range ..\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.334901625320787, "lower_right_x": 0.21644498186215236, "lower_right_y": 0.3481608212147134, "height": 0.013259195893926434, "width": 0.09613059250302297}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-19", "text": "                                      The profit transfer agreement (Gewinnabf\u00fchrungsvertrag) entered into\nProfit Transfer Agreement ..............................\n                                      between Dermapharm AG and the Selling Shareholder on April 13, 2016.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.36911890504704875, "lower_right_x": 0.879081015719468, "lower_right_y": 0.3964927288280582, "height": 0.027373823781009443, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-20", "text": "    This prospectus.\n......................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.35792019347037485, "top_left_y": 0.4033361847733105, "lower_right_x": 0.47702539298669894, "lower_right_y": 0.41659538066723695, "height": 0.013259195893926434, "width": 0.11910519951632409}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-21", "text": "Prospectus .\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4033361847733105, "lower_right_x": 0.20556227327690446, "lower_right_y": 0.4174508126603935, "height": 0.014114627887083009, "width": 0.08524788391777507}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-22", "text": "       Directive 2003/71/EC of the European Parliament and of the Council of\n.........................\n       November 4, 2003 on the prospectus to be published when securities are\n       offered to the public or admitted to trading, as last amended on July 20,\n       2017.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.34582829504232165, "top_left_y": 0.4238665526090676, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4756201881950385, "height": 0.0517536355859709, "width": 0.5344619105199517}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-23", "text": "Prospectus Directive ..\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4238665526090676, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.43798118049615054, "height": 0.014114627887082953, "width": 0.1553808948004837}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-24", "text": "QIBs .\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.48545765611633873, "lower_right_x": 0.16021765417170497, "lower_right_y": 0.49957228400342174, "height": 0.014114627887083009, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-25", "text": "   Qualified institutional buyers as defined in Rule 144A.\n.....................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.36094316807738813, "top_left_y": 0.48545765611633873, "lower_right_x": 0.7394195888754534, "lower_right_y": 0.4991445680068435, "height": 0.01368691189050475, "width": 0.3784764207980653}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-26", "text": "                                           At least 1% of the share capital of the Company.\nQualified Participation .....................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.5059880239520959, "lower_right_x": 0.6958887545344619, "lower_right_y": 0.5201026518391788, "height": 0.014114627887082953, "width": 0.5749697702539298}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-27", "text": "                                                 Regulation\nRegulation S ......................................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5265183917878529, "lower_right_x": 0.4437726723095526, "lower_right_y": 0.5406330196749358, "height": 0.014114627887082953, "width": 0.3234582829504232}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-28", "text": "nS\n", "page_number": 333, "bounding_box": {"top_left_x": 0.4443772672309553, "top_left_y": 0.5265183917878529, "lower_right_x": 0.45223700120918986, "lower_right_y": 0.5372112917023096, "height": 0.010692899914456766, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-29", "text": "S under the Securities Act.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.4528415961305925, "top_left_y": 0.5265183917878529, "lower_right_x": 0.6287787182587666, "lower_right_y": 0.5372112917023096, "height": 0.010692899914456766, "width": 0.17593712212817414}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-30", "text": "                                                  Rule 144A under the Securities Act.\nRule 144A ..........................................................\nSE Regulation....................................................\n                                               Council Regulation (EC) no. 2157/2001 of October 8, 2001 on the statue\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5474764756201882, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5812660393498716, "height": 0.03378956372968345, "width": 0.7593712212817412}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-31", "text": "........\n  Cou\n  for\n", "page_number": 333, "bounding_box": {"top_left_x": 0.3675937122128174, "top_left_y": 0.58169375534645, "lower_right_x": 0.38814993954050786, "lower_right_y": 0.5919589392643285, "height": 0.010265183917878562, "width": 0.02055622732769047}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-32", "text": "ouncil\n ..............\n           Regulation (EC) no. 2\nr a European company (SE).\n", "page_number": 333, "bounding_box": {"top_left_x": 0.3905683192261185, "top_left_y": 0.58169375534645, "lower_right_x": 0.5725513905683193, "lower_right_y": 0.5953806672369547, "height": 0.01368691189050475, "width": 0.18198307134220076}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-33", "text": "                                                    The German Act on the SE-Implementation (SE-Ausf\u00fchrungsgesetz).\nSEAG .................................................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6026518391787853, "lower_right_x": 0.8313180169286578, "lower_right_y": 0.6159110350727117, "height": 0.013259195893926434, "width": 0.7110036275695284}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-34", "text": "Securities Act .\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6236099230111206, "lower_right_x": 0.2267230955259976, "lower_right_y": 0.6360136869118905, "height": 0.012403763900769915, "width": 0.1064087061668682}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-35", "text": "    The United States Securities Act of 1933, as amended.\n......................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.6236099230111206, "lower_right_x": 0.7351874244256348, "lower_right_y": 0.6364414029084687, "height": 0.01283147989734812, "width": 0.3760580411124546}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-36", "text": "                                            Themis Beteiligungs-Aktiengesellschaft.\nSelling Shareholder...........................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6441402908468776, "lower_right_x": 0.6426844014510278, "lower_right_y": 0.6573994867408041, "height": 0.013259195893926434, "width": 0.5217654171704957}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-37", "text": "SHI ..\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6668092386655261, "lower_right_x": 0.15900846432889965, "lower_right_y": 0.6775021385799829, "height": 0.010692899914456766, "width": 0.0380894800483676}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-38", "text": "   Statutory health insurance.\n.....................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.3615477629987908, "top_left_y": 0.6668092386655261, "lower_right_x": 0.5507859733978234, "lower_right_y": 0.6775021385799829, "height": 0.010692899914456766, "width": 0.1892382103990326}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-39", "text": "  Regulation (EU) no. 236/2012 of the European Parliament and of the\n....................\n  Council of March 14, 2012 on short selling and certain aspects of credit\n  default swaps.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.6873396065012831, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7271171941830624, "height": 0.0397775876817793, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-40", "text": "Short Selling Regulation\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6873396065012831, "lower_right_x": 0.2980652962515115, "lower_right_y": 0.7005988023952096, "height": 0.013259195893926434, "width": 0.17775090689238213}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-41", "text": "n.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.29866989117291415, "top_left_y": 0.6946107784431138, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.6976047904191617, "height": 0.0029940119760478723, "width": 0.0006045949214026347}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-42", "text": "...............\n", "page_number": 333, "bounding_box": {"top_left_x": 0.30169286577992743, "top_left_y": 0.6946107784431138, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.69803250641574, "height": 0.0034217279726261873, "width": 0.060459492140266025}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-43", "text": "                                                      SLG Service Logistik G\u00fcnthersdorf GmbH.\nSLG ....................................................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7352437981180496, "lower_right_x": 0.6608222490931076, "lower_right_y": 0.7489307100085543, "height": 0.013686911890504638, "width": 0.5405078597339782}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-44", "text": "                                    The German Social Code, Book V\nV ....................................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.22430471584038694, "top_left_y": 0.7557741659538066, "lower_right_x": 0.596130592503023, "lower_right_y": 0.7664670658682635, "height": 0.010692899914456877, "width": 0.3718258766626361}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-45", "text": "Social Code V .\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7557741659538066, "lower_right_x": 0.22370012091898428, "lower_right_y": 0.7664670658682635, "height": 0.010692899914456877, "width": 0.1033857315598549}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-46", "text": "V (Sozialgesetzbuch F\u00fcnftes Buch).\n", "page_number": 333, "bounding_box": {"top_left_x": 0.5967351874244257, "top_left_y": 0.7557741659538066, "lower_right_x": 0.8264812575574365, "lower_right_y": 0.7690333618477331, "height": 0.013259195893926434, "width": 0.22974607013301085}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-47", "text": "                                             Berenberg.\nSole Bookrunner ...............................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7763045337895638, "lower_right_x": 0.44316807738814995, "lower_right_y": 0.7899914456800684, "height": 0.013686911890504638, "width": 0.3222490931076179}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-48", "text": "                                        Berenberg.\nSole Global Coordinator ..................................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.7968349016253208, "lower_right_x": 0.4437726723095526, "lower_right_y": 0.8109495295124037, "height": 0.014114627887082953, "width": 0.32285368802902054}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-49", "text": "  The period which starts from the date the Company\u2019s shares commence\n....................\n  trading on the regulated market (regulierter Markt) of the Frankfurt Stock\n  Exchange (Frankfurter Wertpapierb\u00f6rse) and must end no later than\n  30 calendar days thereafter (i.e., March 11, 2018).\n", "page_number": 333, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.8173652694610778, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721129170230967, "height": 0.054747647562018886, "width": 0.5133010882708586}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-50", "text": "Stabilization Period .......................\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8173652694610778, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.8280581693755347, "height": 0.010692899914456877, "width": 0.24183796856106407}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-51", "text": "                                                Strathmann GmbH & Co. KG, its sole general partner Strathmann Service\nStrathmann .......................................................\n                                                GmbH and Biokirch GmbH Pharmaproduktion und \u00c4rzteservice.\n", "page_number": 333, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.878956372968349, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9054747647562019, "height": 0.02651839178785287, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-333-52", "text": "G-4", "page_number": 333, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9542343883661248, "height": 0.010265183917878451, "width": 0.028415961305925053}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-0", "text": "                                                SuperMedic (MediLight) Ltd. and various related parties.\nSuperMedic .......................................................\n                                            The Company\u2019s supervisory board (Aufsichtsrat).\nSupervisory Board ............................................\n                                          Directive 2002/46/EC of the European Parliament and\nSupplements Directive ......................................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08511548331907613, "lower_right_x": 0.752720677146312, "lower_right_y": 0.1420017108639863, "height": 0.05688622754491017, "width": 0.6324062877871826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-1", "text": "  Directive 2002/46/EC of the European Parliament and of the Council of\n....................\n  June 10, 2002 on the approximation of the laws of the member states\n  relating to food supplements.\n", "page_number": 334, "bounding_box": {"top_left_x": 0.3675937122128174, "top_left_y": 0.1270316509837468, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16766467065868262, "height": 0.04063301967493582, "width": 0.512696493349456}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-2", "text": "           Trommsdorff GmbH & Co. KG and its sole general partner Cl. Lageman\n.............................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.1740804106073567, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19803250641573994, "height": 0.023952095808383228, "width": 0.5519951632406288}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-3", "text": "Trommsdorff ..................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.1775021385799829, "lower_right_x": 0.29443772672309554, "lower_right_y": 0.18733960650128315, "height": 0.009837467921300247, "width": 0.17412333736396615}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-4", "text": " Gesellschaft mit beschr\u00e4nkter Haftung.\n  The German Transformation Act (Umwandlungsgesetz).\n....................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.19846022241231823, "lower_right_x": 0.7466747279322854, "lower_right_y": 0.22412318220701455, "height": 0.02566295979469632, "width": 0.37968561064087064}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-5", "text": "UmwG .................................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.21171941830624466, "lower_right_x": 0.30713422007255137, "lower_right_y": 0.22241231822070145, "height": 0.010692899914456794, "width": 0.18681983071342198}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-6", "text": "                                      The underwriting agreement, entered into between the Company, the\nUnderwriting Agreement .................................\n                                      Selling Shareholder and the Offering Banks on January 26, 2018.\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2322497861420017, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2583404619332763, "height": 0.02609067579127461, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-7", "text": "  UniCredit Bank AG.\n....................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.36698911729141476, "top_left_y": 0.2583404619332763, "lower_right_x": 0.5078597339782346, "lower_right_y": 0.276732249786142, "height": 0.018391787852865715, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-8", "text": "UniCredit ...\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.26646706586826346, "lower_right_x": 0.20133010882708585, "lower_right_y": 0.2771599657827203, "height": 0.010692899914456822, "width": 0.08101571946795647}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-9", "text": "United States ..\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.28699743370402053, "lower_right_x": 0.22370012091898428, "lower_right_y": 0.29769033361847735, "height": 0.010692899914456822, "width": 0.1033857315598549}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-10", "text": "    The United States of America.\n......................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.3591293833131802, "top_left_y": 0.28699743370402053, "lower_right_x": 0.5743651753325272, "lower_right_y": 0.29769033361847735, "height": 0.010692899914456822, "width": 0.215235792019347}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-11", "text": "VAT...\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3075278015397776, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.31822070145423437, "height": 0.010692899914456766, "width": 0.044135429262394194}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-12", "text": "   Value added tax.\n.....................\n", "page_number": 334, "bounding_box": {"top_left_x": 0.3603385731559855, "top_left_y": 0.3075278015397776, "lower_right_x": 0.4830713422007255, "lower_right_y": 0.31822070145423437, "height": 0.010692899914456766, "width": 0.12273276904474001}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-13", "text": "                                Warth & Klein Grant Thornton AG Wirtschaftspr\u00fcfungsgesellschaft,\nWarth & Klein Grant Thornton .....................\n                                Johannstra\u00dfe 39, 40476 Dusseldorf, Germany.\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.32805816937553467, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3558597091531223, "height": 0.027801539777587647, "width": 0.7587666263603385}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-14", "text": "                                                   The German Securities Trading Act (Wertpapierhandelsgesetz).\nWpHG ................................................................\n                                                   The German Securities Prospectus Act (Wertpapierprospektgesetz).\nWpPG ................................................................\n                                                   The German Securities and Acquisition\nWp\u00dcG ................................................................                             and     Takeover    Act\n                                                   (Wertpapiererwerbs- und \u00dcbernahmegesetz).\n", "page_number": 334, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.36227544910179643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4311377245508982, "height": 0.06886227544910178, "width": 0.7593712212817413}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-334-15", "text": "G-5", "page_number": 334, "bounding_box": {"top_left_x": 0.4836759371221282, "top_left_y": 0.9439692044482464, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9546621043627032, "height": 0.010692899914456766, "width": 0.028415961305925053}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-335-0", "text": "(This page has been left blank intentionally)\n", "page_number": 335, "bounding_box": {"top_left_x": 0.34280532043530837, "top_left_y": 0.42728828058169377, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.4414029084687767, "height": 0.014114627887082953, "width": 0.31499395405078595}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-0", "text": "24.   RECENT DEVELOPMENTS AND OUTLOOK\n", "page_number": 336, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.0645575032064985, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.41172914147521156}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-1", "text": "24.1\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.09277469003847798, "lower_right_x": 0.14993954050785974, "lower_right_y": 0.10474561778537837, "height": 0.011970927746900395, "width": 0.02962515114873035}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-2", "text": "Recent Developments\n", "page_number": 336, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.09277469003847798, "lower_right_x": 0.33796856106408707, "lower_right_y": 0.10602821718683197, "height": 0.013253527148353997, "width": 0.15900846432889965}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-3", "text": "On October 1, 2017, Dermapharm completed the acquisition of all shares in Bio-Di\u00e4t-Berlin.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.11244121419410004, "lower_right_x": 0.805925030229746, "lower_right_y": 0.12654980761008977, "height": 0.014108593415989731, "width": 0.6275695284159613}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-4", "text": "         In November 2017, axicorp Pharma B.V. settled claims brought by private health insurance providers\nin respect of rebates in an aggregate amount of approximately \u20ac1.2 million. Furthermore, it paid \u20ac1.9 million,\nplus interest in an amount of \u20ac0.2 million, in respect of rebates to private health insurance providers for which\nDermapharm had already received invoices, but which had not yet been claimed by these private health\ninsurance providers in court. For further information, see \u201c12.12 Litigation\u201d.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20179563916203505, "height": 0.0688328345446772, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-5", "text": "         On November 19, 2017, Dermapharm repaid the then outstanding variable tranche in an amount of\n\u20ac6.5 million under the 2014 Promissory Notes.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23599828986746474, "height": 0.02778965369816161, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-6", "text": "         On December 6, 2017, the Company\u2019s shareholders\u2019 meeting resolved on the Contribution Capital\nIncrease. In addition, the Selling Shareholder contributed any remaining shares in Dermapharm AG to the\nCompany\u2019s free reserves (freie R\u00fccklagen) without consideration. The contribution and transfer of all shares in\nDermapharm AG were completed with effect from the end of December 31, 2017 and the consummation of the\nContribution Capital Increase was registered in the commercial register of the local court (Amtsgericht) of\nMunich, Germany, on January 4, 2018.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32492518170158186, "height": 0.08251389482684907, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-7", "text": "         On December 20, 2017, Dermapharm acquired all shares in Strathmann, which distributes a broad\nproduct offering primarily comprising OTC products, which complement Dermapharm\u2019s existing product\nportfolio, in particular with respect to the dermatologicals, women\u2019s healthcare and vitamins/minerals/enzymes\nproduct areas. In the fiscal year ended December 31, 2016, Strathmann generated aggregate revenues of\n\u20ac27.9 million and EBITDA of \u20ac3.7 million (based on Strathmann\u2019s financial statements prepared in accordance\nwith HGB).\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.413852073535699, "height": 0.08251389482684907, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-8", "text": "         The Profit Transfer Agreement was terminated with effect from the end of December 31, 2017,\nmeaning that Dermapharm AG is required to transfer its profits for the fiscal year ended December 31, 2017, if\nany, to the Selling Shareholder. However, Dermapharm AG has provided the Selling Shareholder with certain\nshareholder loans. Consequently, the claims of the Selling Shareholder under the Profit Transfer Agreement\nwith respect to the fiscal year ended December 31, 2017 will be offset against Dermapharm AG\u2019s claims under\nthese shareholder loans and Dermapharm AG expects that its claims will exceed those of the Selling\nShareholder by more than \u20ac50 million.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.516460025651988, "height": 0.09277469003847794, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-9", "text": "         On January 2, 2018, Dermapharm repaid the final tranche under its profit participation rights in\nregistered form (auf den Namen lautende Genussrechte) in an amount of \u20ac6.4 million.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5510902094912355, "height": 0.02479692176143644, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-10", "text": "        On January 23, 2018, Dermapharm acquired all shares in Trommsdorff, which manufactures and\nmarkets 23 different prescription pharmaceuticals and OTC products, in particular Keltican\u00ae forte, a dietary\nproduct for the treatment of back pain, and Tromcardin \u00ae complex, which combines certain minerals and\nvitamins for the treatment of cardiac arrhythmia. Trommsdorff also serves its former parent group as a toll\nmanufacturer. In the fiscal year ended December 31, 2016, Trommsdorff generated aggregate revenues of\n\u20ac52.0 million and EBITDA of \u20ac10.6 million (based on Trommsdorff\u2019s financial statements prepared in\naccordance with HGB).\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6532706284737068, "height": 0.09277469003847805, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-11", "text": "         Except as described above, there have been no significant changes to Dermapharm\u2019s financial position,\nfinancial performance, cash flows or trading position between September 30, 2017 and the date of this\nProspectus.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7032920051303976, "height": 0.04018811457887983, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-12", "text": "         The Management Board estimates that in the three-month period ended December 31, 2017,\nDermapharm\u2019s business and revenues developed in line with Dermapharm\u2019s performance in the nine-month\nperiod ended September 30, 2017.\n", "page_number": 336, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7520307823856349, "height": 0.04104318084651559, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-336-13", "text": "O-1", "page_number": 336, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.946985891406584, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.029625151148730378}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-337-0", "text": "24.2   Outlook\n", "page_number": 337, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.0645575032064985, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.07524583155194528, "height": 0.01068832834544678, "width": 0.12152357920193471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-337-1", "text": "       In its most recent world economic outlook, the International Monetary Fund forecasts that the global\neconomy will grow by 3.2% in the fiscal year ended December 31, 2017 and 3.6% in the fiscal year ending\nDecember 31, 2018. Germany\u2019s real gross domestic product is forecast to grow at a slower pace, with increases\nof 2.1% and 1.9% forecasted for the fiscal year ended December 31, 2017 and the fiscal year ending\nDecember 31, 2018, respectively (source: IMF \u2013 World Economic Outlook).\n", "page_number": 337, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15391192817443353, "height": 0.06883283454467722, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-337-2", "text": "         With respect to prescription pharmaceuticals, the global prescription pharmaceuticals market is\nexpected to grow at a CAGR of 6.5% through 2022. Expected growth is even more pronounced for generics,\nleading to an increase of the market share of generics of 10.6% of all prescription pharmaceuticals in the fiscal\nyear ending December 31, 2022 (source: Evaluate \u2013 Global).\n", "page_number": 337, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21547669944420692, "height": 0.05515177426250534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-337-3", "text": "         In Europe, the market size of the European pharmaceuticals market is projected to increase to\n\u20ac206 billion in the fiscal year ending December 31, 2022, up by approximately 21.9% compared to the fiscal\nyear ended December 31, 2015. This growth corresponds to a CAGR of approximately 3.1% through 2020\n(source: Evaluate \u2013 Europe).\n", "page_number": 337, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27704147071398033, "height": 0.05515177426250534, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "blob_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573-337-4", "text": "O-2\n", "page_number": 337, "bounding_box": {"top_left_x": 0.4830713422007255, "top_left_y": 0.946985891406584, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.9572466866182129, "height": 0.010260795211628926, "width": 0.029020556227327743}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}], "document_id": "7c429695d981ca65d60fd6b2d14eeb0e7cf8f9b03249c2501b83a340821f5573", "pages_in_documents": 338}